US20240009169A9 - PPARG Modulators for the Treatment of Osteoporosis - Google Patents
PPARG Modulators for the Treatment of Osteoporosis Download PDFInfo
- Publication number
- US20240009169A9 US20240009169A9 US17/478,235 US202117478235A US2024009169A9 US 20240009169 A9 US20240009169 A9 US 20240009169A9 US 202117478235 A US202117478235 A US 202117478235A US 2024009169 A9 US2024009169 A9 US 2024009169A9
- Authority
- US
- United States
- Prior art keywords
- alkyl
- methyl
- dimethyl
- ethyl
- indole
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 238000011282 treatment Methods 0.000 title claims abstract description 25
- 208000001132 Osteoporosis Diseases 0.000 title claims abstract description 9
- 102100038825 Peroxisome proliferator-activated receptor gamma Human genes 0.000 title abstract description 45
- 101000741790 Homo sapiens Peroxisome proliferator-activated receptor gamma Proteins 0.000 title abstract description 38
- 238000000034 method Methods 0.000 claims abstract description 78
- 208000020084 Bone disease Diseases 0.000 claims abstract description 15
- 230000000750 progressive effect Effects 0.000 claims abstract description 15
- 201000002980 Hyperparathyroidism Diseases 0.000 claims abstract description 7
- 208000034578 Multiple myelomas Diseases 0.000 claims abstract description 7
- 208000010191 Osteitis Deformans Diseases 0.000 claims abstract description 7
- 208000027868 Paget disease Diseases 0.000 claims abstract description 7
- 206010035226 Plasma cell myeloma Diseases 0.000 claims abstract description 7
- 208000027202 mammary Paget disease Diseases 0.000 claims abstract description 7
- 150000001875 compounds Chemical class 0.000 claims description 952
- -1 methylenedioxy Chemical group 0.000 claims description 223
- 125000000217 alkyl group Chemical group 0.000 claims description 116
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 55
- 125000004429 atom Chemical group 0.000 claims description 42
- 150000003839 salts Chemical class 0.000 claims description 41
- 125000003118 aryl group Chemical group 0.000 claims description 39
- 229910052799 carbon Inorganic materials 0.000 claims description 39
- 125000006763 (C3-C9) cycloalkyl group Chemical group 0.000 claims description 36
- 125000001072 heteroaryl group Chemical group 0.000 claims description 35
- 125000004432 carbon atom Chemical group C* 0.000 claims description 33
- 125000000623 heterocyclic group Chemical group 0.000 claims description 32
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 28
- 125000005843 halogen group Chemical group 0.000 claims description 28
- 125000005842 heteroatom Chemical group 0.000 claims description 27
- 125000001424 substituent group Chemical group 0.000 claims description 24
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 21
- 229910052760 oxygen Inorganic materials 0.000 claims description 21
- 125000000041 C6-C10 aryl group Chemical group 0.000 claims description 20
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 20
- 229910052757 nitrogen Inorganic materials 0.000 claims description 20
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 18
- 102000003973 Fibroblast growth factor 21 Human genes 0.000 claims description 17
- 108090000376 Fibroblast growth factor 21 Proteins 0.000 claims description 17
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims description 16
- 125000003545 alkoxy group Chemical group 0.000 claims description 14
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 13
- 230000011164 ossification Effects 0.000 claims description 13
- 125000004043 oxo group Chemical group O=* 0.000 claims description 13
- 229910052717 sulfur Chemical group 0.000 claims description 13
- 125000006719 (C6-C10) aryl (C1-C6) alkyl group Chemical class 0.000 claims description 12
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 12
- 125000003342 alkenyl group Chemical group 0.000 claims description 11
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 10
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 10
- 239000001301 oxygen Substances 0.000 claims description 10
- 125000003831 tetrazolyl group Chemical group 0.000 claims description 10
- 125000000304 alkynyl group Chemical group 0.000 claims description 9
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 9
- 125000002950 monocyclic group Chemical group 0.000 claims description 9
- 125000003107 substituted aryl group Chemical group 0.000 claims description 9
- 125000006526 (C1-C2) alkyl group Chemical group 0.000 claims description 8
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims description 8
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims description 8
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 8
- 125000003435 aroyl group Chemical group 0.000 claims description 8
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 8
- 239000011593 sulfur Chemical group 0.000 claims description 8
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 6
- 125000004438 haloalkoxy group Chemical group 0.000 claims description 6
- 125000001188 haloalkyl group Chemical group 0.000 claims description 6
- 125000004446 heteroarylalkyl group Chemical group 0.000 claims description 6
- 208000006386 Bone Resorption Diseases 0.000 claims description 5
- 230000037180 bone health Effects 0.000 claims description 5
- 230000024279 bone resorption Effects 0.000 claims description 5
- 125000004415 heterocyclylalkyl group Chemical group 0.000 claims description 5
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 5
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 4
- 125000006727 (C1-C6) alkenyl group Chemical class 0.000 claims description 4
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims description 4
- 125000006728 (C1-C6) alkynyl group Chemical class 0.000 claims description 4
- 125000002733 (C1-C6) fluoroalkyl group Chemical group 0.000 claims description 4
- 125000004737 (C1-C6) haloalkoxy group Chemical group 0.000 claims description 4
- WTSXVIMLKCKWIW-UHFFFAOYSA-N 3h-1,3,4-oxadiazol-2-one Chemical compound O=C1NN=CO1 WTSXVIMLKCKWIW-UHFFFAOYSA-N 0.000 claims description 4
- 125000002618 bicyclic heterocycle group Chemical group 0.000 claims description 4
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 claims description 4
- 229910052727 yttrium Inorganic materials 0.000 claims description 4
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 16
- 201000010099 disease Diseases 0.000 abstract description 8
- 239000000556 agonist Substances 0.000 abstract description 6
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 500
- XTINUZLKVBBOAA-UHFFFAOYSA-N 2,3-dimethyl-1-[[4-[2-[(2-methylpropan-2-yl)oxycarbonyl]phenyl]phenyl]methyl]indole-5-carboxylic acid Chemical compound CC1=C(C)C2=CC(C(O)=O)=CC=C2N1CC(C=C1)=CC=C1C1=CC=CC=C1C(=O)OC(C)(C)C XTINUZLKVBBOAA-UHFFFAOYSA-N 0.000 description 162
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 131
- 239000000243 solution Substances 0.000 description 126
- 239000000203 mixture Substances 0.000 description 117
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 105
- SOZMSEPDYJGBEK-LURJTMIESA-N (1s)-1-(4-bromophenyl)ethanamine Chemical compound C[C@H](N)C1=CC=C(Br)C=C1 SOZMSEPDYJGBEK-LURJTMIESA-N 0.000 description 84
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 81
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 76
- OTXINXDGSUFPNU-UHFFFAOYSA-N 4-tert-butylbenzaldehyde Chemical compound CC(C)(C)C1=CC=C(C=O)C=C1 OTXINXDGSUFPNU-UHFFFAOYSA-N 0.000 description 66
- 239000000843 powder Substances 0.000 description 62
- YASAKCUCGLMORW-UHFFFAOYSA-N Rosiglitazone Chemical compound C=1C=CC=NC=1N(C)CCOC(C=C1)=CC=C1CC1SC(=O)NC1=O YASAKCUCGLMORW-UHFFFAOYSA-N 0.000 description 58
- 210000000988 bone and bone Anatomy 0.000 description 55
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 54
- HXITXNWTGFUOAU-UHFFFAOYSA-N phenylboronic acid Chemical compound OB(O)C1=CC=CC=C1 HXITXNWTGFUOAU-UHFFFAOYSA-N 0.000 description 54
- 239000011541 reaction mixture Substances 0.000 description 53
- XJIDIZMEDMODTR-QRPNPIFTSA-N (1s)-1-(3-cyclopropylphenyl)ethanamine;hydrochloride Chemical compound Cl.C[C@H](N)C1=CC=CC(C2CC2)=C1 XJIDIZMEDMODTR-QRPNPIFTSA-N 0.000 description 51
- RLSSMJSEOOYNOY-UHFFFAOYSA-N m-cresol Chemical compound CC1=CC=CC(O)=C1 RLSSMJSEOOYNOY-UHFFFAOYSA-N 0.000 description 50
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 48
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 48
- KPPYUUPTFHUYPW-UHFFFAOYSA-N 1-[[4-(2-methoxy-2-oxoethoxy)phenyl]methyl]-2,3-dimethylindole-5-carboxylic acid Chemical compound C1=CC(OCC(=O)OC)=CC=C1CN1C2=CC=C(C(O)=O)C=C2C(C)=C1C KPPYUUPTFHUYPW-UHFFFAOYSA-N 0.000 description 47
- 239000002904 solvent Substances 0.000 description 46
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 45
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 45
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 44
- ISKUMPHZUFZYAF-NRFANRHFSA-N methyl 2-[4-[[5-[[(1s)-1-(3-cyclopropylphenyl)ethyl]carbamoyl]-2,3-dimethylindol-1-yl]methyl]phenoxy]acetate Chemical compound C1=CC(OCC(=O)OC)=CC=C1CN1C2=CC=C(C(=O)N[C@@H](C)C=3C=C(C=CC=3)C3CC3)C=C2C(C)=C1C ISKUMPHZUFZYAF-NRFANRHFSA-N 0.000 description 44
- 239000012267 brine Substances 0.000 description 43
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 43
- FCELXHDRXJRWNS-FVGYRXGTSA-N (1s)-1-(3-propan-2-ylphenyl)ethanamine;hydrochloride Chemical compound Cl.CC(C)C1=CC=CC([C@H](C)N)=C1 FCELXHDRXJRWNS-FVGYRXGTSA-N 0.000 description 42
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 38
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 38
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 36
- 235000019439 ethyl acetate Nutrition 0.000 description 36
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 35
- AQFLVLHRZFLDDV-UHFFFAOYSA-N 1-phenylpropan-1-amine Chemical compound CCC(N)C1=CC=CC=C1 AQFLVLHRZFLDDV-UHFFFAOYSA-N 0.000 description 34
- BUKHBVPVKOXGSO-UHFFFAOYSA-N methyl 2-(4-methylphenoxy)acetate Chemical compound COC(=O)COC1=CC=C(C)C=C1 BUKHBVPVKOXGSO-UHFFFAOYSA-N 0.000 description 32
- LXLNKSHMUFDIOB-UHFFFAOYSA-N methyl 2-[4-(bromomethyl)phenoxy]acetate Chemical compound COC(=O)COC1=CC=C(CBr)C=C1 LXLNKSHMUFDIOB-UHFFFAOYSA-N 0.000 description 32
- QIRHIUYVMOECMT-UHFFFAOYSA-N prop-2-enyl 1-[[4-(2-methoxy-2-oxoethoxy)phenyl]methyl]-2,3-dimethylindole-5-carboxylate Chemical compound C1=CC(OCC(=O)OC)=CC=C1CN1C2=CC=C(C(=O)OCC=C)C=C2C(C)=C1C QIRHIUYVMOECMT-UHFFFAOYSA-N 0.000 description 32
- 238000002953 preparative HPLC Methods 0.000 description 31
- 229960004586 rosiglitazone Drugs 0.000 description 29
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 28
- 238000006243 chemical reaction Methods 0.000 description 28
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 27
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 26
- 238000003818 flash chromatography Methods 0.000 description 25
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 23
- 235000010290 biphenyl Nutrition 0.000 description 22
- 239000003921 oil Substances 0.000 description 22
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 21
- 241000699670 Mus sp. Species 0.000 description 21
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 21
- WQCMEXXHUOHNLP-FVGYRXGTSA-N [(1s)-1-(4-tert-butylphenyl)ethyl]azanium;chloride Chemical compound Cl.C[C@H](N)C1=CC=C(C(C)(C)C)C=C1 WQCMEXXHUOHNLP-FVGYRXGTSA-N 0.000 description 21
- 239000004305 biphenyl Substances 0.000 description 21
- 210000004027 cell Anatomy 0.000 description 20
- QOWBXWFYRXSBAS-UHFFFAOYSA-N (2,4-dimethoxyphenyl)methanamine Chemical compound COC1=CC=C(CN)C(OC)=C1 QOWBXWFYRXSBAS-UHFFFAOYSA-N 0.000 description 19
- 238000004128 high performance liquid chromatography Methods 0.000 description 19
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 18
- 150000001721 carbon Chemical group 0.000 description 18
- LPEKGGXMPWTOCB-VKHMYHEASA-N methyl (S)-lactate Chemical compound COC(=O)[C@H](C)O LPEKGGXMPWTOCB-VKHMYHEASA-N 0.000 description 18
- PNBUOWFUQDEXJJ-QFIPXVFZSA-N ethyl 4-[4-[[5-[[(1s)-1-(4-nitrophenyl)ethyl]carbamoyl]indol-1-yl]methyl]phenyl]benzoate Chemical compound C1=CC(C(=O)OCC)=CC=C1C(C=C1)=CC=C1CN1C2=CC=C(C(=O)N[C@@H](C)C=3C=CC(=CC=3)[N+]([O-])=O)C=C2C=C1 PNBUOWFUQDEXJJ-QFIPXVFZSA-N 0.000 description 15
- 210000002303 tibia Anatomy 0.000 description 15
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 14
- 239000007821 HATU Substances 0.000 description 14
- 241001465754 Metazoa Species 0.000 description 14
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 14
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 14
- 229910052786 argon Inorganic materials 0.000 description 14
- 229910002092 carbon dioxide Inorganic materials 0.000 description 14
- 230000000155 isotopic effect Effects 0.000 description 14
- 239000000741 silica gel Substances 0.000 description 14
- 229910002027 silica gel Inorganic materials 0.000 description 14
- HYWTVQKMPIPXGT-VIFPVBQESA-N (1s)-1-(3-propan-2-yloxyphenyl)ethanamine Chemical compound CC(C)OC1=CC=CC([C@H](C)N)=C1 HYWTVQKMPIPXGT-VIFPVBQESA-N 0.000 description 13
- JZUYFSLKZPAAQG-INIZCTEOSA-N 1-[(4-bromophenyl)methyl]-n-[(1s)-1-(4-nitrophenyl)ethyl]indole-5-carboxamide Chemical compound N([C@@H](C)C=1C=CC(=CC=1)[N+]([O-])=O)C(=O)C(C=C1C=C2)=CC=C1N2CC1=CC=C(Br)C=C1 JZUYFSLKZPAAQG-INIZCTEOSA-N 0.000 description 13
- NFHFRUOZVGFOOS-UHFFFAOYSA-N Pd(PPh3)4 Substances [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 13
- 235000009200 high fat diet Nutrition 0.000 description 13
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 13
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 13
- 125000004433 nitrogen atom Chemical group N* 0.000 description 13
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 13
- 229910000104 sodium hydride Inorganic materials 0.000 description 13
- CFKMVGJGLGKFKI-UHFFFAOYSA-N 4-chloro-m-cresol Chemical compound CC1=CC(O)=CC=C1Cl CFKMVGJGLGKFKI-UHFFFAOYSA-N 0.000 description 12
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 12
- 230000027455 binding Effects 0.000 description 12
- 230000000694 effects Effects 0.000 description 12
- 229910052739 hydrogen Inorganic materials 0.000 description 12
- IWDCLRJOBJJRNH-UHFFFAOYSA-N p-cresol Chemical compound CC1=CC=C(O)C=C1 IWDCLRJOBJJRNH-UHFFFAOYSA-N 0.000 description 12
- 238000000746 purification Methods 0.000 description 12
- 239000007787 solid Substances 0.000 description 12
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 11
- 239000007832 Na2SO4 Substances 0.000 description 11
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 11
- 239000007864 aqueous solution Substances 0.000 description 11
- 239000001257 hydrogen Substances 0.000 description 11
- DRYBMFJLYYEOBZ-UHFFFAOYSA-N methyl 1h-indole-5-carboxylate Chemical compound COC(=O)C1=CC=C2NC=CC2=C1 DRYBMFJLYYEOBZ-UHFFFAOYSA-N 0.000 description 11
- 229910052938 sodium sulfate Inorganic materials 0.000 description 11
- 238000005160 1H NMR spectroscopy Methods 0.000 description 10
- PCLIMKBDDGJMGD-UHFFFAOYSA-N N-bromosuccinimide Chemical compound BrN1C(=O)CCC1=O PCLIMKBDDGJMGD-UHFFFAOYSA-N 0.000 description 10
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 10
- 125000000392 cycloalkenyl group Chemical group 0.000 description 10
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 10
- LPEKGGXMPWTOCB-GSVOUGTGSA-N methyl (R)-lactate Chemical compound COC(=O)[C@@H](C)O LPEKGGXMPWTOCB-GSVOUGTGSA-N 0.000 description 10
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 10
- BTHPPPVUIUVCLN-QHCPKHFHSA-N tert-butyl 2-[4-[[5-[[(1s)-1-(5-bromopyridin-2-yl)ethyl]carbamoyl]-2,3-dimethylindol-1-yl]methyl]phenyl]benzoate Chemical compound N([C@@H](C)C=1N=CC(Br)=CC=1)C(=O)C(C=C1C(C)=C2C)=CC=C1N2CC(C=C1)=CC=C1C1=CC=CC=C1C(=O)OC(C)(C)C BTHPPPVUIUVCLN-QHCPKHFHSA-N 0.000 description 10
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 10
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 10
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide Chemical compound CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 9
- GQHTUMJGOHRCHB-UHFFFAOYSA-N 2,3,4,6,7,8,9,10-octahydropyrimido[1,2-a]azepine Chemical compound C1CCCCN2CCCN=C21 GQHTUMJGOHRCHB-UHFFFAOYSA-N 0.000 description 9
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 9
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 9
- 125000002252 acyl group Chemical group 0.000 description 9
- 150000001412 amines Chemical class 0.000 description 9
- 238000003556 assay Methods 0.000 description 9
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 9
- 229910052794 bromium Inorganic materials 0.000 description 9
- 230000001054 cortical effect Effects 0.000 description 9
- 239000012043 crude product Substances 0.000 description 9
- 235000005911 diet Nutrition 0.000 description 9
- 230000037213 diet Effects 0.000 description 9
- 239000008103 glucose Substances 0.000 description 9
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 9
- 239000012071 phase Substances 0.000 description 9
- 230000002441 reversible effect Effects 0.000 description 9
- 239000012047 saturated solution Substances 0.000 description 9
- 238000003786 synthesis reaction Methods 0.000 description 9
- ZMBSRUMFDMSSIC-DEOSSOPVSA-N tert-butyl 2-[4-[[5-[[(1s)-1-(4-bromophenyl)ethyl]carbamoyl]-2,3-dimethylindol-1-yl]methyl]phenyl]benzoate Chemical compound N([C@@H](C)C=1C=CC(Br)=CC=1)C(=O)C(C=C1C(C)=C2C)=CC=C1N2CC(C=C1)=CC=C1C1=CC=CC=C1C(=O)OC(C)(C)C ZMBSRUMFDMSSIC-DEOSSOPVSA-N 0.000 description 9
- FFQXEFNKZVGJDI-UHFFFAOYSA-N 3-propan-2-ylbenzaldehyde Chemical compound CC(C)C1=CC=CC(C=O)=C1 FFQXEFNKZVGJDI-UHFFFAOYSA-N 0.000 description 8
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 8
- JGLMVXWAHNTPRF-CMDGGOBGSA-N CCN1N=C(C)C=C1C(=O)NC1=NC2=CC(=CC(OC)=C2N1C\C=C\CN1C(NC(=O)C2=CC(C)=NN2CC)=NC2=CC(=CC(OCCCN3CCOCC3)=C12)C(N)=O)C(N)=O Chemical compound CCN1N=C(C)C=C1C(=O)NC1=NC2=CC(=CC(OC)=C2N1C\C=C\CN1C(NC(=O)C2=CC(C)=NN2CC)=NC2=CC(=CC(OCCCN3CCOCC3)=C12)C(N)=O)C(N)=O JGLMVXWAHNTPRF-CMDGGOBGSA-N 0.000 description 8
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 8
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 8
- 239000012300 argon atmosphere Substances 0.000 description 8
- 230000015572 biosynthetic process Effects 0.000 description 8
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Chemical compound BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 8
- 239000000460 chlorine Substances 0.000 description 8
- 229910052801 chlorine Inorganic materials 0.000 description 8
- 239000012230 colorless oil Substances 0.000 description 8
- 208000035475 disorder Diseases 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 8
- 239000000706 filtrate Substances 0.000 description 8
- NXPHGHWWQRMDIA-UHFFFAOYSA-M magnesium;carbanide;bromide Chemical compound [CH3-].[Mg+2].[Br-] NXPHGHWWQRMDIA-UHFFFAOYSA-M 0.000 description 8
- SQIHTGHREIYGQI-UHFFFAOYSA-N n-(1-phenylpropyl)-1h-indole-5-carboxamide Chemical compound C=1C=C2NC=CC2=CC=1C(=O)NC(CC)C1=CC=CC=C1 SQIHTGHREIYGQI-UHFFFAOYSA-N 0.000 description 8
- 238000003419 tautomerization reaction Methods 0.000 description 8
- YLRBJYMANQKEAW-UHFFFAOYSA-N 1-bromo-4-(bromomethyl)benzene Chemical compound BrCC1=CC=C(Br)C=C1 YLRBJYMANQKEAW-UHFFFAOYSA-N 0.000 description 7
- SMFHPCZZAAMJJO-UHFFFAOYSA-N 2-chloro-5-methylphenol Chemical compound CC1=CC=C(Cl)C(O)=C1 SMFHPCZZAAMJJO-UHFFFAOYSA-N 0.000 description 7
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 7
- RAEVOBPXEHVUFY-LURJTMIESA-N 4187-53-5 Chemical compound C[C@H](N)C1=CC=C([N+]([O-])=O)C=C1 RAEVOBPXEHVUFY-LURJTMIESA-N 0.000 description 7
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 7
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 7
- 108010016731 PPAR gamma Proteins 0.000 description 7
- PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 description 7
- 238000004587 chromatography analysis Methods 0.000 description 7
- 230000003287 optical effect Effects 0.000 description 7
- 230000002829 reductive effect Effects 0.000 description 7
- 229920006395 saturated elastomer Polymers 0.000 description 7
- 238000010898 silica gel chromatography Methods 0.000 description 7
- 238000003756 stirring Methods 0.000 description 7
- YHXCWNQNVMAENQ-UHFFFAOYSA-N tert-butyl 2-[4-(bromomethyl)phenyl]benzoate Chemical compound CC(C)(C)OC(=O)C1=CC=CC=C1C1=CC=C(CBr)C=C1 YHXCWNQNVMAENQ-UHFFFAOYSA-N 0.000 description 7
- ZRAUINRUYJQISN-UHFFFAOYSA-N 1-[(2-bromophenyl)methyl]-2,3-dimethylindole-5-carboxylic acid Chemical compound CC1=C(C)C2=CC(C(O)=O)=CC=C2N1CC1=CC=CC=C1Br ZRAUINRUYJQISN-UHFFFAOYSA-N 0.000 description 6
- NLZXIMPDRRCEAH-AWEZNQCLSA-N 1-[[2-chloro-5-[(2s)-1-methoxy-1-oxopropan-2-yl]oxyphenyl]methyl]-2,3-dimethylindole-5-carboxylic acid Chemical compound COC(=O)[C@H](C)OC1=CC=C(Cl)C(CN2C3=CC=C(C=C3C(C)=C2C)C(O)=O)=C1 NLZXIMPDRRCEAH-AWEZNQCLSA-N 0.000 description 6
- TUNGHFREKGFCTP-HNNXBMFYSA-N 1-[[3-[(2s)-1-methoxy-1-oxopropan-2-yl]oxyphenyl]methyl]-2,3-dimethylindole-5-carboxylic acid Chemical compound COC(=O)[C@H](C)OC1=CC=CC(CN2C3=CC=C(C=C3C(C)=C2C)C(O)=O)=C1 TUNGHFREKGFCTP-HNNXBMFYSA-N 0.000 description 6
- AQJFATAFTQCRGC-UHFFFAOYSA-N 2-Chloro-4-methylphenol Chemical compound CC1=CC=C(O)C(Cl)=C1 AQJFATAFTQCRGC-UHFFFAOYSA-N 0.000 description 6
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 6
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 6
- 239000002585 base Substances 0.000 description 6
- 230000009286 beneficial effect Effects 0.000 description 6
- 210000001185 bone marrow Anatomy 0.000 description 6
- 125000004122 cyclic group Chemical group 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- VQDRHZVLRCGSFX-UHFFFAOYSA-N ethyl 2,3-dimethyl-1h-indole-5-carboxylate Chemical compound CCOC(=O)C1=CC=C2NC(C)=C(C)C2=C1 VQDRHZVLRCGSFX-UHFFFAOYSA-N 0.000 description 6
- 238000011534 incubation Methods 0.000 description 6
- IENZCGNHSIMFJE-UHFFFAOYSA-N indole-5-carboxylic acid Chemical compound OC(=O)C1=CC=C2NC=CC2=C1 IENZCGNHSIMFJE-UHFFFAOYSA-N 0.000 description 6
- 239000012044 organic layer Substances 0.000 description 6
- 125000004430 oxygen atom Chemical group O* 0.000 description 6
- 239000004031 partial agonist Substances 0.000 description 6
- 230000023603 positive regulation of transcription initiation, DNA-dependent Effects 0.000 description 6
- VVWRJUBEIPHGQF-UHFFFAOYSA-N propan-2-yl n-propan-2-yloxycarbonyliminocarbamate Chemical compound CC(C)OC(=O)N=NC(=O)OC(C)C VVWRJUBEIPHGQF-UHFFFAOYSA-N 0.000 description 6
- 102000005962 receptors Human genes 0.000 description 6
- 108020003175 receptors Proteins 0.000 description 6
- 238000010992 reflux Methods 0.000 description 6
- 239000007858 starting material Substances 0.000 description 6
- 238000006467 substitution reaction Methods 0.000 description 6
- HVRIGTRPKTZQKC-QMMMGPOBSA-N (1s)-1-(3-cyclopropylphenyl)ethanamine Chemical compound C[C@H](N)C1=CC=CC(C2CC2)=C1 HVRIGTRPKTZQKC-QMMMGPOBSA-N 0.000 description 5
- HZUDLUBTTHIVTP-VIFPVBQESA-N (1s)-1-(4-tert-butylphenyl)ethanamine Chemical compound C[C@H](N)C1=CC=C(C(C)(C)C)C=C1 HZUDLUBTTHIVTP-VIFPVBQESA-N 0.000 description 5
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 5
- YPFIRRYKYDGFLL-AWEZNQCLSA-N 1-[[4-chloro-3-[(2s)-1-methoxy-1-oxopropan-2-yl]oxyphenyl]methyl]-2,3-dimethylindole-5-carboxylic acid Chemical compound C1=C(Cl)C(O[C@@H](C)C(=O)OC)=CC(CN2C3=CC=C(C=C3C(C)=C2C)C(O)=O)=C1 YPFIRRYKYDGFLL-AWEZNQCLSA-N 0.000 description 5
- WKDKAVKAQXVFJV-DEOSSOPVSA-N 2-[4-[[5-[[(1s)-1-(4-tert-butylphenyl)ethyl]carbamoyl]-2,3-dimethylindol-1-yl]methyl]phenyl]benzoic acid Chemical compound N([C@@H](C)C=1C=CC(=CC=1)C(C)(C)C)C(=O)C(C=C1C(C)=C2C)=CC=C1N2CC(C=C1)=CC=C1C1=CC=CC=C1C(O)=O WKDKAVKAQXVFJV-DEOSSOPVSA-N 0.000 description 5
- 238000011740 C57BL/6 mouse Methods 0.000 description 5
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 5
- 102000004877 Insulin Human genes 0.000 description 5
- 108090001061 Insulin Proteins 0.000 description 5
- 239000002253 acid Substances 0.000 description 5
- DFDGRKNOFOJBAJ-UHFFFAOYSA-N acifran Chemical compound C=1C=CC=CC=1C1(C)OC(C(O)=O)=CC1=O DFDGRKNOFOJBAJ-UHFFFAOYSA-N 0.000 description 5
- 150000001768 cations Chemical class 0.000 description 5
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 5
- 229910052731 fluorine Inorganic materials 0.000 description 5
- 229940125396 insulin Drugs 0.000 description 5
- DDMCDMDOHABRHD-BYPYZUCNSA-N methyl (2s)-2-hydroxybutanoate Chemical compound CC[C@H](O)C(=O)OC DDMCDMDOHABRHD-BYPYZUCNSA-N 0.000 description 5
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 description 5
- 125000003367 polycyclic group Chemical group 0.000 description 5
- 229910000027 potassium carbonate Inorganic materials 0.000 description 5
- 239000002243 precursor Substances 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- AQFLVLHRZFLDDV-SECBINFHSA-N (1r)-1-phenylpropan-1-amine Chemical compound CC[C@@H](N)C1=CC=CC=C1 AQFLVLHRZFLDDV-SECBINFHSA-N 0.000 description 4
- RJPLGQTZHLRZGX-LURJTMIESA-N (1s)-1-(2-chlorophenyl)ethanamine Chemical compound C[C@H](N)C1=CC=CC=C1Cl RJPLGQTZHLRZGX-LURJTMIESA-N 0.000 description 4
- AQFLVLHRZFLDDV-VIFPVBQESA-N (1s)-1-phenylpropan-1-amine Chemical compound CC[C@H](N)C1=CC=CC=C1 AQFLVLHRZFLDDV-VIFPVBQESA-N 0.000 description 4
- QZTWVVOMUCTRSJ-UHFFFAOYSA-N 1-(5-bromopyridin-3-yl)ethylazanium;chloride Chemical compound [Cl-].CC([NH3+])C1=CN=CC(Br)=C1 QZTWVVOMUCTRSJ-UHFFFAOYSA-N 0.000 description 4
- DCWJKMBTJANAJD-UHFFFAOYSA-N 1-[(2-bromophenyl)methyl]-n-(1-phenylpropyl)indole-5-carboxamide Chemical compound C=1C=CC=CC=1C(CC)NC(=O)C(C=C1C=C2)=CC=C1N2CC1=CC=CC=C1Br DCWJKMBTJANAJD-UHFFFAOYSA-N 0.000 description 4
- CETUBSUTKPUXLY-UHFFFAOYSA-N 1-[(3-bromophenyl)methyl]-n-(1-phenylpropyl)indole-5-carboxamide Chemical compound C=1C=CC=CC=1C(CC)NC(=O)C(C=C1C=C2)=CC=C1N2CC1=CC=CC(Br)=C1 CETUBSUTKPUXLY-UHFFFAOYSA-N 0.000 description 4
- ALBPVRWEHNPQNT-UHFFFAOYSA-N 1-[(4-bromophenyl)methyl]indole-5-carboxylic acid Chemical compound C1=CC2=CC(C(=O)O)=CC=C2N1CC1=CC=C(Br)C=C1 ALBPVRWEHNPQNT-UHFFFAOYSA-N 0.000 description 4
- KHRDJOPULYPGKC-UHFFFAOYSA-N 1-[[2-(3-ethoxycarbonylphenyl)phenyl]methyl]-2,3-dimethylindole-5-carboxylic acid Chemical compound CCOC(=O)C1=CC=CC(C=2C(=CC=CC=2)CN2C3=CC=C(C=C3C(C)=C2C)C(O)=O)=C1 KHRDJOPULYPGKC-UHFFFAOYSA-N 0.000 description 4
- ZVKRASHWHMDXAZ-UHFFFAOYSA-N 1-[[2-(4-ethoxycarbonylphenyl)phenyl]methyl]-2,3-dimethylindole-5-carboxylic acid Chemical compound C1=CC(C(=O)OCC)=CC=C1C1=CC=CC=C1CN1C2=CC=C(C(O)=O)C=C2C(C)=C1C ZVKRASHWHMDXAZ-UHFFFAOYSA-N 0.000 description 4
- NMLURNWPNNXKCB-UHFFFAOYSA-N 1-[[3-(2-methoxy-2-oxoethoxy)phenyl]methyl]-2,3-dimethylindole-5-carboxylic acid Chemical compound COC(=O)COC1=CC=CC(CN2C3=CC=C(C=C3C(C)=C2C)C(O)=O)=C1 NMLURNWPNNXKCB-UHFFFAOYSA-N 0.000 description 4
- RIAOMNRYQOJXMG-UHFFFAOYSA-N 1-[[4-(2-cyanophenyl)phenyl]methyl]-2,3-dimethyl-n-(1-phenylpropyl)indole-5-carboxamide Chemical compound C=1C=CC=CC=1C(CC)NC(=O)C(C=C1C(C)=C2C)=CC=C1N2CC(C=C1)=CC=C1C1=CC=CC=C1C#N RIAOMNRYQOJXMG-UHFFFAOYSA-N 0.000 description 4
- OZAIFHULBGXAKX-UHFFFAOYSA-N 2-(2-cyanopropan-2-yldiazenyl)-2-methylpropanenitrile Chemical compound N#CC(C)(C)N=NC(C)(C)C#N OZAIFHULBGXAKX-UHFFFAOYSA-N 0.000 description 4
- LETNSIWDILDIKU-DEOSSOPVSA-N 2-[4-[[2,3-dimethyl-5-[[(1s)-1-(3-propan-2-ylphenyl)ethyl]carbamoyl]indol-1-yl]methyl]phenyl]benzoic acid Chemical compound CC(C)C1=CC=CC([C@H](C)NC(=O)C=2C=C3C(C)=C(C)N(CC=4C=CC(=CC=4)C=4C(=CC=CC=4)C(O)=O)C3=CC=2)=C1 LETNSIWDILDIKU-DEOSSOPVSA-N 0.000 description 4
- HBMXDCXJXYASGW-NRFANRHFSA-N 2-[4-[[5-[[(1s)-1-(4-bromophenyl)ethyl]carbamoyl]-2,3-dimethylindol-1-yl]methyl]phenyl]benzoic acid Chemical compound N([C@@H](C)C=1C=CC(Br)=CC=1)C(=O)C(C=C1C(C)=C2C)=CC=C1N2CC(C=C1)=CC=C1C1=CC=CC=C1C(O)=O HBMXDCXJXYASGW-NRFANRHFSA-N 0.000 description 4
- NWWQNPOCZVMDDV-UHFFFAOYSA-N 3-methyl-1-[[4-[2-[(2-methylpropan-2-yl)oxycarbonyl]phenyl]phenyl]methyl]indole-5-carboxylic acid Chemical compound C12=CC=C(C(O)=O)C=C2C(C)=CN1CC(C=C1)=CC=C1C1=CC=CC=C1C(=O)OC(C)(C)C NWWQNPOCZVMDDV-UHFFFAOYSA-N 0.000 description 4
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 4
- OZAIFHULBGXAKX-VAWYXSNFSA-N AIBN Substances N#CC(C)(C)\N=N\C(C)(C)C#N OZAIFHULBGXAKX-VAWYXSNFSA-N 0.000 description 4
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 4
- 239000005089 Luciferase Substances 0.000 description 4
- 241000124008 Mammalia Species 0.000 description 4
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 4
- CDKKLYSMNMQOIC-FVGYRXGTSA-N [(1s)-1-(3-propan-2-yloxyphenyl)ethyl]azanium;chloride Chemical compound Cl.CC(C)OC1=CC=CC([C@H](C)N)=C1 CDKKLYSMNMQOIC-FVGYRXGTSA-N 0.000 description 4
- 238000009825 accumulation Methods 0.000 description 4
- 150000001408 amides Chemical class 0.000 description 4
- 125000003277 amino group Chemical group 0.000 description 4
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 239000007795 chemical reaction product Substances 0.000 description 4
- VILAVOFMIJHSJA-UHFFFAOYSA-N dicarbon monoxide Chemical group [C]=C=O VILAVOFMIJHSJA-UHFFFAOYSA-N 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 230000037149 energy metabolism Effects 0.000 description 4
- HLUCKYWHSCLEFQ-UHFFFAOYSA-N ethyl 2,3-dimethyl-1-[[4-[2-[(2-methylpropan-2-yl)oxycarbonyl]phenyl]phenyl]methyl]indole-5-carboxylate Chemical compound CC1=C(C)C2=CC(C(=O)OCC)=CC=C2N1CC(C=C1)=CC=C1C1=CC=CC=C1C(=O)OC(C)(C)C HLUCKYWHSCLEFQ-UHFFFAOYSA-N 0.000 description 4
- 238000001914 filtration Methods 0.000 description 4
- 125000001475 halogen functional group Chemical group 0.000 description 4
- 125000001041 indolyl group Chemical group 0.000 description 4
- BUWNMZWSHRTLOV-JTHBVZDNSA-N methyl (2r)-2-[3-chloro-4-[[2,3-dimethyl-5-[[(1s)-1-(3-propan-2-ylphenyl)ethyl]carbamoyl]indol-1-yl]methyl]phenoxy]propanoate Chemical compound ClC1=CC(O[C@H](C)C(=O)OC)=CC=C1CN1C2=CC=C(C(=O)N[C@@H](C)C=3C=C(C=CC=3)C(C)C)C=C2C(C)=C1C BUWNMZWSHRTLOV-JTHBVZDNSA-N 0.000 description 4
- SITBEBOYLOYKGY-QMMMGPOBSA-N methyl (2s)-2-(2-chloro-5-methylphenoxy)propanoate Chemical compound COC(=O)[C@H](C)OC1=CC(C)=CC=C1Cl SITBEBOYLOYKGY-QMMMGPOBSA-N 0.000 description 4
- RDXKFALESKJSHT-VIFPVBQESA-N methyl (2s)-2-(3-methylphenoxy)propanoate Chemical compound COC(=O)[C@H](C)OC1=CC=CC(C)=C1 RDXKFALESKJSHT-VIFPVBQESA-N 0.000 description 4
- KIOGYLCYWQWXQX-QMMMGPOBSA-N methyl (2s)-2-[3-(bromomethyl)phenoxy]propanoate Chemical compound COC(=O)[C@H](C)OC1=CC=CC(CBr)=C1 KIOGYLCYWQWXQX-QMMMGPOBSA-N 0.000 description 4
- OWERYHXBIQEXNI-UHFFFAOYSA-N methyl 1-[(4-bromophenyl)methyl]indole-5-carboxylate Chemical compound C1=CC2=CC(C(=O)OC)=CC=C2N1CC1=CC=C(Br)C=C1 OWERYHXBIQEXNI-UHFFFAOYSA-N 0.000 description 4
- YDCHPLOFQATIDS-UHFFFAOYSA-N methyl 2-bromoacetate Chemical compound COC(=O)CBr YDCHPLOFQATIDS-UHFFFAOYSA-N 0.000 description 4
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 4
- 150000007524 organic acids Chemical class 0.000 description 4
- 230000026731 phosphorylation Effects 0.000 description 4
- 238000006366 phosphorylation reaction Methods 0.000 description 4
- 239000013612 plasmid Substances 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- WJYWTHJPNACDQR-SFHVURJKSA-N prop-2-enyl 1-[[3-[(2s)-1-methoxy-1-oxopropan-2-yl]oxyphenyl]methyl]-2,3-dimethylindole-5-carboxylate Chemical compound COC(=O)[C@H](C)OC1=CC=CC(CN2C3=CC=C(C=C3C(C)=C2C)C(=O)OCC=C)=C1 WJYWTHJPNACDQR-SFHVURJKSA-N 0.000 description 4
- MGCGJBXTNWUHQE-UHFFFAOYSA-N quinoline-4-carbaldehyde Chemical compound C1=CC=C2C(C=O)=CC=NC2=C1 MGCGJBXTNWUHQE-UHFFFAOYSA-N 0.000 description 4
- 239000012312 sodium hydride Substances 0.000 description 4
- RMMXLENWKUUMAY-UHFFFAOYSA-N telmisartan Chemical compound CCCC1=NC2=C(C)C=C(C=3N(C4=CC=CC=C4N=3)C)C=C2N1CC(C=C1)=CC=C1C1=CC=CC=C1C(O)=O RMMXLENWKUUMAY-UHFFFAOYSA-N 0.000 description 4
- JRLOBVFKHABODR-DEOSSOPVSA-N tert-butyl 2-[4-[[5-[[(1s)-1-(3-bromophenyl)ethyl]carbamoyl]-2,3-dimethylindol-1-yl]methyl]phenyl]benzoate Chemical compound N([C@@H](C)C=1C=C(Br)C=CC=1)C(=O)C(C=C1C(C)=C2C)=CC=C1N2CC(C=C1)=CC=C1C1=CC=CC=C1C(=O)OC(C)(C)C JRLOBVFKHABODR-DEOSSOPVSA-N 0.000 description 4
- SVNUBTBREFLTRB-QHCPKHFHSA-N tert-butyl 2-[4-[[5-[[(1s)-1-(4-nitrophenyl)ethyl]carbamoyl]indol-1-yl]methyl]phenyl]benzoate Chemical compound N([C@@H](C)C=1C=CC(=CC=1)[N+]([O-])=O)C(=O)C(C=C1C=C2)=CC=C1N2CC(C=C1)=CC=C1C1=CC=CC=C1C(=O)OC(C)(C)C SVNUBTBREFLTRB-QHCPKHFHSA-N 0.000 description 4
- 125000000335 thiazolyl group Chemical group 0.000 description 4
- DQEYVZASLGNODG-LURJTMIESA-N (1s)-1-(3-chlorophenyl)ethanamine Chemical compound C[C@H](N)C1=CC=CC(Cl)=C1 DQEYVZASLGNODG-LURJTMIESA-N 0.000 description 3
- YIPGPYIRKCOZJP-QMMMGPOBSA-N (1s)-1-(3-ethoxyphenyl)ethanamine Chemical compound CCOC1=CC=CC([C@H](C)N)=C1 YIPGPYIRKCOZJP-QMMMGPOBSA-N 0.000 description 3
- JAUXBJVPSMUQRD-VIFPVBQESA-N (1s)-1-(3-tert-butylphenyl)ethanamine Chemical compound C[C@H](N)C1=CC=CC(C(C)(C)C)=C1 JAUXBJVPSMUQRD-VIFPVBQESA-N 0.000 description 3
- XIBJZVAOMIDJMG-FVGYRXGTSA-N (1s)-1-(3-tert-butylphenyl)ethanamine;hydrochloride Chemical compound Cl.C[C@H](N)C1=CC=CC(C(C)(C)C)=C1 XIBJZVAOMIDJMG-FVGYRXGTSA-N 0.000 description 3
- PINPOEWMCLFRRB-LURJTMIESA-N (1s)-1-(4-chlorophenyl)ethanamine Chemical compound C[C@H](N)C1=CC=C(Cl)C=C1 PINPOEWMCLFRRB-LURJTMIESA-N 0.000 description 3
- JTDGKQNNPKXKII-ZETCQYMHSA-N (1s)-1-(4-methoxyphenyl)ethanamine Chemical compound COC1=CC=C([C@H](C)N)C=C1 JTDGKQNNPKXKII-ZETCQYMHSA-N 0.000 description 3
- ODZXRBRYQGYVJY-LURJTMIESA-N (1s)-1-[3-(trifluoromethyl)phenyl]ethanamine Chemical compound C[C@H](N)C1=CC=CC(C(F)(F)F)=C1 ODZXRBRYQGYVJY-LURJTMIESA-N 0.000 description 3
- GUMZDWPMXGQNBG-LURJTMIESA-N (1s)-1-[4-(trifluoromethyl)phenyl]ethanamine Chemical compound C[C@H](N)C1=CC=C(C(F)(F)F)C=C1 GUMZDWPMXGQNBG-LURJTMIESA-N 0.000 description 3
- WNXAXNUAJHPMKZ-RBBKRZOGSA-N (2r)-2-[3-chloro-4-[[2,3-dimethyl-5-[[(1s)-1-(3-propan-2-ylphenyl)ethyl]carbamoyl]indol-1-yl]methyl]phenoxy]propanoic acid Chemical compound CC(C)C1=CC=CC([C@H](C)NC(=O)C=2C=C3C(C)=C(C)N(CC=4C(=CC(O[C@H](C)C(O)=O)=CC=4)Cl)C3=CC=2)=C1 WNXAXNUAJHPMKZ-RBBKRZOGSA-N 0.000 description 3
- VFKLWVWYBVKXTA-UNMCSNQZSA-N (2s)-2-[3-[[5-[[(1s)-1-(4-tert-butylphenyl)ethyl]carbamoyl]-2,3-dimethylindol-1-yl]methyl]-4-chlorophenoxy]propanoic acid Chemical compound N([C@@H](C)C=1C=CC(=CC=1)C(C)(C)C)C(=O)C(C=C1C(C)=C2C)=CC=C1N2CC1=CC(O[C@@H](C)C(O)=O)=CC=C1Cl VFKLWVWYBVKXTA-UNMCSNQZSA-N 0.000 description 3
- ROQFGMFKGGEJAT-GMAHTHKFSA-N (2s)-2-[3-[[5-[[(1s)-1-(4-tert-butylphenyl)ethyl]carbamoyl]-2,3-dimethylindol-1-yl]methyl]phenoxy]propanoic acid Chemical compound OC(=O)[C@H](C)OC1=CC=CC(CN2C3=CC=C(C=C3C(C)=C2C)C(=O)N[C@@H](C)C=2C=CC(=CC=2)C(C)(C)C)=C1 ROQFGMFKGGEJAT-GMAHTHKFSA-N 0.000 description 3
- NPMSSJHJPGMEJW-UNMCSNQZSA-N (2s)-2-[5-[[5-[[(1s)-1-(4-tert-butylphenyl)ethyl]carbamoyl]-2,3-dimethylindol-1-yl]methyl]-2-chlorophenoxy]propanoic acid Chemical compound N([C@@H](C)C=1C=CC(=CC=1)C(C)(C)C)C(=O)C(C=C1C(C)=C2C)=CC=C1N2CC1=CC=C(Cl)C(O[C@@H](C)C(O)=O)=C1 NPMSSJHJPGMEJW-UNMCSNQZSA-N 0.000 description 3
- REHVCPNQQBDOJJ-UHFFFAOYSA-N (3-ethoxycarbonylphenyl)boronic acid Chemical compound CCOC(=O)C1=CC=CC(B(O)O)=C1 REHVCPNQQBDOJJ-UHFFFAOYSA-N 0.000 description 3
- ZLNFACCFYUFTLD-UHFFFAOYSA-N (4-ethoxycarbonylphenyl)boronic acid Chemical compound CCOC(=O)C1=CC=C(B(O)O)C=C1 ZLNFACCFYUFTLD-UHFFFAOYSA-N 0.000 description 3
- ASNVMKIDRJZXQZ-UHFFFAOYSA-N 1-(3-fluorophenyl)ethanamine Chemical compound CC(N)C1=CC=CC(F)=C1 ASNVMKIDRJZXQZ-UHFFFAOYSA-N 0.000 description 3
- RCXRVBXPJXJNFZ-UHFFFAOYSA-N 1-[(2,4-difluorophenyl)methyl]indole-5-carboxylic acid Chemical compound C1=CC2=CC(C(=O)O)=CC=C2N1CC1=CC=C(F)C=C1F RCXRVBXPJXJNFZ-UHFFFAOYSA-N 0.000 description 3
- IQIHMAOJLLASGE-QFIPXVFZSA-N 1-[4-[[2,3-dimethyl-5-[[(1s)-1-(3-propan-2-ylphenyl)ethyl]carbamoyl]indol-1-yl]methyl]phenyl]cyclopropane-1-carboxylic acid Chemical compound CC(C)C1=CC=CC([C@H](C)NC(=O)C=2C=C3C(C)=C(C)N(CC=4C=CC(=CC=4)C4(CC4)C(O)=O)C3=CC=2)=C1 IQIHMAOJLLASGE-QFIPXVFZSA-N 0.000 description 3
- FPSRCZQTBCBSAX-UHFFFAOYSA-N 1-[[2-(3-ethoxycarbonylphenyl)phenyl]methyl]indole-5-carboxylic acid Chemical compound CCOC(=O)C1=CC=CC(C=2C(=CC=CC=2)CN2C3=CC=C(C=C3C=C2)C(O)=O)=C1 FPSRCZQTBCBSAX-UHFFFAOYSA-N 0.000 description 3
- UZJAUUDMNAFXNI-UHFFFAOYSA-N 1-[[2-(4-ethoxycarbonylphenyl)phenyl]methyl]indole-5-carboxylic acid Chemical compound C1=CC(C(=O)OCC)=CC=C1C1=CC=CC=C1CN1C2=CC=C(C(O)=O)C=C2C=C1 UZJAUUDMNAFXNI-UHFFFAOYSA-N 0.000 description 3
- YXQRKWCKNTVUEF-UHFFFAOYSA-N 1-[[3-(1-methoxy-2-methyl-1-oxopropan-2-yl)oxyphenyl]methyl]-2,3-dimethylindole-5-carboxylic acid Chemical compound COC(=O)C(C)(C)OC1=CC=CC(CN2C3=CC=C(C=C3C(C)=C2C)C(O)=O)=C1 YXQRKWCKNTVUEF-UHFFFAOYSA-N 0.000 description 3
- MWMAGBAJPWCLGB-UHFFFAOYSA-N 1-[[3-(2-cyanopropan-2-yl)phenyl]methyl]-2,3-dimethylindole-5-carboxylic acid Chemical compound CC1=C(C)C2=CC(C(O)=O)=CC=C2N1CC1=CC=CC(C(C)(C)C#N)=C1 MWMAGBAJPWCLGB-UHFFFAOYSA-N 0.000 description 3
- UNLYIJOECLLYIT-QFIPXVFZSA-N 1-[[3-(2-cyanopropan-2-yl)phenyl]methyl]-n-[(1s)-1-(3-cyclopropylphenyl)ethyl]-2,3-dimethylindole-5-carboxamide Chemical compound N([C@@H](C)C=1C=C(C=CC=1)C1CC1)C(=O)C(C=C1C(C)=C2C)=CC=C1N2CC1=CC=CC(C(C)(C)C#N)=C1 UNLYIJOECLLYIT-QFIPXVFZSA-N 0.000 description 3
- XPTHDJGODOANPN-UHFFFAOYSA-N 1-[[3-(cyanomethoxy)phenyl]methyl]-2,3-dimethylindole-5-carboxylic acid Chemical compound CC1=C(C)C2=CC(C(O)=O)=CC=C2N1CC1=CC=CC(OCC#N)=C1 XPTHDJGODOANPN-UHFFFAOYSA-N 0.000 description 3
- TUNGHFREKGFCTP-OAHLLOKOSA-N 1-[[3-[(2r)-1-methoxy-1-oxopropan-2-yl]oxyphenyl]methyl]-2,3-dimethylindole-5-carboxylic acid Chemical compound COC(=O)[C@@H](C)OC1=CC=CC(CN2C3=CC=C(C=C3C(C)=C2C)C(O)=O)=C1 TUNGHFREKGFCTP-OAHLLOKOSA-N 0.000 description 3
- MKRKECBHJLDYLO-UHFFFAOYSA-N 1-[[4-(1-methoxycarbonylcyclopropyl)phenyl]methyl]-2,3-dimethylindole-5-carboxylic acid Chemical compound C=1C=C(CN2C3=CC=C(C=C3C(C)=C2C)C(O)=O)C=CC=1C1(C(=O)OC)CC1 MKRKECBHJLDYLO-UHFFFAOYSA-N 0.000 description 3
- BIDSUBFPJRLFNM-VWLOTQADSA-N 1-[[4-(2-cyanophenyl)phenyl]methyl]-2,3-dimethyl-n-[(1s)-1-(3-propan-2-ylphenyl)ethyl]indole-5-carboxamide Chemical compound CC(C)C1=CC=CC([C@H](C)NC(=O)C=2C=C3C(C)=C(C)N(CC=4C=CC(=CC=4)C=4C(=CC=CC=4)C#N)C3=CC=2)=C1 BIDSUBFPJRLFNM-VWLOTQADSA-N 0.000 description 3
- YQONJRSGVQEUSH-HNNXBMFYSA-N 1-[[4-[(2s)-1-methoxy-1-oxopropan-2-yl]oxyphenyl]methyl]-2,3-dimethylindole-5-carboxylic acid Chemical compound C1=CC(O[C@@H](C)C(=O)OC)=CC=C1CN1C2=CC=C(C(O)=O)C=C2C(C)=C1C YQONJRSGVQEUSH-HNNXBMFYSA-N 0.000 description 3
- SGUWWSMJODLILX-MHZLTWQESA-N 1-[[4-[2-(tert-butylsulfamoyl)phenyl]phenyl]methyl]-2,3-dimethyl-n-[(1s)-1-(3-propan-2-ylphenyl)ethyl]indole-5-carboxamide Chemical compound CC(C)C1=CC=CC([C@H](C)NC(=O)C=2C=C3C(C)=C(C)N(CC=4C=CC(=CC=4)C=4C(=CC=CC=4)S(=O)(=O)NC(C)(C)C)C3=CC=2)=C1 SGUWWSMJODLILX-MHZLTWQESA-N 0.000 description 3
- HDYOUBUPYGVCBL-UHFFFAOYSA-N 1-[[4-[2-[(2-methylpropan-2-yl)oxycarbonyl]phenyl]phenyl]methyl]indole-5-carboxylic acid Chemical compound CC(C)(C)OC(=O)C1=CC=CC=C1C(C=C1)=CC=C1CN1C2=CC=C(C(O)=O)C=C2C=C1 HDYOUBUPYGVCBL-UHFFFAOYSA-N 0.000 description 3
- LZSYGJNFCREHMD-UHFFFAOYSA-N 1-bromo-2-(bromomethyl)benzene Chemical compound BrCC1=CC=CC=C1Br LZSYGJNFCREHMD-UHFFFAOYSA-N 0.000 description 3
- OISVCGZHLKNMSJ-UHFFFAOYSA-N 2,6-dimethylpyridine Chemical compound CC1=CC=CC(C)=N1 OISVCGZHLKNMSJ-UHFFFAOYSA-N 0.000 description 3
- LFFIEVAMVPCZNA-UHFFFAOYSA-N 2-[4-(bromomethyl)phenyl]benzonitrile Chemical compound C1=CC(CBr)=CC=C1C1=CC=CC=C1C#N LFFIEVAMVPCZNA-UHFFFAOYSA-N 0.000 description 3
- DZODKUVBVKEFGB-MHZLTWQESA-N 2-[4-[[2,3-dimethyl-5-[[(1s)-1-(1-phenylmethoxycarbonylpiperidin-4-yl)ethyl]carbamoyl]indol-1-yl]methyl]phenyl]benzoic acid Chemical compound N([C@@H](C)C1CCN(CC1)C(=O)OCC=1C=CC=CC=1)C(=O)C(C=C1C(C)=C2C)=CC=C1N2CC(C=C1)=CC=C1C1=CC=CC=C1C(O)=O DZODKUVBVKEFGB-MHZLTWQESA-N 0.000 description 3
- CSELCEAGAMXNID-UHFFFAOYSA-N 2-methyl-1-[[4-[2-[(2-methylpropan-2-yl)oxycarbonyl]phenyl]phenyl]methyl]indole-5-carboxylic acid Chemical compound CC1=CC2=CC(C(O)=O)=CC=C2N1CC(C=C1)=CC=C1C1=CC=CC=C1C(=O)OC(C)(C)C CSELCEAGAMXNID-UHFFFAOYSA-N 0.000 description 3
- KDFDOINBXBEOLZ-UHFFFAOYSA-N 2-phenylpropan-2-amine Chemical compound CC(C)(N)C1=CC=CC=C1 KDFDOINBXBEOLZ-UHFFFAOYSA-N 0.000 description 3
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 3
- QWFHFNGMCPMOCD-UHFFFAOYSA-N 6-bromopyridine-2-carbaldehyde Chemical compound BrC1=CC=CC(C=O)=N1 QWFHFNGMCPMOCD-UHFFFAOYSA-N 0.000 description 3
- 239000004342 Benzoyl peroxide Substances 0.000 description 3
- OMPJBNCRMGITSC-UHFFFAOYSA-N Benzoylperoxide Chemical compound C=1C=CC=CC=1C(=O)OOC(=O)C1=CC=CC=C1 OMPJBNCRMGITSC-UHFFFAOYSA-N 0.000 description 3
- 206010065687 Bone loss Diseases 0.000 description 3
- 108020004414 DNA Proteins 0.000 description 3
- JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 3
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 3
- FFDARTLRQCBNRB-NUBCRITNSA-N [(1r)-1-(6-chloropyridin-3-yl)ethyl]azanium;chloride Chemical compound [Cl-].C[C@@H]([NH3+])C1=CC=C(Cl)N=C1 FFDARTLRQCBNRB-NUBCRITNSA-N 0.000 description 3
- CZQQGVFHLSBEDV-RGMNGODLSA-N [(1s)-1-(4-nitrophenyl)ethyl]azanium;chloride Chemical compound Cl.C[C@H](N)C1=CC=C([N+]([O-])=O)C=C1 CZQQGVFHLSBEDV-RGMNGODLSA-N 0.000 description 3
- IIJDFXNUWZTHIM-NRFANRHFSA-N [1,1'-biphenyl]-2-carboxylic acid, 4'-[[2,3-dimethyl-5-[[[(1s)-1-(4-nitrophenyl)ethyl]amino]carbonyl]-1h-indol-1-yl]methyl]- Chemical compound N([C@@H](C)C=1C=CC(=CC=1)[N+]([O-])=O)C(=O)C(C=C1C(C)=C2C)=CC=C1N2CC(C=C1)=CC=C1C1=CC=CC=C1C(O)=O IIJDFXNUWZTHIM-NRFANRHFSA-N 0.000 description 3
- 239000012190 activator Substances 0.000 description 3
- 230000001270 agonistic effect Effects 0.000 description 3
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 3
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 3
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 3
- 235000019400 benzoyl peroxide Nutrition 0.000 description 3
- WGQKYBSKWIADBV-UHFFFAOYSA-N benzylamine Chemical compound NCC1=CC=CC=C1 WGQKYBSKWIADBV-UHFFFAOYSA-N 0.000 description 3
- DEGAKNSWVGKMLS-UHFFFAOYSA-N calcein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC(CN(CC(O)=O)CC(O)=O)=C(O)C=C1OC1=C2C=C(CN(CC(O)=O)CC(=O)O)C(O)=C1 DEGAKNSWVGKMLS-UHFFFAOYSA-N 0.000 description 3
- 125000002837 carbocyclic group Chemical group 0.000 description 3
- 125000004452 carbocyclyl group Chemical group 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 3
- WLVKDFJTYKELLQ-UHFFFAOYSA-N cyclopropylboronic acid Chemical compound OB(O)C1CC1 WLVKDFJTYKELLQ-UHFFFAOYSA-N 0.000 description 3
- WSVSCTIQVZZKTF-QFIPXVFZSA-N ethyl 3-[2-[[5-[[(1s)-1-(4-bromophenyl)ethyl]carbamoyl]indol-1-yl]methyl]phenyl]benzoate Chemical compound CCOC(=O)C1=CC=CC(C=2C(=CC=CC=2)CN2C3=CC=C(C=C3C=C2)C(=O)N[C@@H](C)C=2C=CC(Br)=CC=2)=C1 WSVSCTIQVZZKTF-QFIPXVFZSA-N 0.000 description 3
- MEHYWHHVBDVAFS-QFIPXVFZSA-N ethyl 4-[2-[[5-[[(1s)-1-(4-bromophenyl)ethyl]carbamoyl]indol-1-yl]methyl]phenyl]benzoate Chemical compound C1=CC(C(=O)OCC)=CC=C1C1=CC=CC=C1CN1C2=CC=C(C(=O)N[C@@H](C)C=3C=CC(Br)=CC=3)C=C2C=C1 MEHYWHHVBDVAFS-QFIPXVFZSA-N 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 230000014509 gene expression Effects 0.000 description 3
- 238000007446 glucose tolerance test Methods 0.000 description 3
- 229910052736 halogen Inorganic materials 0.000 description 3
- 150000002367 halogens Chemical class 0.000 description 3
- 150000002431 hydrogen Chemical class 0.000 description 3
- 150000002466 imines Chemical class 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 239000000543 intermediate Substances 0.000 description 3
- 229910052740 iodine Inorganic materials 0.000 description 3
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 3
- 125000000842 isoxazolyl group Chemical group 0.000 description 3
- 239000010410 layer Substances 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- 210000002901 mesenchymal stem cell Anatomy 0.000 description 3
- YSGBMDFJWFIEDF-RXMQYKEDSA-N methyl (2r)-2-hydroxy-3-methylbutanoate Chemical compound COC(=O)[C@H](O)C(C)C YSGBMDFJWFIEDF-RXMQYKEDSA-N 0.000 description 3
- DDMCDMDOHABRHD-SCSAIBSYSA-N methyl (2r)-2-hydroxybutanoate Chemical compound CC[C@@H](O)C(=O)OC DDMCDMDOHABRHD-SCSAIBSYSA-N 0.000 description 3
- LMFZTDKRUAKBFE-ZETCQYMHSA-N methyl (2s)-2-[3-(bromomethyl)-4-chlorophenoxy]propanoate Chemical compound COC(=O)[C@H](C)OC1=CC=C(Cl)C(CBr)=C1 LMFZTDKRUAKBFE-ZETCQYMHSA-N 0.000 description 3
- OXGOLYIPXIYRHB-GMAHTHKFSA-N methyl (2s)-2-[3-[[5-[[(1s)-1-(4-tert-butylphenyl)ethyl]carbamoyl]-2,3-dimethylindol-1-yl]methyl]-4-chlorophenoxy]propanoate Chemical compound COC(=O)[C@H](C)OC1=CC=C(Cl)C(CN2C3=CC=C(C=C3C(C)=C2C)C(=O)N[C@@H](C)C=2C=CC(=CC=2)C(C)(C)C)=C1 OXGOLYIPXIYRHB-GMAHTHKFSA-N 0.000 description 3
- TWFPKMOCRPTABZ-ZETCQYMHSA-N methyl (2s)-2-[5-(bromomethyl)-2-chlorophenoxy]propanoate Chemical compound COC(=O)[C@H](C)OC1=CC(CBr)=CC=C1Cl TWFPKMOCRPTABZ-ZETCQYMHSA-N 0.000 description 3
- RQUJUDCQUMPCBH-GMAHTHKFSA-N methyl (2s)-2-[5-[[5-[[(1s)-1-(4-tert-butylphenyl)ethyl]carbamoyl]-2,3-dimethylindol-1-yl]methyl]-2-chlorophenoxy]propanoate Chemical compound C1=C(Cl)C(O[C@@H](C)C(=O)OC)=CC(CN2C3=CC=C(C=C3C(C)=C2C)C(=O)N[C@@H](C)C=2C=CC(=CC=2)C(C)(C)C)=C1 RQUJUDCQUMPCBH-GMAHTHKFSA-N 0.000 description 3
- VDKNOCBCIJGIOC-UHFFFAOYSA-N methyl 1-(4-methylphenyl)cyclopropane-1-carboxylate Chemical compound C=1C=C(C)C=CC=1C1(C(=O)OC)CC1 VDKNOCBCIJGIOC-UHFFFAOYSA-N 0.000 description 3
- 150000007522 mineralic acids Chemical class 0.000 description 3
- PANRSVKVNLUZCW-QFIPXVFZSA-N n-[(1s)-1-(4-bromophenyl)ethyl]-1-[[4-(2-cyanophenyl)phenyl]methyl]-2,3-dimethylindole-5-carboxamide Chemical compound N([C@@H](C)C=1C=CC(Br)=CC=1)C(=O)C(C=C1C(C)=C2C)=CC=C1N2CC(C=C1)=CC=C1C1=CC=CC=C1C#N PANRSVKVNLUZCW-QFIPXVFZSA-N 0.000 description 3
- 125000001624 naphthyl group Chemical group 0.000 description 3
- 125000002868 norbornyl group Chemical group C12(CCC(CC1)C2)* 0.000 description 3
- 229960002378 oftasceine Drugs 0.000 description 3
- 125000002971 oxazolyl group Chemical group 0.000 description 3
- YJVFFLUZDVXJQI-UHFFFAOYSA-L palladium(ii) acetate Chemical compound [Pd+2].CC([O-])=O.CC([O-])=O YJVFFLUZDVXJQI-UHFFFAOYSA-L 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- 230000003389 potentiating effect Effects 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 125000003226 pyrazolyl group Chemical group 0.000 description 3
- 125000004076 pyridyl group Chemical group 0.000 description 3
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 3
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- JQWHASGSAFIOCM-UHFFFAOYSA-M sodium periodate Chemical compound [Na+].[O-]I(=O)(=O)=O JQWHASGSAFIOCM-UHFFFAOYSA-M 0.000 description 3
- 239000012453 solvate Substances 0.000 description 3
- 125000005346 substituted cycloalkyl group Chemical group 0.000 description 3
- OWEDFWZJRNPJIV-UHFFFAOYSA-N tert-butyl 2-(4-methylphenyl)benzoate Chemical compound C1=CC(C)=CC=C1C1=CC=CC=C1C(=O)OC(C)(C)C OWEDFWZJRNPJIV-UHFFFAOYSA-N 0.000 description 3
- BOGZTHARHNVNQP-UHFFFAOYSA-N tert-butyl 2-[4-[[5-[1-(5-bromopyridin-3-yl)ethylcarbamoyl]-2,3-dimethylindol-1-yl]methyl]phenyl]benzoate Chemical compound C=1N=CC(Br)=CC=1C(C)NC(=O)C(C=C1C(C)=C2C)=CC=C1N2CC(C=C1)=CC=C1C1=CC=CC=C1C(=O)OC(C)(C)C BOGZTHARHNVNQP-UHFFFAOYSA-N 0.000 description 3
- ZELNHJFYEDOWLF-UHFFFAOYSA-N tert-butyl 2-bromobenzoate Chemical compound CC(C)(C)OC(=O)C1=CC=CC=C1Br ZELNHJFYEDOWLF-UHFFFAOYSA-N 0.000 description 3
- LSUBZBQILHVMFO-QHCPKHFHSA-N tert-butyl 3-[4-[[5-[[(1s)-1-(4-nitrophenyl)ethyl]carbamoyl]indol-1-yl]methyl]phenyl]benzoate Chemical compound N([C@@H](C)C=1C=CC(=CC=1)[N+]([O-])=O)C(=O)C(C=C1C=C2)=CC=C1N2CC(C=C1)=CC=C1C1=CC=CC(C(=O)OC(C)(C)C)=C1 LSUBZBQILHVMFO-QHCPKHFHSA-N 0.000 description 3
- 125000001544 thienyl group Chemical group 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 125000001425 triazolyl group Chemical group 0.000 description 3
- WLPUWLXVBWGYMZ-UHFFFAOYSA-N tricyclohexylphosphine Chemical compound C1CCCCC1P(C1CCCCC1)C1CCCCC1 WLPUWLXVBWGYMZ-UHFFFAOYSA-N 0.000 description 3
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 3
- DTGKSKDOIYIVQL-WEDXCCLWSA-N (+)-borneol Chemical group C1C[C@@]2(C)[C@@H](O)C[C@@H]1C2(C)C DTGKSKDOIYIVQL-WEDXCCLWSA-N 0.000 description 2
- VCGRFBXVSFAGGA-UHFFFAOYSA-N (1,1-dioxo-1,4-thiazinan-4-yl)-[6-[[3-(4-fluorophenyl)-5-methyl-1,2-oxazol-4-yl]methoxy]pyridin-3-yl]methanone Chemical compound CC=1ON=C(C=2C=CC(F)=CC=2)C=1COC(N=C1)=CC=C1C(=O)N1CCS(=O)(=O)CC1 VCGRFBXVSFAGGA-UHFFFAOYSA-N 0.000 description 2
- CZJMQTZQSNUDNV-RXMQYKEDSA-N (1r)-1-(2,3-dichlorophenyl)ethanamine Chemical compound C[C@@H](N)C1=CC=CC(Cl)=C1Cl CZJMQTZQSNUDNV-RXMQYKEDSA-N 0.000 description 2
- NRWOZHOHRZOVDA-RXMQYKEDSA-N (1r)-1-(2,6-dichlorophenyl)ethanamine Chemical compound C[C@@H](N)C1=C(Cl)C=CC=C1Cl NRWOZHOHRZOVDA-RXMQYKEDSA-N 0.000 description 2
- LIBZHYLTOAGURM-ZCFIWIBFSA-N (1r)-1-(3-bromophenyl)ethanamine Chemical compound C[C@@H](N)C1=CC=CC(Br)=C1 LIBZHYLTOAGURM-ZCFIWIBFSA-N 0.000 description 2
- SOZMSEPDYJGBEK-ZCFIWIBFSA-N (1r)-1-(4-bromophenyl)ethanamine Chemical compound C[C@@H](N)C1=CC=C(Br)C=C1 SOZMSEPDYJGBEK-ZCFIWIBFSA-N 0.000 description 2
- PQHSMXKHCFVFQT-RXMQYKEDSA-N (1r)-1-[2,5-bis(trifluoromethyl)phenyl]ethanamine Chemical compound C[C@@H](N)C1=CC(C(F)(F)F)=CC=C1C(F)(F)F PQHSMXKHCFVFQT-RXMQYKEDSA-N 0.000 description 2
- HIZMJYQEHFJWQY-ZCFIWIBFSA-N (1r)-1-pyridin-4-ylethanamine Chemical compound C[C@@H](N)C1=CC=NC=C1 HIZMJYQEHFJWQY-ZCFIWIBFSA-N 0.000 description 2
- RFPFJPRJGSDGAG-MRVPVSSYSA-N (1r)-1-quinolin-4-ylethanamine Chemical compound C1=CC=C2C([C@H](N)C)=CC=NC2=C1 RFPFJPRJGSDGAG-MRVPVSSYSA-N 0.000 description 2
- JKABBFAHXOOSNQ-LURJTMIESA-N (1s)-1-(1,3-benzodioxol-4-yl)ethanamine Chemical compound C[C@H](N)C1=CC=CC2=C1OCO2 JKABBFAHXOOSNQ-LURJTMIESA-N 0.000 description 2
- VBPKWFKAYDHOQW-YFKPBYRVSA-N (1s)-1-(2,4-difluorophenyl)ethanamine Chemical compound C[C@H](N)C1=CC=C(F)C=C1F VBPKWFKAYDHOQW-YFKPBYRVSA-N 0.000 description 2
- NRWOZHOHRZOVDA-YFKPBYRVSA-N (1s)-1-(2,6-dichlorophenyl)ethanamine Chemical compound C[C@H](N)C1=C(Cl)C=CC=C1Cl NRWOZHOHRZOVDA-YFKPBYRVSA-N 0.000 description 2
- QRBWBDQDDUSRKD-JEDNCBNOSA-N (1s)-1-(2-bromopyridin-4-yl)ethanamine;hydrochloride Chemical compound Cl.C[C@H](N)C1=CC=NC(Br)=C1 QRBWBDQDDUSRKD-JEDNCBNOSA-N 0.000 description 2
- QRNVGMYCAUROPJ-YFKPBYRVSA-N (1s)-1-(2-chloro-3-fluorophenyl)ethanamine Chemical compound C[C@H](N)C1=CC=CC(F)=C1Cl QRNVGMYCAUROPJ-YFKPBYRVSA-N 0.000 description 2
- DIWHJJUFVGEXGS-LURJTMIESA-N (1s)-1-(2-fluorophenyl)ethanamine Chemical compound C[C@H](N)C1=CC=CC=C1F DIWHJJUFVGEXGS-LURJTMIESA-N 0.000 description 2
- VENQOHAPVLVQKV-ZETCQYMHSA-N (1s)-1-(2-methoxyphenyl)ethanamine Chemical compound COC1=CC=CC=C1[C@H](C)N VENQOHAPVLVQKV-ZETCQYMHSA-N 0.000 description 2
- LIBZHYLTOAGURM-LURJTMIESA-N (1s)-1-(3-bromophenyl)ethanamine Chemical compound C[C@H](N)C1=CC=CC(Br)=C1 LIBZHYLTOAGURM-LURJTMIESA-N 0.000 description 2
- RKPIAZZODCNIEH-YFKPBYRVSA-N (1s)-1-(3-chloropyridin-4-yl)ethanamine Chemical compound C[C@H](N)C1=CC=NC=C1Cl RKPIAZZODCNIEH-YFKPBYRVSA-N 0.000 description 2
- XKDDLSQQLGMSCP-LURJTMIESA-N (1s)-1-(3-fluoro-2-methoxyphenyl)ethanamine Chemical compound COC1=C(F)C=CC=C1[C@H](C)N XKDDLSQQLGMSCP-LURJTMIESA-N 0.000 description 2
- UZDDXUMOXKDXNE-QMMMGPOBSA-N (1s)-1-(4-methylphenyl)ethanamine Chemical compound C[C@H](N)C1=CC=C(C)C=C1 UZDDXUMOXKDXNE-QMMMGPOBSA-N 0.000 description 2
- KSGKDUJWJNDXCO-JEDNCBNOSA-N (1s)-1-(5-bromopyridin-2-yl)ethanamine;hydrochloride Chemical compound Cl.C[C@H](N)C1=CC=C(Br)C=N1 KSGKDUJWJNDXCO-JEDNCBNOSA-N 0.000 description 2
- PQHSMXKHCFVFQT-YFKPBYRVSA-N (1s)-1-[2,5-bis(trifluoromethyl)phenyl]ethanamine Chemical compound C[C@H](N)C1=CC(C(F)(F)F)=CC=C1C(F)(F)F PQHSMXKHCFVFQT-YFKPBYRVSA-N 0.000 description 2
- VTLIABOHZPSHRN-LURJTMIESA-N (1s)-1-[4-(trifluoromethoxy)phenyl]ethanamine Chemical compound C[C@H](N)C1=CC=C(OC(F)(F)F)C=C1 VTLIABOHZPSHRN-LURJTMIESA-N 0.000 description 2
- XKOCACARIDJWFH-JEDNCBNOSA-N (1s)-1-[5-fluoro-2-(trifluoromethyl)phenyl]ethanamine;hydrochloride Chemical compound Cl.C[C@H](N)C1=CC(F)=CC=C1C(F)(F)F XKOCACARIDJWFH-JEDNCBNOSA-N 0.000 description 2
- RTCUCQWIICFPOD-VIFPVBQESA-N (1s)-1-naphthalen-1-ylethanamine Chemical compound C1=CC=C2C([C@@H](N)C)=CC=CC2=C1 RTCUCQWIICFPOD-VIFPVBQESA-N 0.000 description 2
- PDNHLCRMUIGNBV-LURJTMIESA-N (1s)-1-pyridin-2-ylethanamine Chemical compound C[C@H](N)C1=CC=CC=N1 PDNHLCRMUIGNBV-LURJTMIESA-N 0.000 description 2
- RFPFJPRJGSDGAG-QMMMGPOBSA-N (1s)-1-quinolin-4-ylethanamine Chemical compound C1=CC=C2C([C@@H](N)C)=CC=NC2=C1 RFPFJPRJGSDGAG-QMMMGPOBSA-N 0.000 description 2
- RWYOYHXWFBRYST-AWEZNQCLSA-N (1s)-3-methyl-1-(3-propan-2-ylphenyl)butan-1-amine Chemical compound CC(C)C[C@H](N)C1=CC=CC(C(C)C)=C1 RWYOYHXWFBRYST-AWEZNQCLSA-N 0.000 description 2
- ZUJXXSVILIUQJX-RBBKRZOGSA-N (2r)-2-[2-chloro-3-[[2,3-dimethyl-5-[[(1s)-1-(3-propan-2-ylphenyl)ethyl]carbamoyl]indol-1-yl]methyl]phenoxy]propanoic acid Chemical compound CC(C)C1=CC=CC([C@H](C)NC(=O)C=2C=C3C(C)=C(C)N(CC=4C(=C(O[C@H](C)C(O)=O)C=CC=4)Cl)C3=CC=2)=C1 ZUJXXSVILIUQJX-RBBKRZOGSA-N 0.000 description 2
- LQPQGEPIEWXGPX-RBBKRZOGSA-N (2r)-2-[2-chloro-4-[[2,3-dimethyl-5-[[(1s)-1-(3-propan-2-ylphenyl)ethyl]carbamoyl]indol-1-yl]methyl]phenoxy]propanoic acid Chemical compound CC(C)C1=CC=CC([C@H](C)NC(=O)C=2C=C3C(C)=C(C)N(CC=4C=C(Cl)C(O[C@H](C)C(O)=O)=CC=4)C3=CC=2)=C1 LQPQGEPIEWXGPX-RBBKRZOGSA-N 0.000 description 2
- PFXHVFGUBJDVRN-GHRAFVERSA-N (2r)-2-[2-chloro-5-[[2,3-dimethyl-5-[[(1s)-1-(3-propan-2-ylphenyl)ethyl]carbamoyl]indol-1-yl]methyl]phenoxy]-3-methylbutanoic acid Chemical compound C1=C(Cl)C(O[C@H](C(C)C)C(O)=O)=CC(CN2C3=CC=C(C=C3C(C)=C2C)C(=O)N[C@@H](C)C=2C=C(C=CC=2)C(C)C)=C1 PFXHVFGUBJDVRN-GHRAFVERSA-N 0.000 description 2
- MYFQOZRGLFJCSB-URAOTHONSA-N (2r)-2-[2-chloro-5-[[2,3-dimethyl-5-[[(1s)-1-(3-propan-2-ylphenyl)ethyl]carbamoyl]indol-1-yl]methyl]phenoxy]butanoic acid Chemical compound C1=C(Cl)C(O[C@H](CC)C(O)=O)=CC(CN2C3=CC=C(C=C3C(C)=C2C)C(=O)N[C@@H](C)C=2C=C(C=CC=2)C(C)C)=C1 MYFQOZRGLFJCSB-URAOTHONSA-N 0.000 description 2
- SJCVXAOIEVAKQO-RBBKRZOGSA-N (2r)-2-[2-chloro-5-[[2,3-dimethyl-5-[[(1s)-1-(3-propan-2-ylphenyl)ethyl]carbamoyl]indol-1-yl]methyl]phenoxy]propanoic acid Chemical compound CC(C)C1=CC=CC([C@H](C)NC(=O)C=2C=C3C(C)=C(C)N(CC=4C=C(O[C@H](C)C(O)=O)C(Cl)=CC=4)C3=CC=2)=C1 SJCVXAOIEVAKQO-RBBKRZOGSA-N 0.000 description 2
- MWRHNILRGUSXPA-JPQMRUPTSA-N (2r)-2-[3-[[2,3-dimethyl-5-[[(1s)-1-(3-propan-2-ylphenyl)ethyl]carbamoyl]indol-1-yl]methyl]phenoxy]-3-methylbutanoic acid Chemical compound CC(C)[C@H](C(O)=O)OC1=CC=CC(CN2C3=CC=C(C=C3C(C)=C2C)C(=O)N[C@@H](C)C=2C=C(C=CC=2)C(C)C)=C1 MWRHNILRGUSXPA-JPQMRUPTSA-N 0.000 description 2
- MOXVLFXJLQXGEU-WKRVVKTRSA-N (2r)-2-[3-[[2,3-dimethyl-5-[[(1s)-1-(3-propan-2-ylphenyl)ethyl]carbamoyl]indol-1-yl]methyl]phenoxy]butanoic acid Chemical compound CC[C@H](C(O)=O)OC1=CC=CC(CN2C3=CC=C(C=C3C(C)=C2C)C(=O)N[C@@H](C)C=2C=C(C=CC=2)C(C)C)=C1 MOXVLFXJLQXGEU-WKRVVKTRSA-N 0.000 description 2
- HJSFJKFQTHNUFG-JTHBVZDNSA-N (2r)-2-[3-[[2,3-dimethyl-5-[[(1s)-1-(3-propan-2-ylphenyl)ethyl]carbamoyl]indol-1-yl]methyl]phenoxy]propanoic acid Chemical compound CC(C)C1=CC=CC([C@H](C)NC(=O)C=2C=C3C(C)=C(C)N(CC=4C=C(O[C@H](C)C(O)=O)C=CC=4)C3=CC=2)=C1 HJSFJKFQTHNUFG-JTHBVZDNSA-N 0.000 description 2
- ROQFGMFKGGEJAT-JTHBVZDNSA-N (2r)-2-[3-[[5-[[(1s)-1-(4-tert-butylphenyl)ethyl]carbamoyl]-2,3-dimethylindol-1-yl]methyl]phenoxy]propanoic acid Chemical compound OC(=O)[C@@H](C)OC1=CC=CC(CN2C3=CC=C(C=C3C(C)=C2C)C(=O)N[C@@H](C)C=2C=CC(=CC=2)C(C)(C)C)=C1 ROQFGMFKGGEJAT-JTHBVZDNSA-N 0.000 description 2
- RVIJBMBTKSUPHI-RBBKRZOGSA-N (2r)-2-[3-chloro-5-[[2,3-dimethyl-5-[[(1s)-1-(3-propan-2-ylphenyl)ethyl]carbamoyl]indol-1-yl]methyl]phenoxy]propanoic acid Chemical compound CC(C)C1=CC=CC([C@H](C)NC(=O)C=2C=C3C(C)=C(C)N(CC=4C=C(O[C@H](C)C(O)=O)C=C(Cl)C=4)C3=CC=2)=C1 RVIJBMBTKSUPHI-RBBKRZOGSA-N 0.000 description 2
- RDTDCRAUIFCXOV-GHRAFVERSA-N (2r)-2-[4-chloro-3-[[2,3-dimethyl-5-[[(1s)-1-(3-propan-2-ylphenyl)ethyl]carbamoyl]indol-1-yl]methyl]phenoxy]-3-methylbutanoic acid Chemical compound CC(C)[C@H](C(O)=O)OC1=CC=C(Cl)C(CN2C3=CC=C(C=C3C(C)=C2C)C(=O)N[C@@H](C)C=2C=C(C=CC=2)C(C)C)=C1 RDTDCRAUIFCXOV-GHRAFVERSA-N 0.000 description 2
- JPSDGIKDMKUJDZ-JCOAXYOVSA-N (2r)-2-[4-chloro-3-[[2,3-dimethyl-5-[[(1s)-1-(3-propan-2-ylphenyl)ethyl]carbamoyl]indol-1-yl]methyl]phenoxy]butanoic acid Chemical compound CC[C@H](C(O)=O)OC1=CC=C(Cl)C(CN2C3=CC=C(C=C3C(C)=C2C)C(=O)N[C@@H](C)C=2C=C(C=CC=2)C(C)C)=C1 JPSDGIKDMKUJDZ-JCOAXYOVSA-N 0.000 description 2
- ZUJXXSVILIUQJX-UNMCSNQZSA-N (2s)-2-[2-chloro-3-[[2,3-dimethyl-5-[[(1s)-1-(3-propan-2-ylphenyl)ethyl]carbamoyl]indol-1-yl]methyl]phenoxy]propanoic acid Chemical compound CC(C)C1=CC=CC([C@H](C)NC(=O)C=2C=C3C(C)=C(C)N(CC=4C(=C(O[C@@H](C)C(O)=O)C=CC=4)Cl)C3=CC=2)=C1 ZUJXXSVILIUQJX-UNMCSNQZSA-N 0.000 description 2
- LQPQGEPIEWXGPX-UNMCSNQZSA-N (2s)-2-[2-chloro-4-[[2,3-dimethyl-5-[[(1s)-1-(3-propan-2-ylphenyl)ethyl]carbamoyl]indol-1-yl]methyl]phenoxy]propanoic acid Chemical compound CC(C)C1=CC=CC([C@H](C)NC(=O)C=2C=C3C(C)=C(C)N(CC=4C=C(Cl)C(O[C@@H](C)C(O)=O)=CC=4)C3=CC=2)=C1 LQPQGEPIEWXGPX-UNMCSNQZSA-N 0.000 description 2
- RUTFUHSPYBUOSP-UNMCSNQZSA-N (2s)-2-[2-chloro-5-[[2,3-dimethyl-5-[[(1s)-1-(3-propan-2-yloxyphenyl)ethyl]carbamoyl]indol-1-yl]methyl]phenoxy]propanoic acid Chemical compound CC(C)OC1=CC=CC([C@H](C)NC(=O)C=2C=C3C(C)=C(C)N(CC=4C=C(O[C@@H](C)C(O)=O)C(Cl)=CC=4)C3=CC=2)=C1 RUTFUHSPYBUOSP-UNMCSNQZSA-N 0.000 description 2
- PFXHVFGUBJDVRN-ICACTRECSA-N (2s)-2-[2-chloro-5-[[2,3-dimethyl-5-[[(1s)-1-(3-propan-2-ylphenyl)ethyl]carbamoyl]indol-1-yl]methyl]phenoxy]-3-methylbutanoic acid Chemical compound C1=C(Cl)C(O[C@@H](C(C)C)C(O)=O)=CC(CN2C3=CC=C(C=C3C(C)=C2C)C(=O)N[C@@H](C)C=2C=C(C=CC=2)C(C)C)=C1 PFXHVFGUBJDVRN-ICACTRECSA-N 0.000 description 2
- MYFQOZRGLFJCSB-JRPXNJEYSA-N (2s)-2-[2-chloro-5-[[2,3-dimethyl-5-[[(1s)-1-(3-propan-2-ylphenyl)ethyl]carbamoyl]indol-1-yl]methyl]phenoxy]butanoic acid Chemical compound C1=C(Cl)C(O[C@@H](CC)C(O)=O)=CC(CN2C3=CC=C(C=C3C(C)=C2C)C(=O)N[C@@H](C)C=2C=C(C=CC=2)C(C)C)=C1 MYFQOZRGLFJCSB-JRPXNJEYSA-N 0.000 description 2
- SJCVXAOIEVAKQO-UNMCSNQZSA-N (2s)-2-[2-chloro-5-[[2,3-dimethyl-5-[[(1s)-1-(3-propan-2-ylphenyl)ethyl]carbamoyl]indol-1-yl]methyl]phenoxy]propanoic acid Chemical compound CC(C)C1=CC=CC([C@H](C)NC(=O)C=2C=C3C(C)=C(C)N(CC=4C=C(O[C@@H](C)C(O)=O)C(Cl)=CC=4)C3=CC=2)=C1 SJCVXAOIEVAKQO-UNMCSNQZSA-N 0.000 description 2
- LVDWBOOOLXZMRO-SLNZLALYSA-N (2s)-2-[3-[1-[5-[[(1s)-1-(3-cyclopropylphenyl)ethyl]carbamoyl]-2,3-dimethylindol-1-yl]ethyl]phenoxy]propanoic acid Chemical compound OC(=O)[C@H](C)OC1=CC=CC(C(C)N2C3=CC=C(C=C3C(C)=C2C)C(=O)N[C@@H](C)C=2C=C(C=CC=2)C2CC2)=C1 LVDWBOOOLXZMRO-SLNZLALYSA-N 0.000 description 2
- OFCWBJAYEIROGZ-KRWDZBQOSA-N (2s)-2-[3-[[1-(4-methoxybenzoyl)-2-methyl-5-(trifluoromethoxy)indol-3-yl]methyl]phenoxy]propanoic acid Chemical compound C1=CC(OC)=CC=C1C(=O)N1C2=CC=C(OC(F)(F)F)C=C2C(CC=2C=C(O[C@@H](C)C(O)=O)C=CC=2)=C1C OFCWBJAYEIROGZ-KRWDZBQOSA-N 0.000 description 2
- IPLSLZRTFNLNCC-GMAHTHKFSA-N (2s)-2-[3-[[2,3-dimethyl-5-[[(1s)-1-(3-propan-2-yloxyphenyl)ethyl]carbamoyl]indol-1-yl]methyl]phenoxy]propanoic acid Chemical compound CC(C)OC1=CC=CC([C@H](C)NC(=O)C=2C=C3C(C)=C(C)N(CC=4C=C(O[C@@H](C)C(O)=O)C=CC=4)C3=CC=2)=C1 IPLSLZRTFNLNCC-GMAHTHKFSA-N 0.000 description 2
- MOXVLFXJLQXGEU-UGDMGKLASA-N (2s)-2-[3-[[2,3-dimethyl-5-[[(1s)-1-(3-propan-2-ylphenyl)ethyl]carbamoyl]indol-1-yl]methyl]phenoxy]butanoic acid Chemical compound CC[C@@H](C(O)=O)OC1=CC=CC(CN2C3=CC=C(C=C3C(C)=C2C)C(=O)N[C@@H](C)C=2C=C(C=CC=2)C(C)C)=C1 MOXVLFXJLQXGEU-UGDMGKLASA-N 0.000 description 2
- HJSFJKFQTHNUFG-GMAHTHKFSA-N (2s)-2-[3-[[2,3-dimethyl-5-[[(1s)-1-(3-propan-2-ylphenyl)ethyl]carbamoyl]indol-1-yl]methyl]phenoxy]propanoic acid Chemical compound CC(C)C1=CC=CC([C@H](C)NC(=O)C=2C=C3C(C)=C(C)N(CC=4C=C(O[C@@H](C)C(O)=O)C=CC=4)C3=CC=2)=C1 HJSFJKFQTHNUFG-GMAHTHKFSA-N 0.000 description 2
- ANVYTPGEGUKCJH-UNMCSNQZSA-N (2s)-2-[3-[[5-[[(1s)-1-(3-cyclopropylphenyl)ethyl]carbamoyl]-2,3-dimethylindol-1-yl]methyl]phenoxy]propanoic acid Chemical compound N([C@@H](C)C=1C=C(C=CC=1)C1CC1)C(=O)C(C=C1C(C)=C2C)=CC=C1N2CC1=CC=CC(O[C@@H](C)C(O)=O)=C1 ANVYTPGEGUKCJH-UNMCSNQZSA-N 0.000 description 2
- BOOVJQGXQIGBIS-UNMCSNQZSA-N (2s)-2-[3-[[5-[[(1s)-1-(3-tert-butylphenyl)ethyl]carbamoyl]-2,3-dimethylindol-1-yl]methyl]-4-chlorophenoxy]propanoic acid Chemical compound N([C@@H](C)C=1C=C(C=CC=1)C(C)(C)C)C(=O)C(C=C1C(C)=C2C)=CC=C1N2CC1=CC(O[C@@H](C)C(O)=O)=CC=C1Cl BOOVJQGXQIGBIS-UNMCSNQZSA-N 0.000 description 2
- WNXAXNUAJHPMKZ-UNMCSNQZSA-N (2s)-2-[3-chloro-4-[[2,3-dimethyl-5-[[(1s)-1-(3-propan-2-ylphenyl)ethyl]carbamoyl]indol-1-yl]methyl]phenoxy]propanoic acid Chemical compound CC(C)C1=CC=CC([C@H](C)NC(=O)C=2C=C3C(C)=C(C)N(CC=4C(=CC(O[C@@H](C)C(O)=O)=CC=4)Cl)C3=CC=2)=C1 WNXAXNUAJHPMKZ-UNMCSNQZSA-N 0.000 description 2
- RVIJBMBTKSUPHI-UNMCSNQZSA-N (2s)-2-[3-chloro-5-[[2,3-dimethyl-5-[[(1s)-1-(3-propan-2-ylphenyl)ethyl]carbamoyl]indol-1-yl]methyl]phenoxy]propanoic acid Chemical compound CC(C)C1=CC=CC([C@H](C)NC(=O)C=2C=C3C(C)=C(C)N(CC=4C=C(O[C@@H](C)C(O)=O)C=C(Cl)C=4)C3=CC=2)=C1 RVIJBMBTKSUPHI-UNMCSNQZSA-N 0.000 description 2
- FUBUVTKQKUDPSS-LMOFDZDWSA-N (2s)-2-[4-[1-[5-[[(1s)-1-(4-tert-butylphenyl)ethyl]carbamoyl]-2,3-dimethylindol-1-yl]ethyl]phenoxy]propanoic acid Chemical compound C1=CC(O[C@@H](C)C(O)=O)=CC=C1C(C)N1C2=CC=C(C(=O)N[C@@H](C)C=3C=CC(=CC=3)C(C)(C)C)C=C2C(C)=C1C FUBUVTKQKUDPSS-LMOFDZDWSA-N 0.000 description 2
- UICJTHIHKDYHEI-UNMCSNQZSA-N (2s)-2-[4-[[5-[[(1s)-1-(3-cyclopropylphenyl)ethyl]carbamoyl]-2,3-dimethylindol-1-yl]methyl]phenoxy]propanoic acid Chemical compound N([C@@H](C)C=1C=C(C=CC=1)C1CC1)C(=O)C(C=C1C(C)=C2C)=CC=C1N2CC1=CC=C(O[C@@H](C)C(O)=O)C=C1 UICJTHIHKDYHEI-UNMCSNQZSA-N 0.000 description 2
- KFKVWMMNAJUTDT-UNMCSNQZSA-N (2s)-2-[4-chloro-3-[[2,3-dimethyl-5-[[(1s)-1-(3-propan-2-yloxyphenyl)ethyl]carbamoyl]indol-1-yl]methyl]phenoxy]propanoic acid Chemical compound CC(C)OC1=CC=CC([C@H](C)NC(=O)C=2C=C3C(C)=C(C)N(CC=4C(=CC=C(O[C@@H](C)C(O)=O)C=4)Cl)C3=CC=2)=C1 KFKVWMMNAJUTDT-UNMCSNQZSA-N 0.000 description 2
- RDTDCRAUIFCXOV-ICACTRECSA-N (2s)-2-[4-chloro-3-[[2,3-dimethyl-5-[[(1s)-1-(3-propan-2-ylphenyl)ethyl]carbamoyl]indol-1-yl]methyl]phenoxy]-3-methylbutanoic acid Chemical compound CC(C)[C@@H](C(O)=O)OC1=CC=C(Cl)C(CN2C3=CC=C(C=C3C(C)=C2C)C(=O)N[C@@H](C)C=2C=C(C=CC=2)C(C)C)=C1 RDTDCRAUIFCXOV-ICACTRECSA-N 0.000 description 2
- JPSDGIKDMKUJDZ-BGOLNKOXSA-N (2s)-2-[4-chloro-3-[[2,3-dimethyl-5-[[(1s)-1-(3-propan-2-ylphenyl)ethyl]carbamoyl]indol-1-yl]methyl]phenoxy]butanoic acid Chemical compound CC[C@@H](C(O)=O)OC1=CC=C(Cl)C(CN2C3=CC=C(C=C3C(C)=C2C)C(=O)N[C@@H](C)C=2C=C(C=CC=2)C(C)C)=C1 JPSDGIKDMKUJDZ-BGOLNKOXSA-N 0.000 description 2
- RBPPDBMDXPPKBU-UNMCSNQZSA-N (2s)-2-[4-chloro-3-[[2,3-dimethyl-5-[[(1s)-1-(3-propan-2-ylphenyl)ethyl]carbamoyl]indol-1-yl]methyl]phenoxy]propanoic acid Chemical compound CC(C)C1=CC=CC([C@H](C)NC(=O)C=2C=C3C(C)=C(C)N(CC=4C(=CC=C(O[C@@H](C)C(O)=O)C=4)Cl)C3=CC=2)=C1 RBPPDBMDXPPKBU-UNMCSNQZSA-N 0.000 description 2
- KRXDIBIZFQXWGE-UNMCSNQZSA-N (2s)-2-[5-[[5-[[(1s)-1-(3-tert-butylphenyl)ethyl]carbamoyl]-2,3-dimethylindol-1-yl]methyl]-2-chlorophenoxy]propanoic acid Chemical compound N([C@@H](C)C=1C=C(C=CC=1)C(C)(C)C)C(=O)C(C=C1C(C)=C2C)=CC=C1N2CC1=CC=C(Cl)C(O[C@@H](C)C(O)=O)=C1 KRXDIBIZFQXWGE-UNMCSNQZSA-N 0.000 description 2
- DIVNUTGTTIRPQA-UHFFFAOYSA-N (3,4-dimethoxyphenyl)methanamine Chemical compound COC1=CC=C(CN)C=C1OC DIVNUTGTTIRPQA-UHFFFAOYSA-N 0.000 description 2
- ANMYMLIUCWWISO-UHFFFAOYSA-N (4-ethylphenyl) acetate Chemical compound CCC1=CC=C(OC(C)=O)C=C1 ANMYMLIUCWWISO-UHFFFAOYSA-N 0.000 description 2
- IIFVWLUQBAIPMJ-UHFFFAOYSA-N (4-fluorophenyl)methanamine Chemical compound NCC1=CC=C(F)C=C1 IIFVWLUQBAIPMJ-UHFFFAOYSA-N 0.000 description 2
- BIWQNIMLAISTBV-UHFFFAOYSA-N (4-methylphenyl)boronic acid Chemical compound CC1=CC=C(B(O)O)C=C1 BIWQNIMLAISTBV-UHFFFAOYSA-N 0.000 description 2
- CCOPOAICKTXTQZ-OBHPCNEJSA-N (ne)-2-methyl-n-[(3-propan-2-ylphenyl)methylidene]propane-2-sulfinamide Chemical compound CC(C)C1=CC=CC(\C=N\[S@@](=O)C(C)(C)C)=C1 CCOPOAICKTXTQZ-OBHPCNEJSA-N 0.000 description 2
- AFELCFFDKRTCHL-UHFFFAOYSA-N 1-(3-methylphenyl)cyclopropane-1-carbonitrile Chemical compound CC1=CC=CC(C2(CC2)C#N)=C1 AFELCFFDKRTCHL-UHFFFAOYSA-N 0.000 description 2
- IBLMYGXJKQIGSN-UHFFFAOYSA-N 1-(bromomethyl)-2,4-difluorobenzene Chemical compound FC1=CC=C(CBr)C(F)=C1 IBLMYGXJKQIGSN-UHFFFAOYSA-N 0.000 description 2
- BLRMZPQNLCVHEV-UHFFFAOYSA-N 1-[(2,4-difluorophenyl)methyl]-2,3-dimethyl-n-(1-phenylpropyl)indole-5-carboxamide Chemical compound C=1C=CC=CC=1C(CC)NC(=O)C(C=C1C(C)=C2C)=CC=C1N2CC1=CC=C(F)C=C1F BLRMZPQNLCVHEV-UHFFFAOYSA-N 0.000 description 2
- DLLSNNOUNYZZGT-UHFFFAOYSA-N 1-[(2,4-difluorophenyl)methyl]-2,3-dimethylindole-5-carboxylic acid Chemical compound CC1=C(C)C2=CC(C(O)=O)=CC=C2N1CC1=CC=C(F)C=C1F DLLSNNOUNYZZGT-UHFFFAOYSA-N 0.000 description 2
- LBIUFFPIGSGAGA-UHFFFAOYSA-N 1-[(2,4-difluorophenyl)methyl]-n-[(2,4-dimethoxyphenyl)methyl]indole-5-carboxamide Chemical compound COC1=CC(OC)=CC=C1CNC(=O)C1=CC=C(N(CC=2C(=CC(F)=CC=2)F)C=C2)C2=C1 LBIUFFPIGSGAGA-UHFFFAOYSA-N 0.000 description 2
- TXNCYVWUWWUHOS-UHFFFAOYSA-N 1-[(2-bromophenyl)methyl]indole-5-carboxylic acid Chemical compound C1=CC2=CC(C(=O)O)=CC=C2N1CC1=CC=CC=C1Br TXNCYVWUWWUHOS-UHFFFAOYSA-N 0.000 description 2
- VMTVFBCVCVDVOS-UHFFFAOYSA-N 1-[(3-bromophenyl)methyl]-2,3-dimethylindole-5-carboxylic acid Chemical compound CC1=C(C)C2=CC(C(O)=O)=CC=C2N1CC1=CC=CC(Br)=C1 VMTVFBCVCVDVOS-UHFFFAOYSA-N 0.000 description 2
- BYVMVYRUJKWYFS-UHFFFAOYSA-N 1-[(3-methoxycarbonylphenyl)methyl]-2,3-dimethylindole-5-carboxylic acid Chemical compound COC(=O)C1=CC=CC(CN2C3=CC=C(C=C3C(C)=C2C)C(O)=O)=C1 BYVMVYRUJKWYFS-UHFFFAOYSA-N 0.000 description 2
- MLBYUONHQISETN-LYKKTTPLSA-N 1-[1-[4-[(2s)-1-methoxy-1-oxopropan-2-yl]oxyphenyl]ethyl]-2,3-dimethylindole-5-carboxylic acid Chemical compound C1=CC(O[C@@H](C)C(=O)OC)=CC=C1C(C)N1C2=CC=C(C(O)=O)C=C2C(C)=C1C MLBYUONHQISETN-LYKKTTPLSA-N 0.000 description 2
- HQLLQQJPHUJXBC-UHFFFAOYSA-N 1-[3-(bromomethyl)phenyl]cyclopropane-1-carbonitrile Chemical compound BrCC1=CC=CC(C2(CC2)C#N)=C1 HQLLQQJPHUJXBC-UHFFFAOYSA-N 0.000 description 2
- BKVYSZWMHVHMRG-NRFANRHFSA-N 1-[3-[[5-[[(1s)-1-(3-cyclopropylphenyl)ethyl]carbamoyl]-2,3-dimethylindol-1-yl]methyl]phenyl]cyclopropane-1-carboxylic acid Chemical compound N([C@@H](C)C=1C=C(C=CC=1)C1CC1)C(=O)C(C=C1C(C)=C2C)=CC=C1N2CC(C=1)=CC=CC=1C1(C(O)=O)CC1 BKVYSZWMHVHMRG-NRFANRHFSA-N 0.000 description 2
- SCRCWNATJLBPLQ-CQSZACIVSA-N 1-[[2-chloro-3-[(2r)-1-methoxy-1-oxopropan-2-yl]oxyphenyl]methyl]-2,3-dimethylindole-5-carboxylic acid Chemical compound COC(=O)[C@@H](C)OC1=CC=CC(CN2C3=CC=C(C=C3C(C)=C2C)C(O)=O)=C1Cl SCRCWNATJLBPLQ-CQSZACIVSA-N 0.000 description 2
- SCRCWNATJLBPLQ-AWEZNQCLSA-N 1-[[2-chloro-3-[(2s)-1-methoxy-1-oxopropan-2-yl]oxyphenyl]methyl]-2,3-dimethylindole-5-carboxylic acid Chemical compound COC(=O)[C@H](C)OC1=CC=CC(CN2C3=CC=C(C=C3C(C)=C2C)C(O)=O)=C1Cl SCRCWNATJLBPLQ-AWEZNQCLSA-N 0.000 description 2
- LLUAXCKDVKZVBB-CQSZACIVSA-N 1-[[2-chloro-4-[(2r)-1-methoxy-1-oxopropan-2-yl]oxyphenyl]methyl]-2,3-dimethylindole-5-carboxylic acid Chemical compound ClC1=CC(O[C@H](C)C(=O)OC)=CC=C1CN1C2=CC=C(C(O)=O)C=C2C(C)=C1C LLUAXCKDVKZVBB-CQSZACIVSA-N 0.000 description 2
- GRAZHNIMLBLZJW-OAQYLSRUSA-N 1-[[2-chloro-5-[(2r)-1-methoxy-1-oxobutan-2-yl]oxyphenyl]methyl]-2,3-dimethylindole-5-carboxylic acid Chemical compound COC(=O)[C@@H](CC)OC1=CC=C(Cl)C(CN2C3=CC=C(C=C3C(C)=C2C)C(O)=O)=C1 GRAZHNIMLBLZJW-OAQYLSRUSA-N 0.000 description 2
- NLZXIMPDRRCEAH-CQSZACIVSA-N 1-[[2-chloro-5-[(2r)-1-methoxy-1-oxopropan-2-yl]oxyphenyl]methyl]-2,3-dimethylindole-5-carboxylic acid Chemical compound COC(=O)[C@@H](C)OC1=CC=C(Cl)C(CN2C3=CC=C(C=C3C(C)=C2C)C(O)=O)=C1 NLZXIMPDRRCEAH-CQSZACIVSA-N 0.000 description 2
- IIDUKOQEOPZWHB-JOCHJYFZSA-N 1-[[2-chloro-5-[(2r)-1-methoxy-3-methyl-1-oxobutan-2-yl]oxyphenyl]methyl]-2,3-dimethylindole-5-carboxylic acid Chemical compound COC(=O)[C@@H](C(C)C)OC1=CC=C(Cl)C(CN2C3=CC=C(C=C3C(C)=C2C)C(O)=O)=C1 IIDUKOQEOPZWHB-JOCHJYFZSA-N 0.000 description 2
- GRAZHNIMLBLZJW-NRFANRHFSA-N 1-[[2-chloro-5-[(2s)-1-methoxy-1-oxobutan-2-yl]oxyphenyl]methyl]-2,3-dimethylindole-5-carboxylic acid Chemical compound COC(=O)[C@H](CC)OC1=CC=C(Cl)C(CN2C3=CC=C(C=C3C(C)=C2C)C(O)=O)=C1 GRAZHNIMLBLZJW-NRFANRHFSA-N 0.000 description 2
- IIDUKOQEOPZWHB-QFIPXVFZSA-N 1-[[2-chloro-5-[(2s)-1-methoxy-3-methyl-1-oxobutan-2-yl]oxyphenyl]methyl]-2,3-dimethylindole-5-carboxylic acid Chemical compound COC(=O)[C@H](C(C)C)OC1=CC=C(Cl)C(CN2C3=CC=C(C=C3C(C)=C2C)C(O)=O)=C1 IIDUKOQEOPZWHB-QFIPXVFZSA-N 0.000 description 2
- XKZDDJNDOXAOOF-NRFANRHFSA-N 1-[[3-(1-amino-2-methyl-1-oxopropan-2-yl)phenyl]methyl]-n-[(1s)-1-(3-cyclopropylphenyl)ethyl]-2,3-dimethylindole-5-carboxamide Chemical compound N([C@@H](C)C=1C=C(C=CC=1)C1CC1)C(=O)C(C=C1C(C)=C2C)=CC=C1N2CC1=CC=CC(C(C)(C)C(N)=O)=C1 XKZDDJNDOXAOOF-NRFANRHFSA-N 0.000 description 2
- QITHVMQLUBSAEI-UHFFFAOYSA-N 1-[[3-(1-cyanocyclopropyl)phenyl]methyl]-2,3-dimethylindole-5-carboxylic acid Chemical compound CC1=C(C)C2=CC(C(O)=O)=CC=C2N1CC(C=1)=CC=CC=1C1(C#N)CC1 QITHVMQLUBSAEI-UHFFFAOYSA-N 0.000 description 2
- QUANKROPKLIJAM-QFIPXVFZSA-N 1-[[3-(1-cyanocyclopropyl)phenyl]methyl]-n-[(1s)-1-(3-cyclopropylphenyl)ethyl]-2,3-dimethylindole-5-carboxamide Chemical compound N([C@@H](C)C=1C=C(C=CC=1)C1CC1)C(=O)C(C=C1C(C)=C2C)=CC=C1N2CC(C=1)=CC=CC=1C1(C#N)CC1 QUANKROPKLIJAM-QFIPXVFZSA-N 0.000 description 2
- DAKOWALUPNTUFV-QFIPXVFZSA-N 1-[[3-(cyanomethoxy)phenyl]methyl]-2,3-dimethyl-n-[(1s)-1-(3-propan-2-ylphenyl)ethyl]indole-5-carboxamide Chemical compound CC(C)C1=CC=CC([C@H](C)NC(=O)C=2C=C3C(C)=C(C)N(CC=4C=C(OCC#N)C=CC=4)C3=CC=2)=C1 DAKOWALUPNTUFV-QFIPXVFZSA-N 0.000 description 2
- WCCHZGMFICMRAC-OAQYLSRUSA-N 1-[[3-[(2r)-1-methoxy-1-oxobutan-2-yl]oxyphenyl]methyl]-2,3-dimethylindole-5-carboxylic acid Chemical compound COC(=O)[C@@H](CC)OC1=CC=CC(CN2C3=CC=C(C=C3C(C)=C2C)C(O)=O)=C1 WCCHZGMFICMRAC-OAQYLSRUSA-N 0.000 description 2
- SOPCJIFFPVARMO-JOCHJYFZSA-N 1-[[3-[(2r)-1-methoxy-3-methyl-1-oxobutan-2-yl]oxyphenyl]methyl]-2,3-dimethylindole-5-carboxylic acid Chemical compound COC(=O)[C@@H](C(C)C)OC1=CC=CC(CN2C3=CC=C(C=C3C(C)=C2C)C(O)=O)=C1 SOPCJIFFPVARMO-JOCHJYFZSA-N 0.000 description 2
- SOPCJIFFPVARMO-QFIPXVFZSA-N 1-[[3-[(2s)-1-methoxy-3-methyl-1-oxobutan-2-yl]oxyphenyl]methyl]-2,3-dimethylindole-5-carboxylic acid Chemical compound COC(=O)[C@H](C(C)C)OC1=CC=CC(CN2C3=CC=C(C=C3C(C)=C2C)C(O)=O)=C1 SOPCJIFFPVARMO-QFIPXVFZSA-N 0.000 description 2
- PBGASZFDDKGLHQ-CQSZACIVSA-N 1-[[3-chloro-4-[(2r)-1-methoxy-1-oxopropan-2-yl]oxyphenyl]methyl]-2,3-dimethylindole-5-carboxylic acid Chemical compound C1=C(Cl)C(O[C@H](C)C(=O)OC)=CC=C1CN1C2=CC=C(C(O)=O)C=C2C(C)=C1C PBGASZFDDKGLHQ-CQSZACIVSA-N 0.000 description 2
- PBGASZFDDKGLHQ-AWEZNQCLSA-N 1-[[3-chloro-4-[(2s)-1-methoxy-1-oxopropan-2-yl]oxyphenyl]methyl]-2,3-dimethylindole-5-carboxylic acid Chemical compound C1=C(Cl)C(O[C@@H](C)C(=O)OC)=CC=C1CN1C2=CC=C(C(O)=O)C=C2C(C)=C1C PBGASZFDDKGLHQ-AWEZNQCLSA-N 0.000 description 2
- ZWHNVVVIFWNTCG-CQSZACIVSA-N 1-[[3-chloro-5-[(2r)-1-methoxy-1-oxopropan-2-yl]oxyphenyl]methyl]-2,3-dimethylindole-5-carboxylic acid Chemical compound COC(=O)[C@@H](C)OC1=CC(Cl)=CC(CN2C3=CC=C(C=C3C(C)=C2C)C(O)=O)=C1 ZWHNVVVIFWNTCG-CQSZACIVSA-N 0.000 description 2
- ZWHNVVVIFWNTCG-AWEZNQCLSA-N 1-[[3-chloro-5-[(2s)-1-methoxy-1-oxopropan-2-yl]oxyphenyl]methyl]-2,3-dimethylindole-5-carboxylic acid Chemical compound COC(=O)[C@H](C)OC1=CC(Cl)=CC(CN2C3=CC=C(C=C3C(C)=C2C)C(O)=O)=C1 ZWHNVVVIFWNTCG-AWEZNQCLSA-N 0.000 description 2
- QEGHNFFTNFXTSU-UHFFFAOYSA-N 1-[[4-(1-methoxy-2-methyl-1-oxopropan-2-yl)oxyphenyl]methyl]-2,3-dimethylindole-5-carboxylic acid Chemical compound C1=CC(OC(C)(C)C(=O)OC)=CC=C1CN1C2=CC=C(C(O)=O)C=C2C(C)=C1C QEGHNFFTNFXTSU-UHFFFAOYSA-N 0.000 description 2
- SCKLYEWEDOTLMY-UHFFFAOYSA-N 1-[[4-(2-cyanophenyl)phenyl]methyl]-2,3-dimethylindole-5-carboxylic acid Chemical compound CC1=C(C)C2=CC(C(O)=O)=CC=C2N1CC(C=C1)=CC=C1C1=CC=CC=C1C#N SCKLYEWEDOTLMY-UHFFFAOYSA-N 0.000 description 2
- GEYWWSHMBVKPRL-DEOSSOPVSA-N 1-[[4-(2-cyanophenyl)phenyl]methyl]-n-[(1s)-1-(3-cyclopropylphenyl)ethyl]-2,3-dimethylindole-5-carboxamide Chemical compound N([C@@H](C)C=1C=C(C=CC=1)C1CC1)C(=O)C(C=C1C(C)=C2C)=CC=C1N2CC(C=C1)=CC=C1C1=CC=CC=C1C#N GEYWWSHMBVKPRL-DEOSSOPVSA-N 0.000 description 2
- YQONJRSGVQEUSH-OAHLLOKOSA-N 1-[[4-[(2r)-1-methoxy-1-oxopropan-2-yl]oxyphenyl]methyl]-2,3-dimethylindole-5-carboxylic acid Chemical compound C1=CC(O[C@H](C)C(=O)OC)=CC=C1CN1C2=CC=C(C(O)=O)C=C2C(C)=C1C YQONJRSGVQEUSH-OAHLLOKOSA-N 0.000 description 2
- HOLDETJMNWZFLL-DEOSSOPVSA-N 1-[[4-[2-(hydrazinecarbonyl)phenyl]phenyl]methyl]-2,3-dimethyl-n-[(1s)-1-(3-propan-2-ylphenyl)ethyl]indole-5-carboxamide Chemical compound CC(C)C1=CC=CC([C@H](C)NC(=O)C=2C=C3C(C)=C(C)N(CC=4C=CC(=CC=4)C=4C(=CC=CC=4)C(=O)NN)C3=CC=2)=C1 HOLDETJMNWZFLL-DEOSSOPVSA-N 0.000 description 2
- CVCGPWWVROZGTB-DEOSSOPVSA-N 1-[[4-[2-(hydroxycarbamoyl)phenyl]phenyl]methyl]-2,3-dimethyl-n-[(1s)-1-(3-propan-2-ylphenyl)ethyl]indole-5-carboxamide Chemical compound CC(C)C1=CC=CC([C@H](C)NC(=O)C=2C=C3C(C)=C(C)N(CC=4C=CC(=CC=4)C=4C(=CC=CC=4)C(=O)NO)C3=CC=2)=C1 CVCGPWWVROZGTB-DEOSSOPVSA-N 0.000 description 2
- QMLXGQJJGLMJIL-UHFFFAOYSA-N 1-[[4-[2-(tert-butylsulfamoyl)phenyl]phenyl]methyl]-2,3-dimethylindole-5-carboxylic acid Chemical compound CC1=C(C)C2=CC(C(O)=O)=CC=C2N1CC(C=C1)=CC=C1C1=CC=CC=C1S(=O)(=O)NC(C)(C)C QMLXGQJJGLMJIL-UHFFFAOYSA-N 0.000 description 2
- REJKHGJQMOWMDB-LJAQVGFWSA-N 1-[[4-[2-[[tert-butyl(dimethyl)silyl]oxycarbamoyl]phenyl]phenyl]methyl]-2,3-dimethyl-n-[(1s)-1-(3-propan-2-ylphenyl)ethyl]indole-5-carboxamide Chemical compound CC(C)C1=CC=CC([C@H](C)NC(=O)C=2C=C3C(C)=C(C)N(CC=4C=CC(=CC=4)C=4C(=CC=CC=4)C(=O)NO[Si](C)(C)C(C)(C)C)C3=CC=2)=C1 REJKHGJQMOWMDB-LJAQVGFWSA-N 0.000 description 2
- XBCCSHOMHZDJHH-HXUWFJFHSA-N 1-[[4-chloro-3-[(2r)-1-methoxy-1-oxobutan-2-yl]oxyphenyl]methyl]-2,3-dimethylindole-5-carboxylic acid Chemical compound C1=C(Cl)C(O[C@H](CC)C(=O)OC)=CC(CN2C3=CC=C(C=C3C(C)=C2C)C(O)=O)=C1 XBCCSHOMHZDJHH-HXUWFJFHSA-N 0.000 description 2
- YPFIRRYKYDGFLL-CQSZACIVSA-N 1-[[4-chloro-3-[(2r)-1-methoxy-1-oxopropan-2-yl]oxyphenyl]methyl]-2,3-dimethylindole-5-carboxylic acid Chemical compound C1=C(Cl)C(O[C@H](C)C(=O)OC)=CC(CN2C3=CC=C(C=C3C(C)=C2C)C(O)=O)=C1 YPFIRRYKYDGFLL-CQSZACIVSA-N 0.000 description 2
- SHHWPEDWJFQMAW-JOCHJYFZSA-N 1-[[4-chloro-3-[(2r)-1-methoxy-3-methyl-1-oxobutan-2-yl]oxyphenyl]methyl]-2,3-dimethylindole-5-carboxylic acid Chemical compound C1=C(Cl)C(O[C@@H](C(=O)OC)C(C)C)=CC(CN2C3=CC=C(C=C3C(C)=C2C)C(O)=O)=C1 SHHWPEDWJFQMAW-JOCHJYFZSA-N 0.000 description 2
- XBCCSHOMHZDJHH-FQEVSTJZSA-N 1-[[4-chloro-3-[(2s)-1-methoxy-1-oxobutan-2-yl]oxyphenyl]methyl]-2,3-dimethylindole-5-carboxylic acid Chemical compound C1=C(Cl)C(O[C@@H](CC)C(=O)OC)=CC(CN2C3=CC=C(C=C3C(C)=C2C)C(O)=O)=C1 XBCCSHOMHZDJHH-FQEVSTJZSA-N 0.000 description 2
- IBYHHJPAARCAIE-UHFFFAOYSA-N 1-bromo-2-chloroethane Chemical compound ClCCBr IBYHHJPAARCAIE-UHFFFAOYSA-N 0.000 description 2
- RTCUCQWIICFPOD-UHFFFAOYSA-N 1-naphthalen-1-ylethanamine Chemical compound C1=CC=C2C(C(N)C)=CC=CC2=C1 RTCUCQWIICFPOD-UHFFFAOYSA-N 0.000 description 2
- JHNURUNMNRSGRO-UHFFFAOYSA-N 2,3-dihydro-1,4-benzodioxin-3-ylmethanamine Chemical compound C1=CC=C2OC(CN)COC2=C1 JHNURUNMNRSGRO-UHFFFAOYSA-N 0.000 description 2
- TVBNTFVSONEKOU-UHFFFAOYSA-N 2,3-dihydro-1,4-benzodioxine-3-carbaldehyde Chemical compound C1=CC=C2OC(C=O)COC2=C1 TVBNTFVSONEKOU-UHFFFAOYSA-N 0.000 description 2
- ONJXXMIOHPFIAB-DEOSSOPVSA-N 2,3-dimethyl-1-[[4-[2-(2-oxo-3h-1,3,4-oxadiazol-5-yl)phenyl]phenyl]methyl]-n-[(1s)-1-(3-propan-2-ylphenyl)ethyl]indole-5-carboxamide Chemical compound CC(C)C1=CC=CC([C@H](C)NC(=O)C=2C=C3C(C)=C(C)N(CC=4C=CC(=CC=4)C=4C(=CC=CC=4)C=4OC(=O)NN=4)C3=CC=2)=C1 ONJXXMIOHPFIAB-DEOSSOPVSA-N 0.000 description 2
- KHJGIMZYCBPOBG-UHFFFAOYSA-N 2,3-dimethyl-1h-indole-5-carboxylic acid Chemical compound C1=C(C(O)=O)C=C2C(C)=C(C)NC2=C1 KHJGIMZYCBPOBG-UHFFFAOYSA-N 0.000 description 2
- DLFKRFBUFCZQAC-DEOSSOPVSA-N 2,3-dimethyl-n-[(1s)-1-(3-propan-2-ylphenyl)ethyl]-1-[[4-(2-sulfamoylphenyl)phenyl]methyl]indole-5-carboxamide Chemical compound CC(C)C1=CC=CC([C@H](C)NC(=O)C=2C=C3C(C)=C(C)N(CC=4C=CC(=CC=4)C=4C(=CC=CC=4)S(N)(=O)=O)C3=CC=2)=C1 DLFKRFBUFCZQAC-DEOSSOPVSA-N 0.000 description 2
- DLRCWXOCZIUZBS-UHFFFAOYSA-N 2,4-bis(trifluoromethyl)benzaldehyde Chemical compound FC(F)(F)C1=CC=C(C=O)C(C(F)(F)F)=C1 DLRCWXOCZIUZBS-UHFFFAOYSA-N 0.000 description 2
- PICGJIQKPLBIES-UHFFFAOYSA-N 2,5-bis(trifluoromethyl)benzaldehyde Chemical compound FC(F)(F)C1=CC=C(C(F)(F)F)C(C=O)=C1 PICGJIQKPLBIES-UHFFFAOYSA-N 0.000 description 2
- DMIYKWPEFRFTPY-UHFFFAOYSA-N 2,6-dichlorobenzaldehyde Chemical compound ClC1=CC=CC(Cl)=C1C=O DMIYKWPEFRFTPY-UHFFFAOYSA-N 0.000 description 2
- RHUCKOJKXSCVOW-UHFFFAOYSA-N 2-(3-methylphenoxy)acetonitrile Chemical compound CC1=CC=CC(OCC#N)=C1 RHUCKOJKXSCVOW-UHFFFAOYSA-N 0.000 description 2
- WOJADIOTNFDWNQ-UHFFFAOYSA-N 2-(3-methylphenyl)acetonitrile Chemical compound CC1=CC=CC(CC#N)=C1 WOJADIOTNFDWNQ-UHFFFAOYSA-N 0.000 description 2
- ZGQVZLSNEBEHFN-UHFFFAOYSA-N 2-(4-methylphenyl)benzonitrile Chemical compound C1=CC(C)=CC=C1C1=CC=CC=C1C#N ZGQVZLSNEBEHFN-UHFFFAOYSA-N 0.000 description 2
- ZDVRPKUWYQVVDX-UHFFFAOYSA-N 2-(trifluoromethyl)benzaldehyde Chemical compound FC(F)(F)C1=CC=CC=C1C=O ZDVRPKUWYQVVDX-UHFFFAOYSA-N 0.000 description 2
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 2
- MWVHPSPXFVCRAD-UHFFFAOYSA-N 2-[2-[[5-(1-phenylpropylcarbamoyl)indol-1-yl]methyl]phenyl]benzoic acid Chemical compound C=1C=CC=CC=1C(CC)NC(=O)C(C=C1C=C2)=CC=C1N2CC1=CC=CC=C1C1=CC=CC=C1C(O)=O MWVHPSPXFVCRAD-UHFFFAOYSA-N 0.000 description 2
- DFAHXTMFVVFMDS-UHFFFAOYSA-N 2-[3-(bromomethyl)phenoxy]acetonitrile Chemical compound BrCC1=CC=CC(OCC#N)=C1 DFAHXTMFVVFMDS-UHFFFAOYSA-N 0.000 description 2
- XXJSPPPXGQYVEO-UHFFFAOYSA-N 2-[3-(bromomethyl)phenyl]-2-methylpropanenitrile Chemical compound N#CC(C)(C)C1=CC=CC(CBr)=C1 XXJSPPPXGQYVEO-UHFFFAOYSA-N 0.000 description 2
- UHLBFUVQAJGUJG-QFIPXVFZSA-N 2-[3-[[2,3-dimethyl-5-[[(1s)-1-(3-propan-2-ylphenyl)ethyl]carbamoyl]indol-1-yl]methyl]phenoxy]-2-methylpropanoic acid Chemical compound CC(C)C1=CC=CC([C@H](C)NC(=O)C=2C=C3C(C)=C(C)N(CC=4C=C(OC(C)(C)C(O)=O)C=CC=4)C3=CC=2)=C1 UHLBFUVQAJGUJG-QFIPXVFZSA-N 0.000 description 2
- MRTRAQLPJVKJAP-NRFANRHFSA-N 2-[3-[[2,3-dimethyl-5-[[(1s)-1-(3-propan-2-ylphenyl)ethyl]carbamoyl]indol-1-yl]methyl]phenoxy]acetic acid Chemical compound CC(C)C1=CC=CC([C@H](C)NC(=O)C=2C=C3C(C)=C(C)N(CC=4C=C(OCC(O)=O)C=CC=4)C3=CC=2)=C1 MRTRAQLPJVKJAP-NRFANRHFSA-N 0.000 description 2
- WMNJUKOUONJXEP-UHFFFAOYSA-N 2-[3-[[5-(1-phenylpropylcarbamoyl)indol-1-yl]methyl]phenyl]benzoic acid Chemical compound C=1C=CC=CC=1C(CC)NC(=O)C(C=C1C=C2)=CC=C1N2CC(C=1)=CC=CC=1C1=CC=CC=C1C(O)=O WMNJUKOUONJXEP-UHFFFAOYSA-N 0.000 description 2
- VUCWMZSYIWSINL-FQEVSTJZSA-N 2-[3-[[5-[[(1s)-1-(3-cyclopropylphenyl)ethyl]carbamoyl]-2,3-dimethylindol-1-yl]methyl]phenoxy]acetic acid Chemical compound N([C@@H](C)C=1C=C(C=CC=1)C1CC1)C(=O)C(C=C1C(C)=C2C)=CC=C1N2CC1=CC=CC(OCC(O)=O)=C1 VUCWMZSYIWSINL-FQEVSTJZSA-N 0.000 description 2
- CONYZBSRCXDICW-NRFANRHFSA-N 2-[3-[[5-[[(1s)-1-(3-cyclopropylphenyl)ethyl]carbamoyl]-2,3-dimethylindol-1-yl]methyl]phenyl]-2-methylpropanoic acid Chemical compound N([C@@H](C)C=1C=C(C=CC=1)C1CC1)C(=O)C(C=C1C(C)=C2C)=CC=C1N2CC1=CC=CC(C(C)(C)C(O)=O)=C1 CONYZBSRCXDICW-NRFANRHFSA-N 0.000 description 2
- DLXSTRGKTJFVEB-QFIPXVFZSA-N 2-[3-[[5-[[(1s)-1-(4-tert-butylphenyl)ethyl]carbamoyl]-2,3-dimethylindol-1-yl]methyl]phenoxy]-2-methylpropanoic acid Chemical compound N([C@@H](C)C=1C=CC(=CC=1)C(C)(C)C)C(=O)C(C=C1C(C)=C2C)=CC=C1N2CC1=CC=CC(OC(C)(C)C(O)=O)=C1 DLXSTRGKTJFVEB-QFIPXVFZSA-N 0.000 description 2
- PLYOIBJSBDWJCO-NRFANRHFSA-N 2-[3-[[5-[[(1s)-1-(4-tert-butylphenyl)ethyl]carbamoyl]-2,3-dimethylindol-1-yl]methyl]phenoxy]acetic acid Chemical compound N([C@@H](C)C=1C=CC(=CC=1)C(C)(C)C)C(=O)C(C=C1C(C)=C2C)=CC=C1N2CC1=CC=CC(OCC(O)=O)=C1 PLYOIBJSBDWJCO-NRFANRHFSA-N 0.000 description 2
- KNUQUBFMOQCVTR-UHFFFAOYSA-N 2-[4-[[2,3-dimethyl-5-(2-phenylpropan-2-ylcarbamoyl)indol-1-yl]methyl]phenyl]benzoic acid Chemical compound CC1=C(C)C2=CC(C(=O)NC(C)(C)C=3C=CC=CC=3)=CC=C2N1CC(C=C1)=CC=C1C1=CC=CC=C1C(O)=O KNUQUBFMOQCVTR-UHFFFAOYSA-N 0.000 description 2
- XSZVVKIGKRRVPW-UHFFFAOYSA-N 2-[4-[[2,3-dimethyl-5-(phenacylcarbamoyl)indol-1-yl]methyl]phenyl]benzoic acid Chemical compound CC1=C(C)C2=CC(C(=O)NCC(=O)C=3C=CC=CC=3)=CC=C2N1CC(C=C1)=CC=C1C1=CC=CC=C1C(O)=O XSZVVKIGKRRVPW-UHFFFAOYSA-N 0.000 description 2
- ZMWATRMDQDIDQQ-UHFFFAOYSA-N 2-[4-[[2,3-dimethyl-5-[(3-methylsulfonylphenyl)methylcarbamoyl]indol-1-yl]methyl]phenyl]benzoic acid Chemical compound CC1=C(C)C2=CC(C(=O)NCC=3C=C(C=CC=3)S(C)(=O)=O)=CC=C2N1CC(C=C1)=CC=C1C1=CC=CC=C1C(O)=O ZMWATRMDQDIDQQ-UHFFFAOYSA-N 0.000 description 2
- YLLWURYUGGBEPU-UHFFFAOYSA-N 2-[4-[[2,3-dimethyl-5-[(4-methylsulfanylphenyl)methylcarbamoyl]indol-1-yl]methyl]phenyl]benzoic acid Chemical compound C1=CC(SC)=CC=C1CNC(=O)C1=CC=C(N(CC=2C=CC(=CC=2)C=2C(=CC=CC=2)C(O)=O)C(C)=C2C)C2=C1 YLLWURYUGGBEPU-UHFFFAOYSA-N 0.000 description 2
- XDMKOYKMCBBADL-UHFFFAOYSA-N 2-[4-[[2,3-dimethyl-5-[(4-methylsulfonylphenyl)methylcarbamoyl]indol-1-yl]methyl]phenyl]benzoic acid Chemical compound CC1=C(C)C2=CC(C(=O)NCC=3C=CC(=CC=3)S(C)(=O)=O)=CC=C2N1CC(C=C1)=CC=C1C1=CC=CC=C1C(O)=O XDMKOYKMCBBADL-UHFFFAOYSA-N 0.000 description 2
- PLVLHFFVGPMWLJ-UHFFFAOYSA-N 2-[4-[[2,3-dimethyl-5-[(4-propan-2-ylphenyl)methylcarbamoyl]indol-1-yl]methyl]phenyl]benzoic acid Chemical compound C1=CC(C(C)C)=CC=C1CNC(=O)C1=CC=C(N(CC=2C=CC(=CC=2)C=2C(=CC=CC=2)C(O)=O)C(C)=C2C)C2=C1 PLVLHFFVGPMWLJ-UHFFFAOYSA-N 0.000 description 2
- ZUZJRWGVIKMNSG-UHFFFAOYSA-N 2-[4-[[2,3-dimethyl-5-[(4-sulfamoylphenyl)methylcarbamoyl]indol-1-yl]methyl]phenyl]benzoic acid Chemical compound CC1=C(C)C2=CC(C(=O)NCC=3C=CC(=CC=3)S(N)(=O)=O)=CC=C2N1CC(C=C1)=CC=C1C1=CC=CC=C1C(O)=O ZUZJRWGVIKMNSG-UHFFFAOYSA-N 0.000 description 2
- BKKFJLQXWHWJPS-JOCHJYFZSA-N 2-[4-[[2,3-dimethyl-5-[[(1r)-1-(4-methylsulfonylphenyl)ethyl]carbamoyl]indol-1-yl]methyl]phenyl]benzoic acid Chemical compound N([C@H](C)C=1C=CC(=CC=1)S(C)(=O)=O)C(=O)C(C=C1C(C)=C2C)=CC=C1N2CC(C=C1)=CC=C1C1=CC=CC=C1C(O)=O BKKFJLQXWHWJPS-JOCHJYFZSA-N 0.000 description 2
- VDAGVTPSIBDMNP-OAQYLSRUSA-N 2-[4-[[2,3-dimethyl-5-[[(1r)-1-pyridin-4-ylethyl]carbamoyl]indol-1-yl]methyl]phenyl]benzoic acid Chemical compound N([C@H](C)C=1C=CN=CC=1)C(=O)C(C=C1C(C)=C2C)=CC=C1N2CC(C=C1)=CC=C1C1=CC=CC=C1C(O)=O VDAGVTPSIBDMNP-OAQYLSRUSA-N 0.000 description 2
- KFHFEWZRWQIOOK-HSZRJFAPSA-N 2-[4-[[2,3-dimethyl-5-[[(1r)-1-quinolin-4-ylethyl]carbamoyl]indol-1-yl]methyl]phenyl]benzoic acid Chemical compound N([C@H](C)C=1C2=CC=CC=C2N=CC=1)C(=O)C(C=C1C(C)=C2C)=CC=C1N2CC(C=C1)=CC=C1C1=CC=CC=C1C(O)=O KFHFEWZRWQIOOK-HSZRJFAPSA-N 0.000 description 2
- QJJCBPOUUSUGAD-PSXMRANNSA-N 2-[4-[[2,3-dimethyl-5-[[(1r)-2-methyl-1-(3-propan-2-ylphenyl)propyl]carbamoyl]indol-1-yl]methyl]phenyl]benzoic acid Chemical compound N([C@H](C(C)C)C=1C=C(C=CC=1)C(C)C)C(=O)C(C=C1C(C)=C2C)=CC=C1N2CC(C=C1)=CC=C1C1=CC=CC=C1C(O)=O QJJCBPOUUSUGAD-PSXMRANNSA-N 0.000 description 2
- IAYHUUPZWBZCHC-IBGZPJMESA-N 2-[4-[[2,3-dimethyl-5-[[(1s)-1-(2,4,5-trifluorophenyl)ethyl]carbamoyl]indol-1-yl]methyl]phenyl]benzoic acid Chemical compound N([C@@H](C)C=1C(=CC(F)=C(F)C=1)F)C(=O)C(C=C1C(C)=C2C)=CC=C1N2CC(C=C1)=CC=C1C1=CC=CC=C1C(O)=O IAYHUUPZWBZCHC-IBGZPJMESA-N 0.000 description 2
- KQFBRMGNESOYGS-QHCPKHFHSA-N 2-[4-[[2,3-dimethyl-5-[[(1s)-1-(3-methylphenyl)ethyl]carbamoyl]indol-1-yl]methyl]phenyl]benzoic acid Chemical compound N([C@@H](C)C=1C=C(C)C=CC=1)C(=O)C(C=C1C(C)=C2C)=CC=C1N2CC(C=C1)=CC=C1C1=CC=CC=C1C(O)=O KQFBRMGNESOYGS-QHCPKHFHSA-N 0.000 description 2
- UAYKPDKWEPQCKH-DEOSSOPVSA-N 2-[4-[[2,3-dimethyl-5-[[(1s)-1-(3-propan-2-yloxyphenyl)ethyl]carbamoyl]indol-1-yl]methyl]phenyl]benzoic acid Chemical compound CC(C)OC1=CC=CC([C@H](C)NC(=O)C=2C=C3C(C)=C(C)N(CC=4C=CC(=CC=4)C=4C(=CC=CC=4)C(O)=O)C3=CC=2)=C1 UAYKPDKWEPQCKH-DEOSSOPVSA-N 0.000 description 2
- RDCMWNANKKFTAL-BHVANESWSA-N 2-[4-[[2,3-dimethyl-5-[[(1s)-1-(3-propan-2-ylphenyl)pentyl]carbamoyl]indol-1-yl]methyl]phenyl]benzoic acid Chemical compound N([C@@H](CCCC)C=1C=C(C=CC=1)C(C)C)C(=O)C(C=C1C(C)=C2C)=CC=C1N2CC(C=C1)=CC=C1C1=CC=CC=C1C(O)=O RDCMWNANKKFTAL-BHVANESWSA-N 0.000 description 2
- QEJLMMNKULRCIG-UMSFTDKQSA-N 2-[4-[[2,3-dimethyl-5-[[(1s)-1-(3-propan-2-ylphenyl)propyl]carbamoyl]indol-1-yl]methyl]phenyl]benzoic acid Chemical compound N([C@@H](CC)C=1C=C(C=CC=1)C(C)C)C(=O)C(C=C1C(C)=C2C)=CC=C1N2CC(C=C1)=CC=C1C1=CC=CC=C1C(O)=O QEJLMMNKULRCIG-UMSFTDKQSA-N 0.000 description 2
- HDXXVUNXHRYZMZ-DEOSSOPVSA-N 2-[4-[[2,3-dimethyl-5-[[(1s)-1-(4-propan-2-yloxyphenyl)ethyl]carbamoyl]indol-1-yl]methyl]phenyl]benzoic acid Chemical compound C1=CC(OC(C)C)=CC=C1[C@H](C)NC(=O)C1=CC=C(N(CC=2C=CC(=CC=2)C=2C(=CC=CC=2)C(O)=O)C(C)=C2C)C2=C1 HDXXVUNXHRYZMZ-DEOSSOPVSA-N 0.000 description 2
- CZVKLWAQRUDGMY-NRFANRHFSA-N 2-[4-[[2,3-dimethyl-5-[[(1s)-1-[3-(trifluoromethyl)phenyl]ethyl]carbamoyl]indol-1-yl]methyl]phenyl]benzoic acid Chemical compound N([C@@H](C)C=1C=C(C=CC=1)C(F)(F)F)C(=O)C(C=C1C(C)=C2C)=CC=C1N2CC(C=C1)=CC=C1C1=CC=CC=C1C(O)=O CZVKLWAQRUDGMY-NRFANRHFSA-N 0.000 description 2
- NFFJROAGHXORLE-NRFANRHFSA-N 2-[4-[[2,3-dimethyl-5-[[(1s)-1-[4-(trifluoromethoxy)phenyl]ethyl]carbamoyl]indol-1-yl]methyl]phenyl]benzoic acid Chemical compound N([C@@H](C)C=1C=CC(OC(F)(F)F)=CC=1)C(=O)C(C=C1C(C)=C2C)=CC=C1N2CC(C=C1)=CC=C1C1=CC=CC=C1C(O)=O NFFJROAGHXORLE-NRFANRHFSA-N 0.000 description 2
- SNDORDPXFWQYTN-NRFANRHFSA-N 2-[4-[[2,3-dimethyl-5-[[(1s)-1-[4-(trifluoromethyl)phenyl]ethyl]carbamoyl]indol-1-yl]methyl]phenyl]benzoic acid Chemical compound N([C@@H](C)C=1C=CC(=CC=1)C(F)(F)F)C(=O)C(C=C1C(C)=C2C)=CC=C1N2CC(C=C1)=CC=C1C1=CC=CC=C1C(O)=O SNDORDPXFWQYTN-NRFANRHFSA-N 0.000 description 2
- RERJUQORLQTXGB-DEOSSOPVSA-N 2-[4-[[2,3-dimethyl-5-[[(1s)-1-[4-[(2-methylpropan-2-yl)oxy]phenyl]ethyl]carbamoyl]indol-1-yl]methyl]phenyl]benzoic acid Chemical compound N([C@@H](C)C=1C=CC(OC(C)(C)C)=CC=1)C(=O)C(C=C1C(C)=C2C)=CC=C1N2CC(C=C1)=CC=C1C1=CC=CC=C1C(O)=O RERJUQORLQTXGB-DEOSSOPVSA-N 0.000 description 2
- KSKLBIYBQQLBTF-DEOSSOPVSA-N 2-[4-[[2,3-dimethyl-5-[[(1s)-1-naphthalen-1-ylethyl]carbamoyl]indol-1-yl]methyl]phenyl]benzoic acid Chemical compound N([C@@H](C)C=1C2=CC=CC=C2C=CC=1)C(=O)C(C=C1C(C)=C2C)=CC=C1N2CC(C=C1)=CC=C1C1=CC=CC=C1C(O)=O KSKLBIYBQQLBTF-DEOSSOPVSA-N 0.000 description 2
- XEGITLAQIKPEDD-DEOSSOPVSA-N 2-[4-[[2,3-dimethyl-5-[[(1s)-1-naphthalen-2-ylethyl]carbamoyl]indol-1-yl]methyl]phenyl]benzoic acid Chemical compound N([C@@H](C)C=1C=C2C=CC=CC2=CC=1)C(=O)C(C=C1C(C)=C2C)=CC=C1N2CC(C=C1)=CC=C1C1=CC=CC=C1C(O)=O XEGITLAQIKPEDD-DEOSSOPVSA-N 0.000 description 2
- GAARULQYFFLRMZ-NRFANRHFSA-N 2-[4-[[2,3-dimethyl-5-[[(1s)-1-pyridin-2-ylethyl]carbamoyl]indol-1-yl]methyl]phenyl]benzoic acid Chemical compound N([C@@H](C)C=1N=CC=CC=1)C(=O)C(C=C1C(C)=C2C)=CC=C1N2CC(C=C1)=CC=C1C1=CC=CC=C1C(O)=O GAARULQYFFLRMZ-NRFANRHFSA-N 0.000 description 2
- KFHFEWZRWQIOOK-QHCPKHFHSA-N 2-[4-[[2,3-dimethyl-5-[[(1s)-1-quinolin-4-ylethyl]carbamoyl]indol-1-yl]methyl]phenyl]benzoic acid Chemical compound N([C@@H](C)C=1C2=CC=CC=C2N=CC=1)C(=O)C(C=C1C(C)=C2C)=CC=C1N2CC(C=C1)=CC=C1C1=CC=CC=C1C(O)=O KFHFEWZRWQIOOK-QHCPKHFHSA-N 0.000 description 2
- QJJCBPOUUSUGAD-BHVANESWSA-N 2-[4-[[2,3-dimethyl-5-[[(1s)-2-methyl-1-(3-propan-2-ylphenyl)propyl]carbamoyl]indol-1-yl]methyl]phenyl]benzoic acid Chemical compound N([C@@H](C(C)C)C=1C=C(C=CC=1)C(C)C)C(=O)C(C=C1C(C)=C2C)=CC=C1N2CC(C=C1)=CC=C1C1=CC=CC=C1C(O)=O QJJCBPOUUSUGAD-BHVANESWSA-N 0.000 description 2
- QHPCWVZZRZXAAW-KDXMTYKHSA-N 2-[4-[[2,3-dimethyl-5-[[(1s)-2-phenyl-1-(3-propan-2-ylphenyl)ethyl]carbamoyl]indol-1-yl]methyl]phenyl]benzoic acid Chemical compound CC(C)C1=CC=CC([C@H](CC=2C=CC=CC=2)NC(=O)C=2C=C3C(C)=C(C)N(CC=4C=CC(=CC=4)C=4C(=CC=CC=4)C(O)=O)C3=CC=2)=C1 QHPCWVZZRZXAAW-KDXMTYKHSA-N 0.000 description 2
- KDBITMBUICXATG-BHVANESWSA-N 2-[4-[[2,3-dimethyl-5-[[(1s)-3-methyl-1-(3-propan-2-ylphenyl)butyl]carbamoyl]indol-1-yl]methyl]phenyl]benzoic acid Chemical compound N([C@@H](CC(C)C)C=1C=C(C=CC=1)C(C)C)C(=O)C(C=C1C(C)=C2C)=CC=C1N2CC(C=C1)=CC=C1C1=CC=CC=C1C(O)=O KDBITMBUICXATG-BHVANESWSA-N 0.000 description 2
- ULDFXGIIGHXCHO-UHFFFAOYSA-N 2-[4-[[2,3-dimethyl-5-[[3-(trifluoromethoxy)phenyl]methylcarbamoyl]indol-1-yl]methyl]phenyl]benzoic acid Chemical compound CC1=C(C)C2=CC(C(=O)NCC=3C=C(OC(F)(F)F)C=CC=3)=CC=C2N1CC(C=C1)=CC=C1C1=CC=CC=C1C(O)=O ULDFXGIIGHXCHO-UHFFFAOYSA-N 0.000 description 2
- OSEXKUMYOMJSNG-UHFFFAOYSA-N 2-[4-[[2,3-dimethyl-5-[[4-(trifluoromethoxy)phenyl]methylcarbamoyl]indol-1-yl]methyl]phenyl]benzoic acid Chemical compound CC1=C(C)C2=CC(C(=O)NCC=3C=CC(OC(F)(F)F)=CC=3)=CC=C2N1CC(C=C1)=CC=C1C1=CC=CC=C1C(O)=O OSEXKUMYOMJSNG-UHFFFAOYSA-N 0.000 description 2
- VOILEHDTPYEZAQ-UHFFFAOYSA-N 2-[4-[[3-methyl-5-(1-phenylpropylcarbamoyl)indol-1-yl]methyl]phenyl]benzoic acid Chemical compound C=1C=CC=CC=1C(CC)NC(=O)C(C=C1C(C)=C2)=CC=C1N2CC(C=C1)=CC=C1C1=CC=CC=C1C(O)=O VOILEHDTPYEZAQ-UHFFFAOYSA-N 0.000 description 2
- PSTYPSMLZZXBHH-NRFANRHFSA-N 2-[4-[[3-methyl-5-[[(1s)-1-(4-nitrophenyl)ethyl]carbamoyl]indol-1-yl]methyl]phenyl]benzoic acid Chemical compound N([C@@H](C)C=1C=CC(=CC=1)[N+]([O-])=O)C(=O)C(C=C1C(C)=C2)=CC=C1N2CC(C=C1)=CC=C1C1=CC=CC=C1C(O)=O PSTYPSMLZZXBHH-NRFANRHFSA-N 0.000 description 2
- COZWCUCYPDPGSM-UHFFFAOYSA-N 2-[4-[[5-(1-phenylpropylcarbamoyl)indol-1-yl]methyl]phenyl]benzoic acid Chemical compound C=1C=CC=CC=1C(CC)NC(=O)C(C=C1C=C2)=CC=C1N2CC(C=C1)=CC=C1C1=CC=CC=C1C(O)=O COZWCUCYPDPGSM-UHFFFAOYSA-N 0.000 description 2
- RHRKQLBHWQDVDZ-UHFFFAOYSA-N 2-[4-[[5-[(2,4-dimethoxyphenyl)methylcarbamoyl]-2,3-dimethylindol-1-yl]methyl]phenyl]benzoic acid Chemical compound COC1=CC(OC)=CC=C1CNC(=O)C1=CC=C(N(CC=2C=CC(=CC=2)C=2C(=CC=CC=2)C(O)=O)C(C)=C2C)C2=C1 RHRKQLBHWQDVDZ-UHFFFAOYSA-N 0.000 description 2
- DCVFFTXZUQINPM-UHFFFAOYSA-N 2-[4-[[5-[(3,4-dimethoxyphenyl)methylcarbamoyl]-2,3-dimethylindol-1-yl]methyl]phenyl]benzoic acid Chemical compound C1=C(OC)C(OC)=CC=C1CNC(=O)C1=CC=C(N(CC=2C=CC(=CC=2)C=2C(=CC=CC=2)C(O)=O)C(C)=C2C)C2=C1 DCVFFTXZUQINPM-UHFFFAOYSA-N 0.000 description 2
- IWGCDQSAKCLDGI-UHFFFAOYSA-N 2-[4-[[5-[(3,5-dimethoxyphenyl)methylcarbamoyl]-2,3-dimethylindol-1-yl]methyl]phenyl]benzoic acid Chemical compound COC1=CC(OC)=CC(CNC(=O)C=2C=C3C(C)=C(C)N(CC=4C=CC(=CC=4)C=4C(=CC=CC=4)C(O)=O)C3=CC=2)=C1 IWGCDQSAKCLDGI-UHFFFAOYSA-N 0.000 description 2
- WLXACAYPZDGLHI-UHFFFAOYSA-N 2-[4-[[5-[(4-bromophenyl)methylcarbamoyl]-2,3-dimethylindol-1-yl]methyl]phenyl]benzoic acid Chemical compound CC1=C(C)C2=CC(C(=O)NCC=3C=CC(Br)=CC=3)=CC=C2N1CC(C=C1)=CC=C1C1=CC=CC=C1C(O)=O WLXACAYPZDGLHI-UHFFFAOYSA-N 0.000 description 2
- LLGJZGDGJMRTCY-UHFFFAOYSA-N 2-[4-[[5-[(4-chlorophenyl)methylcarbamoyl]-2,3-dimethylindol-1-yl]methyl]phenyl]benzoic acid Chemical compound CC1=C(C)C2=CC(C(=O)NCC=3C=CC(Cl)=CC=3)=CC=C2N1CC(C=C1)=CC=C1C1=CC=CC=C1C(O)=O LLGJZGDGJMRTCY-UHFFFAOYSA-N 0.000 description 2
- PKTAALWXPUHTCY-UHFFFAOYSA-N 2-[4-[[5-[(4-cyanophenyl)methylcarbamoyl]-2,3-dimethylindol-1-yl]methyl]phenyl]benzoic acid Chemical compound CC1=C(C)C2=CC(C(=O)NCC=3C=CC(=CC=3)C#N)=CC=C2N1CC(C=C1)=CC=C1C1=CC=CC=C1C(O)=O PKTAALWXPUHTCY-UHFFFAOYSA-N 0.000 description 2
- SEPFCGHYUGMVEJ-UHFFFAOYSA-N 2-[4-[[5-[(4-iodophenyl)methylcarbamoyl]-2,3-dimethylindol-1-yl]methyl]phenyl]benzoic acid Chemical compound CC1=C(C)C2=CC(C(=O)NCC=3C=CC(I)=CC=3)=CC=C2N1CC(C=C1)=CC=C1C1=CC=CC=C1C(O)=O SEPFCGHYUGMVEJ-UHFFFAOYSA-N 0.000 description 2
- JKEOQQHYKJOZQG-UHFFFAOYSA-N 2-[4-[[5-[(4-methoxycarbonylphenyl)methylcarbamoyl]-2,3-dimethylindol-1-yl]methyl]phenyl]benzoic acid Chemical compound C1=CC(C(=O)OC)=CC=C1CNC(=O)C1=CC=C(N(CC=2C=CC(=CC=2)C=2C(=CC=CC=2)C(O)=O)C(C)=C2C)C2=C1 JKEOQQHYKJOZQG-UHFFFAOYSA-N 0.000 description 2
- XFBNSOFEWINXAL-UHFFFAOYSA-N 2-[4-[[5-[(4-tert-butylphenyl)methylcarbamoyl]-2,3-dimethylindol-1-yl]methyl]phenyl]benzoic acid Chemical compound CC1=C(C)C2=CC(C(=O)NCC=3C=CC(=CC=3)C(C)(C)C)=CC=C2N1CC(C=C1)=CC=C1C1=CC=CC=C1C(O)=O XFBNSOFEWINXAL-UHFFFAOYSA-N 0.000 description 2
- MMNOXRNWNIPRCU-UHFFFAOYSA-N 2-[4-[[5-[1-(5-bromopyridin-3-yl)ethylcarbamoyl]-2,3-dimethylindol-1-yl]methyl]phenyl]benzoic acid Chemical compound C=1N=CC(Br)=CC=1C(C)NC(=O)C(C=C1C(C)=C2C)=CC=C1N2CC(C=C1)=CC=C1C1=CC=CC=C1C(O)=O MMNOXRNWNIPRCU-UHFFFAOYSA-N 0.000 description 2
- XBWZDNVXZYDHRJ-UHFFFAOYSA-N 2-[4-[[5-[1-(5-cyclopropylpyridin-3-yl)ethylcarbamoyl]-2,3-dimethylindol-1-yl]methyl]phenyl]benzoic acid Chemical compound C=1N=CC(C2CC2)=CC=1C(C)NC(=O)C(C=C1C(C)=C2C)=CC=C1N2CC(C=C1)=CC=C1C1=CC=CC=C1C(O)=O XBWZDNVXZYDHRJ-UHFFFAOYSA-N 0.000 description 2
- BZYJVCPCETVFBR-UHFFFAOYSA-N 2-[4-[[5-[1-(6-cyclopropylpyridin-2-yl)ethylcarbamoyl]-2,3-dimethylindol-1-yl]methyl]phenyl]benzoic acid Chemical compound C=1C=CC(C2CC2)=NC=1C(C)NC(=O)C(C=C1C(C)=C2C)=CC=C1N2CC(C=C1)=CC=C1C1=CC=CC=C1C(O)=O BZYJVCPCETVFBR-UHFFFAOYSA-N 0.000 description 2
- DHTYOQUOUURZGT-HXUWFJFHSA-N 2-[4-[[5-[[(1r)-1-(2,3-dichlorophenyl)ethyl]carbamoyl]-2,3-dimethylindol-1-yl]methyl]phenyl]benzoic acid Chemical compound N([C@H](C)C=1C(=C(Cl)C=CC=1)Cl)C(=O)C(C=C1C(C)=C2C)=CC=C1N2CC(C=C1)=CC=C1C1=CC=CC=C1C(O)=O DHTYOQUOUURZGT-HXUWFJFHSA-N 0.000 description 2
- BEUDKWBEOCRTDF-HXUWFJFHSA-N 2-[4-[[5-[[(1r)-1-(2,6-dichlorophenyl)ethyl]carbamoyl]-2,3-dimethylindol-1-yl]methyl]phenyl]benzoic acid Chemical compound N([C@H](C)C=1C(=CC=CC=1Cl)Cl)C(=O)C(C=C1C(C)=C2C)=CC=C1N2CC(C=C1)=CC=C1C1=CC=CC=C1C(O)=O BEUDKWBEOCRTDF-HXUWFJFHSA-N 0.000 description 2
- KRCUARCKAHLZKP-HXUWFJFHSA-N 2-[4-[[5-[[(1r)-1-(2-bromopyridin-4-yl)ethyl]carbamoyl]-2,3-dimethylindol-1-yl]methyl]phenyl]benzoic acid Chemical compound N([C@H](C)C=1C=C(Br)N=CC=1)C(=O)C(C=C1C(C)=C2C)=CC=C1N2CC(C=C1)=CC=C1C1=CC=CC=C1C(O)=O KRCUARCKAHLZKP-HXUWFJFHSA-N 0.000 description 2
- DDXPQDHQGVAGBN-JOCHJYFZSA-N 2-[4-[[5-[[(1r)-1-(2-cyclopropylpyridin-4-yl)ethyl]carbamoyl]-2,3-dimethylindol-1-yl]methyl]phenyl]benzoic acid Chemical compound N([C@H](C)C=1C=C(N=CC=1)C1CC1)C(=O)C(C=C1C(C)=C2C)=CC=C1N2CC(C=C1)=CC=C1C1=CC=CC=C1C(O)=O DDXPQDHQGVAGBN-JOCHJYFZSA-N 0.000 description 2
- XTOLBZISFPRQDQ-OAQYLSRUSA-N 2-[4-[[5-[[(1r)-1-(3-bromophenyl)ethyl]carbamoyl]-2,3-dimethylindol-1-yl]methyl]phenyl]benzoic acid Chemical compound N([C@H](C)C=1C=C(Br)C=CC=1)C(=O)C(C=C1C(C)=C2C)=CC=C1N2CC(C=C1)=CC=C1C1=CC=CC=C1C(O)=O XTOLBZISFPRQDQ-OAQYLSRUSA-N 0.000 description 2
- HBMXDCXJXYASGW-OAQYLSRUSA-N 2-[4-[[5-[[(1r)-1-(4-bromophenyl)ethyl]carbamoyl]-2,3-dimethylindol-1-yl]methyl]phenyl]benzoic acid Chemical compound N([C@H](C)C=1C=CC(Br)=CC=1)C(=O)C(C=C1C(C)=C2C)=CC=C1N2CC(C=C1)=CC=C1C1=CC=CC=C1C(O)=O HBMXDCXJXYASGW-OAQYLSRUSA-N 0.000 description 2
- QNANVKGUWWFSIH-JOCHJYFZSA-N 2-[4-[[5-[[(1r)-1-(4-methoxyphenyl)ethyl]carbamoyl]-2,3-dimethylindol-1-yl]methyl]phenyl]benzoic acid Chemical compound C1=CC(OC)=CC=C1[C@@H](C)NC(=O)C1=CC=C(N(CC=2C=CC(=CC=2)C=2C(=CC=CC=2)C(O)=O)C(C)=C2C)C2=C1 QNANVKGUWWFSIH-JOCHJYFZSA-N 0.000 description 2
- QVYBBKLFLNUXHA-HXUWFJFHSA-N 2-[4-[[5-[[(1r)-1-(6-bromopyridin-2-yl)ethyl]carbamoyl]-2,3-dimethylindol-1-yl]methyl]phenyl]benzoic acid Chemical compound N([C@H](C)C=1N=C(Br)C=CC=1)C(=O)C(C=C1C(C)=C2C)=CC=C1N2CC(C=C1)=CC=C1C1=CC=CC=C1C(O)=O QVYBBKLFLNUXHA-HXUWFJFHSA-N 0.000 description 2
- OCMRCQQELDIZEH-JOCHJYFZSA-N 2-[4-[[5-[[(1r)-1-(6-cyclopropylpyridin-3-yl)ethyl]carbamoyl]-2,3-dimethylindol-1-yl]methyl]phenyl]benzoic acid Chemical compound N([C@H](C)C=1C=NC(=CC=1)C1CC1)C(=O)C(C=C1C(C)=C2C)=CC=C1N2CC(C=C1)=CC=C1C1=CC=CC=C1C(O)=O OCMRCQQELDIZEH-JOCHJYFZSA-N 0.000 description 2
- XQPWUAKNJFLZMY-HXUWFJFHSA-N 2-[4-[[5-[[(1r)-1-[2,5-bis(trifluoromethyl)phenyl]ethyl]carbamoyl]-2,3-dimethylindol-1-yl]methyl]phenyl]benzoic acid Chemical compound N([C@H](C)C=1C(=CC=C(C=1)C(F)(F)F)C(F)(F)F)C(=O)C(C=C1C(C)=C2C)=CC=C1N2CC(C=C1)=CC=C1C1=CC=CC=C1C(O)=O XQPWUAKNJFLZMY-HXUWFJFHSA-N 0.000 description 2
- JOHVCXBNJIHHKF-NRFANRHFSA-N 2-[4-[[5-[[(1s)-1-(1,3-benzodioxol-4-yl)ethyl]carbamoyl]-2,3-dimethylindol-1-yl]methyl]phenyl]benzoic acid Chemical compound N([C@@H](C)C=1C=2OCOC=2C=CC=1)C(=O)C(C=C1C(C)=C2C)=CC=C1N2CC(C=C1)=CC=C1C1=CC=CC=C1C(O)=O JOHVCXBNJIHHKF-NRFANRHFSA-N 0.000 description 2
- BUAUNSREZVSWFG-FQEVSTJZSA-N 2-[4-[[5-[[(1s)-1-(2,4-dichlorophenyl)ethyl]carbamoyl]-2,3-dimethylindol-1-yl]methyl]phenyl]benzoic acid Chemical compound N([C@@H](C)C=1C(=CC(Cl)=CC=1)Cl)C(=O)C(C=C1C(C)=C2C)=CC=C1N2CC(C=C1)=CC=C1C1=CC=CC=C1C(O)=O BUAUNSREZVSWFG-FQEVSTJZSA-N 0.000 description 2
- UWRBCJHBEFUNAC-FQEVSTJZSA-N 2-[4-[[5-[[(1s)-1-(2,4-difluorophenyl)ethyl]carbamoyl]-2,3-dimethylindol-1-yl]methyl]phenyl]benzoic acid Chemical compound N([C@@H](C)C=1C(=CC(F)=CC=1)F)C(=O)C(C=C1C(C)=C2C)=CC=C1N2CC(C=C1)=CC=C1C1=CC=CC=C1C(O)=O UWRBCJHBEFUNAC-FQEVSTJZSA-N 0.000 description 2
- BEUDKWBEOCRTDF-FQEVSTJZSA-N 2-[4-[[5-[[(1s)-1-(2,6-dichlorophenyl)ethyl]carbamoyl]-2,3-dimethylindol-1-yl]methyl]phenyl]benzoic acid Chemical compound N([C@@H](C)C=1C(=CC=CC=1Cl)Cl)C(=O)C(C=C1C(C)=C2C)=CC=C1N2CC(C=C1)=CC=C1C1=CC=CC=C1C(O)=O BEUDKWBEOCRTDF-FQEVSTJZSA-N 0.000 description 2
- KRCUARCKAHLZKP-FQEVSTJZSA-N 2-[4-[[5-[[(1s)-1-(2-bromopyridin-4-yl)ethyl]carbamoyl]-2,3-dimethylindol-1-yl]methyl]phenyl]benzoic acid Chemical compound N([C@@H](C)C=1C=C(Br)N=CC=1)C(=O)C(C=C1C(C)=C2C)=CC=C1N2CC(C=C1)=CC=C1C1=CC=CC=C1C(O)=O KRCUARCKAHLZKP-FQEVSTJZSA-N 0.000 description 2
- JUHOZWIMTYAQLN-FQEVSTJZSA-N 2-[4-[[5-[[(1s)-1-(2-chloro-3-fluorophenyl)ethyl]carbamoyl]-2,3-dimethylindol-1-yl]methyl]phenyl]benzoic acid Chemical compound N([C@@H](C)C=1C(=C(F)C=CC=1)Cl)C(=O)C(C=C1C(C)=C2C)=CC=C1N2CC(C=C1)=CC=C1C1=CC=CC=C1C(O)=O JUHOZWIMTYAQLN-FQEVSTJZSA-N 0.000 description 2
- KHUZZOHXJSDFFU-NRFANRHFSA-N 2-[4-[[5-[[(1s)-1-(2-chlorophenyl)ethyl]carbamoyl]-2,3-dimethylindol-1-yl]methyl]phenyl]benzoic acid Chemical compound N([C@@H](C)C=1C(=CC=CC=1)Cl)C(=O)C(C=C1C(C)=C2C)=CC=C1N2CC(C=C1)=CC=C1C1=CC=CC=C1C(O)=O KHUZZOHXJSDFFU-NRFANRHFSA-N 0.000 description 2
- DDXPQDHQGVAGBN-QFIPXVFZSA-N 2-[4-[[5-[[(1s)-1-(2-cyclopropylpyridin-4-yl)ethyl]carbamoyl]-2,3-dimethylindol-1-yl]methyl]phenyl]benzoic acid Chemical compound N([C@@H](C)C=1C=C(N=CC=1)C1CC1)C(=O)C(C=C1C(C)=C2C)=CC=C1N2CC(C=C1)=CC=C1C1=CC=CC=C1C(O)=O DDXPQDHQGVAGBN-QFIPXVFZSA-N 0.000 description 2
- UTHQNYLQWUZRIZ-NRFANRHFSA-N 2-[4-[[5-[[(1s)-1-(2-fluorophenyl)ethyl]carbamoyl]-2,3-dimethylindol-1-yl]methyl]phenyl]benzoic acid Chemical compound N([C@@H](C)C=1C(=CC=CC=1)F)C(=O)C(C=C1C(C)=C2C)=CC=C1N2CC(C=C1)=CC=C1C1=CC=CC=C1C(O)=O UTHQNYLQWUZRIZ-NRFANRHFSA-N 0.000 description 2
- WZECPSLEEFUPDF-QFIPXVFZSA-N 2-[4-[[5-[[(1s)-1-(3,5-dimethoxyphenyl)ethyl]carbamoyl]-2,3-dimethylindol-1-yl]methyl]phenyl]benzoic acid Chemical compound COC1=CC(OC)=CC([C@H](C)NC(=O)C=2C=C3C(C)=C(C)N(CC=4C=CC(=CC=4)C=4C(=CC=CC=4)C(O)=O)C3=CC=2)=C1 WZECPSLEEFUPDF-QFIPXVFZSA-N 0.000 description 2
- XTOLBZISFPRQDQ-NRFANRHFSA-N 2-[4-[[5-[[(1s)-1-(3-bromophenyl)ethyl]carbamoyl]-2,3-dimethylindol-1-yl]methyl]phenyl]benzoic acid Chemical compound N([C@@H](C)C=1C=C(Br)C=CC=1)C(=O)C(C=C1C(C)=C2C)=CC=C1N2CC(C=C1)=CC=C1C1=CC=CC=C1C(O)=O XTOLBZISFPRQDQ-NRFANRHFSA-N 0.000 description 2
- PPVPKFHIMCDMTJ-NRFANRHFSA-N 2-[4-[[5-[[(1s)-1-(3-chloro-4-methoxyphenyl)ethyl]carbamoyl]-2,3-dimethylindol-1-yl]methyl]phenyl]benzoic acid Chemical compound C1=C(Cl)C(OC)=CC=C1[C@H](C)NC(=O)C1=CC=C(N(CC=2C=CC(=CC=2)C=2C(=CC=CC=2)C(O)=O)C(C)=C2C)C2=C1 PPVPKFHIMCDMTJ-NRFANRHFSA-N 0.000 description 2
- KJZLGBIXIVMBFS-FQEVSTJZSA-N 2-[4-[[5-[[(1s)-1-(3-chloropyridin-4-yl)ethyl]carbamoyl]-2,3-dimethylindol-1-yl]methyl]phenyl]benzoic acid Chemical compound N([C@@H](C)C=1C(=CN=CC=1)Cl)C(=O)C(C=C1C(C)=C2C)=CC=C1N2CC(C=C1)=CC=C1C1=CC=CC=C1C(O)=O KJZLGBIXIVMBFS-FQEVSTJZSA-N 0.000 description 2
- WFYZRGARXVIIQQ-QHCPKHFHSA-N 2-[4-[[5-[[(1s)-1-(3-cyclopropylphenyl)ethyl]carbamoyl]-2,3-dimethylindol-1-yl]methyl]phenyl]benzoic acid Chemical compound N([C@@H](C)C=1C=C(C=CC=1)C1CC1)C(=O)C(C=C1C(C)=C2C)=CC=C1N2CC(C=C1)=CC=C1C1=CC=CC=C1C(O)=O WFYZRGARXVIIQQ-QHCPKHFHSA-N 0.000 description 2
- YQSOZZRVEFQIHG-QHCPKHFHSA-N 2-[4-[[5-[[(1s)-1-(3-ethoxyphenyl)ethyl]carbamoyl]-2,3-dimethylindol-1-yl]methyl]phenyl]benzoic acid Chemical compound CCOC1=CC=CC([C@H](C)NC(=O)C=2C=C3C(C)=C(C)N(CC=4C=CC(=CC=4)C=4C(=CC=CC=4)C(O)=O)C3=CC=2)=C1 YQSOZZRVEFQIHG-QHCPKHFHSA-N 0.000 description 2
- YGEWOLMHJJIQSH-NRFANRHFSA-N 2-[4-[[5-[[(1s)-1-(3-fluoro-2-methoxyphenyl)ethyl]carbamoyl]-2,3-dimethylindol-1-yl]methyl]phenyl]benzoic acid Chemical compound COC1=C(F)C=CC=C1[C@H](C)NC(=O)C1=CC=C(N(CC=2C=CC(=CC=2)C=2C(=CC=CC=2)C(O)=O)C(C)=C2C)C2=C1 YGEWOLMHJJIQSH-NRFANRHFSA-N 0.000 description 2
- DRBNKQSJRCXQIJ-QFIPXVFZSA-N 2-[4-[[5-[[(1s)-1-(3-fluoro-2-methylphenyl)ethyl]carbamoyl]-2,3-dimethylindol-1-yl]methyl]phenyl]benzoic acid Chemical compound N([C@@H](C)C=1C(=C(F)C=CC=1)C)C(=O)C(C=C1C(C)=C2C)=CC=C1N2CC(C=C1)=CC=C1C1=CC=CC=C1C(O)=O DRBNKQSJRCXQIJ-QFIPXVFZSA-N 0.000 description 2
- VQTQFVSEINXGLP-NRFANRHFSA-N 2-[4-[[5-[[(1s)-1-(3-fluoro-5-methoxyphenyl)ethyl]carbamoyl]-2,3-dimethylindol-1-yl]methyl]phenyl]benzoic acid Chemical compound COC1=CC(F)=CC([C@H](C)NC(=O)C=2C=C3C(C)=C(C)N(CC=4C=CC(=CC=4)C=4C(=CC=CC=4)C(O)=O)C3=CC=2)=C1 VQTQFVSEINXGLP-NRFANRHFSA-N 0.000 description 2
- HJWIOHAXVGDTNU-NRFANRHFSA-N 2-[4-[[5-[[(1s)-1-(3-fluorophenyl)ethyl]carbamoyl]-2,3-dimethylindol-1-yl]methyl]phenyl]benzoic acid Chemical compound N([C@@H](C)C=1C=C(F)C=CC=1)C(=O)C(C=C1C(C)=C2C)=CC=C1N2CC(C=C1)=CC=C1C1=CC=CC=C1C(O)=O HJWIOHAXVGDTNU-NRFANRHFSA-N 0.000 description 2
- CDLJJRCMFYXSIQ-QFIPXVFZSA-N 2-[4-[[5-[[(1s)-1-(3-methoxyphenyl)ethyl]carbamoyl]-2,3-dimethylindol-1-yl]methyl]phenyl]benzoic acid Chemical compound COC1=CC=CC([C@H](C)NC(=O)C=2C=C3C(C)=C(C)N(CC=4C=CC(=CC=4)C=4C(=CC=CC=4)C(O)=O)C3=CC=2)=C1 CDLJJRCMFYXSIQ-QFIPXVFZSA-N 0.000 description 2
- NMFGWJBEPAMYHB-DEOSSOPVSA-N 2-[4-[[5-[[(1s)-1-(3-tert-butylphenyl)ethyl]carbamoyl]-2,3-dimethylindol-1-yl]methyl]phenyl]benzoic acid Chemical compound N([C@@H](C)C=1C=C(C=CC=1)C(C)(C)C)C(=O)C(C=C1C(C)=C2C)=CC=C1N2CC(C=C1)=CC=C1C1=CC=CC=C1C(O)=O NMFGWJBEPAMYHB-DEOSSOPVSA-N 0.000 description 2
- IUQVGYGFEBDCQE-NRFANRHFSA-N 2-[4-[[5-[[(1s)-1-(4-bromophenyl)ethyl]carbamoyl]-2-methylindol-1-yl]methyl]phenyl]benzoic acid Chemical compound N([C@@H](C)C=1C=CC(Br)=CC=1)C(=O)C(C=C1C=C2C)=CC=C1N2CC(C=C1)=CC=C1C1=CC=CC=C1C(O)=O IUQVGYGFEBDCQE-NRFANRHFSA-N 0.000 description 2
- UVRGRITZFLRYEU-NRFANRHFSA-N 2-[4-[[5-[[(1s)-1-(4-bromophenyl)ethyl]carbamoyl]-3-methylindol-1-yl]methyl]phenyl]benzoic acid Chemical compound N([C@@H](C)C=1C=CC(Br)=CC=1)C(=O)C(C=C1C(C)=C2)=CC=C1N2CC(C=C1)=CC=C1C1=CC=CC=C1C(O)=O UVRGRITZFLRYEU-NRFANRHFSA-N 0.000 description 2
- ASUNKSTYSUPMAS-FQEVSTJZSA-N 2-[4-[[5-[[(1s)-1-(4-bromophenyl)ethyl]carbamoyl]indol-1-yl]methyl]phenyl]benzoic acid Chemical compound N([C@@H](C)C=1C=CC(Br)=CC=1)C(=O)C(C=C1C=C2)=CC=C1N2CC(C=C1)=CC=C1C1=CC=CC=C1C(O)=O ASUNKSTYSUPMAS-FQEVSTJZSA-N 0.000 description 2
- KNMVEKDEOHFNPI-NRFANRHFSA-N 2-[4-[[5-[[(1s)-1-(4-chlorophenyl)ethyl]carbamoyl]-2,3-dimethylindol-1-yl]methyl]phenyl]benzoic acid Chemical compound N([C@@H](C)C=1C=CC(Cl)=CC=1)C(=O)C(C=C1C(C)=C2C)=CC=C1N2CC(C=C1)=CC=C1C1=CC=CC=C1C(O)=O KNMVEKDEOHFNPI-NRFANRHFSA-N 0.000 description 2
- OFOAIQXVFTYDCK-FQEVSTJZSA-N 2-[4-[[5-[[(1s)-1-(4-chloropyridin-2-yl)ethyl]carbamoyl]-2,3-dimethylindol-1-yl]methyl]phenyl]benzoic acid Chemical compound N([C@@H](C)C=1N=CC=C(Cl)C=1)C(=O)C(C=C1C(C)=C2C)=CC=C1N2CC(C=C1)=CC=C1C1=CC=CC=C1C(O)=O OFOAIQXVFTYDCK-FQEVSTJZSA-N 0.000 description 2
- CAXQXGYLTJHCCS-QFIPXVFZSA-N 2-[4-[[5-[[(1s)-1-(4-cyclopropylpyridin-2-yl)ethyl]carbamoyl]-2,3-dimethylindol-1-yl]methyl]phenyl]benzoic acid Chemical compound N([C@@H](C)C=1N=CC=C(C=1)C1CC1)C(=O)C(C=C1C(C)=C2C)=CC=C1N2CC(C=C1)=CC=C1C1=CC=CC=C1C(O)=O CAXQXGYLTJHCCS-QFIPXVFZSA-N 0.000 description 2
- QNANVKGUWWFSIH-QFIPXVFZSA-N 2-[4-[[5-[[(1s)-1-(4-methoxyphenyl)ethyl]carbamoyl]-2,3-dimethylindol-1-yl]methyl]phenyl]benzoic acid Chemical compound C1=CC(OC)=CC=C1[C@H](C)NC(=O)C1=CC=C(N(CC=2C=CC(=CC=2)C=2C(=CC=CC=2)C(O)=O)C(C)=C2C)C2=C1 QNANVKGUWWFSIH-QFIPXVFZSA-N 0.000 description 2
- UDRDLKOPYAODHR-FQEVSTJZSA-N 2-[4-[[5-[[(1s)-1-(5-bromopyridin-2-yl)ethyl]carbamoyl]-2,3-dimethylindol-1-yl]methyl]phenyl]benzoic acid Chemical compound N([C@@H](C)C=1N=CC(Br)=CC=1)C(=O)C(C=C1C(C)=C2C)=CC=C1N2CC(C=C1)=CC=C1C1=CC=CC=C1C(O)=O UDRDLKOPYAODHR-FQEVSTJZSA-N 0.000 description 2
- UYRROCNOXLJOQD-QFIPXVFZSA-N 2-[4-[[5-[[(1s)-1-(5-cyclopropylpyridin-2-yl)ethyl]carbamoyl]-2,3-dimethylindol-1-yl]methyl]phenyl]benzoic acid Chemical compound N([C@@H](C)C=1N=CC(=CC=1)C1CC1)C(=O)C(C=C1C(C)=C2C)=CC=C1N2CC(C=C1)=CC=C1C1=CC=CC=C1C(O)=O UYRROCNOXLJOQD-QFIPXVFZSA-N 0.000 description 2
- QVYBBKLFLNUXHA-FQEVSTJZSA-N 2-[4-[[5-[[(1s)-1-(6-bromopyridin-2-yl)ethyl]carbamoyl]-2,3-dimethylindol-1-yl]methyl]phenyl]benzoic acid Chemical compound N([C@@H](C)C=1N=C(Br)C=CC=1)C(=O)C(C=C1C(C)=C2C)=CC=C1N2CC(C=C1)=CC=C1C1=CC=CC=C1C(O)=O QVYBBKLFLNUXHA-FQEVSTJZSA-N 0.000 description 2
- FHWUAKZRPWCAON-FQEVSTJZSA-N 2-[4-[[5-[[(1s)-1-(6-chloropyridin-3-yl)ethyl]carbamoyl]-2,3-dimethylindol-1-yl]methyl]phenyl]benzoic acid Chemical compound N([C@@H](C)C=1C=NC(Cl)=CC=1)C(=O)C(C=C1C(C)=C2C)=CC=C1N2CC(C=C1)=CC=C1C1=CC=CC=C1C(O)=O FHWUAKZRPWCAON-FQEVSTJZSA-N 0.000 description 2
- BZYJVCPCETVFBR-QFIPXVFZSA-N 2-[4-[[5-[[(1s)-1-(6-cyclopropylpyridin-2-yl)ethyl]carbamoyl]-2,3-dimethylindol-1-yl]methyl]phenyl]benzoic acid Chemical compound N([C@@H](C)C=1N=C(C=CC=1)C1CC1)C(=O)C(C=C1C(C)=C2C)=CC=C1N2CC(C=C1)=CC=C1C1=CC=CC=C1C(O)=O BZYJVCPCETVFBR-QFIPXVFZSA-N 0.000 description 2
- OCMRCQQELDIZEH-QFIPXVFZSA-N 2-[4-[[5-[[(1s)-1-(6-cyclopropylpyridin-3-yl)ethyl]carbamoyl]-2,3-dimethylindol-1-yl]methyl]phenyl]benzoic acid Chemical compound N([C@@H](C)C=1C=NC(=CC=1)C1CC1)C(=O)C(C=C1C(C)=C2C)=CC=C1N2CC(C=C1)=CC=C1C1=CC=CC=C1C(O)=O OCMRCQQELDIZEH-QFIPXVFZSA-N 0.000 description 2
- XQPWUAKNJFLZMY-FQEVSTJZSA-N 2-[4-[[5-[[(1s)-1-[2,5-bis(trifluoromethyl)phenyl]ethyl]carbamoyl]-2,3-dimethylindol-1-yl]methyl]phenyl]benzoic acid Chemical compound N([C@@H](C)C=1C(=CC=C(C=1)C(F)(F)F)C(F)(F)F)C(=O)C(C=C1C(C)=C2C)=CC=C1N2CC(C=C1)=CC=C1C1=CC=CC=C1C(O)=O XQPWUAKNJFLZMY-FQEVSTJZSA-N 0.000 description 2
- LZOGSUAKBUOZLL-FQEVSTJZSA-N 2-[4-[[5-[[(1s)-1-[2-chloro-5-(trifluoromethyl)phenyl]ethyl]carbamoyl]-2,3-dimethylindol-1-yl]methyl]phenyl]benzoic acid Chemical compound N([C@@H](C)C=1C(=CC=C(C=1)C(F)(F)F)Cl)C(=O)C(C=C1C(C)=C2C)=CC=C1N2CC(C=C1)=CC=C1C1=CC=CC=C1C(O)=O LZOGSUAKBUOZLL-FQEVSTJZSA-N 0.000 description 2
- WMZOCGXPHWSBBY-FQEVSTJZSA-N 2-[4-[[5-[[(1s)-1-[2-fluoro-3-(trifluoromethyl)phenyl]ethyl]carbamoyl]-2,3-dimethylindol-1-yl]methyl]phenyl]benzoic acid Chemical compound N([C@@H](C)C=1C(=C(C=CC=1)C(F)(F)F)F)C(=O)C(C=C1C(C)=C2C)=CC=C1N2CC(C=C1)=CC=C1C1=CC=CC=C1C(O)=O WMZOCGXPHWSBBY-FQEVSTJZSA-N 0.000 description 2
- QKTSBTIDGCRCRA-FQEVSTJZSA-N 2-[4-[[5-[[(1s)-1-[2-fluoro-4-(trifluoromethyl)phenyl]ethyl]carbamoyl]-2,3-dimethylindol-1-yl]methyl]phenyl]benzoic acid Chemical compound N([C@@H](C)C=1C(=CC(=CC=1)C(F)(F)F)F)C(=O)C(C=C1C(C)=C2C)=CC=C1N2CC(C=C1)=CC=C1C1=CC=CC=C1C(O)=O QKTSBTIDGCRCRA-FQEVSTJZSA-N 0.000 description 2
- NTTWXQWLQNIXSH-FQEVSTJZSA-N 2-[4-[[5-[[(1s)-1-[2-fluoro-6-(trifluoromethyl)phenyl]ethyl]carbamoyl]-2,3-dimethylindol-1-yl]methyl]phenyl]benzoic acid Chemical compound N([C@@H](C)C=1C(=CC=CC=1F)C(F)(F)F)C(=O)C(C=C1C(C)=C2C)=CC=C1N2CC(C=C1)=CC=C1C1=CC=CC=C1C(O)=O NTTWXQWLQNIXSH-FQEVSTJZSA-N 0.000 description 2
- QWBMMUAFOHSGAA-BHVANESWSA-N 2-[4-[[5-[[(s)-cyclopropyl-(3-propan-2-ylphenyl)methyl]carbamoyl]-2,3-dimethylindol-1-yl]methyl]phenyl]benzoic acid Chemical compound CC(C)C1=CC=CC([C@@H](NC(=O)C=2C=C3C(C)=C(C)N(CC=4C=CC(=CC=4)C=4C(=CC=CC=4)C(O)=O)C3=CC=2)C2CC2)=C1 QWBMMUAFOHSGAA-BHVANESWSA-N 0.000 description 2
- FKLZNFSDXQYIAH-UHFFFAOYSA-N 2-[4-[[5-[[4-(dimethylamino)phenyl]methylcarbamoyl]-2,3-dimethylindol-1-yl]methyl]phenyl]benzoic acid Chemical compound C1=CC(N(C)C)=CC=C1CNC(=O)C1=CC=C(N(CC=2C=CC(=CC=2)C=2C(=CC=CC=2)C(O)=O)C(C)=C2C)C2=C1 FKLZNFSDXQYIAH-UHFFFAOYSA-N 0.000 description 2
- OOQAXNXGYWQSIZ-UHFFFAOYSA-N 2-[4-[[5-[benzyl(methyl)carbamoyl]-2,3-dimethylindol-1-yl]methyl]phenyl]benzoic acid Chemical compound C=1C=C2N(CC=3C=CC(=CC=3)C=3C(=CC=CC=3)C(O)=O)C(C)=C(C)C2=CC=1C(=O)N(C)CC1=CC=CC=C1 OOQAXNXGYWQSIZ-UHFFFAOYSA-N 0.000 description 2
- RTWLIQFKXMWEJY-UHFFFAOYSA-N 2-bromopyridine-4-carbaldehyde Chemical compound BrC1=CC(C=O)=CC=N1 RTWLIQFKXMWEJY-UHFFFAOYSA-N 0.000 description 2
- HKHXLHGVIHQKMK-UHFFFAOYSA-N 2-chloro-m-cresol Chemical compound CC1=CC=CC(O)=C1Cl HKHXLHGVIHQKMK-UHFFFAOYSA-N 0.000 description 2
- KKESHHUPAFNMPH-UHFFFAOYSA-N 2-methoxy-4-(trifluoromethyl)benzaldehyde Chemical compound COC1=CC(C(F)(F)F)=CC=C1C=O KKESHHUPAFNMPH-UHFFFAOYSA-N 0.000 description 2
- FBJGVJKISFKABO-UHFFFAOYSA-N 2-methyl-2-(3-methylphenyl)propanenitrile Chemical compound CC1=CC=CC(C(C)(C)C#N)=C1 FBJGVJKISFKABO-UHFFFAOYSA-N 0.000 description 2
- OWEYIKXEZWBJKD-ASSNKEHSSA-N 2-methyl-n-[(1r)-2,2,2-trifluoro-1-(3-propan-2-ylphenyl)ethyl]propane-2-sulfinamide Chemical compound CC(C)C1=CC=CC([C@@H](N[S@@](=O)C(C)(C)C)C(F)(F)F)=C1 OWEYIKXEZWBJKD-ASSNKEHSSA-N 0.000 description 2
- RAEVOBPXEHVUFY-ZCFIWIBFSA-N 22038-87-5 Chemical compound C[C@@H](N)C1=CC=C([N+]([O-])=O)C=C1 RAEVOBPXEHVUFY-ZCFIWIBFSA-N 0.000 description 2
- SVWDNDQOXZHBRM-UHFFFAOYSA-N 3,4-dihydro-2h-chromen-3-amine Chemical compound C1=CC=C2CC(N)COC2=C1 SVWDNDQOXZHBRM-UHFFFAOYSA-N 0.000 description 2
- VFZRZRDOXPRTSC-UHFFFAOYSA-N 3,5-Dimethoxybenzaldehyde Chemical compound COC1=CC(OC)=CC(C=O)=C1 VFZRZRDOXPRTSC-UHFFFAOYSA-N 0.000 description 2
- RLAOKDGTZKSUJB-UHFFFAOYSA-N 3,5-difluoropyridine-4-carbaldehyde Chemical compound FC1=CN=CC(F)=C1C=O RLAOKDGTZKSUJB-UHFFFAOYSA-N 0.000 description 2
- HMNKTRSOROOSPP-UHFFFAOYSA-N 3-Ethylphenol Chemical compound CCC1=CC=CC(O)=C1 HMNKTRSOROOSPP-UHFFFAOYSA-N 0.000 description 2
- ADUYAJIFZKXWCR-UHFFFAOYSA-N 3-[2-[[2,3-dimethyl-5-(1-phenylpropylcarbamoyl)indol-1-yl]methyl]phenyl]benzoic acid Chemical compound C=1C=CC=CC=1C(CC)NC(=O)C(C=C1C(C)=C2C)=CC=C1N2CC1=CC=CC=C1C1=CC=CC(C(O)=O)=C1 ADUYAJIFZKXWCR-UHFFFAOYSA-N 0.000 description 2
- JXLAMCUTTNKCOO-NRFANRHFSA-N 3-[2-[[2,3-dimethyl-5-[[(1s)-1-(4-nitrophenyl)ethyl]carbamoyl]indol-1-yl]methyl]phenyl]benzoic acid Chemical compound N([C@@H](C)C=1C=CC(=CC=1)[N+]([O-])=O)C(=O)C(C=C1C(C)=C2C)=CC=C1N2CC1=CC=CC=C1C1=CC=CC(C(O)=O)=C1 JXLAMCUTTNKCOO-NRFANRHFSA-N 0.000 description 2
- NICJNANYSZSYDZ-UHFFFAOYSA-N 3-[2-[[5-(1-phenylpropylcarbamoyl)indol-1-yl]methyl]phenyl]benzoic acid Chemical compound C=1C=CC=CC=1C(CC)NC(=O)C(C=C1C=C2)=CC=C1N2CC1=CC=CC=C1C1=CC=CC(C(O)=O)=C1 NICJNANYSZSYDZ-UHFFFAOYSA-N 0.000 description 2
- ATXPGSKFKPBPBI-NRFANRHFSA-N 3-[2-[[5-[[(1s)-1-(4-bromophenyl)ethyl]carbamoyl]-2,3-dimethylindol-1-yl]methyl]phenyl]benzoic acid Chemical compound N([C@@H](C)C=1C=CC(Br)=CC=1)C(=O)C(C=C1C(C)=C2C)=CC=C1N2CC1=CC=CC=C1C1=CC=CC(C(O)=O)=C1 ATXPGSKFKPBPBI-NRFANRHFSA-N 0.000 description 2
- SJXGIVQGIULVMQ-FQEVSTJZSA-N 3-[2-[[5-[[(1s)-1-(4-bromophenyl)ethyl]carbamoyl]indol-1-yl]methyl]phenyl]benzoic acid Chemical compound N([C@@H](C)C=1C=CC(Br)=CC=1)C(=O)C(C=C1C=C2)=CC=C1N2CC1=CC=CC=C1C1=CC=CC(C(O)=O)=C1 SJXGIVQGIULVMQ-FQEVSTJZSA-N 0.000 description 2
- LQNUAIOYMRASIA-FQEVSTJZSA-N 3-[2-[[5-[[(1s)-1-(4-nitrophenyl)ethyl]carbamoyl]indol-1-yl]methyl]phenyl]benzoic acid Chemical compound N([C@@H](C)C=1C=CC(=CC=1)[N+]([O-])=O)C(=O)C(C=C1C=C2)=CC=C1N2CC1=CC=CC=C1C1=CC=CC(C(O)=O)=C1 LQNUAIOYMRASIA-FQEVSTJZSA-N 0.000 description 2
- ROJSHBUDYQAXAJ-UHFFFAOYSA-N 3-[3-[[5-(1-phenylpropylcarbamoyl)indol-1-yl]methyl]phenyl]benzoic acid Chemical compound C=1C=CC=CC=1C(CC)NC(=O)C(C=C1C=C2)=CC=C1N2CC(C=1)=CC=CC=1C1=CC=CC(C(O)=O)=C1 ROJSHBUDYQAXAJ-UHFFFAOYSA-N 0.000 description 2
- YMXRPPNTNMQOFL-IBGZPJMESA-N 3-[[5-[[(1s)-1-(3-cyclopropylphenyl)ethyl]carbamoyl]-2,3-dimethylindol-1-yl]methyl]benzoic acid Chemical compound N([C@@H](C)C=1C=C(C=CC=1)C1CC1)C(=O)C(C=C1C(C)=C2C)=CC=C1N2CC1=CC=CC(C(O)=O)=C1 YMXRPPNTNMQOFL-IBGZPJMESA-N 0.000 description 2
- WYVGYYIZXPXHAZ-UHFFFAOYSA-N 3-chloro-4-methoxybenzaldehyde Chemical compound COC1=CC=C(C=O)C=C1Cl WYVGYYIZXPXHAZ-UHFFFAOYSA-N 0.000 description 2
- VQZRLBWPEHFGCD-UHFFFAOYSA-N 3-chloro-4-methylphenol Chemical compound CC1=CC=C(O)C=C1Cl VQZRLBWPEHFGCD-UHFFFAOYSA-N 0.000 description 2
- QXHZLCYUCTZZNL-UHFFFAOYSA-N 3-chloro-5-methylphenol Chemical compound CC1=CC(O)=CC(Cl)=C1 QXHZLCYUCTZZNL-UHFFFAOYSA-N 0.000 description 2
- SVSUYEJKNSMKKW-UHFFFAOYSA-N 4,4,5,5-tetramethyl-2-prop-1-en-2-yl-1,3,2-dioxaborolane Chemical compound CC(=C)B1OC(C)(C)C(C)(C)O1 SVSUYEJKNSMKKW-UHFFFAOYSA-N 0.000 description 2
- BFWYZZPDZZGSLJ-UHFFFAOYSA-N 4-(aminomethyl)aniline Chemical compound NCC1=CC=C(N)C=C1 BFWYZZPDZZGSLJ-UHFFFAOYSA-N 0.000 description 2
- QNGNSVIICDLXHT-UHFFFAOYSA-N 4-Ethylbenzaldehyde Chemical compound CCC1=CC=C(C=O)C=C1 QNGNSVIICDLXHT-UHFFFAOYSA-N 0.000 description 2
- UEFHAPYDMRIRPQ-UHFFFAOYSA-N 4-[2-[[2,3-dimethyl-5-(1-phenylpropylcarbamoyl)indol-1-yl]methyl]phenyl]benzoic acid Chemical compound C=1C=CC=CC=1C(CC)NC(=O)C(C=C1C(C)=C2C)=CC=C1N2CC1=CC=CC=C1C1=CC=C(C(O)=O)C=C1 UEFHAPYDMRIRPQ-UHFFFAOYSA-N 0.000 description 2
- OADBLYRRQHKIEB-NRFANRHFSA-N 4-[2-[[2,3-dimethyl-5-[[(1s)-1-(4-nitrophenyl)ethyl]carbamoyl]indol-1-yl]methyl]phenyl]benzoic acid Chemical compound N([C@@H](C)C=1C=CC(=CC=1)[N+]([O-])=O)C(=O)C(C=C1C(C)=C2C)=CC=C1N2CC1=CC=CC=C1C1=CC=C(C(O)=O)C=C1 OADBLYRRQHKIEB-NRFANRHFSA-N 0.000 description 2
- ONKNVTVXRZIDCU-UHFFFAOYSA-N 4-[2-[[5-(1-phenylpropylcarbamoyl)indol-1-yl]methyl]phenyl]benzoic acid Chemical compound C=1C=CC=CC=1C(CC)NC(=O)C(C=C1C=C2)=CC=C1N2CC1=CC=CC=C1C1=CC=C(C(O)=O)C=C1 ONKNVTVXRZIDCU-UHFFFAOYSA-N 0.000 description 2
- QZSFNERCXYENDA-NRFANRHFSA-N 4-[2-[[5-[[(1s)-1-(4-bromophenyl)ethyl]carbamoyl]-2,3-dimethylindol-1-yl]methyl]phenyl]benzoic acid Chemical compound N([C@@H](C)C=1C=CC(Br)=CC=1)C(=O)C(C=C1C(C)=C2C)=CC=C1N2CC1=CC=CC=C1C1=CC=C(C(O)=O)C=C1 QZSFNERCXYENDA-NRFANRHFSA-N 0.000 description 2
- BXGOPXUBUSOYPY-FQEVSTJZSA-N 4-[2-[[5-[[(1s)-1-(4-bromophenyl)ethyl]carbamoyl]indol-1-yl]methyl]phenyl]benzoic acid Chemical compound N([C@@H](C)C=1C=CC(Br)=CC=1)C(=O)C(C=C1C=C2)=CC=C1N2CC1=CC=CC=C1C1=CC=C(C(O)=O)C=C1 BXGOPXUBUSOYPY-FQEVSTJZSA-N 0.000 description 2
- UFSYOSFWCQNCEZ-FQEVSTJZSA-N 4-[2-[[5-[[(1s)-1-(4-nitrophenyl)ethyl]carbamoyl]indol-1-yl]methyl]phenyl]benzoic acid Chemical compound N([C@@H](C)C=1C=CC(=CC=1)[N+]([O-])=O)C(=O)C(C=C1C=C2)=CC=C1N2CC1=CC=CC=C1C1=CC=C(C(O)=O)C=C1 UFSYOSFWCQNCEZ-FQEVSTJZSA-N 0.000 description 2
- VHETWSXWIMARSF-UHFFFAOYSA-N 4-[3-[[5-(1-phenylpropylcarbamoyl)indol-1-yl]methyl]phenyl]benzoic acid Chemical compound C=1C=CC=CC=1C(CC)NC(=O)C(C=C1C=C2)=CC=C1N2CC(C=1)=CC=CC=1C1=CC=C(C(O)=O)C=C1 VHETWSXWIMARSF-UHFFFAOYSA-N 0.000 description 2
- KVCQTKNUUQOELD-UHFFFAOYSA-N 4-amino-n-[1-(3-chloro-2-fluoroanilino)-6-methylisoquinolin-5-yl]thieno[3,2-d]pyrimidine-7-carboxamide Chemical compound N=1C=CC2=C(NC(=O)C=3C4=NC=NC(N)=C4SC=3)C(C)=CC=C2C=1NC1=CC=CC(Cl)=C1F KVCQTKNUUQOELD-UHFFFAOYSA-N 0.000 description 2
- HXDOZKJGKXYMEW-UHFFFAOYSA-N 4-ethylphenol Chemical compound CCC1=CC=C(O)C=C1 HXDOZKJGKXYMEW-UHFFFAOYSA-N 0.000 description 2
- YYROPELSRYBVMQ-UHFFFAOYSA-N 4-toluenesulfonyl chloride Chemical compound CC1=CC=C(S(Cl)(=O)=O)C=C1 YYROPELSRYBVMQ-UHFFFAOYSA-N 0.000 description 2
- NGUVGKAEOFPLDT-UHFFFAOYSA-N 5-bromopyridine-3-carbaldehyde Chemical compound BrC1=CN=CC(C=O)=C1 NGUVGKAEOFPLDT-UHFFFAOYSA-N 0.000 description 2
- CRLDWFVRQNUUSZ-UHFFFAOYSA-N 5-fluoro-2-methoxybenzaldehyde Chemical compound COC1=CC=C(F)C=C1C=O CRLDWFVRQNUUSZ-UHFFFAOYSA-N 0.000 description 2
- AFWWKZCPPRPDQK-UHFFFAOYSA-N 6-chloropyridine-3-carbaldehyde Chemical compound ClC1=CC=C(C=O)C=N1 AFWWKZCPPRPDQK-UHFFFAOYSA-N 0.000 description 2
- CYJRNFFLTBEQSQ-UHFFFAOYSA-N 8-(3-methyl-1-benzothiophen-5-yl)-N-(4-methylsulfonylpyridin-3-yl)quinoxalin-6-amine Chemical compound CS(=O)(=O)C1=C(C=NC=C1)NC=1C=C2N=CC=NC2=C(C=1)C=1C=CC2=C(C(=CS2)C)C=1 CYJRNFFLTBEQSQ-UHFFFAOYSA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 2
- 208000010392 Bone Fractures Diseases 0.000 description 2
- 239000005537 C09CA07 - Telmisartan Substances 0.000 description 2
- 101150053721 Cdk5 gene Proteins 0.000 description 2
- 101100007328 Cocos nucifera COS-1 gene Proteins 0.000 description 2
- 206010017076 Fracture Diseases 0.000 description 2
- 102100039556 Galectin-4 Human genes 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical compound NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 2
- 101000608765 Homo sapiens Galectin-4 Proteins 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 108060001084 Luciferase Proteins 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- OKIZCWYLBDKLSU-UHFFFAOYSA-M N,N,N-Trimethylmethanaminium chloride Chemical compound [Cl-].C[N+](C)(C)C OKIZCWYLBDKLSU-UHFFFAOYSA-M 0.000 description 2
- AYCPARAPKDAOEN-LJQANCHMSA-N N-[(1S)-2-(dimethylamino)-1-phenylethyl]-6,6-dimethyl-3-[(2-methyl-4-thieno[3,2-d]pyrimidinyl)amino]-1,4-dihydropyrrolo[3,4-c]pyrazole-5-carboxamide Chemical compound C1([C@H](NC(=O)N2C(C=3NN=C(NC=4C=5SC=CC=5N=C(C)N=4)C=3C2)(C)C)CN(C)C)=CC=CC=C1 AYCPARAPKDAOEN-LJQANCHMSA-N 0.000 description 2
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 2
- 229910020889 NaBH3 Inorganic materials 0.000 description 2
- 102000007399 Nuclear hormone receptor Human genes 0.000 description 2
- 108020005497 Nuclear hormone receptor Proteins 0.000 description 2
- 208000008589 Obesity Diseases 0.000 description 2
- 102000003728 Peroxisome Proliferator-Activated Receptors Human genes 0.000 description 2
- 108090000029 Peroxisome Proliferator-Activated Receptors Proteins 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- WHBMMWSBFZVSSR-UHFFFAOYSA-N R3HBA Natural products CC(O)CC(O)=O WHBMMWSBFZVSSR-UHFFFAOYSA-N 0.000 description 2
- 108091027981 Response element Proteins 0.000 description 2
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 2
- OKJPEAGHQZHRQV-UHFFFAOYSA-N Triiodomethane Natural products IC(I)I OKJPEAGHQZHRQV-UHFFFAOYSA-N 0.000 description 2
- YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 2
- QRBWBDQDDUSRKD-NUBCRITNSA-N [(1r)-1-(2-bromopyridin-4-yl)ethyl]azanium;chloride Chemical compound [Cl-].C[C@@H]([NH3+])C1=CC=NC(Br)=C1 QRBWBDQDDUSRKD-NUBCRITNSA-N 0.000 description 2
- JAECXGZNWPVNEU-OGFXRTJISA-N [(1r)-1-(4-methylsulfonylphenyl)ethyl]azanium;chloride Chemical compound [Cl-].C[C@@H]([NH3+])C1=CC=C(S(C)(=O)=O)C=C1 JAECXGZNWPVNEU-OGFXRTJISA-N 0.000 description 2
- RITFLBZVEWSGLF-NUBCRITNSA-N [(1r)-1-(6-bromopyridin-2-yl)ethyl]azanium;chloride Chemical compound [Cl-].C[C@@H]([NH3+])C1=CC=CC(Br)=N1 RITFLBZVEWSGLF-NUBCRITNSA-N 0.000 description 2
- XSSQHKNXVJIENT-BTQNPOSSSA-N [(1r)-2-methyl-1-(3-propan-2-ylphenyl)propyl]azanium;chloride Chemical compound [Cl-].CC(C)[C@@H]([NH3+])C1=CC=CC(C(C)C)=C1 XSSQHKNXVJIENT-BTQNPOSSSA-N 0.000 description 2
- FKDPTYXZVCGPBA-YDALLXLXSA-N [(1s)-1-(1-phenylmethoxycarbonylpiperidin-4-yl)ethyl]azanium;chloride Chemical compound [Cl-].C1CC([C@@H]([NH3+])C)CCN1C(=O)OCC1=CC=CC=C1 FKDPTYXZVCGPBA-YDALLXLXSA-N 0.000 description 2
- IZERSUMZSHWVCM-RGMNGODLSA-N [(1s)-1-(3-chloro-4-methoxyphenyl)ethyl]azanium;chloride Chemical compound [Cl-].COC1=CC=C([C@H](C)[NH3+])C=C1Cl IZERSUMZSHWVCM-RGMNGODLSA-N 0.000 description 2
- YAHAEBHJOZKNJI-YDALLXLXSA-N [(1s)-1-(3-propan-2-ylphenyl)propyl]azanium;chloride Chemical compound [Cl-].CC[C@H]([NH3+])C1=CC=CC(C(C)C)=C1 YAHAEBHJOZKNJI-YDALLXLXSA-N 0.000 description 2
- HHUAULBXQLLZHV-JEDNCBNOSA-N [(1s)-1-(4-chloropyridin-2-yl)ethyl]azanium;chloride Chemical compound [Cl-].C[C@H]([NH3+])C1=CC(Cl)=CC=N1 HHUAULBXQLLZHV-JEDNCBNOSA-N 0.000 description 2
- ZFAXPIYAUOLSGN-FVGYRXGTSA-N [(1s)-1-(4-propan-2-yloxyphenyl)ethyl]azanium;chloride Chemical compound [Cl-].CC(C)OC1=CC=C([C@H](C)[NH3+])C=C1 ZFAXPIYAUOLSGN-FVGYRXGTSA-N 0.000 description 2
- RITFLBZVEWSGLF-JEDNCBNOSA-N [(1s)-1-(6-bromopyridin-2-yl)ethyl]azanium;chloride Chemical compound [Cl-].C[C@H]([NH3+])C1=CC=CC(Br)=N1 RITFLBZVEWSGLF-JEDNCBNOSA-N 0.000 description 2
- FFDARTLRQCBNRB-JEDNCBNOSA-N [(1s)-1-(6-chloropyridin-3-yl)ethyl]azanium;chloride Chemical compound [Cl-].C[C@H]([NH3+])C1=CC=C(Cl)N=C1 FFDARTLRQCBNRB-JEDNCBNOSA-N 0.000 description 2
- QUIDSCSLPAUKJH-FVGYRXGTSA-N [(1s)-1-[4-[(2-methylpropan-2-yl)oxy]phenyl]ethyl]azanium;chloride Chemical compound [Cl-].C[C@H]([NH3+])C1=CC=C(OC(C)(C)C)C=C1 QUIDSCSLPAUKJH-FVGYRXGTSA-N 0.000 description 2
- TUPUHSXMDIWJQT-UHFFFAOYSA-N [3-(trifluoromethoxy)phenyl]methanamine Chemical compound NCC1=CC=CC(OC(F)(F)F)=C1 TUPUHSXMDIWJQT-UHFFFAOYSA-N 0.000 description 2
- AYQJWECIZULYNV-UHFFFAOYSA-N [4-(1-bromoethyl)phenyl] acetate Chemical compound CC(Br)C1=CC=C(OC(C)=O)C=C1 AYQJWECIZULYNV-UHFFFAOYSA-N 0.000 description 2
- WETWJCDKMRHUPV-UHFFFAOYSA-N acetyl chloride Chemical compound CC(Cl)=O WETWJCDKMRHUPV-UHFFFAOYSA-N 0.000 description 2
- 239000012346 acetyl chloride Substances 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 125000003647 acryloyl group Chemical group O=C([*])C([H])=C([H])[H] 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 125000005073 adamantyl group Chemical group C12(CC3CC(CC(C1)C3)C2)* 0.000 description 2
- 125000005426 adeninyl group Chemical group N1=C(N=C2N=CNC2=C1N)* 0.000 description 2
- 210000001789 adipocyte Anatomy 0.000 description 2
- 230000008484 agonism Effects 0.000 description 2
- 125000003368 amide group Chemical group 0.000 description 2
- 150000001409 amidines Chemical class 0.000 description 2
- 230000001195 anabolic effect Effects 0.000 description 2
- 125000002178 anthracenyl group Chemical group C1(=CC=CC2=CC3=CC=CC=C3C=C12)* 0.000 description 2
- 125000002102 aryl alkyloxo group Chemical group 0.000 description 2
- 125000004104 aryloxy group Chemical group 0.000 description 2
- 125000005602 azabenzimidazolyl group Chemical group 0.000 description 2
- 125000005334 azaindolyl group Chemical group N1N=C(C2=CC=CC=C12)* 0.000 description 2
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 2
- 125000005874 benzothiadiazolyl group Chemical group 0.000 description 2
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 2
- HTZCNXWZYVXIMZ-UHFFFAOYSA-M benzyl(triethyl)azanium;chloride Chemical compound [Cl-].CC[N+](CC)(CC)CC1=CC=CC=C1 HTZCNXWZYVXIMZ-UHFFFAOYSA-M 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 238000003738 britelite plus Methods 0.000 description 2
- 229910000024 caesium carbonate Inorganic materials 0.000 description 2
- 125000003739 carbamimidoyl group Chemical group C(N)(=N)* 0.000 description 2
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 125000006165 cyclic alkyl group Chemical group 0.000 description 2
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 2
- 125000003678 cyclohexadienyl group Chemical group C1(=CC=CCC1)* 0.000 description 2
- KVFDZFBHBWTVID-UHFFFAOYSA-N cyclohexanecarbaldehyde Chemical compound O=CC1CCCCC1 KVFDZFBHBWTVID-UHFFFAOYSA-N 0.000 description 2
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 2
- NISGSNTVMOOSJQ-UHFFFAOYSA-N cyclopentanamine Chemical compound NC1CCCC1 NISGSNTVMOOSJQ-UHFFFAOYSA-N 0.000 description 2
- 125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 description 2
- 125000004855 decalinyl group Chemical group C1(CCCC2CCCCC12)* 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 230000001627 detrimental effect Effects 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 238000010931 ester hydrolysis Methods 0.000 description 2
- PTPYDSGPFHIUEY-UHFFFAOYSA-N ethyl 1-[(2-bromophenyl)methyl]-2,3-dimethylindole-5-carboxylate Chemical compound CC1=C(C)C2=CC(C(=O)OCC)=CC=C2N1CC1=CC=CC=C1Br PTPYDSGPFHIUEY-UHFFFAOYSA-N 0.000 description 2
- NJGNAOBQMZPFPS-UHFFFAOYSA-N ethyl 1-[[4-(2-cyanophenyl)phenyl]methyl]-2,3-dimethylindole-5-carboxylate Chemical compound CC1=C(C)C2=CC(C(=O)OCC)=CC=C2N1CC(C=C1)=CC=C1C1=CC=CC=C1C#N NJGNAOBQMZPFPS-UHFFFAOYSA-N 0.000 description 2
- OPYMFQSHXOEGNU-UHFFFAOYSA-N ethyl 1-[[4-[2-(tert-butylsulfamoyl)phenyl]phenyl]methyl]-2,3-dimethylindole-5-carboxylate Chemical compound CC1=C(C)C2=CC(C(=O)OCC)=CC=C2N1CC(C=C1)=CC=C1C1=CC=CC=C1S(=O)(=O)NC(C)(C)C OPYMFQSHXOEGNU-UHFFFAOYSA-N 0.000 description 2
- DDDKYAPTZPPQAW-UHFFFAOYSA-N ethyl 3-[2-[[2,3-dimethyl-5-(1-phenylpropylcarbamoyl)indol-1-yl]methyl]phenyl]benzoate Chemical compound CCOC(=O)C1=CC=CC(C=2C(=CC=CC=2)CN2C3=CC=C(C=C3C(C)=C2C)C(=O)NC(CC)C=2C=CC=CC=2)=C1 DDDKYAPTZPPQAW-UHFFFAOYSA-N 0.000 description 2
- YVPMJFSWMMJEHO-QHCPKHFHSA-N ethyl 3-[2-[[2,3-dimethyl-5-[[(1s)-1-(4-nitrophenyl)ethyl]carbamoyl]indol-1-yl]methyl]phenyl]benzoate Chemical compound CCOC(=O)C1=CC=CC(C=2C(=CC=CC=2)CN2C3=CC=C(C=C3C(C)=C2C)C(=O)N[C@@H](C)C=2C=CC(=CC=2)[N+]([O-])=O)=C1 YVPMJFSWMMJEHO-QHCPKHFHSA-N 0.000 description 2
- QHNMCGGZTLBACH-QFIPXVFZSA-N ethyl 3-[2-[[5-[[(1s)-1-(4-nitrophenyl)ethyl]carbamoyl]indol-1-yl]methyl]phenyl]benzoate Chemical compound CCOC(=O)C1=CC=CC(C=2C(=CC=CC=2)CN2C3=CC=C(C=C3C=C2)C(=O)N[C@@H](C)C=2C=CC(=CC=2)[N+]([O-])=O)=C1 QHNMCGGZTLBACH-QFIPXVFZSA-N 0.000 description 2
- REVWREBGQKBBNH-QFIPXVFZSA-N ethyl 3-[4-[[5-[[(1s)-1-(4-nitrophenyl)ethyl]carbamoyl]indol-1-yl]methyl]phenyl]benzoate Chemical compound CCOC(=O)C1=CC=CC(C=2C=CC(CN3C4=CC=C(C=C4C=C3)C(=O)N[C@@H](C)C=3C=CC(=CC=3)[N+]([O-])=O)=CC=2)=C1 REVWREBGQKBBNH-QFIPXVFZSA-N 0.000 description 2
- KYTVGUMKTFKNFQ-UHFFFAOYSA-N ethyl 4-[2-[[2,3-dimethyl-5-(1-phenylpropylcarbamoyl)indol-1-yl]methyl]phenyl]benzoate Chemical compound C1=CC(C(=O)OCC)=CC=C1C1=CC=CC=C1CN1C2=CC=C(C(=O)NC(CC)C=3C=CC=CC=3)C=C2C(C)=C1C KYTVGUMKTFKNFQ-UHFFFAOYSA-N 0.000 description 2
- RTMLLGPUJHGUBO-QHCPKHFHSA-N ethyl 4-[2-[[2,3-dimethyl-5-[[(1s)-1-(4-nitrophenyl)ethyl]carbamoyl]indol-1-yl]methyl]phenyl]benzoate Chemical compound C1=CC(C(=O)OCC)=CC=C1C1=CC=CC=C1CN1C2=CC=C(C(=O)N[C@@H](C)C=3C=CC(=CC=3)[N+]([O-])=O)C=C2C(C)=C1C RTMLLGPUJHGUBO-QHCPKHFHSA-N 0.000 description 2
- LCYTZNQFWCKRBZ-UHFFFAOYSA-N ethyl 4-[2-[[5-(1-phenylpropylcarbamoyl)indol-1-yl]methyl]phenyl]benzoate Chemical compound C1=CC(C(=O)OCC)=CC=C1C1=CC=CC=C1CN1C2=CC=C(C(=O)NC(CC)C=3C=CC=CC=3)C=C2C=C1 LCYTZNQFWCKRBZ-UHFFFAOYSA-N 0.000 description 2
- PBHZGFLRONEWTN-QFIPXVFZSA-N ethyl 4-[2-[[5-[[(1s)-1-(4-nitrophenyl)ethyl]carbamoyl]indol-1-yl]methyl]phenyl]benzoate Chemical compound C1=CC(C(=O)OCC)=CC=C1C1=CC=CC=C1CN1C2=CC=C(C(=O)N[C@@H](C)C=3C=CC(=CC=3)[N+]([O-])=O)C=C2C=C1 PBHZGFLRONEWTN-QFIPXVFZSA-N 0.000 description 2
- IHCLYVOYQAMRJV-UHFFFAOYSA-N ethyl 4-[3-[[5-(1-phenylpropylcarbamoyl)indol-1-yl]methyl]phenyl]benzoate Chemical compound C1=CC(C(=O)OCC)=CC=C1C1=CC=CC(CN2C3=CC=C(C=C3C=C2)C(=O)NC(CC)C=2C=CC=CC=2)=C1 IHCLYVOYQAMRJV-UHFFFAOYSA-N 0.000 description 2
- PJYWFCQWDGXMAK-UHFFFAOYSA-N ethyl 4-[amino-[(2-methylpropan-2-yl)oxycarbonyl]amino]benzoate Chemical compound CCOC(=O)C1=CC=C(N(N)C(=O)OC(C)(C)C)C=C1 PJYWFCQWDGXMAK-UHFFFAOYSA-N 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 125000003983 fluorenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3CC12)* 0.000 description 2
- 238000002866 fluorescence resonance energy transfer Methods 0.000 description 2
- 239000011737 fluorine Substances 0.000 description 2
- 125000001153 fluoro group Chemical group F* 0.000 description 2
- 230000037406 food intake Effects 0.000 description 2
- 235000012631 food intake Nutrition 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 210000004349 growth plate Anatomy 0.000 description 2
- 125000002795 guanidino group Chemical group C(N)(=N)N* 0.000 description 2
- 230000035876 healing Effects 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 125000004857 imidazopyridinyl group Chemical group N1C(=NC2=C1C=CC=N2)* 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 2
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- NNPPMTNAJDCUHE-UHFFFAOYSA-N isobutane Chemical compound CC(C)C NNPPMTNAJDCUHE-UHFFFAOYSA-N 0.000 description 2
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 2
- 108020001756 ligand binding domains Proteins 0.000 description 2
- KWGKDLIKAYFUFQ-UHFFFAOYSA-M lithium chloride Chemical compound [Li+].[Cl-] KWGKDLIKAYFUFQ-UHFFFAOYSA-M 0.000 description 2
- 238000004020 luminiscence type Methods 0.000 description 2
- IUYHWZFSGMZEOG-UHFFFAOYSA-M magnesium;propane;chloride Chemical compound [Mg+2].[Cl-].C[CH-]C IUYHWZFSGMZEOG-UHFFFAOYSA-M 0.000 description 2
- 238000004949 mass spectrometry Methods 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- HJBTUFBOHRVZPR-MRVPVSSYSA-N methyl (2r)-2-(2-chloro-3-methylphenoxy)propanoate Chemical compound COC(=O)[C@@H](C)OC1=CC=CC(C)=C1Cl HJBTUFBOHRVZPR-MRVPVSSYSA-N 0.000 description 2
- FBHAEBOISLRMGX-MRVPVSSYSA-N methyl (2r)-2-(2-chloro-4-methylphenoxy)propanoate Chemical compound COC(=O)[C@@H](C)OC1=CC=C(C)C=C1Cl FBHAEBOISLRMGX-MRVPVSSYSA-N 0.000 description 2
- IXVPLUPDCVDSOH-GFCCVEGCSA-N methyl (2r)-2-(2-chloro-5-methylphenoxy)-3-methylbutanoate Chemical compound COC(=O)[C@@H](C(C)C)OC1=CC(C)=CC=C1Cl IXVPLUPDCVDSOH-GFCCVEGCSA-N 0.000 description 2
- CRDDQAVWJONFPJ-SNVBAGLBSA-N methyl (2r)-2-(2-chloro-5-methylphenoxy)butanoate Chemical compound COC(=O)[C@@H](CC)OC1=CC(C)=CC=C1Cl CRDDQAVWJONFPJ-SNVBAGLBSA-N 0.000 description 2
- SITBEBOYLOYKGY-MRVPVSSYSA-N methyl (2r)-2-(2-chloro-5-methylphenoxy)propanoate Chemical compound COC(=O)[C@@H](C)OC1=CC(C)=CC=C1Cl SITBEBOYLOYKGY-MRVPVSSYSA-N 0.000 description 2
- KEYIMJGVSIFQPM-MRVPVSSYSA-N methyl (2r)-2-(3-chloro-4-methylphenoxy)propanoate Chemical compound COC(=O)[C@@H](C)OC1=CC=C(C)C(Cl)=C1 KEYIMJGVSIFQPM-MRVPVSSYSA-N 0.000 description 2
- PSBBWHFAJJWKLK-MRVPVSSYSA-N methyl (2r)-2-(3-chloro-5-methylphenoxy)propanoate Chemical compound COC(=O)[C@@H](C)OC1=CC(C)=CC(Cl)=C1 PSBBWHFAJJWKLK-MRVPVSSYSA-N 0.000 description 2
- RPXKSEYYPXAOCL-LLVKDONJSA-N methyl (2r)-2-(3-methylphenoxy)butanoate Chemical compound COC(=O)[C@@H](CC)OC1=CC=CC(C)=C1 RPXKSEYYPXAOCL-LLVKDONJSA-N 0.000 description 2
- RDXKFALESKJSHT-SECBINFHSA-N methyl (2r)-2-(3-methylphenoxy)propanoate Chemical compound COC(=O)[C@@H](C)OC1=CC=CC(C)=C1 RDXKFALESKJSHT-SECBINFHSA-N 0.000 description 2
- SKCUHLDUIPEZPQ-GFCCVEGCSA-N methyl (2r)-2-(4-chloro-3-methylphenoxy)-3-methylbutanoate Chemical compound COC(=O)[C@@H](C(C)C)OC1=CC=C(Cl)C(C)=C1 SKCUHLDUIPEZPQ-GFCCVEGCSA-N 0.000 description 2
- XBRZHAUWNPCVMO-LLVKDONJSA-N methyl (2r)-2-(4-chloro-3-methylphenoxy)butanoate Chemical compound COC(=O)[C@@H](CC)OC1=CC=C(Cl)C(C)=C1 XBRZHAUWNPCVMO-LLVKDONJSA-N 0.000 description 2
- DQNSZINDFBYSAM-MRVPVSSYSA-N methyl (2r)-2-(4-chloro-3-methylphenoxy)propanoate Chemical compound COC(=O)[C@@H](C)OC1=CC=C(Cl)C(C)=C1 DQNSZINDFBYSAM-MRVPVSSYSA-N 0.000 description 2
- PPNXNYGZKHPNGV-SECBINFHSA-N methyl (2r)-2-(4-methylphenoxy)propanoate Chemical compound COC(=O)[C@@H](C)OC1=CC=C(C)C=C1 PPNXNYGZKHPNGV-SECBINFHSA-N 0.000 description 2
- NVNUPDBTAIVPIL-JTHBVZDNSA-N methyl (2r)-2-[2-chloro-3-[[2,3-dimethyl-5-[[(1s)-1-(3-propan-2-ylphenyl)ethyl]carbamoyl]indol-1-yl]methyl]phenoxy]propanoate Chemical compound COC(=O)[C@@H](C)OC1=CC=CC(CN2C3=CC=C(C=C3C(C)=C2C)C(=O)N[C@@H](C)C=2C=C(C=CC=2)C(C)C)=C1Cl NVNUPDBTAIVPIL-JTHBVZDNSA-N 0.000 description 2
- GWCGCPVQAIMJIU-JTHBVZDNSA-N methyl (2r)-2-[2-chloro-4-[[2,3-dimethyl-5-[[(1s)-1-(3-propan-2-ylphenyl)ethyl]carbamoyl]indol-1-yl]methyl]phenoxy]propanoate Chemical compound C1=C(Cl)C(O[C@H](C)C(=O)OC)=CC=C1CN1C2=CC=C(C(=O)N[C@@H](C)C=3C=C(C=CC=3)C(C)C)C=C2C(C)=C1C GWCGCPVQAIMJIU-JTHBVZDNSA-N 0.000 description 2
- RYOPEBLRPCUJPG-FLASPHMUSA-N methyl (2r)-2-[2-chloro-5-[[2,3-dimethyl-5-[[(1s)-1-(3-propan-2-ylphenyl)ethyl]carbamoyl]indol-1-yl]methyl]phenoxy]-3-methylbutanoate Chemical compound C1=C(Cl)C(O[C@@H](C(=O)OC)C(C)C)=CC(CN2C3=CC=C(C=C3C(C)=C2C)C(=O)N[C@@H](C)C=2C=C(C=CC=2)C(C)C)=C1 RYOPEBLRPCUJPG-FLASPHMUSA-N 0.000 description 2
- DXSCJZPLNDFTMM-WKRVVKTRSA-N methyl (2r)-2-[2-chloro-5-[[2,3-dimethyl-5-[[(1s)-1-(3-propan-2-ylphenyl)ethyl]carbamoyl]indol-1-yl]methyl]phenoxy]butanoate Chemical compound C1=C(Cl)C(O[C@H](CC)C(=O)OC)=CC(CN2C3=CC=C(C=C3C(C)=C2C)C(=O)N[C@@H](C)C=2C=C(C=CC=2)C(C)C)=C1 DXSCJZPLNDFTMM-WKRVVKTRSA-N 0.000 description 2
- PQKXGNNPYNLRHY-JTHBVZDNSA-N methyl (2r)-2-[2-chloro-5-[[2,3-dimethyl-5-[[(1s)-1-(3-propan-2-ylphenyl)ethyl]carbamoyl]indol-1-yl]methyl]phenoxy]propanoate Chemical compound C1=C(Cl)C(O[C@H](C)C(=O)OC)=CC(CN2C3=CC=C(C=C3C(C)=C2C)C(=O)N[C@@H](C)C=2C=C(C=CC=2)C(C)C)=C1 PQKXGNNPYNLRHY-JTHBVZDNSA-N 0.000 description 2
- XXUYSBZZEUTMIE-SSDOTTSWSA-N methyl (2r)-2-[3-(bromomethyl)-2-chlorophenoxy]propanoate Chemical compound COC(=O)[C@@H](C)OC1=CC=CC(CBr)=C1Cl XXUYSBZZEUTMIE-SSDOTTSWSA-N 0.000 description 2
- NOGSLWIVRSQLLD-GFCCVEGCSA-N methyl (2r)-2-[3-(bromomethyl)-4-chlorophenoxy]-3-methylbutanoate Chemical compound COC(=O)[C@@H](C(C)C)OC1=CC=C(Cl)C(CBr)=C1 NOGSLWIVRSQLLD-GFCCVEGCSA-N 0.000 description 2
- FRTZAEDIDJQUFG-LLVKDONJSA-N methyl (2r)-2-[3-(bromomethyl)-4-chlorophenoxy]butanoate Chemical compound COC(=O)[C@@H](CC)OC1=CC=C(Cl)C(CBr)=C1 FRTZAEDIDJQUFG-LLVKDONJSA-N 0.000 description 2
- LMFZTDKRUAKBFE-SSDOTTSWSA-N methyl (2r)-2-[3-(bromomethyl)-4-chlorophenoxy]propanoate Chemical compound COC(=O)[C@@H](C)OC1=CC=C(Cl)C(CBr)=C1 LMFZTDKRUAKBFE-SSDOTTSWSA-N 0.000 description 2
- XUMVWKIPCXBWRT-SSDOTTSWSA-N methyl (2r)-2-[3-(bromomethyl)-5-chlorophenoxy]propanoate Chemical compound COC(=O)[C@@H](C)OC1=CC(Cl)=CC(CBr)=C1 XUMVWKIPCXBWRT-SSDOTTSWSA-N 0.000 description 2
- HPUVOLFSUAXTIU-GFCCVEGCSA-N methyl (2r)-2-[3-(bromomethyl)phenoxy]-3-methylbutanoate Chemical compound COC(=O)[C@@H](C(C)C)OC1=CC=CC(CBr)=C1 HPUVOLFSUAXTIU-GFCCVEGCSA-N 0.000 description 2
- NSFMBVJFFQEKHX-LLVKDONJSA-N methyl (2r)-2-[3-(bromomethyl)phenoxy]butanoate Chemical compound COC(=O)[C@@H](CC)OC1=CC=CC(CBr)=C1 NSFMBVJFFQEKHX-LLVKDONJSA-N 0.000 description 2
- KIOGYLCYWQWXQX-MRVPVSSYSA-N methyl (2r)-2-[3-(bromomethyl)phenoxy]propanoate Chemical compound COC(=O)[C@@H](C)OC1=CC=CC(CBr)=C1 KIOGYLCYWQWXQX-MRVPVSSYSA-N 0.000 description 2
- VQERZAMCMHLJBY-CAQRMWTPSA-N methyl (2r)-2-[3-[[2,3-dimethyl-5-[[(1s)-1-(3-propan-2-ylphenyl)ethyl]carbamoyl]indol-1-yl]methyl]phenoxy]-3-methylbutanoate Chemical compound COC(=O)[C@@H](C(C)C)OC1=CC=CC(CN2C3=CC=C(C=C3C(C)=C2C)C(=O)N[C@@H](C)C=2C=C(C=CC=2)C(C)C)=C1 VQERZAMCMHLJBY-CAQRMWTPSA-N 0.000 description 2
- LKPBQWSLDQSZFM-JPQMRUPTSA-N methyl (2r)-2-[3-[[2,3-dimethyl-5-[[(1s)-1-(3-propan-2-ylphenyl)ethyl]carbamoyl]indol-1-yl]methyl]phenoxy]butanoate Chemical compound COC(=O)[C@@H](CC)OC1=CC=CC(CN2C3=CC=C(C=C3C(C)=C2C)C(=O)N[C@@H](C)C=2C=C(C=CC=2)C(C)C)=C1 LKPBQWSLDQSZFM-JPQMRUPTSA-N 0.000 description 2
- KVOWMJNAOPSUDB-LADGPHEKSA-N methyl (2r)-2-[3-[[2,3-dimethyl-5-[[(1s)-1-(3-propan-2-ylphenyl)ethyl]carbamoyl]indol-1-yl]methyl]phenoxy]propanoate Chemical compound COC(=O)[C@@H](C)OC1=CC=CC(CN2C3=CC=C(C=C3C(C)=C2C)C(=O)N[C@@H](C)C=2C=C(C=CC=2)C(C)C)=C1 KVOWMJNAOPSUDB-LADGPHEKSA-N 0.000 description 2
- SFFVUEZLGATLIW-LADGPHEKSA-N methyl (2r)-2-[3-[[5-[[(1s)-1-(4-tert-butylphenyl)ethyl]carbamoyl]-2,3-dimethylindol-1-yl]methyl]phenoxy]propanoate Chemical compound COC(=O)[C@@H](C)OC1=CC=CC(CN2C3=CC=C(C=C3C(C)=C2C)C(=O)N[C@@H](C)C=2C=CC(=CC=2)C(C)(C)C)=C1 SFFVUEZLGATLIW-LADGPHEKSA-N 0.000 description 2
- YUKWDIBKMQMPNT-JTHBVZDNSA-N methyl (2r)-2-[3-chloro-5-[[2,3-dimethyl-5-[[(1s)-1-(3-propan-2-ylphenyl)ethyl]carbamoyl]indol-1-yl]methyl]phenoxy]propanoate Chemical compound COC(=O)[C@@H](C)OC1=CC(Cl)=CC(CN2C3=CC=C(C=C3C(C)=C2C)C(=O)N[C@@H](C)C=2C=C(C=CC=2)C(C)C)=C1 YUKWDIBKMQMPNT-JTHBVZDNSA-N 0.000 description 2
- OMVUKXJJCSIKCE-SSDOTTSWSA-N methyl (2r)-2-[4-(bromomethyl)-2-chlorophenoxy]propanoate Chemical compound COC(=O)[C@@H](C)OC1=CC=C(CBr)C=C1Cl OMVUKXJJCSIKCE-SSDOTTSWSA-N 0.000 description 2
- COMUMJZTIHZQPG-SSDOTTSWSA-N methyl (2r)-2-[4-(bromomethyl)-3-chlorophenoxy]propanoate Chemical compound COC(=O)[C@@H](C)OC1=CC=C(CBr)C(Cl)=C1 COMUMJZTIHZQPG-SSDOTTSWSA-N 0.000 description 2
- CLGZDULSKRHKJD-MRVPVSSYSA-N methyl (2r)-2-[4-(bromomethyl)phenoxy]propanoate Chemical compound COC(=O)[C@@H](C)OC1=CC=C(CBr)C=C1 CLGZDULSKRHKJD-MRVPVSSYSA-N 0.000 description 2
- KDWIFOROWCXYIX-LADGPHEKSA-N methyl (2r)-2-[4-[[2,3-dimethyl-5-[[(1s)-1-(3-propan-2-ylphenyl)ethyl]carbamoyl]indol-1-yl]methyl]phenoxy]propanoate Chemical compound C1=CC(O[C@H](C)C(=O)OC)=CC=C1CN1C2=CC=C(C(=O)N[C@@H](C)C=3C=C(C=CC=3)C(C)C)C=C2C(C)=C1C KDWIFOROWCXYIX-LADGPHEKSA-N 0.000 description 2
- CFWMYHVKZDTBME-FLASPHMUSA-N methyl (2r)-2-[4-chloro-3-[[2,3-dimethyl-5-[[(1s)-1-(3-propan-2-ylphenyl)ethyl]carbamoyl]indol-1-yl]methyl]phenoxy]-3-methylbutanoate Chemical compound COC(=O)[C@@H](C(C)C)OC1=CC=C(Cl)C(CN2C3=CC=C(C=C3C(C)=C2C)C(=O)N[C@@H](C)C=2C=C(C=CC=2)C(C)C)=C1 CFWMYHVKZDTBME-FLASPHMUSA-N 0.000 description 2
- UAQUIQBWPKNBGV-GHRAFVERSA-N methyl (2r)-2-[4-chloro-3-[[2,3-dimethyl-5-[[(1s)-1-(3-propan-2-ylphenyl)ethyl]carbamoyl]indol-1-yl]methyl]phenoxy]butanoate Chemical compound COC(=O)[C@@H](CC)OC1=CC=C(Cl)C(CN2C3=CC=C(C=C3C(C)=C2C)C(=O)N[C@@H](C)C=2C=C(C=CC=2)C(C)C)=C1 UAQUIQBWPKNBGV-GHRAFVERSA-N 0.000 description 2
- MHOZDHYIMAQGTP-GFCCVEGCSA-N methyl (2r)-2-[5-(bromomethyl)-2-chlorophenoxy]-3-methylbutanoate Chemical compound COC(=O)[C@@H](C(C)C)OC1=CC(CBr)=CC=C1Cl MHOZDHYIMAQGTP-GFCCVEGCSA-N 0.000 description 2
- FSKHFEVHTFARGT-SNVBAGLBSA-N methyl (2r)-2-[5-(bromomethyl)-2-chlorophenoxy]butanoate Chemical compound COC(=O)[C@@H](CC)OC1=CC(CBr)=CC=C1Cl FSKHFEVHTFARGT-SNVBAGLBSA-N 0.000 description 2
- TWFPKMOCRPTABZ-SSDOTTSWSA-N methyl (2r)-2-[5-(bromomethyl)-2-chlorophenoxy]propanoate Chemical compound COC(=O)[C@@H](C)OC1=CC(CBr)=CC=C1Cl TWFPKMOCRPTABZ-SSDOTTSWSA-N 0.000 description 2
- CPJOIVCCCUXGFH-GFCCVEGCSA-N methyl (2r)-3-methyl-2-(3-methylphenoxy)butanoate Chemical compound COC(=O)[C@@H](C(C)C)OC1=CC=CC(C)=C1 CPJOIVCCCUXGFH-GFCCVEGCSA-N 0.000 description 2
- HJBTUFBOHRVZPR-QMMMGPOBSA-N methyl (2s)-2-(2-chloro-3-methylphenoxy)propanoate Chemical compound COC(=O)[C@H](C)OC1=CC=CC(C)=C1Cl HJBTUFBOHRVZPR-QMMMGPOBSA-N 0.000 description 2
- FBHAEBOISLRMGX-QMMMGPOBSA-N methyl (2s)-2-(2-chloro-4-methylphenoxy)propanoate Chemical compound COC(=O)[C@H](C)OC1=CC=C(C)C=C1Cl FBHAEBOISLRMGX-QMMMGPOBSA-N 0.000 description 2
- IXVPLUPDCVDSOH-LBPRGKRZSA-N methyl (2s)-2-(2-chloro-5-methylphenoxy)-3-methylbutanoate Chemical compound COC(=O)[C@H](C(C)C)OC1=CC(C)=CC=C1Cl IXVPLUPDCVDSOH-LBPRGKRZSA-N 0.000 description 2
- CRDDQAVWJONFPJ-JTQLQIEISA-N methyl (2s)-2-(2-chloro-5-methylphenoxy)butanoate Chemical compound COC(=O)[C@H](CC)OC1=CC(C)=CC=C1Cl CRDDQAVWJONFPJ-JTQLQIEISA-N 0.000 description 2
- KEYIMJGVSIFQPM-QMMMGPOBSA-N methyl (2s)-2-(3-chloro-4-methylphenoxy)propanoate Chemical compound COC(=O)[C@H](C)OC1=CC=C(C)C(Cl)=C1 KEYIMJGVSIFQPM-QMMMGPOBSA-N 0.000 description 2
- PSBBWHFAJJWKLK-QMMMGPOBSA-N methyl (2s)-2-(3-chloro-5-methylphenoxy)propanoate Chemical compound COC(=O)[C@H](C)OC1=CC(C)=CC(Cl)=C1 PSBBWHFAJJWKLK-QMMMGPOBSA-N 0.000 description 2
- ZSEWBVIHQUXTAN-VIFPVBQESA-N methyl (2s)-2-(3-ethylphenoxy)propanoate Chemical compound CCC1=CC=CC(O[C@@H](C)C(=O)OC)=C1 ZSEWBVIHQUXTAN-VIFPVBQESA-N 0.000 description 2
- RPXKSEYYPXAOCL-NSHDSACASA-N methyl (2s)-2-(3-methylphenoxy)butanoate Chemical compound COC(=O)[C@H](CC)OC1=CC=CC(C)=C1 RPXKSEYYPXAOCL-NSHDSACASA-N 0.000 description 2
- SKCUHLDUIPEZPQ-LBPRGKRZSA-N methyl (2s)-2-(4-chloro-3-methylphenoxy)-3-methylbutanoate Chemical compound COC(=O)[C@H](C(C)C)OC1=CC=C(Cl)C(C)=C1 SKCUHLDUIPEZPQ-LBPRGKRZSA-N 0.000 description 2
- XBRZHAUWNPCVMO-NSHDSACASA-N methyl (2s)-2-(4-chloro-3-methylphenoxy)butanoate Chemical compound COC(=O)[C@H](CC)OC1=CC=C(Cl)C(C)=C1 XBRZHAUWNPCVMO-NSHDSACASA-N 0.000 description 2
- DQNSZINDFBYSAM-QMMMGPOBSA-N methyl (2s)-2-(4-chloro-3-methylphenoxy)propanoate Chemical compound COC(=O)[C@H](C)OC1=CC=C(Cl)C(C)=C1 DQNSZINDFBYSAM-QMMMGPOBSA-N 0.000 description 2
- PPNXNYGZKHPNGV-VIFPVBQESA-N methyl (2s)-2-(4-methylphenoxy)propanoate Chemical compound COC(=O)[C@H](C)OC1=CC=C(C)C=C1 PPNXNYGZKHPNGV-VIFPVBQESA-N 0.000 description 2
- NVNUPDBTAIVPIL-GMAHTHKFSA-N methyl (2s)-2-[2-chloro-3-[[2,3-dimethyl-5-[[(1s)-1-(3-propan-2-ylphenyl)ethyl]carbamoyl]indol-1-yl]methyl]phenoxy]propanoate Chemical compound COC(=O)[C@H](C)OC1=CC=CC(CN2C3=CC=C(C=C3C(C)=C2C)C(=O)N[C@@H](C)C=2C=C(C=CC=2)C(C)C)=C1Cl NVNUPDBTAIVPIL-GMAHTHKFSA-N 0.000 description 2
- GWCGCPVQAIMJIU-GMAHTHKFSA-N methyl (2s)-2-[2-chloro-4-[[2,3-dimethyl-5-[[(1s)-1-(3-propan-2-ylphenyl)ethyl]carbamoyl]indol-1-yl]methyl]phenoxy]propanoate Chemical compound C1=C(Cl)C(O[C@@H](C)C(=O)OC)=CC=C1CN1C2=CC=C(C(=O)N[C@@H](C)C=3C=C(C=CC=3)C(C)C)C=C2C(C)=C1C GWCGCPVQAIMJIU-GMAHTHKFSA-N 0.000 description 2
- IJLGQLXKTBXMJW-GMAHTHKFSA-N methyl (2s)-2-[2-chloro-5-[[2,3-dimethyl-5-[[(1s)-1-(3-propan-2-yloxyphenyl)ethyl]carbamoyl]indol-1-yl]methyl]phenoxy]propanoate Chemical compound C1=C(Cl)C(O[C@@H](C)C(=O)OC)=CC(CN2C3=CC=C(C=C3C(C)=C2C)C(=O)N[C@@H](C)C=2C=C(OC(C)C)C=CC=2)=C1 IJLGQLXKTBXMJW-GMAHTHKFSA-N 0.000 description 2
- RYOPEBLRPCUJPG-WYOOIXGGSA-N methyl (2s)-2-[2-chloro-5-[[2,3-dimethyl-5-[[(1s)-1-(3-propan-2-ylphenyl)ethyl]carbamoyl]indol-1-yl]methyl]phenoxy]-3-methylbutanoate Chemical compound C1=C(Cl)C(O[C@H](C(=O)OC)C(C)C)=CC(CN2C3=CC=C(C=C3C(C)=C2C)C(=O)N[C@@H](C)C=2C=C(C=CC=2)C(C)C)=C1 RYOPEBLRPCUJPG-WYOOIXGGSA-N 0.000 description 2
- DXSCJZPLNDFTMM-UGDMGKLASA-N methyl (2s)-2-[2-chloro-5-[[2,3-dimethyl-5-[[(1s)-1-(3-propan-2-ylphenyl)ethyl]carbamoyl]indol-1-yl]methyl]phenoxy]butanoate Chemical compound C1=C(Cl)C(O[C@@H](CC)C(=O)OC)=CC(CN2C3=CC=C(C=C3C(C)=C2C)C(=O)N[C@@H](C)C=2C=C(C=CC=2)C(C)C)=C1 DXSCJZPLNDFTMM-UGDMGKLASA-N 0.000 description 2
- PQKXGNNPYNLRHY-GMAHTHKFSA-N methyl (2s)-2-[2-chloro-5-[[2,3-dimethyl-5-[[(1s)-1-(3-propan-2-ylphenyl)ethyl]carbamoyl]indol-1-yl]methyl]phenoxy]propanoate Chemical compound C1=C(Cl)C(O[C@@H](C)C(=O)OC)=CC(CN2C3=CC=C(C=C3C(C)=C2C)C(=O)N[C@@H](C)C=2C=C(C=CC=2)C(C)C)=C1 PQKXGNNPYNLRHY-GMAHTHKFSA-N 0.000 description 2
- VXQWSIACJABVCA-GKAPJAKFSA-N methyl (2s)-2-[3-(1-bromoethyl)phenoxy]propanoate Chemical compound COC(=O)[C@H](C)OC1=CC=CC(C(C)Br)=C1 VXQWSIACJABVCA-GKAPJAKFSA-N 0.000 description 2
- XXUYSBZZEUTMIE-ZETCQYMHSA-N methyl (2s)-2-[3-(bromomethyl)-2-chlorophenoxy]propanoate Chemical compound COC(=O)[C@H](C)OC1=CC=CC(CBr)=C1Cl XXUYSBZZEUTMIE-ZETCQYMHSA-N 0.000 description 2
- NOGSLWIVRSQLLD-LBPRGKRZSA-N methyl (2s)-2-[3-(bromomethyl)-4-chlorophenoxy]-3-methylbutanoate Chemical compound COC(=O)[C@H](C(C)C)OC1=CC=C(Cl)C(CBr)=C1 NOGSLWIVRSQLLD-LBPRGKRZSA-N 0.000 description 2
- FRTZAEDIDJQUFG-NSHDSACASA-N methyl (2s)-2-[3-(bromomethyl)-4-chlorophenoxy]butanoate Chemical compound COC(=O)[C@H](CC)OC1=CC=C(Cl)C(CBr)=C1 FRTZAEDIDJQUFG-NSHDSACASA-N 0.000 description 2
- XUMVWKIPCXBWRT-ZETCQYMHSA-N methyl (2s)-2-[3-(bromomethyl)-5-chlorophenoxy]propanoate Chemical compound COC(=O)[C@H](C)OC1=CC(Cl)=CC(CBr)=C1 XUMVWKIPCXBWRT-ZETCQYMHSA-N 0.000 description 2
- HPUVOLFSUAXTIU-LBPRGKRZSA-N methyl (2s)-2-[3-(bromomethyl)phenoxy]-3-methylbutanoate Chemical compound COC(=O)[C@H](C(C)C)OC1=CC=CC(CBr)=C1 HPUVOLFSUAXTIU-LBPRGKRZSA-N 0.000 description 2
- NSFMBVJFFQEKHX-NSHDSACASA-N methyl (2s)-2-[3-(bromomethyl)phenoxy]butanoate Chemical compound COC(=O)[C@H](CC)OC1=CC=CC(CBr)=C1 NSFMBVJFFQEKHX-NSHDSACASA-N 0.000 description 2
- CJLWNGXDIWISMU-LMOFDZDWSA-N methyl (2s)-2-[3-[1-[5-[[(1s)-1-(3-cyclopropylphenyl)ethyl]carbamoyl]-2,3-dimethylindol-1-yl]ethyl]phenoxy]propanoate Chemical compound COC(=O)[C@H](C)OC1=CC=CC(C(C)N2C3=CC=C(C=C3C(C)=C2C)C(=O)N[C@@H](C)C=2C=C(C=CC=2)C2CC2)=C1 CJLWNGXDIWISMU-LMOFDZDWSA-N 0.000 description 2
- RBHCCAPMXGDENN-UPVQGACJSA-N methyl (2s)-2-[3-[[2,3-dimethyl-5-[[(1s)-1-(3-propan-2-yloxyphenyl)ethyl]carbamoyl]indol-1-yl]methyl]phenoxy]propanoate Chemical compound COC(=O)[C@H](C)OC1=CC=CC(CN2C3=CC=C(C=C3C(C)=C2C)C(=O)N[C@@H](C)C=2C=C(OC(C)C)C=CC=2)=C1 RBHCCAPMXGDENN-UPVQGACJSA-N 0.000 description 2
- VQERZAMCMHLJBY-RBBQXQBVSA-N methyl (2s)-2-[3-[[2,3-dimethyl-5-[[(1s)-1-(3-propan-2-ylphenyl)ethyl]carbamoyl]indol-1-yl]methyl]phenoxy]-3-methylbutanoate Chemical compound COC(=O)[C@H](C(C)C)OC1=CC=CC(CN2C3=CC=C(C=C3C(C)=C2C)C(=O)N[C@@H](C)C=2C=C(C=CC=2)C(C)C)=C1 VQERZAMCMHLJBY-RBBQXQBVSA-N 0.000 description 2
- LKPBQWSLDQSZFM-UDNBHOFDSA-N methyl (2s)-2-[3-[[2,3-dimethyl-5-[[(1s)-1-(3-propan-2-ylphenyl)ethyl]carbamoyl]indol-1-yl]methyl]phenoxy]butanoate Chemical compound COC(=O)[C@H](CC)OC1=CC=CC(CN2C3=CC=C(C=C3C(C)=C2C)C(=O)N[C@@H](C)C=2C=C(C=CC=2)C(C)C)=C1 LKPBQWSLDQSZFM-UDNBHOFDSA-N 0.000 description 2
- KVOWMJNAOPSUDB-UPVQGACJSA-N methyl (2s)-2-[3-[[2,3-dimethyl-5-[[(1s)-1-(3-propan-2-ylphenyl)ethyl]carbamoyl]indol-1-yl]methyl]phenoxy]propanoate Chemical compound COC(=O)[C@H](C)OC1=CC=CC(CN2C3=CC=C(C=C3C(C)=C2C)C(=O)N[C@@H](C)C=2C=C(C=CC=2)C(C)C)=C1 KVOWMJNAOPSUDB-UPVQGACJSA-N 0.000 description 2
- DWPDMBYSMWVWNL-GMAHTHKFSA-N methyl (2s)-2-[3-[[5-[[(1s)-1-(3-cyclopropylphenyl)ethyl]carbamoyl]-2,3-dimethylindol-1-yl]methyl]phenoxy]propanoate Chemical compound COC(=O)[C@H](C)OC1=CC=CC(CN2C3=CC=C(C=C3C(C)=C2C)C(=O)N[C@@H](C)C=2C=C(C=CC=2)C2CC2)=C1 DWPDMBYSMWVWNL-GMAHTHKFSA-N 0.000 description 2
- SFFVUEZLGATLIW-UPVQGACJSA-N methyl (2s)-2-[3-[[5-[[(1s)-1-(4-tert-butylphenyl)ethyl]carbamoyl]-2,3-dimethylindol-1-yl]methyl]phenoxy]propanoate Chemical compound COC(=O)[C@H](C)OC1=CC=CC(CN2C3=CC=C(C=C3C(C)=C2C)C(=O)N[C@@H](C)C=2C=CC(=CC=2)C(C)(C)C)=C1 SFFVUEZLGATLIW-UPVQGACJSA-N 0.000 description 2
- BUWNMZWSHRTLOV-GMAHTHKFSA-N methyl (2s)-2-[3-chloro-4-[[2,3-dimethyl-5-[[(1s)-1-(3-propan-2-ylphenyl)ethyl]carbamoyl]indol-1-yl]methyl]phenoxy]propanoate Chemical compound ClC1=CC(O[C@@H](C)C(=O)OC)=CC=C1CN1C2=CC=C(C(=O)N[C@@H](C)C=3C=C(C=CC=3)C(C)C)C=C2C(C)=C1C BUWNMZWSHRTLOV-GMAHTHKFSA-N 0.000 description 2
- YUKWDIBKMQMPNT-GMAHTHKFSA-N methyl (2s)-2-[3-chloro-5-[[2,3-dimethyl-5-[[(1s)-1-(3-propan-2-ylphenyl)ethyl]carbamoyl]indol-1-yl]methyl]phenoxy]propanoate Chemical compound COC(=O)[C@H](C)OC1=CC(Cl)=CC(CN2C3=CC=C(C=C3C(C)=C2C)C(=O)N[C@@H](C)C=2C=C(C=CC=2)C(C)C)=C1 YUKWDIBKMQMPNT-GMAHTHKFSA-N 0.000 description 2
- OMVUKXJJCSIKCE-ZETCQYMHSA-N methyl (2s)-2-[4-(bromomethyl)-2-chlorophenoxy]propanoate Chemical compound COC(=O)[C@H](C)OC1=CC=C(CBr)C=C1Cl OMVUKXJJCSIKCE-ZETCQYMHSA-N 0.000 description 2
- COMUMJZTIHZQPG-ZETCQYMHSA-N methyl (2s)-2-[4-(bromomethyl)-3-chlorophenoxy]propanoate Chemical compound COC(=O)[C@H](C)OC1=CC=C(CBr)C(Cl)=C1 COMUMJZTIHZQPG-ZETCQYMHSA-N 0.000 description 2
- CLGZDULSKRHKJD-QMMMGPOBSA-N methyl (2s)-2-[4-(bromomethyl)phenoxy]propanoate Chemical compound COC(=O)[C@H](C)OC1=CC=C(CBr)C=C1 CLGZDULSKRHKJD-QMMMGPOBSA-N 0.000 description 2
- KDWIFOROWCXYIX-UPVQGACJSA-N methyl (2s)-2-[4-[[2,3-dimethyl-5-[[(1s)-1-(3-propan-2-ylphenyl)ethyl]carbamoyl]indol-1-yl]methyl]phenoxy]propanoate Chemical compound C1=CC(O[C@@H](C)C(=O)OC)=CC=C1CN1C2=CC=C(C(=O)N[C@@H](C)C=3C=C(C=CC=3)C(C)C)C=C2C(C)=C1C KDWIFOROWCXYIX-UPVQGACJSA-N 0.000 description 2
- ACJAKYNBGXQBNX-GMAHTHKFSA-N methyl (2s)-2-[4-[[5-[[(1s)-1-(3-cyclopropylphenyl)ethyl]carbamoyl]-2,3-dimethylindol-1-yl]methyl]phenoxy]propanoate Chemical compound C1=CC(O[C@@H](C)C(=O)OC)=CC=C1CN1C2=CC=C(C(=O)N[C@@H](C)C=3C=C(C=CC=3)C3CC3)C=C2C(C)=C1C ACJAKYNBGXQBNX-GMAHTHKFSA-N 0.000 description 2
- YMIVDFBMKINPMM-GMAHTHKFSA-N methyl (2s)-2-[4-chloro-3-[[2,3-dimethyl-5-[[(1s)-1-(3-propan-2-yloxyphenyl)ethyl]carbamoyl]indol-1-yl]methyl]phenoxy]propanoate Chemical compound COC(=O)[C@H](C)OC1=CC=C(Cl)C(CN2C3=CC=C(C=C3C(C)=C2C)C(=O)N[C@@H](C)C=2C=C(OC(C)C)C=CC=2)=C1 YMIVDFBMKINPMM-GMAHTHKFSA-N 0.000 description 2
- CFWMYHVKZDTBME-WYOOIXGGSA-N methyl (2s)-2-[4-chloro-3-[[2,3-dimethyl-5-[[(1s)-1-(3-propan-2-ylphenyl)ethyl]carbamoyl]indol-1-yl]methyl]phenoxy]-3-methylbutanoate Chemical compound COC(=O)[C@H](C(C)C)OC1=CC=C(Cl)C(CN2C3=CC=C(C=C3C(C)=C2C)C(=O)N[C@@H](C)C=2C=C(C=CC=2)C(C)C)=C1 CFWMYHVKZDTBME-WYOOIXGGSA-N 0.000 description 2
- UAQUIQBWPKNBGV-ICACTRECSA-N methyl (2s)-2-[4-chloro-3-[[2,3-dimethyl-5-[[(1s)-1-(3-propan-2-ylphenyl)ethyl]carbamoyl]indol-1-yl]methyl]phenoxy]butanoate Chemical compound COC(=O)[C@H](CC)OC1=CC=C(Cl)C(CN2C3=CC=C(C=C3C(C)=C2C)C(=O)N[C@@H](C)C=2C=C(C=CC=2)C(C)C)=C1 UAQUIQBWPKNBGV-ICACTRECSA-N 0.000 description 2
- QWBTVWSHLFXIRC-GMAHTHKFSA-N methyl (2s)-2-[4-chloro-3-[[2,3-dimethyl-5-[[(1s)-1-(3-propan-2-ylphenyl)ethyl]carbamoyl]indol-1-yl]methyl]phenoxy]propanoate Chemical compound COC(=O)[C@H](C)OC1=CC=C(Cl)C(CN2C3=CC=C(C=C3C(C)=C2C)C(=O)N[C@@H](C)C=2C=C(C=CC=2)C(C)C)=C1 QWBTVWSHLFXIRC-GMAHTHKFSA-N 0.000 description 2
- MHOZDHYIMAQGTP-LBPRGKRZSA-N methyl (2s)-2-[5-(bromomethyl)-2-chlorophenoxy]-3-methylbutanoate Chemical compound COC(=O)[C@H](C(C)C)OC1=CC(CBr)=CC=C1Cl MHOZDHYIMAQGTP-LBPRGKRZSA-N 0.000 description 2
- FSKHFEVHTFARGT-JTQLQIEISA-N methyl (2s)-2-[5-(bromomethyl)-2-chlorophenoxy]butanoate Chemical compound COC(=O)[C@H](CC)OC1=CC(CBr)=CC=C1Cl FSKHFEVHTFARGT-JTQLQIEISA-N 0.000 description 2
- YSGBMDFJWFIEDF-YFKPBYRVSA-N methyl (2s)-2-hydroxy-3-methylbutanoate Chemical compound COC(=O)[C@@H](O)C(C)C YSGBMDFJWFIEDF-YFKPBYRVSA-N 0.000 description 2
- CPJOIVCCCUXGFH-LBPRGKRZSA-N methyl (2s)-3-methyl-2-(3-methylphenoxy)butanoate Chemical compound COC(=O)[C@H](C(C)C)OC1=CC=CC(C)=C1 CPJOIVCCCUXGFH-LBPRGKRZSA-N 0.000 description 2
- DLXQZJAIAUIPAZ-UHFFFAOYSA-N methyl 1-[(2,4-difluorophenyl)methyl]indole-5-carboxylate Chemical compound C1=CC2=CC(C(=O)OC)=CC=C2N1CC1=CC=C(F)C=C1F DLXQZJAIAUIPAZ-UHFFFAOYSA-N 0.000 description 2
- LOXCTPDCGDIIIJ-UHFFFAOYSA-N methyl 1-[4-(bromomethyl)phenyl]cyclopropane-1-carboxylate Chemical compound C=1C=C(CBr)C=CC=1C1(C(=O)OC)CC1 LOXCTPDCGDIIIJ-UHFFFAOYSA-N 0.000 description 2
- MONFIJNBXRBNFY-QHCPKHFHSA-N methyl 1-[4-[[2,3-dimethyl-5-[[(1s)-1-(3-prop-1-en-2-ylphenyl)ethyl]carbamoyl]indol-1-yl]methyl]phenyl]cyclopropane-1-carboxylate Chemical compound C=1C=C(CN2C3=CC=C(C=C3C(C)=C2C)C(=O)N[C@@H](C)C=2C=C(C=CC=2)C(C)=C)C=CC=1C1(C(=O)OC)CC1 MONFIJNBXRBNFY-QHCPKHFHSA-N 0.000 description 2
- JEIAHVUJYMFXLY-FQEVSTJZSA-N methyl 1-[4-[[5-[[(1s)-1-(3-bromophenyl)ethyl]carbamoyl]-2,3-dimethylindol-1-yl]methyl]phenyl]cyclopropane-1-carboxylate Chemical compound C=1C=C(CN2C3=CC=C(C=C3C(C)=C2C)C(=O)N[C@@H](C)C=2C=C(Br)C=CC=2)C=CC=1C1(C(=O)OC)CC1 JEIAHVUJYMFXLY-FQEVSTJZSA-N 0.000 description 2
- UAPSSYKQJMTSEB-UHFFFAOYSA-N methyl 2-(3-methylphenoxy)acetate Chemical compound COC(=O)COC1=CC=CC(C)=C1 UAPSSYKQJMTSEB-UHFFFAOYSA-N 0.000 description 2
- JYZZFOSNOTXCKV-UHFFFAOYSA-N methyl 2-[3-(bromomethyl)phenoxy]-2-methylpropanoate Chemical compound COC(=O)C(C)(C)OC1=CC=CC(CBr)=C1 JYZZFOSNOTXCKV-UHFFFAOYSA-N 0.000 description 2
- RHYQCZSFWWWVTB-UHFFFAOYSA-N methyl 2-[3-(bromomethyl)phenoxy]acetate Chemical compound COC(=O)COC1=CC=CC(CBr)=C1 RHYQCZSFWWWVTB-UHFFFAOYSA-N 0.000 description 2
- IHPZXSUKILZMJO-QHCPKHFHSA-N methyl 2-[3-[[2,3-dimethyl-5-[[(1s)-1-(3-propan-2-ylphenyl)ethyl]carbamoyl]indol-1-yl]methyl]phenoxy]-2-methylpropanoate Chemical compound COC(=O)C(C)(C)OC1=CC=CC(CN2C3=CC=C(C=C3C(C)=C2C)C(=O)N[C@@H](C)C=2C=C(C=CC=2)C(C)C)=C1 IHPZXSUKILZMJO-QHCPKHFHSA-N 0.000 description 2
- DGCCUTGBHRKGIY-QFIPXVFZSA-N methyl 2-[3-[[2,3-dimethyl-5-[[(1s)-1-(3-propan-2-ylphenyl)ethyl]carbamoyl]indol-1-yl]methyl]phenoxy]acetate Chemical compound COC(=O)COC1=CC=CC(CN2C3=CC=C(C=C3C(C)=C2C)C(=O)N[C@@H](C)C=2C=C(C=CC=2)C(C)C)=C1 DGCCUTGBHRKGIY-QFIPXVFZSA-N 0.000 description 2
- CPEFOKWTNXTRFM-NRFANRHFSA-N methyl 2-[3-[[5-[[(1s)-1-(3-cyclopropylphenyl)ethyl]carbamoyl]-2,3-dimethylindol-1-yl]methyl]phenoxy]acetate Chemical compound COC(=O)COC1=CC=CC(CN2C3=CC=C(C=C3C(C)=C2C)C(=O)N[C@@H](C)C=2C=C(C=CC=2)C2CC2)=C1 CPEFOKWTNXTRFM-NRFANRHFSA-N 0.000 description 2
- LTNDWEMOAUZDJV-QHCPKHFHSA-N methyl 2-[3-[[5-[[(1s)-1-(4-tert-butylphenyl)ethyl]carbamoyl]-2,3-dimethylindol-1-yl]methyl]phenoxy]-2-methylpropanoate Chemical compound COC(=O)C(C)(C)OC1=CC=CC(CN2C3=CC=C(C=C3C(C)=C2C)C(=O)N[C@@H](C)C=2C=CC(=CC=2)C(C)(C)C)=C1 LTNDWEMOAUZDJV-QHCPKHFHSA-N 0.000 description 2
- GIKVXTBDRJDMEU-QFIPXVFZSA-N methyl 2-[3-[[5-[[(1s)-1-(4-tert-butylphenyl)ethyl]carbamoyl]-2,3-dimethylindol-1-yl]methyl]phenoxy]acetate Chemical compound COC(=O)COC1=CC=CC(CN2C3=CC=C(C=C3C(C)=C2C)C(=O)N[C@@H](C)C=2C=CC(=CC=2)C(C)(C)C)=C1 GIKVXTBDRJDMEU-QFIPXVFZSA-N 0.000 description 2
- IEGGDDUJQCPZCR-UHFFFAOYSA-N methyl 2-[4-(bromomethyl)phenoxy]-2-methylpropanoate Chemical compound COC(=O)C(C)(C)OC1=CC=C(CBr)C=C1 IEGGDDUJQCPZCR-UHFFFAOYSA-N 0.000 description 2
- QCXZPFNJNGVELI-QHCPKHFHSA-N methyl 2-[4-[[2,3-dimethyl-5-[[(1s)-1-(3-propan-2-ylphenyl)ethyl]carbamoyl]indol-1-yl]methyl]phenoxy]-2-methylpropanoate Chemical compound C1=CC(OC(C)(C)C(=O)OC)=CC=C1CN1C2=CC=C(C(=O)N[C@@H](C)C=3C=C(C=CC=3)C(C)C)C=C2C(C)=C1C QCXZPFNJNGVELI-QHCPKHFHSA-N 0.000 description 2
- NJLMRTSBSVGAJD-QFIPXVFZSA-N methyl 2-[4-[[2,3-dimethyl-5-[[(1s)-1-(3-propan-2-ylphenyl)ethyl]carbamoyl]indol-1-yl]methyl]phenoxy]acetate Chemical compound C1=CC(OCC(=O)OC)=CC=C1CN1C2=CC=C(C(=O)N[C@@H](C)C=3C=C(C=CC=3)C(C)C)C=C2C(C)=C1C NJLMRTSBSVGAJD-QFIPXVFZSA-N 0.000 description 2
- RNSHHNPHRLPNBQ-QFIPXVFZSA-N methyl 2-[4-[[5-[[(1s)-1-(4-tert-butylphenyl)ethyl]carbamoyl]-2,3-dimethylindol-1-yl]methyl]phenoxy]acetate Chemical compound C1=CC(OCC(=O)OC)=CC=C1CN1C2=CC=C(C(=O)N[C@@H](C)C=3C=CC(=CC=3)C(C)(C)C)C=C2C(C)=C1C RNSHHNPHRLPNBQ-QFIPXVFZSA-N 0.000 description 2
- RUZLIIJDZBWWSA-INIZCTEOSA-N methyl 2-[[(1s)-1-(7-methyl-2-morpholin-4-yl-4-oxopyrido[1,2-a]pyrimidin-9-yl)ethyl]amino]benzoate Chemical group COC(=O)C1=CC=CC=C1N[C@@H](C)C1=CC(C)=CN2C(=O)C=C(N3CCOCC3)N=C12 RUZLIIJDZBWWSA-INIZCTEOSA-N 0.000 description 2
- PQUSVJVVRXWKDG-UHFFFAOYSA-N methyl 2-bromo-2-methylpropanoate Chemical compound COC(=O)C(C)(C)Br PQUSVJVVRXWKDG-UHFFFAOYSA-N 0.000 description 2
- LXAGLHNHJXCNDN-UHFFFAOYSA-N methyl 2-methyl-1-[[4-[2-[(2-methylpropan-2-yl)oxycarbonyl]phenyl]phenyl]methyl]indole-5-carboxylate Chemical compound CC1=CC2=CC(C(=O)OC)=CC=C2N1CC(C=C1)=CC=C1C1=CC=CC=C1C(=O)OC(C)(C)C LXAGLHNHJXCNDN-UHFFFAOYSA-N 0.000 description 2
- BHYYCJLERNVALT-UHFFFAOYSA-N methyl 2-methyl-2-(3-methylphenoxy)propanoate Chemical compound COC(=O)C(C)(C)OC1=CC=CC(C)=C1 BHYYCJLERNVALT-UHFFFAOYSA-N 0.000 description 2
- MUJHUASZJBJXOQ-UHFFFAOYSA-N methyl 2-methyl-2-(4-methylphenoxy)propanoate Chemical compound COC(=O)C(C)(C)OC1=CC=C(C)C=C1 MUJHUASZJBJXOQ-UHFFFAOYSA-N 0.000 description 2
- SXASYWILYSUBBR-FQEVSTJZSA-N methyl 3-[[5-[[(1s)-1-(3-cyclopropylphenyl)ethyl]carbamoyl]-2,3-dimethylindol-1-yl]methyl]benzoate Chemical compound COC(=O)C1=CC=CC(CN2C3=CC=C(C=C3C(C)=C2C)C(=O)N[C@@H](C)C=2C=C(C=CC=2)C2CC2)=C1 SXASYWILYSUBBR-FQEVSTJZSA-N 0.000 description 2
- UGLRSYDAOVKFIJ-UHFFFAOYSA-N methyl 3-formyl-1h-indole-5-carboxylate Chemical compound COC(=O)C1=CC=C2NC=C(C=O)C2=C1 UGLRSYDAOVKFIJ-UHFFFAOYSA-N 0.000 description 2
- IOHKJJXOLDPGOX-UHFFFAOYSA-N methyl 3-methyl-1-[[4-[2-[(2-methylpropan-2-yl)oxycarbonyl]phenyl]phenyl]methyl]indole-5-carboxylate Chemical compound C1=C(C)C2=CC(C(=O)OC)=CC=C2N1CC(C=C1)=CC=C1C1=CC=CC=C1C(=O)OC(C)(C)C IOHKJJXOLDPGOX-UHFFFAOYSA-N 0.000 description 2
- DJVVYXJJXMUAPJ-UHFFFAOYSA-N methyl 3-methyl-1h-indole-5-carboxylate Chemical compound COC(=O)C1=CC=C2NC=C(C)C2=C1 DJVVYXJJXMUAPJ-UHFFFAOYSA-N 0.000 description 2
- 238000010603 microCT Methods 0.000 description 2
- JZMYWBMCNQFIHE-JOCHJYFZSA-N n-[(1r)-1-(3-bromophenyl)ethyl]-1-[[4-(2-cyanophenyl)phenyl]methyl]-2,3-dimethylindole-5-carboxamide Chemical compound N([C@H](C)C=1C=C(Br)C=CC=1)C(=O)C(C=C1C(C)=C2C)=CC=C1N2CC(C=C1)=CC=C1C1=CC=CC=C1C#N JZMYWBMCNQFIHE-JOCHJYFZSA-N 0.000 description 2
- KZEOTEDWPLTTJG-OAQYLSRUSA-N n-[(1r)-1-(3-bromophenyl)ethyl]-2,3-dimethyl-1-[[4-[2-(2h-tetrazol-5-yl)phenyl]phenyl]methyl]indole-5-carboxamide Chemical compound N([C@H](C)C=1C=C(Br)C=CC=1)C(=O)C(C=C1C(C)=C2C)=CC=C1N2CC(C=C1)=CC=C1C1=CC=CC=C1C1=NN=NN1 KZEOTEDWPLTTJG-OAQYLSRUSA-N 0.000 description 2
- NOIKDSYWJSLLAU-QHCPKHFHSA-N n-[(1s)-1-(3-cyclopropylphenyl)ethyl]-2,3-dimethyl-1-[[4-[2-(2h-tetrazol-5-yl)phenyl]phenyl]methyl]indole-5-carboxamide Chemical compound N([C@@H](C)C=1C=C(C=CC=1)C1CC1)C(=O)C(C=C1C(C)=C2C)=CC=C1N2CC(C=C1)=CC=C1C1=CC=CC=C1C1=NN=NN1 NOIKDSYWJSLLAU-QHCPKHFHSA-N 0.000 description 2
- FDXWDGFINZRXNC-NRFANRHFSA-N n-[(1s)-1-(4-nitrophenyl)ethyl]-1-[(4-phenylphenyl)methyl]indole-5-carboxamide Chemical compound N([C@@H](C)C=1C=CC(=CC=1)[N+]([O-])=O)C(=O)C(C=C1C=C2)=CC=C1N2CC(C=C1)=CC=C1C1=CC=CC=C1 FDXWDGFINZRXNC-NRFANRHFSA-N 0.000 description 2
- XVWYSVNEPDVAGM-HXPMCKFVSA-N n-[(1s)-1-(4-tert-butylphenyl)ethyl]-2-methylpropane-2-sulfinamide Chemical compound CC(C)(C)[S@@](=O)N[C@@H](C)C1=CC=C(C(C)(C)C)C=C1 XVWYSVNEPDVAGM-HXPMCKFVSA-N 0.000 description 2
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- 150000002825 nitriles Chemical group 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 238000013116 obese mouse model Methods 0.000 description 2
- 235000020824 obesity Nutrition 0.000 description 2
- 235000005985 organic acids Nutrition 0.000 description 2
- 150000002894 organic compounds Chemical class 0.000 description 2
- 229910000489 osmium tetroxide Inorganic materials 0.000 description 2
- 239000012285 osmium tetroxide Substances 0.000 description 2
- 210000000963 osteoblast Anatomy 0.000 description 2
- KJIFKLIQANRMOU-UHFFFAOYSA-N oxidanium;4-methylbenzenesulfonate Chemical compound O.CC1=CC=C(S(O)(=O)=O)C=C1 KJIFKLIQANRMOU-UHFFFAOYSA-N 0.000 description 2
- 229910052763 palladium Inorganic materials 0.000 description 2
- LXNAVEXFUKBNMK-UHFFFAOYSA-N palladium(II) acetate Substances [Pd].CC(O)=O.CC(O)=O LXNAVEXFUKBNMK-UHFFFAOYSA-N 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 239000008177 pharmaceutical agent Substances 0.000 description 2
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 2
- HYAFETHFCAUJAY-UHFFFAOYSA-N pioglitazone Chemical compound N1=CC(CC)=CC=C1CCOC(C=C1)=CC=C1CC1C(=O)NC(=O)S1 HYAFETHFCAUJAY-UHFFFAOYSA-N 0.000 description 2
- 125000003386 piperidinyl group Chemical group 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- DTDYRJYLJRCDGD-UHFFFAOYSA-N prop-2-enyl 1-[(3-methoxycarbonylphenyl)methyl]-2,3-dimethylindole-5-carboxylate Chemical compound COC(=O)C1=CC=CC(CN2C3=CC=C(C=C3C(C)=C2C)C(=O)OCC=C)=C1 DTDYRJYLJRCDGD-UHFFFAOYSA-N 0.000 description 2
- WWMBUWZZBRKGHE-UHFFFAOYSA-N prop-2-enyl 1-[1-(4-hydroxyphenyl)ethyl]-2,3-dimethylindole-5-carboxylate Chemical compound CC1=C(C)C2=CC(C(=O)OCC=C)=CC=C2N1C(C)C1=CC=C(O)C=C1 WWMBUWZZBRKGHE-UHFFFAOYSA-N 0.000 description 2
- FIEWHLOBCXGYBK-GGYWPGCISA-N prop-2-enyl 1-[1-[3-[(2s)-1-methoxy-1-oxopropan-2-yl]oxyphenyl]ethyl]-2,3-dimethylindole-5-carboxylate Chemical compound COC(=O)[C@H](C)OC1=CC=CC(C(C)N2C3=CC=C(C=C3C(C)=C2C)C(=O)OCC=C)=C1 FIEWHLOBCXGYBK-GGYWPGCISA-N 0.000 description 2
- FADQURQDSRKUKU-GGYWPGCISA-N prop-2-enyl 1-[1-[4-[(2s)-1-methoxy-1-oxopropan-2-yl]oxyphenyl]ethyl]-2,3-dimethylindole-5-carboxylate Chemical compound C1=CC(O[C@@H](C)C(=O)OC)=CC=C1C(C)N1C2=CC=C(C(=O)OCC=C)C=C2C(C)=C1C FADQURQDSRKUKU-GGYWPGCISA-N 0.000 description 2
- GYAPEZSWZRAFME-UHFFFAOYSA-N prop-2-enyl 1-[[3-(1-cyanocyclopropyl)phenyl]methyl]-2,3-dimethylindole-5-carboxylate Chemical compound CC1=C(C)C2=CC(C(=O)OCC=C)=CC=C2N1CC(C=1)=CC=CC=1C1(C#N)CC1 GYAPEZSWZRAFME-UHFFFAOYSA-N 0.000 description 2
- XHAZUVXFOJHRAA-UHFFFAOYSA-N prop-2-enyl 1-[[3-(2-cyanopropan-2-yl)phenyl]methyl]-2,3-dimethylindole-5-carboxylate Chemical compound CC1=C(C)C2=CC(C(=O)OCC=C)=CC=C2N1CC1=CC=CC(C(C)(C)C#N)=C1 XHAZUVXFOJHRAA-UHFFFAOYSA-N 0.000 description 2
- MWUBUJAVHKWQER-KRWDZBQOSA-N prop-2-enyl 1-[[4-chloro-3-[(2s)-1-methoxy-1-oxopropan-2-yl]oxyphenyl]methyl]-2,3-dimethylindole-5-carboxylate Chemical compound C1=C(Cl)C(O[C@@H](C)C(=O)OC)=CC(CN2C3=CC=C(C=C3C(C)=C2C)C(=O)OCC=C)=C1 MWUBUJAVHKWQER-KRWDZBQOSA-N 0.000 description 2
- 238000011321 prophylaxis Methods 0.000 description 2
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 2
- 125000000168 pyrrolyl group Chemical group 0.000 description 2
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 2
- 238000001953 recrystallisation Methods 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 125000006413 ring segment Chemical group 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- XGVXKJKTISMIOW-ZDUSSCGKSA-N simurosertib Chemical compound N1N=CC(C=2SC=3C(=O)NC(=NC=3C=2)[C@H]2N3CCC(CC3)C2)=C1C XGVXKJKTISMIOW-ZDUSSCGKSA-N 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 230000003068 static effect Effects 0.000 description 2
- 125000000547 substituted alkyl group Chemical group 0.000 description 2
- 229940124530 sulfonamide Drugs 0.000 description 2
- 125000000565 sulfonamide group Chemical group 0.000 description 2
- 150000003456 sulfonamides Chemical class 0.000 description 2
- 125000004434 sulfur atom Chemical group 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 229960005187 telmisartan Drugs 0.000 description 2
- FWJLUUJRTVPGAU-UHFFFAOYSA-N tert-butyl 2-[2-[[5-(1-phenylpropylcarbamoyl)indol-1-yl]methyl]phenyl]benzoate Chemical compound C=1C=CC=CC=1C(CC)NC(=O)C(C=C1C=C2)=CC=C1N2CC1=CC=CC=C1C1=CC=CC=C1C(=O)OC(C)(C)C FWJLUUJRTVPGAU-UHFFFAOYSA-N 0.000 description 2
- TVSVAUNDGYOLAL-UHFFFAOYSA-N tert-butyl 2-[3-[[5-(1-phenylpropylcarbamoyl)indol-1-yl]methyl]phenyl]benzoate Chemical compound C=1C=CC=CC=1C(CC)NC(=O)C(C=C1C=C2)=CC=C1N2CC(C=1)=CC=CC=1C1=CC=CC=C1C(=O)OC(C)(C)C TVSVAUNDGYOLAL-UHFFFAOYSA-N 0.000 description 2
- GQWBRDCJGJFSKP-MHZLTWQESA-N tert-butyl 2-[4-[[2,3-dimethyl-5-[[(1s)-1-(3-prop-1-en-2-ylphenyl)ethyl]carbamoyl]indol-1-yl]methyl]phenyl]benzoate Chemical compound N([C@@H](C)C=1C=C(C=CC=1)C(C)=C)C(=O)C(C=C1C(C)=C2C)=CC=C1N2CC(C=C1)=CC=C1C1=CC=CC=C1C(=O)OC(C)(C)C GQWBRDCJGJFSKP-MHZLTWQESA-N 0.000 description 2
- LODHKWFLUXKQET-UHFFFAOYSA-N tert-butyl 2-[4-[[2-methyl-5-(1-phenylpropylcarbamoyl)indol-1-yl]methyl]phenyl]benzoate Chemical compound C=1C=CC=CC=1C(CC)NC(=O)C(C=C1C=C2C)=CC=C1N2CC(C=C1)=CC=C1C1=CC=CC=C1C(=O)OC(C)(C)C LODHKWFLUXKQET-UHFFFAOYSA-N 0.000 description 2
- KWNVEHIULBVDFP-DEOSSOPVSA-N tert-butyl 2-[4-[[3-methyl-5-[[(1s)-1-(4-nitrophenyl)ethyl]carbamoyl]indol-1-yl]methyl]phenyl]benzoate Chemical compound N([C@@H](C)C=1C=CC(=CC=1)[N+]([O-])=O)C(=O)C(C=C1C(C)=C2)=CC=C1N2CC(C=C1)=CC=C1C1=CC=CC=C1C(=O)OC(C)(C)C KWNVEHIULBVDFP-DEOSSOPVSA-N 0.000 description 2
- JXTVZMJFSDPLFD-UHFFFAOYSA-N tert-butyl 2-[4-[[5-(1-phenylpropylcarbamoyl)indol-1-yl]methyl]phenyl]benzoate Chemical compound C=1C=CC=CC=1C(CC)NC(=O)C(C=C1C=C2)=CC=C1N2CC(C=C1)=CC=C1C1=CC=CC=C1C(=O)OC(C)(C)C JXTVZMJFSDPLFD-UHFFFAOYSA-N 0.000 description 2
- NUSWRXPNJJMMTL-UHFFFAOYSA-N tert-butyl 2-[4-[[5-[1-(6-bromopyridin-2-yl)ethylcarbamoyl]-2,3-dimethylindol-1-yl]methyl]phenyl]benzoate Chemical compound C=1C=CC(Br)=NC=1C(C)NC(=O)C(C=C1C(C)=C2C)=CC=C1N2CC(C=C1)=CC=C1C1=CC=CC=C1C(=O)OC(C)(C)C NUSWRXPNJJMMTL-UHFFFAOYSA-N 0.000 description 2
- GZYFYAIERYNMET-DEOSSOPVSA-N tert-butyl 2-[4-[[5-[[(1S)-1-(4-bromophenyl)ethyl]carbamoyl]-2-methylindol-1-yl]methyl]phenyl]benzoate Chemical compound N([C@@H](C)C=1C=CC(Br)=CC=1)C(=O)C(C=C1C=C2C)=CC=C1N2CC(C=C1)=CC=C1C1=CC=CC=C1C(=O)OC(C)(C)C GZYFYAIERYNMET-DEOSSOPVSA-N 0.000 description 2
- QBMOOGDSRRWBKR-DEOSSOPVSA-N tert-butyl 2-[4-[[5-[[(1S)-1-(4-bromophenyl)ethyl]carbamoyl]-3-methylindol-1-yl]methyl]phenyl]benzoate Chemical compound N([C@@H](C)C=1C=CC(Br)=CC=1)C(=O)C(C=C1C(C)=C2)=CC=C1N2CC(C=C1)=CC=C1C1=CC=CC=C1C(=O)OC(C)(C)C QBMOOGDSRRWBKR-DEOSSOPVSA-N 0.000 description 2
- MOSDZTOTPHOOOF-QHCPKHFHSA-N tert-butyl 2-[4-[[5-[[(1S)-1-(4-bromophenyl)ethyl]carbamoyl]indol-1-yl]methyl]phenyl]benzoate Chemical compound N([C@@H](C)C=1C=CC(Br)=CC=1)C(=O)C(C=C1C=C2)=CC=C1N2CC(C=C1)=CC=C1C1=CC=CC=C1C(=O)OC(C)(C)C MOSDZTOTPHOOOF-QHCPKHFHSA-N 0.000 description 2
- PGQSUKORHKVTTN-HSZRJFAPSA-N tert-butyl 2-[4-[[5-[[(1r)-1-(2-bromopyridin-4-yl)ethyl]carbamoyl]-2,3-dimethylindol-1-yl]methyl]phenyl]benzoate Chemical compound N([C@H](C)C=1C=C(Br)N=CC=1)C(=O)C(C=C1C(C)=C2C)=CC=C1N2CC(C=C1)=CC=C1C1=CC=CC=C1C(=O)OC(C)(C)C PGQSUKORHKVTTN-HSZRJFAPSA-N 0.000 description 2
- JRLOBVFKHABODR-XMMPIXPASA-N tert-butyl 2-[4-[[5-[[(1r)-1-(3-bromophenyl)ethyl]carbamoyl]-2,3-dimethylindol-1-yl]methyl]phenyl]benzoate Chemical compound N([C@H](C)C=1C=C(Br)C=CC=1)C(=O)C(C=C1C(C)=C2C)=CC=C1N2CC(C=C1)=CC=C1C1=CC=CC=C1C(=O)OC(C)(C)C JRLOBVFKHABODR-XMMPIXPASA-N 0.000 description 2
- GUJPICAKSBIHQN-HSZRJFAPSA-N tert-butyl 2-[4-[[5-[[(1r)-1-(6-chloropyridin-3-yl)ethyl]carbamoyl]-2,3-dimethylindol-1-yl]methyl]phenyl]benzoate Chemical compound N([C@H](C)C=1C=NC(Cl)=CC=1)C(=O)C(C=C1C(C)=C2C)=CC=C1N2CC(C=C1)=CC=C1C1=CC=CC=C1C(=O)OC(C)(C)C GUJPICAKSBIHQN-HSZRJFAPSA-N 0.000 description 2
- PGQSUKORHKVTTN-QHCPKHFHSA-N tert-butyl 2-[4-[[5-[[(1s)-1-(2-bromopyridin-4-yl)ethyl]carbamoyl]-2,3-dimethylindol-1-yl]methyl]phenyl]benzoate Chemical compound N([C@@H](C)C=1C=C(Br)N=CC=1)C(=O)C(C=C1C(C)=C2C)=CC=C1N2CC(C=C1)=CC=C1C1=CC=CC=C1C(=O)OC(C)(C)C PGQSUKORHKVTTN-QHCPKHFHSA-N 0.000 description 2
- ZDUOKLRHCFNOGC-QHCPKHFHSA-N tert-butyl 2-[4-[[5-[[(1s)-1-(4-chloropyridin-2-yl)ethyl]carbamoyl]-2,3-dimethylindol-1-yl]methyl]phenyl]benzoate Chemical compound N([C@@H](C)C=1N=CC=C(Cl)C=1)C(=O)C(C=C1C(C)=C2C)=CC=C1N2CC(C=C1)=CC=C1C1=CC=CC=C1C(=O)OC(C)(C)C ZDUOKLRHCFNOGC-QHCPKHFHSA-N 0.000 description 2
- RGHABUULDKFCRX-VWLOTQADSA-N tert-butyl 2-[4-[[5-[[(1s)-1-(4-methoxyphenyl)ethyl]carbamoyl]-2,3-dimethylindol-1-yl]methyl]phenyl]benzoate Chemical compound C1=CC(OC)=CC=C1[C@H](C)NC(=O)C1=CC=C(N(CC=2C=CC(=CC=2)C=2C(=CC=CC=2)C(=O)OC(C)(C)C)C(C)=C2C)C2=C1 RGHABUULDKFCRX-VWLOTQADSA-N 0.000 description 2
- ADNPPXKVUHPWJO-MHZLTWQESA-N tert-butyl 2-[4-[[5-[[(1s)-1-(4-tert-butylphenyl)ethyl]carbamoyl]-2,3-dimethylindol-1-yl]methyl]phenyl]benzoate Chemical compound N([C@@H](C)C=1C=CC(=CC=1)C(C)(C)C)C(=O)C(C=C1C(C)=C2C)=CC=C1N2CC(C=C1)=CC=C1C1=CC=CC=C1C(=O)OC(C)(C)C ADNPPXKVUHPWJO-MHZLTWQESA-N 0.000 description 2
- NUSWRXPNJJMMTL-QHCPKHFHSA-N tert-butyl 2-[4-[[5-[[(1s)-1-(6-bromopyridin-2-yl)ethyl]carbamoyl]-2,3-dimethylindol-1-yl]methyl]phenyl]benzoate Chemical compound N([C@@H](C)C=1N=C(Br)C=CC=1)C(=O)C(C=C1C(C)=C2C)=CC=C1N2CC(C=C1)=CC=C1C1=CC=CC=C1C(=O)OC(C)(C)C NUSWRXPNJJMMTL-QHCPKHFHSA-N 0.000 description 2
- GUJPICAKSBIHQN-QHCPKHFHSA-N tert-butyl 2-[4-[[5-[[(1s)-1-(6-chloropyridin-3-yl)ethyl]carbamoyl]-2,3-dimethylindol-1-yl]methyl]phenyl]benzoate Chemical compound N([C@@H](C)C=1C=NC(Cl)=CC=1)C(=O)C(C=C1C(C)=C2C)=CC=C1N2CC(C=C1)=CC=C1C1=CC=CC=C1C(=O)OC(C)(C)C GUJPICAKSBIHQN-QHCPKHFHSA-N 0.000 description 2
- GWRLCMWYWVGNNZ-UHFFFAOYSA-N tert-butyl 3-[2-[[5-(1-phenylpropylcarbamoyl)indol-1-yl]methyl]phenyl]benzoate Chemical compound C=1C=CC=CC=1C(CC)NC(=O)C(C=C1C=C2)=CC=C1N2CC1=CC=CC=C1C1=CC=CC(C(=O)OC(C)(C)C)=C1 GWRLCMWYWVGNNZ-UHFFFAOYSA-N 0.000 description 2
- DNZOIDFFXXWSAE-UHFFFAOYSA-N tert-butyl 3-[3-[[5-(1-phenylpropylcarbamoyl)indol-1-yl]methyl]phenyl]benzoate Chemical compound C=1C=CC=CC=1C(CC)NC(=O)C(C=C1C=C2)=CC=C1N2CC(C=1)=CC=CC=1C1=CC=CC(C(=O)OC(C)(C)C)=C1 DNZOIDFFXXWSAE-UHFFFAOYSA-N 0.000 description 2
- 125000000147 tetrahydroquinolinyl group Chemical group N1(CCCC2=CC=CC=C12)* 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 125000004927 thianaphthalenyl group Chemical group S1C(C=CC2=CC=CC=C12)* 0.000 description 2
- FKKJJPMGAWGYPN-UHFFFAOYSA-N thiophen-2-ylmethanamine Chemical compound NCC1=CC=CS1 FKKJJPMGAWGYPN-UHFFFAOYSA-N 0.000 description 2
- VXUYXOFXAQZZMF-UHFFFAOYSA-N titanium(IV) isopropoxide Chemical compound CC(C)O[Ti](OC(C)C)(OC(C)C)OC(C)C VXUYXOFXAQZZMF-UHFFFAOYSA-N 0.000 description 2
- 239000012096 transfection reagent Substances 0.000 description 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 2
- MWKJTNBSKNUMFN-UHFFFAOYSA-N trifluoromethyltrimethylsilane Chemical compound C[Si](C)(C)C(F)(F)F MWKJTNBSKNUMFN-UHFFFAOYSA-N 0.000 description 2
- SEDZOYHHAIAQIW-UHFFFAOYSA-N trimethylsilyl azide Chemical compound C[Si](C)(C)N=[N+]=[N-] SEDZOYHHAIAQIW-UHFFFAOYSA-N 0.000 description 2
- 229910052722 tritium Inorganic materials 0.000 description 2
- AELCINSCMGFISI-DTWKUNHWSA-N (1R,2S)-tranylcypromine Chemical compound N[C@@H]1C[C@H]1C1=CC=CC=C1 AELCINSCMGFISI-DTWKUNHWSA-N 0.000 description 1
- ZPEFMSTTZXJOTM-OULXEKPRSA-N (1R,2S)-tranylcypromine hydrochloride Chemical compound Cl.N[C@@H]1C[C@H]1C1=CC=CC=C1 ZPEFMSTTZXJOTM-OULXEKPRSA-N 0.000 description 1
- RQEUFEKYXDPUSK-ZETCQYMHSA-N (1S)-1-phenylethanamine Chemical compound C[C@H](N)C1=CC=CC=C1 RQEUFEKYXDPUSK-ZETCQYMHSA-N 0.000 description 1
- SRTSRSCCRWDHNA-PGMHMLKASA-N (1r)-1-(2,3,6-trifluorophenyl)ethanamine;hydrochloride Chemical compound Cl.C[C@@H](N)C1=C(F)C=CC(F)=C1F SRTSRSCCRWDHNA-PGMHMLKASA-N 0.000 description 1
- DQEYVZASLGNODG-ZCFIWIBFSA-N (1r)-1-(3-chlorophenyl)ethanamine Chemical compound C[C@@H](N)C1=CC=CC(Cl)=C1 DQEYVZASLGNODG-ZCFIWIBFSA-N 0.000 description 1
- CJWGCBRQAHCVHW-SSDOTTSWSA-N (1r)-1-(3-methoxyphenyl)ethanamine Chemical compound COC1=CC=CC([C@@H](C)N)=C1 CJWGCBRQAHCVHW-SSDOTTSWSA-N 0.000 description 1
- QGCLEUGNYRXBMZ-ZCFIWIBFSA-N (1r)-1-(4-fluorophenyl)ethanamine Chemical compound C[C@@H](N)C1=CC=C(F)C=C1 QGCLEUGNYRXBMZ-ZCFIWIBFSA-N 0.000 description 1
- JTDGKQNNPKXKII-SSDOTTSWSA-N (1r)-1-(4-methoxyphenyl)ethanamine Chemical compound COC1=CC=C([C@@H](C)N)C=C1 JTDGKQNNPKXKII-SSDOTTSWSA-N 0.000 description 1
- OWCVWGVXNOYBDP-NUBCRITNSA-N (1r)-1-[2-chloro-3-(trifluoromethyl)phenyl]ethanamine;hydrochloride Chemical compound Cl.C[C@@H](N)C1=CC=CC(C(F)(F)F)=C1Cl OWCVWGVXNOYBDP-NUBCRITNSA-N 0.000 description 1
- NLBPCMJOACOYKH-NUBCRITNSA-N (1r)-1-[3-fluoro-4-(trifluoromethyl)phenyl]ethanamine;hydrochloride Chemical compound Cl.C[C@@H](N)C1=CC=C(C(F)(F)F)C(F)=C1 NLBPCMJOACOYKH-NUBCRITNSA-N 0.000 description 1
- XKOCACARIDJWFH-NUBCRITNSA-N (1r)-1-[5-fluoro-2-(trifluoromethyl)phenyl]ethanamine;hydrochloride Chemical compound Cl.C[C@@H](N)C1=CC(F)=CC=C1C(F)(F)F XKOCACARIDJWFH-NUBCRITNSA-N 0.000 description 1
- SFBSKQGXLTYFLD-SNVBAGLBSA-N (1r)-2,2,2-trifluoro-1-(3-propan-2-ylphenyl)ethanamine Chemical compound CC(C)C1=CC=CC([C@@H](N)C(F)(F)F)=C1 SFBSKQGXLTYFLD-SNVBAGLBSA-N 0.000 description 1
- ZKLNLFMWZVPQDS-CYBMUJFWSA-N (1r)-2-methyl-1-(3-propan-2-ylphenyl)propan-1-amine Chemical compound CC(C)[C@@H](N)C1=CC=CC(C(C)C)=C1 ZKLNLFMWZVPQDS-CYBMUJFWSA-N 0.000 description 1
- SRTSRSCCRWDHNA-WCCKRBBISA-N (1s)-1-(2,3,6-trifluorophenyl)ethanamine;hydrochloride Chemical compound Cl.C[C@H](N)C1=C(F)C=CC(F)=C1F SRTSRSCCRWDHNA-WCCKRBBISA-N 0.000 description 1
- BDCJXEVNICFRSL-JEDNCBNOSA-N (1s)-1-(2,3-difluorophenyl)ethanamine;hydrochloride Chemical compound Cl.C[C@H](N)C1=CC=CC(F)=C1F BDCJXEVNICFRSL-JEDNCBNOSA-N 0.000 description 1
- WXVUGIYMCYJMSN-BYPYZUCNSA-N (1s)-1-(2,4,5-trifluorophenyl)ethanamine Chemical compound C[C@H](N)C1=CC(F)=C(F)C=C1F WXVUGIYMCYJMSN-BYPYZUCNSA-N 0.000 description 1
- OUVZHZAOWDHBOU-YFKPBYRVSA-N (1s)-1-(2,4-dichlorophenyl)ethanamine Chemical compound C[C@H](N)C1=CC=C(Cl)C=C1Cl OUVZHZAOWDHBOU-YFKPBYRVSA-N 0.000 description 1
- BWIGKZOWBCNPTI-JEDNCBNOSA-N (1s)-1-(2,4-difluorophenyl)ethanamine;hydrochloride Chemical compound Cl.C[C@H](N)C1=CC=C(F)C=C1F BWIGKZOWBCNPTI-JEDNCBNOSA-N 0.000 description 1
- VNGAKUOLRVQVHG-QRPNPIFTSA-N (1s)-1-(2-methylphenyl)ethanamine;hydrochloride Chemical compound [Cl-].C[C@H]([NH3+])C1=CC=CC=C1C VNGAKUOLRVQVHG-QRPNPIFTSA-N 0.000 description 1
- UJUFOUVXOUYYRG-YFKPBYRVSA-N (1s)-1-(3,4-dichlorophenyl)ethanamine Chemical compound C[C@H](N)C1=CC=C(Cl)C(Cl)=C1 UJUFOUVXOUYYRG-YFKPBYRVSA-N 0.000 description 1
- KRYCUFKROCITGA-JEDNCBNOSA-N (1s)-1-(3,4-difluorophenyl)ethanamine;hydrochloride Chemical compound Cl.C[C@H](N)C1=CC=C(F)C(F)=C1 KRYCUFKROCITGA-JEDNCBNOSA-N 0.000 description 1
- BVAAZZHQLIEDTA-ZETCQYMHSA-N (1s)-1-(3,5-dimethoxyphenyl)ethanamine Chemical compound COC1=CC(OC)=CC([C@H](C)N)=C1 BVAAZZHQLIEDTA-ZETCQYMHSA-N 0.000 description 1
- CEVBNFPEJNNLJJ-JEDNCBNOSA-N (1s)-1-(3-chloro-2-fluorophenyl)ethanamine;hydrochloride Chemical compound Cl.C[C@H](N)C1=CC=CC(Cl)=C1F CEVBNFPEJNNLJJ-JEDNCBNOSA-N 0.000 description 1
- OBWHGEIVGSITLV-ZETCQYMHSA-N (1s)-1-(3-fluoro-2-methylphenyl)ethanamine Chemical compound C[C@H](N)C1=CC=CC(F)=C1C OBWHGEIVGSITLV-ZETCQYMHSA-N 0.000 description 1
- VRBRYJZXFIHWOQ-LURJTMIESA-N (1s)-1-(3-fluoro-5-methoxyphenyl)ethanamine Chemical compound COC1=CC(F)=CC([C@H](C)N)=C1 VRBRYJZXFIHWOQ-LURJTMIESA-N 0.000 description 1
- CJWGCBRQAHCVHW-ZETCQYMHSA-N (1s)-1-(3-methoxyphenyl)ethanamine Chemical compound COC1=CC=CC([C@H](C)N)=C1 CJWGCBRQAHCVHW-ZETCQYMHSA-N 0.000 description 1
- PKSYWKNIIZWBPE-AWEZNQCLSA-N (1s)-1-(3-propan-2-ylphenyl)pentan-1-amine Chemical compound CCCC[C@H](N)C1=CC=CC(C(C)C)=C1 PKSYWKNIIZWBPE-AWEZNQCLSA-N 0.000 description 1
- FAAKQSKVORTCAV-FJXQXJEOSA-N (1s)-1-(4-chloro-2-methylphenyl)ethanamine;hydrochloride Chemical compound Cl.C[C@H](N)C1=CC=C(Cl)C=C1C FAAKQSKVORTCAV-FJXQXJEOSA-N 0.000 description 1
- AMXXYSXDJUIPMZ-QMMMGPOBSA-N (1s)-1-(4-ethylphenyl)ethanamine Chemical compound CCC1=CC=C([C@H](C)N)C=C1 AMXXYSXDJUIPMZ-QMMMGPOBSA-N 0.000 description 1
- QGCLEUGNYRXBMZ-LURJTMIESA-N (1s)-1-(4-fluorophenyl)ethanamine Chemical compound C[C@H](N)C1=CC=C(F)C=C1 QGCLEUGNYRXBMZ-LURJTMIESA-N 0.000 description 1
- JAECXGZNWPVNEU-FJXQXJEOSA-N (1s)-1-(4-methylsulfonylphenyl)ethanamine;hydrochloride Chemical compound Cl.C[C@H](N)C1=CC=C(S(C)(=O)=O)C=C1 JAECXGZNWPVNEU-FJXQXJEOSA-N 0.000 description 1
- QDLPHPPYMUBDRB-VIFPVBQESA-N (1s)-1-(4-propan-2-yloxyphenyl)ethanamine Chemical compound CC(C)OC1=CC=C([C@H](C)N)C=C1 QDLPHPPYMUBDRB-VIFPVBQESA-N 0.000 description 1
- OWCVWGVXNOYBDP-JEDNCBNOSA-N (1s)-1-[2-chloro-3-(trifluoromethyl)phenyl]ethanamine;hydrochloride Chemical compound Cl.C[C@H](N)C1=CC=CC(C(F)(F)F)=C1Cl OWCVWGVXNOYBDP-JEDNCBNOSA-N 0.000 description 1
- YJWDXKUMDAATTM-YFKPBYRVSA-N (1s)-1-[2-chloro-5-(trifluoromethyl)phenyl]ethanamine Chemical compound C[C@H](N)C1=CC(C(F)(F)F)=CC=C1Cl YJWDXKUMDAATTM-YFKPBYRVSA-N 0.000 description 1
- DPNRVWDJFMNADR-YFKPBYRVSA-N (1s)-1-[2-fluoro-3-(trifluoromethyl)phenyl]ethanamine Chemical compound C[C@H](N)C1=CC=CC(C(F)(F)F)=C1F DPNRVWDJFMNADR-YFKPBYRVSA-N 0.000 description 1
- XTBKFZDHIZYROB-YFKPBYRVSA-N (1s)-1-[2-fluoro-4-(trifluoromethyl)phenyl]ethanamine Chemical compound C[C@H](N)C1=CC=C(C(F)(F)F)C=C1F XTBKFZDHIZYROB-YFKPBYRVSA-N 0.000 description 1
- AVBMULHZUJQLPZ-YFKPBYRVSA-N (1s)-1-[2-fluoro-6-(trifluoromethyl)phenyl]ethanamine Chemical compound C[C@H](N)C1=C(F)C=CC=C1C(F)(F)F AVBMULHZUJQLPZ-YFKPBYRVSA-N 0.000 description 1
- XJVAGOCFOAYRDT-RGMNGODLSA-N (1s)-1-[3-(trifluoromethyl)phenyl]ethanamine;hydrochloride Chemical compound [Cl-].C[C@H]([NH3+])C1=CC=CC(C(F)(F)F)=C1 XJVAGOCFOAYRDT-RGMNGODLSA-N 0.000 description 1
- NLBPCMJOACOYKH-JEDNCBNOSA-N (1s)-1-[3-fluoro-4-(trifluoromethyl)phenyl]ethanamine;hydrochloride Chemical compound Cl.C[C@H](N)C1=CC=C(C(F)(F)F)C(F)=C1 NLBPCMJOACOYKH-JEDNCBNOSA-N 0.000 description 1
- CRAQSXJYHZMDFP-RGMNGODLSA-N (1s)-1-[4-(trifluoromethoxy)phenyl]ethanamine;hydrochloride Chemical compound [Cl-].C[C@H]([NH3+])C1=CC=C(OC(F)(F)F)C=C1 CRAQSXJYHZMDFP-RGMNGODLSA-N 0.000 description 1
- DRNBWVIDYSKOCN-JEDNCBNOSA-N (1s)-1-[4-fluoro-2-(trifluoromethyl)phenyl]ethanamine;hydrochloride Chemical compound Cl.C[C@H](N)C1=CC=C(F)C=C1C(F)(F)F DRNBWVIDYSKOCN-JEDNCBNOSA-N 0.000 description 1
- KHSYYLCXQKCYQX-VIFPVBQESA-N (1s)-1-naphthalen-2-ylethanamine Chemical compound C1=CC=CC2=CC([C@@H](N)C)=CC=C21 KHSYYLCXQKCYQX-VIFPVBQESA-N 0.000 description 1
- ZKLNLFMWZVPQDS-ZDUSSCGKSA-N (1s)-2-methyl-1-(3-propan-2-ylphenyl)propan-1-amine Chemical compound CC(C)[C@H](N)C1=CC=CC(C(C)C)=C1 ZKLNLFMWZVPQDS-ZDUSSCGKSA-N 0.000 description 1
- ASDYKVAPYKEDJK-KRWDZBQOSA-N (1s)-2-phenyl-1-(3-propan-2-ylphenyl)ethanamine Chemical compound CC(C)C1=CC=CC([C@@H](N)CC=2C=CC=CC=2)=C1 ASDYKVAPYKEDJK-KRWDZBQOSA-N 0.000 description 1
- SJUKJZSTBBSGHF-UHFFFAOYSA-N (2,4-dichlorophenyl)methanamine Chemical compound NCC1=CC=C(Cl)C=C1Cl SJUKJZSTBBSGHF-UHFFFAOYSA-N 0.000 description 1
- QDZZDVQGBKTLHV-UHFFFAOYSA-N (2,4-difluorophenyl)methanamine Chemical compound NCC1=CC=C(F)C=C1F QDZZDVQGBKTLHV-UHFFFAOYSA-N 0.000 description 1
- NOYASZMZIBFFNZ-UHFFFAOYSA-N (2-bromophenyl)methanamine Chemical compound NCC1=CC=CC=C1Br NOYASZMZIBFFNZ-UHFFFAOYSA-N 0.000 description 1
- RRCMGJCFMJBHQC-UHFFFAOYSA-N (2-chlorophenyl)boronic acid Chemical compound OB(O)C1=CC=CC=C1Cl RRCMGJCFMJBHQC-UHFFFAOYSA-N 0.000 description 1
- KDDNKZCVYQDGKE-UHFFFAOYSA-N (2-chlorophenyl)methanamine Chemical compound NCC1=CC=CC=C1Cl KDDNKZCVYQDGKE-UHFFFAOYSA-N 0.000 description 1
- YDMRDHQUQIVWBE-UHFFFAOYSA-N (2-hydroxyphenyl)boronic acid Chemical compound OB(O)C1=CC=CC=C1O YDMRDHQUQIVWBE-UHFFFAOYSA-N 0.000 description 1
- ROEQGIFOWRQYHD-UHFFFAOYSA-N (2-methoxyphenyl)boronic acid Chemical compound COC1=CC=CC=C1B(O)O ROEQGIFOWRQYHD-UHFFFAOYSA-N 0.000 description 1
- NSJVYHOPHZMZPN-UHFFFAOYSA-N (2-methylphenyl)boronic acid Chemical compound CC1=CC=CC=C1B(O)O NSJVYHOPHZMZPN-UHFFFAOYSA-N 0.000 description 1
- CJAAPVQEZPAQNI-UHFFFAOYSA-N (2-methylphenyl)methanamine Chemical compound CC1=CC=CC=C1CN CJAAPVQEZPAQNI-UHFFFAOYSA-N 0.000 description 1
- MSQFFCRGQPVQRS-UHFFFAOYSA-N (2-methylsulfonylphenyl)boronic acid Chemical compound CS(=O)(=O)C1=CC=CC=C1B(O)O MSQFFCRGQPVQRS-UHFFFAOYSA-N 0.000 description 1
- PYYRNLDFMZVKCV-UHFFFAOYSA-N (2-nitrophenyl)methanamine Chemical compound NCC1=CC=CC=C1[N+]([O-])=O PYYRNLDFMZVKCV-UHFFFAOYSA-N 0.000 description 1
- DOMQFIFVDIAOOT-ROUUACIJSA-N (2S,3R)-N-[4-(2,6-dimethoxyphenyl)-5-(5-methylpyridin-3-yl)-1,2,4-triazol-3-yl]-3-(5-methylpyrimidin-2-yl)butane-2-sulfonamide Chemical compound COC1=C(C(=CC=C1)OC)N1C(=NN=C1C=1C=NC=C(C=1)C)NS(=O)(=O)[C@@H](C)[C@H](C)C1=NC=C(C=N1)C DOMQFIFVDIAOOT-ROUUACIJSA-N 0.000 description 1
- VDASTJYQNBCBDF-JTHBVZDNSA-N (2r)-2-[3-[[2,3-dimethyl-5-[[(1s)-1-(4-propan-2-ylphenyl)ethyl]carbamoyl]indol-1-yl]methyl]phenoxy]propanoic acid Chemical compound C1=CC(C(C)C)=CC=C1[C@H](C)NC(=O)C1=CC=C(N(CC=2C=C(O[C@H](C)C(O)=O)C=CC=2)C(C)=C2C)C2=C1 VDASTJYQNBCBDF-JTHBVZDNSA-N 0.000 description 1
- MXOHVGBFHYSDRF-JTHBVZDNSA-N (2r)-2-[4-[[2,3-dimethyl-5-[[(1s)-1-(3-propan-2-ylphenyl)ethyl]carbamoyl]indol-1-yl]methyl]phenoxy]propanoic acid Chemical compound CC(C)C1=CC=CC([C@H](C)NC(=O)C=2C=C3C(C)=C(C)N(CC=4C=CC(O[C@H](C)C(O)=O)=CC=4)C3=CC=2)=C1 MXOHVGBFHYSDRF-JTHBVZDNSA-N 0.000 description 1
- RBPPDBMDXPPKBU-RBBKRZOGSA-N (2r)-2-[4-chloro-3-[[2,3-dimethyl-5-[[(1s)-1-(3-propan-2-ylphenyl)ethyl]carbamoyl]indol-1-yl]methyl]phenoxy]propanoic acid Chemical compound CC(C)C1=CC=CC([C@H](C)NC(=O)C=2C=C3C(C)=C(C)N(CC=4C(=CC=C(O[C@H](C)C(O)=O)C=4)Cl)C3=CC=2)=C1 RBPPDBMDXPPKBU-RBBKRZOGSA-N 0.000 description 1
- RINPAMYCLSKNFG-FPOVZHCZSA-N (2s)-2-[2-chloro-3-[[5-[[(1s)-1-(3-cyclopropylphenyl)ethyl]carbamoyl]-2,3-dimethylindol-1-yl]methyl]phenoxy]propanoic acid Chemical compound OC(=O)[C@H](C)OC1=CC=CC(CN2C3=CC=C(C=C3C(C)=C2C)C(=O)N[C@@H](C)C=2C=C(C=CC=2)C2CC2)=C1Cl RINPAMYCLSKNFG-FPOVZHCZSA-N 0.000 description 1
- KQARDPIBJFLQCD-FPOVZHCZSA-N (2s)-2-[2-chloro-4-[[5-[[(1s)-1-(3-cyclopropylphenyl)ethyl]carbamoyl]-2,3-dimethylindol-1-yl]methyl]phenoxy]propanoic acid Chemical compound C1=C(Cl)C(O[C@@H](C)C(O)=O)=CC=C1CN1C2=CC=C(C(=O)N[C@@H](C)C=3C=C(C=CC=3)C3CC3)C=C2C(C)=C1C KQARDPIBJFLQCD-FPOVZHCZSA-N 0.000 description 1
- KKZGYXXIYIKUJK-FPOVZHCZSA-N (2s)-2-[2-chloro-5-[[5-[[(1s)-1-(3-cyclopropylphenyl)ethyl]carbamoyl]-2,3-dimethylindol-1-yl]methyl]phenoxy]propanoic acid Chemical compound C1=C(Cl)C(O[C@@H](C)C(O)=O)=CC(CN2C3=CC=C(C=C3C(C)=C2C)C(=O)N[C@@H](C)C=2C=C(C=CC=2)C2CC2)=C1 KKZGYXXIYIKUJK-FPOVZHCZSA-N 0.000 description 1
- MLFXYZDRAAETQC-LMOFDZDWSA-N (2s)-2-[3-[1-[5-[[(1s)-1-(4-tert-butylphenyl)ethyl]carbamoyl]-2,3-dimethylindol-1-yl]ethyl]phenoxy]propanoic acid Chemical compound OC(=O)[C@H](C)OC1=CC=CC(C(C)N2C3=CC=C(C=C3C(C)=C2C)C(=O)N[C@@H](C)C=2C=CC(=CC=2)C(C)(C)C)=C1 MLFXYZDRAAETQC-LMOFDZDWSA-N 0.000 description 1
- MWRHNILRGUSXPA-UDNBHOFDSA-N (2s)-2-[3-[[2,3-dimethyl-5-[[(1s)-1-(3-propan-2-ylphenyl)ethyl]carbamoyl]indol-1-yl]methyl]phenoxy]-3-methylbutanoic acid Chemical compound CC(C)[C@@H](C(O)=O)OC1=CC=CC(CN2C3=CC=C(C=C3C(C)=C2C)C(=O)N[C@@H](C)C=2C=C(C=CC=2)C(C)C)=C1 MWRHNILRGUSXPA-UDNBHOFDSA-N 0.000 description 1
- UJDJWVXKMUZQKW-ICSRJNTNSA-N (2s)-2-[3-[[2,3-dimethyl-5-[[(1s)-1-[4-(trifluoromethyl)phenyl]ethyl]carbamoyl]indol-1-yl]methyl]phenoxy]propanoic acid Chemical compound N([C@@H](C)C=1C=CC(=CC=1)C(F)(F)F)C(=O)C(C=C1C(C)=C2C)=CC=C1N2CC1=CC=CC(O[C@@H](C)C(O)=O)=C1 UJDJWVXKMUZQKW-ICSRJNTNSA-N 0.000 description 1
- MRTJZDMLAUWFHJ-ICSRJNTNSA-N (2s)-2-[3-[[5-[[(1s)-1-(2-chlorophenyl)ethyl]carbamoyl]-2,3-dimethylindol-1-yl]methyl]phenoxy]propanoic acid Chemical compound N([C@@H](C)C=1C(=CC=CC=1)Cl)C(=O)C(C=C1C(C)=C2C)=CC=C1N2CC1=CC=CC(O[C@@H](C)C(O)=O)=C1 MRTJZDMLAUWFHJ-ICSRJNTNSA-N 0.000 description 1
- PSUJFJNXAXBRJM-ICSRJNTNSA-N (2s)-2-[3-[[5-[[(1s)-1-(3-chlorophenyl)ethyl]carbamoyl]-2,3-dimethylindol-1-yl]methyl]phenoxy]propanoic acid Chemical compound N([C@@H](C)C=1C=C(Cl)C=CC=1)C(=O)C(C=C1C(C)=C2C)=CC=C1N2CC1=CC=CC(O[C@@H](C)C(O)=O)=C1 PSUJFJNXAXBRJM-ICSRJNTNSA-N 0.000 description 1
- YPSJXCAJFZVHKL-GMAHTHKFSA-N (2s)-2-[3-[[5-[[(1s)-1-(3-tert-butylphenyl)ethyl]carbamoyl]-2,3-dimethylindol-1-yl]methyl]phenoxy]propanoic acid Chemical compound OC(=O)[C@H](C)OC1=CC=CC(CN2C3=CC=C(C=C3C(C)=C2C)C(=O)N[C@@H](C)C=2C=C(C=CC=2)C(C)(C)C)=C1 YPSJXCAJFZVHKL-GMAHTHKFSA-N 0.000 description 1
- HXJBOSQWCBRBJK-HKUYNNGSSA-N (2s)-2-[3-[[5-[[(1s)-1-(4-bromophenyl)ethyl]carbamoyl]-2,3-dimethylindol-1-yl]methyl]-4-chlorophenoxy]propanoic acid Chemical compound OC(=O)[C@H](C)OC1=CC=C(Cl)C(CN2C3=CC=C(C=C3C(C)=C2C)C(=O)N[C@@H](C)C=2C=CC(Br)=CC=2)=C1 HXJBOSQWCBRBJK-HKUYNNGSSA-N 0.000 description 1
- ICXQTAGKMKUHRY-ICSRJNTNSA-N (2s)-2-[3-[[5-[[(1s)-1-(4-bromophenyl)ethyl]carbamoyl]-2,3-dimethylindol-1-yl]methyl]phenoxy]propanoic acid Chemical compound N([C@@H](C)C=1C=CC(Br)=CC=1)C(=O)C(C=C1C(C)=C2C)=CC=C1N2CC1=CC=CC(O[C@@H](C)C(O)=O)=C1 ICXQTAGKMKUHRY-ICSRJNTNSA-N 0.000 description 1
- VZZHOSJIJJVZJT-ICSRJNTNSA-N (2s)-2-[3-[[5-[[(1s)-1-(4-chlorophenyl)ethyl]carbamoyl]-2,3-dimethylindol-1-yl]methyl]phenoxy]propanoic acid Chemical compound N([C@@H](C)C=1C=CC(Cl)=CC=1)C(=O)C(C=C1C(C)=C2C)=CC=C1N2CC1=CC=CC(O[C@@H](C)C(O)=O)=C1 VZZHOSJIJJVZJT-ICSRJNTNSA-N 0.000 description 1
- VMLSIEUTNCGMER-FPOVZHCZSA-N (2s)-2-[3-[[5-[[(1s)-1-(4-methoxyphenyl)ethyl]carbamoyl]-2,3-dimethylindol-1-yl]methyl]phenoxy]propanoic acid Chemical compound C1=CC(OC)=CC=C1[C@H](C)NC(=O)C1=CC=C(N(CC=2C=C(O[C@@H](C)C(O)=O)C=CC=2)C(C)=C2C)C2=C1 VMLSIEUTNCGMER-FPOVZHCZSA-N 0.000 description 1
- XXEBBCPQHQNYMJ-UNMCSNQZSA-N (2s)-2-[3-[[5-[[(1s)-1-(4-tert-butylphenyl)ethyl]carbamoyl]-2,3-dimethylindol-1-yl]methyl]-2-chlorophenoxy]propanoic acid Chemical compound N([C@@H](C)C=1C=CC(=CC=1)C(C)(C)C)C(=O)C(C=C1C(C)=C2C)=CC=C1N2CC1=CC=CC(O[C@@H](C)C(O)=O)=C1Cl XXEBBCPQHQNYMJ-UNMCSNQZSA-N 0.000 description 1
- ACMRGQBFZUCBKA-UNMCSNQZSA-N (2s)-2-[3-[[5-[[(1s)-1-(4-tert-butylphenyl)ethyl]carbamoyl]-2,3-dimethylindol-1-yl]methyl]-4-fluorophenoxy]propanoic acid Chemical compound N([C@@H](C)C=1C=CC(=CC=1)C(C)(C)C)C(=O)C(C=C1C(C)=C2C)=CC=C1N2CC1=CC(O[C@@H](C)C(O)=O)=CC=C1F ACMRGQBFZUCBKA-UNMCSNQZSA-N 0.000 description 1
- IZIFPJHHGBTWDQ-UNMCSNQZSA-N (2s)-2-[3-[[5-[[(1s)-1-(4-tert-butylphenyl)ethyl]carbamoyl]-2,3-dimethylindol-1-yl]methyl]-5-chlorophenoxy]propanoic acid Chemical compound N([C@@H](C)C=1C=CC(=CC=1)C(C)(C)C)C(=O)C(C=C1C(C)=C2C)=CC=C1N2CC1=CC(Cl)=CC(O[C@@H](C)C(O)=O)=C1 IZIFPJHHGBTWDQ-UNMCSNQZSA-N 0.000 description 1
- COGQHWZDAOHUIS-FPOVZHCZSA-N (2s)-2-[3-chloro-5-[[5-[[(1s)-1-(3-cyclopropylphenyl)ethyl]carbamoyl]-2,3-dimethylindol-1-yl]methyl]phenoxy]propanoic acid Chemical compound OC(=O)[C@H](C)OC1=CC(Cl)=CC(CN2C3=CC=C(C=C3C(C)=C2C)C(=O)N[C@@H](C)C=2C=C(C=CC=2)C2CC2)=C1 COGQHWZDAOHUIS-FPOVZHCZSA-N 0.000 description 1
- VRJIGDUKSMMZBE-SLNZLALYSA-N (2s)-2-[4-[1-[5-[[(1s)-1-(3-cyclopropylphenyl)ethyl]carbamoyl]-2,3-dimethylindol-1-yl]ethyl]phenoxy]propanoic acid Chemical compound C1=CC(O[C@@H](C)C(O)=O)=CC=C1C(C)N1C2=CC=C(C(=O)N[C@@H](C)C=3C=C(C=CC=3)C3CC3)C=C2C(C)=C1C VRJIGDUKSMMZBE-SLNZLALYSA-N 0.000 description 1
- MXOHVGBFHYSDRF-GMAHTHKFSA-N (2s)-2-[4-[[2,3-dimethyl-5-[[(1s)-1-(3-propan-2-ylphenyl)ethyl]carbamoyl]indol-1-yl]methyl]phenoxy]propanoic acid Chemical compound CC(C)C1=CC=CC([C@H](C)NC(=O)C=2C=C3C(C)=C(C)N(CC=4C=CC(O[C@@H](C)C(O)=O)=CC=4)C3=CC=2)=C1 MXOHVGBFHYSDRF-GMAHTHKFSA-N 0.000 description 1
- PMDPTEHGFFDLGD-GMAHTHKFSA-N (2s)-2-[4-[[2,3-dimethyl-5-[[(1s)-1-(4-propan-2-ylphenyl)ethyl]carbamoyl]indol-1-yl]methyl]phenoxy]propanoic acid Chemical compound C1=CC(C(C)C)=CC=C1[C@H](C)NC(=O)C1=CC=C(N(CC=2C=CC(O[C@@H](C)C(O)=O)=CC=2)C(C)=C2C)C2=C1 PMDPTEHGFFDLGD-GMAHTHKFSA-N 0.000 description 1
- ZPNITCQUPYTZQP-UNMCSNQZSA-N (2s)-2-[4-[[5-[[(1s)-1-(4-tert-butylphenyl)ethyl]carbamoyl]-2,3-dimethylindol-1-yl]methyl]-2-chlorophenoxy]propanoic acid Chemical compound N([C@@H](C)C=1C=CC(=CC=1)C(C)(C)C)C(=O)C(C=C1C(C)=C2C)=CC=C1N2CC1=CC=C(O[C@@H](C)C(O)=O)C(Cl)=C1 ZPNITCQUPYTZQP-UNMCSNQZSA-N 0.000 description 1
- BWSVTVVRQBRYCG-FPOVZHCZSA-N (2s)-2-[4-chloro-3-[[5-[[(1s)-1-(3-cyclopropylphenyl)ethyl]carbamoyl]-2,3-dimethylindol-1-yl]methyl]phenoxy]propanoic acid Chemical compound OC(=O)[C@H](C)OC1=CC=C(Cl)C(CN2C3=CC=C(C=C3C(C)=C2C)C(=O)N[C@@H](C)C=2C=C(C=CC=2)C2CC2)=C1 BWSVTVVRQBRYCG-FPOVZHCZSA-N 0.000 description 1
- HIFPAFBBXMRWTK-UNMCSNQZSA-N (2s)-2-[5-[[2,3-dimethyl-5-[[(1s)-1-(3-propan-2-ylphenyl)ethyl]carbamoyl]indol-1-yl]methyl]-2-fluorophenoxy]propanoic acid Chemical compound CC(C)C1=CC=CC([C@H](C)NC(=O)C=2C=C3C(C)=C(C)N(CC=4C=C(O[C@@H](C)C(O)=O)C(F)=CC=4)C3=CC=2)=C1 HIFPAFBBXMRWTK-UNMCSNQZSA-N 0.000 description 1
- RNMNXSJKLFRDSO-GMAHTHKFSA-N (2s)-2-[5-[[2,3-dimethyl-5-[[(1s)-1-(3-propan-2-ylphenyl)ethyl]carbamoyl]indol-1-yl]methyl]-2-methoxyphenoxy]propanoic acid Chemical compound C1=C(O[C@@H](C)C(O)=O)C(OC)=CC=C1CN1C2=CC=C(C(=O)N[C@@H](C)C=3C=C(C=CC=3)C(C)C)C=C2C(C)=C1C RNMNXSJKLFRDSO-GMAHTHKFSA-N 0.000 description 1
- JFOOVABXXMXZLB-FPOVZHCZSA-N (2s)-2-[5-[[5-[[(1s)-1-(3-cyclopropylphenyl)ethyl]carbamoyl]-2,3-dimethylindol-1-yl]methyl]-2-fluorophenoxy]propanoic acid Chemical compound C1=C(F)C(O[C@@H](C)C(O)=O)=CC(CN2C3=CC=C(C=C3C(C)=C2C)C(=O)N[C@@H](C)C=2C=C(C=CC=2)C2CC2)=C1 JFOOVABXXMXZLB-FPOVZHCZSA-N 0.000 description 1
- YXXMRFGJLLYDME-UNMCSNQZSA-N (2s)-2-[5-[[5-[[(1s)-1-(3-cyclopropylphenyl)ethyl]carbamoyl]-2,3-dimethylindol-1-yl]methyl]-2-methoxyphenoxy]propanoic acid Chemical compound C1=C(O[C@@H](C)C(O)=O)C(OC)=CC=C1CN1C2=CC=C(C(=O)N[C@@H](C)C=3C=C(C=CC=3)C3CC3)C=C2C(C)=C1C YXXMRFGJLLYDME-UNMCSNQZSA-N 0.000 description 1
- ODGSDUIOJXTQJF-HKUYNNGSSA-N (2s)-2-[5-[[5-[[(1s)-1-(4-bromophenyl)ethyl]carbamoyl]-2,3-dimethylindol-1-yl]methyl]-2-chlorophenoxy]propanoic acid Chemical compound C1=C(Cl)C(O[C@@H](C)C(O)=O)=CC(CN2C3=CC=C(C=C3C(C)=C2C)C(=O)N[C@@H](C)C=2C=CC(Br)=CC=2)=C1 ODGSDUIOJXTQJF-HKUYNNGSSA-N 0.000 description 1
- UOROYSIXQQDIFM-UNMCSNQZSA-N (2s)-2-[5-[[5-[[(1s)-1-(4-tert-butylphenyl)ethyl]carbamoyl]-2,3-dimethylindol-1-yl]methyl]-2-fluorophenoxy]propanoic acid Chemical compound N([C@@H](C)C=1C=CC(=CC=1)C(C)(C)C)C(=O)C(C=C1C(C)=C2C)=CC=C1N2CC1=CC=C(F)C(O[C@@H](C)C(O)=O)=C1 UOROYSIXQQDIFM-UNMCSNQZSA-N 0.000 description 1
- UYJKNFRRSPQXSM-GMAHTHKFSA-N (2s)-2-[5-[[5-[[(1s)-1-(4-tert-butylphenyl)ethyl]carbamoyl]-2,3-dimethylindol-1-yl]methyl]-2-methoxyphenoxy]propanoic acid Chemical compound C1=C(O[C@@H](C)C(O)=O)C(OC)=CC=C1CN1C2=CC=C(C(=O)N[C@@H](C)C=3C=CC(=CC=3)C(C)(C)C)C=C2C(C)=C1C UYJKNFRRSPQXSM-GMAHTHKFSA-N 0.000 description 1
- YGZJTYCCONJJGZ-UHFFFAOYSA-N (3,5-dimethoxyphenyl)methanamine Chemical compound COC1=CC(CN)=CC(OC)=C1 YGZJTYCCONJJGZ-UHFFFAOYSA-N 0.000 description 1
- SDEAGACSNFSZCU-UHFFFAOYSA-N (3-chlorophenyl)boronic acid Chemical compound OB(O)C1=CC=CC(Cl)=C1 SDEAGACSNFSZCU-UHFFFAOYSA-N 0.000 description 1
- BJFPYGGTDAYECS-UHFFFAOYSA-N (3-chlorophenyl)methanamine Chemical compound NCC1=CC=CC(Cl)=C1 BJFPYGGTDAYECS-UHFFFAOYSA-N 0.000 description 1
- AZHAJNNLBSKSOB-UHFFFAOYSA-N (3-fluoro-4-methoxyphenyl)methanamine Chemical compound COC1=CC=C(CN)C=C1F AZHAJNNLBSKSOB-UHFFFAOYSA-N 0.000 description 1
- NLLGFYPSWCMUIV-UHFFFAOYSA-N (3-methoxyphenyl)boronic acid Chemical compound COC1=CC=CC(B(O)O)=C1 NLLGFYPSWCMUIV-UHFFFAOYSA-N 0.000 description 1
- GRRIMVWABNHKBX-UHFFFAOYSA-N (3-methoxyphenyl)methanamine Chemical compound COC1=CC=CC(CN)=C1 GRRIMVWABNHKBX-UHFFFAOYSA-N 0.000 description 1
- BJQCPCFFYBKRLM-UHFFFAOYSA-N (3-methylphenyl)boronic acid Chemical compound CC1=CC=CC(B(O)O)=C1 BJQCPCFFYBKRLM-UHFFFAOYSA-N 0.000 description 1
- RGXUCUWVGKLACF-UHFFFAOYSA-N (3-methylphenyl)methanamine Chemical compound CC1=CC=CC(CN)=C1 RGXUCUWVGKLACF-UHFFFAOYSA-N 0.000 description 1
- HZFFUMBZBGETES-UHFFFAOYSA-N (3-methylsulfonylphenyl)boronic acid Chemical compound CS(=O)(=O)C1=CC=CC(B(O)O)=C1 HZFFUMBZBGETES-UHFFFAOYSA-N 0.000 description 1
- DQFOSYRXEOWKOY-UHFFFAOYSA-N (3-methylsulfonylphenyl)methanamine Chemical compound CS(=O)(=O)C1=CC=CC(CN)=C1 DQFOSYRXEOWKOY-UHFFFAOYSA-N 0.000 description 1
- CIUYJYRQKYGNQP-UHFFFAOYSA-N (3-nitrophenyl)methanamine Chemical compound NCC1=CC=CC([N+]([O-])=O)=C1 CIUYJYRQKYGNQP-UHFFFAOYSA-N 0.000 description 1
- UMGGFLATENTNHY-UHFFFAOYSA-N (3-propan-2-ylphenyl)methanamine Chemical compound CC(C)C1=CC=CC(CN)=C1 UMGGFLATENTNHY-UHFFFAOYSA-N 0.000 description 1
- SVWDNDQOXZHBRM-MRVPVSSYSA-N (3r)-3,4-dihydro-2h-chromen-3-amine Chemical compound C1=CC=C2C[C@@H](N)COC2=C1 SVWDNDQOXZHBRM-MRVPVSSYSA-N 0.000 description 1
- MAYZWDRUFKUGGP-VIFPVBQESA-N (3s)-1-[5-tert-butyl-3-[(1-methyltetrazol-5-yl)methyl]triazolo[4,5-d]pyrimidin-7-yl]pyrrolidin-3-ol Chemical compound CN1N=NN=C1CN1C2=NC(C(C)(C)C)=NC(N3C[C@@H](O)CC3)=C2N=N1 MAYZWDRUFKUGGP-VIFPVBQESA-N 0.000 description 1
- SVWDNDQOXZHBRM-QMMMGPOBSA-N (3s)-3,4-dihydro-2h-chromen-3-amine Chemical compound C1=CC=C2C[C@H](N)COC2=C1 SVWDNDQOXZHBRM-QMMMGPOBSA-N 0.000 description 1
- XRNVSPDQTPVECU-UHFFFAOYSA-N (4-bromophenyl)methanamine Chemical compound NCC1=CC=C(Br)C=C1 XRNVSPDQTPVECU-UHFFFAOYSA-N 0.000 description 1
- YMVFJGSXZNNUDW-UHFFFAOYSA-N (4-chlorophenyl)methanamine Chemical compound NCC1=CC=C(Cl)C=C1 YMVFJGSXZNNUDW-UHFFFAOYSA-N 0.000 description 1
- COIQUVGFTILYGA-UHFFFAOYSA-N (4-hydroxyphenyl)boronic acid Chemical compound OB(O)C1=CC=C(O)C=C1 COIQUVGFTILYGA-UHFFFAOYSA-N 0.000 description 1
- KCGZGJOBKAXVSU-UHFFFAOYSA-N (4-iodophenyl)methanamine Chemical compound NCC1=CC=C(I)C=C1 KCGZGJOBKAXVSU-UHFFFAOYSA-N 0.000 description 1
- HMTSWYPNXFHGEP-UHFFFAOYSA-N (4-methylphenyl)methanamine Chemical compound CC1=CC=C(CN)C=C1 HMTSWYPNXFHGEP-UHFFFAOYSA-N 0.000 description 1
- IVUHTLFKBDDICS-UHFFFAOYSA-N (4-methylsulfanylphenyl)boronic acid Chemical compound CSC1=CC=C(B(O)O)C=C1 IVUHTLFKBDDICS-UHFFFAOYSA-N 0.000 description 1
- SBMPBXFNKYJNIC-UHFFFAOYSA-N (4-methylsulfanylphenyl)methanamine Chemical compound CSC1=CC=C(CN)C=C1 SBMPBXFNKYJNIC-UHFFFAOYSA-N 0.000 description 1
- VDUKDQTYMWUSAC-UHFFFAOYSA-N (4-methylsulfonylphenyl)boronic acid Chemical compound CS(=O)(=O)C1=CC=C(B(O)O)C=C1 VDUKDQTYMWUSAC-UHFFFAOYSA-N 0.000 description 1
- VMNXLLDFGVEBLE-UHFFFAOYSA-N (4-methylsulfonylphenyl)methanamine Chemical compound CS(=O)(=O)C1=CC=C(CN)C=C1 VMNXLLDFGVEBLE-UHFFFAOYSA-N 0.000 description 1
- RMSPOVPGDBDYKH-UHFFFAOYSA-N (4-phenylphenyl)methanamine Chemical compound C1=CC(CN)=CC=C1C1=CC=CC=C1 RMSPOVPGDBDYKH-UHFFFAOYSA-N 0.000 description 1
- YQSHYGCCYVPRDI-UHFFFAOYSA-N (4-propan-2-ylphenyl)methanamine Chemical compound CC(C)C1=CC=C(CN)C=C1 YQSHYGCCYVPRDI-UHFFFAOYSA-N 0.000 description 1
- MPWSRGAWRAYBJK-UHFFFAOYSA-N (4-tert-butylphenyl)methanamine Chemical compound CC(C)(C)C1=CC=C(CN)C=C1 MPWSRGAWRAYBJK-UHFFFAOYSA-N 0.000 description 1
- YSEAGSCGERFGBL-UHFFFAOYSA-N (5-methylfuran-2-yl)methanamine Chemical compound CC1=CC=C(CN)O1 YSEAGSCGERFGBL-UHFFFAOYSA-N 0.000 description 1
- UKGJZDSUJSPAJL-YPUOHESYSA-N (e)-n-[(1r)-1-[3,5-difluoro-4-(methanesulfonamido)phenyl]ethyl]-3-[2-propyl-6-(trifluoromethyl)pyridin-3-yl]prop-2-enamide Chemical compound CCCC1=NC(C(F)(F)F)=CC=C1\C=C\C(=O)N[C@H](C)C1=CC(F)=C(NS(C)(=O)=O)C(F)=C1 UKGJZDSUJSPAJL-YPUOHESYSA-N 0.000 description 1
- ZGYIXVSQHOKQRZ-COIATFDQSA-N (e)-n-[4-[3-chloro-4-(pyridin-2-ylmethoxy)anilino]-3-cyano-7-[(3s)-oxolan-3-yl]oxyquinolin-6-yl]-4-(dimethylamino)but-2-enamide Chemical compound N#CC1=CN=C2C=C(O[C@@H]3COCC3)C(NC(=O)/C=C/CN(C)C)=CC2=C1NC(C=C1Cl)=CC=C1OCC1=CC=CC=N1 ZGYIXVSQHOKQRZ-COIATFDQSA-N 0.000 description 1
- MOWXJLUYGFNTAL-DEOSSOPVSA-N (s)-[2-chloro-4-fluoro-5-(7-morpholin-4-ylquinazolin-4-yl)phenyl]-(6-methoxypyridazin-3-yl)methanol Chemical compound N1=NC(OC)=CC=C1[C@@H](O)C1=CC(C=2C3=CC=C(C=C3N=CN=2)N2CCOCC2)=C(F)C=C1Cl MOWXJLUYGFNTAL-DEOSSOPVSA-N 0.000 description 1
- ORNTVXUJWMIYQM-ZDUSSCGKSA-N (s)-cyclopropyl-(3-propan-2-ylphenyl)methanamine Chemical compound CC(C)C1=CC=CC([C@@H](N)C2CC2)=C1 ORNTVXUJWMIYQM-ZDUSSCGKSA-N 0.000 description 1
- KZPYGQFFRCFCPP-UHFFFAOYSA-N 1,1'-bis(diphenylphosphino)ferrocene Chemical compound [Fe+2].C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1 KZPYGQFFRCFCPP-UHFFFAOYSA-N 0.000 description 1
- 125000001607 1,2,3-triazol-1-yl group Chemical group [*]N1N=NC([H])=C1[H] 0.000 description 1
- 125000001305 1,2,4-triazol-3-yl group Chemical group [H]N1N=C([*])N=C1[H] 0.000 description 1
- ZILSBZLQGRBMOR-UHFFFAOYSA-N 1,3-benzodioxol-5-ylmethanamine Chemical compound NCC1=CC=C2OCOC2=C1 ZILSBZLQGRBMOR-UHFFFAOYSA-N 0.000 description 1
- QZMQKPGVXNSITP-UHFFFAOYSA-N 1,3-benzodioxole-4-carbaldehyde Chemical compound O=CC1=CC=CC2=C1OCO2 QZMQKPGVXNSITP-UHFFFAOYSA-N 0.000 description 1
- APWRZPQBPCAXFP-UHFFFAOYSA-N 1-(1-oxo-2H-isoquinolin-5-yl)-5-(trifluoromethyl)-N-[2-(trifluoromethyl)pyridin-4-yl]pyrazole-4-carboxamide Chemical compound O=C1NC=CC2=C(C=CC=C12)N1N=CC(=C1C(F)(F)F)C(=O)NC1=CC(=NC=C1)C(F)(F)F APWRZPQBPCAXFP-UHFFFAOYSA-N 0.000 description 1
- MJUVRTYWUMPBTR-MRXNPFEDSA-N 1-(2,2-difluoro-1,3-benzodioxol-5-yl)-n-[1-[(2r)-2,3-dihydroxypropyl]-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)indol-5-yl]cyclopropane-1-carboxamide Chemical compound FC=1C=C2N(C[C@@H](O)CO)C(C(C)(CO)C)=CC2=CC=1NC(=O)C1(C=2C=C3OC(F)(F)OC3=CC=2)CC1 MJUVRTYWUMPBTR-MRXNPFEDSA-N 0.000 description 1
- WHFGIDAZBKTDRV-UHFFFAOYSA-N 1-(2,3-difluorobenzoyl)-n-(1-phenylpropyl)indole-5-carboxamide Chemical compound C=1C=CC=CC=1C(CC)NC(=O)C(C=C1C=C2)=CC=C1N2C(=O)C1=CC=CC(F)=C1F WHFGIDAZBKTDRV-UHFFFAOYSA-N 0.000 description 1
- IDPURXSQCKYKIJ-UHFFFAOYSA-N 1-(4-methoxyphenyl)methanamine Chemical compound COC1=CC=C(CN)C=C1 IDPURXSQCKYKIJ-UHFFFAOYSA-N 0.000 description 1
- AYUGAOYMYXSOKU-UHFFFAOYSA-N 1-(4-methylphenyl)cyclopropane-1-carboxylic acid Chemical compound C1=CC(C)=CC=C1C1(C(O)=O)CC1 AYUGAOYMYXSOKU-UHFFFAOYSA-N 0.000 description 1
- NEIUETKNDJTHMO-UHFFFAOYSA-N 1-(4-methylphenyl)sulfonyl-n-(1-phenylpropyl)indole-5-carboxamide Chemical compound C=1C=CC=CC=1C(CC)NC(=O)C(C=C1C=C2)=CC=C1N2S(=O)(=O)C1=CC=C(C)C=C1 NEIUETKNDJTHMO-UHFFFAOYSA-N 0.000 description 1
- KXFYOAMQCYPUDS-UHFFFAOYSA-N 1-(4-nitrobenzoyl)-n-(1-phenylpropyl)indole-5-carboxamide Chemical compound C=1C=CC=CC=1C(CC)NC(=O)C(C=C1C=C2)=CC=C1N2C(=O)C1=CC=C([N+]([O-])=O)C=C1 KXFYOAMQCYPUDS-UHFFFAOYSA-N 0.000 description 1
- YEFPTXNVPRKFPQ-UHFFFAOYSA-N 1-(4-nitrophenyl)sulfonyl-n-(1-phenylpropyl)indole-5-carboxamide Chemical compound C=1C=CC=CC=1C(CC)NC(=O)C(C=C1C=C2)=CC=C1N2S(=O)(=O)C1=CC=C([N+]([O-])=O)C=C1 YEFPTXNVPRKFPQ-UHFFFAOYSA-N 0.000 description 1
- RITFLBZVEWSGLF-UHFFFAOYSA-N 1-(6-bromopyridin-2-yl)ethylazanium;chloride Chemical compound [Cl-].CC([NH3+])C1=CC=CC(Br)=N1 RITFLBZVEWSGLF-UHFFFAOYSA-N 0.000 description 1
- MNEIJGDSFRHGMS-UHFFFAOYSA-N 1-(phenylmethyl)benzimidazole Chemical compound C1=NC2=CC=CC=C2N1CC1=CC=CC=C1 MNEIJGDSFRHGMS-UHFFFAOYSA-N 0.000 description 1
- WKDRWTMPOTUIGR-UHFFFAOYSA-N 1-[(2,4-difluorophenyl)methyl]-n-(1-naphthalen-1-ylethyl)indole-5-carboxamide Chemical compound C=1C=CC2=CC=CC=C2C=1C(C)NC(=O)C(C=C1C=C2)=CC=C1N2CC1=CC=C(F)C=C1F WKDRWTMPOTUIGR-UHFFFAOYSA-N 0.000 description 1
- DXAXGTUMUWQTQY-UHFFFAOYSA-N 1-[(2,4-difluorophenyl)methyl]-n-(1-phenylpropyl)indole-5-carboxamide Chemical compound C=1C=CC=CC=1C(CC)NC(=O)C(C=C1C=C2)=CC=C1N2CC1=CC=C(F)C=C1F DXAXGTUMUWQTQY-UHFFFAOYSA-N 0.000 description 1
- LNHXUVCYXUBELO-UHFFFAOYSA-N 1-[(2,4-difluorophenyl)methyl]-n-(2,3-dihydro-1,4-benzodioxin-3-ylmethyl)indole-5-carboxamide Chemical compound FC1=CC(F)=CC=C1CN1C2=CC=C(C(=O)NCC3OC4=CC=CC=C4OC3)C=C2C=C1 LNHXUVCYXUBELO-UHFFFAOYSA-N 0.000 description 1
- GMRYNASLCBBORY-UHFFFAOYSA-N 1-[(2,4-difluorophenyl)methyl]-n-(2-methoxyethyl)indole-5-carboxamide Chemical compound C1=CC2=CC(C(=O)NCCOC)=CC=C2N1CC1=CC=C(F)C=C1F GMRYNASLCBBORY-UHFFFAOYSA-N 0.000 description 1
- SJCBETLHYFGQOI-UHFFFAOYSA-N 1-[(2,4-difluorophenyl)methyl]-n-(2-phenylpropan-2-yl)indole-5-carboxamide Chemical compound C=1C=CC=CC=1C(C)(C)NC(=O)C(C=C1C=C2)=CC=C1N2CC1=CC=C(F)C=C1F SJCBETLHYFGQOI-UHFFFAOYSA-N 0.000 description 1
- QKPBRMOUSUQBNL-UHFFFAOYSA-N 1-[(2,4-difluorophenyl)methyl]-n-(3,4-dihydro-2h-chromen-3-yl)indole-5-carboxamide Chemical compound FC1=CC(F)=CC=C1CN1C2=CC=C(C(=O)NC3CC4=CC=CC=C4OC3)C=C2C=C1 QKPBRMOUSUQBNL-UHFFFAOYSA-N 0.000 description 1
- XPNILBRDAXGICK-UHFFFAOYSA-N 1-[(2,4-difluorophenyl)methyl]-n-(thiophen-2-ylmethyl)indole-5-carboxamide Chemical compound FC1=CC(F)=CC=C1CN1C2=CC=C(C(=O)NCC=3SC=CC=3)C=C2C=C1 XPNILBRDAXGICK-UHFFFAOYSA-N 0.000 description 1
- BZCVWUCLNMTRBT-OAHLLOKOSA-N 1-[(2,4-difluorophenyl)methyl]-n-[(1r)-1-(4-fluorophenyl)ethyl]indole-5-carboxamide Chemical compound N([C@H](C)C=1C=CC(F)=CC=1)C(=O)C(C=C1C=C2)=CC=C1N2CC1=CC=C(F)C=C1F BZCVWUCLNMTRBT-OAHLLOKOSA-N 0.000 description 1
- YIZXDBJRSMOKCY-OAHLLOKOSA-N 1-[(2,4-difluorophenyl)methyl]-n-[(1r)-1-(4-nitrophenyl)ethyl]indole-5-carboxamide Chemical compound N([C@H](C)C=1C=CC(=CC=1)[N+]([O-])=O)C(=O)C(C=C1C=C2)=CC=C1N2CC1=CC=C(F)C=C1F YIZXDBJRSMOKCY-OAHLLOKOSA-N 0.000 description 1
- FCDDSRNKKNDFIA-JTHBVZDNSA-N 1-[(2,4-difluorophenyl)methyl]-n-[(1r,2s)-2-phenylcyclopropyl]indole-5-carboxamide Chemical compound FC1=CC(F)=CC=C1CN1C2=CC=C(C(=O)N[C@H]3[C@@H](C3)C=3C=CC=CC=3)C=C2C=C1 FCDDSRNKKNDFIA-JTHBVZDNSA-N 0.000 description 1
- BZCVWUCLNMTRBT-HNNXBMFYSA-N 1-[(2,4-difluorophenyl)methyl]-n-[(1s)-1-(4-fluorophenyl)ethyl]indole-5-carboxamide Chemical compound N([C@@H](C)C=1C=CC(F)=CC=1)C(=O)C(C=C1C=C2)=CC=C1N2CC1=CC=C(F)C=C1F BZCVWUCLNMTRBT-HNNXBMFYSA-N 0.000 description 1
- YIZXDBJRSMOKCY-HNNXBMFYSA-N 1-[(2,4-difluorophenyl)methyl]-n-[(1s)-1-(4-nitrophenyl)ethyl]indole-5-carboxamide Chemical compound N([C@@H](C)C=1C=CC(=CC=1)[N+]([O-])=O)C(=O)C(C=C1C=C2)=CC=C1N2CC1=CC=C(F)C=C1F YIZXDBJRSMOKCY-HNNXBMFYSA-N 0.000 description 1
- RMFYBVHPLLDKLH-UHFFFAOYSA-N 1-[(2,4-difluorophenyl)methyl]-n-[(3,4-dimethoxyphenyl)methyl]indole-5-carboxamide Chemical compound C1=C(OC)C(OC)=CC=C1CNC(=O)C1=CC=C(N(CC=2C(=CC(F)=CC=2)F)C=C2)C2=C1 RMFYBVHPLLDKLH-UHFFFAOYSA-N 0.000 description 1
- GENQANXQVPXRHK-UHFFFAOYSA-N 1-[(2,4-difluorophenyl)methyl]-n-[[3-(trifluoromethoxy)phenyl]methyl]indole-5-carboxamide Chemical compound FC1=CC(F)=CC=C1CN1C2=CC=C(C(=O)NCC=3C=C(OC(F)(F)F)C=CC=3)C=C2C=C1 GENQANXQVPXRHK-UHFFFAOYSA-N 0.000 description 1
- FAIUIRDVCNDSDA-IBGZPJMESA-N 1-[(3-carbamoylphenyl)methyl]-n-[(1s)-1-(3-cyclopropylphenyl)ethyl]-2,3-dimethylindole-5-carboxamide Chemical compound N([C@@H](C)C=1C=C(C=CC=1)C1CC1)C(=O)C(C=C1C(C)=C2C)=CC=C1N2CC1=CC=CC(C(N)=O)=C1 FAIUIRDVCNDSDA-IBGZPJMESA-N 0.000 description 1
- GHEAQIVVPNEMLM-UHFFFAOYSA-N 1-[(4-chlorophenyl)methyl]-2,3-dimethyl-n-(1-phenylpropyl)indole-5-carboxamide Chemical compound C=1C=CC=CC=1C(CC)NC(=O)C(C=C1C(C)=C2C)=CC=C1N2CC1=CC=C(Cl)C=C1 GHEAQIVVPNEMLM-UHFFFAOYSA-N 0.000 description 1
- UTKFEUWKLHRTKL-UHFFFAOYSA-N 1-[(6-chloropyridin-3-yl)methyl]-n-(1-phenylpropyl)indole-5-carboxamide Chemical compound C=1C=CC=CC=1C(CC)NC(=O)C(C=C1C=C2)=CC=C1N2CC1=CC=C(Cl)N=C1 UTKFEUWKLHRTKL-UHFFFAOYSA-N 0.000 description 1
- ABDDQTDRAHXHOC-QMMMGPOBSA-N 1-[(7s)-5,7-dihydro-4h-thieno[2,3-c]pyran-7-yl]-n-methylmethanamine Chemical compound CNC[C@@H]1OCCC2=C1SC=C2 ABDDQTDRAHXHOC-QMMMGPOBSA-N 0.000 description 1
- XLRRVAFNKHUUCH-LYKKTTPLSA-N 1-[1-[3-[(2s)-1-methoxy-1-oxopropan-2-yl]oxyphenyl]ethyl]-2,3-dimethylindole-5-carboxylic acid Chemical compound COC(=O)[C@H](C)OC1=CC=CC(C(C)N2C3=CC=C(C=C3C(C)=C2C)C(O)=O)=C1 XLRRVAFNKHUUCH-LYKKTTPLSA-N 0.000 description 1
- CZBWXNROPZWNRN-UHFFFAOYSA-N 1-[2-(3-chlorophenyl)ethyl]-n-(1-phenylpropyl)indole-5-carboxamide Chemical compound C=1C=CC=CC=1C(CC)NC(=O)C(C=C1C=C2)=CC=C1N2CCC1=CC=CC(Cl)=C1 CZBWXNROPZWNRN-UHFFFAOYSA-N 0.000 description 1
- KOGGLQJXPZETLX-UHFFFAOYSA-N 1-[4-[[2,3-dimethyl-5-(1-phenylpropylcarbamoyl)indol-1-yl]methyl]phenyl]cyclopropane-1-carboxylic acid Chemical compound C=1C=CC=CC=1C(CC)NC(=O)C(C=C1C(C)=C2C)=CC=C1N2CC(C=C1)=CC=C1C1(C(O)=O)CC1 KOGGLQJXPZETLX-UHFFFAOYSA-N 0.000 description 1
- PXZRJMBINJHXGS-QFIPXVFZSA-N 1-[4-[[2,3-dimethyl-5-[[(1s)-1-(4-propan-2-ylphenyl)ethyl]carbamoyl]indol-1-yl]methyl]phenyl]cyclopropane-1-carboxylic acid Chemical compound C1=CC(C(C)C)=CC=C1[C@H](C)NC(=O)C1=CC=C(N(CC=2C=CC(=CC=2)C2(CC2)C(O)=O)C(C)=C2C)C2=C1 PXZRJMBINJHXGS-QFIPXVFZSA-N 0.000 description 1
- LEEDJQRWXKMKCB-IBGZPJMESA-N 1-[4-[[5-[[(1s)-1-(4-bromophenyl)ethyl]carbamoyl]-2,3-dimethylindol-1-yl]methyl]phenyl]cyclopropane-1-carboxylic acid Chemical compound N([C@@H](C)C=1C=CC(Br)=CC=1)C(=O)C(C=C1C(C)=C2C)=CC=C1N2CC(C=C1)=CC=C1C1(C(O)=O)CC1 LEEDJQRWXKMKCB-IBGZPJMESA-N 0.000 description 1
- LLUAXCKDVKZVBB-AWEZNQCLSA-N 1-[[2-chloro-4-[(2s)-1-methoxy-1-oxopropan-2-yl]oxyphenyl]methyl]-2,3-dimethylindole-5-carboxylic acid Chemical compound ClC1=CC(O[C@@H](C)C(=O)OC)=CC=C1CN1C2=CC=C(C(O)=O)C=C2C(C)=C1C LLUAXCKDVKZVBB-AWEZNQCLSA-N 0.000 description 1
- ULUGOGVQPMMHQS-UNMCSNQZSA-N 1-[[3-[(2s)-1-amino-1-oxopropan-2-yl]oxy-4-chlorophenyl]methyl]-n-[(1s)-1-(4-tert-butylphenyl)ethyl]-2,3-dimethylindole-5-carboxamide Chemical compound N([C@@H](C)C=1C=CC(=CC=1)C(C)(C)C)C(=O)C(C=C1C(C)=C2C)=CC=C1N2CC1=CC=C(Cl)C(O[C@@H](C)C(N)=O)=C1 ULUGOGVQPMMHQS-UNMCSNQZSA-N 0.000 description 1
- RUFOEXFKOJDODD-GMAHTHKFSA-N 1-[[3-[(2s)-1-amino-1-oxopropan-2-yl]oxyphenyl]methyl]-n-[(1s)-1-(4-tert-butylphenyl)ethyl]-2,3-dimethylindole-5-carboxamide Chemical compound NC(=O)[C@H](C)OC1=CC=CC(CN2C3=CC=C(C=C3C(C)=C2C)C(=O)N[C@@H](C)C=2C=CC(=CC=2)C(C)(C)C)=C1 RUFOEXFKOJDODD-GMAHTHKFSA-N 0.000 description 1
- GJPASUXMVRHPLJ-DEOSSOPVSA-N 1-[[4-(2-carbamoylphenyl)phenyl]methyl]-2,3-dimethyl-n-[(1s)-1-(3-propan-2-ylphenyl)ethyl]indole-5-carboxamide Chemical compound CC(C)C1=CC=CC([C@H](C)NC(=O)C=2C=C3C(C)=C(C)N(CC=4C=CC(=CC=4)C=4C(=CC=CC=4)C(N)=O)C3=CC=2)=C1 GJPASUXMVRHPLJ-DEOSSOPVSA-N 0.000 description 1
- JNEKNFZTRJQLQY-FQEVSTJZSA-N 1-[[4-(2-chlorophenyl)phenyl]methyl]-n-[(1s)-1-(4-nitrophenyl)ethyl]indole-5-carboxamide Chemical compound N([C@@H](C)C=1C=CC(=CC=1)[N+]([O-])=O)C(=O)C(C=C1C=C2)=CC=C1N2CC(C=C1)=CC=C1C1=CC=CC=C1Cl JNEKNFZTRJQLQY-FQEVSTJZSA-N 0.000 description 1
- XFHDYJRPAWKDAF-DEOSSOPVSA-N 1-[[4-(2-cyanophenyl)phenyl]methyl]-2,3-dimethyl-n-[(1s)-1-(4-methylphenyl)ethyl]indole-5-carboxamide Chemical compound N([C@@H](C)C=1C=CC(C)=CC=1)C(=O)C(C=C1C(C)=C2C)=CC=C1N2CC(C=C1)=CC=C1C1=CC=CC=C1C#N XFHDYJRPAWKDAF-DEOSSOPVSA-N 0.000 description 1
- MDFPEQDNNJYDMN-VWLOTQADSA-N 1-[[4-(2-cyanophenyl)phenyl]methyl]-2,3-dimethyl-n-[(1s)-1-(4-propan-2-yloxyphenyl)ethyl]indole-5-carboxamide Chemical compound C1=CC(OC(C)C)=CC=C1[C@H](C)NC(=O)C1=CC=C(N(CC=2C=CC(=CC=2)C=2C(=CC=CC=2)C#N)C(C)=C2C)C2=C1 MDFPEQDNNJYDMN-VWLOTQADSA-N 0.000 description 1
- LQQMSEHQQFJJAC-VWLOTQADSA-N 1-[[4-(2-cyanophenyl)phenyl]methyl]-2,3-dimethyl-n-[(1s)-1-(4-propan-2-ylphenyl)ethyl]indole-5-carboxamide Chemical compound C1=CC(C(C)C)=CC=C1[C@H](C)NC(=O)C1=CC=C(N(CC=2C=CC(=CC=2)C=2C(=CC=CC=2)C#N)C(C)=C2C)C2=C1 LQQMSEHQQFJJAC-VWLOTQADSA-N 0.000 description 1
- KGOUMMXJIOOXEF-QFIPXVFZSA-N 1-[[4-(2-cyanophenyl)phenyl]methyl]-2,3-dimethyl-n-[(1s)-1-[3-(trifluoromethyl)phenyl]ethyl]indole-5-carboxamide Chemical compound N([C@@H](C)C=1C=C(C=CC=1)C(F)(F)F)C(=O)C(C=C1C(C)=C2C)=CC=C1N2CC(C=C1)=CC=C1C1=CC=CC=C1C#N KGOUMMXJIOOXEF-QFIPXVFZSA-N 0.000 description 1
- DLRTUJPCQCYMJT-QFIPXVFZSA-N 1-[[4-(2-cyanophenyl)phenyl]methyl]-2,3-dimethyl-n-[(1s)-1-[4-(trifluoromethoxy)phenyl]ethyl]indole-5-carboxamide Chemical compound N([C@@H](C)C=1C=CC(OC(F)(F)F)=CC=1)C(=O)C(C=C1C(C)=C2C)=CC=C1N2CC(C=C1)=CC=C1C1=CC=CC=C1C#N DLRTUJPCQCYMJT-QFIPXVFZSA-N 0.000 description 1
- AAOSGWOPAVRNPL-QFIPXVFZSA-N 1-[[4-(2-cyanophenyl)phenyl]methyl]-2,3-dimethyl-n-[(1s)-1-[4-(trifluoromethyl)phenyl]ethyl]indole-5-carboxamide Chemical compound N([C@@H](C)C=1C=CC(=CC=1)C(F)(F)F)C(=O)C(C=C1C(C)=C2C)=CC=C1N2CC(C=C1)=CC=C1C1=CC=CC=C1C#N AAOSGWOPAVRNPL-QFIPXVFZSA-N 0.000 description 1
- NABIPGTYEGTLCY-QHCPKHFHSA-N 1-[[4-(2-cyanophenyl)phenyl]methyl]-2,3-dimethyl-n-[(1s)-1-phenylethyl]indole-5-carboxamide Chemical compound N([C@@H](C)C=1C=CC=CC=1)C(=O)C(C=C1C(C)=C2C)=CC=C1N2CC(C=C1)=CC=C1C1=CC=CC=C1C#N NABIPGTYEGTLCY-QHCPKHFHSA-N 0.000 description 1
- ZOKCULLSIQRRQO-NRFANRHFSA-N 1-[[4-(2-cyanophenyl)phenyl]methyl]-n-[(1s)-1-(2,4-difluorophenyl)ethyl]-2,3-dimethylindole-5-carboxamide Chemical compound N([C@@H](C)C=1C(=CC(F)=CC=1)F)C(=O)C(C=C1C(C)=C2C)=CC=C1N2CC(C=C1)=CC=C1C1=CC=CC=C1C#N ZOKCULLSIQRRQO-NRFANRHFSA-N 0.000 description 1
- ZKCITDQPZRXLBD-QHCPKHFHSA-N 1-[[4-(2-cyanophenyl)phenyl]methyl]-n-[(1s)-1-(2-methoxyphenyl)ethyl]-2,3-dimethylindole-5-carboxamide Chemical compound COC1=CC=CC=C1[C@H](C)NC(=O)C1=CC=C(N(CC=2C=CC(=CC=2)C=2C(=CC=CC=2)C#N)C(C)=C2C)C2=C1 ZKCITDQPZRXLBD-QHCPKHFHSA-N 0.000 description 1
- IRHSXSNJVCODEQ-NRFANRHFSA-N 1-[[4-(2-cyanophenyl)phenyl]methyl]-n-[(1s)-1-(3,4-dichlorophenyl)ethyl]-2,3-dimethylindole-5-carboxamide Chemical compound N([C@@H](C)C=1C=C(Cl)C(Cl)=CC=1)C(=O)C(C=C1C(C)=C2C)=CC=C1N2CC(C=C1)=CC=C1C1=CC=CC=C1C#N IRHSXSNJVCODEQ-NRFANRHFSA-N 0.000 description 1
- MEDCTTSNYRZUQY-DEOSSOPVSA-N 1-[[4-(2-cyanophenyl)phenyl]methyl]-n-[(1s)-1-(3-ethoxyphenyl)ethyl]-2,3-dimethylindole-5-carboxamide Chemical compound CCOC1=CC=CC([C@H](C)NC(=O)C=2C=C3C(C)=C(C)N(CC=4C=CC(=CC=4)C=4C(=CC=CC=4)C#N)C3=CC=2)=C1 MEDCTTSNYRZUQY-DEOSSOPVSA-N 0.000 description 1
- LBOBKUJSBLDNFF-QFIPXVFZSA-N 1-[[4-(2-cyanophenyl)phenyl]methyl]-n-[(1s)-1-(3-fluorophenyl)ethyl]-2,3-dimethylindole-5-carboxamide Chemical compound N([C@@H](C)C=1C=C(F)C=CC=1)C(=O)C(C=C1C(C)=C2C)=CC=C1N2CC(C=C1)=CC=C1C1=CC=CC=C1C#N LBOBKUJSBLDNFF-QFIPXVFZSA-N 0.000 description 1
- VIMRSIDGYRIJAX-DEOSSOPVSA-N 1-[[4-(2-cyanophenyl)phenyl]methyl]-n-[(1s)-1-(4-ethylphenyl)ethyl]-2,3-dimethylindole-5-carboxamide Chemical compound C1=CC(CC)=CC=C1[C@H](C)NC(=O)C1=CC=C(N(CC=2C=CC(=CC=2)C=2C(=CC=CC=2)C#N)C(C)=C2C)C2=C1 VIMRSIDGYRIJAX-DEOSSOPVSA-N 0.000 description 1
- UPQOQJIOZREBQR-QHCPKHFHSA-N 1-[[4-(2-cyanophenyl)phenyl]methyl]-n-[(1s)-1-(4-methoxyphenyl)ethyl]-2,3-dimethylindole-5-carboxamide Chemical compound C1=CC(OC)=CC=C1[C@H](C)NC(=O)C1=CC=C(N(CC=2C=CC(=CC=2)C=2C(=CC=CC=2)C#N)C(C)=C2C)C2=C1 UPQOQJIOZREBQR-QHCPKHFHSA-N 0.000 description 1
- WTBLWBYNCLCFQH-FQEVSTJZSA-N 1-[[4-(2-hydroxyphenyl)phenyl]methyl]-n-[(1s)-1-(4-nitrophenyl)ethyl]indole-5-carboxamide Chemical compound N([C@@H](C)C=1C=CC(=CC=1)[N+]([O-])=O)C(=O)C(C=C1C=C2)=CC=C1N2CC(C=C1)=CC=C1C1=CC=CC=C1O WTBLWBYNCLCFQH-FQEVSTJZSA-N 0.000 description 1
- RTTCBFRNCSBWJV-NRFANRHFSA-N 1-[[4-(2-methoxyphenyl)phenyl]methyl]-n-[(1s)-1-(4-nitrophenyl)ethyl]indole-5-carboxamide Chemical compound COC1=CC=CC=C1C(C=C1)=CC=C1CN1C2=CC=C(C(=O)N[C@@H](C)C=3C=CC(=CC=3)[N+]([O-])=O)C=C2C=C1 RTTCBFRNCSBWJV-NRFANRHFSA-N 0.000 description 1
- NGGVPSBLHDGFEO-QFIPXVFZSA-N 1-[[4-(2-methylphenyl)phenyl]methyl]-n-[(1s)-1-(4-nitrophenyl)ethyl]indole-5-carboxamide Chemical compound N([C@@H](C)C=1C=CC(=CC=1)[N+]([O-])=O)C(=O)C(C=C1C=C2)=CC=C1N2CC(C=C1)=CC=C1C1=CC=CC=C1C NGGVPSBLHDGFEO-QFIPXVFZSA-N 0.000 description 1
- QAAMJPOAEXTPEE-NRFANRHFSA-N 1-[[4-(2-methylsulfonylphenyl)phenyl]methyl]-n-[(1s)-1-(4-nitrophenyl)ethyl]indole-5-carboxamide Chemical compound N([C@@H](C)C=1C=CC(=CC=1)[N+]([O-])=O)C(=O)C(C=C1C=C2)=CC=C1N2CC(C=C1)=CC=C1C1=CC=CC=C1S(C)(=O)=O QAAMJPOAEXTPEE-NRFANRHFSA-N 0.000 description 1
- MKBLPQIHZUTRKR-FQEVSTJZSA-N 1-[[4-(3-aminophenyl)phenyl]methyl]-n-[(1s)-1-(4-nitrophenyl)ethyl]indole-5-carboxamide Chemical compound N([C@@H](C)C=1C=CC(=CC=1)[N+]([O-])=O)C(=O)C(C=C1C=C2)=CC=C1N2CC(C=C1)=CC=C1C1=CC=CC(N)=C1 MKBLPQIHZUTRKR-FQEVSTJZSA-N 0.000 description 1
- WLXDPQQQWKHQJP-FQEVSTJZSA-N 1-[[4-(3-chlorophenyl)phenyl]methyl]-n-[(1s)-1-(4-nitrophenyl)ethyl]indole-5-carboxamide Chemical compound N([C@@H](C)C=1C=CC(=CC=1)[N+]([O-])=O)C(=O)C(C=C1C=C2)=CC=C1N2CC(C=C1)=CC=C1C1=CC=CC(Cl)=C1 WLXDPQQQWKHQJP-FQEVSTJZSA-N 0.000 description 1
- QJUOMKYQJQHEAC-NRFANRHFSA-N 1-[[4-(3-methoxyphenyl)phenyl]methyl]-n-[(1s)-1-(4-nitrophenyl)ethyl]indole-5-carboxamide Chemical compound COC1=CC=CC(C=2C=CC(CN3C4=CC=C(C=C4C=C3)C(=O)N[C@@H](C)C=3C=CC(=CC=3)[N+]([O-])=O)=CC=2)=C1 QJUOMKYQJQHEAC-NRFANRHFSA-N 0.000 description 1
- IEGQCTISDDMZOL-QFIPXVFZSA-N 1-[[4-(3-methylphenyl)phenyl]methyl]-n-[(1s)-1-(4-nitrophenyl)ethyl]indole-5-carboxamide Chemical compound N([C@@H](C)C=1C=CC(=CC=1)[N+]([O-])=O)C(=O)C(C=C1C=C2)=CC=C1N2CC(C=C1)=CC=C1C1=CC=CC(C)=C1 IEGQCTISDDMZOL-QFIPXVFZSA-N 0.000 description 1
- QSBZBYIANJUKRV-NRFANRHFSA-N 1-[[4-(3-methylsulfonylphenyl)phenyl]methyl]-n-[(1s)-1-(4-nitrophenyl)ethyl]indole-5-carboxamide Chemical compound N([C@@H](C)C=1C=CC(=CC=1)[N+]([O-])=O)C(=O)C(C=C1C=C2)=CC=C1N2CC(C=C1)=CC=C1C1=CC=CC(S(C)(=O)=O)=C1 QSBZBYIANJUKRV-NRFANRHFSA-N 0.000 description 1
- QOCFROGHOHMLDW-FQEVSTJZSA-N 1-[[4-(4-hydroxyphenyl)phenyl]methyl]-n-[(1s)-1-(4-nitrophenyl)ethyl]indole-5-carboxamide Chemical compound N([C@@H](C)C=1C=CC(=CC=1)[N+]([O-])=O)C(=O)C(C=C1C=C2)=CC=C1N2CC(C=C1)=CC=C1C1=CC=C(O)C=C1 QOCFROGHOHMLDW-FQEVSTJZSA-N 0.000 description 1
- UEVUIANBUFWJBQ-QFIPXVFZSA-N 1-[[4-(4-methylphenyl)phenyl]methyl]-n-[(1s)-1-(4-nitrophenyl)ethyl]indole-5-carboxamide Chemical compound N([C@@H](C)C=1C=CC(=CC=1)[N+]([O-])=O)C(=O)C(C=C1C=C2)=CC=C1N2CC(C=C1)=CC=C1C1=CC=C(C)C=C1 UEVUIANBUFWJBQ-QFIPXVFZSA-N 0.000 description 1
- CITMAWXHLGVRLL-NRFANRHFSA-N 1-[[4-(4-methylsulfanylphenyl)phenyl]methyl]-n-[(1s)-1-(4-nitrophenyl)ethyl]indole-5-carboxamide Chemical compound C1=CC(SC)=CC=C1C(C=C1)=CC=C1CN1C2=CC=C(C(=O)N[C@@H](C)C=3C=CC(=CC=3)[N+]([O-])=O)C=C2C=C1 CITMAWXHLGVRLL-NRFANRHFSA-N 0.000 description 1
- LJCFZGSEPCINDX-NRFANRHFSA-N 1-[[4-(4-methylsulfonylphenyl)phenyl]methyl]-n-[(1s)-1-(4-nitrophenyl)ethyl]indole-5-carboxamide Chemical compound N([C@@H](C)C=1C=CC(=CC=1)[N+]([O-])=O)C(=O)C(C=C1C=C2)=CC=C1N2CC(C=C1)=CC=C1C1=CC=C(S(C)(=O)=O)C=C1 LJCFZGSEPCINDX-NRFANRHFSA-N 0.000 description 1
- GVFZTMVQEABQLW-SANMLTNESA-N 1-[[4-[2-(2-hydroxyethylcarbamoyl)phenyl]phenyl]methyl]-2,3-dimethyl-n-[(1s)-1-(3-propan-2-ylphenyl)ethyl]indole-5-carboxamide Chemical compound CC(C)C1=CC=CC([C@H](C)NC(=O)C=2C=C3C(C)=C(C)N(CC=4C=CC(=CC=4)C=4C(=CC=CC=4)C(=O)NCCO)C3=CC=2)=C1 GVFZTMVQEABQLW-SANMLTNESA-N 0.000 description 1
- PFLGTTTYOBZDCE-VWLOTQADSA-N 1-[[4-[2-(acetylsulfamoyl)phenyl]phenyl]methyl]-2,3-dimethyl-n-[(1s)-1-(3-propan-2-ylphenyl)ethyl]indole-5-carboxamide Chemical compound CC(C)C1=CC=CC([C@H](C)NC(=O)C=2C=C3C(C)=C(C)N(CC=4C=CC(=CC=4)C=4C(=CC=CC=4)S(=O)(=O)NC(C)=O)C3=CC=2)=C1 PFLGTTTYOBZDCE-VWLOTQADSA-N 0.000 description 1
- RPSXTZBXWIBCKN-LJAQVGFWSA-N 1-[[4-[2-(cyclohexylcarbamoyl)phenyl]phenyl]methyl]-2,3-dimethyl-n-[(1s)-1-(3-propan-2-ylphenyl)ethyl]indole-5-carboxamide Chemical compound CC(C)C1=CC=CC([C@H](C)NC(=O)C=2C=C3C(C)=C(C)N(CC=4C=CC(=CC=4)C=4C(=CC=CC=4)C(=O)NC4CCCCC4)C3=CC=2)=C1 RPSXTZBXWIBCKN-LJAQVGFWSA-N 0.000 description 1
- POEQHTDGWYUADQ-SANMLTNESA-N 1-[[4-[2-(cyclopropylcarbamoyl)phenyl]phenyl]methyl]-2,3-dimethyl-n-[(1s)-1-(3-propan-2-ylphenyl)ethyl]indole-5-carboxamide Chemical compound CC(C)C1=CC=CC([C@H](C)NC(=O)C=2C=C3C(C)=C(C)N(CC=4C=CC(=CC=4)C=4C(=CC=CC=4)C(=O)NC4CC4)C3=CC=2)=C1 POEQHTDGWYUADQ-SANMLTNESA-N 0.000 description 1
- KUHLANITMBTBHT-SANMLTNESA-N 1-[[4-[2-(dimethylcarbamoyl)phenyl]phenyl]methyl]-2,3-dimethyl-n-[(1s)-1-(3-propan-2-ylphenyl)ethyl]indole-5-carboxamide Chemical compound CC(C)C1=CC=CC([C@H](C)NC(=O)C=2C=C3C(C)=C(C)N(CC=4C=CC(=CC=4)C=4C(=CC=CC=4)C(=O)N(C)C)C3=CC=2)=C1 KUHLANITMBTBHT-SANMLTNESA-N 0.000 description 1
- OQIYXXCSUQXQKX-NRFANRHFSA-N 1-[[4-[2-(hydroxymethyl)phenyl]phenyl]methyl]-n-[(1s)-1-(4-nitrophenyl)ethyl]indole-5-carboxamide Chemical compound N([C@@H](C)C=1C=CC(=CC=1)[N+]([O-])=O)C(=O)C(C=C1C=C2)=CC=C1N2CC(C=C1)=CC=C1C1=CC=CC=C1CO OQIYXXCSUQXQKX-NRFANRHFSA-N 0.000 description 1
- MDDWRIHIIAFAGR-NDEPHWFRSA-N 1-[[4-[2-[2-(dimethylamino)ethylcarbamoyl]phenyl]phenyl]methyl]-2,3-dimethyl-n-[(1s)-1-(3-propan-2-ylphenyl)ethyl]indole-5-carboxamide Chemical compound CC(C)C1=CC=CC([C@H](C)NC(=O)C=2C=C3C(C)=C(C)N(CC=4C=CC(=CC=4)C=4C(=CC=CC=4)C(=O)NCCN(C)C)C3=CC=2)=C1 MDDWRIHIIAFAGR-NDEPHWFRSA-N 0.000 description 1
- MGYJOCPLMCIQNO-MAGLAKDHSA-N 1-[[4-[2-[[(2r)-3-(dimethylamino)-2-hydroxy-3-oxopropyl]carbamoyl]phenyl]phenyl]methyl]-2,3-dimethyl-n-[(1s)-1-(3-propan-2-ylphenyl)ethyl]indole-5-carboxamide Chemical compound CC(C)C1=CC=CC([C@H](C)NC(=O)C=2C=C3C(C)=C(C)N(CC=4C=CC(=CC=4)C=4C(=CC=CC=4)C(=O)NC[C@@H](O)C(=O)N(C)C)C3=CC=2)=C1 MGYJOCPLMCIQNO-MAGLAKDHSA-N 0.000 description 1
- IWGHRXMLEVPTIX-NRFANRHFSA-N 1-[[4-[3-(aminomethyl)phenyl]phenyl]methyl]-n-[(1s)-1-(4-nitrophenyl)ethyl]indole-5-carboxamide Chemical compound N([C@@H](C)C=1C=CC(=CC=1)[N+]([O-])=O)C(=O)C(C=C1C=C2)=CC=C1N2CC(C=C1)=CC=C1C1=CC=CC(CN)=C1 IWGHRXMLEVPTIX-NRFANRHFSA-N 0.000 description 1
- SHHWPEDWJFQMAW-QFIPXVFZSA-N 1-[[4-chloro-3-[(2s)-1-methoxy-3-methyl-1-oxobutan-2-yl]oxyphenyl]methyl]-2,3-dimethylindole-5-carboxylic acid Chemical compound C1=C(Cl)C(O[C@H](C(=O)OC)C(C)C)=CC(CN2C3=CC=C(C=C3C(C)=C2C)C(O)=O)=C1 SHHWPEDWJFQMAW-QFIPXVFZSA-N 0.000 description 1
- SRIQIBVPBDSUNG-AWEZNQCLSA-N 1-[[4-fluoro-3-[(2s)-1-methoxy-1-oxopropan-2-yl]oxyphenyl]methyl]-2,3-dimethylindole-5-carboxylic acid Chemical compound C1=C(F)C(O[C@@H](C)C(=O)OC)=CC(CN2C3=CC=C(C=C3C(C)=C2C)C(O)=O)=C1 SRIQIBVPBDSUNG-AWEZNQCLSA-N 0.000 description 1
- WPPNCWOPKLJMJD-UNMCSNQZSA-N 1-[[5-[(2s)-1-amino-1-oxopropan-2-yl]oxy-2-chlorophenyl]methyl]-n-[(1s)-1-(4-tert-butylphenyl)ethyl]-2,3-dimethylindole-5-carboxamide Chemical compound N([C@@H](C)C=1C=CC(=CC=1)C(C)(C)C)C(=O)C(C=C1C(C)=C2C)=CC=C1N2CC1=CC(O[C@@H](C)C(N)=O)=CC=C1Cl WPPNCWOPKLJMJD-UNMCSNQZSA-N 0.000 description 1
- 125000004173 1-benzimidazolyl group Chemical group [H]C1=NC2=C([H])C([H])=C([H])C([H])=C2N1* 0.000 description 1
- SRLOYBALHLGPTD-UHFFFAOYSA-N 1-benzoyl-n-(1-phenylpropyl)indole-5-carboxamide Chemical compound C=1C=CC=CC=1C(CC)NC(=O)C(C=C1C=C2)=CC=C1N2C(=O)C1=CC=CC=C1 SRLOYBALHLGPTD-UHFFFAOYSA-N 0.000 description 1
- XWJHQOWAYSWCRY-UHFFFAOYSA-N 1-benzylindazole Chemical compound N1=CC2=CC=CC=C2N1CC1=CC=CC=C1 XWJHQOWAYSWCRY-UHFFFAOYSA-N 0.000 description 1
- NJZQOCCEDXRQJM-UHFFFAOYSA-N 1-benzylindole Chemical compound C1=CC2=CC=CC=C2N1CC1=CC=CC=C1 NJZQOCCEDXRQJM-UHFFFAOYSA-N 0.000 description 1
- ZPCJPJQUVRIILS-UHFFFAOYSA-N 1-bromo-3-(bromomethyl)benzene Chemical compound BrCC1=CC=CC(Br)=C1 ZPCJPJQUVRIILS-UHFFFAOYSA-N 0.000 description 1
- UFXJPOIJORJPLO-UHFFFAOYSA-N 1-chloro-3-(2-chloroethyl)benzene Chemical compound ClCCC1=CC=CC(Cl)=C1 UFXJPOIJORJPLO-UHFFFAOYSA-N 0.000 description 1
- JQZAEUFPPSRDOP-UHFFFAOYSA-N 1-chloro-4-(chloromethyl)benzene Chemical compound ClCC1=CC=C(Cl)C=C1 JQZAEUFPPSRDOP-UHFFFAOYSA-N 0.000 description 1
- QXQAPNSHUJORMC-UHFFFAOYSA-N 1-chloro-4-propylbenzene Chemical compound CCCC1=CC=C(Cl)C=C1 QXQAPNSHUJORMC-UHFFFAOYSA-N 0.000 description 1
- VZAWCLCJGSBATP-UHFFFAOYSA-N 1-cycloundecyl-1,2-diazacycloundecane Chemical compound C1CCCCCCCCCC1N1NCCCCCCCCC1 VZAWCLCJGSBATP-UHFFFAOYSA-N 0.000 description 1
- FPIRBHDGWMWJEP-UHFFFAOYSA-N 1-hydroxy-7-azabenzotriazole Chemical compound C1=CN=C2N(O)N=NC2=C1 FPIRBHDGWMWJEP-UHFFFAOYSA-N 0.000 description 1
- SQAINHDHICKHLX-UHFFFAOYSA-N 1-naphthaldehyde Chemical compound C1=CC=C2C(C=O)=CC=CC2=C1 SQAINHDHICKHLX-UHFFFAOYSA-N 0.000 description 1
- SEVOIRSEDVSYGP-UHFFFAOYSA-N 1-naphthalen-1-ylsulfonyl-n-(1-phenylpropyl)indole-5-carboxamide Chemical compound C=1C=C2N(S(=O)(=O)C=3C4=CC=CC=C4C=CC=3)C=CC2=CC=1C(=O)NC(CC)C1=CC=CC=C1 SEVOIRSEDVSYGP-UHFFFAOYSA-N 0.000 description 1
- 125000001637 1-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C(*)=C([H])C([H])=C([H])C2=C1[H] 0.000 description 1
- BAXOFTOLAUCFNW-UHFFFAOYSA-N 1H-indazole Chemical compound C1=CC=C2C=NNC2=C1 BAXOFTOLAUCFNW-UHFFFAOYSA-N 0.000 description 1
- YBYIRNPNPLQARY-UHFFFAOYSA-N 1H-indene Natural products C1=CC=C2CC=CC2=C1 YBYIRNPNPLQARY-UHFFFAOYSA-N 0.000 description 1
- LLMLNAVBOAMOEE-UHFFFAOYSA-N 2,3-dichlorobenzaldehyde Chemical compound ClC1=CC=CC(C=O)=C1Cl LLMLNAVBOAMOEE-UHFFFAOYSA-N 0.000 description 1
- CDCFERWURRNLLA-UHFFFAOYSA-N 2,3-difluorobenzoyl chloride Chemical compound FC1=CC=CC(C(Cl)=O)=C1F CDCFERWURRNLLA-UHFFFAOYSA-N 0.000 description 1
- WEBVDBDZSOJGPB-UHFFFAOYSA-N 2,3-dihydro-1-benzofuran-5-carbaldehyde Chemical compound O=CC1=CC=C2OCCC2=C1 WEBVDBDZSOJGPB-UHFFFAOYSA-N 0.000 description 1
- FITNPEDFWSPOMU-UHFFFAOYSA-N 2,3-dihydrotriazolo[4,5-b]pyridin-5-one Chemical compound OC1=CC=C2NN=NC2=N1 FITNPEDFWSPOMU-UHFFFAOYSA-N 0.000 description 1
- RLURNYDKCPCKIH-DEOSSOPVSA-N 2,3-dimethyl-1-[[4-[2-(5-oxo-2h-1,2,4-oxadiazol-3-yl)phenyl]phenyl]methyl]-n-[(1s)-1-(3-propan-2-ylphenyl)ethyl]indole-5-carboxamide Chemical compound CC(C)C1=CC=CC([C@H](C)NC(=O)C=2C=C3C(C)=C(C)N(CC=4C=CC(=CC=4)C=4C(=CC=CC=4)C=4NC(=O)ON=4)C3=CC=2)=C1 RLURNYDKCPCKIH-DEOSSOPVSA-N 0.000 description 1
- PAGXYYLAMNCOQL-VWLOTQADSA-N 2,3-dimethyl-1-[[4-[2-(methylcarbamoyl)phenyl]phenyl]methyl]-n-[(1s)-1-(3-propan-2-ylphenyl)ethyl]indole-5-carboxamide Chemical compound CNC(=O)C1=CC=CC=C1C(C=C1)=CC=C1CN1C2=CC=C(C(=O)N[C@@H](C)C=3C=C(C=CC=3)C(C)C)C=C2C(C)=C1C PAGXYYLAMNCOQL-VWLOTQADSA-N 0.000 description 1
- ZSVUSKZAVSZXCS-VWLOTQADSA-N 2,3-dimethyl-1-[[4-[2-(methylsulfonylcarbamoyl)phenyl]phenyl]methyl]-n-[(1s)-1-(3-propan-2-ylphenyl)ethyl]indole-5-carboxamide Chemical compound CC(C)C1=CC=CC([C@H](C)NC(=O)C=2C=C3C(C)=C(C)N(CC=4C=CC(=CC=4)C=4C(=CC=CC=4)C(=O)NS(C)(=O)=O)C3=CC=2)=C1 ZSVUSKZAVSZXCS-VWLOTQADSA-N 0.000 description 1
- RZANCXHTRXQJKG-UHFFFAOYSA-N 2,3-dimethyl-n-(1-phenylpropyl)-1-[[4-[2-(2h-tetrazol-5-yl)phenyl]phenyl]methyl]indole-5-carboxamide Chemical compound C=1C=CC=CC=1C(CC)NC(=O)C(C=C1C(C)=C2C)=CC=C1N2CC(C=C1)=CC=C1C1=CC=CC=C1C1=NN=NN1 RZANCXHTRXQJKG-UHFFFAOYSA-N 0.000 description 1
- PDYBKPLDGSBFND-DEOSSOPVSA-N 2,3-dimethyl-n-[(1s)-1-(3-propan-2-ylphenyl)ethyl]-1-[[4-[2-(2h-tetrazol-5-yl)phenyl]phenyl]methyl]indole-5-carboxamide Chemical compound CC(C)C1=CC=CC([C@H](C)NC(=O)C=2C=C3C(C)=C(C)N(CC=4C=CC(=CC=4)C=4C(=CC=CC=4)C4=NNN=N4)C3=CC=2)=C1 PDYBKPLDGSBFND-DEOSSOPVSA-N 0.000 description 1
- ZZFIUCQCSYPPPO-NRFANRHFSA-N 2,3-dimethyl-n-[(1s)-1-(4-nitrophenyl)ethyl]-1-[(4-pyridin-2-ylphenyl)methyl]indole-5-carboxamide Chemical compound N([C@@H](C)C=1C=CC(=CC=1)[N+]([O-])=O)C(=O)C(C=C1C(C)=C2C)=CC=C1N2CC(C=C1)=CC=C1C1=CC=CC=N1 ZZFIUCQCSYPPPO-NRFANRHFSA-N 0.000 description 1
- YMBADRJWNJYVIJ-NRFANRHFSA-N 2,3-dimethyl-n-[(1s)-1-(4-nitrophenyl)ethyl]-1-[(4-pyridin-3-ylphenyl)methyl]indole-5-carboxamide Chemical compound N([C@@H](C)C=1C=CC(=CC=1)[N+]([O-])=O)C(=O)C(C=C1C(C)=C2C)=CC=C1N2CC(C=C1)=CC=C1C1=CC=CN=C1 YMBADRJWNJYVIJ-NRFANRHFSA-N 0.000 description 1
- LVCZYZMWUMBONF-NRFANRHFSA-N 2,3-dimethyl-n-[(1s)-1-(4-nitrophenyl)ethyl]-1-[(4-pyridin-4-ylphenyl)methyl]indole-5-carboxamide Chemical compound N([C@@H](C)C=1C=CC(=CC=1)[N+]([O-])=O)C(=O)C(C=C1C(C)=C2C)=CC=C1N2CC(C=C1)=CC=C1C1=CC=NC=C1 LVCZYZMWUMBONF-NRFANRHFSA-N 0.000 description 1
- GBBSAMQTQCPOBF-UHFFFAOYSA-N 2,4,6-trimethyl-1,3,5,2,4,6-trioxatriborinane Chemical compound CB1OB(C)OB(C)O1 GBBSAMQTQCPOBF-UHFFFAOYSA-N 0.000 description 1
- YSFBEAASFUWWHU-UHFFFAOYSA-N 2,4-dichlorobenzaldehyde Chemical compound ClC1=CC=C(C=O)C(Cl)=C1 YSFBEAASFUWWHU-UHFFFAOYSA-N 0.000 description 1
- WCGPCBACLBHDCI-UHFFFAOYSA-N 2,4-difluorobenzaldehyde Chemical compound FC1=CC=C(C=O)C(F)=C1 WCGPCBACLBHDCI-UHFFFAOYSA-N 0.000 description 1
- IQKKTIWXHJDLFL-UHFFFAOYSA-N 2-(4-bromophenyl)propan-2-amine Chemical compound CC(C)(N)C1=CC=C(Br)C=C1 IQKKTIWXHJDLFL-UHFFFAOYSA-N 0.000 description 1
- GVOYKJPMUUJXBS-UHFFFAOYSA-N 2-(aminomethyl)aniline Chemical compound NCC1=CC=CC=C1N GVOYKJPMUUJXBS-UHFFFAOYSA-N 0.000 description 1
- QUFNKFOFBHFZQH-UHFFFAOYSA-N 2-[4-(bromomethyl)phenyl]-n-tert-butylbenzenesulfonamide Chemical compound CC(C)(C)NS(=O)(=O)C1=CC=CC=C1C1=CC=C(CBr)C=C1 QUFNKFOFBHFZQH-UHFFFAOYSA-N 0.000 description 1
- KSKLBIYBQQLBTF-UHFFFAOYSA-N 2-[4-[[2,3-dimethyl-5-(1-naphthalen-1-ylethylcarbamoyl)indol-1-yl]methyl]phenyl]benzoic acid Chemical compound C=1C=CC2=CC=CC=C2C=1C(C)NC(=O)C(C=C1C(C)=C2C)=CC=C1N2CC(C=C1)=CC=C1C1=CC=CC=C1C(O)=O KSKLBIYBQQLBTF-UHFFFAOYSA-N 0.000 description 1
- QJVWQMAWIIEPHE-UHFFFAOYSA-N 2-[4-[[2,3-dimethyl-5-(2-morpholin-4-ylethylcarbamoyl)indol-1-yl]methyl]phenyl]benzoic acid Chemical compound CC1=C(C)C2=CC(C(=O)NCCN3CCOCC3)=CC=C2N1CC(C=C1)=CC=C1C1=CC=CC=C1C(O)=O QJVWQMAWIIEPHE-UHFFFAOYSA-N 0.000 description 1
- STHCMQVWLCELIQ-UHFFFAOYSA-N 2-[4-[[2,3-dimethyl-5-(4-phenylbutan-2-ylcarbamoyl)indol-1-yl]methyl]phenyl]benzoic acid Chemical compound C=1C=C2N(CC=3C=CC(=CC=3)C=3C(=CC=CC=3)C(O)=O)C(C)=C(C)C2=CC=1C(=O)NC(C)CCC1=CC=CC=C1 STHCMQVWLCELIQ-UHFFFAOYSA-N 0.000 description 1
- BLSMCSSZWCLBLB-UHFFFAOYSA-N 2-[4-[[2,3-dimethyl-5-(naphthalen-1-ylmethylcarbamoyl)indol-1-yl]methyl]phenyl]benzoic acid Chemical compound CC1=C(C)C2=CC(C(=O)NCC=3C4=CC=CC=C4C=CC=3)=CC=C2N1CC(C=C1)=CC=C1C1=CC=CC=C1C(O)=O BLSMCSSZWCLBLB-UHFFFAOYSA-N 0.000 description 1
- IHHFNXUOISFOGV-UHFFFAOYSA-N 2-[4-[[2,3-dimethyl-5-(thiophen-2-ylmethylcarbamoyl)indol-1-yl]methyl]phenyl]benzoic acid Chemical compound CC1=C(C)C2=CC(C(=O)NCC=3SC=CC=3)=CC=C2N1CC(C=C1)=CC=C1C1=CC=CC=C1C(O)=O IHHFNXUOISFOGV-UHFFFAOYSA-N 0.000 description 1
- AZYMZXRTCQCPCR-UHFFFAOYSA-N 2-[4-[[2,3-dimethyl-5-[(2-methylphenyl)methylcarbamoyl]indol-1-yl]methyl]phenyl]benzoic acid Chemical compound CC1=C(C)C2=CC(C(=O)NCC=3C(=CC=CC=3)C)=CC=C2N1CC(C=C1)=CC=C1C1=CC=CC=C1C(O)=O AZYMZXRTCQCPCR-UHFFFAOYSA-N 0.000 description 1
- BCZRVDSWUCBXQS-UHFFFAOYSA-N 2-[4-[[2,3-dimethyl-5-[(2-nitrophenyl)methylcarbamoyl]indol-1-yl]methyl]phenyl]benzoic acid Chemical compound CC1=C(C)C2=CC(C(=O)NCC=3C(=CC=CC=3)[N+]([O-])=O)=CC=C2N1CC(C=C1)=CC=C1C1=CC=CC=C1C(O)=O BCZRVDSWUCBXQS-UHFFFAOYSA-N 0.000 description 1
- ADYIASWOTCCBEE-UHFFFAOYSA-N 2-[4-[[2,3-dimethyl-5-[(3-methylphenyl)methylcarbamoyl]indol-1-yl]methyl]phenyl]benzoic acid Chemical compound CC1=C(C)C2=CC(C(=O)NCC=3C=C(C)C=CC=3)=CC=C2N1CC(C=C1)=CC=C1C1=CC=CC=C1C(O)=O ADYIASWOTCCBEE-UHFFFAOYSA-N 0.000 description 1
- LLKNYGBLYXCNAE-UHFFFAOYSA-N 2-[4-[[2,3-dimethyl-5-[(3-nitrophenyl)methylcarbamoyl]indol-1-yl]methyl]phenyl]benzoic acid Chemical compound CC1=C(C)C2=CC(C(=O)NCC=3C=C(C=CC=3)[N+]([O-])=O)=CC=C2N1CC(C=C1)=CC=C1C1=CC=CC=C1C(O)=O LLKNYGBLYXCNAE-UHFFFAOYSA-N 0.000 description 1
- LQAUHHSQKCNYRO-UHFFFAOYSA-N 2-[4-[[2,3-dimethyl-5-[(3-propan-2-ylphenyl)methylcarbamoyl]indol-1-yl]methyl]phenyl]benzoic acid Chemical compound CC(C)C1=CC=CC(CNC(=O)C=2C=C3C(C)=C(C)N(CC=4C=CC(=CC=4)C=4C(=CC=CC=4)C(O)=O)C3=CC=2)=C1 LQAUHHSQKCNYRO-UHFFFAOYSA-N 0.000 description 1
- RTUKAUUBNBEYRL-UHFFFAOYSA-N 2-[4-[[2,3-dimethyl-5-[(4-methylphenyl)methylcarbamoyl]indol-1-yl]methyl]phenyl]benzoic acid Chemical compound CC1=C(C)C2=CC(C(=O)NCC=3C=CC(C)=CC=3)=CC=C2N1CC(C=C1)=CC=C1C1=CC=CC=C1C(O)=O RTUKAUUBNBEYRL-UHFFFAOYSA-N 0.000 description 1
- FVESTMXTJMNDAU-UHFFFAOYSA-N 2-[4-[[2,3-dimethyl-5-[(4-nitrophenyl)methylcarbamoyl]indol-1-yl]methyl]phenyl]benzoic acid Chemical compound CC1=C(C)C2=CC(C(=O)NCC=3C=CC(=CC=3)[N+]([O-])=O)=CC=C2N1CC(C=C1)=CC=C1C1=CC=CC=C1C(O)=O FVESTMXTJMNDAU-UHFFFAOYSA-N 0.000 description 1
- XKNOKZFJZXAJGT-UHFFFAOYSA-N 2-[4-[[2,3-dimethyl-5-[(4-phenylphenyl)methylcarbamoyl]indol-1-yl]methyl]phenyl]benzoic acid Chemical compound CC1=C(C)C2=CC(C(=O)NCC=3C=CC(=CC=3)C=3C=CC=CC=3)=CC=C2N1CC(C=C1)=CC=C1C1=CC=CC=C1C(O)=O XKNOKZFJZXAJGT-UHFFFAOYSA-N 0.000 description 1
- BHADWFBBXWPZST-UHFFFAOYSA-N 2-[4-[[2,3-dimethyl-5-[(5-methylfuran-2-yl)methylcarbamoyl]indol-1-yl]methyl]phenyl]benzoic acid Chemical compound O1C(C)=CC=C1CNC(=O)C1=CC=C(N(CC=2C=CC(=CC=2)C=2C(=CC=CC=2)C(O)=O)C(C)=C2C)C2=C1 BHADWFBBXWPZST-UHFFFAOYSA-N 0.000 description 1
- YEOUESUHUVOFIU-LJQANCHMSA-N 2-[4-[[2,3-dimethyl-5-[[(1r)-1-(2,3,6-trifluorophenyl)ethyl]carbamoyl]indol-1-yl]methyl]phenyl]benzoic acid Chemical compound N([C@H](C)C=1C(=C(F)C=CC=1F)F)C(=O)C(C=C1C(C)=C2C)=CC=C1N2CC(C=C1)=CC=C1C1=CC=CC=C1C(O)=O YEOUESUHUVOFIU-LJQANCHMSA-N 0.000 description 1
- LETNSIWDILDIKU-XMMPIXPASA-N 2-[4-[[2,3-dimethyl-5-[[(1r)-1-(3-propan-2-ylphenyl)ethyl]carbamoyl]indol-1-yl]methyl]phenyl]benzoic acid Chemical compound CC(C)C1=CC=CC([C@@H](C)NC(=O)C=2C=C3C(C)=C(C)N(CC=4C=CC(=CC=4)C=4C(=CC=CC=4)C(O)=O)C3=CC=2)=C1 LETNSIWDILDIKU-XMMPIXPASA-N 0.000 description 1
- IIJDFXNUWZTHIM-OAQYLSRUSA-N 2-[4-[[2,3-dimethyl-5-[[(1r)-1-(4-nitrophenyl)ethyl]carbamoyl]indol-1-yl]methyl]phenyl]benzoic acid Chemical compound N([C@H](C)C=1C=CC(=CC=1)[N+]([O-])=O)C(=O)C(C=C1C(C)=C2C)=CC=C1N2CC(C=C1)=CC=C1C1=CC=CC=C1C(O)=O IIJDFXNUWZTHIM-OAQYLSRUSA-N 0.000 description 1
- FJOURLWFDVUCAQ-OAQYLSRUSA-N 2-[4-[[2,3-dimethyl-5-[[(1r)-1-[2-(trifluoromethyl)phenyl]ethyl]carbamoyl]indol-1-yl]methyl]phenyl]benzoic acid Chemical compound N([C@H](C)C=1C(=CC=CC=1)C(F)(F)F)C(=O)C(C=C1C(C)=C2C)=CC=C1N2CC(C=C1)=CC=C1C1=CC=CC=C1C(O)=O FJOURLWFDVUCAQ-OAQYLSRUSA-N 0.000 description 1
- GAGNYMUXGIUCTR-WJOKGBTCSA-N 2-[4-[[2,3-dimethyl-5-[[(1r)-1-phenylpropyl]carbamoyl]indol-1-yl]methyl]phenyl]benzoic acid Chemical compound N([C@H](CC)C=1C=CC=CC=1)C(=O)C(C=C1C(C)=C2C)=CC=C1N2CC(C=C1)=CC=C1C1=CC=CC=C1C(O)=O GAGNYMUXGIUCTR-WJOKGBTCSA-N 0.000 description 1
- HUWYEWSRWXKTAX-MGBGTMOVSA-N 2-[4-[[2,3-dimethyl-5-[[(1r)-2,2,2-trifluoro-1-(3-propan-2-ylphenyl)ethyl]carbamoyl]indol-1-yl]methyl]phenyl]benzoic acid Chemical compound CC(C)C1=CC=CC([C@@H](NC(=O)C=2C=C3C(C)=C(C)N(CC=4C=CC(=CC=4)C=4C(=CC=CC=4)C(O)=O)C3=CC=2)C(F)(F)F)=C1 HUWYEWSRWXKTAX-MGBGTMOVSA-N 0.000 description 1
- OKBNYHONEPYWKI-IOWSJCHKSA-N 2-[4-[[2,3-dimethyl-5-[[(1r,2s)-2-phenylcyclopropyl]carbamoyl]indol-1-yl]methyl]phenyl]benzoic acid Chemical compound CC1=C(C)C2=CC(C(=O)N[C@H]3[C@@H](C3)C=3C=CC=CC=3)=CC=C2N1CC(C=C1)=CC=C1C1=CC=CC=C1C(O)=O OKBNYHONEPYWKI-IOWSJCHKSA-N 0.000 description 1
- YEOUESUHUVOFIU-IBGZPJMESA-N 2-[4-[[2,3-dimethyl-5-[[(1s)-1-(2,3,6-trifluorophenyl)ethyl]carbamoyl]indol-1-yl]methyl]phenyl]benzoic acid Chemical compound N([C@@H](C)C=1C(=C(F)C=CC=1F)F)C(=O)C(C=C1C(C)=C2C)=CC=C1N2CC(C=C1)=CC=C1C1=CC=CC=C1C(O)=O YEOUESUHUVOFIU-IBGZPJMESA-N 0.000 description 1
- HIZJHEWINJXBHY-QHCPKHFHSA-N 2-[4-[[2,3-dimethyl-5-[[(1s)-1-(2-methylphenyl)ethyl]carbamoyl]indol-1-yl]methyl]phenyl]benzoic acid Chemical compound N([C@@H](C)C=1C(=CC=CC=1)C)C(=O)C(C=C1C(C)=C2C)=CC=C1N2CC(C=C1)=CC=C1C1=CC=CC=C1C(O)=O HIZJHEWINJXBHY-QHCPKHFHSA-N 0.000 description 1
- GUONGSVVVOLRQE-DEOSSOPVSA-N 2-[4-[[2,3-dimethyl-5-[[(1s)-1-(2-propan-2-yloxyphenyl)ethyl]carbamoyl]indol-1-yl]methyl]phenyl]benzoic acid Chemical compound CC(C)OC1=CC=CC=C1[C@H](C)NC(=O)C1=CC=C(N(CC=2C=CC(=CC=2)C=2C(=CC=CC=2)C(O)=O)C(C)=C2C)C2=C1 GUONGSVVVOLRQE-DEOSSOPVSA-N 0.000 description 1
- YQABQIQJIOZHPN-QFIPXVFZSA-N 2-[4-[[2,3-dimethyl-5-[[(1s)-1-(3-propan-2-ylphenyl)ethyl]carbamoyl]indol-1-yl]methyl]phenoxy]-2-methylpropanoic acid Chemical compound CC(C)C1=CC=CC([C@H](C)NC(=O)C=2C=C3C(C)=C(C)N(CC=4C=CC(OC(C)(C)C(O)=O)=CC=4)C3=CC=2)=C1 YQABQIQJIOZHPN-QFIPXVFZSA-N 0.000 description 1
- LELAQNIIEOLNFZ-NRFANRHFSA-N 2-[4-[[2,3-dimethyl-5-[[(1s)-1-(3-propan-2-ylphenyl)ethyl]carbamoyl]indol-1-yl]methyl]phenoxy]acetic acid Chemical compound CC(C)C1=CC=CC([C@H](C)NC(=O)C=2C=C3C(C)=C(C)N(CC=4C=CC(OCC(O)=O)=CC=4)C3=CC=2)=C1 LELAQNIIEOLNFZ-NRFANRHFSA-N 0.000 description 1
- AEWGUDVDOUFPTB-QHCPKHFHSA-N 2-[4-[[2,3-dimethyl-5-[[(1s)-1-(4-methylphenyl)ethyl]carbamoyl]indol-1-yl]methyl]phenyl]benzoic acid Chemical compound N([C@@H](C)C=1C=CC(C)=CC=1)C(=O)C(C=C1C(C)=C2C)=CC=C1N2CC(C=C1)=CC=C1C1=CC=CC=C1C(O)=O AEWGUDVDOUFPTB-QHCPKHFHSA-N 0.000 description 1
- BKKFJLQXWHWJPS-QFIPXVFZSA-N 2-[4-[[2,3-dimethyl-5-[[(1s)-1-(4-methylsulfonylphenyl)ethyl]carbamoyl]indol-1-yl]methyl]phenyl]benzoic acid Chemical compound N([C@@H](C)C=1C=CC(=CC=1)S(C)(=O)=O)C(=O)C(C=C1C(C)=C2C)=CC=C1N2CC(C=C1)=CC=C1C1=CC=CC=C1C(O)=O BKKFJLQXWHWJPS-QFIPXVFZSA-N 0.000 description 1
- ZVFXZTVFMARNCX-DEOSSOPVSA-N 2-[4-[[2,3-dimethyl-5-[[(1s)-1-(4-propan-2-ylphenyl)ethyl]carbamoyl]indol-1-yl]methyl]phenyl]benzoic acid Chemical compound C1=CC(C(C)C)=CC=C1[C@H](C)NC(=O)C1=CC=C(N(CC=2C=CC(=CC=2)C=2C(=CC=CC=2)C(O)=O)C(C)=C2C)C2=C1 ZVFXZTVFMARNCX-DEOSSOPVSA-N 0.000 description 1
- MDPNVRWNJRXPRJ-DEOSSOPVSA-N 2-[4-[[2,3-dimethyl-5-[[(1s)-1-(4-propylphenyl)ethyl]carbamoyl]indol-1-yl]methyl]phenyl]benzoic acid Chemical compound C1=CC(CCC)=CC=C1[C@H](C)NC(=O)C1=CC=C(N(CC=2C=CC(=CC=2)C=2C(=CC=CC=2)C(O)=O)C(C)=C2C)C2=C1 MDPNVRWNJRXPRJ-DEOSSOPVSA-N 0.000 description 1
- YDGOJIBKRJNRJU-OSPAZUARSA-N 2-[4-[[2,3-dimethyl-5-[[(1s)-1-[(2r)-1-phenylmethoxycarbonylpyrrolidin-2-yl]ethyl]carbamoyl]indol-1-yl]methyl]phenyl]benzoic acid Chemical compound N([C@@H](C)[C@@H]1N(CCC1)C(=O)OCC=1C=CC=CC=1)C(=O)C(C=C1C(C)=C2C)=CC=C1N2CC(C=C1)=CC=C1C1=CC=CC=C1C(O)=O YDGOJIBKRJNRJU-OSPAZUARSA-N 0.000 description 1
- YDGOJIBKRJNRJU-CYFIQEHSSA-N 2-[4-[[2,3-dimethyl-5-[[(1s)-1-[(2s)-1-phenylmethoxycarbonylpyrrolidin-2-yl]ethyl]carbamoyl]indol-1-yl]methyl]phenyl]benzoic acid Chemical compound N([C@@H](C)[C@H]1N(CCC1)C(=O)OCC=1C=CC=CC=1)C(=O)C(C=C1C(C)=C2C)=CC=C1N2CC(C=C1)=CC=C1C1=CC=CC=C1C(O)=O YDGOJIBKRJNRJU-CYFIQEHSSA-N 0.000 description 1
- SFRKAZVKWKFAQN-XYFQYJLHSA-N 2-[4-[[2,3-dimethyl-5-[[(1s)-1-[(3r)-1-phenylmethoxycarbonylpyrrolidin-3-yl]ethyl]carbamoyl]indol-1-yl]methyl]phenyl]benzoic acid Chemical compound N([C@@H](C)[C@H]1CN(CC1)C(=O)OCC=1C=CC=CC=1)C(=O)C(C=C1C(C)=C2C)=CC=C1N2CC(C=C1)=CC=C1C1=CC=CC=C1C(O)=O SFRKAZVKWKFAQN-XYFQYJLHSA-N 0.000 description 1
- DUYBNDTYUWFXKQ-NRFANRHFSA-N 2-[4-[[2,3-dimethyl-5-[[(1s)-1-[2-(trifluoromethoxy)phenyl]ethyl]carbamoyl]indol-1-yl]methyl]phenyl]benzoic acid Chemical compound N([C@@H](C)C=1C(=CC=CC=1)OC(F)(F)F)C(=O)C(C=C1C(C)=C2C)=CC=C1N2CC(C=C1)=CC=C1C1=CC=CC=C1C(O)=O DUYBNDTYUWFXKQ-NRFANRHFSA-N 0.000 description 1
- FJOURLWFDVUCAQ-NRFANRHFSA-N 2-[4-[[2,3-dimethyl-5-[[(1s)-1-[2-(trifluoromethyl)phenyl]ethyl]carbamoyl]indol-1-yl]methyl]phenyl]benzoic acid Chemical compound N([C@@H](C)C=1C(=CC=CC=1)C(F)(F)F)C(=O)C(C=C1C(C)=C2C)=CC=C1N2CC(C=C1)=CC=C1C1=CC=CC=C1C(O)=O FJOURLWFDVUCAQ-NRFANRHFSA-N 0.000 description 1
- TXADUHCIFUMRQM-FQEVSTJZSA-N 2-[4-[[2,3-dimethyl-5-[[(1s)-1-[6-(trifluoromethyl)pyridin-3-yl]ethyl]carbamoyl]indol-1-yl]methyl]phenyl]benzoic acid Chemical compound N([C@@H](C)C=1C=NC(=CC=1)C(F)(F)F)C(=O)C(C=C1C(C)=C2C)=CC=C1N2CC(C=C1)=CC=C1C1=CC=CC=C1C(O)=O TXADUHCIFUMRQM-FQEVSTJZSA-N 0.000 description 1
- GHJHEYQCYJVFJN-YTTGMZPUSA-N 2-[4-[[2,3-dimethyl-5-[[(1s)-1-phenylbutyl]carbamoyl]indol-1-yl]methyl]phenyl]benzoic acid Chemical compound N([C@@H](CCC)C=1C=CC=CC=1)C(=O)C(C=C1C(C)=C2C)=CC=C1N2CC(C=C1)=CC=C1C1=CC=CC=C1C(O)=O GHJHEYQCYJVFJN-YTTGMZPUSA-N 0.000 description 1
- GAGNYMUXGIUCTR-HKBQPEDESA-N 2-[4-[[2,3-dimethyl-5-[[(1s)-1-phenylpropyl]carbamoyl]indol-1-yl]methyl]phenyl]benzoic acid Chemical compound N([C@@H](CC)C=1C=CC=CC=1)C(=O)C(C=C1C(C)=C2C)=CC=C1N2CC(C=C1)=CC=C1C1=CC=CC=C1C(O)=O GAGNYMUXGIUCTR-HKBQPEDESA-N 0.000 description 1
- LGWVIZXPZHDDHD-QFIPXVFZSA-N 2-[4-[[2,3-dimethyl-5-[[(2r)-2-phenylpropyl]carbamoyl]indol-1-yl]methyl]phenyl]benzoic acid Chemical compound C([C@H](C)C=1C=CC=CC=1)NC(=O)C(C=C1C(C)=C2C)=CC=C1N2CC(C=C1)=CC=C1C1=CC=CC=C1C(O)=O LGWVIZXPZHDDHD-QFIPXVFZSA-N 0.000 description 1
- FYVMMEFHWHANIE-PMERELPUSA-N 2-[4-[[2,3-dimethyl-5-[[(3s)-1-phenylmethoxycarbonylpyrrolidin-3-yl]carbamoyl]indol-1-yl]methyl]phenyl]benzoic acid Chemical compound CC1=C(C)C2=CC(C(=O)N[C@@H]3CN(CC3)C(=O)OCC=3C=CC=CC=3)=CC=C2N1CC(C=C1)=CC=C1C1=CC=CC=C1C(O)=O FYVMMEFHWHANIE-PMERELPUSA-N 0.000 description 1
- XBBCZLAGLUBLAQ-UHFFFAOYSA-N 2-[4-[[2,3-dimethyl-5-[[3-(trifluoromethyl)phenyl]methylcarbamoyl]indol-1-yl]methyl]phenyl]benzoic acid Chemical compound CC1=C(C)C2=CC(C(=O)NCC=3C=C(C=CC=3)C(F)(F)F)=CC=C2N1CC(C=C1)=CC=C1C1=CC=CC=C1C(O)=O XBBCZLAGLUBLAQ-UHFFFAOYSA-N 0.000 description 1
- PYBJKDNEDKTUES-UHFFFAOYSA-N 2-[4-[[2,3-dimethyl-5-[[4-(trifluoromethyl)phenyl]methylcarbamoyl]indol-1-yl]methyl]phenyl]benzoic acid Chemical compound CC1=C(C)C2=CC(C(=O)NCC=3C=CC(=CC=3)C(F)(F)F)=CC=C2N1CC(C=C1)=CC=C1C1=CC=CC=C1C(O)=O PYBJKDNEDKTUES-UHFFFAOYSA-N 0.000 description 1
- CAEQBTDFYZGGNT-UHFFFAOYSA-N 2-[4-[[2-methyl-5-(1-phenylpropylcarbamoyl)indol-1-yl]methyl]phenyl]benzoic acid Chemical compound C=1C=CC=CC=1C(CC)NC(=O)C(C=C1C=C2C)=CC=C1N2CC(C=C1)=CC=C1C1=CC=CC=C1C(O)=O CAEQBTDFYZGGNT-UHFFFAOYSA-N 0.000 description 1
- XCYTZHNEBZAPSP-UHFFFAOYSA-N 2-[4-[[5-(1,3-benzodioxol-5-ylmethylcarbamoyl)-2,3-dimethylindol-1-yl]methyl]phenyl]benzoic acid Chemical compound CC1=C(C)C2=CC(C(=O)NCC=3C=C4OCOC4=CC=3)=CC=C2N1CC(C=C1)=CC=C1C1=CC=CC=C1C(O)=O XCYTZHNEBZAPSP-UHFFFAOYSA-N 0.000 description 1
- CFDHTBAARCMHPE-UHFFFAOYSA-N 2-[4-[[5-(2,3-dihydro-1,4-benzodioxin-3-ylmethylcarbamoyl)-2,3-dimethylindol-1-yl]methyl]phenyl]benzoic acid Chemical compound CC1=C(C)C2=CC(C(=O)NCC3OC4=CC=CC=C4OC3)=CC=C2N1CC(C=C1)=CC=C1C1=CC=CC=C1C(O)=O CFDHTBAARCMHPE-UHFFFAOYSA-N 0.000 description 1
- BHWXSVCPOXCBCR-UHFFFAOYSA-N 2-[4-[[5-(2-methoxyethylcarbamoyl)-2,3-dimethylindol-1-yl]methyl]phenyl]benzoic acid Chemical compound CC1=C(C)C2=CC(C(=O)NCCOC)=CC=C2N1CC(C=C1)=CC=C1C1=CC=CC=C1C(O)=O BHWXSVCPOXCBCR-UHFFFAOYSA-N 0.000 description 1
- XPCLROUCHIPBSJ-UHFFFAOYSA-N 2-[4-[[5-(3,4-dihydro-2h-chromen-3-ylcarbamoyl)-2,3-dimethylindol-1-yl]methyl]phenyl]benzoic acid Chemical compound CC1=C(C)C2=CC(C(=O)NC3CC4=CC=CC=C4OC3)=CC=C2N1CC(C=C1)=CC=C1C1=CC=CC=C1C(O)=O XPCLROUCHIPBSJ-UHFFFAOYSA-N 0.000 description 1
- MBGGATWAWMXBBU-UHFFFAOYSA-N 2-[4-[[5-(3,4-dihydro-2h-chromen-3-ylmethylcarbamoyl)-2,3-dimethylindol-1-yl]methyl]phenyl]benzoic acid Chemical compound CC1=C(C)C2=CC(C(=O)NCC3CC4=CC=CC=C4OC3)=CC=C2N1CC(C=C1)=CC=C1C1=CC=CC=C1C(O)=O MBGGATWAWMXBBU-UHFFFAOYSA-N 0.000 description 1
- DJJBUAMECAYUCC-UHFFFAOYSA-N 2-[4-[[5-(benzhydrylcarbamoyl)-2,3-dimethylindol-1-yl]methyl]phenyl]benzoic acid Chemical compound CC1=C(C)C2=CC(C(=O)NC(C=3C=CC=CC=3)C=3C=CC=CC=3)=CC=C2N1CC(C=C1)=CC=C1C1=CC=CC=C1C(O)=O DJJBUAMECAYUCC-UHFFFAOYSA-N 0.000 description 1
- HOWMTYZTQKZIEQ-UHFFFAOYSA-N 2-[4-[[5-(benzylcarbamoyl)-2,3-dimethylindol-1-yl]methyl]phenyl]benzoic acid Chemical compound CC1=C(C)C2=CC(C(=O)NCC=3C=CC=CC=3)=CC=C2N1CC(C=C1)=CC=C1C1=CC=CC=C1C(O)=O HOWMTYZTQKZIEQ-UHFFFAOYSA-N 0.000 description 1
- DHBBZHOMHZKHOC-UHFFFAOYSA-N 2-[4-[[5-(cyclobutylcarbamoyl)-2,3-dimethylindol-1-yl]methyl]phenyl]benzoic acid Chemical compound CC1=C(C)C2=CC(C(=O)NC3CCC3)=CC=C2N1CC(C=C1)=CC=C1C1=CC=CC=C1C(O)=O DHBBZHOMHZKHOC-UHFFFAOYSA-N 0.000 description 1
- RRAVOAZQKUOXKQ-UHFFFAOYSA-N 2-[4-[[5-(cyclohexylmethylcarbamoyl)-2,3-dimethylindol-1-yl]methyl]phenyl]benzoic acid Chemical compound CC1=C(C)C2=CC(C(=O)NCC3CCCCC3)=CC=C2N1CC(C=C1)=CC=C1C1=CC=CC=C1C(O)=O RRAVOAZQKUOXKQ-UHFFFAOYSA-N 0.000 description 1
- QPHDUUHAYMTXKM-UHFFFAOYSA-N 2-[4-[[5-(cyclopentylcarbamoyl)-2,3-dimethylindol-1-yl]methyl]phenyl]benzoic acid Chemical compound CC1=C(C)C2=CC(C(=O)NC3CCCC3)=CC=C2N1CC(C=C1)=CC=C1C1=CC=CC=C1C(O)=O QPHDUUHAYMTXKM-UHFFFAOYSA-N 0.000 description 1
- MGRBZHHORNMNIL-UHFFFAOYSA-N 2-[4-[[5-[(2,4-dichlorophenyl)methylcarbamoyl]-2,3-dimethylindol-1-yl]methyl]phenyl]benzoic acid Chemical compound CC1=C(C)C2=CC(C(=O)NCC=3C(=CC(Cl)=CC=3)Cl)=CC=C2N1CC(C=C1)=CC=C1C1=CC=CC=C1C(O)=O MGRBZHHORNMNIL-UHFFFAOYSA-N 0.000 description 1
- GZHMPPBTJIQWBF-UHFFFAOYSA-N 2-[4-[[5-[(2,4-difluorophenyl)methylcarbamoyl]-2,3-dimethylindol-1-yl]methyl]phenyl]benzoic acid Chemical compound CC1=C(C)C2=CC(C(=O)NCC=3C(=CC(F)=CC=3)F)=CC=C2N1CC(C=C1)=CC=C1C1=CC=CC=C1C(O)=O GZHMPPBTJIQWBF-UHFFFAOYSA-N 0.000 description 1
- DSTBIOVZRVCVDJ-UHFFFAOYSA-N 2-[4-[[5-[(2-aminophenyl)methylcarbamoyl]-2,3-dimethylindol-1-yl]methyl]phenyl]benzoic acid Chemical compound CC1=C(C)C2=CC(C(=O)NCC=3C(=CC=CC=3)N)=CC=C2N1CC(C=C1)=CC=C1C1=CC=CC=C1C(O)=O DSTBIOVZRVCVDJ-UHFFFAOYSA-N 0.000 description 1
- IZOYQELFKKTDJM-UHFFFAOYSA-N 2-[4-[[5-[(2-bromophenyl)methylcarbamoyl]-2,3-dimethylindol-1-yl]methyl]phenyl]benzoic acid Chemical compound CC1=C(C)C2=CC(C(=O)NCC=3C(=CC=CC=3)Br)=CC=C2N1CC(C=C1)=CC=C1C1=CC=CC=C1C(O)=O IZOYQELFKKTDJM-UHFFFAOYSA-N 0.000 description 1
- UCPKWQLVWHLWLW-UHFFFAOYSA-N 2-[4-[[5-[(2-chlorophenyl)methylcarbamoyl]-2,3-dimethylindol-1-yl]methyl]phenyl]benzoic acid Chemical compound CC1=C(C)C2=CC(C(=O)NCC=3C(=CC=CC=3)Cl)=CC=C2N1CC(C=C1)=CC=C1C1=CC=CC=C1C(O)=O UCPKWQLVWHLWLW-UHFFFAOYSA-N 0.000 description 1
- DCBQBBJQTHCGBE-UHFFFAOYSA-N 2-[4-[[5-[(3,4-difluorophenyl)methylcarbamoyl]-2,3-dimethylindol-1-yl]methyl]phenyl]benzoic acid Chemical compound CC1=C(C)C2=CC(C(=O)NCC=3C=C(F)C(F)=CC=3)=CC=C2N1CC(C=C1)=CC=C1C1=CC=CC=C1C(O)=O DCBQBBJQTHCGBE-UHFFFAOYSA-N 0.000 description 1
- WXPGGNHMOQHJJG-UHFFFAOYSA-N 2-[4-[[5-[(3-aminocyclohexyl)carbamoyl]-2,3-dimethylindol-1-yl]methyl]phenyl]benzoic acid Chemical compound CC1=C(C)C2=CC(C(=O)NC3CC(N)CCC3)=CC=C2N1CC(C=C1)=CC=C1C1=CC=CC=C1C(O)=O WXPGGNHMOQHJJG-UHFFFAOYSA-N 0.000 description 1
- PEJDJWGIKRMIKQ-UHFFFAOYSA-N 2-[4-[[5-[(3-aminophenyl)methylcarbamoyl]-2,3-dimethylindol-1-yl]methyl]phenyl]benzoic acid Chemical compound CC1=C(C)C2=CC(C(=O)NCC=3C=C(N)C=CC=3)=CC=C2N1CC(C=C1)=CC=C1C1=CC=CC=C1C(O)=O PEJDJWGIKRMIKQ-UHFFFAOYSA-N 0.000 description 1
- OEUROZWRADRLPK-UHFFFAOYSA-N 2-[4-[[5-[(3-chlorophenyl)methylcarbamoyl]-2,3-dimethylindol-1-yl]methyl]phenyl]benzoic acid Chemical compound CC1=C(C)C2=CC(C(=O)NCC=3C=C(Cl)C=CC=3)=CC=C2N1CC(C=C1)=CC=C1C1=CC=CC=C1C(O)=O OEUROZWRADRLPK-UHFFFAOYSA-N 0.000 description 1
- RAYLRVXTWGAYSN-UHFFFAOYSA-N 2-[4-[[5-[(3-fluoro-4-methoxyphenyl)methylcarbamoyl]-2,3-dimethylindol-1-yl]methyl]phenyl]benzoic acid Chemical compound C1=C(F)C(OC)=CC=C1CNC(=O)C1=CC=C(N(CC=2C=CC(=CC=2)C=2C(=CC=CC=2)C(O)=O)C(C)=C2C)C2=C1 RAYLRVXTWGAYSN-UHFFFAOYSA-N 0.000 description 1
- MPPDOPAMVCVSQN-UHFFFAOYSA-N 2-[4-[[5-[(3-methoxyphenyl)methylcarbamoyl]-2,3-dimethylindol-1-yl]methyl]phenyl]benzoic acid Chemical compound COC1=CC=CC(CNC(=O)C=2C=C3C(C)=C(C)N(CC=4C=CC(=CC=4)C=4C(=CC=CC=4)C(O)=O)C3=CC=2)=C1 MPPDOPAMVCVSQN-UHFFFAOYSA-N 0.000 description 1
- XMYRISTVRJVUHR-UHFFFAOYSA-N 2-[4-[[5-[(4-aminophenyl)methylcarbamoyl]-2,3-dimethylindol-1-yl]methyl]phenyl]benzoic acid Chemical compound CC1=C(C)C2=CC(C(=O)NCC=3C=CC(N)=CC=3)=CC=C2N1CC(C=C1)=CC=C1C1=CC=CC=C1C(O)=O XMYRISTVRJVUHR-UHFFFAOYSA-N 0.000 description 1
- XJALFFPUKNKJSH-UHFFFAOYSA-N 2-[4-[[5-[(4-fluorophenyl)methylcarbamoyl]-2,3-dimethylindol-1-yl]methyl]phenyl]benzoic acid Chemical compound CC1=C(C)C2=CC(C(=O)NCC=3C=CC(F)=CC=3)=CC=C2N1CC(C=C1)=CC=C1C1=CC=CC=C1C(O)=O XJALFFPUKNKJSH-UHFFFAOYSA-N 0.000 description 1
- PXHJADNZRQSFDW-UHFFFAOYSA-N 2-[4-[[5-[(4-methoxyphenyl)methylcarbamoyl]-2,3-dimethylindol-1-yl]methyl]phenyl]benzoic acid Chemical compound C1=CC(OC)=CC=C1CNC(=O)C1=CC=C(N(CC=2C=CC(=CC=2)C=2C(=CC=CC=2)C(O)=O)C(C)=C2C)C2=C1 PXHJADNZRQSFDW-UHFFFAOYSA-N 0.000 description 1
- NEAYZZIQLVPWPT-UHFFFAOYSA-N 2-[4-[[5-[2-(4-bromophenyl)propan-2-ylcarbamoyl]-2,3-dimethylindol-1-yl]methyl]phenyl]benzoic acid Chemical compound CC1=C(C)C2=CC(C(=O)NC(C)(C)C=3C=CC(Br)=CC=3)=CC=C2N1CC(C=C1)=CC=C1C1=CC=CC=C1C(O)=O NEAYZZIQLVPWPT-UHFFFAOYSA-N 0.000 description 1
- GUSPKESWPXTEMH-LWMFVPLKSA-N 2-[4-[[5-[[(1r)-1-(2,3-dihydro-1,4-benzodioxin-3-yl)ethyl]carbamoyl]-2,3-dimethylindol-1-yl]methyl]phenyl]benzoic acid Chemical compound N([C@H](C)C1OC2=CC=CC=C2OC1)C(=O)C(C=C1C(C)=C2C)=CC=C1N2CC(C=C1)=CC=C1C1=CC=CC=C1C(O)=O GUSPKESWPXTEMH-LWMFVPLKSA-N 0.000 description 1
- UTTYAFJRJPPQLF-LJQANCHMSA-N 2-[4-[[5-[[(1r)-1-(3,5-difluoropyridin-4-yl)ethyl]carbamoyl]-2,3-dimethylindol-1-yl]methyl]phenyl]benzoic acid Chemical compound N([C@H](C)C=1C(=CN=CC=1F)F)C(=O)C(C=C1C(C)=C2C)=CC=C1N2CC(C=C1)=CC=C1C1=CC=CC=C1C(O)=O UTTYAFJRJPPQLF-LJQANCHMSA-N 0.000 description 1
- SPZPQRKTGHMKOS-OAQYLSRUSA-N 2-[4-[[5-[[(1r)-1-(3-chlorophenyl)ethyl]carbamoyl]-2,3-dimethylindol-1-yl]methyl]phenyl]benzoic acid Chemical compound N([C@H](C)C=1C=C(Cl)C=CC=1)C(=O)C(C=C1C(C)=C2C)=CC=C1N2CC(C=C1)=CC=C1C1=CC=CC=C1C(O)=O SPZPQRKTGHMKOS-OAQYLSRUSA-N 0.000 description 1
- CDLJJRCMFYXSIQ-JOCHJYFZSA-N 2-[4-[[5-[[(1r)-1-(3-methoxyphenyl)ethyl]carbamoyl]-2,3-dimethylindol-1-yl]methyl]phenyl]benzoic acid Chemical compound COC1=CC=CC([C@@H](C)NC(=O)C=2C=C3C(C)=C(C)N(CC=4C=CC(=CC=4)C=4C(=CC=CC=4)C(O)=O)C3=CC=2)=C1 CDLJJRCMFYXSIQ-JOCHJYFZSA-N 0.000 description 1
- IBXXJKMQNNPXAF-OAQYLSRUSA-N 2-[4-[[5-[[(1r)-1-(4-fluorophenyl)ethyl]carbamoyl]-2,3-dimethylindol-1-yl]methyl]phenyl]benzoic acid Chemical compound N([C@H](C)C=1C=CC(F)=CC=1)C(=O)C(C=C1C(C)=C2C)=CC=C1N2CC(C=C1)=CC=C1C1=CC=CC=C1C(O)=O IBXXJKMQNNPXAF-OAQYLSRUSA-N 0.000 description 1
- XQSKXQCRYOENGC-OAQYLSRUSA-N 2-[4-[[5-[[(1r)-1-(5-fluoro-2-methoxyphenyl)ethyl]carbamoyl]-2,3-dimethylindol-1-yl]methyl]phenyl]benzoic acid Chemical compound COC1=CC=C(F)C=C1[C@@H](C)NC(=O)C1=CC=C(N(CC=2C=CC(=CC=2)C=2C(=CC=CC=2)C(O)=O)C(C)=C2C)C2=C1 XQSKXQCRYOENGC-OAQYLSRUSA-N 0.000 description 1
- VLRMPBZRUVLWBH-HXUWFJFHSA-N 2-[4-[[5-[[(1r)-1-[2,4-bis(trifluoromethyl)phenyl]ethyl]carbamoyl]-2,3-dimethylindol-1-yl]methyl]phenyl]benzoic acid Chemical compound N([C@H](C)C=1C(=CC(=CC=1)C(F)(F)F)C(F)(F)F)C(=O)C(C=C1C(C)=C2C)=CC=C1N2CC(C=C1)=CC=C1C1=CC=CC=C1C(O)=O VLRMPBZRUVLWBH-HXUWFJFHSA-N 0.000 description 1
- JQPNSVQCJMFWGY-HXUWFJFHSA-N 2-[4-[[5-[[(1r)-1-[2-chloro-3-(trifluoromethyl)phenyl]ethyl]carbamoyl]-2,3-dimethylindol-1-yl]methyl]phenyl]benzoic acid Chemical compound N([C@H](C)C=1C(=C(C=CC=1)C(F)(F)F)Cl)C(=O)C(C=C1C(C)=C2C)=CC=C1N2CC(C=C1)=CC=C1C1=CC=CC=C1C(O)=O JQPNSVQCJMFWGY-HXUWFJFHSA-N 0.000 description 1
- GKALYOWBMYAKNE-OAQYLSRUSA-N 2-[4-[[5-[[(1r)-1-[2-methoxy-4-(trifluoromethyl)phenyl]ethyl]carbamoyl]-2,3-dimethylindol-1-yl]methyl]phenyl]benzoic acid Chemical compound COC1=CC(C(F)(F)F)=CC=C1[C@@H](C)NC(=O)C1=CC=C(N(CC=2C=CC(=CC=2)C=2C(=CC=CC=2)C(O)=O)C(C)=C2C)C2=C1 GKALYOWBMYAKNE-OAQYLSRUSA-N 0.000 description 1
- SJOCPHWAOXQNKX-HXUWFJFHSA-N 2-[4-[[5-[[(1r)-1-[3-fluoro-4-(trifluoromethyl)phenyl]ethyl]carbamoyl]-2,3-dimethylindol-1-yl]methyl]phenyl]benzoic acid Chemical compound N([C@H](C)C=1C=C(F)C(=CC=1)C(F)(F)F)C(=O)C(C=C1C(C)=C2C)=CC=C1N2CC(C=C1)=CC=C1C1=CC=CC=C1C(O)=O SJOCPHWAOXQNKX-HXUWFJFHSA-N 0.000 description 1
- OSLYCNZWNHYISV-HXUWFJFHSA-N 2-[4-[[5-[[(1r)-1-[5-fluoro-2-(trifluoromethyl)phenyl]ethyl]carbamoyl]-2,3-dimethylindol-1-yl]methyl]phenyl]benzoic acid Chemical compound N([C@H](C)C=1C(=CC=C(F)C=1)C(F)(F)F)C(=O)C(C=C1C(C)=C2C)=CC=C1N2CC(C=C1)=CC=C1C1=CC=CC=C1C(O)=O OSLYCNZWNHYISV-HXUWFJFHSA-N 0.000 description 1
- RPMOMJICIICUOA-PMERELPUSA-N 2-[4-[[5-[[(1r)-2-hydroxy-1-phenylethyl]carbamoyl]-2,3-dimethylindol-1-yl]methyl]phenyl]benzoic acid Chemical compound CC1=C(C)C2=CC(C(=O)N[C@@H](CO)C=3C=CC=CC=3)=CC=C2N1CC(C=C1)=CC=C1C1=CC=CC=C1C(O)=O RPMOMJICIICUOA-PMERELPUSA-N 0.000 description 1
- SNQPKHWFCWQSBB-FQEVSTJZSA-N 2-[4-[[5-[[(1s)-1-(2,3-difluorophenyl)ethyl]carbamoyl]-2,3-dimethylindol-1-yl]methyl]phenyl]benzoic acid Chemical compound N([C@@H](C)C=1C(=C(F)C=CC=1)F)C(=O)C(C=C1C(C)=C2C)=CC=C1N2CC(C=C1)=CC=C1C1=CC=CC=C1C(O)=O SNQPKHWFCWQSBB-FQEVSTJZSA-N 0.000 description 1
- GUSPKESWPXTEMH-LJPZCQIFSA-N 2-[4-[[5-[[(1s)-1-(2,3-dihydro-1,4-benzodioxin-3-yl)ethyl]carbamoyl]-2,3-dimethylindol-1-yl]methyl]phenyl]benzoic acid Chemical compound N([C@@H](C)C1OC2=CC=CC=C2OC1)C(=O)C(C=C1C(C)=C2C)=CC=C1N2CC(C=C1)=CC=C1C1=CC=CC=C1C(O)=O GUSPKESWPXTEMH-LJPZCQIFSA-N 0.000 description 1
- PSSTXJCYPGOARP-QFIPXVFZSA-N 2-[4-[[5-[[(1s)-1-(2,3-dihydro-1-benzofuran-5-yl)ethyl]carbamoyl]-2,3-dimethylindol-1-yl]methyl]phenyl]benzoic acid Chemical compound N([C@@H](C)C=1C=C2CCOC2=CC=1)C(=O)C(C=C1C(C)=C2C)=CC=C1N2CC(C=C1)=CC=C1C1=CC=CC=C1C(O)=O PSSTXJCYPGOARP-QFIPXVFZSA-N 0.000 description 1
- AMSXUORYXQSRID-NRFANRHFSA-N 2-[4-[[5-[[(1s)-1-(2-bromophenyl)ethyl]carbamoyl]-2,3-dimethylindol-1-yl]methyl]phenyl]benzoic acid Chemical compound N([C@@H](C)C=1C(=CC=CC=1)Br)C(=O)C(C=C1C(C)=C2C)=CC=C1N2CC(C=C1)=CC=C1C1=CC=CC=C1C(O)=O AMSXUORYXQSRID-NRFANRHFSA-N 0.000 description 1
- ZWFGBYOUCRKLHM-QHCPKHFHSA-N 2-[4-[[5-[[(1s)-1-(2-ethylphenyl)ethyl]carbamoyl]-2,3-dimethylindol-1-yl]methyl]phenyl]benzoic acid Chemical compound CCC1=CC=CC=C1[C@H](C)NC(=O)C1=CC=C(N(CC=2C=CC(=CC=2)C=2C(=CC=CC=2)C(O)=O)C(C)=C2C)C2=C1 ZWFGBYOUCRKLHM-QHCPKHFHSA-N 0.000 description 1
- VRTGSKLZGPIRLZ-QFIPXVFZSA-N 2-[4-[[5-[[(1s)-1-(2-fluoro-5-methylphenyl)ethyl]carbamoyl]-2,3-dimethylindol-1-yl]methyl]phenyl]benzoic acid Chemical compound N([C@@H](C)C=1C(=CC=C(C)C=1)F)C(=O)C(C=C1C(C)=C2C)=CC=C1N2CC(C=C1)=CC=C1C1=CC=CC=C1C(O)=O VRTGSKLZGPIRLZ-QFIPXVFZSA-N 0.000 description 1
- FGARMYCGQITLSX-QFIPXVFZSA-N 2-[4-[[5-[[(1s)-1-(2-methoxyphenyl)ethyl]carbamoyl]-2,3-dimethylindol-1-yl]methyl]phenyl]benzoic acid Chemical compound COC1=CC=CC=C1[C@H](C)NC(=O)C1=CC=C(N(CC=2C=CC(=CC=2)C=2C(=CC=CC=2)C(O)=O)C(C)=C2C)C2=C1 FGARMYCGQITLSX-QFIPXVFZSA-N 0.000 description 1
- IFDHNULLKPECDJ-FQEVSTJZSA-N 2-[4-[[5-[[(1s)-1-(3,4-dichlorophenyl)ethyl]carbamoyl]-2,3-dimethylindol-1-yl]methyl]phenyl]benzoic acid Chemical compound N([C@@H](C)C=1C=C(Cl)C(Cl)=CC=1)C(=O)C(C=C1C(C)=C2C)=CC=C1N2CC(C=C1)=CC=C1C1=CC=CC=C1C(O)=O IFDHNULLKPECDJ-FQEVSTJZSA-N 0.000 description 1
- FMOOOOBAFIZVIX-FQEVSTJZSA-N 2-[4-[[5-[[(1s)-1-(3,4-difluorophenyl)ethyl]carbamoyl]-2,3-dimethylindol-1-yl]methyl]phenyl]benzoic acid Chemical compound N([C@@H](C)C=1C=C(F)C(F)=CC=1)C(=O)C(C=C1C(C)=C2C)=CC=C1N2CC(C=C1)=CC=C1C1=CC=CC=C1C(O)=O FMOOOOBAFIZVIX-FQEVSTJZSA-N 0.000 description 1
- JPDJIJPTRINDQA-FQEVSTJZSA-N 2-[4-[[5-[[(1s)-1-(3,5-dichlorophenyl)ethyl]carbamoyl]-2,3-dimethylindol-1-yl]methyl]phenyl]benzoic acid Chemical compound N([C@@H](C)C=1C=C(Cl)C=C(Cl)C=1)C(=O)C(C=C1C(C)=C2C)=CC=C1N2CC(C=C1)=CC=C1C1=CC=CC=C1C(O)=O JPDJIJPTRINDQA-FQEVSTJZSA-N 0.000 description 1
- UTTYAFJRJPPQLF-IBGZPJMESA-N 2-[4-[[5-[[(1s)-1-(3,5-difluoropyridin-4-yl)ethyl]carbamoyl]-2,3-dimethylindol-1-yl]methyl]phenyl]benzoic acid Chemical compound N([C@@H](C)C=1C(=CN=CC=1F)F)C(=O)C(C=C1C(C)=C2C)=CC=C1N2CC(C=C1)=CC=C1C1=CC=CC=C1C(O)=O UTTYAFJRJPPQLF-IBGZPJMESA-N 0.000 description 1
- HFBHBJVXXXZDCU-FQEVSTJZSA-N 2-[4-[[5-[[(1s)-1-(3-chloro-2-fluorophenyl)ethyl]carbamoyl]-2,3-dimethylindol-1-yl]methyl]phenyl]benzoic acid Chemical compound N([C@@H](C)C=1C(=C(Cl)C=CC=1)F)C(=O)C(C=C1C(C)=C2C)=CC=C1N2CC(C=C1)=CC=C1C1=CC=CC=C1C(O)=O HFBHBJVXXXZDCU-FQEVSTJZSA-N 0.000 description 1
- SPZPQRKTGHMKOS-NRFANRHFSA-N 2-[4-[[5-[[(1s)-1-(3-chlorophenyl)ethyl]carbamoyl]-2,3-dimethylindol-1-yl]methyl]phenyl]benzoic acid Chemical compound N([C@@H](C)C=1C=C(Cl)C=CC=1)C(=O)C(C=C1C(C)=C2C)=CC=C1N2CC(C=C1)=CC=C1C1=CC=CC=C1C(O)=O SPZPQRKTGHMKOS-NRFANRHFSA-N 0.000 description 1
- XPSPDUAUITZUPZ-FQEVSTJZSA-N 2-[4-[[5-[[(1s)-1-(3-cyclopropylphenyl)ethyl]carbamoyl]-2,3-dimethylindol-1-yl]methyl]phenoxy]acetic acid Chemical compound N([C@@H](C)C=1C=C(C=CC=1)C1CC1)C(=O)C(C=C1C(C)=C2C)=CC=C1N2CC1=CC=C(OCC(O)=O)C=C1 XPSPDUAUITZUPZ-FQEVSTJZSA-N 0.000 description 1
- IKAZEOSOMNPMQA-NRFANRHFSA-N 2-[4-[[5-[[(1s)-1-(4-aminophenyl)ethyl]carbamoyl]-2,3-dimethylindol-1-yl]methyl]phenyl]benzoic acid Chemical compound N([C@@H](C)C=1C=CC(N)=CC=1)C(=O)C(C=C1C(C)=C2C)=CC=C1N2CC(C=C1)=CC=C1C1=CC=CC=C1C(O)=O IKAZEOSOMNPMQA-NRFANRHFSA-N 0.000 description 1
- GAFZMPLOJOCVMS-QFIPXVFZSA-N 2-[4-[[5-[[(1s)-1-(4-chloro-2-methylphenyl)ethyl]carbamoyl]-2,3-dimethylindol-1-yl]methyl]phenyl]benzoic acid Chemical compound N([C@@H](C)C=1C(=CC(Cl)=CC=1)C)C(=O)C(C=C1C(C)=C2C)=CC=C1N2CC(C=C1)=CC=C1C1=CC=CC=C1C(O)=O GAFZMPLOJOCVMS-QFIPXVFZSA-N 0.000 description 1
- MFHKURILOJWBNE-QHCPKHFHSA-N 2-[4-[[5-[[(1s)-1-(4-cyclopropylphenyl)ethyl]carbamoyl]-2,3-dimethylindol-1-yl]methyl]phenyl]benzoic acid Chemical compound N([C@@H](C)C=1C=CC(=CC=1)C1CC1)C(=O)C(C=C1C(C)=C2C)=CC=C1N2CC(C=C1)=CC=C1C1=CC=CC=C1C(O)=O MFHKURILOJWBNE-QHCPKHFHSA-N 0.000 description 1
- LTVKSFXRQPYAAJ-QHCPKHFHSA-N 2-[4-[[5-[[(1s)-1-(4-ethoxyphenyl)ethyl]carbamoyl]-2,3-dimethylindol-1-yl]methyl]phenyl]benzoic acid Chemical compound C1=CC(OCC)=CC=C1[C@H](C)NC(=O)C1=CC=C(N(CC=2C=CC(=CC=2)C=2C(=CC=CC=2)C(O)=O)C(C)=C2C)C2=C1 LTVKSFXRQPYAAJ-QHCPKHFHSA-N 0.000 description 1
- PGCVCSFPOMUCAN-QHCPKHFHSA-N 2-[4-[[5-[[(1s)-1-(4-ethylphenyl)ethyl]carbamoyl]-2,3-dimethylindol-1-yl]methyl]phenyl]benzoic acid Chemical compound C1=CC(CC)=CC=C1[C@H](C)NC(=O)C1=CC=C(N(CC=2C=CC(=CC=2)C=2C(=CC=CC=2)C(O)=O)C(C)=C2C)C2=C1 PGCVCSFPOMUCAN-QHCPKHFHSA-N 0.000 description 1
- IBXXJKMQNNPXAF-NRFANRHFSA-N 2-[4-[[5-[[(1s)-1-(4-fluorophenyl)ethyl]carbamoyl]-2,3-dimethylindol-1-yl]methyl]phenyl]benzoic acid Chemical compound N([C@@H](C)C=1C=CC(F)=CC=1)C(=O)C(C=C1C(C)=C2C)=CC=C1N2CC(C=C1)=CC=C1C1=CC=CC=C1C(O)=O IBXXJKMQNNPXAF-NRFANRHFSA-N 0.000 description 1
- JIHCIAJCNWUMKM-FQEVSTJZSA-N 2-[4-[[5-[[(1s)-1-(4-nitrophenyl)ethyl]carbamoyl]indol-1-yl]methyl]phenyl]benzoic acid Chemical compound N([C@@H](C)C=1C=CC(=CC=1)[N+]([O-])=O)C(=O)C(C=C1C=C2)=CC=C1N2CC(C=C1)=CC=C1C1=CC=CC=C1C(O)=O JIHCIAJCNWUMKM-FQEVSTJZSA-N 0.000 description 1
- FQLIXOCRBSDYPO-NRFANRHFSA-N 2-[4-[[5-[[(1s)-1-(4-tert-butylphenyl)ethyl]carbamoyl]-2,3-dimethylindol-1-yl]methyl]phenoxy]acetic acid Chemical compound N([C@@H](C)C=1C=CC(=CC=1)C(C)(C)C)C(=O)C(C=C1C(C)=C2C)=CC=C1N2CC1=CC=C(OCC(O)=O)C=C1 FQLIXOCRBSDYPO-NRFANRHFSA-N 0.000 description 1
- XQSKXQCRYOENGC-NRFANRHFSA-N 2-[4-[[5-[[(1s)-1-(5-fluoro-2-methoxyphenyl)ethyl]carbamoyl]-2,3-dimethylindol-1-yl]methyl]phenyl]benzoic acid Chemical compound COC1=CC=C(F)C=C1[C@H](C)NC(=O)C1=CC=C(N(CC=2C=CC(=CC=2)C=2C(=CC=CC=2)C(O)=O)C(C)=C2C)C2=C1 XQSKXQCRYOENGC-NRFANRHFSA-N 0.000 description 1
- YMSQEXJVUBHHLX-MHZLTWQESA-N 2-[4-[[5-[[(1s)-1-[1-(benzylcarbamoyl)piperidin-4-yl]ethyl]carbamoyl]-2,3-dimethylindol-1-yl]methyl]phenyl]benzoic acid Chemical compound N([C@@H](C)C1CCN(CC1)C(=O)NCC=1C=CC=CC=1)C(=O)C(C=C1C(C)=C2C)=CC=C1N2CC(C=C1)=CC=C1C1=CC=CC=C1C(O)=O YMSQEXJVUBHHLX-MHZLTWQESA-N 0.000 description 1
- VLRMPBZRUVLWBH-FQEVSTJZSA-N 2-[4-[[5-[[(1s)-1-[2,4-bis(trifluoromethyl)phenyl]ethyl]carbamoyl]-2,3-dimethylindol-1-yl]methyl]phenyl]benzoic acid Chemical compound N([C@@H](C)C=1C(=CC(=CC=1)C(F)(F)F)C(F)(F)F)C(=O)C(C=C1C(C)=C2C)=CC=C1N2CC(C=C1)=CC=C1C1=CC=CC=C1C(O)=O VLRMPBZRUVLWBH-FQEVSTJZSA-N 0.000 description 1
- JQPNSVQCJMFWGY-FQEVSTJZSA-N 2-[4-[[5-[[(1s)-1-[2-chloro-3-(trifluoromethyl)phenyl]ethyl]carbamoyl]-2,3-dimethylindol-1-yl]methyl]phenyl]benzoic acid Chemical compound N([C@@H](C)C=1C(=C(C=CC=1)C(F)(F)F)Cl)C(=O)C(C=C1C(C)=C2C)=CC=C1N2CC(C=C1)=CC=C1C1=CC=CC=C1C(O)=O JQPNSVQCJMFWGY-FQEVSTJZSA-N 0.000 description 1
- UDDVMLZGMLHVES-FQEVSTJZSA-N 2-[4-[[5-[[(1s)-1-[2-fluoro-5-(trifluoromethyl)phenyl]ethyl]carbamoyl]-2,3-dimethylindol-1-yl]methyl]phenyl]benzoic acid Chemical compound N([C@@H](C)C=1C(=CC=C(C=1)C(F)(F)F)F)C(=O)C(C=C1C(C)=C2C)=CC=C1N2CC(C=C1)=CC=C1C1=CC=CC=C1C(O)=O UDDVMLZGMLHVES-FQEVSTJZSA-N 0.000 description 1
- GKALYOWBMYAKNE-NRFANRHFSA-N 2-[4-[[5-[[(1s)-1-[2-methoxy-4-(trifluoromethyl)phenyl]ethyl]carbamoyl]-2,3-dimethylindol-1-yl]methyl]phenyl]benzoic acid Chemical compound COC1=CC(C(F)(F)F)=CC=C1[C@H](C)NC(=O)C1=CC=C(N(CC=2C=CC(=CC=2)C=2C(=CC=CC=2)C(O)=O)C(C)=C2C)C2=C1 GKALYOWBMYAKNE-NRFANRHFSA-N 0.000 description 1
- SJOCPHWAOXQNKX-FQEVSTJZSA-N 2-[4-[[5-[[(1s)-1-[3-fluoro-4-(trifluoromethyl)phenyl]ethyl]carbamoyl]-2,3-dimethylindol-1-yl]methyl]phenyl]benzoic acid Chemical compound N([C@@H](C)C=1C=C(F)C(=CC=1)C(F)(F)F)C(=O)C(C=C1C(C)=C2C)=CC=C1N2CC(C=C1)=CC=C1C1=CC=CC=C1C(O)=O SJOCPHWAOXQNKX-FQEVSTJZSA-N 0.000 description 1
- YUJXUQACKWEUDN-FQEVSTJZSA-N 2-[4-[[5-[[(1s)-1-[4-chloro-3-(trifluoromethyl)phenyl]ethyl]carbamoyl]-2,3-dimethylindol-1-yl]methyl]phenyl]benzoic acid Chemical compound N([C@@H](C)C=1C=C(C(Cl)=CC=1)C(F)(F)F)C(=O)C(C=C1C(C)=C2C)=CC=C1N2CC(C=C1)=CC=C1C1=CC=CC=C1C(O)=O YUJXUQACKWEUDN-FQEVSTJZSA-N 0.000 description 1
- CHGTWSBVCJGPGP-FQEVSTJZSA-N 2-[4-[[5-[[(1s)-1-[4-fluoro-2-(trifluoromethyl)phenyl]ethyl]carbamoyl]-2,3-dimethylindol-1-yl]methyl]phenyl]benzoic acid Chemical compound N([C@@H](C)C=1C(=CC(F)=CC=1)C(F)(F)F)C(=O)C(C=C1C(C)=C2C)=CC=C1N2CC(C=C1)=CC=C1C1=CC=CC=C1C(O)=O CHGTWSBVCJGPGP-FQEVSTJZSA-N 0.000 description 1
- OSLYCNZWNHYISV-FQEVSTJZSA-N 2-[4-[[5-[[(1s)-1-[5-fluoro-2-(trifluoromethyl)phenyl]ethyl]carbamoyl]-2,3-dimethylindol-1-yl]methyl]phenyl]benzoic acid Chemical compound N([C@@H](C)C=1C(=CC=C(F)C=1)C(F)(F)F)C(=O)C(C=C1C(C)=C2C)=CC=C1N2CC(C=C1)=CC=C1C1=CC=CC=C1C(O)=O OSLYCNZWNHYISV-FQEVSTJZSA-N 0.000 description 1
- GNJIOPXBNZFPPW-QFIPXVFZSA-N 2-[4-[[5-[[(1s)-1-cyclohexylethyl]carbamoyl]-2,3-dimethylindol-1-yl]methyl]phenyl]benzoic acid Chemical compound N([C@@H](C)C1CCCCC1)C(=O)C(C=C1C(C)=C2C)=CC=C1N2CC(C=C1)=CC=C1C1=CC=CC=C1C(O)=O GNJIOPXBNZFPPW-QFIPXVFZSA-N 0.000 description 1
- XPCLROUCHIPBSJ-HHHXNRCGSA-N 2-[4-[[5-[[(3r)-3,4-dihydro-2h-chromen-3-yl]carbamoyl]-2,3-dimethylindol-1-yl]methyl]phenyl]benzoic acid Chemical compound CC1=C(C)C2=CC(C(=O)N[C@@H]3CC4=CC=CC=C4OC3)=CC=C2N1CC(C=C1)=CC=C1C1=CC=CC=C1C(O)=O XPCLROUCHIPBSJ-HHHXNRCGSA-N 0.000 description 1
- XPCLROUCHIPBSJ-MHZLTWQESA-N 2-[4-[[5-[[(3s)-3,4-dihydro-2h-chromen-3-yl]carbamoyl]-2,3-dimethylindol-1-yl]methyl]phenyl]benzoic acid Chemical compound CC1=C(C)C2=CC(C(=O)N[C@H]3CC4=CC=CC=C4OC3)=CC=C2N1CC(C=C1)=CC=C1C1=CC=CC=C1C(O)=O XPCLROUCHIPBSJ-MHZLTWQESA-N 0.000 description 1
- PHDOUMWIVUIBBU-UHFFFAOYSA-N 2-[4-[[5-[[2-fluoro-4-(trifluoromethyl)phenyl]methylcarbamoyl]-2,3-dimethylindol-1-yl]methyl]phenyl]benzoic acid Chemical compound CC1=C(C)C2=CC(C(=O)NCC=3C(=CC(=CC=3)C(F)(F)F)F)=CC=C2N1CC(C=C1)=CC=C1C1=CC=CC=C1C(O)=O PHDOUMWIVUIBBU-UHFFFAOYSA-N 0.000 description 1
- ZVGYCNRDWBXCBC-UHFFFAOYSA-N 2-[4-[[5-[[3-(aminomethyl)phenyl]methylcarbamoyl]-2,3-dimethylindol-1-yl]methyl]phenyl]benzoic acid Chemical compound CC1=C(C)C2=CC(C(=O)NCC=3C=C(CN)C=CC=3)=CC=C2N1CC(C=C1)=CC=C1C1=CC=CC=C1C(O)=O ZVGYCNRDWBXCBC-UHFFFAOYSA-N 0.000 description 1
- BJUCDNKXVSCKRW-UHFFFAOYSA-N 2-[4-[[5-[[4-chloro-2-(trifluoromethyl)phenyl]methylcarbamoyl]-2,3-dimethylindol-1-yl]methyl]phenyl]benzoic acid Chemical compound CC1=C(C)C2=CC(C(=O)NCC=3C(=CC(Cl)=CC=3)C(F)(F)F)=CC=C2N1CC(C=C1)=CC=C1C1=CC=CC=C1C(O)=O BJUCDNKXVSCKRW-UHFFFAOYSA-N 0.000 description 1
- HEQOJEGTZCTHCF-UHFFFAOYSA-N 2-amino-1-phenylethanone Chemical compound NCC(=O)C1=CC=CC=C1 HEQOJEGTZCTHCF-UHFFFAOYSA-N 0.000 description 1
- IJXJGQCXFSSHNL-UHFFFAOYSA-N 2-amino-2-phenylethanol Chemical compound OCC(N)C1=CC=CC=C1 IJXJGQCXFSSHNL-UHFFFAOYSA-N 0.000 description 1
- 125000004174 2-benzimidazolyl group Chemical group [H]N1C(*)=NC2=C([H])C([H])=C([H])C([H])=C12 0.000 description 1
- REXUYBKPWIPONM-UHFFFAOYSA-N 2-bromoacetonitrile Chemical compound BrCC#N REXUYBKPWIPONM-UHFFFAOYSA-N 0.000 description 1
- XRXMNWGCKISMOH-UHFFFAOYSA-N 2-bromobenzoic acid Chemical compound OC(=O)C1=CC=CC=C1Br XRXMNWGCKISMOH-UHFFFAOYSA-N 0.000 description 1
- AFMPMSCZPVNPEM-UHFFFAOYSA-N 2-bromobenzonitrile Chemical compound BrC1=CC=CC=C1C#N AFMPMSCZPVNPEM-UHFFFAOYSA-N 0.000 description 1
- PIZVRLVKXWEMGO-UHFFFAOYSA-N 2-chloro-3-fluorobenzaldehyde Chemical compound FC1=CC=CC(C=O)=C1Cl PIZVRLVKXWEMGO-UHFFFAOYSA-N 0.000 description 1
- FPYUJUBAXZAQNL-UHFFFAOYSA-N 2-chlorobenzaldehyde Chemical compound ClC1=CC=CC=C1C=O FPYUJUBAXZAQNL-UHFFFAOYSA-N 0.000 description 1
- IDLNLGMUINCSGS-UHFFFAOYSA-N 2-fluoro-5-(trifluoromethyl)benzaldehyde Chemical compound FC1=CC=C(C(F)(F)F)C=C1C=O IDLNLGMUINCSGS-UHFFFAOYSA-N 0.000 description 1
- QAWILFXCNRBMDF-UHFFFAOYSA-N 2-fluoro-5-methylbenzaldehyde Chemical compound CC1=CC=C(F)C(C=O)=C1 QAWILFXCNRBMDF-UHFFFAOYSA-N 0.000 description 1
- ZWDVQMVZZYIAHO-UHFFFAOYSA-N 2-fluorobenzaldehyde Chemical compound FC1=CC=CC=C1C=O ZWDVQMVZZYIAHO-UHFFFAOYSA-N 0.000 description 1
- CSDSSGBPEUDDEE-UHFFFAOYSA-N 2-formylpyridine Chemical compound O=CC1=CC=CC=N1 CSDSSGBPEUDDEE-UHFFFAOYSA-N 0.000 description 1
- 125000002941 2-furyl group Chemical group O1C([*])=C([H])C([H])=C1[H] 0.000 description 1
- ASUDFOJKTJLAIK-UHFFFAOYSA-N 2-methoxyethanamine Chemical compound COCCN ASUDFOJKTJLAIK-UHFFFAOYSA-N 0.000 description 1
- XWKFPIODWVPXLX-UHFFFAOYSA-N 2-methyl-5-methylpyridine Natural products CC1=CC=C(C)N=C1 XWKFPIODWVPXLX-UHFFFAOYSA-N 0.000 description 1
- CESUXLKAADQNTB-SSDOTTSWSA-N 2-methylpropane-2-sulfinamide Chemical compound CC(C)(C)[S@](N)=O CESUXLKAADQNTB-SSDOTTSWSA-N 0.000 description 1
- CESUXLKAADQNTB-ZETCQYMHSA-N 2-methylpropane-2-sulfinamide Chemical compound CC(C)(C)[S@@](N)=O CESUXLKAADQNTB-ZETCQYMHSA-N 0.000 description 1
- 125000001622 2-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C(*)C([H])=C([H])C2=C1[H] 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- QPJHNCCFAQDTIX-BQAIUKQQSA-N 2-tert-butyl-6-[4-[[2,3-dimethyl-5-[[(1S)-1-piperidin-4-ylethyl]carbamoyl]indol-1-yl]methyl]phenyl]benzoic acid piperidine Chemical compound C(C)(C)(C)C1=C(C(=CC=C1)C1=CC=C(C=C1)CN1C(=C(C2=CC(=CC=C12)C(N[C@@H](C)C1CCNCC1)=O)C)C)C(=O)O.N1CCCCC1 QPJHNCCFAQDTIX-BQAIUKQQSA-N 0.000 description 1
- 125000000175 2-thienyl group Chemical group S1C([*])=C([H])C([H])=C1[H] 0.000 description 1
- LGCYVLDNGBSOOW-UHFFFAOYSA-N 2H-benzotriazol-4-ol 1-hydroxybenzotriazole Chemical compound OC1=CC=CC2=C1N=NN2.C1=CC=C2N(O)N=NC2=C1 LGCYVLDNGBSOOW-UHFFFAOYSA-N 0.000 description 1
- ZWUSBSHBFFPRNE-UHFFFAOYSA-N 3,4-dichlorobenzaldehyde Chemical compound ClC1=CC=C(C=O)C=C1Cl ZWUSBSHBFFPRNE-UHFFFAOYSA-N 0.000 description 1
- CLWNCRSSFMSHDL-UHFFFAOYSA-N 3,4-dihydro-2h-chromen-3-ylmethanamine Chemical compound C1=CC=C2CC(CN)COC2=C1 CLWNCRSSFMSHDL-UHFFFAOYSA-N 0.000 description 1
- SDXAWLJRERMRKF-UHFFFAOYSA-N 3,5-dimethyl-1h-pyrazole Chemical class CC=1C=C(C)NN=1 SDXAWLJRERMRKF-UHFFFAOYSA-N 0.000 description 1
- HCDMJFOHIXMBOV-UHFFFAOYSA-N 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-ethyl-8-(morpholin-4-ylmethyl)-4,7-dihydropyrrolo[4,5]pyrido[1,2-d]pyrimidin-2-one Chemical compound C=1C2=C3N(CC)C(=O)N(C=4C(=C(OC)C=C(OC)C=4F)F)CC3=CN=C2NC=1CN1CCOCC1 HCDMJFOHIXMBOV-UHFFFAOYSA-N 0.000 description 1
- BYHQTRFJOGIQAO-GOSISDBHSA-N 3-(4-bromophenyl)-8-[(2R)-2-hydroxypropyl]-1-[(3-methoxyphenyl)methyl]-1,3,8-triazaspiro[4.5]decan-2-one Chemical compound C[C@H](CN1CCC2(CC1)CN(C(=O)N2CC3=CC(=CC=C3)OC)C4=CC=C(C=C4)Br)O BYHQTRFJOGIQAO-GOSISDBHSA-N 0.000 description 1
- ZDBWYUOUYNQZBM-UHFFFAOYSA-N 3-(aminomethyl)aniline Chemical compound NCC1=CC=CC(N)=C1 ZDBWYUOUYNQZBM-UHFFFAOYSA-N 0.000 description 1
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 1
- NMTUHPSKJJYGML-UHFFFAOYSA-N 3-(trifluoromethyl)benzaldehyde Chemical compound FC(F)(F)C1=CC=CC(C=O)=C1 NMTUHPSKJJYGML-UHFFFAOYSA-N 0.000 description 1
- YGYGASJNJTYNOL-CQSZACIVSA-N 3-[(4r)-2,2-dimethyl-1,1-dioxothian-4-yl]-5-(4-fluorophenyl)-1h-indole-7-carboxamide Chemical compound C1CS(=O)(=O)C(C)(C)C[C@@H]1C1=CNC2=C(C(N)=O)C=C(C=3C=CC(F)=CC=3)C=C12 YGYGASJNJTYNOL-CQSZACIVSA-N 0.000 description 1
- ADUYAJIFZKXWCR-WJOKGBTCSA-N 3-[2-[[2,3-dimethyl-5-[[(1r)-1-phenylpropyl]carbamoyl]indol-1-yl]methyl]phenyl]benzoic acid Chemical compound N([C@H](CC)C=1C=CC=CC=1)C(=O)C(C=C1C(C)=C2C)=CC=C1N2CC1=CC=CC=C1C1=CC=CC(C(O)=O)=C1 ADUYAJIFZKXWCR-WJOKGBTCSA-N 0.000 description 1
- ADUYAJIFZKXWCR-HKBQPEDESA-N 3-[2-[[2,3-dimethyl-5-[[(1s)-1-phenylpropyl]carbamoyl]indol-1-yl]methyl]phenyl]benzoic acid Chemical compound N([C@@H](CC)C=1C=CC=CC=1)C(=O)C(C=C1C(C)=C2C)=CC=C1N2CC1=CC=CC=C1C1=CC=CC(C(O)=O)=C1 ADUYAJIFZKXWCR-HKBQPEDESA-N 0.000 description 1
- NICJNANYSZSYDZ-GDLZYMKVSA-N 3-[2-[[5-[[(1r)-1-phenylpropyl]carbamoyl]indol-1-yl]methyl]phenyl]benzoic acid Chemical compound N([C@H](CC)C=1C=CC=CC=1)C(=O)C(C=C1C=C2)=CC=C1N2CC1=CC=CC=C1C1=CC=CC(C(O)=O)=C1 NICJNANYSZSYDZ-GDLZYMKVSA-N 0.000 description 1
- WNEODWDFDXWOLU-QHCPKHFHSA-N 3-[3-(hydroxymethyl)-4-[1-methyl-5-[[5-[(2s)-2-methyl-4-(oxetan-3-yl)piperazin-1-yl]pyridin-2-yl]amino]-6-oxopyridin-3-yl]pyridin-2-yl]-7,7-dimethyl-1,2,6,8-tetrahydrocyclopenta[3,4]pyrrolo[3,5-b]pyrazin-4-one Chemical compound C([C@@H](N(CC1)C=2C=NC(NC=3C(N(C)C=C(C=3)C=3C(=C(N4C(C5=CC=6CC(C)(C)CC=6N5CC4)=O)N=CC=3)CO)=O)=CC=2)C)N1C1COC1 WNEODWDFDXWOLU-QHCPKHFHSA-N 0.000 description 1
- SRVXSISGYBMIHR-UHFFFAOYSA-N 3-[3-[3-(2-amino-2-oxoethyl)phenyl]-5-chlorophenyl]-3-(5-methyl-1,3-thiazol-2-yl)propanoic acid Chemical compound S1C(C)=CN=C1C(CC(O)=O)C1=CC(Cl)=CC(C=2C=C(CC(N)=O)C=CC=2)=C1 SRVXSISGYBMIHR-UHFFFAOYSA-N 0.000 description 1
- YLXSERLVJKAICS-FQEVSTJZSA-N 3-[4-[[5-[[(1s)-1-(4-nitrophenyl)ethyl]carbamoyl]indol-1-yl]methyl]phenyl]benzoic acid Chemical compound N([C@@H](C)C=1C=CC(=CC=1)[N+]([O-])=O)C(=O)C(C=C1C=C2)=CC=C1N2CC(C=C1)=CC=C1C1=CC=CC(C(O)=O)=C1 YLXSERLVJKAICS-FQEVSTJZSA-N 0.000 description 1
- ZVGDKOQPJCOCLI-UHFFFAOYSA-N 3-chloropyridine-4-carbaldehyde Chemical compound ClC1=CN=CC=C1C=O ZVGDKOQPJCOCLI-UHFFFAOYSA-N 0.000 description 1
- QZMGMXBYJZVAJN-UHFFFAOYSA-N 3-ethoxybenzaldehyde Chemical compound CCOC1=CC=CC(C=O)=C1 QZMGMXBYJZVAJN-UHFFFAOYSA-N 0.000 description 1
- UMLOYMZBAUIGKF-UHFFFAOYSA-N 3-fluoro-2-methoxybenzaldehyde Chemical compound COC1=C(F)C=CC=C1C=O UMLOYMZBAUIGKF-UHFFFAOYSA-N 0.000 description 1
- HSUCYMJBFHBMTB-UHFFFAOYSA-N 3-fluoro-2-methylbenzaldehyde Chemical compound CC1=C(F)C=CC=C1C=O HSUCYMJBFHBMTB-UHFFFAOYSA-N 0.000 description 1
- IBKNUJGSSUDSSJ-UHFFFAOYSA-N 3-fluoro-5-methoxybenzaldehyde Chemical compound COC1=CC(F)=CC(C=O)=C1 IBKNUJGSSUDSSJ-UHFFFAOYSA-N 0.000 description 1
- PIKNVEVCWAAOMJ-UHFFFAOYSA-N 3-fluorobenzaldehyde Chemical compound FC1=CC=CC(C=O)=C1 PIKNVEVCWAAOMJ-UHFFFAOYSA-N 0.000 description 1
- 125000003682 3-furyl group Chemical group O1C([H])=C([*])C([H])=C1[H] 0.000 description 1
- NOBKCEXLDDGYID-UHFFFAOYSA-N 3-propan-2-yloxybenzaldehyde Chemical compound CC(C)OC1=CC=CC(C=O)=C1 NOBKCEXLDDGYID-UHFFFAOYSA-N 0.000 description 1
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 description 1
- HKEQMVXZDQLSDY-UHFFFAOYSA-N 3-tert-butylbenzaldehyde Chemical compound CC(C)(C)C1=CC=CC(C=O)=C1 HKEQMVXZDQLSDY-UHFFFAOYSA-N 0.000 description 1
- 125000001541 3-thienyl group Chemical group S1C([H])=C([*])C([H])=C1[H] 0.000 description 1
- PDJZOFLRRJQYBF-UHFFFAOYSA-N 4-(aminomethyl)-n,n-dimethylaniline Chemical compound CN(C)C1=CC=C(CN)C=C1 PDJZOFLRRJQYBF-UHFFFAOYSA-N 0.000 description 1
- LFIWXXXFJFOECP-UHFFFAOYSA-N 4-(aminomethyl)benzonitrile Chemical compound NCC1=CC=C(C#N)C=C1 LFIWXXXFJFOECP-UHFFFAOYSA-N 0.000 description 1
- XQNVDQZWOBPLQZ-UHFFFAOYSA-N 4-(trifluoromethoxy)benzaldehyde Chemical compound FC(F)(F)OC1=CC=C(C=O)C=C1 XQNVDQZWOBPLQZ-UHFFFAOYSA-N 0.000 description 1
- BEOBZEOPTQQELP-UHFFFAOYSA-N 4-(trifluoromethyl)benzaldehyde Chemical compound FC(F)(F)C1=CC=C(C=O)C=C1 BEOBZEOPTQQELP-UHFFFAOYSA-N 0.000 description 1
- VWSFZYXXQDKXKQ-UHFFFAOYSA-N 4-[(2-methylpropan-2-yl)oxy]benzaldehyde Chemical compound CC(C)(C)OC1=CC=C(C=O)C=C1 VWSFZYXXQDKXKQ-UHFFFAOYSA-N 0.000 description 1
- VJPPLCNBDLZIFG-ZDUSSCGKSA-N 4-[(3S)-3-(but-2-ynoylamino)piperidin-1-yl]-5-fluoro-2,3-dimethyl-1H-indole-7-carboxamide Chemical compound C(C#CC)(=O)N[C@@H]1CN(CCC1)C1=C2C(=C(NC2=C(C=C1F)C(=O)N)C)C VJPPLCNBDLZIFG-ZDUSSCGKSA-N 0.000 description 1
- UEFHAPYDMRIRPQ-WJOKGBTCSA-N 4-[2-[[2,3-dimethyl-5-[[(1r)-1-phenylpropyl]carbamoyl]indol-1-yl]methyl]phenyl]benzoic acid Chemical compound N([C@H](CC)C=1C=CC=CC=1)C(=O)C(C=C1C(C)=C2C)=CC=C1N2CC1=CC=CC=C1C1=CC=C(C(O)=O)C=C1 UEFHAPYDMRIRPQ-WJOKGBTCSA-N 0.000 description 1
- UEFHAPYDMRIRPQ-HKBQPEDESA-N 4-[2-[[2,3-dimethyl-5-[[(1s)-1-phenylpropyl]carbamoyl]indol-1-yl]methyl]phenyl]benzoic acid Chemical compound N([C@@H](CC)C=1C=CC=CC=1)C(=O)C(C=C1C(C)=C2C)=CC=C1N2CC1=CC=CC=C1C1=CC=C(C(O)=O)C=C1 UEFHAPYDMRIRPQ-HKBQPEDESA-N 0.000 description 1
- ONKNVTVXRZIDCU-GDLZYMKVSA-N 4-[2-[[5-[[(1r)-1-phenylpropyl]carbamoyl]indol-1-yl]methyl]phenyl]benzoic acid Chemical compound N([C@H](CC)C=1C=CC=CC=1)C(=O)C(C=C1C=C2)=CC=C1N2CC1=CC=CC=C1C1=CC=C(C(O)=O)C=C1 ONKNVTVXRZIDCU-GDLZYMKVSA-N 0.000 description 1
- ONKNVTVXRZIDCU-LJAQVGFWSA-N 4-[2-[[5-[[(1s)-1-phenylpropyl]carbamoyl]indol-1-yl]methyl]phenyl]benzoic acid Chemical compound N([C@@H](CC)C=1C=CC=CC=1)C(=O)C(C=C1C=C2)=CC=C1N2CC1=CC=CC=C1C1=CC=C(C(O)=O)C=C1 ONKNVTVXRZIDCU-LJAQVGFWSA-N 0.000 description 1
- YFCIFWOJYYFDQP-PTWZRHHISA-N 4-[3-amino-6-[(1S,3S,4S)-3-fluoro-4-hydroxycyclohexyl]pyrazin-2-yl]-N-[(1S)-1-(3-bromo-5-fluorophenyl)-2-(methylamino)ethyl]-2-fluorobenzamide Chemical compound CNC[C@@H](NC(=O)c1ccc(cc1F)-c1nc(cnc1N)[C@H]1CC[C@H](O)[C@@H](F)C1)c1cc(F)cc(Br)c1 YFCIFWOJYYFDQP-PTWZRHHISA-N 0.000 description 1
- BOBPGICNSWQEMK-FQEVSTJZSA-N 4-[4-[[5-[[(1s)-1-(4-nitrophenyl)ethyl]carbamoyl]indol-1-yl]methyl]phenyl]benzoic acid Chemical compound N([C@@H](C)C=1C=CC(=CC=1)[N+]([O-])=O)C(=O)C(C=C1C=C2)=CC=C1N2CC(C=C1)=CC=C1C1=CC=C(C(O)=O)C=C1 BOBPGICNSWQEMK-FQEVSTJZSA-N 0.000 description 1
- XYWIPYBIIRTJMM-IBGZPJMESA-N 4-[[(2S)-2-[4-[5-chloro-2-[4-(trifluoromethyl)triazol-1-yl]phenyl]-5-methoxy-2-oxopyridin-1-yl]butanoyl]amino]-2-fluorobenzamide Chemical compound CC[C@H](N1C=C(OC)C(=CC1=O)C1=C(C=CC(Cl)=C1)N1C=C(N=N1)C(F)(F)F)C(=O)NC1=CC(F)=C(C=C1)C(N)=O XYWIPYBIIRTJMM-IBGZPJMESA-N 0.000 description 1
- 125000004800 4-bromophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Br 0.000 description 1
- NIHMMULLFBKTOK-UHFFFAOYSA-N 4-chloro-3-(trifluoromethyl)benzaldehyde Chemical compound FC(F)(F)C1=CC(C=O)=CC=C1Cl NIHMMULLFBKTOK-UHFFFAOYSA-N 0.000 description 1
- NZLNQSUMFSPISS-UHFFFAOYSA-N 4-chloropyridine-2-carbaldehyde Chemical compound ClC1=CC=NC(C=O)=C1 NZLNQSUMFSPISS-UHFFFAOYSA-N 0.000 description 1
- 125000005274 4-hydroxybenzoic acid group Chemical group 0.000 description 1
- ICGLPKIVTVWCFT-UHFFFAOYSA-N 4-methylbenzenesulfonohydrazide Chemical compound CC1=CC=C(S(=O)(=O)NN)C=C1 ICGLPKIVTVWCFT-UHFFFAOYSA-N 0.000 description 1
- PSVPUHBSBYJSMQ-UHFFFAOYSA-N 4-methylsulfonylbenzaldehyde Chemical compound CS(=O)(=O)C1=CC=C(C=O)C=C1 PSVPUHBSBYJSMQ-UHFFFAOYSA-N 0.000 description 1
- JXRGUPLJCCDGKG-UHFFFAOYSA-N 4-nitrobenzenesulfonyl chloride Chemical compound [O-][N+](=O)C1=CC=C(S(Cl)(=O)=O)C=C1 JXRGUPLJCCDGKG-UHFFFAOYSA-N 0.000 description 1
- SKDHHIUENRGTHK-UHFFFAOYSA-N 4-nitrobenzoyl chloride Chemical compound [O-][N+](=O)C1=CC=C(C(Cl)=O)C=C1 SKDHHIUENRGTHK-UHFFFAOYSA-N 0.000 description 1
- OZRGLPAXIYOWIG-HZPUXBNGSA-N 4-nitrobenzylamine Chemical compound CC(C)C(CC[C@@H](C)[C@H]1CC[C@H]2[C@@H]3CCC4=CCCC[C@]4(C)[C@H]3CC[C@]12C)=O OZRGLPAXIYOWIG-HZPUXBNGSA-N 0.000 description 1
- WECUIGDEWBNQJJ-UHFFFAOYSA-N 4-phenylbutan-2-amine Chemical compound CC(N)CCC1=CC=CC=C1 WECUIGDEWBNQJJ-UHFFFAOYSA-N 0.000 description 1
- WDANSDASCKBVKH-UHFFFAOYSA-N 4-propan-2-yloxybenzaldehyde Chemical compound CC(C)OC1=CC=C(C=O)C=C1 WDANSDASCKBVKH-UHFFFAOYSA-N 0.000 description 1
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 description 1
- KDDQRKBRJSGMQE-UHFFFAOYSA-N 4-thiazolyl Chemical group [C]1=CSC=N1 KDDQRKBRJSGMQE-UHFFFAOYSA-N 0.000 description 1
- YJOULMMJZAADRY-UHFFFAOYSA-N 5-(bromomethyl)-2-chloropyridine Chemical compound ClC1=CC=C(CBr)C=N1 YJOULMMJZAADRY-UHFFFAOYSA-N 0.000 description 1
- NKOHRVBBQISBSB-UHFFFAOYSA-N 5-[(4-hydroxyphenyl)methyl]-1,3-thiazolidine-2,4-dione Chemical compound C1=CC(O)=CC=C1CC1C(=O)NC(=O)S1 NKOHRVBBQISBSB-UHFFFAOYSA-N 0.000 description 1
- IRPVABHDSJVBNZ-RTHVDDQRSA-N 5-[1-(cyclopropylmethyl)-5-[(1R,5S)-3-(oxetan-3-yl)-3-azabicyclo[3.1.0]hexan-6-yl]pyrazol-3-yl]-3-(trifluoromethyl)pyridin-2-amine Chemical compound C1=C(C(F)(F)F)C(N)=NC=C1C1=NN(CC2CC2)C(C2[C@@H]3CN(C[C@@H]32)C2COC2)=C1 IRPVABHDSJVBNZ-RTHVDDQRSA-N 0.000 description 1
- 125000004539 5-benzimidazolyl group Chemical group N1=CNC2=C1C=CC(=C2)* 0.000 description 1
- ZQVLPMNLLKGGIU-UHFFFAOYSA-N 5-bromopyridine-2-carbaldehyde Chemical compound BrC1=CC=C(C=O)N=C1 ZQVLPMNLLKGGIU-UHFFFAOYSA-N 0.000 description 1
- CWDWFSXUQODZGW-UHFFFAOYSA-N 5-thiazolyl Chemical group [C]1=CN=CS1 CWDWFSXUQODZGW-UHFFFAOYSA-N 0.000 description 1
- LCGTWRLJTMHIQZ-UHFFFAOYSA-N 5H-dibenzo[b,f]azepine Chemical compound C1=CC2=CC=CC=C2NC2=CC=CC=C21 LCGTWRLJTMHIQZ-UHFFFAOYSA-N 0.000 description 1
- ZSMRRZONCYIFNB-UHFFFAOYSA-N 6,11-dihydro-5h-benzo[b][1]benzazepine Chemical compound C1CC2=CC=CC=C2NC2=CC=CC=C12 ZSMRRZONCYIFNB-UHFFFAOYSA-N 0.000 description 1
- KCBWAFJCKVKYHO-UHFFFAOYSA-N 6-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-1-[[4-[1-propan-2-yl-4-(trifluoromethyl)imidazol-2-yl]phenyl]methyl]pyrazolo[3,4-d]pyrimidine Chemical compound C1(CC1)C1=NC=NC(=C1C1=NC=C2C(=N1)N(N=C2)CC1=CC=C(C=C1)C=1N(C=C(N=1)C(F)(F)F)C(C)C)OC KCBWAFJCKVKYHO-UHFFFAOYSA-N 0.000 description 1
- MRPAGRCGPAXOGS-UHFFFAOYSA-N 6-(trifluoromethyl)pyridine-3-carbaldehyde Chemical compound FC(F)(F)C1=CC=C(C=O)C=N1 MRPAGRCGPAXOGS-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- ZRPZPNYZFSJUPA-UHFFFAOYSA-N ARS-1620 Chemical compound Oc1cccc(F)c1-c1c(Cl)cc2c(ncnc2c1F)N1CCN(CC1)C(=O)C=C ZRPZPNYZFSJUPA-UHFFFAOYSA-N 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 102100021253 Antileukoproteinase Human genes 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 1
- 241000237519 Bivalvia Species 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- 238000011746 C57BL/6J (JAX™ mouse strain) Methods 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 1
- 206010007572 Cardiac hypertrophy Diseases 0.000 description 1
- 208000006029 Cardiomegaly Diseases 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- KZBUYRJDOAKODT-UHFFFAOYSA-N Chlorine Chemical compound ClCl KZBUYRJDOAKODT-UHFFFAOYSA-N 0.000 description 1
- AEMOLEFTQBMNLQ-YMDCURPLSA-N D-galactopyranuronic acid Chemical compound OC1O[C@H](C(O)=O)[C@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-YMDCURPLSA-N 0.000 description 1
- 230000004568 DNA-binding Effects 0.000 description 1
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- GISRWBROCYNDME-PELMWDNLSA-N F[C@H]1[C@H]([C@H](NC1=O)COC1=NC=CC2=CC(=C(C=C12)OC)C(=O)N)C Chemical compound F[C@H]1[C@H]([C@H](NC1=O)COC1=NC=CC2=CC(=C(C=C12)OC)C(=O)N)C GISRWBROCYNDME-PELMWDNLSA-N 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- YCKRFDGAMUMZLT-UHFFFAOYSA-N Fluorine atom Chemical compound [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 description 1
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical group NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 1
- DSLZVSRJTYRBFB-UHFFFAOYSA-N Galactaric acid Natural products OC(=O)C(O)C(O)C(O)C(O)C(O)=O DSLZVSRJTYRBFB-UHFFFAOYSA-N 0.000 description 1
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 241001272567 Hominoidea Species 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000741788 Homo sapiens Peroxisome proliferator-activated receptor alpha Proteins 0.000 description 1
- 206010022489 Insulin Resistance Diseases 0.000 description 1
- 229940122355 Insulin sensitizer Drugs 0.000 description 1
- 208000003263 MASS syndrome Diseases 0.000 description 1
- TYMRLRRVMHJFTF-UHFFFAOYSA-N Mafenide Chemical compound NCC1=CC=C(S(N)(=O)=O)C=C1 TYMRLRRVMHJFTF-UHFFFAOYSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- FEYNFHSRETUBEM-UHFFFAOYSA-N N-[3-(1,1-difluoroethyl)phenyl]-1-(4-methoxyphenyl)-3-methyl-5-oxo-4H-pyrazole-4-carboxamide Chemical compound COc1ccc(cc1)N1N=C(C)C(C(=O)Nc2cccc(c2)C(C)(F)F)C1=O FEYNFHSRETUBEM-UHFFFAOYSA-N 0.000 description 1
- CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 description 1
- XTUVJUMINZSXGF-UHFFFAOYSA-N N-methylcyclohexylamine Chemical compound CNC1CCCCC1 XTUVJUMINZSXGF-UHFFFAOYSA-N 0.000 description 1
- 150000001204 N-oxides Chemical group 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- JCXJVPUVTGWSNB-UHFFFAOYSA-N Nitrogen dioxide Chemical compound O=[N]=O JCXJVPUVTGWSNB-UHFFFAOYSA-N 0.000 description 1
- IDRGFNPZDVBSSE-UHFFFAOYSA-N OCCN1CCN(CC1)c1ccc(Nc2ncc3cccc(-c4cccc(NC(=O)C=C)c4)c3n2)c(F)c1F Chemical compound OCCN1CCN(CC1)c1ccc(Nc2ncc3cccc(-c4cccc(NC(=O)C=C)c4)c3n2)c(F)c1F IDRGFNPZDVBSSE-UHFFFAOYSA-N 0.000 description 1
- 229910004679 ONO2 Inorganic materials 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 229910019213 POCl3 Inorganic materials 0.000 description 1
- 102000023984 PPAR alpha Human genes 0.000 description 1
- 108010044210 PPAR-beta Proteins 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 102100038831 Peroxisome proliferator-activated receptor alpha Human genes 0.000 description 1
- 229940080774 Peroxisome proliferator-activated receptor gamma agonist Drugs 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 206010034960 Photophobia Diseases 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- YZCKVEUIGOORGS-IGMARMGPSA-N Protium Chemical compound [1H] YZCKVEUIGOORGS-IGMARMGPSA-N 0.000 description 1
- 241000720974 Protium Species 0.000 description 1
- AXORVIZLPOGIRG-QMMMGPOBSA-N R-BETA-METHYLPHENYLETHYLAMINE Chemical compound NC[C@H](C)C1=CC=CC=C1 AXORVIZLPOGIRG-QMMMGPOBSA-N 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-N Salicylic acid Natural products OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 1
- 206010070834 Sensitisation Diseases 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical class [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 1
- 229910052771 Terbium Inorganic materials 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- LXRZVMYMQHNYJB-UNXOBOICSA-N [(1R,2S,4R)-4-[[5-[4-[(1R)-7-chloro-1,2,3,4-tetrahydroisoquinolin-1-yl]-5-methylthiophene-2-carbonyl]pyrimidin-4-yl]amino]-2-hydroxycyclopentyl]methyl sulfamate Chemical compound CC1=C(C=C(S1)C(=O)C1=C(N[C@H]2C[C@H](O)[C@@H](COS(N)(=O)=O)C2)N=CN=C1)[C@@H]1NCCC2=C1C=C(Cl)C=C2 LXRZVMYMQHNYJB-UNXOBOICSA-N 0.000 description 1
- NOSUUZVVUGUJAI-HNCPQSOCSA-N [(1r)-2,2,2-trifluoro-1-(3-propan-2-ylphenyl)ethyl]azanium;chloride Chemical compound [Cl-].CC(C)C1=CC=CC([C@@H]([NH3+])C(F)(F)F)=C1 NOSUUZVVUGUJAI-HNCPQSOCSA-N 0.000 description 1
- MPTGUFFHOKLEFK-RGMNGODLSA-N [(1s)-1-(2-bromophenyl)ethyl]azanium;chloride Chemical compound [Cl-].C[C@H]([NH3+])C1=CC=CC=C1Br MPTGUFFHOKLEFK-RGMNGODLSA-N 0.000 description 1
- ULKTXCALVGWPAB-QRPNPIFTSA-N [(1s)-1-(2-ethylphenyl)ethyl]azanium;chloride Chemical compound [Cl-].CCC1=CC=CC=C1[C@H](C)[NH3+] ULKTXCALVGWPAB-QRPNPIFTSA-N 0.000 description 1
- OHXINJPCMHFDMO-FVGYRXGTSA-N [(1s)-1-(2-propan-2-yloxyphenyl)ethyl]azanium;chloride Chemical compound [Cl-].CC(C)OC1=CC=CC=C1[C@H](C)[NH3+] OHXINJPCMHFDMO-FVGYRXGTSA-N 0.000 description 1
- YUPSTPMVIYAHMF-FJXQXJEOSA-N [(1s)-1-(3,5-dimethoxyphenyl)ethyl]azanium;chloride Chemical compound [Cl-].COC1=CC(OC)=CC([C@H](C)[NH3+])=C1 YUPSTPMVIYAHMF-FJXQXJEOSA-N 0.000 description 1
- WVEQNNWSAFCZKG-FJXQXJEOSA-N [(1s)-1-(3-fluoro-2-methylphenyl)ethyl]azanium;chloride Chemical compound [Cl-].C[C@H]([NH3+])C1=CC=CC(F)=C1C WVEQNNWSAFCZKG-FJXQXJEOSA-N 0.000 description 1
- CJGPMYYFSGLGKL-RGMNGODLSA-N [(1s)-1-(3-fluoro-5-methoxyphenyl)ethyl]azanium;chloride Chemical compound [Cl-].COC1=CC(F)=CC([C@H](C)[NH3+])=C1 CJGPMYYFSGLGKL-RGMNGODLSA-N 0.000 description 1
- PCKDVJLFIMJMIL-UQKRIMTDSA-N [(1s)-1-(3-propan-2-ylphenyl)pentyl]azanium;chloride Chemical compound [Cl-].CCCC[C@H]([NH3+])C1=CC=CC(C(C)C)=C1 PCKDVJLFIMJMIL-UQKRIMTDSA-N 0.000 description 1
- SWFKPUQRJHGZGE-QRPNPIFTSA-N [(1s)-1-(4-ethoxyphenyl)ethyl]azanium;chloride Chemical compound [Cl-].CCOC1=CC=C([C@H](C)[NH3+])C=C1 SWFKPUQRJHGZGE-QRPNPIFTSA-N 0.000 description 1
- ZYIJBTMIEVKCJK-FVGYRXGTSA-N [(1s)-1-(4-propylphenyl)ethyl]azanium;chloride Chemical compound [Cl-].CCCC1=CC=C([C@H](C)[NH3+])C=C1 ZYIJBTMIEVKCJK-FVGYRXGTSA-N 0.000 description 1
- OUMFYUXGADRZSB-RGMNGODLSA-N [(1s)-1-[2-(trifluoromethoxy)phenyl]ethyl]azanium;chloride Chemical compound [Cl-].C[C@H]([NH3+])C1=CC=CC=C1OC(F)(F)F OUMFYUXGADRZSB-RGMNGODLSA-N 0.000 description 1
- UATMHMOADFFCDU-LMOVPXPDSA-N [(1s)-2-phenyl-1-(3-propan-2-ylphenyl)ethyl]azanium;chloride Chemical compound [Cl-].CC(C)C1=CC=CC([C@@H]([NH3+])CC=2C=CC=CC=2)=C1 UATMHMOADFFCDU-LMOVPXPDSA-N 0.000 description 1
- QTWVDSDXMXHIPC-ZOWNYOTGSA-N [(s)-cyclopropyl-(3-propan-2-ylphenyl)methyl]azanium;chloride Chemical compound [Cl-].CC(C)C1=CC=CC([C@@H]([NH3+])C2CC2)=C1 QTWVDSDXMXHIPC-ZOWNYOTGSA-N 0.000 description 1
- AFHOBSCDNXGFMO-UHFFFAOYSA-N [2-(hydroxymethyl)phenyl]boronic acid Chemical compound OCC1=CC=CC=C1B(O)O AFHOBSCDNXGFMO-UHFFFAOYSA-N 0.000 description 1
- NGCHASOIZPPFBK-UHFFFAOYSA-N [2-[(2-methylpropan-2-yl)oxycarbonyl]phenyl]boronic acid Chemical compound CC(C)(C)OC(=O)C1=CC=CC=C1B(O)O NGCHASOIZPPFBK-UHFFFAOYSA-N 0.000 description 1
- MQTBAGAVFDZXKF-UHFFFAOYSA-N [2-fluoro-4-(trifluoromethyl)phenyl]methanamine Chemical compound NCC1=CC=C(C(F)(F)F)C=C1F MQTBAGAVFDZXKF-UHFFFAOYSA-N 0.000 description 1
- YWZCOYQPEZBEOE-UHFFFAOYSA-N [3-(aminomethyl)phenyl]boronic acid Chemical compound NCC1=CC=CC(B(O)O)=C1 YWZCOYQPEZBEOE-UHFFFAOYSA-N 0.000 description 1
- YKNZTUQUXUXTLE-UHFFFAOYSA-N [3-(trifluoromethyl)phenyl]methanamine Chemical compound NCC1=CC=CC(C(F)(F)F)=C1 YKNZTUQUXUXTLE-UHFFFAOYSA-N 0.000 description 1
- HVJDVHCPCSZDSR-UHFFFAOYSA-N [3-[(2-methylpropan-2-yl)oxycarbonyl]phenyl]boronic acid Chemical compound CC(C)(C)OC(=O)C1=CC=CC(B(O)O)=C1 HVJDVHCPCSZDSR-UHFFFAOYSA-N 0.000 description 1
- DBGROTRFYBSUTR-UHFFFAOYSA-N [4-(trifluoromethoxy)phenyl]methanamine Chemical compound NCC1=CC=C(OC(F)(F)F)C=C1 DBGROTRFYBSUTR-UHFFFAOYSA-N 0.000 description 1
- PRDBLLIPPDOICK-UHFFFAOYSA-N [4-(trifluoromethyl)phenyl]methanamine Chemical compound NCC1=CC=C(C(F)(F)F)C=C1 PRDBLLIPPDOICK-UHFFFAOYSA-N 0.000 description 1
- VPKIGWHSTBKRTA-UHFFFAOYSA-N [4-chloro-2-(trifluoromethyl)phenyl]methanamine Chemical compound NCC1=CC=C(Cl)C=C1C(F)(F)F VPKIGWHSTBKRTA-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 125000000641 acridinyl group Chemical group C1(=CC=CC2=NC3=CC=CC=C3C=C12)* 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 230000011759 adipose tissue development Effects 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 150000001342 alkaline earth metals Chemical class 0.000 description 1
- 150000003973 alkyl amines Chemical class 0.000 description 1
- 125000003282 alkyl amino group Chemical group 0.000 description 1
- 125000005336 allyloxy group Chemical group 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- BIVUUOPIAYRCAP-UHFFFAOYSA-N aminoazanium;chloride Chemical compound Cl.NN BIVUUOPIAYRCAP-UHFFFAOYSA-N 0.000 description 1
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 210000003484 anatomy Anatomy 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 150000003974 aralkylamines Chemical class 0.000 description 1
- 150000004982 aromatic amines Chemical class 0.000 description 1
- 239000012131 assay buffer Substances 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 150000001540 azides Chemical class 0.000 description 1
- 125000000852 azido group Chemical group *N=[N+]=[N-] 0.000 description 1
- 125000003828 azulenyl group Chemical group 0.000 description 1
- 238000005452 bending Methods 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- JUHORIMYRDESRB-UHFFFAOYSA-N benzathine Chemical compound C=1C=CC=CC=1CNCCNCC1=CC=CC=C1 JUHORIMYRDESRB-UHFFFAOYSA-N 0.000 description 1
- 150000001556 benzimidazoles Chemical class 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid group Chemical group C(C1=CC=CC=C1)(=O)O WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- PASDCCFISLVPSO-UHFFFAOYSA-N benzoyl chloride Chemical compound ClC(=O)C1=CC=CC=C1 PASDCCFISLVPSO-UHFFFAOYSA-N 0.000 description 1
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 1
- KWDNXTGQVTUNDF-STEACBGWSA-N benzyl (2r)-2-[(1s)-1-aminoethyl]pyrrolidine-1-carboxylate;hydrochloride Chemical compound Cl.C[C@H](N)[C@H]1CCCN1C(=O)OCC1=CC=CC=C1 KWDNXTGQVTUNDF-STEACBGWSA-N 0.000 description 1
- KWDNXTGQVTUNDF-JZKFLRDJSA-N benzyl (2s)-2-[(1s)-1-aminoethyl]pyrrolidine-1-carboxylate;hydrochloride Chemical compound Cl.C[C@H](N)[C@@H]1CCCN1C(=O)OCC1=CC=CC=C1 KWDNXTGQVTUNDF-JZKFLRDJSA-N 0.000 description 1
- RABRDQRRPPKICE-STEACBGWSA-N benzyl (3r)-3-[(1s)-1-aminoethyl]pyrrolidine-1-carboxylate;hydrochloride Chemical compound Cl.C1[C@H]([C@@H](N)C)CCN1C(=O)OCC1=CC=CC=C1 RABRDQRRPPKICE-STEACBGWSA-N 0.000 description 1
- FPXJNSKAXZNWMQ-NSHDSACASA-N benzyl (3s)-3-aminopyrrolidine-1-carboxylate Chemical compound C1[C@@H](N)CCN1C(=O)OCC1=CC=CC=C1 FPXJNSKAXZNWMQ-NSHDSACASA-N 0.000 description 1
- ZJQMLJFHCKTCSF-UHFFFAOYSA-N benzyl 4-formylpiperidine-1-carboxylate Chemical compound C1CC(C=O)CCN1C(=O)OCC1=CC=CC=C1 ZJQMLJFHCKTCSF-UHFFFAOYSA-N 0.000 description 1
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 description 1
- 238000004166 bioassay Methods 0.000 description 1
- 125000002529 biphenylenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3C12)* 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 230000014461 bone development Effects 0.000 description 1
- 230000008468 bone growth Effects 0.000 description 1
- 230000004097 bone metabolism Effects 0.000 description 1
- 230000010478 bone regeneration Effects 0.000 description 1
- 230000037118 bone strength Effects 0.000 description 1
- 230000008416 bone turnover Effects 0.000 description 1
- 238000005893 bromination reaction Methods 0.000 description 1
- 230000005587 bubbling Effects 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 239000007978 cacodylate buffer Substances 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 238000007707 calorimetry Methods 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 125000000609 carbazolyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3NC12)* 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 150000003857 carboxamides Chemical class 0.000 description 1
- 125000005518 carboxamido group Chemical group 0.000 description 1
- 150000007942 carboxylates Chemical class 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 238000000423 cell based assay Methods 0.000 description 1
- DGLFSNZWRYADFC-UHFFFAOYSA-N chembl2334586 Chemical compound C1CCC2=CN=C(N)N=C2C2=C1NC1=CC=C(C#CC(C)(O)C)C=C12 DGLFSNZWRYADFC-UHFFFAOYSA-N 0.000 description 1
- 125000003636 chemical group Chemical group 0.000 description 1
- 150000003841 chloride salts Chemical class 0.000 description 1
- VDANGULDQQJODZ-UHFFFAOYSA-N chloroprocaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1Cl VDANGULDQQJODZ-UHFFFAOYSA-N 0.000 description 1
- 229960002023 chloroprocaine Drugs 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 125000002676 chrysenyl group Chemical group C1(=CC=CC=2C3=CC=C4C=CC=CC4=C3C=CC12)* 0.000 description 1
- 235000020639 clam Nutrition 0.000 description 1
- 238000012875 competitive assay Methods 0.000 description 1
- 238000013170 computed tomography imaging Methods 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 150000001913 cyanates Chemical class 0.000 description 1
- WZHCOOQXZCIUNC-UHFFFAOYSA-N cyclandelate Chemical compound C1C(C)(C)CC(C)CC1OC(=O)C(O)C1=CC=CC=C1 WZHCOOQXZCIUNC-UHFFFAOYSA-N 0.000 description 1
- 125000004367 cycloalkylaryl group Chemical group 0.000 description 1
- KZZKOVLJUKWSKX-UHFFFAOYSA-N cyclobutanamine Chemical compound NC1CCC1 KZZKOVLJUKWSKX-UHFFFAOYSA-N 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- DEZRYPDIMOWBDS-UHFFFAOYSA-N dcm dichloromethane Chemical compound ClCCl.ClCCl DEZRYPDIMOWBDS-UHFFFAOYSA-N 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 238000000151 deposition Methods 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 229910052805 deuterium Inorganic materials 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 125000004663 dialkyl amino group Chemical group 0.000 description 1
- 125000005265 dialkylamine group Chemical group 0.000 description 1
- 125000005266 diarylamine group Chemical group 0.000 description 1
- JGFBRKRYDCGYKD-UHFFFAOYSA-N dibutyl(oxo)tin Chemical compound CCCC[Sn](=O)CCCC JGFBRKRYDCGYKD-UHFFFAOYSA-N 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- 229940043237 diethanolamine Drugs 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 150000004683 dihydrates Chemical class 0.000 description 1
- 125000000723 dihydrobenzofuranyl group Chemical group O1C(CC2=C1C=CC=C2)* 0.000 description 1
- 125000001070 dihydroindolyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 description 1
- SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 description 1
- UXGNZZKBCMGWAZ-UHFFFAOYSA-N dimethylformamide dmf Chemical compound CN(C)C=O.CN(C)C=O UXGNZZKBCMGWAZ-UHFFFAOYSA-N 0.000 description 1
- 125000005879 dioxolanyl group Chemical group 0.000 description 1
- ZZVUWRFHKOJYTH-UHFFFAOYSA-N diphenhydramine Chemical group C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 ZZVUWRFHKOJYTH-UHFFFAOYSA-N 0.000 description 1
- MGHPNCMVUAKAIE-UHFFFAOYSA-N diphenylmethanamine Chemical compound C=1C=CC=CC=1C(N)C1=CC=CC=C1 MGHPNCMVUAKAIE-UHFFFAOYSA-N 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- CETRZFQIITUQQL-UHFFFAOYSA-N dmso dimethylsulfoxide Chemical compound CS(C)=O.CS(C)=O CETRZFQIITUQQL-UHFFFAOYSA-N 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 229940127004 drugs for type 2 diabetes Drugs 0.000 description 1
- 230000004821 effect on bone Effects 0.000 description 1
- 150000002081 enamines Chemical class 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 201000010063 epididymitis Diseases 0.000 description 1
- 125000003700 epoxy group Chemical group 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- OLAMWIPURJGSKE-UHFFFAOYSA-N et2o diethylether Chemical compound CCOCC.CCOCC OLAMWIPURJGSKE-UHFFFAOYSA-N 0.000 description 1
- 125000001033 ether group Chemical group 0.000 description 1
- MEHJPIZYFYNEQT-UHFFFAOYSA-N ethyl 1-[(2,4-difluorophenyl)methyl]-2,3-dimethylindole-5-carboxylate Chemical compound CC1=C(C)C2=CC(C(=O)OCC)=CC=C2N1CC1=CC=C(F)C=C1F MEHJPIZYFYNEQT-UHFFFAOYSA-N 0.000 description 1
- OTOKFRDFVDUDGJ-QHCPKHFHSA-N ethyl 3-[2-[[5-[[(1s)-1-(4-bromophenyl)ethyl]carbamoyl]-2,3-dimethylindol-1-yl]methyl]phenyl]benzoate Chemical compound CCOC(=O)C1=CC=CC(C=2C(=CC=CC=2)CN2C3=CC=C(C=C3C(C)=C2C)C(=O)N[C@@H](C)C=2C=CC(Br)=CC=2)=C1 OTOKFRDFVDUDGJ-QHCPKHFHSA-N 0.000 description 1
- UAQKGWCORQEAAL-QHCPKHFHSA-N ethyl 4-[2-[[5-[[(1s)-1-(4-bromophenyl)ethyl]carbamoyl]-2,3-dimethylindol-1-yl]methyl]phenyl]benzoate Chemical compound C1=CC(C(=O)OCC)=CC=C1C1=CC=CC=C1CN1C2=CC=C(C(=O)N[C@@H](C)C=3C=CC(Br)=CC=3)C=C2C(C)=C1C UAQKGWCORQEAAL-QHCPKHFHSA-N 0.000 description 1
- XZIAFENWXIQIKR-UHFFFAOYSA-N ethyl 4-bromobenzoate Chemical compound CCOC(=O)C1=CC=C(Br)C=C1 XZIAFENWXIQIKR-UHFFFAOYSA-N 0.000 description 1
- 229940012017 ethylenediamine Drugs 0.000 description 1
- OJCSPXHYDFONPU-UHFFFAOYSA-N etoac etoac Chemical compound CCOC(C)=O.CCOC(C)=O OJCSPXHYDFONPU-UHFFFAOYSA-N 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- DSLZVSRJTYRBFB-DUHBMQHGSA-N galactaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)C(O)=O DSLZVSRJTYRBFB-DUHBMQHGSA-N 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 230000004153 glucose metabolism Effects 0.000 description 1
- 150000002357 guanidines Chemical class 0.000 description 1
- 150000004820 halides Chemical class 0.000 description 1
- 125000005252 haloacyl group Chemical group 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 125000002192 heptalenyl group Chemical group 0.000 description 1
- 150000002391 heterocyclic compounds Chemical group 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 229940042795 hydrazides for tuberculosis treatment Drugs 0.000 description 1
- 150000007857 hydrazones Chemical class 0.000 description 1
- 238000005984 hydrogenation reaction Methods 0.000 description 1
- 125000004356 hydroxy functional group Chemical group O* 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 1
- 150000002443 hydroxylamines Chemical group 0.000 description 1
- 230000003345 hyperglycaemic effect Effects 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 238000003709 image segmentation Methods 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 150000003949 imides Chemical class 0.000 description 1
- 125000001841 imino group Chemical group [H]N=* 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 125000003427 indacenyl group Chemical group 0.000 description 1
- 125000003454 indenyl group Chemical group C1(C=CC2=CC=CC=C12)* 0.000 description 1
- 150000002473 indoazoles Chemical class 0.000 description 1
- 150000002475 indoles Chemical class 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- YDNLNVZZTACNJX-UHFFFAOYSA-N isocyanatomethylbenzene Chemical compound O=C=NCC1=CC=CC=C1 YDNLNVZZTACNJX-UHFFFAOYSA-N 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000000654 isopropylidene group Chemical group C(C)(C)=* 0.000 description 1
- 125000005956 isoquinolyl group Chemical group 0.000 description 1
- 238000005372 isotope separation Methods 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 208000013469 light sensitivity Diseases 0.000 description 1
- 125000005647 linker group Chemical group 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000000622 liquid--liquid extraction Methods 0.000 description 1
- YNESATAKKCNGOF-UHFFFAOYSA-N lithium bis(trimethylsilyl)amide Chemical compound [Li+].C[Si](C)(C)[N-][Si](C)(C)C YNESATAKKCNGOF-UHFFFAOYSA-N 0.000 description 1
- 229910003002 lithium salt Inorganic materials 0.000 description 1
- 159000000002 lithium salts Chemical class 0.000 description 1
- JMZFEHDNIAQMNB-UHFFFAOYSA-N m-aminophenylboronic acid Chemical compound NC1=CC=CC(B(O)O)=C1 JMZFEHDNIAQMNB-UHFFFAOYSA-N 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- YSMZEMQBSONIMJ-UHFFFAOYSA-M magnesium;2-methanidylpropane;chloride Chemical compound [Mg+2].[Cl-].CC(C)[CH2-] YSMZEMQBSONIMJ-UHFFFAOYSA-M 0.000 description 1
- LWLPYZUDBNFNAH-UHFFFAOYSA-M magnesium;butane;bromide Chemical compound [Mg+2].[Br-].CCC[CH2-] LWLPYZUDBNFNAH-UHFFFAOYSA-M 0.000 description 1
- VFZXMEQGIIWBFJ-UHFFFAOYSA-M magnesium;cyclopropane;bromide Chemical compound [Mg+2].[Br-].C1C[CH-]1 VFZXMEQGIIWBFJ-UHFFFAOYSA-M 0.000 description 1
- FRIJBUGBVQZNTB-UHFFFAOYSA-M magnesium;ethane;bromide Chemical compound [Mg+2].[Br-].[CH2-]C FRIJBUGBVQZNTB-UHFFFAOYSA-M 0.000 description 1
- QGEFGPVWRJCFQP-UHFFFAOYSA-M magnesium;methanidylbenzene;bromide Chemical compound [Mg+2].[Br-].[CH2-]C1=CC=CC=C1 QGEFGPVWRJCFQP-UHFFFAOYSA-M 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 238000013227 male C57BL/6J mice Methods 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 229960003194 meglumine Drugs 0.000 description 1
- COTNUBDHGSIOTA-UHFFFAOYSA-N meoh methanol Chemical compound OC.OC COTNUBDHGSIOTA-UHFFFAOYSA-N 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 235000020938 metabolic status Nutrition 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- HNQIVZYLYMDVSB-UHFFFAOYSA-N methanesulfonimidic acid Chemical compound CS(N)(=O)=O HNQIVZYLYMDVSB-UHFFFAOYSA-N 0.000 description 1
- RUTJNBFJXPAGKK-GMAHTHKFSA-N methyl (2s)-2-[3-[[5-[[(1s)-1-(3-tert-butylphenyl)ethyl]carbamoyl]-2,3-dimethylindol-1-yl]methyl]-4-chlorophenoxy]propanoate Chemical compound COC(=O)[C@H](C)OC1=CC=C(Cl)C(CN2C3=CC=C(C=C3C(C)=C2C)C(=O)N[C@@H](C)C=2C=C(C=CC=2)C(C)(C)C)=C1 RUTJNBFJXPAGKK-GMAHTHKFSA-N 0.000 description 1
- ZAXDVPONEZGRJO-GMAHTHKFSA-N methyl (2s)-2-[5-[[5-[[(1s)-1-(3-tert-butylphenyl)ethyl]carbamoyl]-2,3-dimethylindol-1-yl]methyl]-2-chlorophenoxy]propanoate Chemical compound C1=C(Cl)C(O[C@@H](C)C(=O)OC)=CC(CN2C3=CC=C(C=C3C(C)=C2C)C(=O)N[C@@H](C)C=2C=C(C=CC=2)C(C)(C)C)=C1 ZAXDVPONEZGRJO-GMAHTHKFSA-N 0.000 description 1
- SCUWGXISWDUZEX-QHCPKHFHSA-N methyl 1-[4-[[2,3-dimethyl-5-[[(1s)-1-(3-propan-2-ylphenyl)ethyl]carbamoyl]indol-1-yl]methyl]phenyl]cyclopropane-1-carboxylate Chemical compound C=1C=C(CN2C3=CC=C(C=C3C(C)=C2C)C(=O)N[C@@H](C)C=2C=C(C=CC=2)C(C)C)C=CC=1C1(C(=O)OC)CC1 SCUWGXISWDUZEX-QHCPKHFHSA-N 0.000 description 1
- WBTQQYISPCCLIS-UHFFFAOYSA-N methyl 2-methyl-1h-indole-5-carboxylate Chemical compound COC(=O)C1=CC=C2NC(C)=CC2=C1 WBTQQYISPCCLIS-UHFFFAOYSA-N 0.000 description 1
- YUHSMQQNPRLEEJ-UHFFFAOYSA-N methyl 3-(bromomethyl)benzoate Chemical compound COC(=O)C1=CC=CC(CBr)=C1 YUHSMQQNPRLEEJ-UHFFFAOYSA-N 0.000 description 1
- AQBJGAUQEJFPKZ-UHFFFAOYSA-N methyl 4-(aminomethyl)benzoate Chemical compound COC(=O)C1=CC=C(CN)C=C1 AQBJGAUQEJFPKZ-UHFFFAOYSA-N 0.000 description 1
- 238000001000 micrograph Methods 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 125000006682 monohaloalkyl group Chemical group 0.000 description 1
- 150000004682 monohydrates Chemical class 0.000 description 1
- 125000002757 morpholinyl group Chemical group 0.000 description 1
- FMASTMURQSHELY-UHFFFAOYSA-N n-(4-fluoro-2-methylphenyl)-3-methyl-n-[(2-methyl-1h-indol-4-yl)methyl]pyridine-4-carboxamide Chemical compound C1=CC=C2NC(C)=CC2=C1CN(C=1C(=CC(F)=CC=1)C)C(=O)C1=CC=NC=C1C FMASTMURQSHELY-UHFFFAOYSA-N 0.000 description 1
- MODPXTHGDAFMRM-OAHLLOKOSA-N n-[(1r)-1-(4-bromophenyl)ethyl]-1-[(2,4-difluorophenyl)methyl]indole-5-carboxamide Chemical compound N([C@H](C)C=1C=CC(Br)=CC=1)C(=O)C(C=C1C=C2)=CC=C1N2CC1=CC=C(F)C=C1F MODPXTHGDAFMRM-OAHLLOKOSA-N 0.000 description 1
- SZZWFNJQCDEYQY-QFIPXVFZSA-N n-[(1s)-1-(2-chlorophenyl)ethyl]-1-[[4-(2-cyanophenyl)phenyl]methyl]-2,3-dimethylindole-5-carboxamide Chemical compound N([C@@H](C)C=1C(=CC=CC=1)Cl)C(=O)C(C=C1C(C)=C2C)=CC=C1N2CC(C=C1)=CC=C1C1=CC=CC=C1C#N SZZWFNJQCDEYQY-QFIPXVFZSA-N 0.000 description 1
- JZMYWBMCNQFIHE-QFIPXVFZSA-N n-[(1s)-1-(3-bromophenyl)ethyl]-1-[[4-(2-cyanophenyl)phenyl]methyl]-2,3-dimethylindole-5-carboxamide Chemical compound N([C@@H](C)C=1C=C(Br)C=CC=1)C(=O)C(C=C1C(C)=C2C)=CC=C1N2CC(C=C1)=CC=C1C1=CC=CC=C1C#N JZMYWBMCNQFIHE-QFIPXVFZSA-N 0.000 description 1
- PONOHXBHTVYADA-QFIPXVFZSA-N n-[(1s)-1-(3-chlorophenyl)ethyl]-1-[[4-(2-cyanophenyl)phenyl]methyl]-2,3-dimethylindole-5-carboxamide Chemical compound N([C@@H](C)C=1C=C(Cl)C=CC=1)C(=O)C(C=C1C(C)=C2C)=CC=C1N2CC(C=C1)=CC=C1C1=CC=CC=C1C#N PONOHXBHTVYADA-QFIPXVFZSA-N 0.000 description 1
- IJJRFVLUNWDTTL-VWLOTQADSA-N n-[(1s)-1-(3-tert-butylphenyl)ethyl]-1-[[4-(2-cyanophenyl)phenyl]methyl]-2,3-dimethylindole-5-carboxamide Chemical compound N([C@@H](C)C=1C=C(C=CC=1)C(C)(C)C)C(=O)C(C=C1C(C)=C2C)=CC=C1N2CC(C=C1)=CC=C1C1=CC=CC=C1C#N IJJRFVLUNWDTTL-VWLOTQADSA-N 0.000 description 1
- MODPXTHGDAFMRM-HNNXBMFYSA-N n-[(1s)-1-(4-bromophenyl)ethyl]-1-[(2,4-difluorophenyl)methyl]indole-5-carboxamide Chemical compound N([C@@H](C)C=1C=CC(Br)=CC=1)C(=O)C(C=C1C=C2)=CC=C1N2CC1=CC=C(F)C=C1F MODPXTHGDAFMRM-HNNXBMFYSA-N 0.000 description 1
- FDRYAXGCWYFHHK-NRFANRHFSA-N n-[(1s)-1-(4-bromophenyl)ethyl]-2,3-dimethyl-1-[[4-[2-(2h-tetrazol-5-yl)phenyl]phenyl]methyl]indole-5-carboxamide Chemical compound N([C@@H](C)C=1C=CC(Br)=CC=1)C(=O)C(C=C1C(C)=C2C)=CC=C1N2CC(C=C1)=CC=C1C1=CC=CC=C1C1=NN=NN1 FDRYAXGCWYFHHK-NRFANRHFSA-N 0.000 description 1
- ZNOZTZZFDKROJG-QFIPXVFZSA-N n-[(1s)-1-(4-chlorophenyl)ethyl]-1-[[4-(2-cyanophenyl)phenyl]methyl]-2,3-dimethylindole-5-carboxamide Chemical compound N([C@@H](C)C=1C=CC(Cl)=CC=1)C(=O)C(C=C1C(C)=C2C)=CC=C1N2CC(C=C1)=CC=C1C1=CC=CC=C1C#N ZNOZTZZFDKROJG-QFIPXVFZSA-N 0.000 description 1
- KOPWVPOPACIYDR-QFIPXVFZSA-N n-[(1s)-1-(4-tert-butylphenyl)ethyl]-1-[[3-(cyanomethoxy)phenyl]methyl]-2,3-dimethylindole-5-carboxamide Chemical compound N([C@@H](C)C=1C=CC(=CC=1)C(C)(C)C)C(=O)C(C=C1C(C)=C2C)=CC=C1N2CC1=CC=CC(OCC#N)=C1 KOPWVPOPACIYDR-QFIPXVFZSA-N 0.000 description 1
- UTUDRYVDBFBGFB-VWLOTQADSA-N n-[(1s)-1-(4-tert-butylphenyl)ethyl]-1-[[4-(2-cyanophenyl)phenyl]methyl]-2,3-dimethylindole-5-carboxamide Chemical compound N([C@@H](C)C=1C=CC(=CC=1)C(C)(C)C)C(=O)C(C=C1C(C)=C2C)=CC=C1N2CC(C=C1)=CC=C1C1=CC=CC=C1C#N UTUDRYVDBFBGFB-VWLOTQADSA-N 0.000 description 1
- UNXIJXSXWWHSNU-UHFFFAOYSA-N n-[(4-aminophenyl)methyl]-1-[(2,4-difluorophenyl)methyl]indole-5-carboxamide Chemical compound C1=CC(N)=CC=C1CNC(=O)C1=CC=C(N(CC=2C(=CC(F)=CC=2)F)C=C2)C2=C1 UNXIJXSXWWHSNU-UHFFFAOYSA-N 0.000 description 1
- SEBDQZFHHSFVFV-UHFFFAOYSA-N n-benzyl-1-[(2,4-difluorophenyl)methyl]indole-5-carboxamide Chemical compound FC1=CC(F)=CC=C1CN1C2=CC=C(C(=O)NCC=3C=CC=CC=3)C=C2C=C1 SEBDQZFHHSFVFV-UHFFFAOYSA-N 0.000 description 1
- LDTQNSGLVBQVKQ-UHFFFAOYSA-N n-cyclopentyl-1-[(2,4-difluorophenyl)methyl]indole-5-carboxamide Chemical compound FC1=CC(F)=CC=C1CN1C2=CC=C(C(=O)NC3CCCC3)C=C2C=C1 LDTQNSGLVBQVKQ-UHFFFAOYSA-N 0.000 description 1
- NNKPHNTWNILINE-UHFFFAOYSA-N n-cyclopropyl-3-fluoro-4-methyl-5-[3-[[1-[2-[2-(methylamino)ethoxy]phenyl]cyclopropyl]amino]-2-oxopyrazin-1-yl]benzamide Chemical compound CNCCOC1=CC=CC=C1C1(NC=2C(N(C=3C(=C(F)C=C(C=3)C(=O)NC3CC3)C)C=CN=2)=O)CC1 NNKPHNTWNILINE-UHFFFAOYSA-N 0.000 description 1
- 125000003136 n-heptyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
- RIWRFSMVIUAEBX-UHFFFAOYSA-N n-methyl-1-phenylmethanamine Chemical compound CNCC1=CC=CC=C1 RIWRFSMVIUAEBX-UHFFFAOYSA-N 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- NVSYANRBXPURRQ-UHFFFAOYSA-N naphthalen-1-ylmethanamine Chemical compound C1=CC=C2C(CN)=CC=CC2=C1 NVSYANRBXPURRQ-UHFFFAOYSA-N 0.000 description 1
- DASJFYAPNPUBGG-UHFFFAOYSA-N naphthalene-1-sulfonyl chloride Chemical compound C1=CC=C2C(S(=O)(=O)Cl)=CC=CC2=C1 DASJFYAPNPUBGG-UHFFFAOYSA-N 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 125000001893 nitrooxy group Chemical group [O-][N+](=O)O* 0.000 description 1
- PSACHCMMPFMFAJ-UHFFFAOYSA-N nmm n-methylmorpholine Chemical compound CN1CCOCC1.CN1CCOCC1 PSACHCMMPFMFAJ-UHFFFAOYSA-N 0.000 description 1
- 125000006574 non-aromatic ring group Chemical group 0.000 description 1
- 238000002414 normal-phase solid-phase extraction Methods 0.000 description 1
- 108020004017 nuclear receptors Proteins 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- 238000003305 oral gavage Methods 0.000 description 1
- 125000000962 organic group Chemical group 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 150000002902 organometallic compounds Chemical class 0.000 description 1
- 229910052762 osmium Inorganic materials 0.000 description 1
- SYQBFIAQOQZEGI-UHFFFAOYSA-N osmium atom Chemical compound [Os] SYQBFIAQOQZEGI-UHFFFAOYSA-N 0.000 description 1
- 230000004072 osteoblast differentiation Effects 0.000 description 1
- 230000010258 osteoblastogenesis Effects 0.000 description 1
- 210000002997 osteoclast Anatomy 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 125000001715 oxadiazolyl group Chemical group 0.000 description 1
- 150000002923 oximes Chemical class 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 238000005192 partition Methods 0.000 description 1
- VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical class OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 1
- 125000005003 perfluorobutyl group Chemical group FC(F)(F)C(F)(F)C(F)(F)C(F)(F)* 0.000 description 1
- 239000003614 peroxisome proliferator Substances 0.000 description 1
- 108091008725 peroxisome proliferator-activated receptors alpha Proteins 0.000 description 1
- 125000001792 phenanthrenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3C=CC12)* 0.000 description 1
- WLJVXDMOQOGPHL-UHFFFAOYSA-N phenylacetic acid Chemical compound OC(=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-UHFFFAOYSA-N 0.000 description 1
- 125000000286 phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 1
- 235000011007 phosphoric acid Nutrition 0.000 description 1
- 150000003016 phosphoric acids Chemical class 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 230000037081 physical activity Effects 0.000 description 1
- 229960005095 pioglitazone Drugs 0.000 description 1
- 125000004193 piperazinyl group Chemical group 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 125000006684 polyhaloalkyl group Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 102000040430 polynucleotide Human genes 0.000 description 1
- 108091033319 polynucleotide Proteins 0.000 description 1
- 239000002157 polynucleotide Substances 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 150000004804 polysaccharides Chemical class 0.000 description 1
- LZMJNVRJMFMYQS-UHFFFAOYSA-N poseltinib Chemical compound C1CN(C)CCN1C(C=C1)=CC=C1NC1=NC(OC=2C=C(NC(=O)C=C)C=CC=2)=C(OC=C2)C2=N1 LZMJNVRJMFMYQS-UHFFFAOYSA-N 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- CHKVPAROMQMJNQ-UHFFFAOYSA-M potassium bisulfate Chemical compound [K+].OS([O-])(=O)=O CHKVPAROMQMJNQ-UHFFFAOYSA-M 0.000 description 1
- 229910000343 potassium bisulfate Inorganic materials 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 150000003141 primary amines Chemical class 0.000 description 1
- 150000003858 primary carboxamides Chemical group 0.000 description 1
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
- 229960004919 procaine Drugs 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 150000003217 pyrazoles Chemical class 0.000 description 1
- 125000001725 pyrenyl group Chemical group 0.000 description 1
- 125000002206 pyridazin-3-yl group Chemical group [H]C1=C([H])C([H])=C(*)N=N1 0.000 description 1
- 125000004940 pyridazin-4-yl group Chemical group N1=NC=C(C=C1)* 0.000 description 1
- 125000004941 pyridazin-5-yl group Chemical group N1=NC=CC(=C1)* 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- ABMYEXAYWZJVOV-UHFFFAOYSA-N pyridin-3-ylboronic acid Chemical compound OB(O)C1=CC=CN=C1 ABMYEXAYWZJVOV-UHFFFAOYSA-N 0.000 description 1
- QLULGIRFKAWHOJ-UHFFFAOYSA-N pyridin-4-ylboronic acid Chemical compound OB(O)C1=CC=NC=C1 QLULGIRFKAWHOJ-UHFFFAOYSA-N 0.000 description 1
- BGUWFUQJCDRPTL-UHFFFAOYSA-N pyridine-4-carbaldehyde Chemical compound O=CC1=CC=NC=C1 BGUWFUQJCDRPTL-UHFFFAOYSA-N 0.000 description 1
- 125000000246 pyrimidin-2-yl group Chemical group [H]C1=NC(*)=NC([H])=C1[H] 0.000 description 1
- 125000004527 pyrimidin-4-yl group Chemical group N1=CN=C(C=C1)* 0.000 description 1
- 125000004528 pyrimidin-5-yl group Chemical group N1=CN=CC(=C1)* 0.000 description 1
- 125000004943 pyrimidin-6-yl group Chemical group N1=CN=CC=C1* 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 125000005493 quinolyl group Chemical group 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 229940044601 receptor agonist Drugs 0.000 description 1
- 239000000018 receptor agonist Substances 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000009877 rendering Methods 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 238000004366 reverse phase liquid chromatography Methods 0.000 description 1
- 238000004007 reversed phase HPLC Methods 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 150000003335 secondary amines Chemical class 0.000 description 1
- XIIOFHFUYBLOLW-UHFFFAOYSA-N selpercatinib Chemical compound OC(COC=1C=C(C=2N(C=1)N=CC=2C#N)C=1C=NC(=CC=1)N1CC2N(C(C1)C2)CC=1C=NC(=CC=1)OC)(C)C XIIOFHFUYBLOLW-UHFFFAOYSA-N 0.000 description 1
- 230000008313 sensitization Effects 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- BEOOHQFXGBMRKU-UHFFFAOYSA-N sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 description 1
- IHQKEDIOMGYHEB-UHFFFAOYSA-M sodium dimethylarsinate Chemical compound [Na+].C[As](C)([O-])=O IHQKEDIOMGYHEB-UHFFFAOYSA-M 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- IIACRCGMVDHOTQ-UHFFFAOYSA-M sulfamate Chemical compound NS([O-])(=O)=O IIACRCGMVDHOTQ-UHFFFAOYSA-M 0.000 description 1
- 125000005420 sulfonamido group Chemical group S(=O)(=O)(N*)* 0.000 description 1
- 125000001174 sulfone group Chemical group 0.000 description 1
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 1
- 125000003375 sulfoxide group Chemical group 0.000 description 1
- 125000005555 sulfoximide group Chemical group 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 229920001059 synthetic polymer Polymers 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- GZCRRIHWUXGPOV-UHFFFAOYSA-N terbium atom Chemical compound [Tb] GZCRRIHWUXGPOV-UHFFFAOYSA-N 0.000 description 1
- MJUVFNJAKWRYNB-UHFFFAOYSA-N tert-butyl 2-[4-[[2,3-dimethyl-5-(2-phenylpropan-2-ylcarbamoyl)indol-1-yl]methyl]phenyl]benzoate Chemical compound CC1=C(C)C2=CC(C(=O)NC(C)(C)C=3C=CC=CC=3)=CC=C2N1CC(C=C1)=CC=C1C1=CC=CC=C1C(=O)OC(C)(C)C MJUVFNJAKWRYNB-UHFFFAOYSA-N 0.000 description 1
- WQLUPIVXHBIVHZ-UHFFFAOYSA-N tert-butyl 2-[4-[[2,3-dimethyl-5-[(2-nitrophenyl)methylcarbamoyl]indol-1-yl]methyl]phenyl]benzoate Chemical compound CC1=C(C)C2=CC(C(=O)NCC=3C(=CC=CC=3)[N+]([O-])=O)=CC=C2N1CC(C=C1)=CC=C1C1=CC=CC=C1C(=O)OC(C)(C)C WQLUPIVXHBIVHZ-UHFFFAOYSA-N 0.000 description 1
- VXRVOEHTEXYZEG-UHFFFAOYSA-N tert-butyl 2-[4-[[2,3-dimethyl-5-[(3-methylsulfonylphenyl)methylcarbamoyl]indol-1-yl]methyl]phenyl]benzoate Chemical compound CC1=C(C)C2=CC(C(=O)NCC=3C=C(C=CC=3)S(C)(=O)=O)=CC=C2N1CC(C=C1)=CC=C1C1=CC=CC=C1C(=O)OC(C)(C)C VXRVOEHTEXYZEG-UHFFFAOYSA-N 0.000 description 1
- AXPBVPNDQNJUHL-UHFFFAOYSA-N tert-butyl 2-[4-[[2,3-dimethyl-5-[(4-methylsulfanylphenyl)methylcarbamoyl]indol-1-yl]methyl]phenyl]benzoate Chemical compound C1=CC(SC)=CC=C1CNC(=O)C1=CC=C(N(CC=2C=CC(=CC=2)C=2C(=CC=CC=2)C(=O)OC(C)(C)C)C(C)=C2C)C2=C1 AXPBVPNDQNJUHL-UHFFFAOYSA-N 0.000 description 1
- RIWRHRUSHZAXKS-UHFFFAOYSA-N tert-butyl 2-[4-[[2,3-dimethyl-5-[(4-methylsulfonylphenyl)methylcarbamoyl]indol-1-yl]methyl]phenyl]benzoate Chemical compound CC1=C(C)C2=CC(C(=O)NCC=3C=CC(=CC=3)S(C)(=O)=O)=CC=C2N1CC(C=C1)=CC=C1C1=CC=CC=C1C(=O)OC(C)(C)C RIWRHRUSHZAXKS-UHFFFAOYSA-N 0.000 description 1
- FEENZCWTPYGQAM-UHFFFAOYSA-N tert-butyl 2-[4-[[2,3-dimethyl-5-[(4-propan-2-ylphenyl)methylcarbamoyl]indol-1-yl]methyl]phenyl]benzoate Chemical compound C1=CC(C(C)C)=CC=C1CNC(=O)C1=CC=C(N(CC=2C=CC(=CC=2)C=2C(=CC=CC=2)C(=O)OC(C)(C)C)C(C)=C2C)C2=C1 FEENZCWTPYGQAM-UHFFFAOYSA-N 0.000 description 1
- YIOSTQAKCMZXIP-UHFFFAOYSA-N tert-butyl 2-[4-[[2,3-dimethyl-5-[(4-sulfamoylphenyl)methylcarbamoyl]indol-1-yl]methyl]phenyl]benzoate Chemical compound CC1=C(C)C2=CC(C(=O)NCC=3C=CC(=CC=3)S(N)(=O)=O)=CC=C2N1CC(C=C1)=CC=C1C1=CC=CC=C1C(=O)OC(C)(C)C YIOSTQAKCMZXIP-UHFFFAOYSA-N 0.000 description 1
- NJOLLLRHPWSWDK-RUZDIDTESA-N tert-butyl 2-[4-[[2,3-dimethyl-5-[[(1r)-1-(4-methylsulfonylphenyl)ethyl]carbamoyl]indol-1-yl]methyl]phenyl]benzoate Chemical compound N([C@H](C)C=1C=CC(=CC=1)S(C)(=O)=O)C(=O)C(C=C1C(C)=C2C)=CC=C1N2CC(C=C1)=CC=C1C1=CC=CC=C1C(=O)OC(C)(C)C NJOLLLRHPWSWDK-RUZDIDTESA-N 0.000 description 1
- KMEBSNFLZTYOPB-QFIPXVFZSA-N tert-butyl 2-[4-[[2,3-dimethyl-5-[[(1s)-1-(2,4,5-trifluorophenyl)ethyl]carbamoyl]indol-1-yl]methyl]phenyl]benzoate Chemical compound N([C@@H](C)C=1C(=CC(F)=C(F)C=1)F)C(=O)C(C=C1C(C)=C2C)=CC=C1N2CC(C=C1)=CC=C1C1=CC=CC=C1C(=O)OC(C)(C)C KMEBSNFLZTYOPB-QFIPXVFZSA-N 0.000 description 1
- RUJRTDOLWBYFIJ-SANMLTNESA-N tert-butyl 2-[4-[[2,3-dimethyl-5-[[(1s)-1-(3-methylphenyl)ethyl]carbamoyl]indol-1-yl]methyl]phenyl]benzoate Chemical compound N([C@@H](C)C=1C=C(C)C=CC=1)C(=O)C(C=C1C(C)=C2C)=CC=C1N2CC(C=C1)=CC=C1C1=CC=CC=C1C(=O)OC(C)(C)C RUJRTDOLWBYFIJ-SANMLTNESA-N 0.000 description 1
- SJBFDZHEFVWLQL-MHZLTWQESA-N tert-butyl 2-[4-[[2,3-dimethyl-5-[[(1s)-1-(3-propan-2-ylphenyl)ethyl]carbamoyl]indol-1-yl]methyl]phenyl]benzoate Chemical compound CC(C)C1=CC=CC([C@H](C)NC(=O)C=2C=C3C(C)=C(C)N(CC=4C=CC(=CC=4)C=4C(=CC=CC=4)C(=O)OC(C)(C)C)C3=CC=2)=C1 SJBFDZHEFVWLQL-MHZLTWQESA-N 0.000 description 1
- UMKQSALXSWOGND-MHZLTWQESA-N tert-butyl 2-[4-[[2,3-dimethyl-5-[[(1s)-1-naphthalen-2-ylethyl]carbamoyl]indol-1-yl]methyl]phenyl]benzoate Chemical compound N([C@@H](C)C=1C=C2C=CC=CC2=CC=1)C(=O)C(C=C1C(C)=C2C)=CC=C1N2CC(C=C1)=CC=C1C1=CC=CC=C1C(=O)OC(C)(C)C UMKQSALXSWOGND-MHZLTWQESA-N 0.000 description 1
- GTOIXNFTSODFRK-UHFFFAOYSA-N tert-butyl 2-[4-[[2,3-dimethyl-5-[[3-(trifluoromethoxy)phenyl]methylcarbamoyl]indol-1-yl]methyl]phenyl]benzoate Chemical compound CC1=C(C)C2=CC(C(=O)NCC=3C=C(OC(F)(F)F)C=CC=3)=CC=C2N1CC(C=C1)=CC=C1C1=CC=CC=C1C(=O)OC(C)(C)C GTOIXNFTSODFRK-UHFFFAOYSA-N 0.000 description 1
- XYBCMPJTNFAKFC-UHFFFAOYSA-N tert-butyl 2-[4-[[2,3-dimethyl-5-[[4-(trifluoromethoxy)phenyl]methylcarbamoyl]indol-1-yl]methyl]phenyl]benzoate Chemical compound CC1=C(C)C2=CC(C(=O)NCC=3C=CC(OC(F)(F)F)=CC=3)=CC=C2N1CC(C=C1)=CC=C1C1=CC=CC=C1C(=O)OC(C)(C)C XYBCMPJTNFAKFC-UHFFFAOYSA-N 0.000 description 1
- JQHXEYLDKKRBMU-UHFFFAOYSA-N tert-butyl 2-[4-[[3-methyl-5-(1-phenylpropylcarbamoyl)indol-1-yl]methyl]phenyl]benzoate Chemical compound C=1C=CC=CC=1C(CC)NC(=O)C(C=C1C(C)=C2)=CC=C1N2CC(C=C1)=CC=C1C1=CC=CC=C1C(=O)OC(C)(C)C JQHXEYLDKKRBMU-UHFFFAOYSA-N 0.000 description 1
- UKPXVEBGRYPGBS-UHFFFAOYSA-N tert-butyl 2-[4-[[5-[(2,4-dimethoxyphenyl)methylcarbamoyl]-2,3-dimethylindol-1-yl]methyl]phenyl]benzoate Chemical compound COC1=CC(OC)=CC=C1CNC(=O)C1=CC=C(N(CC=2C=CC(=CC=2)C=2C(=CC=CC=2)C(=O)OC(C)(C)C)C(C)=C2C)C2=C1 UKPXVEBGRYPGBS-UHFFFAOYSA-N 0.000 description 1
- WXRVZEYHIVHXKS-UHFFFAOYSA-N tert-butyl 2-[4-[[5-[(2-bromophenyl)methylcarbamoyl]-2,3-dimethylindol-1-yl]methyl]phenyl]benzoate Chemical compound CC1=C(C)C2=CC(C(=O)NCC=3C(=CC=CC=3)Br)=CC=C2N1CC(C=C1)=CC=C1C1=CC=CC=C1C(=O)OC(C)(C)C WXRVZEYHIVHXKS-UHFFFAOYSA-N 0.000 description 1
- WMEARGDYFMBFDH-UHFFFAOYSA-N tert-butyl 2-[4-[[5-[(3,4-dimethoxyphenyl)methylcarbamoyl]-2,3-dimethylindol-1-yl]methyl]phenyl]benzoate Chemical compound C1=C(OC)C(OC)=CC=C1CNC(=O)C1=CC=C(N(CC=2C=CC(=CC=2)C=2C(=CC=CC=2)C(=O)OC(C)(C)C)C(C)=C2C)C2=C1 WMEARGDYFMBFDH-UHFFFAOYSA-N 0.000 description 1
- UNDDNKULRUTNMI-UHFFFAOYSA-N tert-butyl 2-[4-[[5-[(3,5-dimethoxyphenyl)methylcarbamoyl]-2,3-dimethylindol-1-yl]methyl]phenyl]benzoate Chemical compound COC1=CC(OC)=CC(CNC(=O)C=2C=C3C(C)=C(C)N(CC=4C=CC(=CC=4)C=4C(=CC=CC=4)C(=O)OC(C)(C)C)C3=CC=2)=C1 UNDDNKULRUTNMI-UHFFFAOYSA-N 0.000 description 1
- WNMQJMJMLWFERZ-UHFFFAOYSA-N tert-butyl 2-[4-[[5-[(4-bromophenyl)methylcarbamoyl]-2,3-dimethylindol-1-yl]methyl]phenyl]benzoate Chemical compound CC1=C(C)C2=CC(C(=O)NCC=3C=CC(Br)=CC=3)=CC=C2N1CC(C=C1)=CC=C1C1=CC=CC=C1C(=O)OC(C)(C)C WNMQJMJMLWFERZ-UHFFFAOYSA-N 0.000 description 1
- CGFVYBXYAFZGHC-UHFFFAOYSA-N tert-butyl 2-[4-[[5-[(4-chlorophenyl)methylcarbamoyl]-2,3-dimethylindol-1-yl]methyl]phenyl]benzoate Chemical compound CC1=C(C)C2=CC(C(=O)NCC=3C=CC(Cl)=CC=3)=CC=C2N1CC(C=C1)=CC=C1C1=CC=CC=C1C(=O)OC(C)(C)C CGFVYBXYAFZGHC-UHFFFAOYSA-N 0.000 description 1
- FVJODRVRXOZZLS-UHFFFAOYSA-N tert-butyl 2-[4-[[5-[(4-cyanophenyl)methylcarbamoyl]-2,3-dimethylindol-1-yl]methyl]phenyl]benzoate Chemical compound CC1=C(C)C2=CC(C(=O)NCC=3C=CC(=CC=3)C#N)=CC=C2N1CC(C=C1)=CC=C1C1=CC=CC=C1C(=O)OC(C)(C)C FVJODRVRXOZZLS-UHFFFAOYSA-N 0.000 description 1
- AAFQCDSGCXOPEF-UHFFFAOYSA-N tert-butyl 2-[4-[[5-[(4-iodophenyl)methylcarbamoyl]-2,3-dimethylindol-1-yl]methyl]phenyl]benzoate Chemical compound CC1=C(C)C2=CC(C(=O)NCC=3C=CC(I)=CC=3)=CC=C2N1CC(C=C1)=CC=C1C1=CC=CC=C1C(=O)OC(C)(C)C AAFQCDSGCXOPEF-UHFFFAOYSA-N 0.000 description 1
- XCKCEDDUIHNPDJ-UHFFFAOYSA-N tert-butyl 2-[4-[[5-[(4-methoxycarbonylphenyl)methylcarbamoyl]-2,3-dimethylindol-1-yl]methyl]phenyl]benzoate Chemical compound C1=CC(C(=O)OC)=CC=C1CNC(=O)C1=CC=C(N(CC=2C=CC(=CC=2)C=2C(=CC=CC=2)C(=O)OC(C)(C)C)C(C)=C2C)C2=C1 XCKCEDDUIHNPDJ-UHFFFAOYSA-N 0.000 description 1
- LRBLRRGSJSGKDT-UHFFFAOYSA-N tert-butyl 2-[4-[[5-[(4-tert-butylphenyl)methylcarbamoyl]-2,3-dimethylindol-1-yl]methyl]phenyl]benzoate Chemical compound CC1=C(C)C2=CC(C(=O)NCC=3C=CC(=CC=3)C(C)(C)C)=CC=C2N1CC(C=C1)=CC=C1C1=CC=CC=C1C(=O)OC(C)(C)C LRBLRRGSJSGKDT-UHFFFAOYSA-N 0.000 description 1
- AMDGIPBYDOWKAX-UHFFFAOYSA-N tert-butyl 2-[4-[[5-[1-(5-cyclopropylpyridin-3-yl)ethylcarbamoyl]-2,3-dimethylindol-1-yl]methyl]phenyl]benzoate Chemical compound C=1N=CC(C2CC2)=CC=1C(C)NC(=O)C(C=C1C(C)=C2C)=CC=C1N2CC(C=C1)=CC=C1C1=CC=CC=C1C(=O)OC(C)(C)C AMDGIPBYDOWKAX-UHFFFAOYSA-N 0.000 description 1
- LVCOWKIYGWIIOH-UHFFFAOYSA-N tert-butyl 2-[4-[[5-[1-(6-cyclopropylpyridin-2-yl)ethylcarbamoyl]-2,3-dimethylindol-1-yl]methyl]phenyl]benzoate Chemical compound C=1C=CC(C2CC2)=NC=1C(C)NC(=O)C(C=C1C(C)=C2C)=CC=C1N2CC(C=C1)=CC=C1C1=CC=CC=C1C(=O)OC(C)(C)C LVCOWKIYGWIIOH-UHFFFAOYSA-N 0.000 description 1
- RLGDYAOKPDRRIR-RUZDIDTESA-N tert-butyl 2-[4-[[5-[[(1r)-1-(2-cyclopropylpyridin-4-yl)ethyl]carbamoyl]-2,3-dimethylindol-1-yl]methyl]phenyl]benzoate Chemical compound N([C@H](C)C=1C=C(N=CC=1)C1CC1)C(=O)C(C=C1C(C)=C2C)=CC=C1N2CC(C=C1)=CC=C1C1=CC=CC=C1C(=O)OC(C)(C)C RLGDYAOKPDRRIR-RUZDIDTESA-N 0.000 description 1
- ZMBSRUMFDMSSIC-XMMPIXPASA-N tert-butyl 2-[4-[[5-[[(1r)-1-(4-bromophenyl)ethyl]carbamoyl]-2,3-dimethylindol-1-yl]methyl]phenyl]benzoate Chemical compound N([C@H](C)C=1C=CC(Br)=CC=1)C(=O)C(C=C1C(C)=C2C)=CC=C1N2CC(C=C1)=CC=C1C1=CC=CC=C1C(=O)OC(C)(C)C ZMBSRUMFDMSSIC-XMMPIXPASA-N 0.000 description 1
- RGHABUULDKFCRX-RUZDIDTESA-N tert-butyl 2-[4-[[5-[[(1r)-1-(4-methoxyphenyl)ethyl]carbamoyl]-2,3-dimethylindol-1-yl]methyl]phenyl]benzoate Chemical compound C1=CC(OC)=CC=C1[C@@H](C)NC(=O)C1=CC=C(N(CC=2C=CC(=CC=2)C=2C(=CC=CC=2)C(=O)OC(C)(C)C)C(C)=C2C)C2=C1 RGHABUULDKFCRX-RUZDIDTESA-N 0.000 description 1
- NUSWRXPNJJMMTL-HSZRJFAPSA-N tert-butyl 2-[4-[[5-[[(1r)-1-(6-bromopyridin-2-yl)ethyl]carbamoyl]-2,3-dimethylindol-1-yl]methyl]phenyl]benzoate Chemical compound N([C@H](C)C=1N=C(Br)C=CC=1)C(=O)C(C=C1C(C)=C2C)=CC=C1N2CC(C=C1)=CC=C1C1=CC=CC=C1C(=O)OC(C)(C)C NUSWRXPNJJMMTL-HSZRJFAPSA-N 0.000 description 1
- GPJURSOPDADNPB-RUZDIDTESA-N tert-butyl 2-[4-[[5-[[(1r)-1-(6-cyclopropylpyridin-3-yl)ethyl]carbamoyl]-2,3-dimethylindol-1-yl]methyl]phenyl]benzoate Chemical compound N([C@H](C)C=1C=NC(=CC=1)C1CC1)C(=O)C(C=C1C(C)=C2C)=CC=C1N2CC(C=C1)=CC=C1C1=CC=CC=C1C(=O)OC(C)(C)C GPJURSOPDADNPB-RUZDIDTESA-N 0.000 description 1
- WXITXMHZMDKUCZ-QHCPKHFHSA-N tert-butyl 2-[4-[[5-[[(1s)-1-(2,4-dichlorophenyl)ethyl]carbamoyl]-2,3-dimethylindol-1-yl]methyl]phenyl]benzoate Chemical compound N([C@@H](C)C=1C(=CC(Cl)=CC=1)Cl)C(=O)C(C=C1C(C)=C2C)=CC=C1N2CC(C=C1)=CC=C1C1=CC=CC=C1C(=O)OC(C)(C)C WXITXMHZMDKUCZ-QHCPKHFHSA-N 0.000 description 1
- RLGDYAOKPDRRIR-VWLOTQADSA-N tert-butyl 2-[4-[[5-[[(1s)-1-(2-cyclopropylpyridin-4-yl)ethyl]carbamoyl]-2,3-dimethylindol-1-yl]methyl]phenyl]benzoate Chemical compound N([C@@H](C)C=1C=C(N=CC=1)C1CC1)C(=O)C(C=C1C(C)=C2C)=CC=C1N2CC(C=C1)=CC=C1C1=CC=CC=C1C(=O)OC(C)(C)C RLGDYAOKPDRRIR-VWLOTQADSA-N 0.000 description 1
- MDMOTRMOUYPAAV-SANMLTNESA-N tert-butyl 2-[4-[[5-[[(1s)-1-(3-cyclopropylphenyl)ethyl]carbamoyl]-2,3-dimethylindol-1-yl]methyl]phenyl]benzoate Chemical compound N([C@@H](C)C=1C=C(C=CC=1)C1CC1)C(=O)C(C=C1C(C)=C2C)=CC=C1N2CC(C=C1)=CC=C1C1=CC=CC=C1C(=O)OC(C)(C)C MDMOTRMOUYPAAV-SANMLTNESA-N 0.000 description 1
- WATNPRGUVWXSDV-VWLOTQADSA-N tert-butyl 2-[4-[[5-[[(1s)-1-(3-methoxyphenyl)ethyl]carbamoyl]-2,3-dimethylindol-1-yl]methyl]phenyl]benzoate Chemical compound COC1=CC=CC([C@H](C)NC(=O)C=2C=C3C(C)=C(C)N(CC=4C=CC(=CC=4)C=4C(=CC=CC=4)C(=O)OC(C)(C)C)C3=CC=2)=C1 WATNPRGUVWXSDV-VWLOTQADSA-N 0.000 description 1
- BDLXVJGMFCDKST-DEOSSOPVSA-N tert-butyl 2-[4-[[5-[[(1s)-1-(4-chlorophenyl)ethyl]carbamoyl]-2,3-dimethylindol-1-yl]methyl]phenyl]benzoate Chemical compound N([C@@H](C)C=1C=CC(Cl)=CC=1)C(=O)C(C=C1C(C)=C2C)=CC=C1N2CC(C=C1)=CC=C1C1=CC=CC=C1C(=O)OC(C)(C)C BDLXVJGMFCDKST-DEOSSOPVSA-N 0.000 description 1
- BQYWVPLKJWGIBC-VWLOTQADSA-N tert-butyl 2-[4-[[5-[[(1s)-1-(4-cyclopropylpyridin-2-yl)ethyl]carbamoyl]-2,3-dimethylindol-1-yl]methyl]phenyl]benzoate Chemical compound N([C@@H](C)C=1N=CC=C(C=1)C1CC1)C(=O)C(C=C1C(C)=C2C)=CC=C1N2CC(C=C1)=CC=C1C1=CC=CC=C1C(=O)OC(C)(C)C BQYWVPLKJWGIBC-VWLOTQADSA-N 0.000 description 1
- DCPYLMACUMMKOL-VWLOTQADSA-N tert-butyl 2-[4-[[5-[[(1s)-1-(5-cyclopropylpyridin-2-yl)ethyl]carbamoyl]-2,3-dimethylindol-1-yl]methyl]phenyl]benzoate Chemical compound N([C@@H](C)C=1N=CC(=CC=1)C1CC1)C(=O)C(C=C1C(C)=C2C)=CC=C1N2CC(C=C1)=CC=C1C1=CC=CC=C1C(=O)OC(C)(C)C DCPYLMACUMMKOL-VWLOTQADSA-N 0.000 description 1
- LVCOWKIYGWIIOH-VWLOTQADSA-N tert-butyl 2-[4-[[5-[[(1s)-1-(6-cyclopropylpyridin-2-yl)ethyl]carbamoyl]-2,3-dimethylindol-1-yl]methyl]phenyl]benzoate Chemical compound N([C@@H](C)C=1N=C(C=CC=1)C1CC1)C(=O)C(C=C1C(C)=C2C)=CC=C1N2CC(C=C1)=CC=C1C1=CC=CC=C1C(=O)OC(C)(C)C LVCOWKIYGWIIOH-VWLOTQADSA-N 0.000 description 1
- GPJURSOPDADNPB-VWLOTQADSA-N tert-butyl 2-[4-[[5-[[(1s)-1-(6-cyclopropylpyridin-3-yl)ethyl]carbamoyl]-2,3-dimethylindol-1-yl]methyl]phenyl]benzoate Chemical compound N([C@@H](C)C=1C=NC(=CC=1)C1CC1)C(=O)C(C=C1C(C)=C2C)=CC=C1N2CC(C=C1)=CC=C1C1=CC=CC=C1C(=O)OC(C)(C)C GPJURSOPDADNPB-VWLOTQADSA-N 0.000 description 1
- LTHRQHWRPPDTIE-QHCPKHFHSA-N tert-butyl 2-[4-[[5-[[(1s)-1-[2-chloro-5-(trifluoromethyl)phenyl]ethyl]carbamoyl]-2,3-dimethylindol-1-yl]methyl]phenyl]benzoate Chemical compound N([C@@H](C)C=1C(=CC=C(C=1)C(F)(F)F)Cl)C(=O)C(C=C1C(C)=C2C)=CC=C1N2CC(C=C1)=CC=C1C1=CC=CC=C1C(=O)OC(C)(C)C LTHRQHWRPPDTIE-QHCPKHFHSA-N 0.000 description 1
- ZODCDZWPRVFDKA-QHCPKHFHSA-N tert-butyl 2-[4-[[5-[[(1s)-1-[2-fluoro-3-(trifluoromethyl)phenyl]ethyl]carbamoyl]-2,3-dimethylindol-1-yl]methyl]phenyl]benzoate Chemical compound N([C@@H](C)C=1C(=C(C=CC=1)C(F)(F)F)F)C(=O)C(C=C1C(C)=C2C)=CC=C1N2CC(C=C1)=CC=C1C1=CC=CC=C1C(=O)OC(C)(C)C ZODCDZWPRVFDKA-QHCPKHFHSA-N 0.000 description 1
- NFACNELYIJFQSE-QHCPKHFHSA-N tert-butyl 2-[4-[[5-[[(1s)-1-[2-fluoro-4-(trifluoromethyl)phenyl]ethyl]carbamoyl]-2,3-dimethylindol-1-yl]methyl]phenyl]benzoate Chemical compound N([C@@H](C)C=1C(=CC(=CC=1)C(F)(F)F)F)C(=O)C(C=C1C(C)=C2C)=CC=C1N2CC(C=C1)=CC=C1C1=CC=CC=C1C(=O)OC(C)(C)C NFACNELYIJFQSE-QHCPKHFHSA-N 0.000 description 1
- NMCXOEIZWLFQOW-QHCPKHFHSA-N tert-butyl 2-[4-[[5-[[(1s)-1-[2-fluoro-6-(trifluoromethyl)phenyl]ethyl]carbamoyl]-2,3-dimethylindol-1-yl]methyl]phenyl]benzoate Chemical compound N([C@@H](C)C=1C(=CC=CC=1F)C(F)(F)F)C(=O)C(C=C1C(C)=C2C)=CC=C1N2CC(C=C1)=CC=C1C1=CC=CC=C1C(=O)OC(C)(C)C NMCXOEIZWLFQOW-QHCPKHFHSA-N 0.000 description 1
- MGLAFYFADWAQAP-UHFFFAOYSA-N tert-butyl 2-[4-[[5-[[4-(dimethylamino)phenyl]methylcarbamoyl]-2,3-dimethylindol-1-yl]methyl]phenyl]benzoate Chemical compound C1=CC(N(C)C)=CC=C1CNC(=O)C1=CC=C(N(CC=2C=CC(=CC=2)C=2C(=CC=CC=2)C(=O)OC(C)(C)C)C(C)=C2C)C2=C1 MGLAFYFADWAQAP-UHFFFAOYSA-N 0.000 description 1
- YZQQBZOUSDPTTH-UHFFFAOYSA-N tert-butyl 2-[4-[[5-[benzyl(methyl)carbamoyl]-2,3-dimethylindol-1-yl]methyl]phenyl]benzoate Chemical compound C=1C=C2N(CC=3C=CC(=CC=3)C=3C(=CC=CC=3)C(=O)OC(C)(C)C)C(C)=C(C)C2=CC=1C(=O)N(C)CC1=CC=CC=C1 YZQQBZOUSDPTTH-UHFFFAOYSA-N 0.000 description 1
- RUPAXCPQAAOIPB-UHFFFAOYSA-N tert-butyl formate Chemical compound CC(C)(C)OC=O RUPAXCPQAAOIPB-UHFFFAOYSA-N 0.000 description 1
- OBSACSBMTRJNPH-UHFFFAOYSA-N tert-butyl n-(3-aminocyclohexyl)carbamate Chemical compound CC(C)(C)OC(=O)NC1CCCC(N)C1 OBSACSBMTRJNPH-UHFFFAOYSA-N 0.000 description 1
- GQAUPTTUSSLXPS-UHFFFAOYSA-N tert-butyl n-[[3-(aminomethyl)phenyl]methyl]carbamate Chemical compound CC(C)(C)OC(=O)NCC1=CC=CC(CN)=C1 GQAUPTTUSSLXPS-UHFFFAOYSA-N 0.000 description 1
- DKACXUFSLUYRFU-UHFFFAOYSA-N tert-butyl n-aminocarbamate Chemical compound CC(C)(C)OC(=O)NN DKACXUFSLUYRFU-UHFFFAOYSA-N 0.000 description 1
- 150000003512 tertiary amines Chemical class 0.000 description 1
- 125000001302 tertiary amino group Chemical group 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 150000005621 tetraalkylammonium salts Chemical class 0.000 description 1
- DZLFLBLQUQXARW-UHFFFAOYSA-N tetrabutylammonium Chemical compound CCCC[N+](CCCC)(CCCC)CCCC DZLFLBLQUQXARW-UHFFFAOYSA-N 0.000 description 1
- 125000001935 tetracenyl group Chemical group C1(=CC=CC2=CC3=CC4=CC=CC=C4C=C3C=C12)* 0.000 description 1
- WHRNULOCNSKMGB-UHFFFAOYSA-N tetrahydrofuran thf Chemical compound C1CCOC1.C1CCOC1 WHRNULOCNSKMGB-UHFFFAOYSA-N 0.000 description 1
- WROMPOXWARCANT-UHFFFAOYSA-N tfa trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.OC(=O)C(F)(F)F WROMPOXWARCANT-UHFFFAOYSA-N 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 125000002813 thiocarbonyl group Chemical group *C(*)=S 0.000 description 1
- 125000000101 thioether group Chemical group 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- 238000002877 time resolved fluorescence resonance energy transfer Methods 0.000 description 1
- CMQCNTNASCDNGR-UHFFFAOYSA-N toluene;hydrate Chemical compound O.CC1=CC=CC=C1 CMQCNTNASCDNGR-UHFFFAOYSA-N 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000440 toxicity profile Toxicity 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 229910052723 transition metal Inorganic materials 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 125000005270 trialkylamine group Chemical group 0.000 description 1
- 125000004954 trialkylamino group Chemical group 0.000 description 1
- 125000005259 triarylamine group Chemical group 0.000 description 1
- GYUURHMITDQTRU-UHFFFAOYSA-N tributyl(pyridin-2-yl)stannane Chemical compound CCCC[Sn](CCCC)(CCCC)C1=CC=CC=N1 GYUURHMITDQTRU-UHFFFAOYSA-N 0.000 description 1
- STMPXDBGVJZCEX-UHFFFAOYSA-N triethylsilyl trifluoromethanesulfonate Chemical compound CC[Si](CC)(CC)OS(=O)(=O)C(F)(F)F STMPXDBGVJZCEX-UHFFFAOYSA-N 0.000 description 1
- 125000004044 trifluoroacetyl group Chemical group FC(C(=O)*)(F)F 0.000 description 1
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 description 1
- SZYJELPVAFJOGJ-UHFFFAOYSA-N trimethylamine hydrochloride Chemical compound Cl.CN(C)C SZYJELPVAFJOGJ-UHFFFAOYSA-N 0.000 description 1
- NRZWQKGABZFFKE-UHFFFAOYSA-N trimethylsulfonium Chemical compound C[S+](C)C NRZWQKGABZFFKE-UHFFFAOYSA-N 0.000 description 1
- 125000003960 triphenylenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3C3=CC=CC=C3C12)* 0.000 description 1
- 229910000404 tripotassium phosphate Inorganic materials 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
- 125000001834 xanthenyl group Chemical group C1=CC=CC=2OC3=CC=CC=C3C(C12)* 0.000 description 1
- 150000003751 zinc Chemical class 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
Definitions
- the peroxisome proliferator active receptors members of the nuclear hormone receptor superfamily, comprise several subtypes such as PPAR ⁇ , PPAR ⁇ , and PPAR ⁇ .
- the PPAR ⁇ subtype also referred to as PPARG, is the target of the glitazone pharmaceutical agents used for treatment of type II diabetes.
- PPARG is also known as NR 1 C 3 (the gene ID) and there exist PPARG1 and PPARG2, the two major isoforms of PPARG.
- the glitazones such as pioglitazone and rosiglitazone, act as PPARG receptor agonists.
- the present invention is directed to methods of use of compounds that are non-activating (non-agonist) PPARG modulators, compounds of formula (I) including compounds of formula (IA) and of formula (IB) as described herein, in modulating the activity of PPARG, in treatment of conditions wherein non-activating modulation of PPARG is medically indicated, such as for treatment of a progressive bone disease.
- Compounds of the invention can block kinase-mediated, such as cdk5-mediated, phosphorylation of PPARG, but are not agonists of the receptor itself.
- the compounds may exhibit no or reduced side effects associated with administration of full and partial agonists of PPARG, such as significant weight gain, edema, impairment of bone growth or formation, or cardiac hypertrophy, or any combination thereof, in the mammal receiving the compound.
- administration of an effective amount of a compound of formula (I) as disclosed herein can be used to treat the disease, wherein the effective dose of the compound acts to inhibit bone resorption, improve bone formation, or both, in the patient.
- the method of treatment of the invention for the progressive bone disease can act to increase FGF21 while increasing bone health.
- FIG. 1 is a schematic showing the differentiation of mesenchymal stem cells into osteoblasts and adipocytes under mediation of PPARG, along with bar graphs showing relative effects on PPARG target genes aP2 and ALP induced by rosiglitazone, MRL24 (a Merck PPARG partial agonist) and a compound of formula (I), SR1664.
- FIG. 2 is a bar graph showing the extent of bone formation marker in human mesenchymal stem cells upon treatment with a compound effective for practice of a method of the invention.
- FIG. 3 schematically shows desirable molecular features of compounds for practicing a method of the invention.
- FIG. 4 provides bioactivity details for compounds effective for carrying out a method of the invention.
- FIG. 5 indicates the results of a 4-week study of SR10171, a compound effective for carrying out a method of the invention, in comparison with rosiglitazone.
- FIG. 6 shows bar graphs related to bone development, relative to control, of SR10171, a compound effective for carrying out a method of the invention, in comparison with rosiglitazone.
- FIG. 7 shows the results of a glucose tolerance test on mice fed a regular chow diet (RD) or obese mice fed a high fat diet (HFD). Mice were fasted overnight and then administered a bolus of glucose. At several time intervals plasma glucose was measured. The data confirms the insulin sensitization effects and improved glucose disposal for TZD rosiglitazone treated mice. Similar results were obtained with SR10171 demonstrating that this compound is an insulin sensitizer. Both drug treated arms resulted in similar glucose disposal rates as the lean mice on RD.
- RD regular chow diet
- HFD high fat diet
- FIG. 8 shows serum levels of FGF21, a liver-secreted hormone believed to have beneficial effects in terms of metabolism, although over-expression of FGF21 can be detrimental to bone.
- FGF21 The endocrine hormone fibroblast growth factor 21 (FGF21) is a powerful modulator of glucose and lipid metabolism and a promising drug for type 2 diabetes.
- FGF21 a potent regulator of skeletal homeostasis.
- Both genetic and pharmacologic FGF21 gains of function lead to a striking decrease in bone mass.
- FGF21 loss of function leads to a reciprocal high-bone-mass phenotype.
- FGF21 inhibits osteoblastogenesis and stimulates adipogenesis from bone marrow mesenchymal stem cells by potentiating the activity of peroxisome proliferator-activated receptor ⁇ (PPAR- ⁇ ). Consequently, FGF21 deletion prevents the deleterious bone loss side effect of the PPAR- ⁇ agonist rosiglitazone. Therefore, FGF21 is a critical rheostat for bone turnover and a key integrator of bone and energy metabolism. These results reveal that skeletal fragility may be an undesirable consequence of chronic FGF21 administration.” Thus, while our compounds increase FGF21 expression likely due to activation of PPARA, we inhibit the bad effects by blocking PPARG.
- PPAR- ⁇ peroxisome proliferator-activated receptor ⁇
- FIG. 9 shows photographs depicting results of osmium staining in whole tibia and juxtaposed trabecular bone (gray) and fat (yellow) in proximal tibia.
- RD regular diet (normal chow)
- HFD high fat diet (chow is 45% fat).
- Mice on HFD have increased fat accumulation in the bone marrow as compared to lean controls.
- Mice on HFD and treated with a TZD, rosiglitazone have significant fat accumulation in the bone marrow.
- Treatment of mice with SR10171 reduces the fat accumulation in bone marrow to that below vehicle controls on high fat diet alone.
- FIG. 10 shows quantitation of cortical bone mass from the midshaft tibia from mice treated under the conditions described above in FIG. 7 .
- Treatment of mice with SR10171 resulted in a statistically significant increase in total tissue area, cortical bone area, and medular area.
- FIG. 11 shows quantitative data on serum markers of bone resporption (TRACP5b) and bone formation (BALP) in mice treated under the conditions described in FIG. 7 .
- Treatment of mice on HFD with SR10171 reduced the level of TRACP5b to that of lean mice on normal chow diet. Likewise SR10171 increase BALP significantly over the other treatment arms.
- mammals include, for example, humans; non-human primates, e.g., apes and monkeys; and non-primates, e.g., dogs, cats, cattle, horses, sheep, and goats.
- Non-mammals include, for example, fish and birds.
- disease or “disorder” or “malcondition” are used interchangeably, and are used to refer to diseases or conditions wherein PPARG plays a role in the biochemical mechanisms involved in the disease or condition or symptom(s) thereof such that a therapeutically beneficial effect can be achieved by acting on PPARG.
- Acting on” PPARG, or “modulating” PPARG can include binding to PPARG and/or inhibiting the bioactivity of PPARG and/or allosterically regulating the bioactivity of PPARG in vivo.
- module when the term “modulator” is used herein, the term alludes to a compound of the invention, and it is understood that the terms “modulator” and “compound” or “compound of the invention” are synonymous when the context indicates that a compound of the present invention is being referred to.
- the compounds of the invention are not agonists of PPARG, i.e., binding of the compound to PPARG does not activate the receptor, as discussed in greater detail below.
- compounds of the invention bring about inhibition of cdk5-mediated phosphorylation of PPARG while being devoid of classical agonism. Such compounds are referred to herein as “non-agonist PPARG modulatory compounds.”
- an effective amount when used to describe therapy to an individual suffering from a disorder, refers to the amount of a compound of the invention that is effective to inhibit or otherwise act on PPARG in the individual's tissues wherein PPARG involved in the disorder is active, wherein such inhibition or other action occurs to an extent sufficient to produce a beneficial therapeutic effect.
- “Substantially” as the term is used herein means completely or almost completely; for example, a composition that is “substantially free” of a component either has none of the component or contains such a trace amount that any relevant functional property of the composition is unaffected by the presence of the trace amount, or a compound is “substantially pure” is there are only negligible traces of impurities present.
- Treating” or “treatment” within the meaning herein refers to an alleviation of symptoms associated with a disorder or disease, or inhibition of further progression or worsening of those symptoms, or prevention or prophylaxis of the disease or disorder, or curing the disease or disorder.
- an “effective amount” or a “therapeutically effective amount” of a compound of the invention refers to an amount of the compound that alleviates, in whole or in part, symptoms associated with the disorder or condition, or halts or slows further progression or worsening of those symptoms, or prevents or provides prophylaxis for the disorder or condition.
- a “therapeutically effective amount” refers to an amount effective, at dosages and for periods of time necessary, to achieve the desired therapeutic result.
- a therapeutically effective amount is also one in which any toxic or detrimental effects of compounds of the invention are outweighed by the therapeutically beneficial effects.
- phrases such as “under conditions suitable to provide” or “under conditions sufficient to yield” or the like, in the context of methods of synthesis, as used herein refers to reaction conditions, such as time, temperature, solvent, reactant concentrations, and the like, that are within ordinary skill for an experimenter to vary, that provide a useful quantity or yield of a reaction product. It is not necessary that the desired reaction product be the only reaction product or that the starting materials be entirely consumed, provided the desired reaction product can be isolated or otherwise further used.
- chemically feasible is meant a bonding arrangement or a compound where the generally understood rules of organic structure are not violated; for example a structure within a definition of a claim that would contain in certain situations a pentavalent carbon atom that would not exist in nature would be understood to not be within the claim.
- the structures disclosed herein, in all of their embodiments are intended to include only “chemically feasible” structures, and any recited structures that are not chemically feasible, for example in a structure shown with variable atoms or groups, are not intended to be disclosed or claimed herein.
- an “analog” of a chemical structure refers to a chemical structure that preserves substantial similarity with the parent structure, although it may not be readily derived synthetically from the parent structure.
- a related chemical structure that is readily derived synthetically from a parent chemical structure is referred to as a “derivative.”
- a substituent is specified to be an atom or atoms of specified identity, “or a bond”, a configuration is referred to when the substituent is “a bond” that the groups that are immediately adjacent to the specified substituent are directly connected to each other in a chemically feasible bonding configuration.
- stable compound and “stable structure” are meant to indicate a compound that is sufficiently robust to survive isolation to a useful degree of purity from a reaction mixture, and formulation into an efficacious therapeutic agent. Only stable compounds are contemplated herein.
- a “small molecule” refers to an organic compound, including an organometallic compound, of a molecular weight less than about 2 kDa, that is not a polynucleotide, a polypeptide, a polysaccharide, or a synthetic polymer composed of a plurality of repeating units.
- any of the groups described herein, which contain one or more substituents it is understood that such groups do not contain any substitution or substitution patterns which are sterically impractical and/or synthetically non-feasible.
- the compounds of this disclosed subject matter include all stereochemical isomers arising from the substitution of these compounds.
- a group e.g., an “alkyl” group
- the claim is definite and limited with respect the size of the alkyl group, both by definition; i.e., the size (the number of carbon atoms) possessed by a group such as an alkyl group is a finite number, less than the total number of carbon atoms in the universe and bounded by the understanding of the person of ordinary skill as to the size of the group as being reasonable for a molecular entity; and by functionality, i.e., the size of the group such as the alkyl group is bounded by the functional properties the group bestows on a molecule containing the group such as solubility in aqueous or organic liquid media. Therefore, a claim reciting an “alkyl” or other chemical group or moiety is definite and bounded, as the number of atoms in the group cannot be infinite.
- an isotopic form of one or more atoms in a molecule that is different from the naturally occurring isotopic distribution of the atom in nature is referred to as an “isotopically labeled form” of the molecule.
- All isotopic forms of atoms are included as options in the composition of any molecule, unless a specific isotopic form of an atom is indicated.
- any hydrogen atom or set thereof in a molecule can be any of the isotopic forms of hydrogen, i.e., protium ( 1 H), deuterium ( 2 H), or tritium ( 3 H) in any combination.
- any carbon atom or set thereof in a molecule can be any of the isotopic form of carbons, such as 11 C, 12 C, 13 C, or 14 C, or any nitrogen atom or set thereof in a molecule can be any of the isotopic forms of nitrogen, such as 13 N, 14 N, or 15 N.
- a molecule can include any combination of isotopic forms in the component atoms making up the molecule, the isotopic form of every atom forming the molecule being independently selected. In a multi-molecular sample of a compound, not every individual molecule necessarily has the same isotopic composition.
- a sample of a compound can include molecules containing various different isotopic compositions, such as in a tritium or 14 C radiolabeled sample where only some fraction of the set of molecules making up the macroscopic sample contains a radioactive atom. It is also understood that many elements that are not artificially isotopically enriched themselves are mixtures of naturally occurring isotopic forms, such as 14 N and 15 N, 32 S and 34 S, and so forth. A molecule as recited herein is defined as including isotopic forms of all its constituent elements at each position in the molecule. As is well known in the art, isotopically labeled compounds can be prepared by the usual methods of chemical synthesis, except substituting an isotopically labeled precursor molecule.
- the isotopes can be obtained by any method known in the art, such as generation by neutron absorption of a precursor nuclide in a nuclear reactor, by cyclotron reactions, or by isotopic separation such as by mass spectrometry.
- the isotopic forms are incorporated into precursors as required for use in any particular synthetic route.
- 14 C and 3 H can be prepared using neutrons generated in a nuclear reactor. Following nuclear transformation, 14 C and 3 H are incorporated into precursor molecules, followed by further elaboration as needed.
- substituted refers to an organic group as defined herein in which one or more bonds to a hydrogen atom contained therein are replaced by one or more bonds to a non-hydrogen atom such as, but not limited to, a halogen (i.e., F, Cl, Br, and I); an oxygen atom in groups such as hydroxyl groups, alkoxy groups, aryloxy groups, aralkyloxy groups, oxo(carbonyl) groups, carboxyl groups including carboxylic acids, carboxylates, and carboxylate esters; a sulfur atom in groups such as thiol groups, alkyl and aryl sulfide groups, sulfoxide groups, sulfone groups, sulfonyl groups, and sulfonamide groups; a nitrogen atom in groups such as amines, hydroxylamines, nitriles, nitro groups, N-oxides, hydrazides, azides, and enamines;
- Non-limiting examples of substituents J that can be bonded to a substituted carbon (or other) atom include F, Cl, Br, I, OR′, OC(O)N(R′) 2 , CN, NO, NO 2 , ONO 2 , azido, CF 3 , OCF 3 , R′, O (oxo), S (thiono), methylenedioxy, ethylenedioxy, N(R′) 2 , SR′, SOR′, SO 2 R′, SO 2 N(R′) 2 , SO 3 R′, C(O)R′, C(O)C(O)R′, C(O)CH 2 C(O)R′, C(S)R′, C(O)OR′, OC(O)R′, C(O)N(R′) 2 , OC(O)N(R′) 2 , C(S)N(R′) 2 , (CH 2 ) 0-2 N(R′)C(O)R′, (CH
- a substituent When a substituent is monovalent, such as, for example, F or Cl, it is bonded to the atom it is substituting by a single bond.
- a substituent When a substituent is more than monovalent, such as O, which is divalent, it can be bonded to the atom it is substituting by more than one bond, i.e., a divalent substituent is bonded by a double bond; for example, a C substituted with O forms a carbonyl group, C ⁇ O, which can also be written as “CO”, “C(O)”, or “C( ⁇ O)”, wherein the C and the O are double bonded.
- a carbon atom When a carbon atom is substituted with a double-bonded oxygen ( ⁇ O) group, the oxygen substituent is termed an “oxo” group.
- a divalent substituent such as NR is double-bonded to a carbon atom, the resulting C( ⁇ NR) group is termed an “imino” group.
- a divalent substituent such as O or S can be connected by two single bonds to two different carbon atoms.
- O a divalent substituent
- any substituent can be bonded to a carbon or other atom by a linker, such as (CH 2 ) n or (CR′ 2 ) n wherein n is 1, 2, 3, or more, and each R′ is independently selected.
- C(O) and S(O) 2 groups can also be bound to one or two heteroatoms, such as nitrogen or oxygen, rather than to a carbon atom.
- a C(O) group is bound to one carbon and one nitrogen atom, the resulting group is called an “amide” or “carboxamide.”
- the functional group is termed a “urea.”
- a C(O) is bonded to one oxygen and one nitrogen atom, the resulting group is termed a “carbamate” or “urethane.”
- a S(O) 2 group is bound to one carbon and one nitrogen atom, the resulting unit is termed a “sulfonamide.”
- a S(O) 2 group is bound to two nitrogen atoms, the resulting unit is termed a “sulfamate.”
- Substituted alkyl, alkenyl, alkynyl, cycloalkyl, and cycloalkenyl groups as well as other substituted groups also include groups in which one or more bonds to a hydrogen atom are replaced by one or more bonds, including double or triple bonds, to a carbon atom, or to a heteroatom such as, but not limited to, oxygen in carbonyl (oxo), carboxyl, ester, amide, imide, urethane, and urea groups; and nitrogen in imines, hydroxyimines, oximes, hydrazones, amidines, guanidines, and nitriles.
- Substituted ring groups such as substituted cycloalkyl, aryl, heterocyclyl and heteroaryl groups also include rings and fused ring systems in which a bond to a hydrogen atom is replaced with a bond to a carbon atom. Therefore, substituted cycloalkyl, aryl, heterocyclyl and heteroaryl groups can also be substituted with alkyl, alkenyl, and alkynyl groups as defined herein.
- ring system as the term is used herein is meant a moiety comprising one, two, three or more rings, which can be substituted with non-ring groups or with other ring systems, or both, which can be fully saturated, partially unsaturated, fully unsaturated, or aromatic, and when the ring system includes more than a single ring, the rings can be fused, bridging, or spirocyclic.
- spirocyclic is meant the class of structures wherein two rings are fused at a single tetrahedral carbon atom, as is well known in the art.
- any of the groups described herein, which contain one or more substituents it is understood, of course, that such groups do not contain any substitution or substitution patterns which are sterically impractical and/or synthetically non-feasible.
- the compounds of this disclosed subject matter include all stereochemical isomers arising from the substitution of these compounds.
- Alkyl groups include straight chain and branched alkyl groups and cycloalkyl groups having from 1 to about 20 carbon atoms, and typically from 1 to 12 carbons or, in some embodiments, from 1 to 8 carbon atoms.
- straight chain alkyl groups include those with from 1 to 8 carbon atoms such as methyl, ethyl, n-propyl, n-butyl, n-pentyl, n-hexyl, n-heptyl, and n-octyl groups.
- branched alkyl groups include, but are not limited to, isopropyl, iso-butyl, sec-butyl, t-butyl, neopentyl, isopentyl, and 2,2-dimethylpropyl groups.
- alkyl encompasses n-alkyl, isoalkyl, and anteisoalkyl groups as well as other branched chain forms of alkyl.
- Representative substituted alkyl groups can be substituted one or more times with any of the groups listed above, for example, amino, hydroxy, cyano, carboxy, nitro, thio, alkoxy, and halogen groups.
- Cycloalkyl groups are cyclic alkyl groups such as, but not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, and cyclooctyl groups.
- the cycloalkyl group can have 3 to about 8-12 ring members, whereas in other embodiments the number of ring carbon atoms range from 3 to 4, 5, 6, or 7.
- Cycloalkyl groups further include polycyclic cycloalkyl groups such as, but not limited to, norbornyl, adamantyl, bornyl, camphenyl, isocamphenyl, and carenyl groups, and fused rings such as, but not limited to, decalinyl, and the like. Cycloalkyl groups also include rings that are substituted with straight or branched chain alkyl groups as defined above.
- Representative substituted cycloalkyl groups can be mono-substituted or substituted more than once, such as, but not limited to, 2,2-, 2,3-, 2,4- 2,5- or 2,6-disubstituted cyclohexyl groups or mono-, di- or tri-substituted norbornyl or cycloheptyl groups, which can be substituted with, for example, amino, hydroxy, cyano, carboxy, nitro, thio, alkoxy, and halogen groups.
- cycloalkenyl alone or in combination denotes a cyclic alkenyl group.
- carbocyclic denotes a ring structure wherein the atoms of the ring are carbon, such as a cycloalkyl group or an aryl group.
- the carbocycle has 3 to 8 ring members, whereas in other embodiments the number of ring carbon atoms is 4, 5, 6, or 7.
- the carbocyclic ring can be substituted with as many as N ⁇ 1 substituents wherein N is the size of the carbocyclic ring with, for example, alkyl, alkenyl, alkynyl, amino, aryl, hydroxy, cyano, carboxy, heteroaryl, heterocyclyl, nitro, thio, alkoxy, and halogen groups, or other groups as are listed above.
- a carbocyclyl ring can be a cycloalkyl ring, a cycloalkenyl ring, or an aryl ring.
- a carbocyclyl can be monocyclic or polycyclic, and if polycyclic each ring can be independently be a cycloalkyl ring, a cycloalkenyl ring, or an aryl ring.
- (Cycloalkyl)alkyl groups are alkyl groups as defined above in which a hydrogen or carbon bond of the alkyl group is replaced with a bond to a cycloalkyl group as defined above.
- Alkenyl groups include straight and branched chain and cyclic alkyl groups as defined above, except that at least one double bond exists between two carbon atoms.
- alkenyl groups have from 2 to about 20 carbon atoms, and typically from 2 to 12 carbons or, in some embodiments, from 2 to 8 carbon atoms.
- Examples include, but are not limited to vinyl, —CH ⁇ CH(CH 3 ), —CH ⁇ C(CH 3 ) 2 , —C(CH 3 ) ⁇ CH 2 , —C(CH 3 ) ⁇ CH(CH 3 ), —C(CH 2 CH 3 ) ⁇ CH 2 , cyclohexenyl, cyclopentenyl, cyclohexadienyl, butadienyl, pentadienyl, and hexadienyl among others.
- Cycloalkenyl groups include cycloalkyl groups having at least one double bond between 2 carbons.
- cycloalkenyl groups include but are not limited to cyclohexenyl, cyclopentenyl, and cyclohexadienyl groups.
- Cycloalkenyl groups can have from 3 to about 8-12 ring members, whereas in other embodiments the number of ring carbon atoms range from 3 to 5, 6, or 7.
- Cycloalkyl groups further include polycyclic cycloalkyl groups such as, but not limited to, norbornyl, adamantyl, bornyl, camphenyl, isocamphenyl, and carenyl groups, and fused rings such as, but not limited to, decalinyl, and the like, provided they include at least one double bond within a ring.
- Cycloalkenyl groups also include rings that are substituted with straight or branched chain alkyl groups as defined above.
- (Cycloalkenyl)alkyl groups are alkyl groups as defined above in which a hydrogen or carbon bond of the alkyl group is replaced with a bond to a cycloalkenyl group as defined above.
- Alkynyl groups include straight and branched chain alkyl groups, except that at least one triple bond exists between two carbon atoms.
- alkynyl groups have from 2 to about 20 carbon atoms, and typically from 2 to 12 carbons or, in some embodiments, from 2 to 8 carbon atoms. Examples include, but are not limited to —C ⁇ CH, —C ⁇ C(CH 3 ), —C ⁇ C(CH 2 CH 3 ), —CH 2 C ⁇ CH, —CH 2 C ⁇ C(CH 3 ), and —CH 2 C ⁇ C(CH 2 CH 3 ) among others.
- Aryl groups are cyclic aromatic hydrocarbons that do not contain heteroatoms in the ring.
- aryl groups include, but are not limited to, phenyl, azulenyl, heptalenyl, biphenyl, indacenyl, fluorenyl, phenanthrenyl, triphenylenyl, pyrenyl, naphthacenyl, chrysenyl, biphenylenyl, anthracenyl, and naphthyl groups.
- aryl groups contain about 6 to about 14 carbons in the ring portions of the groups.
- Aryl groups can be unsubstituted or substituted, as defined above.
- Representative substituted aryl groups can be mono-substituted or substituted more than once, such as, but not limited to, 2-, 3-, 4-, 5-, or 6-substituted phenyl or 2-8 substituted naphthyl groups, which can be substituted with carbon or non-carbon groups such as those listed above.
- Aralkyl or arylalkyl groups are alkyl groups as defined above in which a hydrogen or carbon bond of an alkyl group is replaced with a bond to an aryl group as defined above.
- Representative aralkyl groups include benzyl and phenylethyl groups and fused (cycloalkylaryl)alkyl groups such as 4-ethyl-indanyl.
- Aralkenyl group are alkenyl groups as defined above in which a hydrogen or carbon bond of an alkyl group is replaced with a bond to an aryl group as defined above.
- Heterocyclyl groups or the term “heterocyclyl” includes aromatic and non-aromatic ring compounds containing 3 or more ring members, of which, one or more is a heteroatom such as, but not limited to, N, O, and S.
- a heterocyclyl can be a cycloheteroalkyl, or a heteroaryl, or if polycyclic, any combination thereof.
- heterocyclyl groups include 3 to about 20 ring members, whereas other such groups have 3 to about 15 ring members.
- a heterocyclyl group designated as a C 2 -heterocyclyl can be a 5-ring with two carbon atoms and three heteroatoms, a 6-ring with two carbon atoms and four heteroatoms and so forth.
- a C 4 -heterocyclyl can be a 5-ring with one heteroatom, a 6-ring with two heteroatoms, and so forth.
- the number of carbon atoms plus the number of heteroatoms sums up to equal the total number of ring atoms.
- a heterocyclyl ring can also include one or more double bonds.
- a heteroaryl ring is an embodiment of a heterocyclyl group.
- the phrase “heterocyclyl group” includes fused ring species including those comprising fused aromatic and non-aromatic groups.
- a dioxolanyl ring and a benzdioxolanyl ring system are both heterocyclyl groups within the meaning herein.
- the phrase also includes polycyclic ring systems containing a heteroatom such as, but not limited to, quinuclidyl.
- Heterocyclyl groups can be unsubstituted, or can be substituted as discussed above.
- Heterocyclyl groups include, but are not limited to, pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl, pyrrolyl, pyrazolyl, triazolyl, tetrazolyl, oxazolyl, isoxazolyl, thiazolyl, pyridinyl, thiophenyl, benzothiophenyl, benzofuranyl, dihydrobenzofuranyl, indolyl, dihydroindolyl, azaindolyl, indazolyl, benzimidazolyl, azabenzimidazolyl, benzoxazolyl, benzothiazolyl, benzothiadiazolyl, imidazopyridinyl, isoxazolopyridinyl, thianaphthalenyl, purinyl, xant
- Representative substituted heterocyclyl groups can be mono-substituted or substituted more than once, such as, but not limited to, piperidinyl or quinolinyl groups, which are 2-, 3-, 4-, 5-, or 6-substituted, or disubstituted with groups such as those listed above.
- Heteroaryl groups are aromatic ring compounds containing 5 or more ring members, of which, one or more is a heteroatom such as, but not limited to, N, O, and S; for instance, heteroaryl rings can have 5 to about 8-12 ring members.
- a heteroaryl group is a variety of a heterocyclyl group that possesses an aromatic electronic structure.
- a heteroaryl group designated as a C 2 -heteroaryl can be a 5-ring with two carbon atoms and three heteroatoms, a 6-ring with two carbon atoms and four heteroatoms and so forth.
- a C 4 -heteroaryl can be a 5-ring with one heteroatom, a 6-ring with two heteroatoms, and so forth.
- Heteroaryl groups include, but are not limited to, groups such as pyrrolyl, pyrazolyl, triazolyl, tetrazolyl, oxazolyl, isoxazolyl, thiazolyl, pyridinyl, thiophenyl, benzothiophenyl, benzofuranyl, indolyl, azaindolyl, indazolyl, benzimidazolyl, azabenzimidazolyl, benzoxazolyl, benzothiazolyl, benzothiadiazolyl, imidazopyridinyl, isoxazolopyridinyl, thianaphthalenyl, purinyl, xanthinyl, adeninyl, guaninyl, quinolinyl, isoquinolinyl, tetrahydroquinolin
- aryl and heteroaryl groups include but are not limited to phenyl, biphenyl, indenyl, naphthyl (1-naphthyl, 2-naphthyl), N-hydroxytetrazolyl, N-hydroxytriazolyl, N-hydroxyimidazolyl, anthracenyl (1-anthracenyl, 2-anthracenyl, 3-anthracenyl), thiophenyl (2-thienyl, 3-thienyl), furyl (2-furyl, 3-furyl), indolyl, oxadiazolyl, isoxazolyl, quinazolinyl, fluorenyl, xanthenyl, isoindanyl, benzhydryl, acridinyl, thiazolyl, pyrrolyl (2-pyrrolyl), pyrazolyl (3-pyrazolyl), imidazolyl (1-imidazolyl, 2-imidazo
- Heterocyclylalkyl groups are alkyl groups as defined above in which a hydrogen or carbon bond of an alkyl group as defined above is replaced with a bond to a heterocyclyl group as defined above.
- Representative heterocyclyl alkyl groups include, but are not limited to, furan-2-yl methyl, furan-3-yl methyl, pyridine-3-yl methyl, tetrahydrofuran-2-yl ethyl, and indol-2-yl propyl.
- Heteroarylalkyl groups are alkyl groups as defined above in which a hydrogen or carbon bond of an alkyl group is replaced with a bond to a heteroaryl group as defined above.
- alkoxy refers to an oxygen atom connected to an alkyl group, including a cycloalkyl group, as are defined above.
- linear alkoxy groups include but are not limited to methoxy, ethoxy, propoxy, butoxy, pentyloxy, hexyloxy, and the like.
- branched alkoxy include but are not limited to isopropoxy, sec-butoxy, tert-butoxy, isopentyloxy, isohexyloxy, and the like.
- cyclic alkoxy include but are not limited to cyclopropyloxy, cyclobutyloxy, cyclopentyloxy, cyclohexyloxy, and the like.
- An alkoxy group can include one to about 12-20 carbon atoms bonded to the oxygen atom, and can further include double or triple bonds, and can also include heteroatoms.
- an allyloxy group is an alkoxy group within the meaning herein.
- a methoxyethoxy group is also an alkoxy group within the meaning herein, as is a methylenedioxy group in a context where two adjacent atoms of a structures are substituted therewith.
- halo or “halogen” or “halide” by themselves or as part of another substituent mean, unless otherwise stated, a fluorine, chlorine, bromine, or iodine atom, preferably, fluorine, chlorine, or bromine.
- haloalkyl group includes mono-halo alkyl groups, poly-halo alkyl groups wherein all halo atoms can be the same or different, and per-halo alkyl groups, wherein all hydrogen atoms are replaced by halogen atoms, such as fluoro.
- haloalkyl include trifluoromethyl, 1,1-dichloroethyl, 1,2-dichloroethyl, 1,3-dibromo-3,3-difluoropropyl, perfluorobutyl, and the like.
- a “haloalkoxy” group includes mono-halo alkoxy groups, poly-halo alkoxy groups wherein all halo atoms can be the same or different, and per-halo alkoxy groups, wherein all hydrogen atoms are replaced by halogen atoms, such as fluoro.
- haloalkoxy include trifluoromethoxy, 1,1-dichloroethoxy, 1,2-dichloroethoxy, 1,3-dibromo-3,3-difluoropropoxy, perfluorobutoxy, and the like.
- aryloxy and arylalkoxy refer to, respectively, an aryl group bonded to an oxygen atom and an aralkyl group bonded to the oxygen atom at the alkyl moiety. Examples include but are not limited to phenoxy, naphthyloxy, and benzyloxy.
- acyl refers to a group containing a carbonyl moiety wherein the group is bonded via the carbonyl carbon atom.
- the carbonyl carbon atom is also bonded to another carbon atom, which can be part of an alkyl, aryl, aralkyl cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, heteroaryl, heteroarylalkyl group or the like.
- the group is a “formyl” group, an acyl group as the term is defined herein.
- An acyl group can include 0 to about 12-20 additional carbon atoms bonded to the carbonyl group.
- An acyl group can include double or triple bonds within the meaning herein.
- An acryloyl group is an example of an acyl group.
- An acyl group can also include heteroatoms within the meaning here.
- a nicotinoyl group (pyridyl-3-carbonyl) group is an example of an acyl group within the meaning herein.
- Other examples include acetyl, benzoyl, phenylacetyl, pyridylacetyl, cinnamoyl, and acryloyl groups and the like.
- the group containing the carbon atom that is bonded to the carbonyl carbon atom contains a halogen, the group is termed a “haloacyl” group.
- An example is a trifluoroacetyl group.
- amine includes primary, secondary, and tertiary amines having, e.g., the formula N(group) 3 wherein each group can independently be H or non-H, such as alkyl, aryl, and the like.
- Amines include but are not limited to R—NH 2 , for example, alkylamines, arylamines, alkylarylamines; R 2 NH wherein each R is independently selected, such as dialkylamines, diarylamines, aralkylamines, heterocyclylamines and the like; and R 3 N wherein each R is independently selected, such as trialkylamines, dialkylarylamines, alkyldiarylamines, triarylamines, and the like.
- the term “amine” also includes ammonium ions as used herein.
- amino group is a substituent of the form —NH 2 , —NHR, —NR 2 , —NR 3 + , wherein each R is independently selected, and protonated forms of each, except for —NR 3 + , which cannot be protonated. Accordingly, any compound substituted with an amino group can be viewed as an amine.
- An “amino group” within the meaning herein can be a primary, secondary, tertiary or quaternary amino group.
- alkylamino includes a monoalkylamino, dialkylamino, and trialkylamino group.
- ammonium ion includes the unsubstituted ammonium ion NH 4 + , but unless otherwise specified, it also includes any protonated or quaternarized forms of amines. Thus, trimethylammonium hydrochloride and tetramethylammonium chloride are both ammonium ions, and amines, within the meaning herein.
- amide includes C- and N-amide groups, i.e., —C(O)NR 2 , and —NRC(O)R groups, respectively.
- Amide groups therefore include but are not limited to primary carboxamide groups (—C(O)NH 2 ) and formamide groups (—NHC(O)H).
- a “carboxamido” group is a group of the formula C(O)NR 2 , wherein R can be H, alkyl, aryl, etc.
- urethane (“carbamoyl” or “carbamyl”) includes N- and O-urethane groups, i.e., —NRC(O)OR and —OC(O)NR 2 groups, respectively.
- sulfonamide includes S- and N-sulfonamide groups, i.e., —SO 2 NR 2 and —NRSO 2 R groups, respectively. Sulfonamide groups therefore include but are not limited to sulfamoyl groups (—SO 2 NH 2 ).
- An organosulfur structure represented by the formula —S(O)(NR)— is understood to refer to a sulfoximine, wherein both the oxygen and the nitrogen atoms are bonded to the sulfur atom, which is also bonded to two carbon atoms.
- amidine or “amidino” includes groups of the formula —C(NR)NR 2 . Typically, an amidino group is —C(NH)NH 2 .
- guanidine or “guanidino” includes groups of the formula —NRC(NR)NR 2 .
- a guanidino group is —NHC(NH)NH 2 .
- a “salt” as is well known in the art includes an organic compound such as a carboxylic acid, a sulfonic acid, or an amine, in ionic form, in combination with a counterion.
- acids in their anionic form can form salts with cations such as metal cations, for example sodium, potassium, and the like; with ammonium salts such as NH 4 + or the cations of various amines, including tetraalkyl ammonium salts such as tetramethylammonium, or other cations such as trimethylsulfonium, and the like.
- a “pharmaceutically acceptable” or “pharmacologically acceptable” salt is a salt formed from an ion that has been approved for human consumption and is generally non-toxic, such as a chloride salt or a sodium salt.
- a “zwitterion” is an internal salt such as can be formed in a molecule that has at least two ionizable groups, one forming an anion and the other a cation, which serve to balance each other. For example, amino acids such as glycine can exist in a zwitterionic form.
- a “zwitterion” is a salt within the meaning herein.
- the compounds of the present invention may take the form of salts.
- the term “salts” embraces addition salts of free acids or free bases which are compounds of the invention.
- Salts can be “pharmaceutically-acceptable salts.”
- pharmaceutically-acceptable salt refers to salts which possess toxicity profiles within a range that affords utility in pharmaceutical applications. Pharmaceutically unacceptable salts may nonetheless possess properties such as high crystallinity, which have utility in the practice of the present invention, such as for example utility in process of synthesis, purification or formulation of compounds of the invention.
- Suitable pharmaceutically-acceptable acid addition salts may be prepared from an inorganic acid or from an organic acid.
- inorganic acids include hydrochloric, hydrobromic, hydriodic, nitric, carbonic, sulfuric, and phosphoric acids.
- organic acids may be selected from aliphatic, cycloaliphatic, aromatic, araliphatic, heterocyclic, carboxylic and sulfonic classes of organic acids, examples of which include formic, acetic, propionic, succinic, glycolic, gluconic, lactic, malic, tartaric, citric, ascorbic, glucuronic, maleic, fumaric, pyruvic, aspartic, glutamic, benzoic, anthranilic, 4-hydroxybenzoic, phenylacetic, mandelic, embonic (pamoic), methanesulfonic, ethanesulfonic, benzenesulfonic, pantothenic, trifluoromethanesulfonic, 2-hydroxyethanesulfonic, p-toluenesulfonic, sulfanilic, cyclohexylaminosulfonic, stearic, alginic, ⁇ -hydroxybutyric, sal
- Suitable pharmaceutically acceptable base addition salts of compounds of the invention include, for example, metallic salts including alkali metal, alkaline earth metal and transition metal salts such as, for example, calcium, magnesium, potassium, sodium and zinc salts.
- Pharmaceutically acceptable base addition salts also include organic salts made from basic amines such as, for example, N,N′-dibenzylethylenediamine, chloroprocaine, choline, diethanolamine, ethylenediamine, meglumine (N-methylglucamine) and procaine.
- Examples of pharmaceutically unacceptable base addition salts include lithium salts and cyanate salts.
- salts may be useful, for example as intermediates in the synthesis of Formula (I) compounds, for example in their purification by recrystallization. All of these salts may be prepared by conventional means from the corresponding compound according to Formula (I) by reacting, for example, the appropriate acid or base with the compound according to Formula (I).
- pharmaceutically acceptable salts refers to nontoxic inorganic or organic acid and/or base addition salts, see, for example, Lit et al., Salt Selection for Basic Drugs (1986), Int J. Pharm., 33, 201-217, incorporated by reference herein.
- a “hydrate” is a compound that exists in a composition with water molecules.
- the composition can include water in stoichiometric quantities, such as a monohydrate or a dihydrate, or can include water in random amounts.
- a “hydrate” refers to a solid form, i.e., a compound in water solution, while it may be hydrated, is not a hydrate as the term is used herein.
- a “solvate” is a similar composition except that a solvent other that water replaces the water.
- a solvent other that water replaces the water.
- methanol or ethanol can form an “alcoholate”, which can again be stoichiometric or non-stoichiometric.
- a “solvate” refers to a solid form, i.e., a compound in solution in a solvent, while it may be solvated, is not a solvate as the term is used herein.
- a value of a variable that is necessarily an integer, e.g., the number of carbon atoms in an alkyl group or the number of substituents on a ring is described as a range, e.g., 0-4, what is meant is that the value can be any integer between 0 and 4 inclusive, i.e., 0, 1, 2, 3, or 4.
- the compound or set of compounds, such as are used in the inventive methods can be any one of any of the combinations and/or sub-combinations of the above-listed embodiments.
- a compound as shown in any of the Examples, or among the exemplary compounds is provided. Provisos may apply to any of the disclosed categories or embodiments wherein any one or more of the other above disclosed embodiments or species may be excluded from such categories or embodiments.
- the present invention further embraces isolated compounds of the invention.
- isolated compound refers to a preparation of a compound of the invention, or a mixture of compounds the invention, wherein the isolated compound has been separated from the reagents used, and/or byproducts formed, in the synthesis of the compound or compounds. “Isolated” does not mean that the preparation is technically pure (homogeneous), but it is sufficiently pure to compound in a form in which it can be used therapeutically.
- an “isolated compound” refers to a preparation of a compound of the invention or a mixture of compounds of the invention, which contains the named compound or mixture of compounds of the invention in an amount of at least 10 percent by weight of the total weight.
- the preparation contains the named compound or mixture of compounds in an amount of at least 50 percent by weight of the total weight; more preferably at least 80 percent by weight of the total weight; and most preferably at least 90 percent, at least 95 percent or at least 98 percent by weight of the total weight of the preparation.
- the compounds of the invention and intermediates may be isolated from their reaction mixtures and purified by standard techniques such as filtration, liquid-liquid extraction, solid phase extraction, distillation, recrystallization or chromatography, including flash column chromatography, or HPLC.
- a compound of the formula (I) or a salt thereof may exhibit the phenomenon of tautomerism whereby two chemical compounds that are capable of facile interconversion by exchanging a hydrogen atom between two atoms, to either of which it forms a covalent bond. Since the tautomeric compounds exist in mobile equilibrium with each other they may be regarded as different isomeric forms of the same compound. It is to be understood that the formulae drawings within this specification can represent only one of the possible tautomeric forms. However, it is also to be understood that the invention encompasses any tautomeric form, and is not to be limited merely to any one tautomeric form utilized within the formulae drawings.
- Such tautomerism can also occur with substituted pyrazoles such as 3-methyl, 5-methyl, or 3,5-dimethylpyrazoles, and the like.
- Another example of tautomerism is amido-imido (lactam-lactim when cyclic) tautomerism, such as is seen in heterocyclic compounds bearing a ring oxygen atom adjacent to a ring nitrogen atom.
- tautomerism is an example of tautomerism. Accordingly, a structure depicted herein as one tautomer is intended to also include the other tautomer.
- the isomers resulting from the presence of a chiral center comprise a pair of non-superimposable isomers that are called “enantiomers.”
- Single enantiomers of a pure compound are optically active, i.e., they are capable of rotating the plane of plane polarized light.
- Single enantiomers are designated according to the Cahn-Ingold-Prelog system.
- the priority of substituents is ranked based on atomic weights, a higher atomic weight, as determined by the systematic procedure, having a higher priority ranking. Once the priority ranking of the four groups is determined, the molecule is oriented so that the lowest ranking group is pointed away from the viewer.
- the molecule is designated as having an (R) absolute configuration, and if the descending rank of the other groups proceeds counterclockwise, the molecule is designated as having an (5) absolute configuration.
- the Cahn-Ingold-Prelog ranking is A>B>C>D. The lowest ranking atom, D is oriented away from the viewer.
- the solid wedge indicates that the atom bonded thereby projects toward the viewer out of the plane of the paper, and a dashed wedge indicates that the atom bonded thereby projects away from the viewer out of the plan of the paper, i.e., the plane “of the paper” being defined by atoms A, C, and the chiral carbon atom for the (R) configuration shown below.
- a carbon atom bearing the A-D atoms as shown above is known as a “chiral” carbon atom, and the position of such a carbon atom in a molecule is termed a “chiral center.”
- Compounds of the invention may contain more than one chiral center, and the configuration at each chiral center is described in the same fashion.
- the present invention is meant to encompass diastereomers as well as their racemic and resolved, diastereomerically and enantiomerically pure forms and salts thereof. Diastereomeric pairs may be resolved by known separation techniques including normal and reverse phase chromatography, and crystallization.
- isolated optical isomer means a compound which has been substantially purified from the corresponding optical isomer(s) of the same formula.
- the isolated isomer is at least about 80%, more preferably at least 90% pure, even more preferably at least 98% pure, most preferably at least about 99% pure, by weight.
- Isolated optical isomers may be purified from racemic mixtures by well-known chiral separation techniques. According to one such method, a racemic mixture of a compound of the invention, or a chiral intermediate thereof, is separated into 99% wt. % pure optical isomers by HPLC using a suitable chiral column, such as a member of the series of DAICEL® CHIRALPAK® family of columns (Daicel Chemical Industries, Ltd., Tokyo, Japan). The column is operated according to the manufacturer's instructions.
- a suitable chiral column such as a member of the series of DAICEL® CHIRALPAK® family of columns (Daicel Chemical Industries, Ltd., Tokyo, Japan). The column is operated according to the manufacturer's instructions.
- the invention is directed, in various embodiments, to a method for treatment of a patient afflicted by a progressive bone disease, comprising administering to the patient an effective dose of a compound of formula (I)
- R is H, (C 1 -C 6 )alkyl, (C 3 -C 9 )cycloalkyl, or (C 3 -C 9 )cycloalkyl(C 1 -C 6 )alkyl;
- Y 1 or Y 2 are each independently C or N, provided that when Y 1 or Y 2 is N, le or R 2 , respectively, is absent;
- R 1 and R 2 are independently H, (C 1 -C 6 )alkyl, (C 3 -C 9 )cycloalkyl, or (C 1 -C 6 )haloalkyl; or R 1 and R 2 together with the atoms to which they are bonded form a 5- to 9-membered ring, comprising 0-3 heteroatoms selected from the group consisting of O, NR, and SO q wherein q is 0, 1, or 2, and optionally mono- or multi-substituted with independently selected (C 1 -C 6 )alkyl, (C 2 -C 6 )alkenyl, (C 2 -C 6 )alkynyl, (C 6 -C 10 )aryl, (C 3 -C 9 )cycloalkyl, halo, oxo, (C 1 -C 6 )haloalkyl, nitro, cyano-(C 0 -C 6 )alkyl, R′O 2 C—(
- R 3 is optionally mono- or multi-substituted (C 1 -C 6 )alkyl, (C 1 -C 6 )alkenyl, (C 1 -C 6 )alkynyl, (C 6 -C 10 )aryl, (C 6 -C 10 )aryl(C 1 -C 6 )alkyl, (3-9 membered)heterocyclyl, (3-9 membered)heterocyclyl(C 1 -C 6 )alkyl, (3-9 membered)heteroaryl, or (3-9 membered)heteroaryl(C 1 -C 6 )alkyl; wherein if present each substituent on R 3 is independently selected from the group consisting of (C 1 -C 6 )alkyl, (C 2 -C 6 )alkenyl, (C 2 -C 6 )alkynyl, (C 6 -C 10 )aryl, (C 3 -C 9 )cycloal
- each R′ is independently H, (C 1 -C 6 ) alkyl, (C 3 -C 9 )cycloalkyl, (C 3 -C 9 )cycloalkyl(C 1 -C 6 )alkyl, (C 6 -C 10 )aryl, or (C 6 -C 10 )aryl(C 1 -C 6 ) alkyl, or wherein two R′ bonded to an atom together with the atom form a 3-9 membered ring optionally further comprising a heteroatom selected from the group consisting of O, NR′, and S(O) q ;
- any alkyl, alkenyl, alkynyl, aryl, arylalkyl, or cycloalkyl is optionally mono- or independently multi-substituted with (C 1 -C 6 )alkyl, (C 1 -C 6 )haloalkyl, (C 1 -C 6 )alkoxy, (C 1 -C 6 )haloalkoxy, halo, oxo, aryl, or aroyl;
- each of X 1 -X 5 is independently N or CH, or is C substituted with an independently selected R 4 or is C substituted with Z, provided that no more than two of X 1 -X 5 are N, and provided that there is no more than one Z group bonded to the ring comprising X 1 —X 5 ;
- each R 4 is independently halo, nitro, (C 1 -C 6 )fluoroalkyl, R′—(C 0 -C 6 )alkyl, R′O 2 C—(C 0 -C 6 )alkyl, NC—(C 0 -C 6 )alkyl, R′O—(C 0 -C 6 )alkyl, (R′) 2 N—(C 0 -C 6 )alkyl, (R′) 2 NC( ⁇ O)—(C 0 -C 6 )alkyl, R′C( ⁇ O)N(R′)—(C 0 -C 6 )alkyl, C-bonded tetrazolyl, 3-hydroxypyrrolidin-1-carbonyl, 2-hydroxyethylaminocarbonyl, cyclohexylaminocarbonyl, 2-(N,N-dimethylaminocarbonyl)-2-hydroxyethylaminocarbonyl, N,N-d
- R′′ is H, halo, (C 1 -C 6 ) alkyl, (C 1 -C 6 ) haloalkyl, (C 3 -C 9 )cycloalkyl, (C 3 -C 9 )cycloalkyl(C 1 -C 6 )alkyl, (C 6 -C 10 )aryl, or (C 6 -C 10 )aryl(C 1 -C 6 ) alkyl, or two R′′ together with an atom to which they are bonded form a 3- to 9-membered ring;
- Z is a group of formula
- each of Z 1 -Z 5 is independently N or is C substituted with an independently selected H or R 4 ; provided that no more than two of Z 1 -Z 5 are N;
- Y is (C 1 -C 2 )alkyl, or sulfur
- R 5 and R 6 are independently H or (C 1 -C 4 )alkyl or independently each R 5 and R 6 together with the carbon atom to which they are bonded form a carbonyl, or, one R 5 group can further be bonded to X 5 to form a 4- to 8-membered ring; and,
- the effective dose of the compound acts to inhibit bone resorption, improve bone formation, or both, in the patient.
- Y 1 or Y 2 can each be C, providing an indole nucleus.
- R 1 and R 2 can be independently H or methyl.
- Y 1 is N and Y 2 is C, providing a benzimidazole nucleus, or Y 1 is C and Y 2 is N, providing an indazole nucleus for the compound of formula (I) used in a method of the invention.
- R 3 can be benzyl, ⁇ -phenethyl, ⁇ -phenpropyl, cycloalkyl or cycloalkylalkyl, any of which can be unsubstituted or substituted, as described herein.
- R 3 can be heterocyclyl, heterocyclylalkyl, heteroaryl, or heteroarylalkyl, any of which can be unsubstituted or substituted.
- R 3 can be any one of:
- YR 5 R 6 can be SO 2 .
- Y can be C 1 -alkyl; and R 5 and R 6 be H, or Y can be C 2 -alkyl, and R 5 and R 6 be H.
- no Z group is present on the ring comprising X 1 —X 5 , providing a compound of formula (IA), which can be an N-benzyl-indole, an N-benzyl-benzimidazole, or an N-benzyl-indazole, or an analog thereof.
- the compound of formula (IA) can be any one of:
- Z can be present, providing a compound of formula (IB).
- a compound of formula (IB) can be an N-biphenylmethyl-indole, an N-biphenylmethyl-benzimidazole, an N-biphenylmethyl-indazole, or an analog thereof.
- Z 1 -Z 5 can all be carbon. In other embodiments, one of two of Z 1 -Z 5 can be nitrogen.
- the compound of formula (IB) can be any one of:
- the invention provides, in various embodiments, methods of treatment of a progressive bone disease, wherein the progressive bone disease is osteoporosis, Paget's Disease, multiple myeloma, or hyperparathyroidism.
- the progressive bone disease is osteoporosis, Paget's Disease, multiple myeloma, or hyperparathyroidism.
- administration of the compound of formula (I) acts to increase FGF21 while increasing bone health.
- the invention provides the use of a compound of formula (I) for treatment of a progressive bone disease, wherein the compound of formula (I) is
- R is H, (C 1 -C 6 )alkyl, (C 3 -C 9 )cycloalkyl, or (C 3 -C 9 )cycloalkyl(C 1 -C 6 )alkyl;
- Y 1 or Y 2 are each independently C or N, provided that when Y 1 or Y 2 is N, le or R 2 , respectively, is absent;
- R 1 and R 2 are independently H, (C 1 -C 6 )alkyl, (C 3 -C 9 )cycloalkyl, or (C 1 -C 6 )haloalkyl; or R 1 and R 2 together with the atoms to which they are bonded form a 5- to 9-membered ring, comprising 0-3 heteroatoms selected from the group consisting of O, NR, and SO q wherein q is 0, 1, or 2, and optionally mono- or multi-substituted with independently selected (C 1 -C 6 )alkyl, (C 2 -C 6 )alkenyl, (C 2 -C 6 )alkynyl, (C 6 -C 10 )aryl, (C 3 -C 9 )cycloalkyl, halo, oxo, (C 1 -C 6 )haloalkyl, nitro, cyano-(C 0 -C 6 )alkyl, R′O 2 C—(
- R 3 is optionally mono- or multi-substituted (C 1 -C 6 )alkyl, (C 1 -C 6 )alkenyl, (C 1 -C 6 )alkynyl, (C 6 -C 10 )aryl, (C 6 -C 10 )aryl(C 1 -C 6 )alkyl, (3-9 membered)heterocyclyl, (3-9 membered)heterocyclyl(C 1 -C 6 )alkyl, (3-9 membered)heteroaryl, or (3-9 membered)heteroaryl(C 1 -C 6 )alkyl; wherein if present each substituent on R 3 is independently selected from the group consisting of (C 1 -C 6 )alkyl, (C 2 -C 6 )alkenyl, (C 2 -C 6 )alkynyl, (C 6 -C 10 )aryl, (C 3 -C 9 )cycloal
- each R′ is independently H, (C 1 -C 6 ) alkyl, (C 3 -C 9 )cycloalkyl, (C 3 -C 9 )cycloalkyl(C 1 -C 6 )alkyl, (C 6 -C 10 )aryl, or (C 6 -C 10 )aryl(C 1 -C 6 ) alkyl, or wherein two R′ bonded to an atom together with the atom form a 3-9 membered ring optionally further comprising a heteroatom selected from the group consisting of O, NR′, and S(O) q ;
- any alkyl, alkenyl, alkynyl, aryl, arylalkyl, or cycloalkyl is optionally mono- or independently multi-substituted with (C 1 -C 6 )alkyl, (C 1 -C 6 )haloalkyl, (C 1 -C 6 )alkoxy, (C 1 -C 6 )haloalkoxy, halo, oxo, aryl, or aroyl;
- each of X 1 -X 5 is independently N or CH, or is C substituted with an independently selected R 4 or is C substituted with Z, provided that no more than two of X 1 -X 5 are N, and provided that there is no more than one Z group bonded to the ring comprising X 1 —X 5 ;
- each R 4 is independently halo, nitro, (C 1 -C 6 )fluoroalkyl, R′—(C 0 -C 6 )alkyl, R′O 2 C—(C 0 -C 6 )alkyl, NC—(C 0 -C 6 )alkyl, R′O—(C 0 -C 6 )alkyl, (R′) 2 N—(C 0 -C 6 )alkyl, (R′) 2 NC( ⁇ O)—(C 0 -C 6 )alkyl, R′C( ⁇ O)N(R′)—(C 0 -C 6 )alkyl, C-bonded tetrazolyl, 3-hydroxypyrrolidin-1-carbonyl, 2-hydroxyethylaminocarbonyl, cyclohexylaminocarbonyl, 2-(N,N-dimethylaminocarbonyl)-2-hydroxyethylaminocarbonyl, N,N-d
- R′′ is H, halo, (C 1 -C 6 ) alkyl, (C 1 -C 6 ) haloalkyl, (C 3 -C 9 )cycloalkyl, (C 3 -C 9 )cycloalkyl(C 1 -C 6 )alkyl, (C 6 -C 10 )aryl, or (C 6 -C 10 )aryl(C 1 -C 6 ) alkyl, or two R′′ together with an atom to which they are bonded form a 3- to 9-membered ring;
- Z is a group of formula
- each of Z 1 -Z 5 is independently N or is C substituted with an independently selected H or R 4 ; provided that no more than two of Z 1 -Z 5 are N;
- Y is (C 1 -C 2 )alkyl, or sulfur
- R 5 and R 6 are independently H or (C 1 -C 4 )alkyl or independently each R 5 and R 6 together with the carbon atom to which they are bonded form a carbonyl, or, one R 5 group can further be bonded to X 5 to form a 4- to 8-membered ring; and,
- the effective dose of the compound acts to inhibit bone resorption, improve bone formation, or both, in the patient.
- the progressive bone disease can be osteoporosis, Paget's Disease, multiple myeloma, or hyperparathyroidism.
- administration of the compound of formula (I) acts to increase FGF21 while increasing bone health.
- the invention provides a compound of formula
- the invention provides a method for practice of the invention wherein the compound of formula (I) is
- the invention provides a use of a compound of formula (I), wherein the compound is
- a progressive bone disease for instance, for treatment of osteoporosis, Paget's Disease, multiple myeloma, or hyperparathyroidism.
- This bromomethyl compound can be prepared as described in Example 35, step 2, below, substituting methyl 1-methyl-1-(p-tolyl)-propionate for methyl 1-(p-tolyl)cyclopropanecarboxylate in the bromination reaction.
- the bromomethyl compound can be purchased from Chinglu Pharmaceutical Research LLC, 705 North Mountain Rd., Suite C115, Newington, Conn.
- Step 5 (S)-Methyl 1-(4-((5-((1-(3-bromophenyl)ethyl)carbamoyl)-2,3-dimethyl-1H-indol-1-yl)methyl)phenyl)cyclopropanecarboxylate
- Step 6 (S)-Methyl 1-(4-((2,3-dimethyl-5-((1-(3-(prop-1-en-2-yl)phenyl)ethyl)carbamoyl)-1H-indol-1-yl)methyl)phenyl)cyclopropanecarboxylate
- Step 7 (S)-Methyl 1-(4-((5-((1-(3-isopropylphenyl)ethyl)carbamoyl)-2,3-dimethyl-1H-indol-1-yl)methyl)phenyl)cyclopropanecarboxylate
- Step 8 (S)-1-(4-((5-((1-(3-Isopropylphenyl)ethyl)carbamoyl)-2,3-dimethyl-1H-indol-1-yl)methyl)phenyl)cyclopropanecarboxylic Acid
- Step 5 (S)-Methyl 2-(4-((5-((1-(3-cyclopropylphenyl)ethyl)carbamoyl)-2,3-dimethyl-1H-indol-1-yl)methyl)phenoxy)acetate
- Step 6 (S)-2-(4-((5-((1-(3-Cyclopropylphenyl)ethyl)carbamoyl)-2,3-dimethyl-1H-indol-1-yl)methyl)phenoxy)acetic Acid
- Step 1 (S)-Methyl 2-(4-((5-((1-(3-isopropylphenyl)ethyl)carbamoyl)-2,3-dimethyl-1H-indol-1-yl)methyl)phenoxy)acetate
- Step 2 (S)-2-(4-((5-((1-(3-Isopropylphenyl)ethyl)carbamoyl)-2,3-dimethyl-1H-indol-1-yl)methyl)phenoxy)acetic Acid
- Step 1 (S)-Methyl 2-(4-((5-((1-(4-(tert-butyl)phenyl)ethyl)carbamoyl)-2,3-dimethyl-1H-indol-1-yl)methyl)phenoxy)acetate
- Step 2 (S)-2-(4-((5-((1-(4-(tert-Butyl)phenyl)ethyl)carbamoyl)-2,3-dimethyl-1H-indol-1-yl)methyl)phenoxy)acetic Acid
- Step 5 (S)-Methyl 2-(3-((5-((1-(3-cyclopropylphenyl)ethyl)carbamoyl)-2,3-dimethyl-1H-indol-1-yl)methyl)phenoxy)acetate
- the title compound was prepared following the same protocol as described in Step 5, Example 36, using the 1-(3-(2-methoxy-2-oxoethoxy)benzyl)-2,3-dimethyl-1H-indole-5-carboxylic acid instead of the 1-(4-(2-methoxy-2-oxoethoxy)benzyl)-2,3-dimethyl-1H-indole-5-carboxylic acid.
- Step 6 (S)-2-(3-((5-((1-(3-Cyclopropylphenyl)ethyl)carbamoyl)-2,3-dimethyl-1H-indol-1-yl)methyl)phenoxy)acetic Acid
- Step 1 (S)-Methyl 2-(3-((5-((1-(3-isopropylphenyl)ethyl)carbamoyl)-2,3-dimethyl-1H-indol-1-yl)methyl)phenoxy)acetate
- the title compound was prepared following the same protocol as described in Step 5, Example 36, using the (S)-1-(3-isopropylphenyl)ethanamine hydrochloride instead of the (S)-1-(3-cyclopropylphenyl)ethanamine hydrochloride and the 1-(3-(2-methoxy-2-oxoethoxy)benzyl)-2,3-dimethyl-1H-indole-5-carboxylic acid instead of the 1-(4-(2-methoxy-2-oxoethoxy)benzyl)-2,3-dimethyl-1H-indole-5-carboxylic acid.
- Step 2 (S)-2-(3-((5-((1-(3-Isopropylphenyl)ethyl)carbamoyl)-2,3-dimethyl-1H-indol-1-yl)methyl)phenoxy)acetic Acid
- Step 1 (S)-Methyl 2-(3-((5-((1-(4-(tert-butyl)phenyl)ethyl)carbamoyl)-2,3-dimethyl-1H-indol-1-yl)methyl)phenoxy)acetate
- the title compound was prepared following the same protocol as described in Step 5, Example 36, using the (S)-1-(4-(tert-butyl)phenyl)ethanamine hydrochloride instead of the (S)-1-(3-cyclopropylphenyl)ethanamine hydrochloride and the 1-(3-(2-methoxy-2-oxoethoxy)benzyl)-2,3-dimethyl-1H-indole-5-carboxylic acid instead of the 1-(4-(2-methoxy-2-oxoethoxy)benzyl)-2,3-dimethyl-1H-indole-5-carboxylic acid.
- Step 2 (S)-2-(3-((5-((1-(4-(tert-Butyl)phenyl)ethyl)carbamoyl)-2,3-dimethyl-1H-indol-1-yl)methyl)phenoxy)acetic Acid
- Step 3 (R)-Allyl 1-(3-((1-methoxy-1-oxopropan-2-yl)oxy)benzyl)-2,3-dimethyl-1H-indole-5-carboxylate
- Step 4 (R)-1-(3-((1-Methoxy-1-oxopropan-2-yl)oxy)benzyl)-2,3-dimethyl-1H-indole-5-carboxylic Acid
- Step 5 (R)-Methyl 2-(3-((5-(((S)-1-(3-isopropylphenyl)ethyl)carbamoyl)-2,3-dimethyl-1H-indol-1-yl)methyl)phenoxy)propanoate
- the title compound was prepared following the same protocol as described in Step 5, Example 36, using the (S)-1-(3-isopropylphenyl)ethanamine hydrochloride instead of the (S)-1-(3-cyclopropylphenyl)ethanamine hydrochloride and the (R)-1-(3-((1-methoxy-1-oxopropan-2-yl)oxy)benzyl)-2,3-dimethyl-1H-indole-5-carboxylic acid instead of the 1-(4-(2-methoxy-2-oxoethoxy)benzyl)-2,3-dimethyl-1H-indole-5-carboxylic acid.
- Step 6 (R)-2-(3-((5-(((S)-1-(3-Isopropylphenyl)ethyl)carbamoyl)-2,3-dimethyl-1H-indol-1-yl)methyl)phenoxy)propanoic Acid
- Step 1 (R)-Methyl 2-(3-((5-(((S)-1-(4-(tert-butyl)phenyl)ethyl)carbamoyl)-2,3-dimethyl-1H-indol-1-yl)methyl)phenoxy)propanoate
- the title compound was prepared following the same protocol as described in Step 5, Example 36, using the (S)-1-(4-(tert-butyl)phenyl)ethanamine hydrochloride instead of the (S)-1-(3-cyclopropylphenyl)ethanamine hydrochloride and the (R)-1-(3-((1-methoxy-1-oxopropan-2-yl)oxy)benzyl)-2,3-dimethyl-1H-indole-5-carboxylic acid instead of the 1-(4-(2-methoxy-2-oxoethoxy)benzyl)-2,3-dimethyl-1H-indole-5-carboxylic acid.
- Step 2 (R)-2-(3-((5-(((S)-1-(4-(tert-Butyl)phenyl)ethyl)carbamoyl)-2,3-dimethyl-1H-indol-1-yl)methyl)phenoxy)propanoic Acid
- Step 3 (S)-Allyl 1-(3-((1-methoxy-1-oxopropan-2-yl)oxy)benzyl)-2,3-dimethyl-1H-indole-5-carboxylate
- Step 4 (S)-1-(3-((1-Methoxy-1-oxopropan-2-yl)oxy)benzyl)-2,3-dimethyl-1H-indole-5-carboxylic Acid
- Step 5 (S)-Methyl 2-(3-((5-(((S)-1-(3-isopropylphenyl)ethyl)carbamoyl)-2,3-dimethyl-1H-indol-1-yl)methyl)phenoxy)propanoate
- the title compound was prepared following the same protocol as described in Step 5, Example 36, using the (S)-1-(3-isopropylphenyl)ethanamine hydrochloride instead of the (S)-1-(3-cyclopropylphenyl)ethanamine hydrochloride and the (S)-1-(3-((1-methoxy-1-oxopropan-2-yl)oxy)benzyl)-2,3-dimethyl-1H-indole-5-carboxylic acid instead of the 1-(4-(2-methoxy-2-oxoethoxy)benzyl)-2,3-dimethyl-1H-indole-5-carboxylic acid.
- Step 6 (S)-2-(3-((5-(((S)-1-(3-Isopropylphenyl)ethyl)carbamoyl)-2,3-dimethyl-1H-indol-1-yl)methyl)phenoxy)propanoic Acid
- Step 1 (S)-Methyl 2-(3-((5-(((S)-1-(4-(tert-butyl)phenyl)ethyl)carbamoyl)-2,3-dimethyl-1H-indol-1-yl)methyl)phenoxy)propanoate
- the title compound was prepared following the same protocol as described in Step 5, Example 36, using the (S)-1-(4-(tert-Butyl)phenyl)ethanamine hydrochloride instead of the (S)-1-(3-cyclopropylphenyl)ethanamine hydrochloride and the (S)-1-(3-((1-methoxy-1-oxopropan-2-yl)oxy)benzyl)-2,3-dimethyl-1H-indole-5-carboxylic acid instead of the 1-(4-(2-methoxy-2-oxoethoxy)benzyl)-2,3-dimethyl-1H-indole-5-carboxylic acid.
- Step 2 (S)-2-(3-((5-(((S)-1-(4-(tert-Butyl)phenyl)ethyl)carbamoyl)-2,3-dimethyl-1H-indol-1-yl)methyl)phenoxy)propanoic Acid
- Step 1 (S)-Methyl 2-(3-((5-(((S)-1-(3-cyclopropylphenyl)ethyl)carbamoyl)-2,3-dimethyl-1H-indol-1-yl)methyl)phenoxy)propanoate
- the title compound was prepared following the same protocol as described in Step 5, Example 36, using the (S)-1-(3-((1-methoxy-1-oxopropan-2-yl)oxy)benzyl)-2,3-dimethyl-1H-indole-5-carboxylic acid instead of the 1-(4-(2-methoxy-2-oxoethoxy)benzyl)-2,3-dimethyl-1H-indole-5-carboxylic acid.
- Step 2 (S)-2-(3-((5-(((S)-1-(3-Cyclopropylphenyl)ethyl)carbamoyl)-2,3-dimethyl-1H-indol-1-yl)methyl)phenoxy)propanoic Acid
- Step 3 Allyl 1-(3-((1-methoxy-2-methyl-1-oxopropan-2-yl)oxy)benzyl)-2,3-dimethyl-1H-indole-5-carboxylate
- Step 4 1-(3-((1-Methoxy-2-methyl-1-oxopropan-2-yl)oxy)benzyl)-2,3-dimethyl-1H-indole-5-carboxylic Acid
- Step 5 (S)-Methyl 2-(3-((5-((1-(3-isopropylphenyl)ethyl)carbamoyl)-2,3-dimethyl-1H-indol-1-yl)methyl)phenoxy)-2-methylpropanoate
- the title compound was prepared following the same protocol as described in Step 5, Example 36, using the (S)-1-(3-isopropylphenyl)ethanamine hydrochloride instead of the (S)-1-(3-cyclopropylphenyl)ethanamine hydrochloride and the 1-(3-((1-methoxy-2-methyl-1-oxopropan-2-yl)oxy)benzyl)-2,3-dimethyl-1H-indole-5-carboxylic acid instead of the 1-(4-(2-methoxy-2-oxoethoxy)benzyl)-2,3-dimethyl-1H-indole-5-carboxylic acid.
- Step 6 (S)-2-(3-((5-((1-(3-Isopropylphenyl)ethyl)carbamoyl)-2,3-dimethyl-1H-indol-1-yl)methyl)phenoxy)-2-methylpropanoic Acid
- Step 1 (S)-Methyl 2-(3-((5-((1-(4-(tert-butyl)phenyl)ethyl)carbamoyl)-2,3-dimethyl-1H-indol-1-yl)methyl)phenoxy)-2-methylpropanoate
- the title compound was prepared following the same protocol as described in Step 5, Example 36, using the (S)-1-(4-(tert-butyl)phenyl)ethanamine hydrochloride instead of the (S)-1-(3-cyclopropylphenyl)ethanamine hydrochloride and the 1-(3-((1-methoxy-2-methyl-1-oxopropan-2-yl)oxy)benzyl)-2,3-dimethyl-1H-indole-5-carboxylic acid instead of the 1-(4-(2-methoxy-2-oxoethoxy)benzyl)-2,3-dimethyl-1H-indole-5-carboxylic acid.
- Step 2 (S)-2-(3-((5-((1-(4-(tert-Butyl)phenyl)ethyl)carbamoyl)-2,3-dimethyl-1H-indol-1-yl)methyl)phenoxy)-2-methylpropanoic Acid
- Step 5 (S)-1-(3-(Cyanomethoxy)benzyl)-N-(1-(3-isopropylphenyl)ethyl)-2,3-dimethyl-1H-indole-5-carboxamide
- Step 3 (S)-Allyl 1-(4-((1-methoxy-1-oxopropan-2-yl)oxy)benzyl)-2,3-dimethyl-1H-indole-5-carboxylate
- Step 4 (S)-1-(4-((1-Methoxy-1-oxopropan-2-yl)oxy)benzyl)-2,3-dimethyl-1H-indole-5-carboxylic Acid
- Step 5 (S)-Methyl 2-(4-((5-(((S)-1-(3-isopropylphenyl)ethyl)carbamoyl)-2,3-dimethyl-1H-indol-1-yl)methyl)phenoxy)propanoate
- the title compound was prepared following the same protocol as described in Step 5, Example 36, using the (S)-1-(3-isopropylphenyl)ethanamine hydrochloride instead of the (S)-1-(3-cyclopropylphenyl)ethanamine hydrochloride and the (S)-1-(4-((1-methoxy-1-oxopropan-2-yl)oxy)benzyl)-2,3-dimethyl-1H-indole-5-carboxylic acid instead of the 1-(4-(2-methoxy-2-oxoethoxy)benzyl)-2,3-dimethyl-1H-indole-5-carboxylic acid.
- Step 6 (S)-2-(4-((5-(((S)-1-(4-Isopropylphenyl)ethyl)carbamoyl)-2,3-dimethyl-1H-indol-1-yl)methyl)phenoxy)propanoic Acid
- Step 1 (S)-Methyl 2-(4-((5-(((S)-1-(3-cyclopropylphenyl)ethyl)carbamoyl)-2,3-dimethyl-1H-indol-1-yl)methyl)phenoxy)propanoate
- Step 2 (S)-2-(4-((5-(((S)-1-(3-Cyclopropylphenyl)ethyl)carbamoyl)-2,3-dimethyl-1H-indol-1-yl)methyl)phenoxy)propanoic Acid
- Step 3 (R)-Allyl 1-(4-((1-methoxy-1-oxopropan-2-yl)oxy)benzyl)-2,3-dimethyl-1H-indole-5-carboxylate
- Step 4 (R)-1-(4-((1-Methoxy-1-oxopropan-2-yl)oxy)benzyl)-2,3-dimethyl-1H-indole-5-carboxylic Acid
- Step 5 (R)-Methyl 2-(4-((5-(((S)-1-(3-isopropylphenyl)ethyl)carbamoyl)-2,3-dimethyl-1H-indol-1-yl)methyl)phenoxy)propanoate
- the title compound was prepared following the same protocol as described in Step 5, Example 36, using the (S)-1-(3-isopropylphenyl)ethanamine hydrochloride instead of the (S)-1-(3-cyclopropylphenyl)ethanamine hydrochloride and the (R)-1-(4-((1-methoxy-1-oxopropan-2-yl)oxy)benzyl)-2,3-dimethyl-1H-indole-5-carboxylic acid instead of the 1-(4-(2-methoxy-2-oxoethoxy)benzyl)-2,3-dimethyl-1H-indole-5-carboxylic acid.
- Step 6 (R)-2-(3-((5-(((S)-1-(4-Isopropylphenyl)ethyl)carbamoyl)-2,3-dimethyl-1H-indol-1-yl)methyl)phenoxy)propanoic Acid
- Step 4 1-(4-((1-Methoxy-2-methyl-1-oxopropan-2-yl)oxy)benzyl)-2,3-dimethyl-1H-indole-5-carboxylic Acid
- Step 5 (S)-Methyl 2-(4-((5-((1-(3-isopropylphenyl)ethyl)carbamoyl)-2,3-dimethyl-1H-indol-1-yl)methyl)phenoxy)-2-methylpropanoate
- the title compound was prepared following the same protocol as described in Step 5, Example 36, using the (S)-1-(3-isopropylphenyl)ethanamine hydrochloride instead of the (S)-1-(3-cyclopropylphenyl)ethanamine hydrochloride and the 1-(4-((1-methoxy-2-methyl-1-oxopropan-2-yl)oxy)benzyl)-2,3-dimethyl-1H-indole-5-carboxylic acid instead of the 1-(4-(2-methoxy-2-oxoethoxy)benzyl)-2,3-dimethyl-1H-indole-5-carboxylic acid.
- Step 6 (S)-2-(4-((5-((1-(3-Isopropylphenyl)ethyl)carbamoyl)-2,3-dimethyl-1H-indol-1-yl)methyl)phenoxy)-2-methylpropanoic Acid
- Step 3 (S)-Allyl 1-(4-chloro-3-((1-methoxy-1-oxopropan-2-yl)oxy)benzyl)-2,3-dimethyl-1H-indole-5-carboxylate
- Step 4 (S)-1-(4-Chloro-3-((1-methoxy-1-oxopropan-2-yl)oxy)benzyl)-2,3-dimethyl-1H-indole-5-carboxylic Acid
- Step 5 (S)-Methyl 2-(2-chloro-5-((5-(((S)-1-(3-isopropylphenyl)ethyl)carbamoyl)-2,3-dimethyl-1H-indol-1-yl)methyl)phenoxy)propanoate
- Step 6 (S)-2-(2-Chloro-5-((5-(((S)-1-(3-isopropylphenyl)ethyl)carbamoyl)-2,3-dimethyl-1H-indol-1-yl)methyl)phenoxy)propanoic Acid
- Step 1 (S)-Methyl 2-(5-((5-(((S)-1-(4-(tert-butyl)phenyl)ethyl)carbamoyl)-2,3-dimethyl-1H-indol-1-yl)methyl)-2-chlorophenoxy)propanoate
- Step 2 (S)-2-(5-((5-(((S)-1-(4-(tert-Butyl)phenyl)ethyl)carbamoyl)-2,3-dimethyl-1H-indol-1-yl)methyl)-2-chlorophenoxy)propanoic Acid
- Step 1 (S)-Methyl 2-(5-((5-(((S)-1-(3-(tert-butyl)phenyl)ethyl)carbamoyl)-2,3-dimethyl-1H-indol-1-yl)methyl)-2-chlorophenoxy)propanoate
- Example 36 using the (S)-1-(3-(tert-butyl)phenyl)ethanamine hydrochloride instead of the (S)-1-(3-cyclopropylphenyl)ethanamine hydrochloride the (S)-1-(4-chloro-3-((1-methoxy-1-oxopropan-2-yl)oxy)benzyl)-2,3-dimethyl-1H-indole-5-carboxylic acid instead of the 1-(4-(2-methoxy-2-oxoethoxy)benzyl)-2,3-dimethyl-1H-indole-5-carboxylic acid.
- Step 2 (S)-2-(5-((5-(((S)-1-(3-(tert-Butyl)phenyl)ethyl)carbamoyl)-2,3-dimethyl-1H-indol-1-yl)methyl)-2-chlorophenoxy)propanoic Acid
- Step 1 (S)-Methyl 2-(5-((5-(((S)-1-(3-isopropoxyphenyl)ethyl)carbamoyl)-2,3-dimethyl-1H-indol-1-yl)methyl)-2-chlorophenoxy)propanoate
- the title compound was prepared following the same protocol as described in Step 5, Example 36, using the (S)-1-(3-isopropoxyphenyl)ethanamine hydrochloride instead of the (S)-1-(3-cyclopropylphenyl)ethanamine hydrochloride and (S)-1-(4-chloro-3-((1-methoxy-1-oxopropan-2-yl)oxy)benzyl)-2,3-dimethyl-1H-indole-5-carboxylic acid instead of the 1-(4-(2-methoxy-2-oxoethoxy)benzyl)-2,3-dimethyl-1H-indole-5-carboxylic acid.
- Step 2 (S)-2-(5-((5-(((S)-1-(3-isopropoxyphenyl)ethyl)carbamoyl)-2,3-dimethyl-1H-indol-1-yl)methyl)-2-chlorophenoxy)propanoic Acid
- the title compound was prepared following the same general protocol as described for the synthesis of the (S)-methyl 2-(5-(bromomethyl)-2-chlorophenoxy)propanoate (Step 2, Example 55), using the (S)-methyl 2-(4-chloro-3-methylphenoxy)propanoate instead of the (S)-methyl 2-(2-chloro-5-methylphenoxy)propanoate.
- Step 3 (S)-Allyl 1-(2-chloro-5-((1-methoxy-1-oxopropan-2-yl)oxy)benzyl)-2,3-dimethyl-1H-indole-5-carboxylate
- Step 4 (S)-1-(2-Chloro-5-((1-methoxy-1-oxopropan-2-yl)oxy)benzyl)-2,3-dimethyl-1H-indole-5-carboxylic Acid
- Step 5 (S)-Methyl 2-(4-chloro-3-((5-(((S)-1-(3-isopropylphenyl)ethyl)carbamoyl)-2,3-dimethyl-1H-indol-1-yl)methyl)phenoxy)propanoate
- Step 6 (S)-2-(4-Chloro-3-((5-(((S)-1-(3-isopropylphenyl)ethyl)carbamoyl)-2,3-dimethyl-1H-indol-1-yl)methyl)phenoxy)propanoic Acid
- Step 1 (S)-Methyl 2-(3-((5-(((S)-1-(4-(tert-butyl)phenyl)ethyl)carbamoyl)-2,3-dimethyl-1H-indol-1-yl)methyl)-4-chlorophenoxy)propanoate
- the title compound was prepared following the same protocol as described in Step 5, Example 36, using the (S)-1-(4-(tert-butyl)phenyl)ethanamine hydrochloride instead of the (S)-1-(3-cyclopropylphenyl)ethanamine hydrochloride the (S)-1-(2-chloro-5-((1-methoxy-1-oxopropan-2-yl)oxy)benzyl)-2,3-dimethyl-1H-indole-5-carboxylic acid instead of the 1-(4-(2-methoxy-2-oxoethoxy)benzyl)-2,3-dimethyl-1H-indole-5-carboxylic acid.
- Step 2 (S)-2-(3-((5-(((S)-1-(4-(tert-Butyl)phenyl)ethyl)carbamoyl)-2,3-dimethyl-1H-indol-1-yl)methyl)-4-chlorophenoxy)propanoic Acid
- Step 1 (S)-Methyl 2-(3-((5-(((S)-1-(3-(tert-butyl)phenyl)ethyl)carbamoyl)-2,3-dimethyl-1H-indol-1-yl)methyl)-4-chlorophenoxy)propanoate
- the title compound was prepared following the same protocol as described in Step 5, Example 36, using the (S)-1-(3-(tert-butyl)phenyl)ethanamine hydrochloride instead of the (S)-1-(3-cyclopropylphenyl)ethanamine hydrochloride the (S)-1-(2-chloro-5-((1-methoxy-1-oxopropan-2-yl)oxy)benzyl)-2,3-dimethyl-1H-indole-5-carboxylic acid instead of the 1-(4-(2-methoxy-2-oxoethoxy)benzyl)-2,3-dimethyl-1H-indole-5-carboxylic acid.
- Step 2 (S)-2-(3-((5-(((S)-1-(3-(tert-Butyl)phenyl)ethyl)carbamoyl)-2,3-dimethyl-1H-indol-1-yl)methyl)-4-chlorophenoxy)propanoic Acid
- Example 36 using the (S)-methyl 2-(3-((5-(((S)-1-(4-(tert-butyl)phenyl)ethyl)carbamoyl)-2,3-dimethyl-1H-indol-1-yl)methyl)-4-chlorophenoxy)propanoate instead of the (S)-methyl 2-(4-((5-((1-(3-cyclopropylphenyl)ethyl)carbamoyl)-2,3-dimethyl-1H-indol-1-yl)methyl)phenoxy)acetate.
- ESI-MS (m/z): 561/562/563 [M+H] + .
- Step 1 (S)-Methyl 2-(3-((5-(((S)-1-(3-isopropoxyphenyl)ethyl)carbamoyl)-2,3-dimethyl-1H-indol-1-yl)methyl)-4-chlorophenoxy)propanoate
- the title compound was prepared following the same protocol as described in Step 5, Example 36, using the (S)-1-(3-isopropoxyphenyl)ethanamine hydrochloride instead of the (S)-1-(3-cyclopropylphenyl)ethanamine hydrochloride the (S)-1-(2-chloro-5-((1-methoxy-1-oxopropan-2-yl)oxy)benzyl)-2,3-dimethyl-1H-indole-5-carboxylic acid instead of the 1-(4-(2-methoxy-2-oxoethoxy)benzyl)-2,3-dimethyl-1H-indole-5-carboxylic acid.
- Step 2 (S)-2-(4-Chloro-3-((5-(((S)-1-(3-isopropoxyphenyl)ethyl)carbamoyl)-2,3-dimethyl-1H-indol-1-yl)methyl)phenoxy)propanoic Acid
- Step 3 (S)-Allyl 1-(3-chloro-5-((1-methoxy-1-oxopropan-2-yl)oxy)benzyl)-2,3-dimethyl-1H-indole-5-carboxylate
- Step 4 (S)-1-(3-Chloro-5-((1-methoxy-1-oxopropan-2-yl)oxy)benzyl)-2,3-dimethyl-1H-indole-5-carboxylic Acid
- Step 5 (S)-methyl 2-(3-chloro-5-((5-(((S)-1-(3-isopropylphenyl)ethyl)carbamoyl)-2,3-dimethyl-1H-indol-1-yl)methyl)phenoxy)propanoate
- the title compound was prepared following the same protocol as described in Step 5, Example 36, using the (S)-1-(3-isopropylphenyl)ethanamine hydrochloride instead of the (S)-1-(3-cyclopropylphenyl)ethanamine hydrochloride and the (S)-1-(3-chloro-5-((1-methoxy-1-oxopropan-2-yl)oxy)benzyl)-2,3-dimethyl-1H-indole-5-carboxylic acid instead of the 1-(4-(2-methoxy-2-oxoethoxy)benzyl)-2,3-dimethyl-1H-indole-5-carboxylic acid.
- Step 6 (S)-2-(3-chloro-5-((5-(((S)-1-(3-isopropylphenyl)ethyl)carbamoyl)-2,3-dimethyl-1H-indol-1-yl)methyl)phenoxy)propanoic Acid
- Step 3 (S)-Allyl 1-(2-chloro-3-((1-methoxy-1-oxopropan-2-yl)oxy)benzyl)-2,3-dimethyl-1H-indole-5-carboxylate
- Step 4 (S)-1-(2-Chloro-3-((1-methoxy-1-oxopropan-2-yl)oxy)benzyl)-2,3-dimethyl-1H-indole-5-carboxylic Acid
- Step 5 (S)-methyl 2-(2-chloro-3-((5-(((S)-1-(3-isopropylphenyl)ethyl)carbamoyl)-2,3-dimethyl-1H-indol-1-yl)methyl)phenoxy)propanoate
- the title compound was prepared following the same protocol as described in Step 5, Example 36, using the (S)-1-(3-isopropylphenyl)ethanamine hydrochloride instead of the (S)-1-(3-cyclopropylphenyl)ethanamine hydrochloride and the (S)-1-(2-chloro-3-((1-methoxy-1-oxopropan-2-yl)oxy)benzyl)-2,3-dimethyl-1H-indole-5-carboxylic acid instead of the 1-(4-(2-methoxy-2-oxoethoxy)benzyl)-2,3-dimethyl-1H-indole-5-carboxylic acid.
- Step 6 (S)-2-(2-chloro-3-((5-(((S)-1-(3-isopropylphenyl)ethyl)carbamoyl)-2,3-dimethyl-1H-indol-1-yl)methyl)phenoxy)propanoic Acid
- Step 3 (R)-Allyl 1-(4-chloro-3-((1-methoxy-1-oxopropan-2-yl)oxy)benzyl)-2,3-dimethyl-1H-indole-5-carboxylate
- Step 4 (R)-1-(4-Chloro-3-((1-methoxy-1-oxopropan-2-yl)oxy)benzyl)-2,3-dimethyl-1H-indole-5-carboxylic Acid
- Step 5 (R)-Methyl 2-(2-chloro-5-((5-(((S)-1-(3-isopropylphenyl)ethyl)carbamoyl)-2,3-dimethyl-1H-indol-1-yl)methyl)phenoxy)propanoate
- the title compound was prepared following the same protocol as described in Step 5, Example 36, using the (S)-1-(3-isopropylphenyl)ethanamine hydrochloride instead of the (S)-1-(3-cyclopropylphenyl)ethanamine hydrochloride and the (R)-1-(4-chloro-3-((1-methoxy-1-oxopropan-2-yl)oxy)benzyl)-2,3-dimethyl-1H-indole-5-carboxylic acid instead of the 1-(4-(2-methoxy-2-oxoethoxy)benzyl)-2,3-dimethyl-1H-indole-5-carboxylic acid.
- Step 6 (R)-2-(2-Chloro-5-((5-(((S)-1-(3-isopropylphenyl)ethyl)carbamoyl)-2,3-dimethyl-1H-indol-1-yl)methyl)phenoxy)propanoic Acid
- Step 3 (R)-Allyl 1-(2-chloro-5-((1-methoxy-1-oxopropan-2-yl)oxy)benzyl)-2,3-dimethyl-1H-indole-5-carboxylate
- Step 4 (R)-1-(2-Chloro-5-((1-methoxy-1-oxopropan-2-yl)oxy)benzyl)-2,3-dimethyl-1H-indole-5-carboxylic Acid
- Step 5 (R)-Methyl 2-(3-chloro-4-((5-(((S)-1-(3-isopropylphenyl)ethyl)carbamoyl)-2,3-dimethyl-1H-indol-1-yl)methyl)phenoxy)propanoate
- the title compound was prepared following the same protocol as described in Step 5, Example 36, using the (S)-1-(3-isopropylphenyl)ethanamine hydrochloride instead of the (S)-1-(3-cyclopropylphenyl)ethanamine hydrochloride and the (R)-1-(2-chloro-5-((1-methoxy-1-oxopropan-2-yl)oxy)benzyl)-2,3-dimethyl-1H-indole-5-carboxylic acid instead of the 1-(4-(2-methoxy-2-oxoethoxy)benzyl)-2,3-dimethyl-1H-indole-5-carboxylic acid.
- Step 6 (R)-2-(3-Chloro-4-((5-(((S)-1-(3-isopropylphenyl)ethyl)carbamoyl)-2,3-dimethyl-1H-indol-1-yl)methyl)phenoxy)propanoic Acid
- Step 3 (R)-Allyl 1-(3-chloro-5-((1-methoxy-1-oxopropan-2-yl)oxy)benzyl)-2,3-dimethyl-1H-indole-5-carboxylate
- Step 4 (R)-1-(3-Chloro-5-((1-methoxy-1-oxopropan-2-yl)oxy)benzyl)-2,3-dimethyl-1H-indole-5-carboxylic Acid
- Step 5 (R)-methyl 2-(3-chloro-5-((5-(((S)-1-(3-isopropylphenyl)ethyl)carbamoyl)-2,3-dimethyl-1H-indol-1-yl)methyl)phenoxy)propanoate
- the title compound was prepared following the same protocol as described in Step 5, Example 36, using the (S)-1-(3-isopropylphenyl)ethanamine hydrochloride instead of the (S)-1-(3-cyclopropylphenyl)ethanamine hydrochloride and the (R)-1-(3-chloro-5-((1-methoxy-1-oxopropan-2-yl)oxy)benzyl)-2,3-dimethyl-1H-indole-5-carboxylic acid instead of the 1-(4-(2-methoxy-2-oxoethoxy)benzyl)-2,3-dimethyl-1H-indole-5-carboxylic acid.
- Step 6 (R)-2-(3-chloro-5-((5-(((S)-1-(3-isopropylphenyl)ethyl)carbamoyl)-2,3-dimethyl-1H-indol-1-yl)methyl)phenoxy)propanoic Acid
- Step 3 (R)-Allyl 1-(2-chloro-3-((1-methoxy-1-oxopropan-2-yl)oxy)benzyl)-2,3-dimethyl-1H-indole-5-carboxylate
- Step 4 (R)-1-(2-Chloro-3-((1-methoxy-1-oxopropan-2-yl)oxy)benzyl)-2,3-dimethyl-1H-indole-5-carboxylic Acid
- Step 5 (R)-methyl 2-(2-chloro-3-((5-(((S)-1-(3-isopropylphenyl)ethyl)carbamoyl)-2,3-dimethyl-1H-indol-1-yl)methyl)phenoxy)propanoate
- the title compound was prepared following the same protocol as described in Step 5, Example 36, using the (S)-1-(3-isopropylphenyl)ethanamine hydrochloride instead of the (S)-1-(3-cyclopropylphenyl)ethanamine hydrochloride and the (R)-1-(2-chloro-3-((1-methoxy-1-oxopropan-2-yl)oxy)benzyl)-2,3-dimethyl-1H-indole-5-carboxylic acid instead of the 1-(4-(2-methoxy-2-oxoethoxy)benzyl)-2,3-dimethyl-1H-indole-5-carboxylic acid.
- Step 6 (R)-2-(2-chloro-3-((5-(((S)-1-(3-isopropylphenyl)ethyl)carbamoyl)-2,3-dimethyl-1H-indol-1-yl)methyl)phenoxy)propanoic Acid
- Step 3 (S)-Allyl 1-(3-chloro-4-((1-methoxy-1-oxopropan-2-yl)oxy)benzyl)-2,3-dimethyl-1H-indole-5-carboxylate
- Step 4 (S)-1-(3-chloro-4-((1-Methoxy-1-oxopropan-2-yl)oxy)benzyl)-2,3-dimethyl-1H-indole-5-carboxylic Acid
- Step 5 (S)-Methyl 2-(2-chloro-4-((5-(((S)-1-(3-isopropylphenyl)ethyl)carbamoyl)-2,3-dimethyl-1H-indol-1-yl)methyl)phenoxy)propanoate
- the title compound was prepared following the same protocol as described in Step 5, Example 36, using the (S)-1-(3-isopropylphenyl)ethanamine hydrochloride instead of the (S)-1-(3-cyclopropylphenyl)ethanamine hydrochloride and the (S)-1-(3-chloro-4-((1-methoxy-1-oxopropan-2-yl)oxy)benzyl)-2,3-dimethyl-1H-indole-5-carboxylic acid instead of the 1-(4-(2-methoxy-2-oxoethoxy)benzyl)-2,3-dimethyl-1H-indole-5-carboxylic acid.
- Step 6 (S)-2-(2-chloro-4-((5-(((S)-1-(3-Isopropylphenyl)ethyl)carbamoyl)-2,3-dimethyl-1H-indol-1-yl)methyl)phenoxy)propanoic Acid
- Step 3 (S)-Allyl 1-(2-chloro-4-((1-methoxy-1-oxopropan-2-yl)oxy)benzyl)-2,3-dimethyl-1H-indole-5-carboxylate
- Step 4 (S)-1-(2-chloro-4-((1-Methoxy-1-oxopropan-2-yl)oxy)benzyl)-2,3-dimethyl-1H-indole-5-carboxylic Acid
- Step 5 (S)-Methyl 2-(3-chloro-4-((5-(((S)-1-(3-isopropylphenyl)ethyl)carbamoyl)-2,3-dimethyl-1H-indol-1-yl)methyl)phenoxy)propanoate
- the title compound was prepared following the same protocol as described in Step 5, Example 36, using the (S)-1-(3-isopropylphenyl)ethanamine hydrochloride instead of the (S)-1-(3-cyclopropylphenyl)ethanamine hydrochloride and the (S)-1-(2-chloro-4-(1-methoxy-1-oxopropan-2-yl)oxy)benzyl)-2,3-dimethyl-1H-indole-5-carboxylic acid instead of the 1-(4-(2-methoxy-2-oxoethoxy)benzyl)-2,3-dimethyl-1H-indole-5-carboxylic acid.
- Step 6 (S)-2-(3-chloro-4-((5-(((S)-1-(3-Isopropylphenyl)ethyl)carbamoyl)-2,3-dimethyl-1H-indol-1-yl)methyl)phenoxy)propanoic Acid
- Step 3 (R)-Allyl 1-(3-chloro-4-((1-methoxy-1-oxopropan-2-yl)oxy)benzyl)-2,3-dimethyl-1H-indole-5-carboxylate
- Step 4 (R)-1-(3-chloro-4-((1-Methoxy-1-oxopropan-2-yl)oxy)benzyl)-2,3-dimethyl-1H-indole-5-carboxylic Acid
- Step 5 (R)-Methyl 2-(2-chloro-4-((5-(((S)-1-(3-isopropylphenyl)ethyl)carbamoyl)-2,3-dimethyl-1H-indol-1-yl)methyl)phenoxy)propanoate
- the title compound was prepared following the same protocol as described in Step 5, Example 36, using the (S)-1-(3-isopropylphenyl)ethanamine hydrochloride instead of the (S)-1-(3-cyclopropylphenyl)ethanamine hydrochloride and the (R)-1-(3-chloro-4-((1-methoxy-1-oxopropan-2-yl)oxy)benzyl)-2,3-dimethyl-1H-indole-5-carboxylic acid instead of the 1-(4-(2-methoxy-2-oxoethoxy)benzyl)-2,3-dimethyl-1H-indole-5-carboxylic acid.
- Step 6 (R)-2-(2-chloro-4-((5-(((S)-1-(3-Isopropylphenyl)ethyl)carbamoyl)-2,3-dimethyl-1H-indol-1-yl)methyl)phenoxy)propanoic Acid
- Step 3 (R)-Allyl 1-(2-chloro-4-((1-methoxy-1-oxopropan-2-yl)oxy)benzyl)-2,3-dimethyl-1H-indole-5-carboxylate
- Step 4 (R)-1-(2-chloro-4-((1-Methoxy-1-oxopropan-2-yl)oxy)benzyl)-2,3-dimethyl-1H-indole-5-carboxylic Acid
- Step 5 (R)-Methyl 2-(3-chloro-4-((5-(((S)-1-(3-isopropylphenyl)ethyl)carbamoyl)-2,3-dimethyl-1H-indol-1-yl)methyl)phenoxy)propanoate
- the title compound was prepared following the same protocol as described in Step 5, Example 36, using the (S)-1-(3-isopropylphenyl)ethanamine hydrochloride instead of the (S)-1-(3-cyclopropylphenyl)ethanamine hydrochloride and the (R)-1-(2-chloro-4-((1-methoxy-1-oxopropan-2-yl)oxy)benzyl)-2,3-dimethyl-1H-indole-5-carboxylic acid instead of the 1-(4-(2-methoxy-2-oxoethoxy)benzyl)-2,3-dimethyl-1H-indole-5-carboxylic acid.
- Step 6 (R)-2-(3-chloro-4-((5-(((S)-1-(3-Isopropylphenyl)ethyl)carbamoyl)-2,3-dimethyl-1H-indol-1-yl)methyl)phenoxy)propanoic Acid
- Step 3 (S)-Allyl 1-(3-((1-methoxy-1-oxobutan-2-yl)oxy)benzyl)-2,3-dimethyl-1H-indole-5-carboxylate
- Step 4 (S)-1-((3-((1-Methoxy-1-oxobutan-2-yl)oxy)benzyl)-2,3-dimethyl-1H-indole-5-carboxylic Acid
- Step 5 (S)-Methyl 2-(3-((5-(((S)-1-(3-isopropylphenyl)ethyl)carbamoyl)-2,3-dimethyl-1H-indol-1-yl)methyl)phenoxy)butanoate
- the title compound was prepared following the same protocol as described in Step 5, Example 36, using the (S)-1-(3-isopropylphenyl)ethanamine hydrochloride instead of the (S)-1-(3-cyclopropylphenyl)ethanamine hydrochloride and the (S)-1-((3-((1-methoxy-1-oxobutan-2-yl)oxy)benzyl)-2,3-dimethyl-1H-indole-5-carboxylic acid instead of the 1-(4-(2-methoxy-2-oxoethoxy)benzyl)-2,3-dimethyl-1H-indole-5-carboxylic acid.
- Step 6 (S)-2-(3-((5-(((S)-1-(3-Isopropylphenyl)ethyl)carbamoyl)-2,3-dimethyl-1H-indol-1-yl)methyl)phenoxy)butanoic Acid
- Step 3 (R)-Allyl 1-(3-((1-methoxy-1-oxobutan-2-yl)oxy)benzyl)-2,3-dimethyl-1H-indole-5-carboxylate
- Step 4 (R)-1-(3-((1-Methoxy-1-oxobutan-2-yl)oxy)benzyl)-2,3-dimethyl-1H-indole-5-carboxylic Acid
- Step 5 (R)-Methyl 2-(3-((5-(((S)-1-(3-isopropylphenyl)ethyl)carbamoyl)-2,3-dimethyl-1H-indol-1-yl)methyl)phenoxy)butanoate
- the title compound was prepared following the same protocol as described in Step 5, Example 36, using the (S)-1-(3-isopropylphenyl)ethanamine hydrochloride instead of the (S)-1-(3-cyclopropylphenyl)ethanamine hydrochloride and the (R)-1-(3-((1-methoxy-1-oxobutan-2-yl)oxy)benzyl)-2,3-dimethyl-1H-indole-5-carboxylic acid instead of the 1-(4-(2-methoxy-2-oxoethoxy)benzyl)-2,3-dimethyl-1H-indole-5-carboxylic acid.
- Step 6 (R)-2-(3-((5-(((S)-1-(3-Isopropylphenyl)ethyl)carbamoyl)-2,3-dimethyl-1H-indol-1-yl)methyl)phenoxy)butanoic Acid
- Step 3 (S)-Allyl 1-(3-((1-methoxy-3-methyl-1-oxobutan-2-yl)oxy)benzyl)-2,3-dimethyl-1H-indole-5-carboxylate
- Step 4 (S)-1-(3-((1-Methoxy-3-methyl-1-oxobutan-2-yl)oxy)benzyl)-2,3-dimethyl-1H-indole-5-carboxylic Acid
- Step 5 (S)-Methyl 2-(3-((5-(((S)-1-(3-isopropylphenyl)ethyl)carbamoyl)-2,3-dimethyl-1H-indol-1-yl)methyl)phenoxy)-3-methylbutanoate
- the title compound was prepared following the same protocol as described in Step 5, Example 36, using the (S)-1-(3-isopropylphenyl)ethanamine hydrochloride instead of the (S)-1-(3-cyclopropylphenyl)ethanamine hydrochloride and the (S)-1-(3-((1-methoxy-3-methyl-1-oxobutan-2-yl)oxy)benzyl)-2,3-dimethyl-1H-indole-5-carboxylic acid instead of the 1-(4-(2-methoxy-2-oxoethoxy)benzyl)-2,3-dimethyl-1H-indole-5-carboxylic acid.
- Step 6 (S)-2-(3-((5-(((S)-1-((3-Isopropylphenyl)ethyl)carbamoyl)-2,3-dimethyl-1H-indol-1-yl)methyl)phenoxy)-3-methylbutanoic Acid
- Step 3 (R)-Allyl 1-(3-((1-methoxy-3-methyl-1-oxobutan-2-yl)oxy)benzyl)-2,3-dimethyl-1H-indole-5-carboxylate
- Step 4 (R)-1-(3-((1-Methoxy-3-methyl-1-oxobutan-2-yl)oxy)benzyl)-2,3-dimethyl-1H-indole-5-carboxylic Acid
- Step 5 (R)-Methyl 2-(3-((5-(((S)-1-(3-isopropylphenyl)ethyl)carbamoyl)-2,3-dimethyl-1H-indol-1-yl)methyl)phenoxy)-3-methylbutanoate
- the title compound was prepared following the same protocol as described in Step 5, Example 36, using the (S)-1-(3-isopropylphenyl)ethanamine hydrochloride instead of the (S)-1-(3-cyclopropylphenyl)ethanamine hydrochloride and the (R)-1-(3-((1-methoxy-3-methyl-1-oxobutan-2-yl)oxy)benzyl)-2,3-dimethyl-1H-indole-5-carboxylic acid instead of the 1-(4-(2-methoxy-2-oxoethoxy)benzyl)-2,3-dimethyl-1H-indole-5-carboxylic acid.
- Step 6 (R)-2-(3-((5-(((S)-1-(3-Isopropylphenyl)ethyl)carbamoyl)-2,3-dimethyl-1H-indol-1-yl)methyl)phenoxy)-3-methylbutanoic Acid
- Step 3 (S)-Allyl 1-(4-chloro-3-((1-methoxy-1-oxobutan-2-yl)oxy)benzyl)-2,3-dimethyl-1H-indole-5-carboxylate
- Step 4 (S)-1-(4-Chloro-3-((1-methoxy-1-oxobutan-2-yl)oxy)benzyl)-2,3-dimethyl-1H-indole-5-carboxylic Acid
- Step 5 (S)-Methyl 2-(2-chloro-5-((5-(((S)-1-(3-isopropylphenyl)ethyl)carbamoyl)-2,3-dimethyl-1H-indol-1-yl)methyl)phenoxy)butanoate
- the title compound was prepared following the same protocol as described in Step 5, Example 36, using the (S)-1-(3-isopropylphenyl)ethanamine hydrochloride instead of the (S)-1-(3-cyclopropylphenyl)ethanamine hydrochloride and the (S)-1-(4-chloro-3-((1-methoxy-1-oxobutan-2-yl)oxy)benzyl)-2,3-dimethyl-1H-indole-5-carboxylic acid instead of the 1-(4-(2-methoxy-2-oxoethoxy)benzyl)-2,3-dimethyl-1H-indole-5-carboxylic acid.
- Step 6 (S)-2-(2-Chloro-5-((5-(((S)-1-(3-isopropylphenyl)ethyl)carbamoyl)-2,3-dimethyl-1H-indol-1-yl)methyl)phenoxy)butanoic Acid
- Step 3 (S)-Allyl 1-(2-chloro-5-((1-methoxy-1-oxobutan-2-yl)oxy)benzyl)-2,3-dimethyl-1H-indole-5-carboxylate
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
- This application is a continuation of U.S. patent application Ser. No. 17/168,690 (filed Feb. 5, 2021), which is a continuation of U.S. patent application Ser. No. 16/909,324 (filed Jun. 23, 2020; now abandoned), which is a continuation of U.S. patent application Ser. No. 16/028,730 (filed Jul. 6, 2018; now U.S. Pat. No. 10,744,117), which is a continuation of U.S. patent application Ser. No. 15/302,862 (filed Oct. 7, 2016; now U.S. Pat. No. 10,016,394), which is a national stage application of International Application No. PCT/US2015/026226 (filed Apr. 16, 2015; now expired), which claims the benefit of priority to U.S. Provisional Patent Application No. 61/980,444 (filed on Apr. 16, 2014; now expired).
- The disclosed subject matter herein is related to the subject matter of U.S. Ser. No. 13/490,324 (now U.S. Pat. No. 8,957,093), Ser. No. 13/811,965 (now U.S. Pat. No. 9,309,227), Ser. No. 13/490,342 (now U.S. Pat. No. 9,051,265), Ser. No. 13/811,969 (now abandoned), and Ser. No. 13/811,973 (now abandoned).
- The full disclosures of the aforementioned applications are incorporated herein by reference in their entirety and for all purposes.
- The peroxisome proliferator active receptors (PPARs), members of the nuclear hormone receptor superfamily, comprise several subtypes such as PPARα, PPARβ, and PPARγ. The PPARγ subtype, also referred to as PPARG, is the target of the glitazone pharmaceutical agents used for treatment of type II diabetes. PPARG is also known as NR1C3 (the gene ID) and there exist PPARG1 and PPARG2, the two major isoforms of PPARG. The glitazones, such as pioglitazone and rosiglitazone, act as PPARG receptor agonists. However, other classes of pharmaceutical agents, such as Telmisartan, have been reported to act as partial agonists, binding in a different mode to PPARG and having different cofactor requirements. See Y. Lamotte, et al., Bioorg. Med. Chem. Lett. (2010), 20, 1399-1404.
- The present invention is directed to methods of use of compounds that are non-activating (non-agonist) PPARG modulators, compounds of formula (I) including compounds of formula (IA) and of formula (IB) as described herein, in modulating the activity of PPARG, in treatment of conditions wherein non-activating modulation of PPARG is medically indicated, such as for treatment of a progressive bone disease. Compounds of the invention can block kinase-mediated, such as cdk5-mediated, phosphorylation of PPARG, but are not agonists of the receptor itself. By avoiding agonism of the receptor, it is believed that the compounds may exhibit no or reduced side effects associated with administration of full and partial agonists of PPARG, such as significant weight gain, edema, impairment of bone growth or formation, or cardiac hypertrophy, or any combination thereof, in the mammal receiving the compound. For instance, in practice of a method of treatment of a progressive bone disease in a patient, such as treatment of osteoporosis, Paget's Disease, multiple myeloma, hyperparathyroidism, and related progressive bone diseases, administration of an effective amount of a compound of formula (I) as disclosed herein can be used to treat the disease, wherein the effective dose of the compound acts to inhibit bone resorption, improve bone formation, or both, in the patient. For example, the method of treatment of the invention for the progressive bone disease can act to increase FGF21 while increasing bone health.
-
FIG. 1 is a schematic showing the differentiation of mesenchymal stem cells into osteoblasts and adipocytes under mediation of PPARG, along with bar graphs showing relative effects on PPARG target genes aP2 and ALP induced by rosiglitazone, MRL24 (a Merck PPARG partial agonist) and a compound of formula (I), SR1664. -
FIG. 2 is a bar graph showing the extent of bone formation marker in human mesenchymal stem cells upon treatment with a compound effective for practice of a method of the invention. -
FIG. 3 schematically shows desirable molecular features of compounds for practicing a method of the invention. -
FIG. 4 provides bioactivity details for compounds effective for carrying out a method of the invention. -
FIG. 5 indicates the results of a 4-week study of SR10171, a compound effective for carrying out a method of the invention, in comparison with rosiglitazone. -
FIG. 6 shows bar graphs related to bone development, relative to control, of SR10171, a compound effective for carrying out a method of the invention, in comparison with rosiglitazone. -
FIG. 7 shows the results of a glucose tolerance test on mice fed a regular chow diet (RD) or obese mice fed a high fat diet (HFD). Mice were fasted overnight and then administered a bolus of glucose. At several time intervals plasma glucose was measured. The data confirms the insulin sensitization effects and improved glucose disposal for TZD rosiglitazone treated mice. Similar results were obtained with SR10171 demonstrating that this compound is an insulin sensitizer. Both drug treated arms resulted in similar glucose disposal rates as the lean mice on RD. -
FIG. 8 shows serum levels of FGF21, a liver-secreted hormone believed to have beneficial effects in terms of metabolism, although over-expression of FGF21 can be detrimental to bone. From Wei et al PNAS 2012 “The endocrine hormone fibroblast growth factor 21 (FGF21) is a powerful modulator of glucose and lipid metabolism and a promising drug fortype 2 diabetes. Here we identify FGF21 as a potent regulator of skeletal homeostasis. Both genetic and pharmacologic FGF21 gains of function lead to a striking decrease in bone mass. In contrast, FGF21 loss of function leads to a reciprocal high-bone-mass phenotype. Mechanistically, FGF21 inhibits osteoblastogenesis and stimulates adipogenesis from bone marrow mesenchymal stem cells by potentiating the activity of peroxisome proliferator-activated receptor γ (PPAR-γ). Consequently, FGF21 deletion prevents the deleterious bone loss side effect of the PPAR-γ agonist rosiglitazone. Therefore, FGF21 is a critical rheostat for bone turnover and a key integrator of bone and energy metabolism. These results reveal that skeletal fragility may be an undesirable consequence of chronic FGF21 administration.” Thus, while our compounds increase FGF21 expression likely due to activation of PPARA, we inhibit the bad effects by blocking PPARG. -
FIG. 9 shows photographs depicting results of osmium staining in whole tibia and juxtaposed trabecular bone (gray) and fat (yellow) in proximal tibia. RD is regular diet (normal chow) and HFD is high fat diet (chow is 45% fat). Mice on HFD have increased fat accumulation in the bone marrow as compared to lean controls. Mice on HFD and treated with a TZD, rosiglitazone, have significant fat accumulation in the bone marrow. Treatment of mice with SR10171 reduces the fat accumulation in bone marrow to that below vehicle controls on high fat diet alone. -
FIG. 10 shows quantitation of cortical bone mass from the midshaft tibia from mice treated under the conditions described above inFIG. 7 . Treatment of mice with SR10171 resulted in a statistically significant increase in total tissue area, cortical bone area, and medular area. -
FIG. 11 shows quantitative data on serum markers of bone resporption (TRACP5b) and bone formation (BALP) in mice treated under the conditions described inFIG. 7 . Treatment of mice on HFD with SR10171 reduced the level of TRACP5b to that of lean mice on normal chow diet. Likewise SR10171 increase BALP significantly over the other treatment arms. -
FIG. 12 shows pharmacokinetic properties of rosiglitazone and SR2595 concentration in lean C57BL/6J mice treated for 21 days, two hours following drug administration (n=5) (a) plasma concentration (b) epididymal WAT concentration. Error bars are s.e.m. -
FIG. 13 shows (A) mCT renderings and (B) measurements of trabecular bone in proximal tibia in lean C57BL/6 mice (BV/TV—bone mass; Tb.N—number of trabeculae; Tb.Th—trabecular thickness; C=control; R=rosiglitazone; 71=SR10171). -
FIG. 14 shows dynamic histomorphometry of trabecular bone in proximal tibia double-labeled with calcein in lean C57BL/6 mice: (A) representative microphotographs of bone surface labeled with calcein, and (B) quantification of marrow apposition rate (MAR) and bone formation rate (BFR) (C=control; R=rosiglitazone; 71=SR10171). -
FIG. 15 shows static histomorphometry of trabecular bone in proximal tibia in lean C57BL/6 mice (N.Ob—number of osteoblasts per bone perimeter; N.Oc—number of osteoclasts per bone perimeter; N.Ad—number of adipocytes per region of interest; C=control; R=rosiglitazone; 71=SR10171). - As used in the specification and the appended claims, the singular forms “a,” “an” and “the” include plural referents unless the context clearly dictates otherwise.
- The term “about” as used herein, when referring to a numerical value or range, allows for a degree of variability in the value or range, for example, within 10%, or within 5% of a stated value or of a stated limit of a range.
- All percent compositions are given as weight-percentages, unless otherwise stated.
- All average molecular weights of polymers are weight-average molecular weights, unless otherwise specified.
- As used herein, “individual” (as in the subject of the treatment) or “patient” means both mammals and non-mammals. Mammals include, for example, humans; non-human primates, e.g., apes and monkeys; and non-primates, e.g., dogs, cats, cattle, horses, sheep, and goats. Non-mammals include, for example, fish and birds.
- The term “disease” or “disorder” or “malcondition” are used interchangeably, and are used to refer to diseases or conditions wherein PPARG plays a role in the biochemical mechanisms involved in the disease or condition or symptom(s) thereof such that a therapeutically beneficial effect can be achieved by acting on PPARG. “Acting on” PPARG, or “modulating” PPARG, can include binding to PPARG and/or inhibiting the bioactivity of PPARG and/or allosterically regulating the bioactivity of PPARG in vivo. When the term “modulator” is used herein, the term alludes to a compound of the invention, and it is understood that the terms “modulator” and “compound” or “compound of the invention” are synonymous when the context indicates that a compound of the present invention is being referred to.
- In various embodiments, the compounds of the invention are not agonists of PPARG, i.e., binding of the compound to PPARG does not activate the receptor, as discussed in greater detail below. In various embodiments, compounds of the invention bring about inhibition of cdk5-mediated phosphorylation of PPARG while being devoid of classical agonism. Such compounds are referred to herein as “non-agonist PPARG modulatory compounds.”
- The expression “effective amount”, when used to describe therapy to an individual suffering from a disorder, refers to the amount of a compound of the invention that is effective to inhibit or otherwise act on PPARG in the individual's tissues wherein PPARG involved in the disorder is active, wherein such inhibition or other action occurs to an extent sufficient to produce a beneficial therapeutic effect.
- “Substantially” as the term is used herein means completely or almost completely; for example, a composition that is “substantially free” of a component either has none of the component or contains such a trace amount that any relevant functional property of the composition is unaffected by the presence of the trace amount, or a compound is “substantially pure” is there are only negligible traces of impurities present.
- “Treating” or “treatment” within the meaning herein refers to an alleviation of symptoms associated with a disorder or disease, or inhibition of further progression or worsening of those symptoms, or prevention or prophylaxis of the disease or disorder, or curing the disease or disorder. Similarly, as used herein, an “effective amount” or a “therapeutically effective amount” of a compound of the invention refers to an amount of the compound that alleviates, in whole or in part, symptoms associated with the disorder or condition, or halts or slows further progression or worsening of those symptoms, or prevents or provides prophylaxis for the disorder or condition. In particular, a “therapeutically effective amount” refers to an amount effective, at dosages and for periods of time necessary, to achieve the desired therapeutic result.
- A therapeutically effective amount is also one in which any toxic or detrimental effects of compounds of the invention are outweighed by the therapeutically beneficial effects. Phrases such as “under conditions suitable to provide” or “under conditions sufficient to yield” or the like, in the context of methods of synthesis, as used herein refers to reaction conditions, such as time, temperature, solvent, reactant concentrations, and the like, that are within ordinary skill for an experimenter to vary, that provide a useful quantity or yield of a reaction product. It is not necessary that the desired reaction product be the only reaction product or that the starting materials be entirely consumed, provided the desired reaction product can be isolated or otherwise further used.
- By “chemically feasible” is meant a bonding arrangement or a compound where the generally understood rules of organic structure are not violated; for example a structure within a definition of a claim that would contain in certain situations a pentavalent carbon atom that would not exist in nature would be understood to not be within the claim. The structures disclosed herein, in all of their embodiments are intended to include only “chemically feasible” structures, and any recited structures that are not chemically feasible, for example in a structure shown with variable atoms or groups, are not intended to be disclosed or claimed herein.
- An “analog” of a chemical structure, as the term is used herein, refers to a chemical structure that preserves substantial similarity with the parent structure, although it may not be readily derived synthetically from the parent structure. A related chemical structure that is readily derived synthetically from a parent chemical structure is referred to as a “derivative.”
- When a substituent is specified to be an atom or atoms of specified identity, “or a bond”, a configuration is referred to when the substituent is “a bond” that the groups that are immediately adjacent to the specified substituent are directly connected to each other in a chemically feasible bonding configuration.
- All chiral, diastereomeric, racemic forms of a structure are intended, unless a particular stereochemistry or isomeric form is specifically indicated. Compounds used in the present invention can include enriched or resolved optical isomers at any or all asymmetric atoms as are apparent from the depictions, at any degree of enrichment. Both racemic and diastereomeric mixtures, as well as the individual optical isomers can be isolated or synthesized so as to be substantially free of their enantiomeric or diastereomeric partners, and these are all within the scope of the invention.
- As used herein, the terms “stable compound” and “stable structure” are meant to indicate a compound that is sufficiently robust to survive isolation to a useful degree of purity from a reaction mixture, and formulation into an efficacious therapeutic agent. Only stable compounds are contemplated herein.
- A “small molecule” refers to an organic compound, including an organometallic compound, of a molecular weight less than about 2 kDa, that is not a polynucleotide, a polypeptide, a polysaccharide, or a synthetic polymer composed of a plurality of repeating units.
- As to any of the groups described herein, which contain one or more substituents, it is understood that such groups do not contain any substitution or substitution patterns which are sterically impractical and/or synthetically non-feasible. In addition, the compounds of this disclosed subject matter include all stereochemical isomers arising from the substitution of these compounds.
- When a group, e.g., an “alkyl” group, is referred to without any limitation on the number of atoms in the group, it is understood that the claim is definite and limited with respect the size of the alkyl group, both by definition; i.e., the size (the number of carbon atoms) possessed by a group such as an alkyl group is a finite number, less than the total number of carbon atoms in the universe and bounded by the understanding of the person of ordinary skill as to the size of the group as being reasonable for a molecular entity; and by functionality, i.e., the size of the group such as the alkyl group is bounded by the functional properties the group bestows on a molecule containing the group such as solubility in aqueous or organic liquid media. Therefore, a claim reciting an “alkyl” or other chemical group or moiety is definite and bounded, as the number of atoms in the group cannot be infinite.
- The inclusion of an isotopic form of one or more atoms in a molecule that is different from the naturally occurring isotopic distribution of the atom in nature is referred to as an “isotopically labeled form” of the molecule. All isotopic forms of atoms are included as options in the composition of any molecule, unless a specific isotopic form of an atom is indicated. For example, any hydrogen atom or set thereof in a molecule can be any of the isotopic forms of hydrogen, i.e., protium (1H), deuterium (2H), or tritium (3H) in any combination. Similarly, any carbon atom or set thereof in a molecule can be any of the isotopic form of carbons, such as 11C, 12C, 13C, or 14C, or any nitrogen atom or set thereof in a molecule can be any of the isotopic forms of nitrogen, such as 13N, 14N, or 15N. A molecule can include any combination of isotopic forms in the component atoms making up the molecule, the isotopic form of every atom forming the molecule being independently selected. In a multi-molecular sample of a compound, not every individual molecule necessarily has the same isotopic composition. For example, a sample of a compound can include molecules containing various different isotopic compositions, such as in a tritium or 14C radiolabeled sample where only some fraction of the set of molecules making up the macroscopic sample contains a radioactive atom. It is also understood that many elements that are not artificially isotopically enriched themselves are mixtures of naturally occurring isotopic forms, such as 14N and 15N, 32S and 34S, and so forth. A molecule as recited herein is defined as including isotopic forms of all its constituent elements at each position in the molecule. As is well known in the art, isotopically labeled compounds can be prepared by the usual methods of chemical synthesis, except substituting an isotopically labeled precursor molecule. The isotopes, radiolabeled or stable, can be obtained by any method known in the art, such as generation by neutron absorption of a precursor nuclide in a nuclear reactor, by cyclotron reactions, or by isotopic separation such as by mass spectrometry. The isotopic forms are incorporated into precursors as required for use in any particular synthetic route. For example, 14C and 3H can be prepared using neutrons generated in a nuclear reactor. Following nuclear transformation, 14C and 3H are incorporated into precursor molecules, followed by further elaboration as needed.
- In general, “substituted” refers to an organic group as defined herein in which one or more bonds to a hydrogen atom contained therein are replaced by one or more bonds to a non-hydrogen atom such as, but not limited to, a halogen (i.e., F, Cl, Br, and I); an oxygen atom in groups such as hydroxyl groups, alkoxy groups, aryloxy groups, aralkyloxy groups, oxo(carbonyl) groups, carboxyl groups including carboxylic acids, carboxylates, and carboxylate esters; a sulfur atom in groups such as thiol groups, alkyl and aryl sulfide groups, sulfoxide groups, sulfone groups, sulfonyl groups, and sulfonamide groups; a nitrogen atom in groups such as amines, hydroxylamines, nitriles, nitro groups, N-oxides, hydrazides, azides, and enamines; and other heteroatoms in various other groups. Non-limiting examples of substituents J that can be bonded to a substituted carbon (or other) atom include F, Cl, Br, I, OR′, OC(O)N(R′)2, CN, NO, NO2, ONO2, azido, CF3, OCF3, R′, O (oxo), S (thiono), methylenedioxy, ethylenedioxy, N(R′)2, SR′, SOR′, SO2R′, SO2N(R′)2, SO3R′, C(O)R′, C(O)C(O)R′, C(O)CH2C(O)R′, C(S)R′, C(O)OR′, OC(O)R′, C(O)N(R′)2, OC(O)N(R′)2, C(S)N(R′)2, (CH2)0-2N(R′)C(O)R′, (CH2)0-2N(R′)N(R′)2, N(R′)N(R′)C(O)R′, N(R′)N(R′)C(O)OR′, N(R′)N(R′)CON(R′)2, N(R′)SO2R′, N(R′)SO2N(R′)2, N(R′)C(O)OR′, N(R′)C(O)R′, N(R′)C(S)R′, N(R′)C(O)N(R′)2, N(R′)C(S)N(R′)2, N(COR′)COR′, N(OR′)R′, C(═NH)N(R′)2, C(O)N(OR′)R′, or C(═NOR′)R′ wherein R′ can be hydrogen or a carbon-based moiety, and wherein the carbon-based moiety can itself be further substituted; for example, wherein R′ can be hydrogen, alkyl, acyl, cycloalkyl, aryl, aralkyl, heterocyclyl, heteroaryl, or heteroarylalkyl, wherein any alkyl, acyl, cycloalkyl, aryl, aralkyl, heterocyclyl, heteroaryl, or heteroarylalkyl or R′ can be independently mono- or multi-substituted with J; or wherein two R′ groups bonded to a nitrogen atom or to adjacent nitrogen atoms can together with the nitrogen atom or atoms form a heterocyclyl, which can be mono- or independently multi-substituted with J.
- When a substituent is monovalent, such as, for example, F or Cl, it is bonded to the atom it is substituting by a single bond. When a substituent is more than monovalent, such as O, which is divalent, it can be bonded to the atom it is substituting by more than one bond, i.e., a divalent substituent is bonded by a double bond; for example, a C substituted with O forms a carbonyl group, C═O, which can also be written as “CO”, “C(O)”, or “C(═O)”, wherein the C and the O are double bonded. When a carbon atom is substituted with a double-bonded oxygen (═O) group, the oxygen substituent is termed an “oxo” group. When a divalent substituent such as NR is double-bonded to a carbon atom, the resulting C(═NR) group is termed an “imino” group.
- When a divalent substituent such as S is double-bonded to a carbon atom, the results C(═S) group is termed a “thiocarbonyl” or “thiono” group.
- Alternatively, a divalent substituent such as O or S can be connected by two single bonds to two different carbon atoms. For example, O, a divalent substituent, can be bonded to each of two adjacent carbon atoms to provide an epoxide group, or the O can form a bridging ether group, termed an “oxy” group, between adjacent or non-adjacent carbon atoms, for example bridging the 1,4-carbons of a cyclohexyl group to form a [2.2.1]-oxabicyclo system. Further, any substituent can be bonded to a carbon or other atom by a linker, such as (CH2)n or (CR′2)n wherein n is 1, 2, 3, or more, and each R′ is independently selected.
- C(O) and S(O)2 groups can also be bound to one or two heteroatoms, such as nitrogen or oxygen, rather than to a carbon atom. For example, when a C(O) group is bound to one carbon and one nitrogen atom, the resulting group is called an “amide” or “carboxamide.” When a C(O) group is bound to two nitrogen atoms, the functional group is termed a “urea.” When a C(O) is bonded to one oxygen and one nitrogen atom, the resulting group is termed a “carbamate” or “urethane.” When a S(O)2 group is bound to one carbon and one nitrogen atom, the resulting unit is termed a “sulfonamide.” When a S(O)2 group is bound to two nitrogen atoms, the resulting unit is termed a “sulfamate.”
- Substituted alkyl, alkenyl, alkynyl, cycloalkyl, and cycloalkenyl groups as well as other substituted groups also include groups in which one or more bonds to a hydrogen atom are replaced by one or more bonds, including double or triple bonds, to a carbon atom, or to a heteroatom such as, but not limited to, oxygen in carbonyl (oxo), carboxyl, ester, amide, imide, urethane, and urea groups; and nitrogen in imines, hydroxyimines, oximes, hydrazones, amidines, guanidines, and nitriles.
- Substituted ring groups such as substituted cycloalkyl, aryl, heterocyclyl and heteroaryl groups also include rings and fused ring systems in which a bond to a hydrogen atom is replaced with a bond to a carbon atom. Therefore, substituted cycloalkyl, aryl, heterocyclyl and heteroaryl groups can also be substituted with alkyl, alkenyl, and alkynyl groups as defined herein.
- By a “ring system” as the term is used herein is meant a moiety comprising one, two, three or more rings, which can be substituted with non-ring groups or with other ring systems, or both, which can be fully saturated, partially unsaturated, fully unsaturated, or aromatic, and when the ring system includes more than a single ring, the rings can be fused, bridging, or spirocyclic.
- By “spirocyclic” is meant the class of structures wherein two rings are fused at a single tetrahedral carbon atom, as is well known in the art.
- As to any of the groups described herein, which contain one or more substituents, it is understood, of course, that such groups do not contain any substitution or substitution patterns which are sterically impractical and/or synthetically non-feasible. In addition, the compounds of this disclosed subject matter include all stereochemical isomers arising from the substitution of these compounds.
- Alkyl groups include straight chain and branched alkyl groups and cycloalkyl groups having from 1 to about 20 carbon atoms, and typically from 1 to 12 carbons or, in some embodiments, from 1 to 8 carbon atoms. Examples of straight chain alkyl groups include those with from 1 to 8 carbon atoms such as methyl, ethyl, n-propyl, n-butyl, n-pentyl, n-hexyl, n-heptyl, and n-octyl groups. Examples of branched alkyl groups include, but are not limited to, isopropyl, iso-butyl, sec-butyl, t-butyl, neopentyl, isopentyl, and 2,2-dimethylpropyl groups. As used herein, the term “alkyl” encompasses n-alkyl, isoalkyl, and anteisoalkyl groups as well as other branched chain forms of alkyl. Representative substituted alkyl groups can be substituted one or more times with any of the groups listed above, for example, amino, hydroxy, cyano, carboxy, nitro, thio, alkoxy, and halogen groups.
- Cycloalkyl groups are cyclic alkyl groups such as, but not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, and cyclooctyl groups. In some embodiments, the cycloalkyl group can have 3 to about 8-12 ring members, whereas in other embodiments the number of ring carbon atoms range from 3 to 4, 5, 6, or 7. Cycloalkyl groups further include polycyclic cycloalkyl groups such as, but not limited to, norbornyl, adamantyl, bornyl, camphenyl, isocamphenyl, and carenyl groups, and fused rings such as, but not limited to, decalinyl, and the like. Cycloalkyl groups also include rings that are substituted with straight or branched chain alkyl groups as defined above. Representative substituted cycloalkyl groups can be mono-substituted or substituted more than once, such as, but not limited to, 2,2-, 2,3-, 2,4- 2,5- or 2,6-disubstituted cyclohexyl groups or mono-, di- or tri-substituted norbornyl or cycloheptyl groups, which can be substituted with, for example, amino, hydroxy, cyano, carboxy, nitro, thio, alkoxy, and halogen groups. The term “cycloalkenyl” alone or in combination denotes a cyclic alkenyl group.
- The terms “carbocyclic,” “carbocyclyl,” and “carbocycle” denote a ring structure wherein the atoms of the ring are carbon, such as a cycloalkyl group or an aryl group. In some embodiments, the carbocycle has 3 to 8 ring members, whereas in other embodiments the number of ring carbon atoms is 4, 5, 6, or 7. Unless specifically indicated to the contrary, the carbocyclic ring can be substituted with as many as N−1 substituents wherein N is the size of the carbocyclic ring with, for example, alkyl, alkenyl, alkynyl, amino, aryl, hydroxy, cyano, carboxy, heteroaryl, heterocyclyl, nitro, thio, alkoxy, and halogen groups, or other groups as are listed above. A carbocyclyl ring can be a cycloalkyl ring, a cycloalkenyl ring, or an aryl ring. A carbocyclyl can be monocyclic or polycyclic, and if polycyclic each ring can be independently be a cycloalkyl ring, a cycloalkenyl ring, or an aryl ring.
- (Cycloalkyl)alkyl groups, also denoted cycloalkylalkyl, are alkyl groups as defined above in which a hydrogen or carbon bond of the alkyl group is replaced with a bond to a cycloalkyl group as defined above.
- Alkenyl groups include straight and branched chain and cyclic alkyl groups as defined above, except that at least one double bond exists between two carbon atoms. Thus, alkenyl groups have from 2 to about 20 carbon atoms, and typically from 2 to 12 carbons or, in some embodiments, from 2 to 8 carbon atoms. Examples include, but are not limited to vinyl, —CH═CH(CH3), —CH═C(CH3)2, —C(CH3)═CH2, —C(CH3)═CH(CH3), —C(CH2CH3)═CH2, cyclohexenyl, cyclopentenyl, cyclohexadienyl, butadienyl, pentadienyl, and hexadienyl among others.
- Cycloalkenyl groups include cycloalkyl groups having at least one double bond between 2 carbons. Thus for example, cycloalkenyl groups include but are not limited to cyclohexenyl, cyclopentenyl, and cyclohexadienyl groups. Cycloalkenyl groups can have from 3 to about 8-12 ring members, whereas in other embodiments the number of ring carbon atoms range from 3 to 5, 6, or 7. Cycloalkyl groups further include polycyclic cycloalkyl groups such as, but not limited to, norbornyl, adamantyl, bornyl, camphenyl, isocamphenyl, and carenyl groups, and fused rings such as, but not limited to, decalinyl, and the like, provided they include at least one double bond within a ring. Cycloalkenyl groups also include rings that are substituted with straight or branched chain alkyl groups as defined above.
- (Cycloalkenyl)alkyl groups are alkyl groups as defined above in which a hydrogen or carbon bond of the alkyl group is replaced with a bond to a cycloalkenyl group as defined above.
- Alkynyl groups include straight and branched chain alkyl groups, except that at least one triple bond exists between two carbon atoms. Thus, alkynyl groups have from 2 to about 20 carbon atoms, and typically from 2 to 12 carbons or, in some embodiments, from 2 to 8 carbon atoms. Examples include, but are not limited to —C≡CH, —C≡C(CH3), —C≡C(CH2CH3), —CH2C≡CH, —CH2C≡C(CH3), and —CH2C≡C(CH2CH3) among others.
- Aryl groups are cyclic aromatic hydrocarbons that do not contain heteroatoms in the ring. Thus aryl groups include, but are not limited to, phenyl, azulenyl, heptalenyl, biphenyl, indacenyl, fluorenyl, phenanthrenyl, triphenylenyl, pyrenyl, naphthacenyl, chrysenyl, biphenylenyl, anthracenyl, and naphthyl groups. In some embodiments, aryl groups contain about 6 to about 14 carbons in the ring portions of the groups. Aryl groups can be unsubstituted or substituted, as defined above. Representative substituted aryl groups can be mono-substituted or substituted more than once, such as, but not limited to, 2-, 3-, 4-, 5-, or 6-substituted phenyl or 2-8 substituted naphthyl groups, which can be substituted with carbon or non-carbon groups such as those listed above.
- Aralkyl or arylalkyl groups are alkyl groups as defined above in which a hydrogen or carbon bond of an alkyl group is replaced with a bond to an aryl group as defined above. Representative aralkyl groups include benzyl and phenylethyl groups and fused (cycloalkylaryl)alkyl groups such as 4-ethyl-indanyl. Aralkenyl group are alkenyl groups as defined above in which a hydrogen or carbon bond of an alkyl group is replaced with a bond to an aryl group as defined above.
- Heterocyclyl groups or the term “heterocyclyl” includes aromatic and non-aromatic ring compounds containing 3 or more ring members, of which, one or more is a heteroatom such as, but not limited to, N, O, and S. Thus a heterocyclyl can be a cycloheteroalkyl, or a heteroaryl, or if polycyclic, any combination thereof. In some embodiments, heterocyclyl groups include 3 to about 20 ring members, whereas other such groups have 3 to about 15 ring members. A heterocyclyl group designated as a C2-heterocyclyl can be a 5-ring with two carbon atoms and three heteroatoms, a 6-ring with two carbon atoms and four heteroatoms and so forth. Likewise a C4-heterocyclyl can be a 5-ring with one heteroatom, a 6-ring with two heteroatoms, and so forth. The number of carbon atoms plus the number of heteroatoms sums up to equal the total number of ring atoms. A heterocyclyl ring can also include one or more double bonds. A heteroaryl ring is an embodiment of a heterocyclyl group. The phrase “heterocyclyl group” includes fused ring species including those comprising fused aromatic and non-aromatic groups. For example, a dioxolanyl ring and a benzdioxolanyl ring system (methylenedioxyphenyl ring system) are both heterocyclyl groups within the meaning herein. The phrase also includes polycyclic ring systems containing a heteroatom such as, but not limited to, quinuclidyl.
- Heterocyclyl groups can be unsubstituted, or can be substituted as discussed above. Heterocyclyl groups include, but are not limited to, pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl, pyrrolyl, pyrazolyl, triazolyl, tetrazolyl, oxazolyl, isoxazolyl, thiazolyl, pyridinyl, thiophenyl, benzothiophenyl, benzofuranyl, dihydrobenzofuranyl, indolyl, dihydroindolyl, azaindolyl, indazolyl, benzimidazolyl, azabenzimidazolyl, benzoxazolyl, benzothiazolyl, benzothiadiazolyl, imidazopyridinyl, isoxazolopyridinyl, thianaphthalenyl, purinyl, xanthinyl, adeninyl, guaninyl, quinolinyl, isoquinolinyl, tetrahydroquinolinyl, quinoxalinyl, and quinazolinyl groups. Representative substituted heterocyclyl groups can be mono-substituted or substituted more than once, such as, but not limited to, piperidinyl or quinolinyl groups, which are 2-, 3-, 4-, 5-, or 6-substituted, or disubstituted with groups such as those listed above.
- Heteroaryl groups are aromatic ring compounds containing 5 or more ring members, of which, one or more is a heteroatom such as, but not limited to, N, O, and S; for instance, heteroaryl rings can have 5 to about 8-12 ring members. A heteroaryl group is a variety of a heterocyclyl group that possesses an aromatic electronic structure. A heteroaryl group designated as a C2-heteroaryl can be a 5-ring with two carbon atoms and three heteroatoms, a 6-ring with two carbon atoms and four heteroatoms and so forth. Likewise a C4-heteroaryl can be a 5-ring with one heteroatom, a 6-ring with two heteroatoms, and so forth. The number of carbon atoms plus the number of heteroatoms sums up to equal the total number of ring atoms. Heteroaryl groups include, but are not limited to, groups such as pyrrolyl, pyrazolyl, triazolyl, tetrazolyl, oxazolyl, isoxazolyl, thiazolyl, pyridinyl, thiophenyl, benzothiophenyl, benzofuranyl, indolyl, azaindolyl, indazolyl, benzimidazolyl, azabenzimidazolyl, benzoxazolyl, benzothiazolyl, benzothiadiazolyl, imidazopyridinyl, isoxazolopyridinyl, thianaphthalenyl, purinyl, xanthinyl, adeninyl, guaninyl, quinolinyl, isoquinolinyl, tetrahydroquinolinyl, quinoxalinyl, and quinazolinyl groups. Heteroaryl groups can be unsubstituted, or can be substituted with groups as is discussed above. Representative substituted heteroaryl groups can be substituted one or more times with groups such as those listed above.
- Additional examples of aryl and heteroaryl groups include but are not limited to phenyl, biphenyl, indenyl, naphthyl (1-naphthyl, 2-naphthyl), N-hydroxytetrazolyl, N-hydroxytriazolyl, N-hydroxyimidazolyl, anthracenyl (1-anthracenyl, 2-anthracenyl, 3-anthracenyl), thiophenyl (2-thienyl, 3-thienyl), furyl (2-furyl, 3-furyl), indolyl, oxadiazolyl, isoxazolyl, quinazolinyl, fluorenyl, xanthenyl, isoindanyl, benzhydryl, acridinyl, thiazolyl, pyrrolyl (2-pyrrolyl), pyrazolyl (3-pyrazolyl), imidazolyl (1-imidazolyl, 2-imidazolyl, 4-imidazolyl, 5-imidazolyl), triazolyl (1,2,3-triazol-1-yl, 1,2,3-triazol-2-yl 1,2,3-triazol-4-yl, 1,2,4-triazol-3-yl), oxazolyl (2-oxazolyl, 4-oxazolyl, 5-oxazolyl), thiazolyl (2-thiazolyl, 4-thiazolyl, 5-thiazolyl), pyridyl (2-pyridyl, 3-pyridyl, 4-pyridyl), pyrimidinyl (2-pyrimidinyl, 4-pyrimidinyl, 5-pyrimidinyl, 6-pyrimidinyl), pyrazinyl, pyridazinyl (3-pyridazinyl, 4-pyridazinyl, 5-pyridazinyl), quinolyl (2-quinolyl, 3-quinolyl, 4-quinolyl, 5-quinolyl, 6-quinolyl, 7-quinolyl, 8-quinolyl), isoquinolyl (1-isoquinolyl, 3-isoquinolyl, 4-isoquinolyl, 5-isoquinolyl, 6-isoquinolyl, 7-isoquinolyl, 8-isoquinolyl), benzo[b]furanyl (2-benzo[b]furanyl, 3-benzo[b]furanyl, 4-benzo[b]furanyl, 5-benzo[b]furanyl, 6-benzo[b]furanyl, 7-benzo[b]furanyl), 2,3-dihydro-benzo[b]furanyl (2-(2,3-dihydro-benzo[b]furanyl), 3-(2,3-dihydro-benzo[b]furanyl), 4-(2,3-dihydro-benzo[b]furanyl), 5-(2,3-dihydro-benzo[b]furanyl), 6-(2,3-dihydro-benzo[b]furanyl), 7-(2,3-dihydro-benzo[b]furanyl), benzo[b]thiophenyl (2-benzo[b]thiophenyl, 3-benzo[b]thiophenyl, 4-benzo[b]thiophenyl, 5-benzo[b]thiophenyl, 6-benzo[b]thiophenyl, 7-benzo[b]thiophenyl), 2,3-dihydro-benzo[b]thiophenyl, (2-(2,3-dihydro-benzo[b]thiophenyl), 3-(2,3-dihydro-benzo[b]thiophenyl), 4-(2,3-dihydro-benzo[b]thiophenyl), 5-(2,3-dihydro-benzo[b]thiophenyl), 6-(2,3-dihydro-benzo[b]thiophenyl), 7-(2,3-dihydro-benzo[b]thiophenyl), indolyl (1-indolyl, 2-indolyl, 3-indolyl, 4-indolyl, 5-indolyl, 6-indolyl, 7-indolyl), indazole (1-indazolyl, 3-indazolyl, 4-indazolyl, 5-indazolyl, 6-indazolyl, 7-indazolyl), benzimidazolyl (1-benzimidazolyl, 2-benzimidazolyl, 4-benzimidazolyl, 5-benzimidazolyl, 6-benzimidazolyl, 7-benzimidazolyl, 8-benzimidazolyl), benzoxazolyl (1-benzoxazolyl, 2-benzoxazolyl), benzothiazolyl (1-benzothiazolyl, 2-benzothiazolyl, 4-benzothiazolyl, 5-benzothiazolyl, 6-benzothiazolyl, 7-benzothiazolyl), carbazolyl (1-carbazolyl, 2-carbazolyl, 3-carbazolyl, 4-carbazolyl), 5H-dibenz[b,f]azepine (5H-dibenz[b,f]azepin-1-yl, 5H-dibenz[b,f]azepine-2-yl, 5H-dibenz[b,f]azepine-3-yl, 5H-dibenz[b,f]azepine-4-yl, 5H-dibenz[b,f]azepine-5-yl), 10,11-dihydro-5H-dibenz[b,f]azepine (10,11-dihydro-5H-dibenz[b,f]azepine-1-yl, 10,11-dihydro-5H-dibenz[b,f]azepine-2-yl, 10,11-dihydro-5H-dibenz[b,f]azepine-3-yl, 10,11-dihydro-5H-dibenz[b,f]azepine-4-yl, 10,11-dihydro-5H-dibenz[b,f]azepine-5-yl), and the like.
- Heterocyclylalkyl groups are alkyl groups as defined above in which a hydrogen or carbon bond of an alkyl group as defined above is replaced with a bond to a heterocyclyl group as defined above. Representative heterocyclyl alkyl groups include, but are not limited to, furan-2-yl methyl, furan-3-yl methyl, pyridine-3-yl methyl, tetrahydrofuran-2-yl ethyl, and indol-2-yl propyl.
- Heteroarylalkyl groups are alkyl groups as defined above in which a hydrogen or carbon bond of an alkyl group is replaced with a bond to a heteroaryl group as defined above.
- The term “alkoxy” refers to an oxygen atom connected to an alkyl group, including a cycloalkyl group, as are defined above. Examples of linear alkoxy groups include but are not limited to methoxy, ethoxy, propoxy, butoxy, pentyloxy, hexyloxy, and the like. Examples of branched alkoxy include but are not limited to isopropoxy, sec-butoxy, tert-butoxy, isopentyloxy, isohexyloxy, and the like. Examples of cyclic alkoxy include but are not limited to cyclopropyloxy, cyclobutyloxy, cyclopentyloxy, cyclohexyloxy, and the like. An alkoxy group can include one to about 12-20 carbon atoms bonded to the oxygen atom, and can further include double or triple bonds, and can also include heteroatoms. For example, an allyloxy group is an alkoxy group within the meaning herein. A methoxyethoxy group is also an alkoxy group within the meaning herein, as is a methylenedioxy group in a context where two adjacent atoms of a structures are substituted therewith.
- The terms “halo” or “halogen” or “halide” by themselves or as part of another substituent mean, unless otherwise stated, a fluorine, chlorine, bromine, or iodine atom, preferably, fluorine, chlorine, or bromine.
- A “haloalkyl” group includes mono-halo alkyl groups, poly-halo alkyl groups wherein all halo atoms can be the same or different, and per-halo alkyl groups, wherein all hydrogen atoms are replaced by halogen atoms, such as fluoro. Examples of haloalkyl include trifluoromethyl, 1,1-dichloroethyl, 1,2-dichloroethyl, 1,3-dibromo-3,3-difluoropropyl, perfluorobutyl, and the like.
- A “haloalkoxy” group includes mono-halo alkoxy groups, poly-halo alkoxy groups wherein all halo atoms can be the same or different, and per-halo alkoxy groups, wherein all hydrogen atoms are replaced by halogen atoms, such as fluoro. Examples of haloalkoxy include trifluoromethoxy, 1,1-dichloroethoxy, 1,2-dichloroethoxy, 1,3-dibromo-3,3-difluoropropoxy, perfluorobutoxy, and the like.
- The terms “aryloxy” and “arylalkoxy” refer to, respectively, an aryl group bonded to an oxygen atom and an aralkyl group bonded to the oxygen atom at the alkyl moiety. Examples include but are not limited to phenoxy, naphthyloxy, and benzyloxy.
- An “acyl” group as the term is used herein refers to a group containing a carbonyl moiety wherein the group is bonded via the carbonyl carbon atom. The carbonyl carbon atom is also bonded to another carbon atom, which can be part of an alkyl, aryl, aralkyl cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, heteroaryl, heteroarylalkyl group or the like. In the special case wherein the carbonyl carbon atom is bonded to a hydrogen, the group is a “formyl” group, an acyl group as the term is defined herein. An acyl group can include 0 to about 12-20 additional carbon atoms bonded to the carbonyl group. An acyl group can include double or triple bonds within the meaning herein. An acryloyl group is an example of an acyl group. An acyl group can also include heteroatoms within the meaning here. A nicotinoyl group (pyridyl-3-carbonyl) group is an example of an acyl group within the meaning herein. Other examples include acetyl, benzoyl, phenylacetyl, pyridylacetyl, cinnamoyl, and acryloyl groups and the like. When the group containing the carbon atom that is bonded to the carbonyl carbon atom contains a halogen, the group is termed a “haloacyl” group. An example is a trifluoroacetyl group.
- The term “amine” includes primary, secondary, and tertiary amines having, e.g., the formula N(group)3 wherein each group can independently be H or non-H, such as alkyl, aryl, and the like. Amines include but are not limited to R—NH2, for example, alkylamines, arylamines, alkylarylamines; R2NH wherein each R is independently selected, such as dialkylamines, diarylamines, aralkylamines, heterocyclylamines and the like; and R3N wherein each R is independently selected, such as trialkylamines, dialkylarylamines, alkyldiarylamines, triarylamines, and the like. The term “amine” also includes ammonium ions as used herein.
- An “amino” group is a substituent of the form —NH2, —NHR, —NR2, —NR3 +, wherein each R is independently selected, and protonated forms of each, except for —NR3 +, which cannot be protonated. Accordingly, any compound substituted with an amino group can be viewed as an amine. An “amino group” within the meaning herein can be a primary, secondary, tertiary or quaternary amino group. An “alkylamino” group includes a monoalkylamino, dialkylamino, and trialkylamino group.
- An “ammonium” ion includes the unsubstituted ammonium ion NH4 +, but unless otherwise specified, it also includes any protonated or quaternarized forms of amines. Thus, trimethylammonium hydrochloride and tetramethylammonium chloride are both ammonium ions, and amines, within the meaning herein.
- The term “amide” (or “amido”) includes C- and N-amide groups, i.e., —C(O)NR2, and —NRC(O)R groups, respectively. Amide groups therefore include but are not limited to primary carboxamide groups (—C(O)NH2) and formamide groups (—NHC(O)H). A “carboxamido” group is a group of the formula C(O)NR2, wherein R can be H, alkyl, aryl, etc.
- The term “urethane” (“carbamoyl” or “carbamyl”) includes N- and O-urethane groups, i.e., —NRC(O)OR and —OC(O)NR2 groups, respectively.
- The term “sulfonamide” (or “sulfonamido”) includes S- and N-sulfonamide groups, i.e., —SO2NR2 and —NRSO2R groups, respectively. Sulfonamide groups therefore include but are not limited to sulfamoyl groups (—SO2NH2). An organosulfur structure represented by the formula —S(O)(NR)— is understood to refer to a sulfoximine, wherein both the oxygen and the nitrogen atoms are bonded to the sulfur atom, which is also bonded to two carbon atoms.
- The term “amidine” or “amidino” includes groups of the formula —C(NR)NR2. Typically, an amidino group is —C(NH)NH2.
- The term “guanidine” or “guanidino” includes groups of the formula —NRC(NR)NR2. Typically, a guanidino group is —NHC(NH)NH2.
- A “salt” as is well known in the art includes an organic compound such as a carboxylic acid, a sulfonic acid, or an amine, in ionic form, in combination with a counterion. For example, acids in their anionic form can form salts with cations such as metal cations, for example sodium, potassium, and the like; with ammonium salts such as NH4 + or the cations of various amines, including tetraalkyl ammonium salts such as tetramethylammonium, or other cations such as trimethylsulfonium, and the like. A “pharmaceutically acceptable” or “pharmacologically acceptable” salt is a salt formed from an ion that has been approved for human consumption and is generally non-toxic, such as a chloride salt or a sodium salt. A “zwitterion” is an internal salt such as can be formed in a molecule that has at least two ionizable groups, one forming an anion and the other a cation, which serve to balance each other. For example, amino acids such as glycine can exist in a zwitterionic form. A “zwitterion” is a salt within the meaning herein. The compounds of the present invention may take the form of salts. The term “salts” embraces addition salts of free acids or free bases which are compounds of the invention. Salts can be “pharmaceutically-acceptable salts.” The term “pharmaceutically-acceptable salt” refers to salts which possess toxicity profiles within a range that affords utility in pharmaceutical applications. Pharmaceutically unacceptable salts may nonetheless possess properties such as high crystallinity, which have utility in the practice of the present invention, such as for example utility in process of synthesis, purification or formulation of compounds of the invention.
- Suitable pharmaceutically-acceptable acid addition salts may be prepared from an inorganic acid or from an organic acid. Examples of inorganic acids include hydrochloric, hydrobromic, hydriodic, nitric, carbonic, sulfuric, and phosphoric acids. Appropriate organic acids may be selected from aliphatic, cycloaliphatic, aromatic, araliphatic, heterocyclic, carboxylic and sulfonic classes of organic acids, examples of which include formic, acetic, propionic, succinic, glycolic, gluconic, lactic, malic, tartaric, citric, ascorbic, glucuronic, maleic, fumaric, pyruvic, aspartic, glutamic, benzoic, anthranilic, 4-hydroxybenzoic, phenylacetic, mandelic, embonic (pamoic), methanesulfonic, ethanesulfonic, benzenesulfonic, pantothenic, trifluoromethanesulfonic, 2-hydroxyethanesulfonic, p-toluenesulfonic, sulfanilic, cyclohexylaminosulfonic, stearic, alginic, β-hydroxybutyric, salicylic, galactaric and galacturonic acid. Examples of pharmaceutically unacceptable acid addition salts include, for example, perchlorates and tetrafluoroborates.
- Suitable pharmaceutically acceptable base addition salts of compounds of the invention include, for example, metallic salts including alkali metal, alkaline earth metal and transition metal salts such as, for example, calcium, magnesium, potassium, sodium and zinc salts. Pharmaceutically acceptable base addition salts also include organic salts made from basic amines such as, for example, N,N′-dibenzylethylenediamine, chloroprocaine, choline, diethanolamine, ethylenediamine, meglumine (N-methylglucamine) and procaine. Examples of pharmaceutically unacceptable base addition salts include lithium salts and cyanate salts. Although pharmaceutically unacceptable salts are not generally useful as medicaments, such salts may be useful, for example as intermediates in the synthesis of Formula (I) compounds, for example in their purification by recrystallization. All of these salts may be prepared by conventional means from the corresponding compound according to Formula (I) by reacting, for example, the appropriate acid or base with the compound according to Formula (I). The term “pharmaceutically acceptable salts” refers to nontoxic inorganic or organic acid and/or base addition salts, see, for example, Lit et al., Salt Selection for Basic Drugs (1986), Int J. Pharm., 33, 201-217, incorporated by reference herein.
- A “hydrate” is a compound that exists in a composition with water molecules. The composition can include water in stoichiometric quantities, such as a monohydrate or a dihydrate, or can include water in random amounts. As the term is used herein a “hydrate” refers to a solid form, i.e., a compound in water solution, while it may be hydrated, is not a hydrate as the term is used herein.
- A “solvate” is a similar composition except that a solvent other that water replaces the water. For example, methanol or ethanol can form an “alcoholate”, which can again be stoichiometric or non-stoichiometric. As the term is used herein a “solvate” refers to a solid form, i.e., a compound in solution in a solvent, while it may be solvated, is not a solvate as the term is used herein.
- In addition, where features or aspects of the invention are described in terms of Markush groups, those skilled in the art will recognize that the invention is also thereby described in terms of any individual member or subgroup of members of the Markush group. For example, if X is described as selected from the group consisting of bromine, chlorine, and iodine, claims for X being bromine and claims for X being bromine and chlorine are fully described. Moreover, where features or aspects of the invention are described in terms of Markush groups, those skilled in the art will recognize that the invention is also thereby described in terms of any combination of individual members or subgroups of members of Markush groups. Thus, for example, if X is described as selected from the group consisting of bromine, chlorine, and iodine, and Y is described as selected from the group consisting of methyl, ethyl, and propyl, claims for X being bromine and Y being methyl are fully described.
- If a value of a variable that is necessarily an integer, e.g., the number of carbon atoms in an alkyl group or the number of substituents on a ring, is described as a range, e.g., 0-4, what is meant is that the value can be any integer between 0 and 4 inclusive, i.e., 0, 1, 2, 3, or 4.
- In various embodiments, the compound or set of compounds, such as are used in the inventive methods, can be any one of any of the combinations and/or sub-combinations of the above-listed embodiments.
- In various embodiments, a compound as shown in any of the Examples, or among the exemplary compounds, is provided. Provisos may apply to any of the disclosed categories or embodiments wherein any one or more of the other above disclosed embodiments or species may be excluded from such categories or embodiments.
- The present invention further embraces isolated compounds of the invention. The expression “isolated compound” refers to a preparation of a compound of the invention, or a mixture of compounds the invention, wherein the isolated compound has been separated from the reagents used, and/or byproducts formed, in the synthesis of the compound or compounds. “Isolated” does not mean that the preparation is technically pure (homogeneous), but it is sufficiently pure to compound in a form in which it can be used therapeutically. Preferably an “isolated compound” refers to a preparation of a compound of the invention or a mixture of compounds of the invention, which contains the named compound or mixture of compounds of the invention in an amount of at least 10 percent by weight of the total weight. Preferably the preparation contains the named compound or mixture of compounds in an amount of at least 50 percent by weight of the total weight; more preferably at least 80 percent by weight of the total weight; and most preferably at least 90 percent, at least 95 percent or at least 98 percent by weight of the total weight of the preparation.
- The compounds of the invention and intermediates may be isolated from their reaction mixtures and purified by standard techniques such as filtration, liquid-liquid extraction, solid phase extraction, distillation, recrystallization or chromatography, including flash column chromatography, or HPLC.
- Within the present invention it is to be understood that a compound of the formula (I) or a salt thereof may exhibit the phenomenon of tautomerism whereby two chemical compounds that are capable of facile interconversion by exchanging a hydrogen atom between two atoms, to either of which it forms a covalent bond. Since the tautomeric compounds exist in mobile equilibrium with each other they may be regarded as different isomeric forms of the same compound. It is to be understood that the formulae drawings within this specification can represent only one of the possible tautomeric forms. However, it is also to be understood that the invention encompasses any tautomeric form, and is not to be limited merely to any one tautomeric form utilized within the formulae drawings. The formulae drawings within this specification can represent only one of the possible tautomeric forms and it is to be understood that the specification encompasses all possible tautomeric forms of the compounds drawn not just those forms which it has been convenient to show graphically herein. For example, tautomerism may be exhibited by a pyrazolyl group bonded as indicated by the wavy line. While both substituents would be termed a 4-pyrazolyl group, it is evident that a different nitrogen atom bears the hydrogen atom in each structure.
- Such tautomerism can also occur with substituted pyrazoles such as 3-methyl, 5-methyl, or 3,5-dimethylpyrazoles, and the like. Another example of tautomerism is amido-imido (lactam-lactim when cyclic) tautomerism, such as is seen in heterocyclic compounds bearing a ring oxygen atom adjacent to a ring nitrogen atom. For example, the equilibrium:
- is an example of tautomerism. Accordingly, a structure depicted herein as one tautomer is intended to also include the other tautomer.
- It will be understood that when compounds of the present invention contain one or more chiral centers, the compounds may exist in, and may be isolated as pure enantiomeric or diastereomeric forms or as racemic mixtures. The present invention therefore includes any possible enantiomers, diastereomers, racemates or mixtures thereof of the compounds of the invention.
- The isomers resulting from the presence of a chiral center comprise a pair of non-superimposable isomers that are called “enantiomers.” Single enantiomers of a pure compound are optically active, i.e., they are capable of rotating the plane of plane polarized light. Single enantiomers are designated according to the Cahn-Ingold-Prelog system. The priority of substituents is ranked based on atomic weights, a higher atomic weight, as determined by the systematic procedure, having a higher priority ranking. Once the priority ranking of the four groups is determined, the molecule is oriented so that the lowest ranking group is pointed away from the viewer. Then, if the descending rank order of the other groups proceeds clockwise, the molecule is designated as having an (R) absolute configuration, and if the descending rank of the other groups proceeds counterclockwise, the molecule is designated as having an (5) absolute configuration. In the example in the Scheme below, the Cahn-Ingold-Prelog ranking is A>B>C>D. The lowest ranking atom, D is oriented away from the viewer. The solid wedge indicates that the atom bonded thereby projects toward the viewer out of the plane of the paper, and a dashed wedge indicates that the atom bonded thereby projects away from the viewer out of the plan of the paper, i.e., the plane “of the paper” being defined by atoms A, C, and the chiral carbon atom for the (R) configuration shown below.
- A carbon atom bearing the A-D atoms as shown above is known as a “chiral” carbon atom, and the position of such a carbon atom in a molecule is termed a “chiral center.” Compounds of the invention may contain more than one chiral center, and the configuration at each chiral center is described in the same fashion.
- There are various conventions for depicting chiral structures using solid and dashed wedges. For example, for the (R) configuration shown above, the following two depictions are equivalent:
- The present invention is meant to encompass diastereomers as well as their racemic and resolved, diastereomerically and enantiomerically pure forms and salts thereof. Diastereomeric pairs may be resolved by known separation techniques including normal and reverse phase chromatography, and crystallization.
- “Isolated optical isomer” means a compound which has been substantially purified from the corresponding optical isomer(s) of the same formula. Preferably, the isolated isomer is at least about 80%, more preferably at least 90% pure, even more preferably at least 98% pure, most preferably at least about 99% pure, by weight.
- Isolated optical isomers may be purified from racemic mixtures by well-known chiral separation techniques. According to one such method, a racemic mixture of a compound of the invention, or a chiral intermediate thereof, is separated into 99% wt. % pure optical isomers by HPLC using a suitable chiral column, such as a member of the series of DAICEL® CHIRALPAK® family of columns (Daicel Chemical Industries, Ltd., Tokyo, Japan). The column is operated according to the manufacturer's instructions.
- The invention is directed, in various embodiments, to a method for treatment of a patient afflicted by a progressive bone disease, comprising administering to the patient an effective dose of a compound of formula (I)
- wherein:
- R is H, (C1-C6)alkyl, (C3-C9)cycloalkyl, or (C3-C9)cycloalkyl(C1-C6)alkyl;
- Y1 or Y2 are each independently C or N, provided that when Y1 or Y2 is N, le or R2, respectively, is absent;
- R1 and R2 are independently H, (C1-C6)alkyl, (C3-C9)cycloalkyl, or (C1-C6)haloalkyl; or R1 and R2 together with the atoms to which they are bonded form a 5- to 9-membered ring, comprising 0-3 heteroatoms selected from the group consisting of O, NR, and SOq wherein q is 0, 1, or 2, and optionally mono- or multi-substituted with independently selected (C1-C6)alkyl, (C2-C6)alkenyl, (C2-C6)alkynyl, (C6-C10)aryl, (C3-C9)cycloalkyl, halo, oxo, (C1-C6)haloalkyl, nitro, cyano-(C0-C6)alkyl, R′O2C—(C0-C6)alkyl, methylenedioxy, R′O—(C0-C6)alkyl, (R′)2N—(C0-C6)alkyl, (R′)2NC(═O)—(C0-C6)alkyl, R′C(═O)N(R′)—(C0-C6)alkyl, (C1-C6)alkyl-S(O)q(C0-C6)alkyl, aryl, aroyl, or SO2NR′2;
- R3 is optionally mono- or multi-substituted (C1-C6)alkyl, (C1-C6)alkenyl, (C1-C6)alkynyl, (C6-C10)aryl, (C6-C10)aryl(C1-C6)alkyl, (3-9 membered)heterocyclyl, (3-9 membered)heterocyclyl(C1-C6)alkyl, (3-9 membered)heteroaryl, or (3-9 membered)heteroaryl(C1-C6)alkyl; wherein if present each substituent on R3 is independently selected from the group consisting of (C1-C6)alkyl, (C2-C6)alkenyl, (C2-C6)alkynyl, (C6-C10)aryl, (C3-C9)cycloalkyl, 3-9 membered mono- and bicyclic heterocyclyl, 3-9 membered mono- and bicyclic heteroaryl, halo, oxo, haloalkyl, haloalkoxy, nitro, cyano, CO2R′, methylenedioxy, OR′, N(R′)2, C(O)N(R′)2, (C1-C6)alkyl-S(O)q, SO2NR′2, and (C1-C6)alkoxyl; and provided that group R3N(R)C(═O)— can be bonded to any one of the four carbon atoms of the phenyl ring not bonded to N1 or Y1;
- wherein each R′ is independently H, (C1-C6) alkyl, (C3-C9)cycloalkyl, (C3-C9)cycloalkyl(C1-C6)alkyl, (C6-C10)aryl, or (C6-C10)aryl(C1-C6) alkyl, or wherein two R′ bonded to an atom together with the atom form a 3-9 membered ring optionally further comprising a heteroatom selected from the group consisting of O, NR′, and S(O)q;
- wherein any alkyl, alkenyl, alkynyl, aryl, arylalkyl, or cycloalkyl is optionally mono- or independently multi-substituted with (C1-C6)alkyl, (C1-C6)haloalkyl, (C1-C6)alkoxy, (C1-C6)haloalkoxy, halo, oxo, aryl, or aroyl;
- each of X1-X5 is independently N or CH, or is C substituted with an independently selected R4 or is C substituted with Z, provided that no more than two of X1-X5 are N, and provided that there is no more than one Z group bonded to the ring comprising X1—X5;
- each R4 is independently halo, nitro, (C1-C6)fluoroalkyl, R′—(C0-C6)alkyl, R′O2C—(C0-C6)alkyl, NC—(C0-C6)alkyl, R′O—(C0-C6)alkyl, (R′)2N—(C0-C6)alkyl, (R′)2NC(═O)—(C0-C6)alkyl, R′C(═O)N(R′)—(C0-C6)alkyl, C-bonded tetrazolyl, 3-hydroxypyrrolidin-1-carbonyl, 2-hydroxyethylaminocarbonyl, cyclohexylaminocarbonyl, 2-(N,N-dimethylaminocarbonyl)-2-hydroxyethylaminocarbonyl, N,N-dimethylaminoethylcarbonyl, N-methylaminocarbonyl, N-hydroxylaminocarbonyl, (1,3,4-oxadiazol-2(3H)-on)-yl, (1,2,4-oxadiazol-5(4H)-on)-3-yl, (C1-C6)alkyl-S(O)q(C0-C6)alkyl, R'S(O)2NHC(O), R′C(O)NHS(O)2, an unsubstituted or substituted aryl, an unsubstituted or substituted heteroaryl, (C1-C6)alkyl or (C3-C9)cycloalkyl-(C0-C6)alkyl, wherein any alkyl or cycloalkyl is optionally mono- or independently multi-substituted with R′, OR′, N(R′)2, C-bonded tetrazolyl, (C1-C6)alkyl-S(O)q(C0-C6)alkyl, an unsubstituted or substituted aryl, or an unsubstituted or substituted heteroaryl; or R4 is —(C(R″)2)mCO2R′, —(C(R″)2)mCON(R′)2, —(C(R″)2)mCN, —O(C(R″)2)mCO2R′, —O(C(R″)2)mCON(R′)2, or —O(C(R″)2)mCN, wherein m is 1, 2, or 3;
- R″ is H, halo, (C1-C6) alkyl, (C1-C6) haloalkyl, (C3-C9)cycloalkyl, (C3-C9)cycloalkyl(C1-C6)alkyl, (C6-C10)aryl, or (C6-C10)aryl(C1-C6) alkyl, or two R″ together with an atom to which they are bonded form a 3- to 9-membered ring;
- Z is a group of formula
- wherein a wavy line indicates a point of bonding, each of Z1-Z5 is independently N or is C substituted with an independently selected H or R4; provided that no more than two of Z1-Z5 are N;
- Y is (C1-C2)alkyl, or sulfur;
- when Y is (C1-C2)alkyl, R5 and R6 are independently H or (C1-C4)alkyl or independently each R5 and R6 together with the carbon atom to which they are bonded form a carbonyl, or, one R5 group can further be bonded to X5 to form a 4- to 8-membered ring; and,
- when Y is sulfur, R5 and R6 are both oxygen;
- or a pharmaceutically acceptable salt thereof;
- wherein the effective dose of the compound acts to inhibit bone resorption, improve bone formation, or both, in the patient.
- For example, in various embodiments of practice of a method of the invention, for a compound of formula (I), Y1 or Y2 can each be C, providing an indole nucleus. R1 and R2 can be independently H or methyl. In other embodiments, Y1 is N and Y2 is C, providing a benzimidazole nucleus, or Y1 is C and Y2 is N, providing an indazole nucleus for the compound of formula (I) used in a method of the invention.
- More specifically, R3 can be benzyl, α-phenethyl, α-phenpropyl, cycloalkyl or cycloalkylalkyl, any of which can be unsubstituted or substituted, as described herein. Or, R3 can be heterocyclyl, heterocyclylalkyl, heteroaryl, or heteroarylalkyl, any of which can be unsubstituted or substituted. For instance, R3 can be any one of:
- wherein a wavy line indicates a point of attachment.
- In various embodiments for practice of a method of the invention, for a compound of formula (I), YR5R6 can be SO2. In other embodiments, Y can be C1-alkyl; and R5 and R6 be H, or Y can be C2-alkyl, and R5 and R6 be H.
- Further embodiments for practice of a method of the invention comprise the use of an effective dose of a compound of formula (I) wherein R4 is —CO2H, —(CH2)mCO2H, —O(CH2)mCO2H, —CN, —(CH2)mCN, —O(CH2)mCN, —C(CH3)2CO2H, —C(CH3)2CN, —OC(CH3)2CO2H, —OC(CH3)2CN, —CH(CH3)CO2H, —CH(CH3)CN, —OCH(CH3)CO2H, —OCH(CH3)CN; —CH(CH2CH3)CO2H, —CH(CH2CH3)CN, —OCH(CH2CH3)CO2H, —OCH(CH2CH3)CN; —CH(i-Pr)CO2H, —CH(i-Pr)CN, —OCH(i-Pr)CO2H, —OCH(i-Pr)CN, wherein iPr indicates isopropyl; —CH(t-Bu)CO2H, —CH(t-Bu)CN, —OCH(t-Bu)CO2H, —OCH(t-Bu)CN, wherein t-Bu indicates t-butyl; or —(CHR″)mC(═O)N(R″)2, —O(CHR″)mC(═O)N(R″)2,
- wherein a wavy line indicates a point of attachment.
- In various embodiments for practice of a method of the invention, for the compound of formula (I), no Z group is present on the ring comprising X1—X5, providing a compound of formula (IA), which can be an N-benzyl-indole, an N-benzyl-benzimidazole, or an N-benzyl-indazole, or an analog thereof.
- More specifically, for practice of a method of the invention, the compound of formula (IA) can be any one of:
- or a pharmaceutically acceptable salt thereof.
- In other embodiments for practice of a method of the invention, for the compound of formula (I), Z can be present, providing a compound of formula (IB). A compound of formula (IB) can be an N-biphenylmethyl-indole, an N-biphenylmethyl-benzimidazole, an N-biphenylmethyl-indazole, or an analog thereof. For instance, in various embodiments, Z1-Z5 can all be carbon. In other embodiments, one of two of Z1-Z5 can be nitrogen.
- In specific embodiments for practice of a method of the invention, the compound of formula (IB) can be any one of:
- or a pharmaceutically acceptable salt thereof.
- The invention provides, in various embodiments, methods of treatment of a progressive bone disease, wherein the progressive bone disease is osteoporosis, Paget's Disease, multiple myeloma, or hyperparathyroidism. For instance, administration of the compound of formula (I) acts to increase FGF21 while increasing bone health.
- In various embodiments, the invention provides the use of a compound of formula (I) for treatment of a progressive bone disease, wherein the compound of formula (I) is
- wherein:
- R is H, (C1-C6)alkyl, (C3-C9)cycloalkyl, or (C3-C9)cycloalkyl(C1-C6)alkyl;
- Y1 or Y2 are each independently C or N, provided that when Y1 or Y2 is N, le or R2, respectively, is absent;
- R1 and R2 are independently H, (C1-C6)alkyl, (C3-C9)cycloalkyl, or (C1-C6)haloalkyl; or R1 and R2 together with the atoms to which they are bonded form a 5- to 9-membered ring, comprising 0-3 heteroatoms selected from the group consisting of O, NR, and SOq wherein q is 0, 1, or 2, and optionally mono- or multi-substituted with independently selected (C1-C6)alkyl, (C2-C6)alkenyl, (C2-C6)alkynyl, (C6-C10)aryl, (C3-C9)cycloalkyl, halo, oxo, (C1-C6)haloalkyl, nitro, cyano-(C0-C6)alkyl, R′O2C—(C0-C6)alkyl, methylenedioxy, R′O—(C0-C6)alkyl, (R′)2N—(C0-C6)alkyl, (R′)2NC(═O)—(C0-C6)alkyl, R′C(═O)N(R′)—(C0-C6)alkyl, (C1-C6)alkyl-S(O)q(C0-C6)alkyl, aryl, aroyl, or SO2NR′2;
- R3 is optionally mono- or multi-substituted (C1-C6)alkyl, (C1-C6)alkenyl, (C1-C6)alkynyl, (C6-C10)aryl, (C6-C10)aryl(C1-C6)alkyl, (3-9 membered)heterocyclyl, (3-9 membered)heterocyclyl(C1-C6)alkyl, (3-9 membered)heteroaryl, or (3-9 membered)heteroaryl(C1-C6)alkyl; wherein if present each substituent on R3 is independently selected from the group consisting of (C1-C6)alkyl, (C2-C6)alkenyl, (C2-C6)alkynyl, (C6-C10)aryl, (C3-C9)cycloalkyl, 3-9 membered mono- and bicyclic heterocyclyl, 3-9 membered mono- and bicyclic heteroaryl, halo, oxo, haloalkyl, haloalkoxy, nitro, cyano, CO2R′, methylenedioxy, OR′, N(R′)2, C(O)N(R′)2, (C1-C6)alkyl-S(O)q, SO2NR′2, and (C1-C6)alkoxyl; and provided that group R3N(R)C(═O)— can be bonded to any one of the four carbon atoms of the phenyl ring not bonded to N1 or Y1;
- wherein each R′ is independently H, (C1-C6) alkyl, (C3-C9)cycloalkyl, (C3-C9)cycloalkyl(C1-C6)alkyl, (C6-C10)aryl, or (C6-C10)aryl(C1-C6) alkyl, or wherein two R′ bonded to an atom together with the atom form a 3-9 membered ring optionally further comprising a heteroatom selected from the group consisting of O, NR′, and S(O)q;
- wherein any alkyl, alkenyl, alkynyl, aryl, arylalkyl, or cycloalkyl is optionally mono- or independently multi-substituted with (C1-C6)alkyl, (C1-C6)haloalkyl, (C1-C6)alkoxy, (C1-C6)haloalkoxy, halo, oxo, aryl, or aroyl;
- each of X1-X5 is independently N or CH, or is C substituted with an independently selected R4 or is C substituted with Z, provided that no more than two of X1-X5 are N, and provided that there is no more than one Z group bonded to the ring comprising X1—X5;
- each R4 is independently halo, nitro, (C1-C6)fluoroalkyl, R′—(C0-C6)alkyl, R′O2C—(C0-C6)alkyl, NC—(C0-C6)alkyl, R′O—(C0-C6)alkyl, (R′)2N—(C0-C6)alkyl, (R′)2NC(═O)—(C0-C6)alkyl, R′C(═O)N(R′)—(C0-C6)alkyl, C-bonded tetrazolyl, 3-hydroxypyrrolidin-1-carbonyl, 2-hydroxyethylaminocarbonyl, cyclohexylaminocarbonyl, 2-(N,N-dimethylaminocarbonyl)-2-hydroxyethylaminocarbonyl, N,N-dimethylaminoethylcarbonyl, N-methylaminocarbonyl, N-hydroxylaminocarbonyl, (1,3,4-oxadiazol-2(3H)-on)-yl, (1,2,4-oxadiazol-5(4H)-on)-3-yl, (C1-C6)alkyl-S(O)q(C0-C6)alkyl, R'S(O)2NHC(O), R′C(O)NHS(O)2, an unsubstituted or substituted aryl, an unsubstituted or substituted heteroaryl, (C1-C6)alkyl or (C3-C9)cycloalkyl-(C0-C6)alkyl, wherein any alkyl or cycloalkyl is optionally mono- or independently multi-substituted with R′, OR′, N(R′)2, C-bonded tetrazolyl, (C1-C6)alkyl-S(O)q(C0-C6)alkyl, an unsubstituted or substituted aryl, or an unsubstituted or substituted heteroaryl; or R4 is —(C(R″)2)mCO2R′, —(C(R″)2)mCON(R′)2, —(C(R″)2)mCN, —O(C(R″)2)mCO2R′, —O(C(R″)2)mCON(R′)2, or —O(C(R″)2)mCN, wherein m is 1, 2, or 3;
- R″ is H, halo, (C1-C6) alkyl, (C1-C6) haloalkyl, (C3-C9)cycloalkyl, (C3-C9)cycloalkyl(C1-C6)alkyl, (C6-C10)aryl, or (C6-C10)aryl(C1-C6) alkyl, or two R″ together with an atom to which they are bonded form a 3- to 9-membered ring;
- Z is a group of formula
- wherein a wavy line indicates a point of bonding, each of Z1-Z5 is independently N or is C substituted with an independently selected H or R4; provided that no more than two of Z1-Z5 are N;
- Y is (C1-C2)alkyl, or sulfur;
- when Y is (C1-C2)alkyl, R5 and R6 are independently H or (C1-C4)alkyl or independently each R5 and R6 together with the carbon atom to which they are bonded form a carbonyl, or, one R5 group can further be bonded to X5 to form a 4- to 8-membered ring; and,
- when Y is sulfur, R5 and R6 are both oxygen;
- or a pharmaceutically acceptable salt thereof;
- wherein the effective dose of the compound acts to inhibit bone resorption, improve bone formation, or both, in the patient.
- For instance, the progressive bone disease can be osteoporosis, Paget's Disease, multiple myeloma, or hyperparathyroidism. For instance, administration of the compound of formula (I) acts to increase FGF21 while increasing bone health.
- In various embodiments, the invention provides a compound of formula
- or a pharmaceutically acceptable salt thereof.
- The invention provides a method for practice of the invention wherein the compound of formula (I) is
- or a pharmaceutically acceptable salt thereof.
- The invention provides a use of a compound of formula (I), wherein the compound is
- or a pharmaceutically acceptable salt thereof, for treatment of a progressive bone disease, for instance, for treatment of osteoporosis, Paget's Disease, multiple myeloma, or hyperparathyroidism.
- The following abbreviations are used throughout this document.
- BOP Benzotriazol-1-yl-oxy-tris-(dimethylamino)phosphonium hexafluorophosphate
- CDI Carbonyl diimidazole
- DBU Diazabicycloundecane
- DCM Dichloromethane
- DIPEA, iPr2EtN N,N-Diisopropylethylamine
- DMAP 4-(N,N-dimethylamino)pyridine
- DMF N,N-Dimethylformamide
- DMSO Dimethylsulfoxide
- EDAC 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride
- eq Equivalents
- Et2O Diethyl ether
- EtOAc Ethyl acetate
- h Hours
- HATU O-(7-Azabenzotriazole-1-yl)-N, N,N′N′-tetramethyluronium hexafluorophosphate
- HCl Hydrochloric acid
- HOAT Hydroxyazabenztriazole
- HOBT Hydroxybenzotriazole
- LiHDMS Lithium hexamethyldisilazide
- LiOH Lithium hydroxide
- mg Milligrams
- min Minutes
- mL Milliliters
- μL Microliters
- mmole Millimoles
- MS Mass spectroscopy
- MeOH Methanol
- NaBH3CN Sodium cyanoborohydride
- NaH Sodium hydride
- NaIO4 Sodium periodate
- NMM N-Methylmorpholine
- rb Round-bottom
- RT, rt Room temperature
- sat. Saturated
- TEA Triethylamine
- TFA Trifluoroacetic acid
- THF Tetrahydrofuran
- Compounds of formula (IA)
-
-
- To a solution of 1H-indole-5-carboxylic acid (1 g, 6.2 mmol, 1.0 equiv) in acetonitrile (40 mL) were added 1,8-Diazabicyclo[5.4.0]undec-7-ene (1.1 mL, 7.4 mmol, 1.2 equiv) and iodomethane (2.3 mL, 37.2 mmol, 6 equiv). The solution was stirred under reflux overnight. The reaction mixture was concentrated in vacuo. The residue was dissolved in AcOEt, washed with a 0.5 N HCl aqueous solution, a saturated NaHCO3 solution and brine, dried over MgSO4 and concentrated in vacuo. The obtained oil was used in the next step without further purification.
-
- To a solution of methyl 1H-indole-5-carboxylate (2 g, 11.4 mmol, 1 equiv) and 1-(bromomethyl)-2,4-difluorobenzene (1.61 mL, 12.6 mmol, 1.1 equiv) in anhydrous DMF (50 mL) under argon atmosphere was added sodium hydride (913 mg, 22.8 mmol, 2 equiv) in small portions. The mixture was stirred 2 h at room temperature. The reaction mixture was then neutralized by addition of methanol and concentrated in vacuo. The residue was dissolved in AcOEt, washed with brine and dried over MgSO4. The crude was purified by flash chromatography (Hexane/
AcOEt 7/3) to afford the title compound as a colorless oil (3.14 g, 10.4 mmol, 91%). ESI-MS (m/z): 302 [M+H]+. -
- To a solution of methyl 1-(2,4-difluorobenzyl)-1H-indole-5-carboxylate (3.14 g, 10.4 mmol, 1 equiv) in methanol (50 mL) was added a 5 N NaOH solution (50 mL, 104 mmol, 10 equiv). The reaction mixture was stirred 2 h at 40° C. The mixture was then acidified and extracted with DCM. After concentration in vacuo, the title compound was precipitated in Et2O to afford a white powder (2.82 g, 9.8 mmol, 96%). ESI-MS (m/z): 288 [M+H]+.
-
- To a solution of 1-(2,4-difluorobenzyl)-1H-indole-5-carboxylic acid (50 mg, 0.17 mmol, 1 equiv) in DCM (2 mL) were added the (2,4-dimethoxyphenyl)methanamine (27 μL, 0.18 mmol, 1.05 equiv) and 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide (35 mg, 0.18 mmol, 1.05 equiv). The reaction mixture was stirred 2 h at room temperature. The solvent was removed in vacuo. The residue was dissolved in AcOEt and washed with a 0.5 N HCl aqueous solution, a saturated NaHCO3 solution and brine, dried over MgSO4 and concentrated in vacuo to afford a beige powder (56 mg, 0.13 mmol, 76%). ESI-MS (m/z): 437 [M+H]+.
-
- The title compound was prepared following the same general protocol as described in
Step 4, Example 1, using (3-(trifluoromethoxy)phenyl)methanamine instead of the (2,4-dimethoxyphenyl)methanamine. A white powder was obtained (55 mg, 0.12 mmol, 70%). ESI-MS (m/z): 461 [M+H]+. -
- The title compound was prepared following the same general protocol as described in
Step 4, Example 1, using (3,4-dimethoxyphenyl)methanamine instead of the (2,4-dimethoxyphenyl)methanamine. A white powder was obtained (44 mg, 0.10 mmol, 59%). ESI-MS (m/z): 437 [M+H]+. -
- The title compound was prepared following the same general protocol as described in
Step 4, Example 1, using (S)-1-(4-nitrophenyl)ethanamine instead of the (2,4-dimethoxyphenyl)methanamine. A beige powder was obtained (46 mg, 0.11 mmol, 62%). ESI-MS (m/z): 436 [M+H]+. -
- The title compound was prepared following the same general protocol as described in
Step 4, Example 1, using (S)-1-(4-bromophenyl)ethanamine instead of the (2,4-dimethoxyphenyl)methanamine. A white powder was obtained (50 mg, 0.11 mmol, 63%). ESI-MS (m/z): 469/471 [M+H]+. -
- The title compound was prepared following the same general protocol as described in
Step 4, Example 1, using chroman-3-amine instead of the (2,4-dimethoxyphenyl)methanamine. A white powder was obtained (52 mg, 0.12 mmol, 73%). ESI-MS (m/z): 419 [M+H]+. -
- The title compound was prepared following the same general protocol as described in
Step 4, Example 1, using (R)-1-(4-bromophenyl)ethanamine instead of the (2,4-dimethoxyphenyl)methanamine. A white powder was obtained (55 mg, 0.12 mmol, 69%). ESI-MS (m/z): 469/471 [M+H]+. -
- The title compound was prepared following the same general protocol as described in
Step 4, Example 1, using 1-phenylpropan-1-amine instead of the (2,4-dimethoxyphenyl)methanamine. A beige powder was obtained (46 mg, 0.12 mmol, 67%). ESI-MS (m/z): 405 [M+H]+. -
- The title compound was prepared following the same general protocol as described in
Step 4, Example 1, using phenylmethanamine instead of the (2,4-dimethoxyphenyl)methanamine. A light green powder was obtained (49 mg, 0.13 mmol, 77%). ESI-MS (m/z): 377 [M+H]+. -
- The title compound was prepared following the same general protocol as described in
Step 4, Example 1, using (R)-1-(4-nitrophenyl)ethanamine instead of the (2,4-dimethoxyphenyl)methanamine. A beige powder was obtained (45 mg, 0.10 mmol, 60%). ESI-MS (m/z): 436 [M+H]+. -
- To a solution of 1-(2,4-difluorobenzyl)-1H-indole-5-carboxylic acid (50 mg, 0.17 mmol, 1 equiv) in DCM (2 mL) was added 2-phenylpropane-2-amine (27 μL, 0.18 mmol, 1.05 equiv), DIEA (30 μL, 0.17 mmol, 1 equiv) and HATU (68 mg, 0.18 mmol, 1.05 equiv). The reaction mixture was stirred 2 h at room temperature. The solvent was removed in vacuo. The residue was dissolved in AcOEt and washed with a 0.5N HCl aqueous solution, a saturated NaHCO3 solution and brine, dried over MgSO4 and concentrated in vacuo to afford a white powder (63 mg, 0.15 mmol, 92%). ESI-MS (m/z): 405 [M+H]+.
-
- The title compound was prepared following the same general protocol as described in
Step 4, Example 1, using thiophen-2-ylmethanamine instead of the (2,4-dimethoxyphenyl)methanamine. A white powder was obtained (45 mg, 0.12 mmol, 69%). ESI-MS (m/z): 383 [M+H]+. -
- The title compound was prepared following the same general protocol as described in
Step 4, Example 1, using 2-methoxyethanamine instead of the (2,4-dimethoxyphenyl)methanamine. A light green powder was obtained (47 mg, 0.14 mmol, 80%). ESI-MS (m/z): 345 [M+H]+. -
- The title compound was prepared following the same general protocol as described in
Step 4, Example 1, using (2,3-dihydrobenzo[b][1,4]dioxin-2-yl)methanamine instead of the (2,4-dimethoxyphenyl)methanamine. A beige powder was obtained (65 mg, 0.15 mmol, 88%). ESI-MS (m/z): 435 [M+H]+. -
- The title compound was prepared following the same general protocol as described in
Step 4, Example 1, using 1-(naphthalen-1-yl)ethanamine instead of the (2,4-dimethoxyphenyl)methanamine. A white powder was obtained (55 mg, 0.12 mmol, 73%). ESI-MS (m/z): 441 [M+H]+. -
- The title compound was prepared following the same general protocol as described in
Step 4, Example 1, using (S)-1-(4-fluorophenyl)ethanamine instead of the (2,4-dimethoxyphenyl)methanamine. A white powder was obtained (45 mg, 0.11 mmol, 65%). ESI-MS (m/z): 409 [M+H]+. -
- The title compound was prepared following the same general protocol as described in
Step 4, Example 1, using (R)-1-(4-fluorophenyl)ethanamine instead of the (2,4-dimethoxyphenyl)methanamine. A white powder was obtained (41 mg, 0.10 mmol, 59%). ESI-MS (m/z): 409 [M+H]+. -
- The title compound was prepared following the same general protocol as described in
Step 4, Example 1, using cyclopentanamine instead of the (2,4-dimethoxyphenyl)methanamine. A white powder was obtained (35 mg, 0.10 mmol, 58%). ESI-MS (m/z): 355 [M+H]+. -
- The title compound was prepared following the same general protocol as described in
Step 4, Example 1, using (1R,2S)-2-phenylcyclopropanamine instead of the (2,4-dimethoxyphenyl)methanamine. A beige powder was obtained (49 mg, 0.12 mmol, 72%). ESI-MS (m/z): 403 [M+H]+. -
- The title compound was prepared following the same general protocol as described in Example 11, using 4-(aminomethyl)aniline instead of the 2-phenylpropane-2-amine. A yellow powder was obtained (19 mg, 0.05 mmol, 29%). ESI-MS (m/z): 392 [M+H]+.
-
-
- NaH (1.1 equiv) was added to a solution of
ethyl 2,3-dimethyl-1H-indole-5-carboxylate in DMF at room temperature. After 30 min, 2,4-difluorobenzyl bromide (1.1 equiv) was added to the reaction mixture and stirred for 1 h. After the reaction was completed, the solvent was removed in vacuo to obtain the crude which was purified by flash chromatography to obtain the compound. LC-MS 344 (M+H). -
- A mixture of above compound and NaOH (10 equiv) in EtOH was refluxed at 100° C. for 2 h. The reaction mixture was cooled to rt, then acidified to pH-4 with sat′d citric acid. The mixture was evaporated in vacuo to obtain the crude, which was precipitated in water and filtered to obtain the compound. LC-MS 316 (M+H).
- To a mixture of 1-(2,4-difluorobenzyl)-2,3-dimethyl-1H-indole-5-carboxylic acid in DMF was added DIPEA (1.3 equiv) and HATU (1.2 equiv). The mixture was stirred for 5 min, and then α-ethylbenzylamine (1.1 equiv) was added. The reaction mixture was stirred at rt for 1 h. After the reaction was completed, the solvent was removed in vacuo to obtain the crude which was purified by flash chromatography to obtain the title compound. LC-MS 433 (M+H).
-
- The title compound was prepared following the same general protocol as described in
Steps ethyl 2,3-dimethyl-1H-indole-5-carboxylate. LC-MS 431 (M+H). -
- The title compound was prepared following the same general protocol as described in
Step 1 of Example 21, using 2-(3-chlorophenyl)ethyl chloride and N-(1-phenylpropyl)-1H-indole-5-carboxamide. LC-MS 417 (M+H). -
- Benzoyl chloride (1.1 equiv) was added to a solution of N-(1-phenylpropyl)-1H-indole-5-carboxamide in CH2Cl2, Et3N (1.3 equiv) at room temperature. After the reaction was completed, the solvent was evaporated and the residual was purified by silica gel column chromatography to get the product. LC-MS 383 (M+H).
-
- The title compound was prepared following the same general protocol as described in Example 25, using 4-nitrobenzoylchloride and N-(1-phenylpropyl)-1H-indole-5-carboxamide. LC-MS 428 (M+H).
-
- The title compound was prepared following the same general protocol as described in Example 25, using 2,3-difluorobenzoylchloride and N-(1-phenylpropyl)-1H-indole-5-carboxamide. LC-MS 419 (M+H).
-
- Tosyl chloride (1.1 equiv), benzyltriethylammonium chloride (0.5 equiv) was added to a solution of N-(1-phenylpropyl)-1H-indole-5-carboxamide in CH2Cl2, KOH (1.3 equiv) at room temperature. After the reaction was completed, the solvent was evaporated and the residual was purified by silica gel column chromatography to get the product. LC-MS 433 (M+H).
-
- The title compound was prepared following the same general protocol as described in Example 28, using 1-naphthyl sulfonyl chloride and N-(1-phenylpropyl)-1H-indole-5-carboxamide. LC-MS 469 (M+H).
-
- The title compound was prepared following the same general protocol as described in Example 28, using 4-nitrophenylsulfonyl chloride and N-(1-phenylpropyl)-1H-indole-5-carboxamide. LC-MS 464 (M+H).
-
- The title compound was prepared following the same general protocol as described in
Step 1, Example 21, using 5-(bromomethyl)-2-chloropyridine and N-(1-phenylpropyl)-1H-indole-5-carboxamide. LC-MS 404 (M+H). -
- The title compounds can be prepared analogously to Example 35, below, but substituting
- This bromomethyl compound can be prepared as described in Example 35,
step 2, below, substituting methyl 1-methyl-1-(p-tolyl)-propionate for methyl 1-(p-tolyl)cyclopropanecarboxylate in the bromination reaction. Alternatively the bromomethyl compound can be purchased from Chinglu Pharmaceutical Research LLC, 705 North Mountain Rd., Suite C115, Newington, Conn. - Various compounds such as 33 and 34 can then be prepared, as is apparent to a person of skill in the art, by use of the appropriate precursors and reagents as indicated in Example 35, steps 3-8.
-
-
- To a solution of 1-(p-tolyl)cyclopropanecarboxylic acid (900 mg, 5.1 mmol) in acetonitrile (20 mL) was added DBU (917 μL) followed by methyl iodide (1.91 mL). The resulting solution was heated at reflux overnight, and then diluted with AcOEt. The mixture was washed with a 0.5 N HCl solution, a saturated solution of NaHCO3, and brine, dried on MgSO4, and concentrated. The resulting colorless oil was purified by chromatography on silica gel (Hexane/ethyl acetate 9/1) to afford the title compound as a colorless oil (622 mg, 64%).
-
- To a solution of methyl 1-(p-tolyl)cyclopropanecarboxylate (622 mg, 3.27 mmol) in carbon tetrachloride (16 mL) was added N-bromosuccinimide (611 mg) followed by benzoyl peroxide (40 mg). The resulting solution was heated at reflux overnight, and then diluted with methylene chloride. The mixture was washed with brine, dried on MgSO4, and concentrated to afford a colorless oil (860 mg, 97%).
-
- To a solution of
ethyl 2,3-dimethyl-1H-indole-5-carboxylate (500 mg, 2.3 mmol) in ethanol (10 mL) was added a 5N NaOH solution (9.2 mL). The resulting solution was heated at 50° C. for 4 h, and then quenched carefully by addition of a 6N HCl solution (10 mL). The mixture was diluted with ethyl acetate, washed with a 0.5 N HCl solution and brine, dried on MgSO4, and concentrated to afford a yellow powder (500 mg, 100%). ESI-MS (m/z): 190 [MH]+ -
- To a solution of 2,3-dimethyl-1H-indole-5-carboxylic acid (500 mg, 2.3 mmol) in anhydrous DMF (20 mL) was added methyl 1-(4-(bromomethyl)phenyl)cyclopropanecarboxylate (620 mg) followed by NaH (230 mg). The resulting solution was allowed to stir overnight under argon atmosphere. The remaining NaH was hydrolyzed by the careful addition of a 0.5 N HCl solution. The mixture was diluted with ethyl acetate, washed with a 0.5 N HCl solution and brine, dried on MgSO4, and concentrated. The crude residue was purified by chromatography on silica gel (Hexane/
Ethyl acetate 5/5) to afford an orange powder (361 mg). ESI-MS (m/z): 378 [MH]+ -
- To a solution of 1-(4-(1-(methoxycarbonyl)cyclopropyl)benzyl)-2,3-dimethyl-1H-indole-5-carboxylic acid (50 mg, 0.13 mmol) in DMF (1 mL) was added (S)-1-(3-bromophenyl)ethylamine (21 DIEA (45 μL) and HATU (54 mg). The reaction mixture was allowed to stir at rt for 30 min, and then was diluted by ethyl acetate. The resulting mixture was washed with a 0.5 N HCl solution, a saturated solution of NaHCO3, and brine, dried on MgSO4, and concentrated to afford a yellow oil (73 mg) which was directly used without further purification. ESI-MS (m/z): 559/561 [MH]+
-
- To a solution of (S)-methyl 1-(4-((5-((1-(3-bromophenyl)ethyl)carbamoyl)-2,3-dimethyl-1H-indol-1-yl)methyl)phenyl)cyclopropanecarboxylate (73 mg) in dioxane/water (1.2 mL/0.3 mL) was added isopropenylboronic acid pinacol ester (49 K2CO3 (36 mg) and Pd(PPh3)4 (15 mg). The solution was degassed with argon and then stirred for 1 h at 100° C. under microwave. The resulting mixture was diluted with ethyl acetate washed with a 0.5 N HCl solution, a saturated solution of NaHCO3, and brine, dried on MgSO4, and concentrated to afford a yellow oil which was directly used without further purification. ESI-MS (m/z): 521 [MH]+
-
- To a solution of (S)-methyl 1-(4-((2,3-dimethyl-5-((1-(3-(prop-1-en-2-yl)phenyl)ethyl)carbamoyl)-1H-indol-1-yl)methyl)phenyl)cyclopropanecarboxylate in EtOH (5 mL) was added Pd/
C 10%. The resulting mixture was stirred for 5 h under hydrogen atmosphere. The solution was then filtered and concentrated to afford a yellow oil which was directly used without further purification. ESI-MS (m/z): 523 [MH]+ -
- To a solution of (S)-1-(4-((5-((1-(3-isopropylphenyl)ethyl)carbamoyl)-2,3-dimethyl-1H-indol-1-yl)methyl)phenyl)cyclopropanecarboxylic acid in methanol (1 mL) was added a 5 N NaOH solution (1 mL). The resulting solution was heated at 50° C. for 4 h, and then quenched carefully by addition of a 6 N HCl solution (1 mL). The mixture was diluted with ethyl acetate, washed with a 0.5 N HCl solution and brine, dried on MgSO4, and concentrated. The resulting oil was purified by preparative HPLC to afford a white powder (9 mg). ESI-MS (m/z): 509 [MH]+
-
-
- To a solution of p-cresol (2 mL, 19.1 mmol) in anhydrous DMF (50 mL) were added Cs2CO3 (8.1 g, 24.9 mmol) and methyl bromoacetate (1.9 mL, 20.1 mmol). The suspension was stirred at room temperature for 3 h. After dilution with ethyl acetate, the reaction mixture was washed with a 0.5 N HCl solution, a saturated solution of NaHCO3, and brine, dried on MgSO4, and concentrated. The resulting oil was purified by chromatography on silica gel (Hexane/
ethyl acetate 8/2) to afford the title compound as a colorless oil (3.10 g, 90%). -
- To a solution of the methyl 2-(p-tolyloxy)acetate (3.10 g, 17.2 mmol) in carbon tetrachloride (60 mL) was added N-bromosuccinimide (3.57 g, 20 mmol) followed by benzoyl peroxide (463 mg, 1.9 mmol). The resulting solution was heated at reflux overnight, and then diluted with methylene chloride. The mixture was washed with brine, dried on MgSO4, and concentrated. The resulting colorless oil was purified by chromatography on silica gel (Hexane/ethyl acetate 9/1) to afford a colorless oil (2.5 g, 56%).
-
- To a solution of the
allyl 2,3-dimethyl-1H-indole-5-carboxylate (500 mg, 2.2 mmol) in anhydrous DMF (20 mL) was added the methyl 2-(4-(bromomethyl)phenoxy)acetate (565 mg, 2.2 mmol) followed by NaH (131 mg, 3.3 mmol). The resulting solution was allowed to stir overnight under argon atmosphere. The remaining NaH was hydrolyzed by the careful addition of a 0.5 N HCl solution. The mixture was diluted with ethyl acetate, washed with a 0.5 N HCl solution and brine, dried on MgSO4, and concentrated. The crude residue was purified by chromatography on silica gel (Hexane/Ethyl acetate 5/5) to afford yellow oil (536 mg, 61%). ESI-MS (m/z): 408 [M+H]+. -
- A solution of the allyl 1-(4-(2-methoxy-2-oxoethoxy)benzyl)-2,3-dimethyl-1H-indole-5-carboxylate (536 mg, 1.3 mmol) and morpholine (1.14 mL, 13.2 mmol) in anhydrous THF was degassed with argon. Then Pd(PPh3)4 (152 mg, 0.13 mmol) was added and the reaction stirred under argon protection for 1.5 h. The reaction mixture was diluted with ethyl acetate, washed with brine, concentrated. The title compound was precipitated in ethyl ether as a beige powder (430 mg, 89%). ESI-MS (m/z): 368 [M+H]+.
-
- To a solution of the 1-(4-(2-methoxy-2-oxoethoxy)benzyl)-2,3-dimethyl-1H-indole-5-carboxylic acid (50 mg, 0.14 mmol) in DCM (1 mL) was added the (S)-1-(3-cyclopropylphenyl)ethanamine hydrochloride (28 mg), DIEA (73 μL) and HATU (53 mg). The reaction mixture was allowed to stir at rt for 30 min, and then was diluted by ethyl acetate. The resulting mixture was washed with a 0.5 N HCl solution, a saturated solution of NaHCO3, and brine, dried on MgSO4, and concentrated to afford a yellow oil (73 mg) which was directly used without further purification. ESI-MS (m/z): 497 [M+H]+
-
- To a solution of the (S)-methyl 2-(4-((5-((1-(3-cyclopropylphenyl)ethyl)carbamoyl)-2,3-dimethyl-1H-indol-1-yl)methyl)phenoxy)acetate in methanol (1 mL) was added a 5N NaOH solution (1 mL). The resulting solution was heated at 50° C. for 4 h, and then quenched carefully by addition of a 6N HCl solution (1 mL). The mixture was diluted with ethyl acetate, washed with a 0.5 N HCl solution and brine, dried on MgSO4, and concentrated. The resulting oil was purified by preparative HPLC to afford a white powder (46 mg). ESI-MS (m/z): 497 [MH]+
-
-
- The title compound was prepared following the same protocol as described in
Step 5, Example 36, using the (S)-1-(3-isopropylphenyl)ethanamine hydrochloride instead of the (S)-1-(3-cyclopropylphenyl)ethanamine hydrochloride. -
- The title compound was prepared following the same protocol as described in
Step 6, Example 36, using the (S)-methyl 2-(4-((5-((1-(3-isopropylphenyl)ethyl)carbamoyl)-2,3-dimethyl-1H-indol-1-yl)methyl)phenoxy)acetate instead of the (S)-methyl 2-(4-((5-((1-(3-cyclopropylphenyl)ethyl)carbamoyl)-2,3-dimethyl-1H-indol-1-yl)methyl)phenoxy)acetate. ESI-MS (m/z): 499 [MH]+ -
-
- The title compound was prepared following the same protocol as described in
Step 5, Example 36, using the (S)-1-(4-(tert-butyl)phenyl)ethanamine hydrochloride instead of the (S)-1-(3-cyclopropylphenyl)ethanamine hydrochloride. -
- The title compound was prepared following the same protocol as described in
Step 6, Example 36, using the (S)-methyl 2-(4-((5-((1-(4-(tert-butyl)phenyl)ethyl)carbamoyl)-2,3-dimethyl-1H-indol-1-yl)methyl)phenoxy)acetate instead of the (S)-methyl 2-(4-((5-((1-(3-cyclopropylphenyl)ethyl)carbamoyl)-2,3-dimethyl-1H-indol-1-yl)methyl)phenoxy)acetate. ESI-MS (m/z): 513 [MH]+. -
-
- The title compound was prepared following the same protocol as described in
Step 1, Example 36, using the m-cresol instead of the p-cresol. -
- The title compound was prepared following the same protocol as described in
Step 2, Example 36, using the methyl 2-(m-tolyloxy)acetate instead of the methyl 2-(p-tolyloxy)acetate. -
- The title compound was prepared following the same general protocol as described in
Step 3, Example 36, using the methyl 2-(3-(bromomethyl)phenoxy)acetate instead of the methyl 2-(4-(bromomethyl)phenoxy)acetate. ESI-MS (m/z): 408 [M+H]+. -
- The title compound was prepared following the same general protocol as described in
Step 4, Example 36, using the allyl 1-(3-(2-methoxy-2-oxoethoxy)benzyl)-2,3-dimethyl-1H-indole-5-carboxylate instead of the allyl 1-(4-(2-methoxy-2-oxoethoxy)benzyl)-2,3-dimethyl-1H-indole-5-carboxylate. ESI-MS (m/z): 368 [M+H]+. -
- The title compound was prepared following the same protocol as described in
Step 5, Example 36, using the 1-(3-(2-methoxy-2-oxoethoxy)benzyl)-2,3-dimethyl-1H-indole-5-carboxylic acid instead of the 1-(4-(2-methoxy-2-oxoethoxy)benzyl)-2,3-dimethyl-1H-indole-5-carboxylic acid. -
- The title compound was prepared following the same protocol as described in
Step 6, Example 36, using the (S)-methyl 2-(3-((5-((1-(3-cyclopropylphenyl)ethyl)carbamoyl)-2,3-dimethyl-1H-indol-1-yl)methyl)phenoxy)acetate instead of the (S)-methyl 2-(4-((5-((1-(3-cyclopropylphenyl)ethyl)carbamoyl)-2,3-dimethyl-1H-indol-1-yl)methyl)phenoxy)acetate. ESI-MS (m/z): 497 [MH]+ -
-
- The title compound was prepared following the same protocol as described in
Step 5, Example 36, using the (S)-1-(3-isopropylphenyl)ethanamine hydrochloride instead of the (S)-1-(3-cyclopropylphenyl)ethanamine hydrochloride and the 1-(3-(2-methoxy-2-oxoethoxy)benzyl)-2,3-dimethyl-1H-indole-5-carboxylic acid instead of the 1-(4-(2-methoxy-2-oxoethoxy)benzyl)-2,3-dimethyl-1H-indole-5-carboxylic acid. -
- The title compound was prepared following the same protocol as described in
Step 6, Example 36, using the (S)-methyl 2-(3-((5-((1-(3-isopropylphenyl)ethyl)carbamoyl)-2,3-dimethyl-1H-indol-1-yl)methyl)phenoxy)acetate instead of the (S)-methyl 2-(4-((5-((1-(3-cyclopropylphenyl)ethyl)carbamoyl)-2,3-dimethyl-1H-indol-1-yl)methyl)phenoxy)acetate. ESI-MS (m/z): 499 [MH]+. -
-
- The title compound was prepared following the same protocol as described in
Step 5, Example 36, using the (S)-1-(4-(tert-butyl)phenyl)ethanamine hydrochloride instead of the (S)-1-(3-cyclopropylphenyl)ethanamine hydrochloride and the 1-(3-(2-methoxy-2-oxoethoxy)benzyl)-2,3-dimethyl-1H-indole-5-carboxylic acid instead of the 1-(4-(2-methoxy-2-oxoethoxy)benzyl)-2,3-dimethyl-1H-indole-5-carboxylic acid. -
- The title compound was prepared following the same protocol as described in
Step 6, Example 36, using the (S)-methyl 2-(3-((5-((1-(4-(tert-butyl)phenyl)ethyl)carbamoyl)-2,3-dimethyl-1H-indol-1-yl)methyl)phenoxy)acetate instead of the (S)-methyl 2-(4-((5-((1-(3-cyclopropylphenyl)ethyl)carbamoyl)-2,3-dimethyl-1H-indol-1-yl)methyl)phenoxy)acetate. ESI-MS (m/z): 513 [M+H]+. -
-
- To a solution of the m-cresol (1.0 g, 9.2 mmol) in anhydrous THF (15 mL) at 0° C. under argon protection was added triphenylphosphine (2.55 g, 9.7 mmol), followed by addition of the (S)-methyl 2-hydroxypropanoate (926 μL, 9.7 mmol). Then diisopropylazodicarboxylate (DIAD) (2.85 mL, 13.8 mmol) was added dropwise at 0° C. The reaction mixture was stirred at room temperature overnight. The resulting mixture was diluted by ethyl acetate, washed with a 0.5 N HCl solution, a saturated solution of NaHCO3, and brine, dried on MgSO4, and concentrated. The obtained oil was purified by flash chromatography (Hexane/Ethyl acetate 0-50%) to afford a colorless oil (820 mg, 46%).
-
- The title compound was prepared following the same protocol as described in
Step 2, Example 36, using the (R)-methyl 2-(m-tolyloxy)propanoate instead of the methyl 2-(p-tolyloxy)acetate. -
- The title compound was prepared following the same general protocol as described in
Step 3, Example 36, using the (R)-methyl 2-(3-(bromomethyl)phenoxy)propanoate instead of the methyl 2-(4-(bromomethyl)phenoxy)acetate. ESI-MS (m/z): 422 [M+H]+. -
- The title compound was prepared following the same general protocol as described in
Step 4, Example 36, using the (R)-allyl 1-(3-((1-methoxy-1-oxopropan-2-yl)oxy)benzyl)-2,3-dimethyl-1H-indole-5-carboxylate instead of the allyl 1-(4-(2-methoxy-2-oxoethoxy)benzyl)-2,3-dimethyl-1H-indole-5-carboxylate. ESI-MS (m/z): 368 [M+H]+. -
- The title compound was prepared following the same protocol as described in
Step 5, Example 36, using the (S)-1-(3-isopropylphenyl)ethanamine hydrochloride instead of the (S)-1-(3-cyclopropylphenyl)ethanamine hydrochloride and the (R)-1-(3-((1-methoxy-1-oxopropan-2-yl)oxy)benzyl)-2,3-dimethyl-1H-indole-5-carboxylic acid instead of the 1-(4-(2-methoxy-2-oxoethoxy)benzyl)-2,3-dimethyl-1H-indole-5-carboxylic acid. -
- The title compound was prepared following the same protocol as described in
Step 6, Example 36, using the (R)-methyl 2-(3-((5-(((S)-1-(3-isopropylphenyl)ethyl)carbamoyl)-2,3-dimethyl-1H-indol-1-yl)methyl)phenoxy)propanoate instead of the (S)-methyl 2-(4-((5-((1-(3-cyclopropylphenyl)ethyl)carbamoyl)-2,3-dimethyl-1H-indol-1-yl)methyl)phenoxy)acetate. ESI-MS (m/z): 513 [MH]+ -
-
- The title compound was prepared following the same protocol as described in
Step 5, Example 36, using the (S)-1-(4-(tert-butyl)phenyl)ethanamine hydrochloride instead of the (S)-1-(3-cyclopropylphenyl)ethanamine hydrochloride and the (R)-1-(3-((1-methoxy-1-oxopropan-2-yl)oxy)benzyl)-2,3-dimethyl-1H-indole-5-carboxylic acid instead of the 1-(4-(2-methoxy-2-oxoethoxy)benzyl)-2,3-dimethyl-1H-indole-5-carboxylic acid. -
- The title compound was prepared following the same protocol as described in
Step 6, Example 36, using the (R)-methyl 2-(3-((5-(((S)-1-(4-(tert-butyl)phenyl)ethyl)carbamoyl)-2,3-dimethyl-1H-indol-1-yl)methyl)phenoxy)propanoate instead of the (S)-methyl 2-(4-((5-((1-(3-cyclopropylphenyl)ethyl)carbamoyl)-2,3-dimethyl-1H-indol-1-yl)methyl)phenoxy)acetate. ESI-MS (m/z): 527 [MH]+. -
-
- The title compound was prepared following the same protocol as described in
Step 1, Example 42, using the (R)-methyl 2-hydroxypropanoate instead of the (S)-methyl 2-hydroxypropanoate. -
- The title compound was prepared following the same protocol as described in
Step 2, Example 36, using the (S)-methyl 2-(m-tolyloxy)propanoate instead of the methyl 2-(p-tolyloxy)acetate. -
- The title compound was prepared following the same general protocol as described in
Step 3, Example 36, using the (S)-methyl 2-(3-(bromomethyl)phenoxy)propanoate instead of the methyl 2-(4-(bromomethyl)phenoxy)acetate. ESI-MS (m/z): 422 [M+H]+. -
- The title compound was prepared following the same general protocol as described in
Step 4, Example 36, using the (S)-allyl 1-(3-((1-methoxy-1-oxopropan-2-yl)oxy)benzyl)-2,3-dimethyl-1H-indole-5-carboxylate instead of the allyl 1-(4-(2-methoxy-2-oxoethoxy)benzyl)-2,3-dimethyl-1H-indole-5-carboxylate. ESI-MS (m/z): 368 [M+H]+. -
- The title compound was prepared following the same protocol as described in
Step 5, Example 36, using the (S)-1-(3-isopropylphenyl)ethanamine hydrochloride instead of the (S)-1-(3-cyclopropylphenyl)ethanamine hydrochloride and the (S)-1-(3-((1-methoxy-1-oxopropan-2-yl)oxy)benzyl)-2,3-dimethyl-1H-indole-5-carboxylic acid instead of the 1-(4-(2-methoxy-2-oxoethoxy)benzyl)-2,3-dimethyl-1H-indole-5-carboxylic acid. -
- The title compound was prepared following the same protocol as described in
Step 6, Example 36, using the (S)-methyl 2-(3-((5-(((S)-1-(3-isopropylphenyl)ethyl)carbamoyl)-2,3-dimethyl-1H-indol-1-yl)methyl)phenoxy)propanoate instead of the (S)-methyl 2-(4-((5-((1-(3-cyclopropylphenyl)ethyl)carbamoyl)-2,3-dimethyl-1H-indol-1-yl)methyl)phenoxy)acetate. ESI-MS (m/z): 513 [M+H]+ -
-
- The title compound was prepared following the same protocol as described in
Step 5, Example 36, using the (S)-1-(4-(tert-Butyl)phenyl)ethanamine hydrochloride instead of the (S)-1-(3-cyclopropylphenyl)ethanamine hydrochloride and the (S)-1-(3-((1-methoxy-1-oxopropan-2-yl)oxy)benzyl)-2,3-dimethyl-1H-indole-5-carboxylic acid instead of the 1-(4-(2-methoxy-2-oxoethoxy)benzyl)-2,3-dimethyl-1H-indole-5-carboxylic acid. -
- The title compound was prepared following the same protocol as described in
Step 6, Example 36, using the (S)-methyl 2-(3-((5-(((S)-1-(4-(tert-Butyl)phenyl)ethyl)carbamoyl)-2,3-dimethyl-1H-indol-1-yl)methyl)phenoxy)propanoate instead of the (S)-methyl 2-(4-((5-((1-(3-cyclopropylphenyl)ethyl)carbamoyl)-2,3-dimethyl-1H-indol-1-yl)methyl)phenoxy)acetate. ESI-MS (m/z): 527 [MH]+ -
-
- The title compound was prepared following the same protocol as described in
Step 5, Example 36, using the (S)-1-(3-((1-methoxy-1-oxopropan-2-yl)oxy)benzyl)-2,3-dimethyl-1H-indole-5-carboxylic acid instead of the 1-(4-(2-methoxy-2-oxoethoxy)benzyl)-2,3-dimethyl-1H-indole-5-carboxylic acid. -
- The title compound was prepared following the same protocol as described in
Step 6, Example 36, using the (S)-methyl 2-(3-((5-(((S)-1-(3-cyclopropylphenyl)ethyl)carbamoyl)-2,3-dimethyl-1H-indol-1-yl)methyl)phenoxy)propanoate instead of the (S)-methyl 2-(4-((5-((1-(3-cyclopropylphenyl)ethyl)carbamoyl)-2,3-dimethyl-1H-indol-1-yl)methyl)phenoxy)acetate. ESI-MS (m/z): 511 [MH]+. -
-
- The title compound was prepared following the same protocol as described in
Step 1, Example 36, using the m-cresol instead of the p-cresol and the methyl α-bromoisobutyrate instead of the methyl bromoacetate. -
- The title compound was prepared following the same protocol as described in
Step 2, Example 36, using the methyl 2-methyl-2-(m-tolyloxy)propanoate instead of the methyl 2-(p-tolyloxy)acetate. -
- The title compound was prepared following the same general protocol as described in
Step 3, Example 36, using the methyl 2-(3-(bromomethyl)phenoxy)-2-methylpropanoate instead of the methyl 2-(4-(bromomethyl)phenoxy)acetate. ESI-MS (m/z): 436 [M+H]+. -
- The title compound was prepared following the same general protocol as described in
Step 4, Example 36, using the allyl 1-(34(1-methoxy-2-methyl-1-oxopropan-2-yl)oxy)benzyl)-2,3-dimethyl-1H-indole-5-carboxylate instead of the allyl 1-(4-(2-methoxy-2-oxoethoxy)benzyl)-2,3-dimethyl-1H-indole-5-carboxylate. ESI-MS (m/z): 396 [M+H]+. -
- The title compound was prepared following the same protocol as described in
Step 5, Example 36, using the (S)-1-(3-isopropylphenyl)ethanamine hydrochloride instead of the (S)-1-(3-cyclopropylphenyl)ethanamine hydrochloride and the 1-(3-((1-methoxy-2-methyl-1-oxopropan-2-yl)oxy)benzyl)-2,3-dimethyl-1H-indole-5-carboxylic acid instead of the 1-(4-(2-methoxy-2-oxoethoxy)benzyl)-2,3-dimethyl-1H-indole-5-carboxylic acid. -
- The title compound was prepared following the same protocol as described in
Step 6, Example 36, using the (S)-methyl 2-(3-((5-((1-(3-isopropylphenyl)ethyl)carbamoyl)-2,3-dimethyl-1H-indol-1-yl)methyl)phenoxy)-2-methylpropanoate instead of the (S)-methyl 2-(4-((5-((1-(3-cyclopropylphenyl)ethyl)carbamoyl)-2,3-dimethyl-1H-indol-1-yl)methyl)phenoxy)acetate. ESI-MS (m/z): 527 [MH]+ -
-
- The title compound was prepared following the same protocol as described in
Step 5, Example 36, using the (S)-1-(4-(tert-butyl)phenyl)ethanamine hydrochloride instead of the (S)-1-(3-cyclopropylphenyl)ethanamine hydrochloride and the 1-(3-((1-methoxy-2-methyl-1-oxopropan-2-yl)oxy)benzyl)-2,3-dimethyl-1H-indole-5-carboxylic acid instead of the 1-(4-(2-methoxy-2-oxoethoxy)benzyl)-2,3-dimethyl-1H-indole-5-carboxylic acid. -
- The title compound was prepared following the same protocol as described in
Step 6, Example 36, using the (S)-methyl 2-(3-((5-((1-(4-(tert-butyl)phenyl)ethyl)carbamoyl)-2,3-dimethyl-1H-indol-1-yl)methyl)phenoxy)-2-methylpropanoate instead of the (S)-methyl 2-(4-((5-((1-(3-cyclopropylphenyl)ethyl)carbamoyl)-2,3-dimethyl-1H-indol-1-yl)methyl)phenoxy)acetate. ESI-MS (m/z): 541 [MH]+. -
-
- The title compound was prepared following the same protocol as described in
Step 1, Example 36, using the m-cresol instead of the p-cresol and the bromoacetonitrile instead of the methyl bromoacetate. -
- The title compound was prepared following the same protocol as described in
Step 2, Example 36, using the 2-(m-Tolyloxy)acetonitrile instead of the methyl 2-(p-tolyloxy)acetate. -
- The title compound was prepared following the same general protocol as described in
Step 3, Example 36, using the 2-(3-(Bromomethyl)phenoxy)acetonitrile instead of the methyl 2-(4-(bromomethyl)phenoxy)acetate. ESI-MS (m/z): 375 [M+H]+. -
- The title compound was prepared following the same general protocol as described in
Step 4, Example 36, using the allyl 1-(3-(cyanomethoxy)benzyl)-2,3-dimethyl-1H-indole-5-carboxylate instead of the allyl 1-(4-(2-methoxy-2-oxoethoxy)benzyl)-2,3-dimethyl-1H-indole-5-carboxylate. ESI-MS (m/z): 335 [M+H]+. -
- The title compound was prepared following the same protocol as described in
Step 5, Example 36, using the (S)-1-(3-isopropylphenyl)ethanamine hydrochloride instead of the (S)-1-(3-cyclopropylphenyl)ethanamine hydrochloride and the 1-(3-(cyanomethoxy)benzyl)-2,3-dimethyl-1H-indole-5-carboxylic acid instead of the 1-(4-(2-methoxy-2-oxoethoxy)benzyl)-2,3-dimethyl-1H-indole-5-carboxylic acid. ESI-MS (m/z): 480 [M+H]+. -
- The title compound was prepared following the same protocol as described in
Step 5, Example 36, using the (S)-1-(4-(tert-butyl)phenyl)ethanamine hydrochloride instead of the (S)-1-(3-cyclopropylphenyl)ethanamine hydrochloride and the 1-(3-(cyanomethoxy)benzyl)-2,3-dimethyl-1H-indole-5-carboxylic acid instead of the 1-(4-(2-methoxy-2-oxoethoxy)benzyl)-2,3-dimethyl-1H-indole-5-carboxylic acid. ESI-MS (m/z): 494 [M+H]+. -
-
- The title compound was prepared following the same protocol as described in
Step 1, Example 42, using the p-cresol instead of the m-cresol and the (R)-methyl 2-hydroxypropanoate instead of the (S)-methyl 2-hydroxypropanoate. -
- The title compound was prepared following the same protocol as described in
Step 2, Example 36, using the (S)-methyl 2-(p-tolyloxy)propanoate instead of the methyl 2-(p-tolyloxy)acetate. -
- The title compound was prepared following the same general protocol as described in
Step 3, Example 36, using the (S)-methyl 2-(4-(bromomethyl)phenoxy)propanoate instead of the methyl 2-(4-(bromomethyl)phenoxy)acetate. ESI-MS (m/z): 422 [M+H]+. -
- The title compound was prepared following the same general protocol as described in
Step 4, Example 36, using the (S)-allyl 1-(4-((1-methoxy-1-oxopropan-2-yl)oxy)benzyl)-2,3-dimethyl-1H-indole-5-carboxylate instead of the allyl 1-(4-(2-methoxy-2-oxoethoxy)benzyl)-2,3-dimethyl-1H-indole-5-carboxylate. ESI-MS (m/z): 368 [M+H]+. -
- The title compound was prepared following the same protocol as described in
Step 5, Example 36, using the (S)-1-(3-isopropylphenyl)ethanamine hydrochloride instead of the (S)-1-(3-cyclopropylphenyl)ethanamine hydrochloride and the (S)-1-(4-((1-methoxy-1-oxopropan-2-yl)oxy)benzyl)-2,3-dimethyl-1H-indole-5-carboxylic acid instead of the 1-(4-(2-methoxy-2-oxoethoxy)benzyl)-2,3-dimethyl-1H-indole-5-carboxylic acid. -
- The title compound was prepared following the same protocol as described in
Step 6, Example 36, using the (S)-methyl 2-(4-((5-(((S)-1-(3-isopropylphenyl)ethyl)carbamoyl)-2,3-dimethyl-1H-indol-1-yl)methyl)phenoxy)propanoate instead of the (S)-methyl 2-(4-((5-((1-(3-cyclopropylphenyl)ethyl)carbamoyl)-2,3-dimethyl-1H-indol-1-yl)methyl)phenoxy)acetate. ESI-MS (m/z): 513 [MH]+ -
-
- The title compound was prepared following the same protocol as described in
Step 5, Example 36, using the (S)-1-(4-((1-methoxy-1-oxopropan-2-yl)oxy)benzyl)-2,3-dimethyl-1H-indole-5-carboxylic acid instead of the 1-(4-(2-methoxy-2-oxoethoxy)benzyl)-2,3-dimethyl-1H-indole-5-carboxylic acid. -
- The title compound was prepared following the same protocol as described in
Step 6, Example 36, using the (S)-methyl 2-(4-((5-(((S)-1-(3-cyclopropylphenyl)ethyl)carbamoyl)-2,3-dimethyl-1H-indol-1-yl)methyl)phenoxy)propanoate instead of the (S)-methyl 2-(4-((5-((1-(3-cyclopropylphenyl)ethyl)carbamoyl)-2,3-dimethyl-1H-indol-1-yl)methyl)phenoxy)acetate. ESI-MS (m/z): 511 [MH]+ -
-
- The title compound was prepared following the same protocol as described in
Step 1, Example 42, using the p-cresol instead of the m-cresol. -
- The title compound was prepared following the same protocol as described in
Step 2, Example 36, using the (R)-methyl 2-(p-tolyloxy)propanoate instead of the methyl 2-(p-tolyloxy)acetate. -
- The title compound was prepared following the same general protocol as described in
Step 3, Example 36, using the (R)-methyl 2-(4-(bromomethyl)phenoxy)propanoate instead of the methyl 2-(4-(bromomethyl)phenoxy)acetate. ESI-MS (m/z): 422 [M+H]+. -
- The title compound was prepared following the same general protocol as described in
Step 4, Example 36, using the (R)-allyl 1-(4-((1-methoxy-1-oxopropan-2-yl)oxy)benzyl)-2,3-dimethyl-1H-indole-5-carboxylate instead of the allyl 1-(4-(2-methoxy-2-oxoethoxy)benzyl)-2,3-dimethyl-1H-indole-5-carboxylate. ESI-MS (m/z): 368 [M+H]+. -
- The title compound was prepared following the same protocol as described in
Step 5, Example 36, using the (S)-1-(3-isopropylphenyl)ethanamine hydrochloride instead of the (S)-1-(3-cyclopropylphenyl)ethanamine hydrochloride and the (R)-1-(4-((1-methoxy-1-oxopropan-2-yl)oxy)benzyl)-2,3-dimethyl-1H-indole-5-carboxylic acid instead of the 1-(4-(2-methoxy-2-oxoethoxy)benzyl)-2,3-dimethyl-1H-indole-5-carboxylic acid. -
- The title compound was prepared following the same protocol as described in
Step 6, Example 36, using the (R)-methyl 2-(4-((5-(((S)-1-(3-isopropylphenyl)ethyl)carbamoyl)-2,3-dimethyl-1H-indol-1-yl)methyl)phenoxy)propanoate instead of the (S)-methyl 2-(4-((5-((1-(3-cyclopropylphenyl)ethyl)carbamoyl)-2,3-dimethyl-1H-indol-1-yl)methyl)phenoxy)acetate. ESI-MS (m/z): 513 [MH]+ -
-
- The title compound was prepared following the same protocol as described in
Step 1, Example 36, using the methyl α-bromoisobutyrate instead of the methyl bromoacetate. -
- The title compound was prepared following the same protocol as described in
Step 2, Example 36, using the methyl 2-methyl-2-(p-tolyloxy)propanoate instead of the methyl 2-(p-tolyloxy)acetate. -
- The title compound was prepared following the same general protocol as described in
Step 3, Example 36, using the methyl 2-(4-(bromomethyl)phenoxy)-2-methylpropanoate instead of the methyl 2-(4-(bromomethyl)phenoxy)acetate. ESI-MS (m/z): 436 [M+H]+. -
- The title compound was prepared following the same general protocol as described in
Step 4, Example 36, using the allyl 1-(4-((1-methoxy-2-methyl-1-oxopropan-2-yl)oxy)benzyl)-2,3-dimethyl-1H-indole-5-carboxylate instead of the allyl 1-(4-(2-methoxy-2-oxoethoxy)benzyl)-2,3-dimethyl-1H-indole-5-carboxylate. ESI-MS (m/z): 396 [M+H]+. -
- The title compound was prepared following the same protocol as described in
Step 5, Example 36, using the (S)-1-(3-isopropylphenyl)ethanamine hydrochloride instead of the (S)-1-(3-cyclopropylphenyl)ethanamine hydrochloride and the 1-(4-((1-methoxy-2-methyl-1-oxopropan-2-yl)oxy)benzyl)-2,3-dimethyl-1H-indole-5-carboxylic acid instead of the 1-(4-(2-methoxy-2-oxoethoxy)benzyl)-2,3-dimethyl-1H-indole-5-carboxylic acid. -
- The title compound was prepared following the same protocol as described in
Step 6, Example 36, using the (S)-methyl 2-(4-((5-((1-(3-isopropylphenyl)ethyl)carbamoyl)-2,3-dimethyl-1H-indol-1-yl)methyl)phenoxy)-2-methylpropanoate instead of the (S)-methyl 2-(4-((5-((1-(3-cyclopropylphenyl)ethyl)carbamoyl)-2,3-dimethyl-1H-indol-1-yl)methyl)phenoxy)acetate. ESI-MS (m/z): 527 [MH]+ -
-
- To a solution of the 2-chloro-5-methylphenol (4.0 g, 28 mmol) in anhydrous THF (24 mL) at 0° C. under argon protection was added triphenylphosphine (9.5 g, 36.4 mmol), followed by addition of the (R)-methyl 2-hydroxypropanoate (3.89 g, 31 mmol). Then DIAD (8.2 mL, 42 mmol) was added slowly to the solution at 0° C. The reaction mixture was stirred at room temperature for 20 h. The solvent was removed and the crude was purified by flash chromatography (AcOEt/hexane 0-30%) to obtain the title compound.
-
- To (S)-methyl 2-(2-chloro-5-methylphenoxy)propanoate (2.4 g, 10.5 mmol) in CCl4 (20 mL) was added NBS (1.92 g, 11.55 mmol) and AIBN (0.35 g, 2.1 mmol). The mixture was refluxed overnight. The reaction mixture was cooled and the solvent was removed to obtain the crude. The crude was purified by flash chromatography (AcOEt/
Hexane 0˜30%) to obtain the title compound. -
- The title compound was prepared following the same general protocol as described for the synthesis of the (5-allyl 1-(2-chloro-5-((1-methoxy-1-oxopropan-2-yl)oxy)benzyl)-2,3-dimethyl-1H-indole-5-carboxylate (
Step 3, Example 26), using the (S)-methyl 2-(5-(bromomethyl)-2-chlorophenoxy)propanoate instead of the (S)-methyl 2-(3-(bromomethyl)-4-chlorophenoxy)propanoate ESI-MS (m/z): 456 [M+1]+. -
- The title compound was prepared following the same general protocol as described for the synthesis of the (S)-1-(2-chloro-5-((1-methoxy-1-oxopropan-2-yl)oxy)benzyl)-2,3-dimethyl-1H-indole-5-carboxylic acid (
Step 4, Example 26), using the (S)-allyl 1-(4-chloro-3-((1-methoxy-1-oxopropan-2-yl)oxy)benzyl)-2,3-dimethyl-1H-indole-5-carboxylate instead of the (S)-allyl 1-(2-chloro-5-((1-methoxy-1-oxopropan-2-yl)oxy)benzyl)-2,3-dimethyl-1H-indole-5-carboxylate. ESI-MS (m/z): 416 [M+1]+. -
- The (S)-1-(4-chloro-3-((1-methoxy-1-oxopropan-2-yl)oxy)benzyl)-2,3-dimethyl-1H-indole-5-carboxylic acid (55 mg, 0.13 mmol), the (S)-1-(3-isopropylphenyl)ethanamine hydrochloride (37 mg, 0.19 mmol) and HATU (61 mg, 0.16 mmol) were dissolved in DMF (3 mL) and DIEA (0.1 mL). It was stirred for 15 h. The solution was filtered and purified by preparative HPLC.
-
- The (S)-methyl 2-(2-chloro-5-((5-(((S)-1-(3-isopropylphenyl)ethyl)carbamoyl)-2,3-dimethyl-1H-indol-1-yl)methyl)phenoxy)propanoate was dissolved in methanol (1.5 mL), DMSO (˜1.5 mL) and water (0.1 mL) then NaOH (2 N, 0.1 mL) was added dropwise. The reaction was monitored by LC/MS. It was stirred until all the starting material was consumed (˜3 h). It was acidified with trifluoroacetic acid, filtered and purified by preparative HPLC to yield the title compound. ESI-MS (m/z): 547.1 [M+H]+.
-
- A similar procedure was followed as described in the previous example (Example 20) to yield the title compound. ESI-MS (m/z): 545.1 [M+H]+.
-
- A similar procedure was followed as described in the previous example (Example 20) using (S)-1-(4-bromophenyl)ethanamine to yield the title compound. ESI-MS (m/z): 585.0 [M+H]+.
-
-
- The title compound was prepared following the same protocol as described in
Step 5, Example 36, using the (S)-1-(4-(tert-butyl)phenyl)ethanamine hydrochloride instead of the (S)-1-(3-cyclopropylphenyl)ethanamine hydrochloride the (S)-1-(4-chloro-3-((1-methoxy-1-oxopropan-2-yl)oxy)benzyl)-2,3-dimethyl-1H-indole-5-carboxylic acid instead of the 1-(4-(2-methoxy-2-oxoethoxy)benzyl)-2,3-dimethyl-1H-indole-5-carboxylic acid. -
- The title compound was prepared following the same protocol as described in
Step 6, Example 36, using the (S)-methyl 2-(5-((5-(((S)-1-(4-(tert-butyl)phenyl)ethyl)carbamoyl)-2,3-dimethyl-1H-indol-1-yl)methyl)-2-chlorophenoxy)propanoate instead of the (S)-methyl 2-(4-((5-((1-(3-cyclopropylphenyl)ethyl)carbamoyl)-2,3-dimethyl-1H-indol-1-yl)methyl)phenoxy)acetate. ESI-MS (m/z): 561/562/563 [M+H]+. -
-
- The title compound was prepared following the same protocol as described in
Step 5, - Example 36, using the (S)-1-(3-(tert-butyl)phenyl)ethanamine hydrochloride instead of the (S)-1-(3-cyclopropylphenyl)ethanamine hydrochloride the (S)-1-(4-chloro-3-((1-methoxy-1-oxopropan-2-yl)oxy)benzyl)-2,3-dimethyl-1H-indole-5-carboxylic acid instead of the 1-(4-(2-methoxy-2-oxoethoxy)benzyl)-2,3-dimethyl-1H-indole-5-carboxylic acid.
-
- The title compound was prepared following the same protocol as described in
Step 6, Example 36, using the (S)-methyl 2-(5-((5-(((S)-1-(4-(tert-butyl)phenyl)ethyl)carbamoyl)-2,3-dimethyl-1H-indol-1-yl)methyl)-2-chlorophenoxy)propanoate instead of the (S)-methyl 2-(4-((5-((1-(3-cyclopropylphenyl)ethyl)carbamoyl)-2,3-dimethyl-1H-indol-1-yl)methyl)phenoxy)acetate. ESI-MS (m/z): 561/562/563 [M+H]+. -
-
- The title compound was prepared following the same protocol as described in
Step 5, Example 36, using the (S)-1-(3-isopropoxyphenyl)ethanamine hydrochloride instead of the (S)-1-(3-cyclopropylphenyl)ethanamine hydrochloride and (S)-1-(4-chloro-3-((1-methoxy-1-oxopropan-2-yl)oxy)benzyl)-2,3-dimethyl-1H-indole-5-carboxylic acid instead of the 1-(4-(2-methoxy-2-oxoethoxy)benzyl)-2,3-dimethyl-1H-indole-5-carboxylic acid. -
- The title compound was prepared following the same protocol as described in
Step 6, Example 36, using the (S)-methyl 2-(5-((5-(((S)-1-(3-isopropoxyphenyl)ethyl)carbamoyl)-2,3-dimethyl-1H-indol-1-yl)methyl)-2-chlorophenoxy)propanoate instead of the (S)-methyl 2-(4-((5-((1-(3-cyclopropylphenyl)ethyl)carbamoyl)-2,3-dimethyl-1H-indol-1-yl)methyl)phenoxy)acetate. ESI-MS (m/z): 561/562/563 [M+H]+. -
-
- The title compound was prepared following the same general protocol as described for the synthesis of the (S)-methyl 2-(2-chloro-5-methylphenoxy)propanoate (
Step 1, Example 55), using the 4-chloro-3-methylphenol instead of the 2-chloro-5-methylphenol. -
- The title compound was prepared following the same general protocol as described for the synthesis of the (S)-methyl 2-(5-(bromomethyl)-2-chlorophenoxy)propanoate (
Step 2, Example 55), using the (S)-methyl 2-(4-chloro-3-methylphenoxy)propanoate instead of the (S)-methyl 2-(2-chloro-5-methylphenoxy)propanoate. -
- To a solution of the
allyl 2,3-dimethyl-1H-indole-5-carboxylate (0.34 g, 1.483 mmol) in anhydrous DMF (3 mL) at 0° C. under argon protection was added NaH (0.08 g, 2.22 mmol). The mixture was stirred at rt for 30 min and re-cooled to 0° C., and then the (S)-methyl 2-(3-(bromomethyl)-4-chlorophenoxy)propanoate (0.55 g, 1.78 mmol) was added. The reaction was stirred at rt for another 1 h. The solvent was removed to obtain the crude, which was dissolved in EtOAc, then washed with water and brine and dried over Na2SO4. The solvent was removed to obtain the crude. The crude was purified by flash chromatography (AcOEt/Hexane 0˜100%) to obtain the title compound. ESI-MS (m/z): 456 [M+1]+. -
- A solution of (S)-allyl 1-(2-chloro-5-((1-methoxy-1-oxopropan-2-yl)oxy)benzyl)-2,3-dimethyl-1H-indole-5-carboxylate (0.327 g, 0.72 mmol) and morpholine (0.63 mL, 7.2 mmol) in anhydrous THF (10 mL) was degassed, then Pd(PPh3)4 (0.083 g, 0.072 mmol) was added under argon protection. The reaction mixture was stirred at rt for 1 h. The solvent was removed and the resulting crude was dissolved in MeOH. The mixture was acidified with 2 N HCl to
pH 3. The mixture was filtered and the solid was washed with water. The solid was dried for the next Step with no further purification. ESI-MS (m/z): 416 [M+1]+. -
- The (S)-1-(2-chloro-5-((1-methoxy-1-oxopropan-2-yl)oxy)benzyl)-2,3-dimethyl-1H-indole-5-carboxylic acid (71 mg, 0.17 mmol), the (S)-1-(3-isopropylphenyl)ethanamine hydrochloride (53 mg, 0.27 mmol) and HATU (88 mg, 0.23 mmol) were dissolved in DMF (3 mL) and DIEA (0.15 mL). It was stirred for 15 h. The solution was filtered and purified by preparative HPLC.
-
- The (S)-methyl 2-(4-chloro-3-((5-(((S)-1-(3-isopropylphenyl)ethyl)carbamoyl)-2,3-dimethyl-1H-indol-1-yl)methyl)phenoxy)propanoate was dissolved in methanol (1.5 mL) and DMSO (˜1 mL), water (0.1 mL) and NaOH (2 N, 0.1 mL) were added dropwise. The reaction was monitored by LC/MS. It was stirred until all the starting material was consumed (˜3 h). It was acidified with trifluoroacetic acid, filtered and purified by preparative HPLC to yield the title compound. ESI-MS (m/z): 547.1 [M+H]+.
-
- A similar procedure was followed as described in the previous example (Example 61) to yield the title compound. ESI-MS (m/z): 545.1 [M+H]+.
-
- A similar procedure was followed as described in the previous example (Example 61) to yield the title compound. ESI-MS (m/z): 585.0 [M+H]+.
-
-
- The title compound was prepared following the same protocol as described in
Step 5, Example 36, using the (S)-1-(4-(tert-butyl)phenyl)ethanamine hydrochloride instead of the (S)-1-(3-cyclopropylphenyl)ethanamine hydrochloride the (S)-1-(2-chloro-5-((1-methoxy-1-oxopropan-2-yl)oxy)benzyl)-2,3-dimethyl-1H-indole-5-carboxylic acid instead of the 1-(4-(2-methoxy-2-oxoethoxy)benzyl)-2,3-dimethyl-1H-indole-5-carboxylic acid. -
- The title compound was prepared following the same protocol as described in
Step 6, Example 36, using the (S)-methyl 2-(3-((5-(((S)-1-(4-(tert-butyl)phenyl)ethyl)carbamoyl)-2,3-dimethyl-1H-indol-1-yl)methyl)-4-chlorophenoxy)propanoate instead of the (S)-methyl 2-(4-((5-((1-(3-cyclopropylphenyl)ethyl)carbamoyl)-2,3-dimethyl-1H-indol-1-yl)methyl)phenoxy)acetate. ESI-MS (m/z): 561/562/563 [M+H]+. -
-
- The title compound was prepared following the same protocol as described in
Step 5, Example 36, using the (S)-1-(3-(tert-butyl)phenyl)ethanamine hydrochloride instead of the (S)-1-(3-cyclopropylphenyl)ethanamine hydrochloride the (S)-1-(2-chloro-5-((1-methoxy-1-oxopropan-2-yl)oxy)benzyl)-2,3-dimethyl-1H-indole-5-carboxylic acid instead of the 1-(4-(2-methoxy-2-oxoethoxy)benzyl)-2,3-dimethyl-1H-indole-5-carboxylic acid. -
- The title compound was prepared following the same protocol as described in
Step 6, - Example 36, using the (S)-methyl 2-(3-((5-(((S)-1-(4-(tert-butyl)phenyl)ethyl)carbamoyl)-2,3-dimethyl-1H-indol-1-yl)methyl)-4-chlorophenoxy)propanoate instead of the (S)-methyl 2-(4-((5-((1-(3-cyclopropylphenyl)ethyl)carbamoyl)-2,3-dimethyl-1H-indol-1-yl)methyl)phenoxy)acetate. ESI-MS (m/z): 561/562/563 [M+H]+.
-
-
- The title compound was prepared following the same protocol as described in
Step 5, Example 36, using the (S)-1-(3-isopropoxyphenyl)ethanamine hydrochloride instead of the (S)-1-(3-cyclopropylphenyl)ethanamine hydrochloride the (S)-1-(2-chloro-5-((1-methoxy-1-oxopropan-2-yl)oxy)benzyl)-2,3-dimethyl-1H-indole-5-carboxylic acid instead of the 1-(4-(2-methoxy-2-oxoethoxy)benzyl)-2,3-dimethyl-1H-indole-5-carboxylic acid. -
- The title compound was prepared following the same protocol as described in
Step 6, Example 36, using the (S)-methyl 2-(3-((5-(((S)-1-(3-isopropoxyphenyl)ethyl)carbamoyl)-2,3-dimethyl-1H-indol-1-yl)methyl)-4-chlorophenoxy)propanoate instead of the (S)-methyl 2-(4-((5-((1-(3-cyclopropylphenyl)ethyl)carbamoyl)-2,3-dimethyl-1H-indol-1-yl)methyl)phenoxy)acetate. ESI-MS (m/z): 561/562/563 [M+H]+. -
-
- The title compound was prepared following the same protocol as described in
Step 1, Example 42, using the 3-chloro-5-methylphenol instead of the m-cresol and the (R)-methyl 2-hydroxypropanoate instead of the (S)-methyl 2-hydroxypropanoate. -
- The title compound was prepared following the same protocol as described in
Step 2, Example 36, using the (S)-methyl 2-(3-chloro-5-methylphenoxy)propanoate instead of the methyl 2-(p-tolyloxy)acetate. -
- The title compound was prepared following the same general protocol as described in
Step 3, Example 36, using the (S)-methyl 2-(3-(bromomethyl)-5-chlorophenoxy)propanoate instead of the methyl 2-(4-(bromomethyl)phenoxy)acetate. ESI-MS (m/z): 456/457/458 [M+H]+. -
- The title compound was prepared following the same general protocol as described in
Step 4, Example 36, using the (S)-allyl 1-(3-chloro-5-((1-methoxy-1-oxopropan-2-yl)oxy)benzyl)-2,3-dimethyl-1H-indole-5-carboxylate instead of the allyl 1-(4-(2-methoxy-2-oxoethoxy)benzyl)-2,3-dimethyl-1H-indole-5-carboxylate. ESI-MS (m/z): 416/417/418 [M+H]+. -
- The title compound was prepared following the same protocol as described in
Step 5, Example 36, using the (S)-1-(3-isopropylphenyl)ethanamine hydrochloride instead of the (S)-1-(3-cyclopropylphenyl)ethanamine hydrochloride and the (S)-1-(3-chloro-5-((1-methoxy-1-oxopropan-2-yl)oxy)benzyl)-2,3-dimethyl-1H-indole-5-carboxylic acid instead of the 1-(4-(2-methoxy-2-oxoethoxy)benzyl)-2,3-dimethyl-1H-indole-5-carboxylic acid. -
- The title compound was prepared following the same protocol as described in
Step 6, Example 36, using the (S)-methyl 2-(3-chloro-5-((5-(((S)-1-(3-isopropylphenyl)ethyl)carbamoyl)-2,3-dimethyl-1H-indol-1-yl)methyl)phenoxy)propanoate instead of the (S)-methyl 2-(4-((5-((1-(3-cyclopropylphenyl)ethyl)carbamoyl)-2,3-dimethyl-1H-indol-1-yl)methyl)phenoxy)acetate. ESI-MS (m/z): 547/548/549 [M+H]+. -
-
- The title compound was prepared following the same protocol as described in
Step 1, Example 42, using the 2-chloro-3-methylphenol instead of the m-cresol and the (R)-methyl 2-hydroxypropanoate instead of the (S)-methyl 2-hydroxypropanoate. -
- The title compound was prepared following the same protocol as described in
Step 2, Example 36, using the (S)-methyl 2-(2-chloro-3-methylphenoxy)propanoate instead of the methyl 2-(p-tolyloxy)acetate. -
- The title compound was prepared following the same general protocol as described in
Step 3, Example 36, using the (S)-methyl 2-(3-(bromomethyl)-2-chlorophenoxy)propanoate instead of the methyl 2-(4-(bromomethyl)phenoxy)acetate. ESI-MS (m/z): 456/457/458 [M+H]+. -
- The title compound was prepared following the same general protocol as described in
Step 4, Example 36, using the (S)-allyl 1-(2-chloro-3-((1-methoxy-1-oxopropan-2-yl)oxy)benzyl)-2,3-dimethyl-1H-indole-5-carboxylate instead of the allyl 1-(4-(2-methoxy-2-oxoethoxy)benzyl)-2,3-dimethyl-1H-indole-5-carboxylate. ESI-MS (m/z): 416/417/418 [M+H]+. -
- The title compound was prepared following the same protocol as described in
Step 5, Example 36, using the (S)-1-(3-isopropylphenyl)ethanamine hydrochloride instead of the (S)-1-(3-cyclopropylphenyl)ethanamine hydrochloride and the (S)-1-(2-chloro-3-((1-methoxy-1-oxopropan-2-yl)oxy)benzyl)-2,3-dimethyl-1H-indole-5-carboxylic acid instead of the 1-(4-(2-methoxy-2-oxoethoxy)benzyl)-2,3-dimethyl-1H-indole-5-carboxylic acid. -
- The title compound was prepared following the same protocol as described in
Step 6, Example 36, using the (S)-methyl 2-(2-chloro-3-((5-(((S)-1-(3-isopropylphenyl)ethyl)carbamoyl)-2,3-dimethyl-1H-indol-1-yl)methyl)phenoxy)propanoate instead of the (S)-methyl 2-(4-((5-((1-(3-cyclopropylphenyl)ethyl)carbamoyl)-2,3-dimethyl-1H-indol-1-yl)methyl)phenoxy)acetate. ESI-MS (m/z): 547/548/549 [M+H]+. -
-
- The title compound was prepared following the same protocol as described in
Step 1, Example 42, using the 2-chloro-5-methylphenol instead of the m-cresol. -
- The title compound was prepared following the same protocol as described in
Step 2, Example 36, using the (R)-methyl 2-(2-chloro-5-methylphenoxy)propanoate instead of the methyl 2-(p-tolyloxy)acetate. -
- The title compound was prepared following the same general protocol as described in
step 3, Example 36, using the (R)-methyl 2-(5-(bromomethyl)-2-chlorophenoxy)propanoate instead of the methyl 2-(4-(bromomethyl)phenoxy)acetate ESI-MS (m/z): 456 [M+1]+. -
- The title compound was prepared following the same general protocol as described in
Step 4, Example 36, using the (R)-allyl 1-(4-chloro-3-((1-methoxy-1-oxopropan-2-yl)oxy)benzyl)-2,3-dimethyl-1H-indole-5-carboxylate instead of the allyl 1-(4-(2-methoxy-2-oxoethoxy)benzyl)-2,3-dimethyl-1H-indole-5-carboxylate. ESI-MS (m/z): 416 [M+1]+. -
- The title compound was prepared following the same protocol as described in
Step 5, Example 36, using the (S)-1-(3-isopropylphenyl)ethanamine hydrochloride instead of the (S)-1-(3-cyclopropylphenyl)ethanamine hydrochloride and the (R)-1-(4-chloro-3-((1-methoxy-1-oxopropan-2-yl)oxy)benzyl)-2,3-dimethyl-1H-indole-5-carboxylic acid instead of the 1-(4-(2-methoxy-2-oxoethoxy)benzyl)-2,3-dimethyl-1H-indole-5-carboxylic acid. -
- The title compound was prepared following the same protocol as described in
Step 6, Example 36, using the (R)-methyl 2-(2-chloro-5-((5-(((S)-1-(3-isopropylphenyl)ethyl)carbamoyl)-2,3-dimethyl-1H-indol-1-yl)methyl)phenoxy)propanoate instead of the (S)-methyl 2-(4-((5-((1-(3-cyclopropylphenyl)ethyl)carbamoyl)-2,3-dimethyl-1H-indol-1-yl)methyl)phenoxy)acetate. ESI-MS (m/z): 547/548/549 [M+H]+. -
-
- The title compound was prepared following the same protocol as described in
Step 1, Example 42, using the 4-chloro-3-methylphenol instead of the m-cresol. -
- The title compound was prepared following the same protocol as described in
Step 2, Example 36, using the (R)-methyl 2-(4-chloro-3-methylphenoxy)propanoate instead of the methyl 2-(p-tolyloxy)acetate. -
- The title compound was prepared following the same general protocol as described in
step 3, Example 36, using the (R)-methyl 2-(3-(bromomethyl)-4-chlorophenoxy)propanoate instead of the methyl 2-(4-(bromomethyl)phenoxy)acetate ESI-MS (m/z): 456 [M+1]+. -
- The title compound was prepared following the same general protocol as described in
Step 4, Example 36, using the (R)-allyl 1-(2-chloro-5-((1-methoxy-1-oxopropan-2-yl)oxy)benzyl)-2,3-dimethyl-1H-indole-5-carboxylate instead of the allyl 1-(4-(2-methoxy-2-oxoethoxy)benzyl)-2,3-dimethyl-1H-indole-5-carboxylate. ESI-MS (m/z): 416 [M+1]+. -
- The title compound was prepared following the same protocol as described in
Step 5, Example 36, using the (S)-1-(3-isopropylphenyl)ethanamine hydrochloride instead of the (S)-1-(3-cyclopropylphenyl)ethanamine hydrochloride and the (R)-1-(2-chloro-5-((1-methoxy-1-oxopropan-2-yl)oxy)benzyl)-2,3-dimethyl-1H-indole-5-carboxylic acid instead of the 1-(4-(2-methoxy-2-oxoethoxy)benzyl)-2,3-dimethyl-1H-indole-5-carboxylic acid. -
- The title compound was prepared following the same protocol as described in
Step 6, Example 36, using the (R)-methyl 2-(3-chloro-4-((5-(((S)-1-(3-isopropylphenyl)ethyl)carbamoyl)-2,3-dimethyl-1H-indol-1-yl)methyl)phenoxy)propanoate instead of the (S)-methyl 2-(4-((5-((1-(3-cyclopropylphenyl)ethyl)carbamoyl)-2,3-dimethyl-1H-indol-1-yl)methyl)phenoxy)acetate. ESI-MS (m/z): 547/548/549 [M+H]+. -
-
- The title compound was prepared following the same protocol as described in
Step 1, Example 42, using the 3-chloro-5-methylphenol instead of the m-cresol. -
- The title compound was prepared following the same protocol as described in
Step 2, Example 36, using the (R)-methyl 2-(3-chloro-5-methylphenoxy)propanoate instead of the methyl 2-(p-tolyloxy)acetate. -
- The title compound was prepared following the same general protocol as described in
Step 3, Example 36, using the (R)-methyl 2-(3-(bromomethyl)-5-chlorophenoxy)propanoate instead of the methyl 2-(4-(bromomethyl)phenoxy)acetate. ESI-MS (m/z): 456/457/458 [M+H]+. -
- The title compound was prepared following the same general protocol as described in
Step 4, Example 36, using the (R)-allyl 1-(3-chloro-5-((1-methoxy-1-oxopropan-2-yl)oxy)benzyl)-2,3-dimethyl-1H-indole-5-carboxylate instead of the allyl 1-(4-(2-methoxy-2-oxoethoxy)benzyl)-2,3-dimethyl-1H-indole-5-carboxylate. ESI-MS (m/z): 416/417/418 [M+H]+. -
- The title compound was prepared following the same protocol as described in
Step 5, Example 36, using the (S)-1-(3-isopropylphenyl)ethanamine hydrochloride instead of the (S)-1-(3-cyclopropylphenyl)ethanamine hydrochloride and the (R)-1-(3-chloro-5-((1-methoxy-1-oxopropan-2-yl)oxy)benzyl)-2,3-dimethyl-1H-indole-5-carboxylic acid instead of the 1-(4-(2-methoxy-2-oxoethoxy)benzyl)-2,3-dimethyl-1H-indole-5-carboxylic acid. -
- The title compound was prepared following the same protocol as described in
Step 6, Example 36, using the (R)-methyl 2-(3-chloro-5-((5-(((S)-1-(3-isopropylphenyl)ethyl)carbamoyl)-2,3-dimethyl-1H-indol-1-yl)methyl)phenoxy)propanoate instead of the (S)-methyl 2-(4-((5-((1-(3-cyclopropylphenyl)ethyl)carbamoyl)-2,3-dimethyl-1H-indol-1-yl)methyl)phenoxy)acetate. ESI-MS (m/z): 547/548/549 [M+H]+. -
-
- The title compound was prepared following the same protocol as described in
Step 1, Example 42, using the 2-chloro-3-methylphenol instead of the m-cresol. -
- The title compound was prepared following the same protocol as described in
Step 2, Example 36, using the (R)-methyl 2-(2-chloro-3-methylphenoxy)propanoate instead of the methyl 2-(p-tolyloxy)acetate. -
- The title compound was prepared following the same general protocol as described in
Step 3, Example 36, using the (R)-methyl 2-(3-(bromomethyl)-2-chlorophenoxy)propanoate instead of the methyl 2-(4-(bromomethyl)phenoxy)acetate. ESI-MS (m/z): 456/457/458 [M+H]+. -
- The title compound was prepared following the same general protocol as described in
Step 4, Example 36, using the (R)-allyl 1-(2-chloro-3-((1-methoxy-1-oxopropan-2-yl)oxy)benzyl)-2,3-dimethyl-1H-indole-5-carboxylate instead of the allyl 1-(4-(2-methoxy-2-oxoethoxy)benzyl)-2,3-dimethyl-1H-indole-5-carboxylate. ESI-MS (m/z): 416/417/418 [M+H]+. -
- The title compound was prepared following the same protocol as described in
Step 5, Example 36, using the (S)-1-(3-isopropylphenyl)ethanamine hydrochloride instead of the (S)-1-(3-cyclopropylphenyl)ethanamine hydrochloride and the (R)-1-(2-chloro-3-((1-methoxy-1-oxopropan-2-yl)oxy)benzyl)-2,3-dimethyl-1H-indole-5-carboxylic acid instead of the 1-(4-(2-methoxy-2-oxoethoxy)benzyl)-2,3-dimethyl-1H-indole-5-carboxylic acid. -
- The title compound was prepared following the same protocol as described in
Step 6, Example 36, using the (R)-methyl 2-(2-chloro-3-((5-(((S)-1-(3-isopropylphenyl)ethyl)carbamoyl)-2,3-dimethyl-1H-indol-1-yl)methyl)phenoxy)propanoate instead of the (S)-methyl 2-(4-((5-((1-(3-cyclopropylphenyl)ethyl)carbamoyl)-2,3-dimethyl-1H-indol-1-yl)methyl)phenoxy)acetate. ESI-MS (m/z): 547/548/549 [M+H]+. -
-
- The title compound was prepared following the same protocol as described in
Step 1, Example 42, using the 2-chloro-4-methylphenol instead of the m-cresol and the (R)-methyl 2-hydroxypropanoate instead of the (S)-methyl 2-hydroxypropanoate. -
- The title compound was prepared following the same protocol as described in
Step 2, Example 36, using the (S)-methyl 2-(2-chloro-4-methylphenoxy)propanoate instead of the methyl 2-(p-tolyloxy)acetate. -
- The title compound was prepared following the same general protocol as described in
Step 3, Example 36, using the (S)-methyl 2-(4-(bromomethyl)-2-chlorophenoxy)propanoate instead of the methyl 2-(4-(bromomethyl)phenoxy)acetate. ESI-MS (m/z): 456/457/458 [M+H]+. -
- The title compound was prepared following the same general protocol as described in
Step 4, Example 36, using the (S)-allyl 1-(3-chloro-4-((1-methoxy-1-oxopropan-2-yl)oxy)benzyl)-2,3-dimethyl-1H-indole-5-carboxylate instead of the allyl 1-(4-(2-methoxy-2-oxoethoxy)benzyl)-2,3-dimethyl-1H-indole-5-carboxylate. ESI-MS (m/z): 416/417/418 [M+H]+. -
- The title compound was prepared following the same protocol as described in
Step 5, Example 36, using the (S)-1-(3-isopropylphenyl)ethanamine hydrochloride instead of the (S)-1-(3-cyclopropylphenyl)ethanamine hydrochloride and the (S)-1-(3-chloro-4-((1-methoxy-1-oxopropan-2-yl)oxy)benzyl)-2,3-dimethyl-1H-indole-5-carboxylic acid instead of the 1-(4-(2-methoxy-2-oxoethoxy)benzyl)-2,3-dimethyl-1H-indole-5-carboxylic acid. -
- The title compound was prepared following the same protocol as described in
Step 6, Example 36, using the (S)-methyl 2-(2-chloro-4-((5-(((S)-1-(3-isopropylphenyl)ethyl)carbamoyl)-2,3-dimethyl-1H-indol-1-yl)methyl)phenoxy)propanoate instead of the (S)-methyl 2-(4-((5-((1-(3-cyclopropylphenyl)ethyl)carbamoyl)-2,3-dimethyl-1H-indol-1-yl)methyl)phenoxy)acetate. ESI-MS (m/z): 547/548/549 [MH]+. -
-
- The title compound was prepared following the same protocol as described in
Step 1, Example 42, using the 3-chloro-4-methylphenol instead of the m-cresol and the (R)-methyl 2-hydroxypropanoate instead of the (S)-methyl 2-hydroxypropanoate. -
- The title compound was prepared following the same protocol as described in
Step 2, Example 36, using the (S)-methyl 2-(3-chloro-4-methylphenoxy)propanoate instead of the methyl 2-(p-tolyloxy)acetate. -
- The title compound was prepared following the same general protocol as described in
Step 3, Example 36, using the (S)-methyl 2-(4-(bromomethyl)-3-chlorophenoxy)propanoate instead of the methyl 2-(4-(bromomethyl)phenoxy)acetate. ESI-MS (m/z): 456/457/458 [M+H]+. -
- The title compound was prepared following the same general protocol as described in
Step 4, Example 36, using the (S)-allyl 1-(2-chloro-4-((1-methoxy-1-oxopropan-2-yl)oxy)benzyl)-2,3-dimethyl-1H-indole-5-carboxylate instead of the allyl 1-(4-(2-methoxy-2-oxoethoxy)benzyl)-2,3-dimethyl-1H-indole-5-carboxylate. ESI-MS (m/z): 416/417/418 [M+H]+. -
- The title compound was prepared following the same protocol as described in
Step 5, Example 36, using the (S)-1-(3-isopropylphenyl)ethanamine hydrochloride instead of the (S)-1-(3-cyclopropylphenyl)ethanamine hydrochloride and the (S)-1-(2-chloro-4-(1-methoxy-1-oxopropan-2-yl)oxy)benzyl)-2,3-dimethyl-1H-indole-5-carboxylic acid instead of the 1-(4-(2-methoxy-2-oxoethoxy)benzyl)-2,3-dimethyl-1H-indole-5-carboxylic acid. -
- The title compound was prepared following the same protocol as described in
Step 6, Example 36, using the (S)-methyl 2-(3-chloro-4-((5-(((S)-1-(3-isopropylphenyl)ethyl)carbamoyl)-2,3-dimethyl-1H-indol-1-yl)methyl)phenoxy)propanoate instead of the (S)-methyl 2-(4-((5-((1-(3-cyclopropylphenyl)ethyl)carbamoyl)-2,3-dimethyl-1H-indol-1-yl)methyl)phenoxy)acetate. ESI-MS (m/z): 547/548/549 [MH]+. -
-
- The title compound was prepared following the same protocol as described in
Step 1, Example 42, using the 2-chloro-4-methylphenol instead of the m-cresol. -
- The title compound was prepared following the same protocol as described in
Step 2, Example 36, using the (R)-methyl 2-(2-chloro-4-methylphenoxy)propanoate instead of the methyl 2-(p-tolyloxy)acetate. -
- The title compound was prepared following the same general protocol as described in
Step 3, Example 36, using the (R)-methyl 2-(4-(bromomethyl)-2-chlorophenoxy)propanoate instead of the methyl 2-(4-(bromomethyl)phenoxy)acetate. ESI-MS (m/z): 456/457/458 [M+H]+. -
- The title compound was prepared following the same general protocol as described in
Step 4, Example 36, using the (R)-allyl 1-(3-chloro-4-((1-methoxy-1-oxopropan-2-yl)oxy)benzyl)-2,3-dimethyl-1H-indole-5-carboxylate instead of the allyl 1-(4-(2-methoxy-2-oxoethoxy)benzyl)-2,3-dimethyl-1H-indole-5-carboxylate. ESI-MS (m/z): 416/417/418 [M+H]+. -
- The title compound was prepared following the same protocol as described in
Step 5, Example 36, using the (S)-1-(3-isopropylphenyl)ethanamine hydrochloride instead of the (S)-1-(3-cyclopropylphenyl)ethanamine hydrochloride and the (R)-1-(3-chloro-4-((1-methoxy-1-oxopropan-2-yl)oxy)benzyl)-2,3-dimethyl-1H-indole-5-carboxylic acid instead of the 1-(4-(2-methoxy-2-oxoethoxy)benzyl)-2,3-dimethyl-1H-indole-5-carboxylic acid. -
- The title compound was prepared following the same protocol as described in
Step 6, Example 36, using the (R)-methyl 2-(2-chloro-4-((5-(((S)-1-(3-isopropylphenyl)ethyl)carbamoyl)-2,3-dimethyl-1H-indol-1-yl)methyl)phenoxy)propanoate instead of the (S)-methyl 2-(4-((5-((1-(3-cyclopropylphenyl)ethyl)carbamoyl)-2,3-dimethyl-1H-indol-1-yl)methyl)phenoxy)acetate. ESI-MS (m/z): 547/548/549 [MH]+ -
-
- The title compound was prepared following the same protocol as described in
Step 1, Example 42, using the 3-chloro-4-methylphenol instead of the m-cresol. -
- The title compound was prepared following the same protocol as described in
Step 2, Example 36, using the (R)-methyl 2-(3-chloro-4-methylphenoxy)propanoate instead of the methyl 2-(p-tolyloxy)acetate. -
- The title compound was prepared following the same general protocol as described in
Step 3, Example 36, using the (R)-methyl 2-(4-(bromomethyl)-3-chlorophenoxy)propanoate instead of the methyl 2-(4-(bromomethyl)phenoxy)acetate. ESI-MS (m/z): 456/457/458 [M+H]+. -
- The title compound was prepared following the same general protocol as described in
Step 4, Example 36, using the (R)-allyl 1-(2-chloro-4-((1-methoxy-1-oxopropan-2-yl)oxy)benzyl)-2,3-dimethyl-1H-indole-5-carboxylate instead of the allyl 1-(4-(2-methoxy-2-oxoethoxy)benzyl)-2,3-dimethyl-1H-indole-5-carboxylate. ESI-MS (m/z): 416/417/418 [M+H]+. -
- The title compound was prepared following the same protocol as described in
Step 5, Example 36, using the (S)-1-(3-isopropylphenyl)ethanamine hydrochloride instead of the (S)-1-(3-cyclopropylphenyl)ethanamine hydrochloride and the (R)-1-(2-chloro-4-((1-methoxy-1-oxopropan-2-yl)oxy)benzyl)-2,3-dimethyl-1H-indole-5-carboxylic acid instead of the 1-(4-(2-methoxy-2-oxoethoxy)benzyl)-2,3-dimethyl-1H-indole-5-carboxylic acid. -
- The title compound was prepared following the same protocol as described in
Step 6, Example 36, using the (R)-methyl 2-(3-chloro-4-((5-(((S)-1-(3-isopropylphenyl)ethyl)carbamoyl)-2,3-dimethyl-1H-indol-1-yl)methyl)phenoxy)propanoate instead of the (S)-methyl 2-(4-((5-((1-(3-cyclopropylphenyl)ethyl)carbamoyl)-2,3-dimethyl-1H-indol-1-yl)methyl)phenoxy)acetate. ESI-MS (m/z): 547/548/549 [MH]+. -
-
- The title compound was prepared following the same protocol as described in
Step 1, Example 42, using the (R)-methyl 2-hydroxybutanoate instead of the (S)-methyl 2-hydroxypropanoate. -
- The title compound was prepared following the same protocol as described in
Step 2, Example 36, using the (S)-methyl 2-(m-tolyloxy)butanoate instead of the methyl 2-(p-tolyloxy)acetate. -
- The title compound was prepared following the same general protocol as described in
Step 3, Example 36, using the (S)-methyl 2-(3-(bromomethyl)phenoxy)butanoate instead of the methyl 2-(4-(bromomethyl)phenoxy)acetate. ESI-MS (m/z): 436 [M+H]+. -
- The title compound was prepared following the same general protocol as described in
Step 4, Example 36, using the (S)-allyl 1-(3-((1-methoxy-1-oxobutan-2-yl)oxy)benzyl)-2,3-dimethyl-1H-indole-5-carboxylate instead of the allyl 1-(4-(2-methoxy-2-oxoethoxy)benzyl)-2,3-dimethyl-1H-indole-5-carboxylate. ESI-MS (m/z): 382 [M+H]+. -
- The title compound was prepared following the same protocol as described in
Step 5, Example 36, using the (S)-1-(3-isopropylphenyl)ethanamine hydrochloride instead of the (S)-1-(3-cyclopropylphenyl)ethanamine hydrochloride and the (S)-1-((3-((1-methoxy-1-oxobutan-2-yl)oxy)benzyl)-2,3-dimethyl-1H-indole-5-carboxylic acid instead of the 1-(4-(2-methoxy-2-oxoethoxy)benzyl)-2,3-dimethyl-1H-indole-5-carboxylic acid. -
- The title compound was prepared following the same protocol as described in
Step 6, Example 36, using the (S)-methyl 2-(3-((5-(((S)-1-(3-isopropylphenyl)ethyl)carbamoyl)-2,3-dimethyl-1H-indol-1-yl)methyl)phenoxy)butanoate instead of the (S)-methyl 2-(4-((5-((1-(3-cyclopropylphenyl)ethyl)carbamoyl)-2,3-dimethyl-1H-indol-1-yl)methyl)phenoxy)acetate. ESI-MS (m/z): 527 [M+H]+. -
-
- The title compound was prepared following the same protocol as described in
Step 1, Example 42, using the (S)-methyl 2-hydroxybutanoate instead of the (S)-methyl 2-hydroxypropanoate. -
- The title compound was prepared following the same protocol as described in
Step 2, Example 36, using the (R)-methyl 2-(m-tolyloxy)butanoate instead of the methyl 2-(p-tolyloxy)acetate. -
- The title compound was prepared following the same general protocol as described in
Step 3, Example 36, using the (R)-methyl 2-(3-(bromomethyl)phenoxy)butanoate instead of the methyl 2-(4-(bromomethyl)phenoxy)acetate. ESI-MS (m/z): 436 [M+H]+. -
- The title compound was prepared following the same general protocol as described in
Step 4, Example 36, using the (R)-allyl 1-(3-((1-methoxy-1-oxobutan-2-yl)oxy)benzyl)-2,3-dimethyl-1H-indole-5-carboxylate instead of the allyl 1-(4-(2-methoxy-2-oxoethoxy)benzyl)-2,3-dimethyl-1H-indole-5-carboxylate. ESI-MS (m/z): 382 [M+H]+. -
- The title compound was prepared following the same protocol as described in
Step 5, Example 36, using the (S)-1-(3-isopropylphenyl)ethanamine hydrochloride instead of the (S)-1-(3-cyclopropylphenyl)ethanamine hydrochloride and the (R)-1-(3-((1-methoxy-1-oxobutan-2-yl)oxy)benzyl)-2,3-dimethyl-1H-indole-5-carboxylic acid instead of the 1-(4-(2-methoxy-2-oxoethoxy)benzyl)-2,3-dimethyl-1H-indole-5-carboxylic acid. -
- The title compound was prepared following the same protocol as described in
Step 6, Example 36, using the (R)-methyl 2-(3-((5-(((S)-1-(3-isopropylphenyl)ethyl)carbamoyl)-2,3-dimethyl-1H-indol-1-yl)methyl)phenoxy)butanoate instead of the (S)-methyl 2-(4-((5-((1-(3-cyclopropylphenyl)ethyl)carbamoyl)-2,3-dimethyl-1H-indol-1-yl)methyl)phenoxy)acetate. ESI-MS (m/z): 527 [M+H]+. -
-
- The title compound was prepared following the same protocol as described in
Step 1, Example 42, using the (R)-methyl 2-hydroxy-3-methylbutanoate instead of the (S)-methyl 2-hydroxypropanoate. -
- The title compound was prepared following the same protocol as described in
Step 2, Example 36, using the (S)-methyl 3-methyl-2-(m-tolyloxy)butanoate instead of the methyl 2-(p-tolyloxy)acetate. -
- The title compound was prepared following the same general protocol as described in
Step 3, Example 36, using the (S)-methyl 2-(3-(bromomethyl)phenoxy)-3-methylbutanoate instead of the methyl 2-(4-(bromomethyl)phenoxy)acetate. ESI-MS (m/z): 450 [M+H]+. -
- The title compound was prepared following the same general protocol as described in
Step 4, Example 36, using the (S)-allyl 1-(3-((1-methoxy-3-methyl-1-oxobutan-2-yl)oxy)benzyl)-2,3-dimethyl-1H-indole-5-carboxylate instead of the allyl 1-(4-(2-methoxy-2-oxoethoxy)benzyl)-2,3-dimethyl-1H-indole-5-carboxylate. ESI-MS (m/z): 396 [M+H]+. -
- The title compound was prepared following the same protocol as described in
Step 5, Example 36, using the (S)-1-(3-isopropylphenyl)ethanamine hydrochloride instead of the (S)-1-(3-cyclopropylphenyl)ethanamine hydrochloride and the (S)-1-(3-((1-methoxy-3-methyl-1-oxobutan-2-yl)oxy)benzyl)-2,3-dimethyl-1H-indole-5-carboxylic acid instead of the 1-(4-(2-methoxy-2-oxoethoxy)benzyl)-2,3-dimethyl-1H-indole-5-carboxylic acid. -
- The title compound was prepared following the same protocol as described in
Step 6, Example 36, using the (S)-methyl 2-(3-((5-(((S)-1-(3-isopropylphenyl)ethyl)carbamoyl)-2,3-dimethyl-1H-indol-1-yl)methyl)phenoxy)-3-methylbutanoate instead of the (S)-methyl 2-(4-((5-((1-(3-cyclopropylphenyl)ethyl)carbamoyl)-2,3-dimethyl-1H-indol-1-yl)methyl)phenoxy)acetate. ESI-MS (m/z): 541 [M+H]+. -
-
- The title compound was prepared following the same protocol as described in
Step 1, Example 42, using the (S)-methyl 2-hydroxy-3-methylbutanoate instead of the (S)-methyl 2-hydroxypropanoate. -
- The title compound was prepared following the same protocol as described in
Step 2, Example 36, using the (R)-methyl 3-methyl-2-(m-tolyloxy)butanoate instead of the methyl 2-(p-tolyloxy)acetate. -
- The title compound was prepared following the same general protocol as described in
Step 3, Example 36, using the (R)-methyl 2-(3-(bromomethyl)phenoxy)-3-methylbutanoate instead of the methyl 2-(4-(bromomethyl)phenoxy)acetate. ESI-MS (m/z): 450 [M+H]+. -
- The title compound was prepared following the same general protocol as described in
Step 4, Example 36, using the (R)-allyl 1-(34(1-methoxy-3-methyl-1-oxobutan-2-yl)oxy)benzyl)-2,3-dimethyl-1H-indole-5-carboxylate instead of the allyl 1-(4-(2-methoxy-2-oxoethoxy)benzyl)-2,3-dimethyl-1H-indole-5-carboxylate. ESI-MS (m/z): 396 [M+H]+. -
- The title compound was prepared following the same protocol as described in
Step 5, Example 36, using the (S)-1-(3-isopropylphenyl)ethanamine hydrochloride instead of the (S)-1-(3-cyclopropylphenyl)ethanamine hydrochloride and the (R)-1-(3-((1-methoxy-3-methyl-1-oxobutan-2-yl)oxy)benzyl)-2,3-dimethyl-1H-indole-5-carboxylic acid instead of the 1-(4-(2-methoxy-2-oxoethoxy)benzyl)-2,3-dimethyl-1H-indole-5-carboxylic acid. -
- The title compound was prepared following the same protocol as described in
Step 6, Example 36, using the (R)-methyl 2-(3-((5-(((S)-1-(3-isopropylphenyl)ethyl)carbamoyl)-2,3-dimethyl-1H-indol-1-yl)methyl)phenoxy)-3-methylbutanoate instead of the (S)-methyl 2-(4-((5-((1-(3-cyclopropylphenyl)ethyl)carbamoyl)-2,3-dimethyl-1H-indol-1-yl)methyl)phenoxy)acetate. ESI-MS (m/z): 541 [M+H]+ -
-
- The title compound was prepared following the same protocol as described in
Step 1, Example 42, using the (R)-methyl 2-hydroxybutanoate instead of the (S)-methyl 2-hydroxypropanoate and the 2-chloro-5-methylphenol instead of the m-cresol. -
- The title compound was prepared following the same protocol as described in
Step 2, Example 36, using the (S)-methyl 2-(2-chloro-5-methylphenoxy)butanoate instead of the methyl 2-(p-tolyloxy)acetate. -
- The title compound was prepared following the same general protocol as described in
Step 3, Example 36, using the (S)-methyl 2-(5-(bromomethyl)-2-chlorophenoxy)butanoate instead of the methyl 2-(4-(bromomethyl)phenoxy)acetate. ESI-MS (m/z): 470/471/472 [M+H]+. -
- The title compound was prepared following the same general protocol as described in
Step 4, Example 36, using the (S)-allyl 1-(4-chloro-3-((1-methoxy-1-oxobutan-2-yl)oxy)benzyl)-2,3-dimethyl-1H-indole-5-carboxylate instead of the allyl 1-(4-(2-methoxy-2-oxoethoxy)benzyl)-2,3-dimethyl-1H-indole-5-carboxylate. ESI-MS (m/z): 430/431/432 [M+H]+. -
- The title compound was prepared following the same protocol as described in
Step 5, Example 36, using the (S)-1-(3-isopropylphenyl)ethanamine hydrochloride instead of the (S)-1-(3-cyclopropylphenyl)ethanamine hydrochloride and the (S)-1-(4-chloro-3-((1-methoxy-1-oxobutan-2-yl)oxy)benzyl)-2,3-dimethyl-1H-indole-5-carboxylic acid instead of the 1-(4-(2-methoxy-2-oxoethoxy)benzyl)-2,3-dimethyl-1H-indole-5-carboxylic acid. -
- The title compound was prepared following the same protocol as described in
Step 6, Example 36, using the (S)-methyl 2-(2-chloro-5-((5-(((S)-1-(3-isopropylphenyl)ethyl)carbamoyl)-2,3-dimethyl-1H-indol-1-yl)methyl)phenoxy)butanoate instead of the (S)-methyl 2-(4-((5-((1-(3-cyclopropylphenyl)ethyl)carbamoyl)-2,3-dimethyl-1H-indol-1-yl)methyl)phenoxy)acetate. ESI-MS (m/z): 561/562/563 [M+H]+. -
-
- The title compound was prepared following the same protocol as described in
Step 1, Example 42, using the (R)-methyl 2-hydroxybutanoate instead of the (S)-methyl 2-hydroxypropanoate and the 4-chloro-3-methylphenol instead of the m-cresol. -
- The title compound was prepared following the same protocol as described in
Step 2, Example 36, using the (S)-methyl 2-(4-chloro-3-methylphenoxy)butanoate instead of the methyl 2-(p-tolyloxy)acetate. -
- The title compound was prepared following the same general protocol as described in
Step 3, Example 36, using the (S)-methyl 2-(3-(bromomethyl)-4-chlorophenoxy)butanoate instead of the methyl 2-(4-(bromomethyl)phenoxy)acetate. ESI-MS (m/z): 470/471/472 [M+H]+. -
- The title compound was prepared following the same general protocol as described in
Step 4, Example 36, using the (S)-allyl 1-(2-chloro-5-((1-methoxy-1-oxobutan-2-yl)oxy)benzyl)-2,3-dimethyl-1H-indole-5-carboxylate instead of the allyl 1-(4-(2-methoxy-2-oxoethoxy)benzyl)-2,3-dimethyl-1H-indole-5-carboxylate. ESI-MS (m/z): 430/431/432 [M+H]+. -
- The title compound was prepared following the same protocol as described in
Step 5, Example 36, using the (S)-1-(3-isopropylphenyl)ethanamine hydrochloride instead of the (S)-1-(3-cyclopropylphenyl)ethanamine hydrochloride and the (S)-1-(2-chloro-5-((1-methoxy-1-oxobutan-2-yl)oxy)benzyl)-2,3-dimethyl-1H-indole-5-carboxylic acid instead of the 1-(4-(2-methoxy-2-oxoethoxy)benzyl)-2,3-dimethyl-1H-indole-5-carboxylic acid. -
- The title compound was prepared following the same protocol as described in
Step 6, Example 36, using the (S)-methyl 2-(4-chloro-3-((5-(((S)-1-(3-isopropylphenyl)ethyl)carbamoyl)-2,3-dimethyl-1H-indol-1-yl)methyl)phenoxy)butanoate instead of the (S)-methyl 2-(4-((5-((1-(3-cyclopropylphenyl)ethyl)carbamoyl)-2,3-dimethyl-1H-indol-1-yl)methyl)phenoxy)acetate. ESI-MS (m/z): 561/562/563 [M+H]+. -
-
- The title compound was prepared following the same protocol as described in
Step 1, Example 42, using the (S)-methyl 2-hydroxybutanoate instead of the (S)-methyl 2-hydroxypropanoate and the 2-chloro-5-methylphenol instead of the m-cresol. -
- The title compound was prepared following the same protocol as described in
Step 2, Example 36, using the (R)-methyl 2-(2-chloro-5-methylphenoxy)butanoate instead of the methyl 2-(p-tolyloxy)acetate. -
- The title compound was prepared following the same general protocol as described in
Step 3, Example 36, using the (R)-methyl 2-(5-(bromomethyl)-2-chlorophenoxy)butanoate instead of the methyl 2-(4-(bromomethyl)phenoxy)acetate. ESI-MS (m/z): 470/471/472 [M+H]+. -
- The title compound was prepared following the same general protocol as described in
Step 4, Example 36, using the (R)-allyl 1-(4-chloro-3-((1-methoxy-1-oxobutan-2-yl)oxy)benzyl)-2,3-dimethyl-1H-indole-5-carboxylate instead of the allyl 1-(4-(2-methoxy-2-oxoethoxy)benzyl)-2,3-dimethyl-1H-indole-5-carboxylate. ESI-MS (m/z): 430/431/432 [M+H]+. -
- The title compound was prepared following the same protocol as described in
Step 5, Example 36, using the (S)-1-(3-isopropylphenyl)ethanamine hydrochloride instead of the (S)-1-(3-cyclopropylphenyl)ethanamine hydrochloride and the (R)-1-(4-chloro-3-((1-methoxy-1-oxobutan-2-yl)oxy)benzyl)-2,3-dimethyl-1H-indole-5-carboxylic acid instead of the 1-(4-(2-methoxy-2-oxoethoxy)benzyl)-2,3-dimethyl-1H-indole-5-carboxylic acid. -
- The title compound was prepared following the same protocol as described in
Step 6, Example 36, using the (R)-methyl 2-(2-chloro-5-((5-(((S)-1-(3-isopropylphenyl)ethyl)carbamoyl)-2,3-dimethyl-1H-indol-1-yl)methyl)phenoxy)butanoate instead of the (S)-methyl 2-(4-((5-((1-(3-cyclopropylphenyl)ethyl)carbamoyl)-2,3-dimethyl-1H-indol-1-yl)methyl)phenoxy)acetate. ESI-MS (m/z): 561/562/563 [M+H]+. -
-
- The title compound was prepared following the same protocol as described in
Step 1, Example 42, using the (S)-methyl 2-hydroxybutanoate instead of the (S)-methyl 2-hydroxypropanoate and the 4-chloro-3-methylphenol instead of the m-cresol. -
- The title compound was prepared following the same protocol as described in
Step 2, Example 36, using the (R)-methyl 2-(4-chloro-3-methylphenoxy)butanoate instead of the methyl 2-(p-tolyloxy)acetate. -
- The title compound was prepared following the same general protocol as described in
Step 3, Example 36, using the (R)-methyl 2-(3-(bromomethyl)-4-chlorophenoxy)butanoate instead of the methyl 2-(4-(bromomethyl)phenoxy)acetate. ESI-MS (m/z): 470/471/472 [M+H]+. -
- The title compound was prepared following the same general protocol as described in
Step 4, Example 36, using the (R)-allyl 1-(2-chloro-5-((1-methoxy-1-oxobutan-2-yl)oxy)benzyl)-2,3-dimethyl-1H-indole-5-carboxylate instead of the allyl 1-(4-(2-methoxy-2-oxoethoxy)benzyl)-2,3-dimethyl-1H-indole-5-carboxylate. ESI-MS (m/z): 430/431/432 [M+H]+. -
- The title compound was prepared following the same protocol as described in
Step 5, Example 36, using the (S)-1-(3-isopropylphenyl)ethanamine hydrochloride instead of the (S)-1-(3-cyclopropylphenyl)ethanamine hydrochloride and the (R)-1-(2-chloro-5-((1-methoxy-1-oxobutan-2-yl)oxy)benzyl)-2,3-dimethyl-1H-indole-5-carboxylic acid instead of the 1-(4-(2-methoxy-2-oxoethoxy)benzyl)-2,3-dimethyl-1H-indole-5-carboxylic acid. -
- The title compound was prepared following the same protocol as described in
Step 6, Example 36, using the (R)-methyl 2-(4-chloro-3-((5-(((S)-1-(3-isopropylphenyl)ethyl)carbamoyl)-2,3-dimethyl-1H-indol-1-yl)methyl)phenoxy)butanoate instead of the (S)-methyl 2-(4-((5-((1-(3-cyclopropylphenyl)ethyl)carbamoyl)-2,3-dimethyl-1H-indol-1-yl)methyl)phenoxy)acetate. ESI-MS (m/z): 561/562/563 [M+H]+. -
-
- The title compound was prepared following the same protocol as described in
Step 1, Example 42, using the (R)-methyl 2-hydroxy-3-methylbutanoate instead of the (S)-methyl 2-hydroxypropanoate and the 2-chloro-5-methylphenol instead of the m-cresol. -
- The title compound was prepared following the same protocol as described in
Step 2, Example 36, using the (S)-methyl 2-(2-chloro-5-methylphenoxy)-3-methylbutanoate instead of the methyl 2-(p-tolyloxy)acetate. -
- The title compound was prepared following the same general protocol as described in
Step 3, Example 36, using the (S)-methyl 2-(5-(bromomethyl)-2-chlorophenoxy)-3-methylbutanoate instead of the methyl 2-(4-(bromomethyl)phenoxy)acetate. ESI-MS (m/z): 470/471/472 [M+H]+. -
- The title compound was prepared following the same general protocol as described in
Step 4, Example 36, using the (S)-allyl 1-(4-chloro-3-((1-methoxy-3-methyl-1-oxobutan-2-yl)oxy)benzyl)-2,3-dimethyl-1H-indole-5-carboxylate instead of the allyl 1-(4-(2-methoxy-2-oxoethoxy)benzyl)-2,3-dimethyl-1H-indole-5-carboxylate. ESI-MS (m/z): 430/431/432 [M+H]+. -
- The title compound was prepared following the same protocol as described in
Step 5, Example 36, using the (S)-1-(3-isopropylphenyl)ethanamine hydrochloride instead of the (S)-1-(3-cyclopropylphenyl)ethanamine hydrochloride and the (S)-1-(4-chloro-34(1-methoxy-3-methyl-1-oxobutan-2-yl)oxy)benzyl)-2,3-dimethyl-1H-indole-5-carboxylic acid instead of the 1-(4-(2-methoxy-2-oxoethoxy)benzyl)-2,3-dimethyl-1H-indole-5-carboxylic acid. -
- The title compound was prepared following the same protocol as described in
Step 6, Example 36, using the (S)-methyl 2-(2-chloro-5-((5-(((S)-1-(3-isopropylphenyl)ethyl)carbamoyl)-2,3-dimethyl-1H-indol-1-yl)methyl)phenoxy)-3-methylbutanoate instead of the (S)-methyl 2-(4-(((5-((1-(3-cyclopropylphenyl)ethyl)carbamoyl)-2,3-dimethyl-1H-indol-1-yl)methyl)phenoxy)acetate. ESI-MS (m/z): 561/562/563 [M+H]+. -
-
- The title compound was prepared following the same protocol as described in
Step 1, Example 42, using the (R)-methyl 2-hydroxy-3-methylbutanoate instead of the (S)-methyl 2-hydroxypropanoate and the 4-chloro-3-methylphenol instead of the m-cresol. -
- The title compound was prepared following the same protocol as described in
Step 2, Example 36, using the (S)-methyl 2-(4-chloro-3-methylphenoxy)-3-methylbutanoate instead of the methyl 2-(p-tolyloxy)acetate. -
- The title compound was prepared following the same general protocol as described in
Step 3, Example 36, using the (S)-methyl 2-(3-(bromomethyl)-4-chlorophenoxy)-3-methylbutanoate instead of the methyl 2-(4-(bromomethyl)phenoxy)acetate. ESI-MS (m/z): 470/471/472 [M+H]+. -
- The title compound was prepared following the same general protocol as described in
Step 4, Example 36, using the (S)-allyl 1-(2-chloro-5-((1-methoxy-3-methyl-1-oxobutan-2-yl)oxy)benzyl)-2,3-dimethyl-1H-indole-5-carboxylate instead of the allyl 1-(4-(2-methoxy-2-oxoethoxy)benzyl)-2,3-dimethyl-1H-indole-5-carboxylate. ESI-MS (m/z): 430/431/432 [M+H]+. -
- The title compound was prepared following the same protocol as described in
Step 5, Example 36, using the (S)-1-(3-isopropylphenyl)ethanamine hydrochloride instead of the (S)-1-(3-cyclopropylphenyl)ethanamine hydrochloride and the (S)-1-(2-chloro-5-((1-methoxy-3-methyl-1-oxobutan-2-yl)oxy)benzyl)-2,3-dimethyl-1H-indole-5-carboxylic acid instead of the 1-(4-(2-methoxy-2-oxoethoxy)benzyl)-2,3-dimethyl-1H-indole-5-carboxylic acid. -
- The title compound was prepared following the same protocol as described in
Step 6, Example 36, using the (S)-methyl 2-(4-chloro-3-((5-(((S)-1-(3-isopropylphenyl)ethyl)carbamoyl)-2,3-dimethyl-1H-indol-1-yl)methyl)phenoxy)-3-methylbutanoate instead of the (S)-methyl 2-(4-((5-((1-(3-cyclopropylphenyl)ethyl)carbamoyl)-2,3-dimethyl-1H-indol-1-yl)methyl)phenoxy)acetate. ESI-MS (m/z): 561/562/563 [M+H]+. -
-
- The title compound was prepared following the same protocol as described in
Step 1, Example 42, using the (S)-methyl 2-hydroxy-3-methylbutanoate instead of the (S)-methyl 2-hydroxypropanoate and the 2-chloro-5-methylphenol instead of the m-cresol. -
- The title compound was prepared following the same protocol as described in
Step 2, Example 36, using the (R)-methyl 2-(2-chloro-5-methylphenoxy)-3-methylbutanoate instead of the methyl 2-(p-tolyloxy)acetate. -
- The title compound was prepared following the same general protocol as described in
Step 3, Example 36, using the (R)-methyl 2-(5-(bromomethyl)-2-chlorophenoxy)-3-methylbutanoate instead of the methyl 2-(4-(bromomethyl)phenoxy)acetate. ESI-MS (m/z): 470/471/472 [M+H]+. -
- The title compound was prepared following the same general protocol as described in
Step 4, Example 36, using the (R)-allyl 1-(4-chloro-3-((1-methoxy-3-methyl-1-oxobutan-2-yl)oxy)benzyl)-2,3-dimethyl-1H-indole-5-carboxylate instead of the allyl 1-(4-(2-methoxy-2-oxoethoxy)benzyl)-2,3-dimethyl-1H-indole-5-carboxylate. ESI-MS (m/z): 430/431/432 [M+H]+. -
- The title compound was prepared following the same protocol as described in
Step 5, Example 36, using the (S)-1-(3-isopropylphenyl)ethanamine hydrochloride instead of the (S)-1-(3-cyclopropylphenyl)ethanamine hydrochloride and the (R)-1-(4-chloro-3-((1-methoxy-3-methyl-1-oxobutan-2-yl)oxy)benzyl)-2,3-dimethyl-1H-indole-5-carboxylic acid instead of the 1-(4-(2-methoxy-2-oxoethoxy)benzyl)-2,3-dimethyl-1H-indole-5-carboxylic acid. -
- The title compound was prepared following the same protocol as described in
Step 6, Example 36, using the (R)-methyl 2-(2-chloro-5-((5-(((S)-1-(3-isopropylphenyl)ethyl)carbamoyl)-2,3-dimethyl-1H-indol-1-yl)methyl)phenoxy)-3-methylbutanoate instead of the (S)-methyl 2-(4-(((5-((1-(3-cyclopropylphenyl)ethyl)carbamoyl)-2,3-dimethyl-1H-indol-1-yl)methyl)phenoxy)acetate. ESI-MS (m/z): 561/562/563 [M+H]+. -
-
- The title compound was prepared following the same protocol as described in
Step 1, Example 42, using the (S)-methyl 2-hydroxybutanoate instead of the (S)-methyl 2-hydroxy-3-methylpropanoate and the 4-chloro-3-methylphenol instead of the m-cresol. -
- The title compound was prepared following the same protocol as described in
Step 2, Example 36, using the (R)-methyl 2-(4-chloro-3-methylphenoxy)-3-methylbutanoate instead of the methyl 2-(p-tolyloxy)acetate. -
- The title compound was prepared following the same general protocol as described in
Step 3, Example 36, using the (R)-methyl 2-(3-(bromomethyl)-4-chlorophenoxy)-3-methylbutanoate instead of the methyl 2-(4-(bromomethyl)phenoxy)acetate. ESI-MS (m/z): 470/471/472 [M+H]+. -
- The title compound was prepared following the same general protocol as described in
Step 4, Example 36, using the (R)-allyl 1-(2-chloro-5-((1-methoxy-3-methyl-1-oxobutan-2-yl)oxy)benzyl)-2,3-dimethyl-1H-indole-5-carboxylate instead of the allyl 1-(4-(2-methoxy-2-oxoethoxy)benzyl)-2,3-dimethyl-1H-indole-5-carboxylate. ESI-MS (m/z): 430/431/432 [M+H]+. -
- The title compound was prepared following the same protocol as described in
Step 5, Example 36, using the (S)-1-(3-isopropylphenyl)ethanamine hydrochloride instead of the (S)-1-(3-cyclopropylphenyl)ethanamine hydrochloride and the (R)-1-(2-chloro-5-((1-methoxy-3-methyl-1-oxobutan-2-yl)oxy)benzyl)-2,3-dimethyl-1H-indole-5-carboxylic acid instead of the 1-(4-(2-methoxy-2-oxoethoxy)benzyl)-2,3-dimethyl-1H-indole-5-carboxylic acid. -
- The title compound was prepared following the same protocol as described in
Step 6, Example 36, using the (R)-methyl 2-(4-chloro-3-((5-(((S)-1-(3-isopropylphenyl)ethyl)carbamoyl)-2,3-dimethyl-1H-indol-1-yl)methyl)phenoxy)-3-methylbutanoate instead of the (S)-methyl 2-(4-((5-((1-(3-cyclopropylphenyl)ethyl)carbamoyl)-2,3-dimethyl-1H-indol-1-yl)methyl)phenoxy)acetate. ESI-MS (m/z): 561/562/563 [M+H]+. -
- The title compound was prepared following the same protocol as described in
Step -
- The title compound was prepared following the same protocol as described in
Step -
- The title compound was prepared following the same protocol as described in Step 5-8, Example 35, using the (S)-1-(4-bromophenyl)ethanamine instead of the (S)-1-(3-bromophenyl)ethanamine. ESI-MS (m/z): 509 [MH]+.
-
- The title compound was prepared following the same protocol as described in Step 5-6, Example 67, using the (S)-1-(3-cyclopropylphenyl)ethanamine hydrochloride instead of the (S)-1-(3-isopropylphenyl)ethanamine hydrochloride. ESI-MS (m/z): 545/546/547 [MH]+.
-
- The title compound was prepared following the same protocol as described in Step 5-6, Example 67, using the (S)-1-(4-tert-butylphenyl)ethanamine hydrochloride instead of the (S)-1-(3-isopropylphenyl)ethanamine hydrochloride. ESI-MS (m/z): 561/562/563 [MH]+.
-
- The title compound was prepared following the same protocol as described in Step 5-6, Example 73, using the (S)-1-(3-cyclopropylphenyl)ethanamine hydrochloride instead of the (S)-1-(3-isopropylphenyl)ethanamine hydrochloride. ESI-MS (m/z): 545/546/547 [MH]+.
-
- The title compound was prepared following the same protocol as described in Step 5-6, Example 73, using the (S)-1-(4-tert-butylphenyl)ethanamine hydrochloride instead of the (S)-1-(3-isopropylphenyl)ethanamine hydrochloride. ESI-MS (m/z): 561/562/563 [MH]+.
-
- The title compound was prepared following the same protocol as described in Step 5-6, Example 68, using the (S)-1-(3-cyclopropylphenyl)ethanamine hydrochloride instead of the (S)-1-(3-isopropylphenyl)ethanamine hydrochloride. ESI-MS (m/z): 545/546/547 [MH]+.
-
- The title compound was prepared following the same protocol as described in Step 5-6, Example 68, using the (S)-1-(4-tert-butylphenyl)ethanamine hydrochloride instead of the (S)-1-(3-isopropylphenyl)ethanamine hydrochloride. ESI-MS (m/z): 561/562/563 [MH]+.
-
- A solution of (S)-2-(5-((5-(((S)-1-(4-(tert-butyl)phenyl)ethyl)carbamoyl)-2,3-dimethyl-1H-indol-1-yl)methyl)-2-chlorophenoxy)propanoic acid (20 mg, 0.036 mmol), NH4Cl (19 mg, 0.36 mmol), HATU (14 mg, 0.036 mmol) and DIEA (25 μl, 0.144 mmol) in DCM (0.5 ml) was stirred at rt for 1 h. After concentration, the obtained oil was purified by reverse phase prep-HPLC (MeOH/Acetonitrile/water) to afford a white powder (18 mg). ESI-MS (m/z): 560/561/562 [MH]+.
-
- A solution of (S)-2-(3-((5-(((S)-1-(4-(tert-butyl)phenyl)ethyl)carbamoyl)-2,3-dimethyl-1H-indol-1-yl)methyl)-4-chlorophenoxy)propanoic acid (20 mg, 0.036 mmol), NH4Cl (19 mg, 0.36 mmol), HATU (14 mg, 0.036 mmol) and DIEA (25 μl, 0.144 mmol) in DCM (0.5 ml) was stirred at rt for 1 h. After concentration, the obtained oil was purified by reverse phase prep-HPLC (MeOH/Acetonitrile/water) to afford a white powder (18 mg). ESI-MS (m/z): 560/561/562 [MH]+.
-
- A solution of (S)-2-(3-((5-(((S)-1-(4-(tert-butyl)phenyl)ethyl)carbamoyl)-2,3-dimethyl-1H-indol-1-yl)methyl)phenoxy)propanoic acid (20 mg, 0.036 mmol), NH4Cl (19 mg, 0.36 mmol), HATU (14 mg, 0.036 mmol) and DIEA (25 μl, 0.144 mmol) in DCM (0.5 ml) was stirred at rt for 1 h. After concentration, the obtained oil was purified by reverse phase prep-HPLC (MeOH/Acetonitrile/water) to afford a white powder (18 mg). ESI-MS (m/z): 526 [MH]+.
-
-
- 2-(m-tolyl)acetonitrile (3.75 g, 28.6 mmol) in dry THF (20 mL) was cooled at ice bath, and then NaH (60% in dispension, 2.9 g, 71.5 mmol) was added gradually. The mixture was stirred at room temperature for 30 min, and recooled at ice bath. Mel (3.91 mL, 62.8 mmol) was then added dropwise. The reaction mixture was stirred at room temperature for 16 hr. isopropanol was carefully added to the mixture followed by ethyl acetate. The organic layer was washed with water and brine, dried over anhydrous sodium sulfate. The solvent was removed and the residue was purified by silica gel to obtain the title compound. 1H NMR (400 MHz, CDCl3) δ 7.28-7.24 (m, 3H), 7.11 (s, 1H), 2.36 (s, 3H), 1.70 (s, 6H).
-
- The title compound was prepared following the same general protocol as described in
Step 2, Example 35, using 2-methyl-2-(m-tolyl)propanenitrile. -
- The title compound was prepared following the same general protocol as described in
Step 2, Example 1, using 2-(3-(bromomethyl)phenyl)-2-methylpropanenitrile andallyl 2,3-dimethyl-1H-indole-5-carboxylate. ESI-MS (m/z): 387 [M+H]+. -
- The mixture of allyl 1-(3-(2-cyanopropan-2-yl)benzyl)-2,3-dimethyl-1H-indole-5-carboxylate (0.688 g, 1.78 mmol) and morpholine (1.6 mL, 17.8 mmol) in THF (5 mL) was degassed and then Pd(PPh3)4 (0.21 g, 0.18 mmol) was added. The mixture was stirred at room temperature for 1 h. The solvent was removed and the residue was dissolved in Methanol and acidified to pH4. The solvent was removed and the residue was purified by silica gel to obtain the title compound. ESI-MS (m/z): 347 [M+H]+.
- The title compound was prepared following the same general protocol as described in
Step 4, Example 1, using (S)-1-(3-cyclopropylphenyl)ethanamine hydrochloride and 1-(3-(2-cyanopropan-2-yl)benzyl)-2,3-dimethyl-1H-indole-5-carboxylic acid. ESI-MS (m/z): 490 [M+H]+. -
- To (S)-1-(3-(2-cyanopropan-2-yl)benzyl)-N-(1-(3-cyclopropylphenyl)ethyl)-2,3-dimethyl-1H-indole-5-carboxamide (0.1 g, 0.2 mmol) in ethanol added NaOH (5 N, 1 mL). The mixture was heated at 130° C. oil bath for 2 days. The mixture was cooled to room temperature and acidified to
pH 4. The solvent was removed and residue was purified by preparative-HPLC to obtain the title compounds. (S)-1-(3-(1-amino-2-methyl-1-oxopropan-2-yl)benzyl)-N-(1-(3-cyclopropylphenyl)ethyl)-2,3-dimethyl-1H-indole-5-carboxamide ESI-MS (m/z): 508 [M+H]+: (S)-2-(3-((5-((1-(3-cyclopropylphenyl)ethyl)carbamoyl)-2,3-dimethyl-1H-indol-1-yl)methyl)phenyl)-2-methylpropanoic acid. ESI-MS (m/z): 509 [M+H]+. -
-
- To 3-ethylphenol (3.42 g, 28 mmol) in THF (20 mL) at ice bath was added triphenylphosphine (9.5 g, 36.4 mmol) and then (R)-methyl 2-hydroxypropanoate (2.94 mL, 31 mmol). And then DIAD (8.2 mL, 42 mmol) was added dropwise to the above cole solution. The mixture was stirred at room temperature for 16 hr. The solvent was removed and the residue was purified by silica gel to obtain the title compound.
-
- The title compound was prepared following the same general protocol as described in
Step 2, Example 35, using (S)-methyl 2-(3-ethylphenoxy)propanoate. -
- The title compound was prepared following the same general protocol as described in
Step 2, Example 1, using (2S)-methyl 2-(3-(1-bromoethyl)phenoxy)propanoate andallyl 2,3-dimethyl-1H-indole-5-carboxylate. ESI-MS (m/z): 436 [M+H]+. -
- The title compound was prepared following the same general protocol as described in
Step 4. Example 36, using allyl 1-(1-(3-(((S)-1-methoxy-1-oxopropan-2-yl)oxy)phenyl)ethyl)-2,3-dimethyl-1H-indole-5-carboxylate. ESI-MS (m/z): 396 [M+H]+. -
- The title compound was prepared following the same general protocol as described in
Step 4, Example 1, using (S)-1-(3-cyclopropylphenyl)ethanamine hydrochloride and 1-(3-(2-cyanopropan-2-yl)benzyl)-2,3-dimethyl-1H-indole-5-carboxylic acid. ESI-MS (m/z): 539 [M+H]+. - NaOH (2 N, 0.1 mL, 0.2 mmol) was added to (2S)-methyl 2-(3-(1-(5-(((S)-1-(3-cyclopropylphenyl)ethyl)carbamoyl)-2,3-dimethyl-1H-indol-1-yl)ethyl)phenoxy)propanoate (0.03 g, 0.06 mmol) in Methanol (0.5 mL). The reaction mixture was acidified to
pH 4. The solvent was removed and the residue was purified by preparative-HPLC to obtain the title compound. ESI-MS (m/z): 525 [M+H]+. -
- The title compound was prepared following the same general protocol as described in Step 5-6. Example 103, using (S)-1-(4-(tert-butyl)phenyl)ethanamine hydrochloride. ESI-MS (m/z): 541 [M+H]+.
-
-
- To a solution of m-cresol (5.0 g, 46 mmol, 1 equiv), methyl-D(+) lactate (4.8 g, 46 mmol, 1 equiv) and PPh3 (14.5 g, 55.2 mmol, 1.2 equiv) in anhydrous THF (200 mL) under argon and at 0° C., was added dropwise DIAD (9.96 g, 48.2 mmol, 1.5 equiv). The reaction mixture was stirred at 0° C. until room temperature overnight. The crude mixture was dissolved in AcOEt (200 mL) and washed with a 0.5 N HCl aqueous solution (×2), a saturated NaHCO3 solution (×2), brine and then dried over Na2SO4. After filtration, solvent was evaporated. The crude product was purified by flash chromatography on silica gel (AcOEt/hexane 0->60%) to obtain the title compound.
-
- To a 250 mL round-bottom flask was (S)-methyl 2-(m-tolyloxy)propanoate (2.0 g, 10.3 mmol, 1 equiv), NBS (1.83 g, 10.3 mmol, 1 equiv), AIBN (169 mg, 1.03 mmol, 0.1 equiv) and CCl4 (100 mL). The reaction mixture was refluxed for 16 h at 80° C. The completion of the reaction was monitored by analytical HPLC. The reaction mixture was allowed to cool to room temperature. The crude mixture was dissolved in AcOEt (100 mL) and washed with a 0.5N HCl aqueous solution (×2), a saturated NaHCO3 solution (×2) and brine, dried over Na2SO4. The filtrate was concentrated to obtain the crude product which was purified by flash chromatography (AcOEt/Hexane 0->60%) to obtain the title compound.
-
- To a solution of
allyl 2,3-dimethyl-1H-indole-5-carboxylate (1.0 g, 4.4 mmol, 1 equiv) and (S)-methyl 2-(3-(bromomethyl)phenoxy)propanoate (1.30 g, 4.84 mmol, 1.1 equiv) in anhydrous DMF (30 mL) under argon atmosphere was added sodium hydride (211 mg, 8.8 mmol, 2 equiv) in small portions. The mixture was stirred 2 h at room temperature. The reaction mixture was then quenched slowly with a solution of HCl 0.5 N. The residue was dissolved in AcOEt, washed with a saturated NaHCO3 solution and brine, dried over MgSO4. The crude was purified by flash chromatography (AcOEt/Hexane 0->60%) to afford the title compound. -
- A mixture of (S)-allyl 1-(3-((1-methoxy-1-oxopropan-2-yl)oxy)benzyl)-2,3-dimethyl-1H-indole-5-carboxylate (1.0 g, 2.37 mmol, 1 equiv), Pd(PPh3)4 (277 mg, 0.24 mmol, 0.1 equiv), and morpholine (2 mL, 23.7 mmol, 10 equiv) in anhydrous THF (30 mL) was stirred at room temperature under argon atmosphere for 16 h. The completion of the reaction was monitored by anal. HPLC. The crude mixture was dissolved in AcOEt (100 mL) and washed with a 0.5N HCl aqueous solution (×2) and brine, then dried over Na2SO4. The filtrate was concentrated to obtain the crude product which was purified by flash chromatography (AcOEt/Hexane 0->60%) to obtain the title compound.
-
- To a solution of (S)-1-(3-((1-methoxy-1-oxopropan-2-yl)oxy)benzyl)-2,3-dimethyl-1H-indole-5-carboxylic acid (50 mg, 0.13 mmol, 1 equiv) in DCM (2 mL) was added (S)-1-(3-isopropoxyphenyl)ethanamine (34 mg, 0.16 mmol, 1.2 equiv), DIEA (70 μL, 0.39 mmol, 3 equiv) and HATU (50 mg, 0.13 mmol, 1 equiv). The reaction mixture was stirred 2 h at room temperature. The solvent was removed in vacuo. The residue was dissolved in AcOEt and washed with a 0.5N HCl aqueous solution, a saturated NaHCO3 solution and brine, dried over MgSO4. The filtrate was concentrated to obtain the crude product which was purified by flash chromatography (AcOEt/Hexane 0->50%) to obtain the title compound.
-
- To a solution of (S)-methyl 2-(3-((5-(((S)-1-(3-isopropoxyphenyl)ethyl) carbamoyl)-2,3-dimethyl-1H-indol-1-yl)methyl)phenoxy)propanoate (70 mg, 0.13 mmol, 1 equiv) in THF (2 mL) was added a 1 N LiOH aqueous solution of (1 mL). The reaction mixture was stirred 6 h at room temperature, then acidified with a 0.5 N HCl aqueous solution. The mixture was filtered and the precipate was dissolved in methanol and concentrated to obtain the crude product which was purified by prep. HPLC (MeOH/Acetonitrile/water 0.1% TFA) to obtain the title compound. ESI-MS (m/z): 529 [M+H]+.
-
- The title compound was prepared following the same protocol as described in Steps 4-6, Example 105, using (S)-1-(3-(tert-butyl)phenyl)ethanamine instead of the (S)-1-(3-isopropoxyphenyl)ethanamine. ESI-MS (m/z): 527 [M+H]+.
-
- The title compound was prepared following the same protocol as described in Steps 4-6, Example 105, using (S)-1-(4-bromophenyl)ethanamine instead of the (S)-1-(3-isopropoxyphenyl)ethanamine. ESI-MS (m/z): 549 [M+H]+.
-
- The title compound was prepared following the same protocol as described in Steps 4-6, Example 105, using (S)-1-(3-(trifluoromethyl)phenyl)ethanamine instead of the (S)-1-(3-isopropoxyphenyl)ethanamine. ESI-MS (m/z): 539 [M+H]+.
-
- The title compound was prepared following the same protocol as described in Steps 4-6, Example 105, using (S)-1-(3-chlorophenyl)ethanamine instead of the (S)-1-(3-isopropoxyphenyl)ethanamine. ESI-MS (m/z): 505 [M+H]+.
-
- The title compound was prepared following the same protocol as described in Steps 4-6, Example 105, using (S)-1-(4-chlorophenyl)ethanamine instead of the (S)-1-(3-isopropoxyphenyl)ethanamine. ESI-MS (m/z): 505 [M+H]+.
-
- The title compound was prepared following the same protocol as described in Steps 4-6, Example 105, using (S)-1-(2-chlorophenyl)ethanamine instead of the (S)-1-(3-isopropoxyphenyl)ethanamine. ESI-MS (m/z): 505 [M+H]+.
-
- The title compound was prepared following the same protocol as described in Steps 4-6, Example 105, using (S)-1-(4-(tert-butyl)phenyl)ethanamine instead of the (S)-1-(3-isopropoxyphenyl)ethanamine. ESI-MS (m/z): 557 [M+H]+.
-
- The title compound was prepared following the same protocol as described in Steps 4-6, Example 105, using (S)-1-(3-cyclopropylphenyl)ethanamine instead of the (S)-1-(3-isopropoxyphenyl)ethanamine. ESI-MS (m/z): 541 [M+H]+.
-
- The title compound was prepared following the same protocol as described in Steps 4-6, Example 105, using (S)-1-(4-(tert-butyl)phenyl)ethanamine instead of the (S)-1-(3-isopropoxyphenyl)ethanamine. ESI-MS (m/z): 545 [M+H]+.
-
- The title compound was prepared following the same protocol as described in Steps 4-6, Example 105, using (S)-1-(4-(tert-butyl)phenyl)ethanamine instead of the (S)-1-(3-isopropoxyphenyl)ethanamine. ESI-MS (m/z): 545 [M+H]+.
-
- The title compound was prepared following the same protocol as described in Steps 4-6, Example 105, using (S)-1-(3-cyclopropylphenyl)ethanamine instead of the (S)-1-(3-isopropoxyphenyl)ethanamine. ESI-MS (m/z): 529 [M+H]+.
-
- The title compound was prepared following the same protocol as described in Steps 4-6, Example 105, using (S)-1-(4-methoxyphenyl)ethanamine instead of the (S)-1-(3-isopropoxyphenyl)ethanamine. ESI-MS (m/z): 501 [M+H]+.
-
-
- To a stirred solution of 4-ethylphenol (3.38 g, 27.67 mmol) in DCM (50 mL) in an ice bath was added TEA (7.2 mL, 55.34 mmol), followed by the dropwise addition of acetyl chloride (2.2 mL, 30.44 mmol). The mixture was stirred at room temperature for 30 min. The reaction mixture was quenched with water (40 mL) and extracted with DCM (3×50 mL). The combined organic layers were washed with brine, dried over Na2SO4, filtered and concentrated under reduced pressure and purified by silica gel chromatography to obtain the title compound.
-
- The title compound was prepared following the same general protocol as described in
Step 2, Example 35, using 4-ethylphenyl acetate. - 1H NMR (400 MHz, CDCl3) δ 7.45 (d, J=8.8 Hz, 2H), 7.06 (d, J=8.8 Hz, 2H), 5.21 (q, J=7.2 Hz, 1H), 2.99 (s, 3H), 2.04 (d, J=6.8 Hz, 3H).
-
- The title compound was prepared following the same general protocol as described in
Step 2, Example 1, using 4-(1-bromoethyl)phenyl acetate andallyl 2,3-dimethyl-1H-indole-5-carboxylate. - To the above reaction mixture was added saturated Na2CO3 solution (20 mL) and the mixture was stirred at room temperature for 1 h. The mixture was diluted with EtOAc, followed by the addition of a saturated NH4Cl solution. The aqueous layer was removed and the organic layer was washed with water and then brine and dried over Na2SO4. The solvent was removed under reduced pressure and the residue was purified by silica gel chromatography to obtain the title compound. ESI-MS (m/z): 350 [M+H]+.
-
- To allyl 1-(1-(4-hydroxyphenyl)ethyl)-2,3-dimethyl-1H-indole-5-carboxylate (0.286 g, 0.82 mmol) in THF (0.8 mL) in an ice bath was added triphenylphosphine (0.28 g, 1.07 mmol) and then (R)-methyl 2-hydroxypropanoate (0.093 mL, 0.98 mmol). DIAD (0.24 mL, 1.23 mmol) was added dropwise to the cold solution. The mixture was stirred at room temperature for 16 hr. The solvent was removed and the residue was purified by silica gel chromatography to obtain the title compound. ESI-MS (m/z): 436 [M+H]+.
-
- The mixture of allyl 1-(1-(4-(((S)-1-methoxy-1-oxopropan-2-yl)oxy)phenyl)ethyl)-2,3-dimethyl-1H-indole-5-carboxylate (0.55 g, 1.26 mmol) and morpholine (1.0 mL, 12.6 mmol) in THF (5 mL) was degassed and then Pd(PPh3)4 (0.15 g, 0.13 mmol) was added. The mixture was stirred at room temperature for 1 h. The solvent was removed and the residue was dissolved in Methanol and acidified to
pH 4. The solvent was removed and the residue was purified by silica gel chromatography to obtain the title compound. ESI-MS (m/z): 396 [M+H]+. -
- The title compound was prepared following the same general protocol as described in
Step 5, Example 35, using (S)-1-(4-(tert-butyl)phenyl)ethanamine instead of (S)-1-(3-bromophenyl)ethylamine and 1-(1-(4-(((S)-1-methoxy-1-oxopropan-2-yl)oxy)phenyl)ethyl)-2,3-dimethyl-1H-indole-5-carboxylic acid instead of 1-(4-(1-(methoxycarbonyl)cyclopropyl)benzyl)-2,3-dimethyl-1H-indole-5-carboxylic acid′ -
- A solution of (25)-methyl 2-(4-(1-(5-(((S)-1-(4-(tert-butyl)phenyl)ethyl)carbamoyl)-2,3-dimethyl-1H-indol-1-yl)ethyl)phenoxy)propanoate (˜0.07 mmol) and NaOH (2 M, 0.2 mL) in MeOH (2 mL) and DMF (1 mL) was stirred at rt for 5 h. It was neutralized and purified by preparative HPLC to yield the title compound as a white solid. ESI-MS (m/z): 541 [M+H]+.
-
- The title compound was prepared following the same general protocol as described in the previous example. ESI-MS (m/z): 525 [M+H]+.
-
-
- To a stirred solution of 2-(m-tolyl)acetonitrile (4.2 g, 32 mmol) in toluene (15 mL) was added sodium hydroxide (30 mL, 50% w/w in water, 375 mmol), 1-bromo-2-chloroethane (9.3 mL, 112 mmol) and (n-Bu)4Br (0.5 g, 1.55 mmol). The mixture was heated at 60° C. overnight. After cooling to room temperature, the reaction mixture was diluted with water (40 mL) and extracted with EtOAc (3×50 mL). The combined organic layers were washed with brine, dried over Na2SO4, filtered and concentrated under reduced pressure and purified by silica gel chromatography to obtain the title compound.
- 1H NMR (400 MHz, CDCl3) δ 7.26-7.22 (m, 1H), 7.13-7.05 (m, 3H), 2.36 (s, 3H), 1.72-1.68 (m, 2H), 1.41-1.38 (m, 2H).
-
- The title compound was prepared following the same general protocol as described in
Step 2, Example 35, using 1-(m-tolyl)cyclopropanecarbonitrile. -
- The title compound was prepared following the same general protocol as described in
Step 2, Example 1, using 1-(3-(bromomethyl)phenyl)cyclopropanecarbonitrile andallyl 2,3-dimethyl-1H-indole-5-carboxylate -
- The mixture of allyl 1-(3-(1-cyanocyclopropyl)benzyl)-2,3-dimethyl-1H-indole-5-carboxylate (375 mg, 0.98 mmol) and morpholine (0.8 mL, 9.2 mmol) in THF (8 mL) was degassed and then Pd(PPh3)4 (117 mg, 0.10 mmol) was added. The mixture was stirred at room temperature for 1 h. The solvent was removed and the residue was dissolved in Methanol and acidified to
pH 4. The precipitate was collected and washed with water to obtain the title compound. -
- The title compound was prepared following the same general protocol as described in
Step 5, Example 35, using 1-(3-(1-cyanocyclopropyl)benzyl)-2,3-dimethyl-1H-indole-5-carboxylic acid and (S)-1-(3-cyclopropylphenyl)ethanamine. -
- To a solution of (S)-1-(3-(1-Cyanocyclopropyl)benzyl)-N-(1-(3-cyclopropylphenyl)ethyl)-2,3-dimethyl-1H-indole-5-carboxamide (˜0.2 mmol) in Ethanol was added NaOH (5 N, 1 mL). The mixture was heated at 130° C. in an oil bath for 14 days. The mixture was cooled to room temperature and acidified to
pH 4. The solvent was removed and the residue was purified by preparative-HPLC to obtain the title compound. ESI-MS (m/z): 507 [M+H]+. -
-
- The title compound was prepared following the same general protocol as described in
Step 2, Example 1, using methyl 3-(bromomethyl)benzoate andallyl 2,3-dimethyl-1H-indole-5-carboxylate. -
- The mixture of allyl 1-(3-(methoxycarbonyl)benzyl)-2,3-dimethyl-1H-indole-5-carboxylate (133 mg, 0.35 mmol) and morpholine (0.3 mL, 3.4 mmol) in THF (4 mL) was degassed and then Pd(PPh3)4 (41 mg, 0.035 mmol) was added. The mixture was stirred at room temperature for 1 h. The solvent was removed and the residue was dissolved in Methanol and acidified to
pH 4. The precipitate was collected and washed with water to obtain the title compound. -
- The title compound was prepared following the same general protocol as described in
Step 5, Example 35, using 1-(3-(methoxycarbonyl)benzyl)-2,3-dimethyl-1H-indole-5-carboxylic acid and (S)-1-(3-cyclopropylphenyl)ethanamine. -
- A solution of (S)-Methyl 3-((5-((1-(3-cyclopropylphenyl)ethyl)carbamoyl)-2,3-dimethyl-1H-indol-1-yl)methyl)benzoate (˜0.07 mmol) and NaOH (2 M, 0.5 mL) in MeOH (2 mL) and DMSO (1 mL) was stirred at rt for 15 h. It was neutralized and purified by preparative HPLC to yield the title compound as a white solid. ESI-MS (m/z): 467 [M+H]+.
-
- The title compound was prepared following the same general protocol as described in
Step 5, Example 35. ESI-MS (m/z): 466 [M+H]+. -
- The title compound was prepared following the same protocol as described in
Step 5, Example 36, using the (S)-1-(3-isopropylphenyl)ethanamine hydrochloride instead of the (S)-1-(3-cyclopropylphenyl)ethanamine hydrochloride, followed by an ester hydrolysis step as outlined inStep 6, example 36. -
- The title compound was prepared following the same protocol as described in
Step 5, Example 36, using the (S)-1-(3-isopropylphenyl)ethanamine hydrochloride instead of the (S)-1-(3-cyclopropylphenyl)ethanamine hydrochloride and (S)-1-(4-fluoro-3-((1-methoxy-1-oxopropan-2-yl)oxy)benzyl)-2,3-dimethyl-1H-indole-5-carboxylic acid instead of the 1-(4-(2-methoxy-2-oxoethoxy)benzyl)-2,3-dimethyl-1H-indole-5-carboxylic acid, followed by an ester hydrolysis step as outlined inStep 6, example 36. -
-
- To a solution of 2-bromobenzoic acid (8.08 g, 40.2 mmol), DMAP (0.492 g, 8.0 mmol) and t-BuOH (9.3 mL, 80.4 mmol) in dry DCM (300 mL) under argon, was added DCC (9.96 g, 48.2 mmol). The reaction mixture was stirred at room temperature for 20 h. The resulting mixture was filtered and the filtrate was evaporated in vacuo. The crude mixture was dissolved in AcOEt (300 mL) and washed with saturated aqueous NaHCO3 (261), brine and then dried over Na2SO4. After filtration, solvent was evaporated. The crude product was purified by flash chromatography on silica gel (AcOEt/hexane 0->30%) to obtain the title compound.
-
- To a 350 mL high-pressure vial was added tert-butyl 2-bromobenzoate (5.142 g, 20.0 mmol), p-tolylboronic acid (4.08 g, 30.0 mmol), Pd(PPh3)4 (3.47 g, 3.0 mmol), potassium carbonate (8.29 g, 60.0 mmol) and dioxane with water (4:1, 200 mL). The mixture was degassed for 5 min and sealed. The mixture was heated at 100° C. for 40 min wherein analytical HPLC analysis indicated the completion of the reaction. The mixture was filtered through Celite and MeOH was used to wash the Celite pad. The solvent was removed and the crude was purified by flash chromatography (AcOEt/Hexane 0->30%) to obtain the title compound.
-
- To a 500 mL round-bottom flask was added tert-
butyl 4′-methylbiphenyl-2-carboxylate (7.04 g, 26.23 mmol), NBS (5.14 g, 28.85 mmol), AIBN (0.43 g, 2.62 mmol) and CCl4 (200 mL). The reaction mixture was refluxed for 2 h at 100° C. The completion of the reaction was monitored by analytical HPLC. The reaction mixture was allowed to cool to room temperature and filtered. The filtrate was concentrated to obtain the crude product which was purified by flash chromatography (AcOEt/Hexane 0->30%) to obtain the title compound. -
- To a 350 mL high-pressure vial was added ethyl 4-bromobenzoate (12.92 g, 56.4 mmol), t-butyl carbazate (14.91 g, 112.8 mmol), Pd2(dba)3 (0.516 g, 0.56 mmol), dppf (0.938 g, 1.69 mmol), Cs2CO3 (18.4 g, 56.4 mmol), and dry toluene (113 mL). The reaction mixture was degassed for 5 min, sealed and heated to 100° C. for 16 h. The completion of the reaction was monitored by analytical HPLC. The reaction mixture was allowed to cool to room temperature, diluted with DCM, filtered and the filtrate was concentrated. The crude was then purified by flash chromatography (AcOEt/Hexane (0->30%) to afford the desired product. ESI-MS (m/z): 265 [M+H—NH3]+, 225 [M+H-tBu]+, 181 [M+H-Boc]+. 1H NMR (400 MHz, DMSO-d6): δ (ppm) 1.31 (t, J=7.1 Hz, 3H, CH3 ethyl), 1.50 (s, 9H, CH3 Boc), 4.28 (q, J=7.1 Hz, 2H, CH2 ethyl), 5.14 (s, 2H, NH2), 7.70 (dt, J=8.8, 2.2 Hz, 2H, H2 and H6 phenyl), 7.87 (dt, J=8.8, 2.2 Hz, 2H, H3 and H5 phenyl).
-
- A mixture of tert-butyl 1-(4-(ethoxycarbonyl)phenyl)hydrazinecarboxylate (5.27 g, 18.8 mmol), butan-2-one (2.53 mL, 28.2 mmol), and TsOH monohydrate (21.5 g, 112.8 mmol) in toluene (300 mL) was heated at 80° C. for 2 h. The reaction mixture was allowed to cool to room temperature and filtered. The filtrate was concentrated and then purified by flash chromatography (AcOEt/
Hexane 5%) to obtain the title compound. ESI-MS (m/z): 218 [M+H]+. 1H NMR (400 MHz, DMSO-d6): δ (ppm) 1.33 (t, J=7.2 Hz, 3H, CH3 ethyl), 2.18 (s, 3H, CH3), 2.32 (s, 3H, CH3), 4.29 (q, J=7.2 Hz, 2H, CH2 ethyl), 7.28 (dd, J=8.4, 0.4 Hz, 1H, H7 indole), 7.64 (dd, J=8.4, 1.6 Hz, 1H, H6 indole), 8.05 (m, 1H, H4 indole). -
- To a mixture of
ethyl 2,3-dimethyl-1H-indole-5-carboxylate (1.493 g, 6.87 mmol) in dry DMF (10 mL) at 0° C. under argon was added NaH (0.3 g, 60% dispersion in mineral oil, 7.56 mmol) in portions. The reaction mixture was stirred at rt for 30 min and then re-cooled to 0° C. Tert-butyl 4′-(bromomethyl)biphenyl-2-carboxylate (2.62 g, 7.56 mmol) in DMF (2 mL) was slowly added. The reaction mixture was stirred at rt for another 1 h. The completion of the reaction was monitored by anal. HPLC. The reaction was quenched with MeOH, and then the solvent was removed in vacuo. The crude was dissolved in AcOEt, washed with saturated aqueous NaHCO3, brine and dried over Na2SO4 and filtered. The filtrate was evaporated in vacuo to obtain the crude which was purified by flash chromatography (AcOEt/Hex 10->100%) to obtain the title compound. ESI-MS (m/z): 484 [M+H]+. -
- A mixture of ethyl 1-((2′-(tert-butoxycarbonyl)biphenyl-4-yl)methyl)-2,3-dimethyl-1H-indole-5-carboxylate (3.72 g, 7.69 mmol) and NaOH (7.7 mL, 2 N, 15.4 mmol) in EtOH (30 mL) was refluxed at 100° C. for 2 h. The completion of the reaction was monitored by anal. HPLC. The reaction mixture was cooled to rt, then acidified to pH-4 with 2 N HCl solution. The mixture was evaporated in vacuo to obtain the crude, which was precipitated from water and filtered to obtain the title compound. ESI-MS (m/z): 456 [M+H]+. 1H NMR (400 MHz, DMSO-d6): δ (ppm) 1.13 (s, 9H, CH3 tBu), 2.26 (s, 3H, CH3 indole), 2.33 (s, 3H, CH3 indole), 5.49 (s, 2H, CH2-biphenyl), 7.01 (d, J=8 Hz, 2H, H7 and H9 biphenyl), 7.19 (d, J=8 Hz, 2H, H6 and H10 biphenyl), 7.30 (d, J=7.6 Hz, 1H, H7 indole), 7.40-7.47 (m, 2H, H2 and H4 biphenyl), 7.53 (dt, J=1.2, 7.6 Hz, 1H, H3 biphenyl), 7.63-7.69 (m, 2H H6 indole and H5 biphenyl), 8.13 (d, J=1.2 Hz, 1H, H4 indole).
-
- To a mixture of 1-((2′-(tert-butoxycarbonyl)biphenyl-4-yl)methyl)-2,3-dimethyl-1H-indole-5-carboxylic acid (46 mg, 0.1 mmol) in DMF (1 mL) was added DIEA (26 mg, 0.2 mmol) and HATU (46 mg, 0.12 mmol). The mixture was stirred for 5 min, and then (S)-1-(4-bromophenyl)ethanamine (20 mg, 0.13 mmol) was added. The reaction mixture was stirred at rt for 30 min. The completion of the reaction was monitored by anal. HPLC. The solvent was removed in vacuo to obtain the crude which was purified by flash chromatography (AcOEt/Hex 10->100%) to obtain the title compound. ESI-MS (m/z): 637/639 [M+H]+.
-
- A mixture of (S)-tert-
butyl 4′-((5-(1-(4-bromophenyl)ethylcarbamoyl)-2,3-dimethyl-1H-indol-1-yl)methyl)biphenyl-2-carboxylate (20 mg, 0.03 mmol) in TFA/DCM (1 mL, 30%) was stirred at rt for 2 h. The completion of the reaction was monitored by anal. HPLC. The solvent was removed to obtain the crude which was purified by reverse phase prep-HPLC (MeOH/Acetonitrile/water) to obtain the title compound. ESI-MS (m/z): 581/583 [M+H]+. 1H NMR (400 MHz, DMSO-d6): δ (ppm) 1.48 (d, J=6.8 Hz, 3H, CH3 (4-bromophenyl)ethylcarbamoyl), 2.28 (s, 3H, CH3 indole), 2.32 (s, 3H, CH3 indole), 5.17 (quintuplet, J=7.6 Hz, 1H, CH (4-bromophenyl)ethylcarbamoyl), 5.47 (s, 2H, CH2-biphenyl), 6.99 (d, J=8 Hz, 2H, H7 and H9 biphenyl), 7.24 (d, J=8 Hz, 2H, H6 and H10 biphenyl), 7.31 (d, J=7.6 Hz, 1H, H7 indole), 7.36-7.55 (m, 7H, Hz, H3 and H4 biphenyl, H6 indole and H 4-bromophenyl), 8.10 (d, J=1.6 Hz, 1H, H4 indole), 8.65 (d, J=8 Hz, 1H, NH amide). -
-
- To a solution of 4-t-butylbenzaldehyde (753 μL) in THF (8 mL) was added (R)-2-methylpropane-2-sulfinamide (500 mg) followed by Ti(OiPr)4 (2.5 mL). The resulting solution was allowed to stir at room temperature for 18 h, and then quenched with saturated aqueous NH4Cl and diluted with EtOAc. The mixture was filtered through a pad of celite, and washed with EtOAc. The layers were separated, and the organic phase was washed with brine (2×), dried (MgSO4) and concentrated to give the imine as a light yellow oil (1.20 g) which was used without further purification.
- To a solution of the crude imine in CH2Cl2 (10 mL) at −50° C. was added MeMgBr (2.7 mL, 3.0 M in Et2O). The reaction was maintained at −50° C. for 6 h, and then allowed to warm to room temperature overnight. After 16 h, the reaction was quenched with brine and diluted with EtOAc and the layers were separated. The organic layer was washed with brine (2×), dried (MgSO4) and concentrated. The crude residue was purified by chromatography on silica gel (EtOAc/hex) to afford the title compound as a colorless solid (1.01 g). ESI-MS (m/z): 282 [MH]+
-
- To a solution of (R)—N—((S)-1-(4-(tert-butyl)phenyl)ethyl)-2-methylpropane-2-sulfinamide (977 mg) in MeOH (1.75 mL) was added conc. HCl (1.75 mL). The reaction was aged at room temperature monitoring disappearance of starting material by analytical reverse-phase HPLC. When the starting material was consumed, the reaction was concentrated in vacuo. The crude residue was resuspended in MeOH (1 mL) and crashed out of solution by the addition of Et2O. Filtration afforded the title compound as a colorless solid (559 mg). ESI-MS (m/z): 161 [M+H—NH3]+, 338 [2M+H—NH3]+.
-
- To a mixture of 1-((2′-(tert-butoxycarbonyl)biphenyl-4-yl)methyl)-2,3-dimethyl-1H-indole-5-carboxylic acid (100 mg) in DMF (2 mL) was added DIEA (116 μL) and HATU (88 mg). The mixture was stirred for 5 min, and then (S)-1-(4-(tert-butyl)phenyl)ethanaminium chloride (49 mg) was added. The reaction mixture was stirred at rt for 30 min. The completion of the reaction was monitored by anal. HPLC. The solvent was removed in vacuo to obtain the crude which was purified by flash chromatography (AcOEt/Hex 10->100%) to obtain the title compound (120 mg). ESI-MS (m/z): 559 [M+H-tBu]+, 615 [M+H]+, 637 [M+Na]+.
-
- A mixture of (S)-tert-
butyl 4′-((5-((1-(4-(tert-butyl)phenyl)ethyl)carbamoyl)-2,3-dimethyl-1H-indol-1-yl)methyl)-[1,1′-biphenyl]-2-carboxylate (120 mg) in TFA/DCM (1 mL, 30%) was stirred at rt for 2 h. The completion of the reaction was monitored by anal. HPLC. The solvent was removed to obtain the crude which was purified by reverse phase prep-HPLC (MeOH/Acetonitrile/water) to obtain the title compound (70 mg). ESI-MS (m/z): 559 [M+H]+ 1H NMR (400 MHz, DMSO-d6): δ (ppm) 1.26 (s, 9H), 1.49 (d, J=7.2 Hz, 3H), 2.28 (s, 3H), 2.32 (s, 3H), 5.19 (quintuplet, 1H), 5.47 (s, 2H), 6.99 (d, J=8.0 Hz, 2H), 7.24 (d, J=8.0 Hz, 2H), 7.29-7.39 (m, 5H), 7.39-7.49 (m, 2H), 7.53 (t, J=7.2 Hz, 1H), 7.65 (d, J=8.4 Hz, 1H), 7.69 (d, J=7.6 Hz, 1H), 8.1 (s, 1H,), 8.58 (d, J=8.0 Hz, 1H). -
-
- The title compound was prepared following the same general protocol as described in
Step 8, Example 1, using N-methyl-1-phenylmethanamine instead of (S)-1-(4-bromophenyl)ethanamine. ESI-MS (m/z): 559 [M+H]+. -
- The title compound was prepared following the same general protocol as described in Step 9, Example 1. ESI-MS (m/z): 503 [M+H]+.
-
-
- The title compound was prepared following the same general protocol as described in
Step 8, Example 1, using (3-(methylsulfonyl)phenyl)methanamine instead of (S)-1-(4-bromophenyl)ethanamine. ESI-MS (m/z): 567 [M+H]+-tert-butyl. -
- The title compound was prepared following the same general protocol as described in Step 9, Example 1. ESI-MS (m/z): 567 [M+H]+.
-
-
- The title compound was prepared following the same general protocol as described in
Step 8, Example 1, using (3-(trifluoromethoxy)phenyl)methanamine instead of (S)-1-(4-bromophenyl)ethanamine. ESI-MS (m/z): 629 [M+H]+. -
- The title compound was prepared following the same general protocol as described in Step 9, Example 1. ESI-MS (m/z): 573 [M+H]+.
-
-
- The title compound was prepared following the same general protocol as described in
Step 8, Example 1, using (R)-1-(4-bromophenyl)ethanamine instead of (S)-1-(4-bromophenyl)ethanamine. ESI-MS (m/z): 637/639 [M+H]+. -
- The title compound was prepared following the same general protocol as described in Step 9, Example 1. ESI-MS (m/z): 581/583 [M+H]+.
-
-
- The title compound was prepared following the same general protocol as described in
Step 8, Example 1, using (4-iodophenyl)methanamine instead of (S)-1-(4-bromophenyl)ethanamine. ESI-MS (m/z): 671 [M+H]+. -
- The title compound was prepared following the same general protocol as described in Step 9, Example 1. ESI-MS (m/z): 615 [M+H]+.
-
-
- The title compound was prepared following the same general protocol as described in
Step 8, Example 1, using 4-(aminomethyl)benzonitrile instead of (S)-1-(4-bromophenyl)ethanamine. ESI-MS (m/z): 514 [M+H]+-tert-butyl. -
- The title compound was prepared following the same general protocol as described in Step 9, Example 1. ESI-MS (m/z): 514 [M+H]+.
-
-
- The title compound was prepared following the same general protocol as described in
Step 8, Example 1, using (4-isopropylphenyl)methanamine instead of (S)-1-(4-bromophenyl)ethanamine. ESI-MS (m/z): 587 [M+H]+. -
- The title compound was prepared following the same general protocol as described in Step 9, Example 1. ESI-MS (m/z): 531 [M+H]+.
-
-
- The title compound was prepared following the same general protocol as described in
Step 8, Example 1, using (4-(methylsulfonyl)phenyl)methanamine instead of (S)-1-(4-bromophenyl)ethanamine. ESI-MS (m/z): 567 [M+H]+-tert-butyl. -
- The title compound was prepared following the same general protocol as described in Step 9, Example 1. ESI-MS (m/z): 567 [M+H]+.
-
-
- The title compound was prepared following the same general protocol as described in
Step 8, Example 1, using 4-(aminomethyl)-N,N-dimethylaniline instead of (S)-1-(4-bromophenyl)ethanamine. ESI-MS (m/z): 588 [M+H]+. -
- The title compound was prepared following the same general protocol as described in Step 9, Example 1. ESI-MS (m/z): 532 [M+H]+.
-
-
- The title compound was prepared following the same general protocol as described in
Step 8, Example 1, using (4-bromophenyl)methanamine instead of (S)-1-(4-bromophenyl)ethanamine. - ESI-MS (m/z): 567/569, [M+H]+-tert-butyl.
-
- The title compound was prepared following the same general protocol as described in Step 9, Example 1. ESI-MS (m/z): 567/569 [M+H]+.
-
-
- The title compound was prepared following the same general protocol as described in
Step 8, Example 1, using (4-tert-butylphenyl)methanamine instead of (S)-1-(4-bromophenyl)ethanamine. ESI-MS (m/z): 601 [M+H]+. -
- The title compound was prepared following the same general protocol as described in Step 9, Example 1. ESI-MS (m/z): 545 [M+H]+.
-
-
- The title compound was prepared following the same general protocol as described in
Step 8, Example 1, using (4-chlorophenyl)methanamine instead of (S)-1-(4-bromophenyl)ethanamine. ESI-MS (m/z): 523 [M+H]+-tert-butyl. -
- The title compound was prepared following the same general protocol as described in Step 9, Example 1. ESI-MS (m/z): 523 [M+H]+.
-
-
- The title compound was prepared following the same general protocol as described in
Step 8, Example 1, using (4-(trifluoromethoxy)phenyl)methanamine instead of (S)-1-(4-bromophenyl)ethanamine. ESI-MS (m/z): 573 [M+H]+-tert-butyl. -
- The title compound was prepared following the same general protocol as described in Step 9, Example 1. ESI-MS (m/z): 573 [M+H]+.
-
-
- The title compound was prepared following the same general protocol as described in
Step 8, Example 1, using methyl 4-(aminomethyl)benzoate instead of (S)-1-(4-bromophenyl)ethanamine. ESI-MS (m/z): 547 [M+H]+-tert-butyl. -
- The title compound was prepared following the same general protocol as described in Step 9, Example 1. ESI-MS (m/z): 547 [M+H]+.
-
-
- The title compound was prepared following the same general protocol as described in
Step 8, Example 1, using 4-(aminomethyl)benzenesulfonamide instead of (S)-1-(4-bromophenyl)ethanamine. ESI-MS (m/z): 568 [M+1-1]+-tert-butyl. -
- The title compound was prepared following the same general protocol as described in Step 9, Example 1. ESI-MS (m/z): 568 [M+H]+.
-
-
- The title compound was prepared following the same general protocol as described in
Step 8, Example 1, using (4-(methylthio)phenyl)methanamine instead of (S)-1-(4-bromophenyl)ethanamine. ESI-MS (m/z): 591 [M+H]+. -
- The title compound was prepared following the same general protocol as described in Step 9, Example 1. ESI-MS (m/z): 535 [M+H]+.
-
-
- The title compound was prepared following the same general protocol as described in
Step 8, Example 1, using (S)-1-(4-methoxyphenyl)ethanamine instead of (S)-1-(4-bromophenyl)ethanamine. ESI-MS (m/z): 589 [M+H]+. -
- To a mixture of (S)-tert-
butyl 4′-((5-(1-(4-methoxyphenyl)ethylcarbamoyl)-2,3-dimethyl-1H-indol-1-yl)methyl)biphenyl-2-carboxylate (58.9 mg, 0.1 mmol) and 2,6-lutidine (0.13 mL, 1.15 mmol) in DCM (1 mL) at 0° C. was added TESOTf (0.17 mL, 0.75 mmol). The reaction mixture was stirred at rt for 2 h. The completion of the reaction was monitored by anal. HPLC. The mixture was evaporated in vacuo to obtain the crude which was purified by prep. HPLC (MeOH/Acetonitrile/water) to obtain the title compound. ESI-MS (m/z): 533 [M+H]+. -
-
- The title compound was prepared following the same general protocol as described in
Step 8, Example 1, using (2,4-dimethoxyphenyl)methanamine instead of (S)-1-(4-bromophenyl)ethanamine. ESI-MS (m/z): 605 [M+H]+. -
- The title compound was prepared following the same general protocol as described in
Step 2, Example 19. ESI-MS (m/z): 549 [M+H]+. -
-
- The title compound was prepared following the same general protocol as described in
Step 8, Example 1, using (S)-1-(3-methoxyphenyl)ethanamine instead of (S)-1-(4-bromophenyl)ethanamine. ESI-MS (m/z): 589 [M+H]+. -
- The title compound was prepared following the same general protocol as described in
Step 2, Example 19. ESI-MS (m/z): 533 [M+H]+. -
-
- The title compound was prepared following the same general protocol as described in
Step 8, Example 1, using (3,5-dimethoxyphenyl)methanamine instead of (S)-1-(4-bromophenyl)ethanamine. ESI-MS (m/z): 605 [M+H]+. -
- The title compound was prepared following the same general protocol as described in
Step 2, Example 19. ESI-MS (m/z): 549 [M+H]+. -
-
- The title compound was prepared following the same general protocol as described in
Step 8, Example 1, using (R)-1-(4-methoxyphenyl)ethanamine instead of (S)-1-(4-bromophenyl)ethanamine. ESI-MS (m/z): 589 [M+H]+. -
- The title compound was prepared following the same general protocol as described in
Step 2, Example 19. ESI-MS (m/z): 533 [M+H]+. -
-
- The title compound was prepared following the same general protocol as described in
Step 8, Example 1, using (3,4-dimethoxyphenyl)methanamine instead of (S)-1-(4-bromophenyl)ethanamine. ESI-MS (m/z): 605 [M+H]+. -
- The title compound was prepared following the same general protocol as described in
Step 2, Example 19. ESI-MS (m/z): 549 [M+H]+. -
-
- The title compound was prepared following the same general protocol as described in
Step 8, Example 1, using 2-phenylpropan-2-amine instead of (S)-1-(4-bromophenyl)ethanamine. ESI-MS (m/z): 573 [M+H]+. -
- The title compound was prepared following the same general protocol as described in
Step 2, Example 19. ESI-MS (m/z): 517 [M+H]+. -
-
- The title compound was prepared following the same general protocol as described in
Step 8, Example 1, using (S)-1-(naphthalen-2-yl)ethanamine instead of (S)-1-(4-bromophenyl)ethanamine. ESI-MS (m/z): 609 [M+H]+. -
- The title compound was prepared following the same general protocol as described in Step 9, Example 1. ESI-MS (m/z): 553 [M+H]+.
-
-
- The title compound was prepared following the same general protocol as described in
Step 8, Example 1, using (S)-1-(4-chlorophenyl)ethanamine instead of (S)-1-(4-bromophenyl)ethanamine. ESI-MS (m/z): 537 [M+H]+-tert-butyl. -
- The title compound was prepared following the same general protocol as described in Step 9, Example 1. ESI-MS (m/z): 537 [M+H]+.
-
-
- The title compound was prepared following the same general protocol as described in
Step 8, Example 1, using (S)-1-(3-bromophenyl)ethanamine was used instead of (S)-1-(4-bromophenyl)ethanamine. ESI-MS (m/z): 659/661 [M+H]+. -
- The title compound was prepared following the same general protocol as described in Step 9, Example 1. ESI-MS (m/z): 581/583 [M+H]+.
-
-
- The title compound was prepared following the same general protocol as described in
Step 8, Example 1, using 2-amino-1-phenylethanone instead of (S)-1-(4-bromophenyl)ethanamine. ESI-MS (m/z): 573 [M+H]+. -
- The title compound was prepared following the same general protocol as described in Step 9, Example 1. ESI-MS (m/z): 517 [M+H]+.
-
-
- The title compound was prepared following the same protocol as described in
Step 2, Example 1, using 2-bromobenzonitrile instead of the tert-butyl 2-bromobenzoate. 1H NMR (400 MHz, DMSO-d6): δ (ppm) 2.38 (s, 3H, CH3), 7.34 (d, J=8 Hz, 2H, H7 and H8 biphenyl), 7.47 (d, J=8 Hz, 2H, H5 and H6 biphenyl), 7.55 (dt, J=1.2, 7.6 Hz, 1H, H4 biphenyl), 7.59 (m, 1H, H2 biphenyl), 7.77 (dt, J=1.2, 7.6 Hz, 1H, H3 biphenyl), 7.93 (m, 1H, H5 biphenyl). -
- The title compound was prepared following the same protocol as described in
Step 3, Example 1, using 4′-methyl-[1,1′-biphenyl]-2-carbonitrile instead of the tert-butyl 4′-methylbiphenyl-2-carboxylate and benzoyl peroxide instead of AIBN. 1H NMR (400 MHz, DMSO-d6): δ (ppm) 4.79 (s, 2H, CH2), 7.55-7.68 (m, 6H, Hz, H4, H5, H6, H7 and H8 biphenyl), 7.77 (t, J=7.2 Hz, 1H, H3 biphenyl), 7.93 (d, J=7.2 Hz, 1H, H5 biphenyl). -
- The title compound was prepared following the same protocol as described in
Step 6, Example 1, using 4′-(Bromomethyl)-[1,1′-biphenyl]-2-carbonitrile instead of the tert-butyl 4′-(bromomethyl)biphenyl-2-carboxylate. ESI-MS (m/z): 409 [M+H]+. -
- The title compound was prepared following the same protocol as described in
Step 7, Example 1, using ethyl 1-((2′-cyano-[1,1′-biphenyl]-4-yl)methyl)-2,3-dimethyl-1H-indole-5-carboxylate instead of the ethyl 1-((2′-(tert-butoxycarbonyl)biphenyl-4-yl)methyl)-2,3-dimethyl-1H-indole-5-carboxylate. ESI-MS (m/z): 381 [M+H]+. -
- The title compound was prepared following the same protocol as described in
Step 8, Example 1, using 1-((2′-cyano-[1,1′-biphenyl]-4-yl)methyl)-2,3-dimethyl-1H-indole-5-carboxylic acid instead of the 1-((2′-(tert-butoxycarbonyl)biphenyl-4-yl)methyl)-2,3-dimethyl-1H-indole-5-carboxylic acid, and 1-phenylpropan-1-amine instead of the (S)-1-(4-bromophenyl)ethanamine. ESI-MS (m/z): 498 [M+H]+. -
- The title compound was prepared following the same protocol as described in
Step 5, Example 34, using (S)-1-(4-bromophenyl)ethanamine instead of the 1-phenylpropan-1-amine. ESI-MS (m/z): 562/564 [M+H]+. -
- To a solution of 1-((2′-cyano-[1,1′-biphenyl]-4-yl)methyl)-2,3-dimethyl-N-(1-phenylpropyl)-1H-indole-5-carboxamide (27 mg, 0.05 mmol, 1 equiv) in toluene (0.6 mL) in a high-pressure vial were added TMSN3 (14 μL, 0.05 mmol, 2 equiv) and Bu2SnO (2 mg, 0.005 mmol, 0.1 equiv). The vial was sealed and the reaction mixture was heated at reflux for 2 h. After concentration, the residue was purified by preparative HPLC to afford a beige powder. ESI-MS (m/z): 541 [M+H]+.
-
- The title compound was prepared following the same protocol as described in Example 36, using (S)—N-(1-(4-bromophenyl)ethyl)-1-((2′-cyano-[1,1′-biphenyl]-4-yl)methyl)-2,3-dimethyl-1H-indole-5-carboxamide instead of the 1-((2′-cyano-[1,1′-biphenyl]-4-yl)methyl)-2,3-dimethyl-N-(1-phenylpropyl)-1H-indole-5-carboxamide. ESI-MS (m/z): 605/607 [M+H]+.
-
-
- To a solution of 1H-indole-5-carboxylic acid (1 g, 6.2 mmol, 1.0 equiv) in acetonitrile (40 mL) were added 1,8-Diazabicyclo[5.4.0]undec-7-ene (1.1 mL, 7.4 mmol, 1.2 equiv) and iodomethane (2.3 mL, 37.2 mmol, 6 equiv). The solution was stirred under reflux overnight. The reaction mixture was concentrated in vacuo. The residue was dissolved in AcOEt, washed with a 0.5 N HCl aqueous solution, a saturated NaHCO3 solution and brine, dried over MgSO4 and concentrated in vacuo. The obtained oil was used in the next step without further purification.
-
- To a solution of methyl 1H-indole-5-carboxylate (1.09 g, 6.2 mmol, 1 equiv) and 1-(bromomethyl)-4-bromobenzene (1.70 g, 6.82 mmol, 1.1 equiv) in anhydrous DMF (30 mL) under argon atmosphere was added sodium hydride (500 mg, 12.4 mmol, 2 equiv) in small portions. The mixture was stirred 2 h at room temperature. The reaction mixture was then neutralized by addition of methanol and concentrated in vacuo. The residue was dissolved in AcOEt, washed with brine and dried over MgSO4. The crude was purified by flash chromatography (Hexane/AcOEt 7.5/2.5) to afford the title compound as a white powder (1.09 g, 3.2 mmol, 52%). ESI-MS (m/z): 344/346 [M+H]+.
-
- To a solution of methyl 1-(4-bromobenzyl)-1H-indole-5-carboxylate (1.09 g, 3.2 mmol, 1 equiv) in methanol (30 mL) was added a 5 N NaOH solution (6.3 mL, 32 mmol, 10 equiv). The reaction mixture was stirred 2 h at 40° C. The mixture was then acidified and extracted with DCM. After concentration in vacuo, the title compound was precipitated in Et2O to afford a white powder (1.03 g, 3.1 mmol, 99%). ESI-MS (m/z): 330/332 [M+H]+.
-
- To a solution of 1-(4-bromobenzyl)-1H-indole-5-carboxylic acid (1.03 g, 3.1 mmol, 1 equiv) in DMF (30 mL) were added the (S)-1-(4-nitrophenyl)ethanamine hydrochloride (695 mg, 3.4 mmol, 1.1 equiv), DIEA (600 μL, 3.4 mmol, 1.1 equiv), HOBt (525 mg, 3.4 mmol, 1.1 equiv) and EDC (658 mg, 3.4 mmol, 1.1 equiv). After stirring 4 h at room temperature, the mixture was diluted with AcOEt and washed with a 0.5 N HCl aqueous solution, a saturated NaHCO3 solution and brine, dried over MgSO4 and concentrated in vacuo. The crude was purified by flash chromatography (Hexane/
AcOEt 1/1) to afford a yellow powder (1.3 g, 2.7 mmol, 87%). ESI-MS (m/z): 478/480 [M+H]+. -
- A high-pressure vial was filled with the (S)-1-(4-bromobenzyl)-N-(1-(4-nitrophenyl)ethyl)-1H-indole-5-carboxamide (50 mg, 0.1 mmol, 1 equiv), the phenylboronic acid (19 mg, 0.15 mmol, 1.5 equiv), K2CO3 (29 mg, 0.2 mmol, 2 equiv), Pd(PPh3)4 (12 mg, 0.01 mmol, 0.1 equiv), dioxane (1.5 mL) and water (0.3 mL). The mixture was degassed for 5 min under argon atmosphere and the vial was sealed. The reaction mixture was heated at 100° C. for 30 min under microwaves. The solution was then concentrated in vacuo, filtered and purified by preparative HPLC to afford a beige powder (50 mg, 0.1 mmol, 100%). ESI-MS (m/z): 476 [M+H]+.
-
- The title compound was prepared following the same general protocol as described in
Step 5, Example 38, using (2-methoxyphenyl)boronic acid instead of the phenylboronic acid. A yellow powder was obtained (32 mg, 0.06 mmol, 61%). ESI-MS (m/z): 506 [M+H]+. -
- The title compound was prepared following the same general protocol as described in
Step 5, Example 38, using (2-hydroxyphenyl)boronic acid instead of the phenylboronic acid. A yellow powder was obtained (39 mg, 0.08 mmol, 76%). ESI-MS (m/z): 492 [M+H]+. -
- The title compound was prepared following the same general protocol as described in
Step 5, Example 38, using (2-(methylsulfonyl)phenyl)boronic acid instead of the phenylboronic acid. A beige powder was obtained (46 mg, 0.08 mmol, 80%). ESI-MS (m/z): 554 [M+H]+. -
- The title compound was prepared following the same general protocol as described in
Step 5, Example 38, using o-tolylboronic acid instead of the phenylboronic acid. A yellow powder was obtained (35 mg, 0.07 mmol, 69%). ESI-MS (m/z): 490 [M+H]+. -
- The title compound was prepared following the same general protocol as described in
Step 5, Example 38, using (4-(ethoxycarbonyl)phenyl)boronic acid instead of the phenylboronic acid. A yellow powder was obtained (41 mg, 0.07 mmol, 72%). ESI-MS (m/z): 548 [M+H]+. -
- The title compound was prepared following the same general protocol as described in
Step 5, Example 38, using (3-methoxyphenyl)boronic acid instead of the phenylboronic acid. A yellow powder was obtained (44 mg, 0.09 mmol, 84%). ESI-MS (m/z): 506 [M+H]+. -
- The title compound was prepared following the same general protocol as described in
Step 5, Example 38, using (3-(methylsulfonyl)phenyl)boronic acid instead of the phenylboronic acid. A yellow powder was obtained (49 mg, 0.09 mmol, 85%). ESI-MS (m/z): 554 [M+H]+. -
- The title compound was prepared following the same general protocol as described in
Step 5, Example 38, using (2-chlorophenyl)boronic acid instead of the phenylboronic acid. A beige powder was obtained (39 mg, 0.08 mmol, 74%). ESI-MS (m/z): 510 [M+H]+. -
- The title compound was prepared following the same general protocol as described in
Step 5, Example 38, using (4-hydroxyphenyl)boronic acid instead of the phenylboronic acid. A yellow powder was obtained (37 mg, 0.08 mmol, 72%). ESI-MS (m/z): 492 [M+H]+. -
- The title compound was prepared following the same general protocol as described in
Step 5, Example 38, using (3-(ethoxycarbonyl)phenyl)boronic acid instead of the phenylboronic acid. A yellow powder was obtained (48 mg, 0.09 mmol, 84%). ESI-MS (m/z): 548 [M+H]+. -
- The title compound was prepared following the same general protocol as described in
Step 5, Example 38, using m-tolylboronic acid instead of the phenylboronic acid. A yellow powder was obtained (38 mg, 0.08 mmol, 75%). ESI-MS (m/z): 490 [M+H]+. -
- The title compound was prepared following the same general protocol as described in
Step 5, Example 38, using (4-(methylsulfonyl)phenyl)boronic acid instead of the phenylboronic acid. A beige powder was obtained (46 mg, 0.08 mmol, 80%). ESI-MS (m/z): 554 [M+H]+. -
- The title compound was prepared following the same general protocol as described in
Step 5, Example 38, using (4-(methylthio)phenyl)boronic acid instead of the phenylboronic acid. A yellow powder was obtained (29 mg, 0.06 mmol, 53%). ESI-MS (m/z): 522 [M+H]+. -
- The title compound was prepared following the same general protocol as described in
Step 5, Example 38, using (3-aminophenyl)boronic acid instead of the phenylboronic acid. A beige powder was obtained (40 mg, 0.08 mmol, 78%). ESI-MS (m/z): 491 [M+H]+. -
- The title compound was prepared following the same general protocol as described in
Step 5, Example 38, using (3-(aminomethyl)phenyl)boronic acid instead of the phenylboronic acid. A beige powder was obtained (47 mg, 0.09 mmol, 90%). ESI-MS (m/z): 505 [M+H]+. -
- The title compound was prepared following the same general protocol as described in
Step 5, Example 38, using (2-(hydroxymethyl)phenyl)boronic acid instead of the phenylboronic acid. A beige powder was obtained (17 mg, 0.03 mmol, 32%). ESI-MS (m/z): 506 [M+H]+. -
- The title compound was prepared following the same general protocol as described in
Step 5, Example 38, using (2-(tert-butoxycarbonyl)phenyl)boronic acid instead of the phenylboronic acid. A yellow powder was obtained (47 mg, 0.08 mmol, 79%). ESI-MS (m/z): 576 [M+H]+. -
- The title compound was prepared following the same general protocol as described in
Step 5, Example 38, using (3-(tert-butoxycarbonyl)phenyl)boronic acid instead of the phenylboronic acid. A yellow powder was obtained (43 mg, 0.07 mmol, 72%). ESI-MS (m/z): 576 [M+H]+. -
- The title compound was prepared following the same general protocol as described in
Step 5, Example 38, using p-tolylboronic acid instead of the phenylboronic acid. A beige powder was obtained (13 mg, 0.03 mmol, 26%). ESI-MS (m/z): 490 [M+H]+. -
- The title compound was prepared following the same general protocol as described in
Step 5, Example 38, using (3-chlorophenyl)boronic acid instead of the phenylboronic acid. A beige powder was obtained (18 mg, 0.04 mmol, 34%). ESI-MS (m/z): 510 [M+H]+. -
- To a solution of (S)-
ethyl 4′-((5-((1-(4-nitrophenyl)ethyl)carbamoyl)-1H-indol-1-yl)methyl)-[1,1′-biphenyl]-4-carboxylate (23 mg, 0.04 mmol, 1 equiv) in MeOH (1 mL) was added 100 μL of a 5 N NaOH solution. The mixture is stirred at room temperature overnight and then hydrolyzed by addition of a 1 N HCl solution. After concentration, the crude is purified by preparative HPLC to afford a beige powder (9 mg, 0.02 mmol, 43%). ESI-MS (m/z): 520 [M+H]+. -
- The title compound was prepared following the same general protocol as described in Example 59, using (S)-
ethyl 4′-((5-((1-(4-nitrophenyl)ethyl)carbamoyl)-1H-indol-1-yl)methyl)-[1,1′-biphenyl]-3-carboxylate instead of the (S)-ethyl 4′-((5-((1-(4-nitrophenyl)ethyl)carbamoyl)-1H-indol-1-yl)methyl)-[1,1′-biphenyl]-4-carboxylate. A beige powder was obtained (18 mg, 0.04 mmol, 34%). ESI-MS (m/z): 520 [M+H]+. -
- A solution of (S)-tert-
butyl 4′-((5-((1-(4-nitrophenyl)ethyl)carbamoyl)-1H-indol-1-yl)methyl)-[1,1′-biphenyl]-2-carboxylate (23 mg, 0.04 mmol, 1 equiv) in DCM/TFA 1/1 was stirred for 30 min at room temperature. The reaction mixture was neutralized by addition of DIEA, concentrated and purified by preparative HPLC to afford a beige powder (9 mg, 0.02 mmol, 43%). ESI-MS (m/z): 520 [M+H]+. -
- The title compound was prepared following the same general protocol as described in
Step 5, Example 38, using pyridin-3-ylboronic acid instead of the phenylboronic acid. A beige powder was obtained (34 mg, 0.07 mmol, 69%). ESI-MS (m/z): 477 [M+H]+. -
- The title compound was prepared following the same general protocol as described in
Step 5, Example 38, using pyridin-4-ylboronic acid instead of the phenylboronic acid. A beige powder was obtained (37 mg, 0.08 mmol, 75%). - ESI-MS (m/z): 477 [M+H]+
-
- A high-pressure vial was filled with the (S)-1-(4-bromobenzyl)-N-(1-(4-nitrophenyl)ethyl)-1H-indole-5-carboxamide (37 mg, 0.08 mmol, 1 equiv), 2-(tributylstannyl)pyridine (28 μL, 0.09 mmol, 1.1 equiv), LiCl (10 mg, 0.24 mmol, 3 equiv), Pd(PPh3)4 (9 mg, 0.008 mmol, 0.1 equiv), and anhydrous DMF (1 mL). The mixture was degassed for 5 min under argon atmosphere and the vial was sealed. The reaction mixture was heated at 120° C. for 1 h under microwaves. The solution was then concentrated in vacuo, filtered and purified by preparative HPLC to afford a beige powder (18 mg, 0.4 mmol, 50%). ESI-MS (m/z): 477 [M+H]+.
-
-
- The title compound is prepared following the same protocol as described in
Step 2, Example 38, using 1H-indole-5-carboxylic acid instead of the methyl 1H-indole-5-carboxylate, and 1-bromo-3-(bromomethyl)benzene instead of the 1-bromo-4-(bromomethyl)benzene. ESI-MS (m/z): 331 [M+H]+. -
- The title compound was prepared following the same protocol as described in
Step 4, Example 38, using 1-phenylpropan-1-amine instead of the (S)-1-(4-nitrophenyl)ethanamine hydrochloride, and 1-(2-Bromobenzyl)-2,3-dimethyl-1H-indole-5-carboxylic acid instead of the 1-(4-bromobenzyl)-1H-indole-5-carboxylic acid. ESI-MS (m/z): 447/449 [M+H]+. -
- The title compound was prepared following the same protocol as described in Example 55, using 1-(3-Bromobenzyl)-N-(1-phenylpropyl)-1H-indole-5-carboxamide instead of the (S)-1-(4-bromobenzyl)-N-(1-(4-nitrophenyl)ethyl)-1H-indole-5-carboxamide.
-
- The title compound was prepared following the same protocol as described in Example 61, using tert-
butyl 3′-((5-((1-phenylpropyl)carbamoyl)-1H-indol-1-yl)methyl)-[1,1′-biphenyl]-2-carboxylate instead of the (S)-tert-butyl 4′-((5-((1-(4-nitrophenyl)ethyl)carbamoyl)-1H-indol-1-yl)methyl)-[1,1′-biphenyl]-2-carboxylate. ESI-MS (m/z): 489 [M+H]+. -
-
- The title compound was prepared following the same protocol as described in Example 56, using 1-(3-Bromobenzyl)-N-(1-phenylpropyl)-1H-indole-5-carboxamide instead of the (S)-1-(4-bromobenzyl)-N-(1-(4-nitrophenyl)ethyl)-1H-indole-5-carboxamide.
-
- The title compound was prepared following the same protocol as described in Example 60, using tert-
butyl 3′-((5-((1-phenylpropyl)carbamoyl)-1H-indol-1-yl)methyl)-[1,1′-biphenyl]-3-carboxylate instead of the (S)-tert-butyl 4′-((5-((1-(4-nitrophenyl)ethyl)carbamoyl)-1H-indol-1-yl)methyl)-[1,1′-biphenyl]-3-carboxylate. ESI-MS (m/z): 489 [M+H]+. -
-
- The title compound was prepared following the same protocol as described in Example 43, using 1-(3-Bromobenzyl)-N-(1-phenylpropyl)-1H-indole-5-carboxamide instead of the (S)-1-(4-bromobenzyl)-N-(1-(4-nitrophenyl)ethyl)-1H-indole-5-carboxamide.
-
- The title compound was prepared following the same protocol as described in Example 59, using
ethyl 3′-((5-((1-phenylpropyl)carbamoyl)-1H-indol-1-yl)methyl)-[1,1′-biphenyl]-4-carboxylate instead of the (S)-ethyl 4′-((5-((1-(4-nitrophenyl)ethyl)carbamoyl)-1H-indol-1-yl)methyl)-[1,1′-biphenyl]-4-carboxylate. ESI-MS (m/z): 489 [M+H]+. -
-
- The title compound was prepared following the same protocol as described in
Step 2, Example 38, using 1H-indole-5-carboxylic acid instead of the methyl 1H-indole-5-carboxylate, and 1-bromo-2-(bromomethyl)benzene instead of the 1-bromo-4-(bromomethyl)benzene. - ESI-MS (m/z): 331 [M+H]+.
-
- The title compound was prepared following the same protocol as described in
Step 4, Example 38, using 1-phenylpropan-1-amine instead of the (S)-1-(4-nitrophenyl)ethanamine hydrochloride, and 1-(2-Bromobenzyl)-2,3-dimethyl-1H-indole-5-carboxylic acid instead of the 1-(4-bromobenzyl)-1H-indole-5-carboxylic acid. ESI-MS (m/z): 447/449 [M+H]+. -
- The title compound was prepared following the same protocol as described in Example 55, using 1-(2-Bromobenzyl)-N-(1-phenylpropyl)-1H-indole-5-carboxamide instead of the (S)-1-(4-bromobenzyl)-N-(1-(4-nitrophenyl)ethyl)-1H-indole-5-carboxamide.
-
- The title compound was prepared following the same protocol as described in Example 61, using tert-
butyl 2′-((5-((1-phenylpropyl)carbamoyl)-1H-indol-1-yl)methyl)-[1,1′-biphenyl]-2-carboxylate instead of the (S)-tert-butyl 4′-((5-((1-(4-nitrophenyl)ethyl)carbamoyl)-1H-indol-1-yl)methyl)-[1,1′-biphenyl]-2-carboxylate. ESI-MS (m/z): 489 [M+H]+. -
-
- The title compound was prepared following the same protocol as described in Example 56, using 1-(2-Bromobenzyl)-N-(1-phenylpropyl)-1H-indole-5-carboxamide instead of the (S)-1-(4-bromobenzyl)-N-(1-(4-nitrophenyl)ethyl)-1H-indole-5-carboxamide.
-
- The title compound was prepared following the same protocol as described in Example 60, using tert-
butyl 2′-((5-((1-phenylpropyl)carbamoyl)-1H-indol-1-yl)methyl)-[1,1′-biphenyl]-3-carboxylate instead of the (S)-tert-butyl 4′-((5-((1-(4-nitrophenyl)ethyl)carbamoyl)-1H-indol-1-yl)methyl)-[1,1′-biphenyl]-3-carboxylate. ESI-MS (m/z): 489 [M+H]+. -
-
- The title compound was prepared following the same protocol as described in Example 43, using 1-(2-Bromobenzyl)-N-(1-phenylpropyl)-1H-indole-5-carboxamide instead of the (S)-1-(4-bromobenzyl)-N-(1-(4-nitrophenyl)ethyl)-1H-indole-5-carboxamide.
-
- The title compound was prepared following the same protocol as described in Example 59, using
ethyl 2′-((5-((1-phenylpropyl)carbamoyl)-1H-indol-1-yl)methyl)-[1,1′-biphenyl]-4-carboxylate instead of the (S)-ethyl 4′-((5-((1-(4-nitrophenyl)ethyl)carbamoyl)-1H-indol-1-yl)methyl)-[1,1′-biphenyl]-4-carboxylate. ESI-MS (m/z): 489 [M+H]+. -
- The title compound was prepared following the same general protocol as described in Steps 8-9, Example 1, using (R)-α-methyl-4-nitrobenzylamine and 1-((2′-(tert-butoxycarbonyl)biphenyl-4-yl)methyl)-2,3-dimethyl-1H-indole-5-carboxylic acid. LC-MS 548 (M+H).
-
- The title compound was prepared following the same general protocol as described in Steps 8-9, Example 1, using (S)-α-methyl-4-nitrobenzylamine and 1-((2′-(tert-butoxycarbonyl)biphenyl-4-yl)methyl)-2,3-dimethyl-1H-indole-5-carboxylic acid. LC-MS 548 (M+H).
-
- The title compound was prepared following the same general protocol as described in Steps 8-9, Example 1, using (R)-2-phenylpropan-1-amine and 1-((2′-(tert-butoxycarbonyl)biphenyl-4-yl)methyl)-2,3-dimethyl-1H-indole-5-carboxylic acid. LC-MS 517 (M+H).
-
- The title compound was prepared following the same general protocol as described in Steps 8-9, Example 1, using diphenylmethanamine and 1-((2′-(tert-butoxycarbonyl)biphenyl-4-yl)methyl)-2,3-dimethyl-1H-indole-5-carboxylic acid. LC-MS 515 (M+H).
-
- The title compound was prepared following the same general protocol as described in Steps 8-9, Example 1, using 4-fluorobenzylamine and 1-((2′-(tert-butoxycarbonyl)biphenyl-4-yl)methyl)-2,3-dimethyl-1H-indole-5-carboxylic acid. LC-MS 507 (M+H).
-
- The title compound was prepared following the same general protocol as described in Steps 8-9, Example 1, using 3,4-fluorobenzylamine and 1-((2′-(tert-butoxycarbonyl)biphenyl-4-yl)methyl)-2,3-dimethyl-1H-indole-5-carboxylic acid. LC-MS 524 (M+H).
-
- The title compound was prepared following the same general protocol as described in Steps 8-9, Example 1, using benzo[d][1,3]dioxol-5-ylmethanamine and 1-((2′-(tert-butoxycarbonyl)biphenyl-4-yl)methyl)-2,3-dimethyl-1H-indole-5-carboxylic acid. LC-MS 533 (M+H).
-
- The title compound was prepared following the same general protocol as described in Steps 8-9, Example 1, using (R)-2-amino-2-phenylethanol and 1-((2′-(tert-butoxycarbonyl)biphenyl-4-yl)methyl)-2,3-dimethyl-1H-indole-5-carboxylic acid. LC-MS 519 (M+H).
-
- The title compound was prepared following the same general protocol as described in Steps 8-9, Example 1, using 3-aminobenzylamine and 1-((2′-(tert-butoxycarbonyl)biphenyl-4-yl)methyl)-2,3-dimethyl-1H-indole-5-carboxylic acid. LC-MS 504 (M+H).
-
- The title compound was prepared following the same general protocol as described in Steps 8-9, Example 1, using cyclohexylmethylamine and 1-((2′-(tert-butoxycarbonyl)biphenyl-4-yl)methyl)-2,3-dimethyl-1H-indole-5-carboxylic acid. LC-MS 495 (M+H).
-
- The title compound was prepared following the same general protocol as described in Steps 8-9, Example 1, using tert-butyl 3-(aminomethyl)benzylcarbamate and 1-((2′-(tert-butoxycarbonyl)biphenyl-4-yl)methyl)-2,3-dimethyl-1H-indole-5-carboxylic acid. LC-MS 518 (M+H).
-
- The title compound was prepared following the same general protocol as described in Steps 8-9, Example 1, using 2-thiophenemethylamine and 1-((2′-(tert-butoxycarbonyl)biphenyl-4-yl)methyl)-2,3-dimethyl-1H-indole-5-carboxylic acid. LC-MS 495 (M+H).
-
- The title compound was prepared following the same general protocol as described in Steps 8-9, Example 1, using 5-methyl-2-furanylmethylamine and 1-((2′-(tert-butoxycarbonyl)biphenyl-4-yl)methyl)-2,3-dimethyl-1H-indole-5-carboxylic acid. LC-MS 493 (M+H).
-
- The title compound was prepared following the same general protocol as described in Steps 8-9, Example 1, using 2-morphorinethylamine and 1-((2′-(tert-butoxycarbonyl)biphenyl-4-yl)methyl)-2,3-dimethyl-1H-indole-5-carboxylic acid. LC-MS 512 (M+H).
-
- The title compound was prepared following the same general protocol as described in Steps 8-9, Example 1, using chroman-3-amine and 1-((2′-(tert-butoxycarbonyl)biphenyl-4-yl)methyl)-2,3-dimethyl-1H-indole-5-carboxylic acid. LC-MS 531 (M+H).
-
- The title compound was prepared following the same general protocol as described in Steps 8-9, Example 1, using chroman-3-ylmethanamine and 1-((2′-(tert-butoxycarbonyl)biphenyl-4-yl)methyl)-2,3-dimethyl-1H-indole-5-carboxylic acid. LC-MS 545 (M+H).
-
- The title compound was prepared following the same general protocol as described in Steps 8-9, Example 1, using (2,3-dihydrobenzo[b][1,4]dioxin-2-yl)methanamine and 1-((2′-(tert-butoxycarbonyl)biphenyl-4-yl)methyl)-2,3-dimethyl-1H-indole-5-carboxylic acid. LC-MS 547 (M+H).
-
- The title compound was prepared following the same general protocol as described in Steps 8-9, Example 1, using cyclobutylamine and 1-((2′-(tert-butoxycarbonyl)biphenyl-4-yl)methyl)-2,3-dimethyl-1H-indole-5-carboxylic acid. LC-MS 453 (M+H).
-
- The title compound was prepared following the same general protocol as described in Steps 8-9, Example 1, using cyclopentylamine and 1-((2′-(tert-butoxycarbonyl)biphenyl-4-yl)methyl)-2,3-dimethyl-1H-indole-5-carboxylic acid. LC-MS 467 (M+H).
-
- The title compound was prepared following the same general protocol as described in Steps 8-9, Example 1, using tert-butyl 3-aminocyclohexylcarbamate and 1-((2′-(tert-butoxycarbonyl)biphenyl-4-yl)methyl)-2,3-dimethyl-1H-indole-5-carboxylic acid. LC-MS 496 (M+H).
-
- The title compound was prepared following the same general protocol as described in Steps 8-9, Example 1, using 2-methoxyethyleneamine and 1-((2′-(tert-butoxycarbonyl)biphenyl-4-yl)methyl)-2,3-dimethyl-1H-indole-5-carboxylic acid. LC-MS 457 (M+H).
-
- The title compound was prepared following the same general protocol as described in Steps 8-9, Example 1, using benzylamine and 1-((2′-(tert-butoxycarbonyl)biphenyl-4-yl)methyl)-2,3-dimethyl-1H-indole-5-carboxylic acid. LC-MS 489 (M+H).
-
- The title compound was prepared following the same general protocol as described in Steps 8-9, Example 1, using 2-aminobenzylamine and 1-((2′-(tert-butoxycarbonyl)biphenyl-4-yl)methyl)-2,3-dimethyl-1H-indole-5-carboxylic acid. LC-MS 504 (M+H).
-
- The title compound was prepared following the same general protocol as described in Steps 8-9, Example 1, using 4-aminobenzylamine and 1-((2′-(tert-butoxycarbonyl)biphenyl-4-yl)methyl)-2,3-dimethyl-1H-indole-5-carboxylic acid. LC-MS 504 (M+H).
-
- The title compound was prepared following the same general protocol as described in Steps 8-9, Example 1, using 4-nitrobenzylamine and 1-((2′-(tert-butoxycarbonyl)biphenyl-4-yl)methyl)-2,3-dimethyl-1H-indole-5-carboxylic acid. LC-MS 534 (M+H).
-
- The title compound was prepared following the same general protocol as described in Steps 8-9, Example 1, using (R)-a-ethylbenzylamine and 1-((2′-(tert-butoxycarbonyl)biphenyl-4-yl)methyl)-2,3-dimethyl-1H-indole-5-carboxylic acid. LC-MS 517 (M+H).
-
- The title compound was prepared following the same general protocol as described in Steps 8-9, Example 1, using (S)-a-ethylbenzylamine and 1-((2′-(tert-butoxycarbonyl)biphenyl-4-yl)methyl)-2,3-dimethyl-1H-indole-5-carboxylic acid. LC-MS 517 (M+H).
-
- The title compound was prepared following the same general protocol as described in Steps 8-9, Example 1, using 4-amino-(S)-a-methylbenzylamine and 1-((2′-(tert-butoxycarbonyl)biphenyl-4-yl)methyl)-2,3-dimethyl-1H-indole-5-carboxylic acid. LC-MS 518 (M+H).
-
- The title compound was prepared following the same general protocol as described in Steps 8-9, Example 1, using 3-trifluoromethylbenzylamine and 1-((2′-(tert-butoxycarbonyl)biphenyl-4-yl)methyl)-2,3-dimethyl-1H-indole-5-carboxylic acid. LC-MS 557 (M+H).
-
- The title compound was prepared following the same general protocol as described in Steps 8-9, Example 1, using 4-trifluoromethylbenzylamine and 1-((2′-(tert-butoxycarbonyl)biphenyl-4-yl)methyl)-2,3-dimethyl-1H-indole-5-carboxylic acid. LC-MS 557 (M+H).
-
- The title compound was prepared following the same general protocol as described in Steps 8-9, Example 1, using 4-phenylbenzylamine and 1-((2′-(tert-butoxycarbonyl)biphenyl-4-yl)methyl)-2,3-dimethyl-1H-indole-5-carboxylic acid. LC-MS 565 (M+H).
-
- The title compound was prepared following the same general protocol as described in Steps 8-9, Example 1, using 3-methoxylbenzylamine and 1-((2′-(tert-butoxycarbonyl)biphenyl-4-yl)methyl)-2,3-dimethyl-1H-indole-5-carboxylic acid. LC-MS 519 (M+H).
-
- The title compound was prepared following the same general protocol as described in Steps 8-9, Example 1, using 4-methoxylbenzylamine and 1-((2′-(tert-butoxycarbonyl)biphenyl-4-yl)methyl)-2,3-dimethyl-1H-indole-5-carboxylic acid. LC-MS 519 (M+H).
-
- The title compound was prepared following the same general protocol as described in Steps 8-9, Example 1, using 3-methylbenzylamine and 1-((2′-(tert-butoxycarbonyl)biphenyl-4-yl)methyl)-2,3-dimethyl-1H-indole-5-carboxylic acid. LC-MS 503 (M+H).
-
- The title compound was prepared following the same general protocol as described in Steps 8-9, Example 1, using 4-methylbenzylamine and 1-((2′-(tert-butoxycarbonyl)biphenyl-4-yl)methyl)-2,3-dimethyl-1H-indole-5-carboxylic acid. LC-MS 503 (M+H).
-
- The title compound was prepared following the same general protocol as described in Steps 8-9, Example 1, using 2-methylbenzylamine and 1-((2′-(tert-butoxycarbonyl)biphenyl-4-yl)methyl)-2,3-dimethyl-1H-indole-5-carboxylic acid. LC-MS 503 (M+H).
-
- The title compound was prepared following the same general protocol as described in Steps 8-9, Example 1, using 2-chlorobenzylamine and 1-((2′-(tert-butoxycarbonyl)biphenyl-4-yl)methyl)-2,3-dimethyl-1H-indole-5-carboxylic acid. LC-MS 523 (M+H).
-
- The title compound was prepared following the same general protocol as described in Steps 8-9, Example 1, using 3-chlorobenzylamine and 1-((2′-(tert-butoxycarbonyl)biphenyl-4-yl)methyl)-2,3-dimethyl-1H-indole-5-carboxylic acid. LC-MS 523 (M+H).
-
- The title compound was prepared following the same general protocol as described in Steps 8-9, Example 1, using 3-nitrobenzylamine and 1-((2′-(tert-butoxycarbonyl)biphenyl-4-yl)methyl)-2,3-dimethyl-1H-indole-5-carboxylic acid. LC-MS 534 (M+H).
-
- The title compound was prepared following the same general protocol as described in Steps 8-9, Example 1, using 3-fluoro-4-methoxybenzylamine and 1-((2′-(tert-butoxycarbonyl)biphenyl-4-yl)methyl)-2,3-dimethyl-1H-indole-5-carboxylic acid. LC-MS 537 (M+H).
-
- The title compound was prepared following the same general protocol as described in Steps 8-9, Example 1, using 4-fluoro-a-(S)-methylbenzylamine and 1-((2′-(tert-butoxycarbonyl)biphenyl-4-yl)methyl)-2,3-dimethyl-1H-indole-5-carboxylic acid. LC-MS 521 (M+H).
-
- The title compound was prepared following the same general protocol as described in Steps 8-9, Example 1, using 4-fluoro-a-(R)-methylbenzylamine and 1-((2′-(tert-butoxycarbonyl)biphenyl-4-yl)methyl)-2,3-dimethyl-1H-indole-5-carboxylic acid. LC-MS 521 (M+H).
-
- The title compound was prepared following the same general protocol as described in Steps 8-9, Example 1, using a-(S)-ethylbenzylamine and 1-((2′-(tert-butoxycarbonyl)biphenyl-4-yl)methyl)-2,3-dimethyl-1H-indole-5-carboxylic acid. LC-MS 531 (M+H).
-
- The title compound was prepared following the same general protocol as described in Steps 8-9, Example 1, using 1-naphthylmethylamine and 1-((2′-(tert-butoxycarbonyl)biphenyl-4-yl)methyl)-2,3-dimethyl-1H-indole-5-carboxylic acid. LC-MS 539 (M+H).
-
- The title compound was prepared following the same general protocol as described in Steps 8-9, Example 1, using 1-(naphthalen-1-yl)ethanamine and 1-((2′-(tert-butoxycarbonyl)biphenyl-4-yl)methyl)-2,3-dimethyl-1H-indole-5-carboxylic acid. LC-MS 553 (M+H).
-
- The title compound was prepared following the same general protocol as described in Steps 8-9, Example 1, using 4-phenylbutan-2-amine and 1-((2′-(tert-butoxycarbonyl)biphenyl-4-yl)methyl)-2,3-dimethyl-1H-indole-5-carboxylic acid. LC-MS 531 (M+H).
-
-
- The title compound was prepared following the same general protocol as described in
Step 8, Example 1, the (2-bromophenyl)methanamine was used instead of the (S)-1-(4-bromophenyl)ethanamine. - ESI-MS (m/z): 623/625 [M+H]+.
-
- The title compound was prepared following the same general protocol as described in Step 9, Example 1.
- ESI-MS (m/z): 567/569 [M+H]+.
-
-
- The title compound was prepared following the same general protocol as described in
Step 8, Example 1, the (2-nitrophenyl)methanamine was used instead of the (S)-1-(4-bromophenyl)ethanamine. - ESI-MS (m/z): 590 [M+H]+.
-
- The title compound was prepared following the same general protocol as described in Step 9, Example 1.
- ESI-MS (m/z): 534 [M+H]+.
-
-
- The title compound was prepared following the same protocol as described in
Step 2, Example 38, using 1H-indole-5-carboxylic acid instead of the methyl 1H-indole-5-carboxylate, and 1-bromo-2-(bromomethyl)benzene instead of the 1-bromo-4-(bromomethyl)benzene. ESI-MS (m/z): 330/332 [M+H]+. -
- The title compound was prepared following the same protocol as described in
Step 5, Example 38, using 1-(2-bromobenzyl)-1H-indole-5-carboxylic acid instead of the (S)-1-(4-bromobenzyl)-N-(1-(4-nitrophenyl)ethyl)-1H-indole-5-carboxamide and the (4-(ethoxycarbonyl)phenyl)boronic acid instead of the phenylboronic acid. ESI-MS (m/z): 400 [M+H]+. -
- The title compound was prepared following the same protocol as described in
Step 8, Example 1, using the 1-((4′-(ethoxycarbonyl)-[1,1′-biphenyl]-2-yl)methyl)-1H-indole-5-carboxylic acid instead of the 1-((2′-(tert-Butoxycarbonyl)biphenyl-4-yl)methyl)-2,3-dimethyl-1H-indole-5-carboxylic acid. -
- The title compound was prepared following the same protocol as described in Example 59, using (S)-
ethyl 2′-((5-((1-(4-bromophenyl)ethyl)carbamoyl)-1H-indol-1-yl)methyl)-[1,1′-biphenyl]-4-carboxylate instead of the (S)-ethyl 4′-((5-((1-(4-nitrophenyl)ethyl)carbamoyl)-1H-indol-1-yl)methyl)-[1,1′-biphenyl]-4-carboxylate. ESI-MS (m/z): 553/555 [M+H]+. -
-
- The title compound was prepared following the same protocol as described in
Step 8, Example 1, using the 1-((4′-(ethoxycarbonyl)-[1,1′-biphenyl]-2-yl)methyl)-1H-indole-5-carboxylic acid instead of the 1-((2′-(tert-Butoxycarbonyl)biphenyl-4-yl)methyl)-2,3-dimethyl-1H-indole-5-carboxylic acid and the (S)-1-(4-nitrophenyl)ethanamine instead of the (S)-1-(4-bromophenyl)ethanamine. -
- The title compound was prepared following the same protocol as described in Example 59, using (S)-
ethyl 2′-((5-((1-(4-nitrophenyl)ethyl)carbamoyl)-1H-indol-1-yl)methyl)-[1,1′-biphenyl]-4-carboxylate instead of the (S)-ethyl 4′-((5-((1-(4-nitrophenyl)ethyl)carbamoyl)-1H-indol-1-yl)methyl)-[1,1′-biphenyl]-4-carboxylate. ESI-MS (m/z): 520 [M+H]+. -
-
- The title compound was prepared following the same protocol as described in
Step 5, Example 38, using 1-(2-bromobenzyl)-1H-indole-5-carboxylic acid instead of the (S)-1-(4-bromobenzyl)-N-(1-(4-nitrophenyl)ethyl)-1H-indole-5-carboxamide and the (3-(ethoxycarbonyl)phenyl)boronic acid instead of the phenylboronic acid. ESI-MS (m/z): 400 [M+H]+. -
- The title compound was prepared following the same protocol as described in
Step 8, Example 1, using the 1-((3′-(ethoxycarbonyl)-[1,1′-biphenyl]-2-yl)methyl)-1H-indole-5-carboxylic acid instead of the 1-((2′-(tert-Butoxycarbonyl)biphenyl-4-yl)methyl)-2,3-dimethyl-1H-indole-5-carboxylic acid. -
- The title compound was prepared following the same protocol as described in Example 59, using (S)-
ethyl 2′-((5-((1-(4-bromophenyl)ethyl)carbamoyl)-1H-indol-1-yl)methyl)-[1,1′-biphenyl]-3-carboxylate instead of the (S)-ethyl 4′-((5-((1-(4-nitrophenyl)ethyl)carbamoyl)-1H-indol-1-yl)methyl)-[1,1′-biphenyl]-4-carboxylate. ESI-MS (m/z): 553/555 [M+H]+. -
-
- The title compound was prepared following the same protocol as described in
Step 8, Example 1, using the 1-((3′-(ethoxycarbonyl)-[1,1′-biphenyl]-2-yl)methyl)-1H-indole-5-carboxylic acid instead of the 1-((2′-(tert-Butoxycarbonyl)biphenyl-4-yl)methyl)-2,3-dimethyl-1H-indole-5-carboxylic acid and the (S)-1-(4-nitrophenyl)ethanamine instead of the (S)-1-(4-bromophenyl)ethanamine. -
- The title compound was prepared following the same protocol as described in Example 59, using (S)-
ethyl 2′-((5-((1-(4-nitrophenyl)ethyl)carbamoyl)-1H-indol-1-yl)methyl)-[1,1′-biphenyl]-3-carboxylate instead of the (S)-ethyl 4′-((5-((1-(4-nitrophenyl)ethyl)carbamoyl)-1H-indol-1-yl)methyl)-[1,1′-biphenyl]-4-carboxylate. ESI-MS (m/z): 520 [M+H]+. -
-
- The title compound was prepared following the same protocol as described in
Step 6, Example 1, using the 1-bromo-2-(bromomethyl)benzene instead of the tert-butyl 4′-(bromomethyl)biphenyl-2-carboxylate. ESI-MS (m/z): 386/388 [M+H]+. -
- The title compound was prepared following the same protocol as described in
Step 7, Example 1, using the ethyl 1-(2-bromobenzyl)-2,3-dimethyl-1H-indole-5-carboxylate instead of the ethyl 1-((2′-(tert-butoxycarbonyl)biphenyl-4-yl)methyl)-2,3-dimethyl-1H-indole-5-carboxylate. ESI-MS (m/z): 358/360 [M+H]+. -
- The title compound was prepared following the same protocol as described in
Step 5, Example 38, using 1-(2-bromobenzyl)-2,3-dimethyl-1H-indole-5-carboxylic acid instead of the (S)-1-(4-bromobenzyl)-N-(1-(4-nitrophenyl)ethyl)-1H-indole-5-carboxamide and the (3-(ethoxycarbonyl)phenyl)boronic acid instead of the phenylboronic acid. ESI-MS (m/z): 428 [M+H]+. -
- The title compound was prepared following the same protocol as described in
Step 8, Example 1, using the 1-((3′-(ethoxycarbonyl)-[1,1′-biphenyl]-2-yl)methyl)-2,3-dimethyl-1H-indole-5-carboxylic acid instead of the 1-((2′-(tert-Butoxycarbonyl)biphenyl-4-yl)methyl)-2,3-dimethyl-1H-indole-5-carboxylic acid. -
- The title compound was prepared following the same protocol as described in Example 59, using (S)-
ethyl 2′-((5-((1-(4-bromophenyl)ethyl)carbamoyl)-1H-indol-1-yl)methyl)-[1,1′-biphenyl]-3-carboxylate instead of the (S)-ethyl 4′-((5-((1-(4-nitrophenyl)ethyl)carbamoyl)-1H-indol-1-yl)methyl)-[1,1′-biphenyl]-4-carboxylate. ESI-MS (m/z): 581/583 [M+H]+. -
-
- The title compound was prepared following the same protocol as described in
Step 8, Example 1, using the 1-((3′-(ethoxycarbonyl)-[1,1′-biphenyl]-2-yl)methyl)-2,3-dimethyl-1H-indole-5-carboxylic acid instead of the 1-((2′-(tert-Butoxycarbonyl)biphenyl-4-yl)methyl)-2,3-dimethyl-1H-indole-5-carboxylic acid and the (S)-1-(4-nitrophenyl)ethanamine instead of the (S)-1-(4-bromophenyl)ethanamine. -
- The title compound was prepared following the same protocol as described in Example 59, using (S)-
ethyl 2′-((2,3-dimethyl-5-((1-(4-nitrophenyl)ethyl)carbamoyl)-1H-indol-1-yl)methyl)-[1,1′-biphenyl]-3-carboxylate instead of the (S)-ethyl 4′-((5-((1-(4-nitrophenyl)ethyl)carbamoyl)-1H-indol-1-yl)methyl)-[1,1′-biphenyl]-4-carboxylate. ESI-MS (m/z): 548 [M+H]+. -
-
- The title compound was prepared following the same protocol as described in
Step 8, Example 1, using the 1-((3′-(ethoxycarbonyl)-[1,1′-biphenyl]-2-yl)methyl)-2,3-dimethyl-1H-indole-5-carboxylic acid instead of the 1-((2′-(tert-Butoxycarbonyl)biphenyl-4-yl)methyl)-2,3-dimethyl-1H-indole-5-carboxylic acid and the 1-phenylpropan-1-amine instead of the (S)-1-(4-bromophenyl)ethanamine. -
- The title compound was prepared following the same protocol as described in Example 59, using
ethyl 2′-((2,3-dimethyl-5-((1-phenylpropyl)carbamoyl)-1H-indol-1-yl)methyl)-[1,1′-biphenyl]-3-carboxylate instead of the (S)-ethyl 4′-((5-((1-(4-nitrophenyl)ethyl)carbamoyl)-1H-indol-1-yl)methyl)-[1,1′-biphenyl]-4-carboxylate. ESI-MS (m/z): 517 [M+H]+. -
-
- The title compound was prepared following the same protocol as described in
Step 5, Example 38, using 1-(2-bromobenzyl)-2,3-dimethyl-1H-indole-5-carboxylic acid instead of the (S)-1-(4-bromobenzyl)-N-(1-(4-nitrophenyl)ethyl)-1H-indole-5-carboxamide and the (4-(ethoxycarbonyl)phenyl)boronic acid instead of the phenylboronic acid. ESI-MS (m/z): 428 [M+H]+. -
- The title compound was prepared following the same protocol as described in
Step 8, Example 1, using the 1-((4′-(ethoxycarbonyl)-[1,1′-biphenyl]-2-yl)methyl)-2,3-dimethyl-1H-indole-5-carboxylic acid instead of the 1-((2′-(tert-Butoxycarbonyl)biphenyl-4-yl)methyl)-2,3-dimethyl-1H-indole-5-carboxylic acid. -
- The title compound was prepared following the same protocol as described in Example 59, using (S)-
ethyl 2′-((5-((1-(4-bromophenyl)ethyl)carbamoyl)-1H-indol-1-yl)methyl)-[1,1′-biphenyl]-4-carboxylate instead of the (S)-ethyl 4′-((5-((1-(4-nitrophenyl)ethyl)carbamoyl)-1H-indol-1-yl)methyl)-[1,1′-biphenyl]-4-carboxylate. ESI-MS (m/z): 581/583 [M+H]+. -
-
- The title compound was prepared following the same protocol as described in
Step 8, Example 1, using the 1-((4′-(ethoxycarbonyl)-[1,1′-biphenyl]-2-yl)methyl)-2,3-dimethyl-1H-indole-5-carboxylic acid instead of the 1-((2′-(tert-Butoxycarbonyl)biphenyl-4-yl)methyl)-2,3-dimethyl-1H-indole-5-carboxylic acid and the (S)-1-(4-nitrophenyl)ethanamine instead of the (S)-1-(4-bromophenyl)ethanamine. -
- The title compound was prepared following the same protocol as described in Example 59, using (S)-
ethyl 2′-((2,3-dimethyl-5-((1-(4-nitrophenyl)ethyl)carbamoyl)-1H-indol-1-yl)methyl)-[1,1′-biphenyl]-4-carboxylate instead of the (S)-ethyl 4′-((5-((1-(4-nitrophenyl)ethyl)carbamoyl)-1H-indol-1-yl)methyl)-[1,1′-biphenyl]-4-carboxylate. ESI-MS (m/z): 548 [M+H]+. -
-
- The title compound was prepared following the same protocol as described in
Step 8, Example 1, using the 1-((4′-(ethoxycarbonyl)-[1,1′-biphenyl]-2-yl)methyl)-2,3-dimethyl-1H-indole-5-carboxylic acid instead of the 1-((2′-(tert-Butoxycarbonyl)biphenyl-4-yl)methyl)-2,3-dimethyl-1H-indole-5-carboxylic acid and the 1-phenylpropan-1-amine instead of the (S)-1-(4-bromophenyl)ethanamine. -
- The title compound was prepared following the same protocol as described in Example 59, using
ethyl 2′-((2,3-dimethyl-5-((1-phenylpropyl)carbamoyl)-1H-indol-1-yl)methyl)-[1,1′-biphenyl]-4-carboxylate instead of the (S)-ethyl 4′-((5-((1-(4-nitrophenyl)ethyl)carbamoyl)-1H-indol-1-yl)methyl)-[1,1′-biphenyl]-4-carboxylate. ESI-MS (m/z): 517 [M+H]+. -
-
- The title compound was prepared following the same protocol as described in
Step 2, Example 38, using 1H-indole-5-carboxylic acid instead of the methyl 1H-indole-5-carboxylate, and the tert-butyl 4′-(bromomethyl)biphenyl-2-carboxylate instead of the 1-bromo-4-(bromomethyl)benzene. ESI-MS (m/z): 428 [M+H]+. -
- The title compound was prepared following the same protocol as described in
Step 8, Example 1, using the 1-((2′-(tert-butoxycarbonyl)-[1,1′-biphenyl]-4-yl)methyl)-1H-indole-5-carboxylic acid instead of the 1-((2′-(tert-Butoxycarbonyl)biphenyl-4-yl)methyl)-2,3-dimethyl-1H-indole-5-carboxylic acid. -
- The title compound was prepared following the same protocol as described in Step 9, Example 1, using (S)-tert-
Butyl 4′-((5-((1-(4-bromophenyl)ethyl)carbamoyl)-1H-indol-1-yl)methyl)-[1,1′-biphenyl]-2-carboxylate instead of the (S)-tert-Butyl 4′-((5-((1-(4-bromophenyl)ethyl)carbamoyl)-2,3-dimethyl-1H-indol-1-yl)methyl)-[1,1′-biphenyl]-2-carboxylate. ESI-MS (m/z): 553/555 [M+H]+. -
-
- The title compound was prepared following the same protocol as described in
Step 8, Example 1, using the 1-((2′-(tert-butoxycarbonyl)-[1,1′-biphenyl]-4-yl)methyl)-1H-indole-5-carboxylic acid instead of the 1-((2′-(tert-Butoxycarbonyl)biphenyl-4-yl)methyl)-2,3-dimethyl-1H-indole-5-carboxylic acid and the 1-phenylpropan-1-amine instead of the (S)-1-(4-bromophenyl)ethanamine. -
- The title compound was prepared following the same protocol as described in Step 9, Example 1, using tert-
butyl 4′-((5-((1-phenylpropyl)carbamoyl)-1H-indol-1-yl)methyl)-[1,1′-biphenyl]-2-carboxylate instead of the (S)-tert-butyl 4′-((5-((1-(4-bromophenyl)ethyl)carbamoyl)-2,3-dimethyl-1H-indol-1-yl)methyl)-[1,1′-biphenyl]-2-carboxylate. ESI-MS (m/z): 489 [M+H]+. -
-
- To a solution of anhydrous DMF (12 mL) under argon at 0° C. was added POCl3 (446 μL, 4.9 mmol). The reaction mixture has been stirred at 0° C. for 5 min. The methyl 1H-indole-5-carboxylate (854 mg, 4.9 mmol) in solution in DMF was added dropwise. The resulting mixture has been heated at 120° C. for 1 h. Then, it is quenched by addition of a saturated solution of NaHCO3 (2 mL). The mixture is diluted with DCM, washed with brine, dried over MgSO4 and concentrated. The product is precipitated in hexane/diethyl ether (1/1) to yield a red powder (896 mg, 4.4 mmol, 91%). ESI-MS (m/z): 204 [M+H]+.
-
- To a solution of the methyl 3-formyl-1H-indole-5-carboxylate (893 mg, 4.4 mmol) in DMF (20 mL) was added the p-toluenesulfonic acid monohydrate (125 mg, 0.7 mmol) and the p-toluenesulfonyl hydrazide (982 mg, 5.3 mmol). The solution has been heated for 20 min at 100° C. The resulting mixture was diluted with ethyl acetate, washed with brine, dried over MgSO4 and concentrated. The crude product is dissolved in THF (40 mL) and NaBH3CN (1.1 g, 17.6 mmol) was added. The solution has been heated for 8 h at 75° C. The resulting mixture was diluted with ethyl acetate, washed with a solution of 0.5 N HCl, a saturated solution of NaHCO3 and brine, dried over MgSO4 and concentrated. The crude product was purified by flash chromatography (Hexane/AcOEt, from 0 to 30%) to yield a white powder (500 mg, 2.6 mmol, 60%). ESI-MS (m/z): 190 [M+H]+.
-
- The title compound was prepared following the same protocol as described in
Step 2, Example 38, using the methyl 3-methyl-1H-indole-5-carboxylate instead of the methyl 1H-indole-5-carboxylate, and the tert-butyl 4′-(bromomethyl)biphenyl-2-carboxylate instead of the 1-bromo-4-(bromomethyl)benzene. ESI-MS (m/z): 456 [M+H]+. -
- The title compound was prepared following the same protocol as described in
Step 3, Example 38, using the methyl 1-((2′-(tert-butoxycarbonyl)-[1,1′-biphenyl]-4-yl)methyl)-3-methyl-1H-indole-5-carboxylate instead of the methyl 1-(4-bromobenzyl)-1H-indole-5-carboxylate. ESI-MS (m/z): 442 [M+H]+. -
- The title compound was prepared following the same protocol as described in
Step 8, Example 1, using the 1-((2′-(tert-butoxycarbonyl)-[1,1′-biphenyl]-4-yl)methyl)-3-methyl-1H-indole-5-carboxylic acid instead of the 1-((2′-(tert-Butoxycarbonyl)biphenyl-4-yl)methyl)-2,3-dimethyl-1H-indole-5-carboxylic acid. -
- The title compound was prepared following the same protocol as described in Step 9, Example 1, using the (S)-tert-
Butyl 4′-((5-((1-(4-bromophenyl)ethyl)carbamoyl)-3-methyl-1H-indol-1-yl)methyl)-[1,1′-biphenyl]-2-carboxylate instead of the (S)-tert-Butyl 4′-((5-((1-(4-bromophenyl)ethyl)carbamoyl)-2,3-dimethyl-1H-indol-1-yl)methyl)-[1,1′-biphenyl]-2-carboxylate. ESI-MS (m/z): 566/568 [M+H]+. -
-
- The title compound was prepared following the same protocol as described in
Step 8, Example 1, using the 1-((2′-(tert-Butoxycarbonyl)biphenyl-4-yl)methyl)-3-methyl-1H-indole-5-carboxylic acid instead of the 1-((2′-(tert-Butoxycarbonyl)biphenyl-4-yl)methyl)-2,3-dimethyl-1H-indole-5-carboxylic acid and the 1-phenylpropan-1-amine instead of the (S)-1-(4-bromophenyl)ethanamine. -
- The title compound was prepared following the same protocol as described in Step 9, Example 1, using the tert-
Butyl 4′-((3-methyl-5-((1-phenylpropyl)carbamoyl)-1H-indol-1-yl)methyl)-[1,1′-biphenyl]-2-carboxylate instead of the (S)-tert-butyl 4′-((5-((1-(4-bromophenyl)ethyl)carbamoyl)-2,3-dimethyl-1H-indol-1-yl)methyl)-[1,1′-biphenyl]-2-carboxylate. ESI-MS (m/z): 559 [M+H]+. -
-
- The title compound was prepared following the same protocol as described in
Step 8, Example 1, using the 1-((2′-(tert-butoxycarbonyl)-[1,1′-biphenyl]-4-yl)methyl)-3-methyl-1H-indole-5-carboxylic acid instead of the 1-((2′-(tert-Butoxycarbonyl)biphenyl-4-yl)methyl)-2,3-dimethyl-1H-indole-5-carboxylic acid and the (S)-1-(4-nitrophenyl)ethanamine instead of the (S)-1-(4-bromophenyl)ethanamine. -
- The title compound was prepared following the same protocol as described in Step 9, Example 1, using the (S)-tert-
Butyl 4′-((5-((1-(4-nitrophenyl)ethyl)carbamoyl)-3-methyl-1H-indol-1-yl)methyl)-[1,1′-biphenyl]-2-carboxylate instead of the (S)-tert-Butyl 4′-((5-((1-(4-bromophenyl)ethyl)carbamoyl)-2,3-dimethyl-1H-indol-1-yl)methyl)-[1,1′-biphenyl]-2-carboxylate. ESI-MS (m/z): 533 [M+H]+. -
-
- The title compound was prepared following the same protocol as described in
Step 2, Example 38, using the methyl 2-methyl-1H-indole-5-carboxylate instead of the methyl 1H-indole-5-carboxylate, and the tert-butyl 4′-(bromomethyl)biphenyl-2-carboxylate instead of the 1-bromo-4-(bromomethyl)benzene. ESI-MS (m/z): 456 [M+H]+. -
- The title compound was prepared following the same protocol as described in
Step 3, Example 38, using the methyl 1-((2′-(tert-butoxycarbonyl)-[1,1′-biphenyl]-4-yl)methyl)-2-methyl-1H-indole-5-carboxylate instead of the methyl 1-(4-bromobenzyl)-1H-indole-5-carboxylate. ESI-MS (m/z): 442 [M+H]+. -
- The title compound was prepared following the same protocol as described in
Step 8, Example 1, using the 1-((2′-(tert-butoxycarbonyl)-[1,1′-biphenyl]-4-yl)methyl)-2-methyl-1H-indole-5-carboxylic acid instead of the 1-((2′-(tert-Butoxycarbonyl)biphenyl-4-yl)methyl)-2,3-dimethyl-1H-indole-5-carboxylic acid. -
- The title compound was prepared following the same protocol as described in Step 9, Example 1, using the (S)-tert-
Butyl 4′-((5-((1-(4-bromophenyl)ethyl)carbamoyl)-2-methyl-1H-indol-1-yl)methyl)-[1,1′-biphenyl]-2-carboxylate instead of the (S)-tert-Butyl 4′-((5-((1-(4-bromophenyl)ethyl)carbamoyl)-2,3-dimethyl-1H-indol-1-yl)methyl)-[1,1′-biphenyl]-2-carboxylate. ESI-MS (m/z): 566/568 [M+H]+. -
-
- The title compound was prepared following the same protocol as described in
Step 8, Example 1, using the 1-((2′-(tert-Butoxycarbonyl)biphenyl-4-yl)methyl)-2-methyl-1H-indole-5-carboxylic acid instead of the 1-((2′-(tert-Butoxycarbonyl)biphenyl-4-yl)methyl)-2,3-dimethyl-1H-indole-5-carboxylic acid and the 1-phenylpropan-1-amine instead of the (S)-1-(4-bromophenyl)ethanamine. -
- The title compound was prepared following the same protocol as described in Step 9, Example 1, using the tert-
Butyl 4′-((2-methyl-5-((1-phenylpropyl)carbamoyl)-1H-indol-1-yl)methyl)-[1,1′-biphenyl]-2-carboxylate instead of the (S)-tert-butyl 4′-((5-((1-((4-bromophenyl)ethyl)carbamoyl)-2,3-dimethyl-1H-indol-1-yl)methyl)-[1,1′-biphenyl]-2-carboxylate. ESI-MS (m/z): 559 [M+H]+. -
-
- A solution of (S)-tert-
butyl 4′-((5-((1-(3-bromophenyl)ethyl)carbamoyl)-2,3-dimethyl-1H-indol-1-yl)methyl)-[1,1′-biphenyl]-2-carboxylate (83 mg, 0.13 mmol, 1 equiv.), K2CO3 (36 mg, 0.26 mmol, 2 equiv.) and Pd(PPh3)4 (15 mg, 0.013 mmol, 0.1 equiv.) in dioxane/water (1.2 mL/0.3 mL) was degassed with argon. The isopropenylboronic acid pinacol ester (49 μL, 0.26 mmol, 2 equiv.) was added and the solution was heated at 100° C. for 1 h under microwave irradiation. The resulting solution was diluted with ethyl acetate, washed with a 0.5 N HCl solution, saturated aqueous NaHCO3 and brine, and then dried over Na2SO4. The obtained oil was used without further purification. ESI-MS (m/z): 599 [M+H]+. -
- A solution of (S)-tert-
butyl 4′-((2,3-dimethyl-5-((1-(3-(prop-1-en-2-yl)phenyl)ethyl)carbamoyl)-1H-indol-1-yl)methyl)-[1,1′-biphenyl]-2-carboxylate (0.13 mmol, 1 equiv.) in ethanol (5 mL) was degassed with argon. A hint of Pd/C 10% was added to the solution. The suspension was stirred at rt for 5 h under H2 bubbling. The resulting mixture was then filtered and concentrated. The obtained oil was used without further purification. ESI-MS (m/z): 601 [M+H]+. -
- The title compound was prepared following the same general protocol as described in Step 9, Example 1. ESI-MS (m/z): 545 [M+H]+.
-
-
- The title compound was prepared following the same general synthetic procedure as described in Steps 1-2, Example 2, using 3-(tert-butyl)benzaldehyde instead of 4-(tert-butyl)benzaldehyde.
- The title compound was prepared following the same general protocol as described in Step 8-9, Example 1, using (S)-1-(3-(tert-butyl)phenyl)ethanamine and 1-((2′-(tert-butoxycarbonyl)-[1,1′-biphenyl]-4-yl)methyl)-2,3-dimethyl-1H-indole-5-carboxylic acid. ESI-MS (m/z): 559 [M+H]+.
-
-
- To a solution of 3-isopropylbenzaldehyde (0.711 g, 4.75 mmol) in THF (5 mL) was added (S)-2-methyl-2-propanesulfinamide (0.534 g, 4.32 mmol) and Ti(OiPr)4 (2.75 mL, 8.64 mmol). The resulting mixture was allowed to stir over night at rt where it was then quenched with aqueous NH4Cl (5 mL) and diluted with EtOAc (100 mL). The mixture was then filtered through celite using excess EtOAc to rinse, concentrated to an oil crude and separated by silica gel (EtOAc:Hexanes) to isolate the title compound.
-
- Tetra-n-butylammonium difluorotriphenylsilicate (TBAT) (1.19 g, 2.13 mmol) and (trifluoromethyl)trimethylsilane (TMS-CF3) (0.371 mL, 2.33 mmmol) was added to a solution of (S,E)-N-(3-isopropylbenzylidene)-2-methylpropane-2-sulfinamide (0.487 g, 1.937 mmol) in anhydrous THF (16 mL) at −20° C. under argon. The reaction was allowed to proceed for ˜2 h where the starting material appeared to have been consumed as determined by analytical-HPLC. A saturated solution of NH4Cl (20 mL) was added to quench and the mixture was extracted with EtOAc (100 mL×3) and dried over Na2SO4. The organic partition was then concentrated to an oil and the title compound was isolated by flash chromatography using silica gel (EtOAc:Hexanes). ESI-MS (m/z): 321 [M+1]+.
-
- The title compound was prepared following the same general synthetic procedure as described in
Step 2, Example 2, using (S)-2-methyl-N—((R)-2,2,2-trifluoro-1-(3-isopropylphenyl)ethyl)propane-2-sulfinamide instead of 4-(tert-butyl)benzaldehyde. - The title compound was prepared following the same general protocol as described in Step 8-9, Example 1, using (R)-2,2,2-trifluoro-1-(3-isopropylphenyl)ethanamine and 1-((2′-(tert-butoxycarbonyl)-[1,1′-biphenyl]-4-yl)methyl)-2,3-dimethyl-1H-indole-5-carboxylic acid. ESI-MS (m/z): 599 [M+H]+.
-
-
- The title compound was prepared following the same general synthetic procedure as described in Steps 1-2, Example 2, using 3-isopropylbenzaldehyde and cyclopropylmagnesium bromide instead of 4-(tert-butyl)benzaldehyde and methylmagnesium bromide.
- The title compound was prepared following the same general protocol as described in Step 1-2, Example 19, using (S)-cyclopropyl(3-isopropylphenyl)methanamine and 1-((2′-(tert-butoxycarbonyl)-[1,1′-biphenyl]-4-yl)methyl)-2,3-dimethyl-1H-indole-5-carboxylic acid. ESI-MS (m/z): 571 [M+H]+.
-
-
- The title compound was prepared following the same general protocol as described in Step 1-2, Example 2, using 2,6-dichlorobenzaldehyde.
- The title compound was prepared following the same general protocol as described in Step 8-9, Example 1, using (R)-1-(2,6-dichlorophenyl)ethanamine and 1-((2′-(tert-butoxycarbonyl)-[1,1′-biphenyl]-4-yl)methyl)-2,3-dimethyl-1H-indole-5-carboxylic acid. ESI-MS (m/z): 571 [M+H]+.
-
-
- The title compound was prepared following the same general protocol as described in Step 1-2, Example 2, using 2,6-dichlorobenzaldehyde.
- The title compound was prepared following the same general protocol as described in Step 8-9, Example 1, using (S)-1-(2,6-dichlorophenyl)ethanamine and 1-((2′-(tert-butoxycarbonyl)-[1,1′-biphenyl]-4-yl)methyl)-2,3-dimethyl-1H-indole-5-carboxylic acid. ESI-MS (m/z): 571 [M+H]+.
-
-
- The title compound was prepared following the same general protocol as described in Step 1-2, Example 2, using benzo[d][1,3]dioxole-4-carbaldehyde.
- The title compound was prepared following the same general protocol as described in Step 8-9, Example 1, using (S)-1-(benzo[d][1,3]dioxol-4-yl)ethanamine and 1-((2′-(tert-butoxycarbonyl)-[1,1′-biphenyl]-4-yl)methyl)-2,3-dimethyl-1H-indole-5-carboxylic acid. ESI-MS (m/z): 547 [M+H]+.
-
-
- The title compound was prepared following the same general protocol as described in Step 1-2, Example 2, using the picolinaldehyde.
- The title compound was prepared following the same general protocol as described in Step 8-9, Example 1, using the (S)-1-(pyridin-2-yl)ethanamine and the 1-((2′-(tert-butoxycarbonyl)-[1,1′-biphenyl]-4-yl)methyl)-2,3-dimethyl-1H-indole-5-carboxylic acid. ESI-MS (m/z): 504 [M+H]+.
-
-
- The title compound was prepared following the same general synthetic procedure as described in Steps 1-2, Example 2, using 3-fluoro-2-methylbenzaldehyde instead of 4-(tert-butyl)benzaldehyde.
- The title compound was prepared following the same general protocol as described in Step 8-9, Example 1, using the (S)-1-(3-fluoro-2-methylphenyl)ethanamine and the 1-((2′-(tert-butoxycarbonyl)-[1,1′-biphenyl]-4-yl)methyl)-2,3-dimethyl-1H-indole-5-carboxylic acid. ESI-MS (m/z): 535 [M+H]+.
-
-
- The title compound was prepared following the same general synthetic procedure as described in Steps 1-2, Example 2, using 3-fluoro-5-methoxybenzaldehyde instead of 4-(tert-butyl)benzaldehyde.
- The title compound was prepared following the same general protocol as described in Step 8-9, Example 1, using the (S)-1-(3-fluoro-5-methoxyphenyl)ethanamine and the 1-((2′-(tert-butoxycarbonyl)-[1,1′-biphenyl]-4-yl)methyl)-2,3-dimethyl-1H-indole-5-carboxylic acid. ESI-MS (m/z): 551 [M+H]+.
-
-
- The title compound was prepared following the same general synthetic procedure as described in Steps 1-2, Example 2, using 3,5-dimethoxybenzaldehyde instead of 4-(tert-butyl)benzaldehyde.
- The title compound was prepared following the same general protocol as described in Step 8-9, Example 1, using the (S)-1-(3,5-dimethoxyphenyl)ethanamine and the 1-((2′-(tert-butoxycarbonyl)-[1,1′-biphenyl]-4-yl)methyl)-2,3-dimethyl-1H-indole-5-carboxylic acid. ESI-MS (m/z): 563 [M+H]+.
-
-
- The title compound was prepared following the same general protocol as described in Step 1-2, Example 2, using the 3-chloroisonicotinaldehyde.
- The title compound was prepared following the same general protocol as described in Step 8-9, Example 1, using the (S)-1-(3-chloropyridin-4-yl)ethanamine and the 1-((2′-(tert-butoxycarbonyl)-[1,1′-biphenyl]-4-yl)methyl)-2,3-dimethyl-1H-indole-5-carboxylic acid. ESI-MS (m/z): 538/539/540 [M+H]+.
-
-
- The title compound was prepared following the same general protocol as described in Step 1-2, Example 2, using the quinoline-4-carbaldehyde.
- The title compound was prepared following the same general protocol as described in Step 8-9, Example 1, using the (S)-1-(quinolin-4-yl)ethanamine and the 1-((2′-(tert-butoxycarbonyl)-[1,1′-biphenyl]-4-yl)methyl)-2,3-dimethyl-1H-indole-5-carboxylic acid. ESI-MS (m/z): 554 [M+H]+.
-
-
- The title compound was prepared following the same general synthetic procedure as described in Steps 1-2, Example 2, using 2,4-difluorobenzaldehyde instead of 4-(tert-butyl)benzaldehyde.
- The title compound was prepared following the same general protocol as described in Step 8-9, Example 1, using the (S)-1-(2,4-difluorophenyl)ethanamine and the 1-((2′-(tert-butoxycarbonyl)-[1,1′-biphenyl]-4-yl)methyl)-2,3-dimethyl-1H-indole-5-carboxylic acid. ESI-MS (m/z): 539 [M+H]+.
-
-
- The title compound was prepared following the same general protocol as described in Step 1-2, Example 2, using the 3-ethoxybenzaldehyde.
- The title compound was prepared following the same general protocol as described in Step 8-9, Example 1, using the (S)-1-(3-ethoxyphenyl)ethanamine and the 1-((2′-(tert-butoxycarbonyl)-[1,1′-biphenyl]-4-yl)methyl)-2,3-dimethyl-1H-indole-5-carboxylic acid. ESI-MS (m/z): 545 [M+H]+.
-
-
- The title compound was prepared following the same general protocol as described in Step 1-2, Example 2, using the 1-naphthaldehyde.
- The title compound was prepared following the same general protocol as described in Step 8-9, Example 1, using the (S)-1-(naphthalen-1-yl)ethanamine and the 1-((2′-(tert-butoxycarbonyl)-[1,1′-biphenyl]-4-yl)methyl)-2,3-dimethyl-1H-indole-5-carboxylic acid. ESI-MS (m/z): 553 [M+H]+.
-
-
- The title compound was prepared following the same general synthetic procedure as described in Steps 1-2, Example 2, using 4-(trifluoromethoxy)benzaldehyde instead of 4-(tert-butyl)benzaldehyde.
- The title compound was prepared following the same general protocol as described in Step 8-9, Example 1, using the (S)-1-(4-(trifluoromethoxy)phenyl)ethanamine and the 1-((T-(tert-butoxycarbonyl)-[1,1′-biphenyl]-4-yl)methyl)-2,3-dimethyl-1H-indole-5-carboxylic acid. ESI-MS (m/z): 587 [M+H]+.
-
-
- The title compound was prepared following the same general protocol as described in Step 1-2, Example 2, using the 4-trifluoromethylbenzaldehyde.
- The title compound was prepared following the same general protocol as described in Step 8-9, Example 1, using the (S)-1-(4-(trifluoromethyl)phenyl)ethanamine and the 1-((2′-(tert-butoxycarbonyl)-[1,1′-biphenyl]-4-yl)methyl)-2,3-dimethyl-1H-indole-5-carboxylic acid. ESI-MS (m/z): 571 [M+H]+.
-
-
- The title compound was prepared following the same general synthetic procedure as described in Steps 1-2, Example 2, using 3-isopropylbenzaldehyde and isobutylmagnesium chloride instead of 4-(tert-butyl)benzaldehyde and methylmagnesium bromide.
- The title compound was prepared following the same general protocol as described in Step 8-9, Example 1, using the (S)-1-(3-isopropylphenyl)-3-methylbutan-1-amine and the 1-((2′-(tert-butoxycarbonyl)-[1,1′-biphenyl]-4-yl)methyl)-2,3-dimethyl-1H-indole-5-carboxylic acid. ESI-MS (m/z): 587 [M+H]+.
-
-
- The title compound was prepared following the same general synthetic procedure as described in Steps 1-2, Example 2, using 3-isopropylbenzaldehyde and 2-propyl-magnesium chloride instead of 4-(tert-butyl)benzaldehyde and methylmagnesium bromide.
- The title compound was prepared following the same general protocol as described in Step 8-9, Example 1, using the (R)-1-(3-isopropylphenyl)-2-methylpropan-1-amine and the 1-((2′-(tert-butoxycarbonyl)-[1,1′-biphenyl]-4-yl)methyl)-2,3-dimethyl-1H-indole-5-carboxylic acid. ESI-MS (m/z): 573 [M+H]+.
-
-
- The title compound was prepared following the same general synthetic procedure as described in Steps 1-2, Example 2, using 3-isopropylbenzaldehyde and 2-propyl-magnesium chloride instead of 4-(tert-butyl)benzaldehyde and methylmagnesium bromide.
- The title compound was prepared following the same general protocol as described in Step 8-9, Example 1, using the (S)-1-(3-isopropylphenyl)-2-methylpropan-1-amine and the 1-((2′-(tert-butoxycarbonyl)-[1,1′-biphenyl]-4-yl)methyl)-2,3-dimethyl-1H-indole-5-carboxylic acid. ESI-MS (m/z): 573 [M+H]+.
-
-
- The title compound was prepared following the same general protocol as described in Step 1-2, Example 2, using the 3-fluorobenzaldehyde.
- The title compound was prepared following the same general protocol as described in Step 8-9, Example 1, using the (S)-1-(3-fluorophenyl)ethanamine and the 1-((2′-(tert-butoxycarbonyl)-[1,1′-biphenyl]-4-yl)methyl)-2,3-dimethyl-1H-indole-5-carboxylic acid. ESI-MS (m/z): 521 [M+H]+.
-
-
- The title compound was prepared following the same general protocol as described in Step 1-2, Example 2, using the 2-chlorobenzaldehyde.
- The title compound was prepared following the same general protocol as described in Step 8-9, Example 1, using the (S)-1-(2-chlorophenyl)ethanamine and the 1-((2′-(tert-butoxycarbonyl)-[1,1′-biphenyl]-4-yl)methyl)-2,3-dimethyl-1H-indole-5-carboxylic acid. ESI-MS (m/z): 537/538/539 [M+H]+.
-
-
- The title compound was prepared following the same general protocol as described in Step 1-2, Example 2, using the 2-fluorobenzaldehyde.
- The title compound was prepared following the same general protocol as described in Step 8-9, Example 1, using the (S)-1-(2-fluorophenyl)ethanamine and the 1-((2′-(tert-butoxycarbonyl)-[1,1′-biphenyl]-4-yl)methyl)-2,3-dimethyl-1H-indole-5-carboxylic acid. ESI-MS (m/z): 521 [M+H]+.
-
- The title compound was prepared following the same general protocol as described in Step 8-9, Example 1, using the (R)-1-(3-methoxyphenyl)ethanamine and the 1-((2′-(tert-butoxycarbonyl)-[1,1′-biphenyl]-4-yl)methyl)-2,3-dimethyl-1H-indole-5-carboxylic acid. ESI-MS (m/z): 533 [M+H]+.
-
- The title compound was prepared following the same general protocol as described in Step 8-9, Example 1, using the (R)-1-(3-chlorophenyl)ethanamine and the 1-((2′-(tert-butoxycarbonyl)-[1,1′-biphenyl]-4-yl)methyl)-2,3-dimethyl-1H-indole-5-carboxylic acid. ESI-MS (m/z): 537/538/539 [M+H]+.
-
- The title compound was prepared following the same general protocol as described in Step 1-2-3, Example 137, using the (S)-tert-
butyl 4′-((5-((1-(4-bromophenyl)ethyl)carbamoyl)-2,3-dimethyl-1H-indol-1-yl)methyl)-[1,1′-biphenyl]-2-carboxylate. ESI-MS (m/z): 545 [M+H]+. -
- The title compound was prepared following the same general protocol as described in Step 8-9, Example 1, using the (2,4-difluorophenyl)methanamine and the 1-((2′-(tert-butoxycarbonyl)-[1,1′-biphenyl]-4-yl)methyl)-2,3-dimethyl-1H-indole-5-carboxylic acid. ESI-MS (m/z): 525 [M+H]+.
-
- The title compound was prepared following the same general protocol as described in Step 8-9, Example 1, using the (4-chloro-2-(trifluoromethyl)phenyl)methanamine and the 1-((2′-(tert-butoxycarbonyl)-[1,1′-biphenyl]-4-yl)methyl)-2,3-dimethyl-1H-indole-5-carboxylic acid. ESI-MS (m/z): 591 [M+H]+.
-
- The title compound was prepared following the same general protocol as described in Step 1-2-3, Example 137, using the (R)-tert-
butyl 4′-((5-((1-(3-bromophenyl)ethyl)carbamoyl)-2,3-dimethyl-1H-indol-1-yl)methyl)-[1,1′-biphenyl]-2-carboxylate. ESI-MS (m/z): 545 [M+H]+. -
- The title compound was prepared following the same general protocol as described in Step 8-9, Example 1, using the (2-fluoro-4-(trifluoromethyl)phenyl)methanamine and the 1-((2′-(tert-butoxycarbonyl)-[1,1′-biphenyl]-4-yl)methyl)-2,3-dimethyl-1H-indole-5-carboxylic acid. ESI-MS (m/z): 575 [M+H]+.
-
- The title compound was prepared following the same general protocol as described in Step 8-9, Example 1, using the (2,4-dichlorophenyl)methanamine and the 1-((2′-(tert-butoxycarbonyl)-[1,1′-biphenyl]-4-yl)methyl)-2,3-dimethyl-1H-indole-5-carboxylic acid. ESI-MS (m/z): 557/559 [M+H]+.
-
-
- The title compound was prepared following the same general protocol as described in Step 1-2, Example 2, using the isonicotinaldehyde.
- The title compound was prepared following the same general protocol as described in Step 8-9, Example 1, using the (R)-1-(pyridin-4-yl)ethanamine and the 1-((2′-(tert-butoxycarbonyl)-[1,1′-biphenyl]-4-yl)methyl)-2,3-dimethyl-1H-indole-5-carboxylic acid. ESI-MS (m/z): 504 [M+H]+.
-
-
- The title compound was prepared following the same general protocol as described in Step 1-2, Example 2, using the 2-chloro-3-fluorobenzaldehyde.
- The title compound was prepared following the same general protocol as described in Step 8-9, Example 1, using the (S)-1-(2-chloro-3-fluorophenyl)ethanamine and the 1-((2′-(tert-butoxycarbonyl)-[1,1′-biphenyl]-4-yl)methyl)-2,3-dimethyl-1H-indole-5-carboxylic acid. ESI-MS (m/z): 504 [M+H]+.
-
-
- The title compound was prepared following the same general protocol as described in Step 1-2, Example 2, using the 2,3-dichlorobenzaldehyde.
- The title compound was prepared following the same general protocol as described in Step 8-9, Example 1, using the (R)-1-(2,3-dichlorophenyl)ethanamine and the 1-((2′-(tert-butoxycarbonyl)-[1,1′-biphenyl]-4-yl)methyl)-2,3-dimethyl-1H-indole-5-carboxylic acid. ESI-MS (m/z): 571 [M+H]+.
-
-
- The title compound was prepared following the same general protocol as described in Step 1-2, Example 2, using the 2,5-bis(trifluoromethyl)benzaldehyde.
- The title compound was prepared following the same general protocol as described in Step 8-9, Example 1, using the (S)-1-(2,5-bis(trifluoromethyl)phenyl)ethanamine and the 1-((2′-(tert-butoxycarbonyl)-[1,1′-biphenyl]-4-yl)methyl)-2,3-dimethyl-1H-indole-5-carboxylic acid. ESI-MS (m/z): 639 [M+H]+.
-
-
- The title compound was prepared following the same general protocol as described in Step 1-2, Example 2, using the 2,5-bis(trifluoromethyl)benzaldehyde.
- The title compound was prepared following the same general protocol as described in Step 8-9, Example 1, using the (R)-1-(2,5-bis(trifluoromethyl)phenyl)ethanamine and the 1-((2′-(tert-butoxycarbonyl)-[1,1′-biphenyl]-4-yl)methyl)-2,3-dimethyl-1H-indole-5-carboxylic acid. ESI-MS (m/z): 639 [M+H]+.
-
- The title compound was prepared following the same general protocol as described in Step 8-9, Example 1, using the (S)-1-(3-chlorophenyl)ethanamine and the 1-((2′-(tert-butoxycarbonyl)-[1,1′-biphenyl]-4-yl)methyl)-2,3-dimethyl-1H-indole-5-carboxylic acid. ESI-MS (m/z): 537/538/539 [M+H]+.
-
- The title compound was prepared following the same general protocol as described in Step 8-9, Example 1, using the (S)-1-(2-methoxyphenyl)ethanamine and the 1-((2′-(tert-butoxycarbonyl)-[1,1′-biphenyl]-4-yl)methyl)-2,3-dimethyl-1H-indole-5-carboxylic acid. ESI-MS (m/z): 533 [M+H]+.
-
-
- The title compound was prepared following the same general synthetic procedure as described in Steps 1-2, Example 2, using 3-(trifluoromethyl)benzaldehyde instead of 4-(tert-butyl)benzaldehyde.
- The title compound was prepared following the same general protocol as described in Step 8-9, Example 1, using the (S)-1-(3-(trifluoromethyl)phenyl)ethanamine and the 1-((2′-(tert-butoxycarbonyl)-[1,1′-biphenyl]-4-yl)methyl)-2,3-dimethyl-1H-indole-5-carboxylic acid. ESI-MS (m/z): 571 [M+H]+.
-
-
- The title compound was prepared following the same general protocol as described in Step 1-2, Example 2, using the 3-fluoro-2-methoxybenzaldehyde.
- The title compound was prepared following the same general protocol as described in Step 1-2, Example 2, using the (S)-1-(3-fluoro-2-methoxyphenyl)ethanamine and the 1-((2′-(tert-butoxycarbonyl)-[1,1′-biphenyl]-4-yl)methyl)-2,3-dimethyl-1H-indole-5-carboxylic acid. ESI-MS (m/z): 551 [M+H]+.
-
-
- The title compound was prepared following the same general synthetic procedure as described in Steps 1-2, Example 2, using 3-isopropylbenzaldehyde and n-butyl-magnesium bromide instead of 4-(tert-butyl)benzaldehyde and methylmagnesium bromide.
- The title compound was prepared following the same general protocol as described in Step 8-9, Example 1, using the (S)-1-(3-isopropylphenyl)pentan-1-amine and the 1-((2′-(tert-butoxycarbonyl)-[1,1′-biphenyl]-4-yl)methyl)-2,3-dimethyl-1H-indole-5-carboxylic acid. ESI-MS (m/z): 587 [M+H]+.
-
- The title compound was prepared following the same general protocol as described in Step 8-9, Example 1, using the (S)-1-(p-tolyl)ethanamine and the 1-((2′-(tert-butoxycarbonyl)-[1,1′-biphenyl]-4-yl)methyl)-2,3-dimethyl-1H-indole-5-carboxylic acid. ESI-MS (m/z): 517 [M+H]+.
-
- The title compound was prepared following the same general protocol as described in Step 8-9, Example 1, using the 2-(4-bromophenyl)propan-2-amine and the 1-((2′-(tert-butoxycarbonyl)-[1,1′-biphenyl]-4-yl)methyl)-2,3-dimethyl-1H-indole-5-carboxylic acid. ESI-MS (m/z): 595/597 [M+H]+.
-
-
- The title compound was prepared following the same general protocol as described in Step 1-2, Example 2, using the quinoline-4-carbaldehyde.
- The title compound was prepared following the same general protocol as described in Step 8-9, Example 1, using the (R)-1-(quinolin-4-yl)ethanamine and the 1-((2′-(tert-butoxycarbonyl)-[1,1′-biphenyl]-4-yl)methyl)-2,3-dimethyl-1H-indole-5-carboxylic acid. ESI-MS (m/z): 554 [M+H]+.
-
- The title compound was prepared following the same general protocol as described in Step 8-9, Example 1, using the (3-isopropylphenyl)methanamine and the 1-((2′-(tert-butoxycarbonyl)-[1,1′-biphenyl]-4-yl)methyl)-2,3-dimethyl-1H-indole-5-carboxylic acid. ESI-MS (m/z): 531 [M+H]+.
-
-
- The title compound was prepared following the same general synthetic procedure as described in Steps 1-2, Example 2, using 3-isopropylbenzaldehyde and benzylmagnesium bromide instead of 4-(tert-butyl)benzaldehyde and methylmagnesium bromide.
- The title compound was prepared following the same general protocol as described in Step 8-9, Example 1, using the (S)-1-(3-isopropylphenyl)-2-phenylethanamine and the 1-((2′-(tert-butoxycarbonyl)-[1,1′-biphenyl]-4-yl)methyl)-2,3-dimethyl-1H-indole-5-carboxylic acid. ESI-MS (m/z): 587 [M+H]+.
-
- The title compound was prepared following the same general protocol as described in
Step 5, Example 34, using the (S)-1-(4-(tert-butyl)phenyl)ethanamine instead of the 1-phenylpropan-1-amine. ESI-MS (m/z): 540 [M+H]+. -
- The title compound was prepared following the same general protocol as described in
Step 5, Example 34, using the (S)-1-(3-(tert-butyl)phenyl)ethanamine instead of the 1-phenylpropan-1-amine. ESI-MS (m/z): 540 [M+H]+. -
- The title compound was prepared following the same general protocol as described in Step 1-2-3, Example 137, using the (S)—N-(1-(4-bromophenyl)ethyl)-1-((2′-cyano-[1,1′-biphenyl]-4-yl)methyl)-2,3-dimethyl-1H-indole-5-carboxamide. ESI-MS (m/z): 526 [M+H]+.
-
-
- The title compound was prepared following the same general protocol as described in
Step 5, Example 34, using the (R)-1-(3-bromophenyl)ethanamine instead of the 1-phenylpropan-1-amine. - The title compound was prepared following the same general protocol as described in Example 36, using the (R)—N-(1-(3-bromophenyl)ethyl)-1-((2′-cyano-[1,1′-biphenyl]-4-yl)methyl)-2,3-dimethyl-1H-indole-5-carboxamide. ESI-MS (m/z): 605/607 [M+H]+.
-
-
- The title compound was prepared following the same general protocol as described in
Step 5, Example 34, using the (S)-1-(3-cyclopropylphenyl)ethanamine instead of the 1-phenylpropan-1-amine. ESI-MS (m/z): 524 [M+H]+. - The title compound was prepared following the same general protocol as described in Example 36, using the (S)-1-((2′-cyano-[1,1′-biphenyl]-4-yl)methyl)-N-(1-(3-cyclopropylphenyl)ethyl)-2,3-dimethyl-1H-indole-5-carboxamide. ESI-MS (m/z): 567 [M+H]+.
-
- The title compound was prepared following the same protocol as described in Step 3-4, Example 120 using the (S)-1-phenylpropylamine instead of the (S)-1-(4-bromophenyl)ethanamine. ESI-MS (m/z): 489 [M+H]+.
-
- The title compound was prepared following the same protocol as described in Step 3-4, Example 120 using the (R)-1-phenylpropylamine instead of the (S)-1-(4-bromophenyl)ethanamine. ESI-MS (m/z): 489 [M+H]+.
-
- The title compound was prepared following the same protocol as described in Step 3-4, Example 122 using the (S)-1-phenylpropylamine instead of the (S)-1-(4-bromophenyl)ethanamine. ESI-MS (m/z): 489 [M+H]+.
-
- The title compound was prepared following the same protocol as described in Step 2-3, Example 122 using the (R)-1-phenylpropylamine instead of the (S)-1-(4-bromophenyl)ethanamine. ESI-MS (m/z): 489 [M+H]+.
-
- The title compound was prepared following the same protocol as described in Step 4-5, Example 124 using the (R)-1-phenylpropylamine instead of the (S)-1-(4-bromophenyl)ethanamine. ESI-MS (m/z): 489 [M+H]+.
-
- The title compound was prepared following the same protocol as described in Step 4-5, Example 124 using the (S)-1-phenylpropylamine instead of the (S)-1-(4-bromophenyl)ethanamine. ESI-MS (m/z): 489 [M+H]+.
-
- The title compound was prepared following the same protocol as described in Step 2-3, Example 127 using the (R)-1-phenylpropylamine instead of the (S)-1-(4-bromophenyl)ethanamine. ESI-MS (m/z): 489 [M+H]+.
-
- The title compound was prepared following the same protocol as described in Step 2-3, Example 127 using the (S)-1-phenylpropylamine instead of the (S)-1-(4-bromophenyl)ethanamine. ESI-MS (m/z): 489 [M+H]+.
-
-
- The title compound was prepared following the same general synthetic procedure as described in Steps 1-2, Example 2, using 3-chloro-4-methoxybenzaldehyde instead of 4-(tert-butyl)benzaldehyde.
-
- The title compound was prepared following the same general synthetic procedure as described in Steps 3-4, Example 2, starting with (S)-1-(3-chloro-4-methoxyphenyl)ethanaminium chloride and 1-((2′-(tert-butoxycarbonyl)-[1,1′-biphenyl]-4-yl)methyl)-2,3-dimethyl-1H-indole-5-carboxylic acid instead of (S)-1-(4-(tert-butyl)phenyl)ethanaminium chloride and 1-((2′-(tert-butoxycarbonyl)-[1,1′-biphenyl]-4-yl)methyl)-2,3-dimethyl-1H-indole-5-carboxylic acid. ESI-MS (m/z): 567 [M+1]+.
-
-
- The title compound was prepared following the same general synthetic procedure as described in Steps 1-2, Example 2, using 3-isopropylbenzaldehyde and ethylmagnesium bromide instead of 4-(tert-butyl)benzaldehyde and methylmagnesium bromide.
-
- The title compound was prepared following the same general synthetic procedure as described in Steps 3-4, Example 2, starting with (S)-1-(3-isopropylphenyl)propan-1-aminium chloride and 1-((2′-(tert-butoxycarbonyl)-[1,1′-biphenyl]-4-yl)methyl)-2,3-dimethyl-1H-indole-5-carboxylic acid instead of (S)-1-(4-(tert-butyl)phenyl)ethanaminium chloride and 1-((2′-(tert-butoxycarbonyl)-[1,1′-biphenyl]-4-yl)methyl)-2,3-dimethyl-1H-indole-5-carboxylic acid. ESI-MS (m/z): 558 [M+1]+.
-
-
- The title compound was prepared following the same general synthetic procedure as described in Steps 1-2, Example 2, using 3-isopropoxybenzaldehyde instead of 4-(tert-butyl)benzaldehyde.
-
- The title compound was prepared following the same general synthetic procedure as described in Steps 3-4, Example 2, starting with (S)-1-(3-isopropoxyphenyl)ethanaminium chloride and 1-((2′-(tert-butoxycarbonyl)-[1,1′-biphenyl]-4-yl)methyl)-2,3-dimethyl-1H-indole-5-carboxylic acid instead of (S)-1-(4-(tert-butyl)phenyl)ethanaminium chloride and 1-((2′-(tert-butoxycarbonyl)-[1,1′-biphenyl]-4-yl)methyl)-2,3-dimethyl-1H-indole-5-carboxylic acid. ESI-MS (m/z): 560 [M+1]+.
-
-
- The title compound was prepared following the same general synthetic procedure as described in Steps 1-2, Example 2, using 4-(tert-butoxy)benzaldehyde instead of 4-(tert-butyl)benzaldehyde.
-
- The title compound was prepared following the same general synthetic procedure as described in Steps 3-4, Example 2, starting with (S)-1-(4-(tert-butoxy)phenyl)ethanaminium chloride and 1-((2′-(tert-butoxycarbonyl)-[1,1′-biphenyl]-4-yl)methyl)-2,3-dimethyl-1H-indole-5-carboxylic acid instead of (S)-1-(4-(tert-butyl)phenyl)ethanaminium chloride and 1-((2′-(tert-butoxycarbonyl)-[1,1′-biphenyl]-4-yl)methyl)-2,3-dimethyl-1H-indole-5-carboxylic acid. ESI-MS (m/z): 574 [M+1]+.
-
-
- The title compound was prepared following the same general synthetic procedure as described in Steps 1-2, Example 2, using 4-isopropoxybenzaldehyde instead of 4-(tert-butyl)benzaldehyde.
-
- The title compound was prepared following the same general synthetic procedure as described in Steps 3-4, Example 2, starting with (S)-1-(4-isopropoxyphenyl)ethanaminium chloride and 1-((2′-(tert-butoxycarbonyl)-[1,1′-biphenyl]-4-yl)methyl)-2,3-dimethyl-1H-indole-5-carboxylic acid instead of (S)-1-(4-(tert-butyl)phenyl)ethanaminium chloride and 1-((2′-(tert-butoxycarbonyl)-[1,1′-biphenyl]-4-yl)methyl)-2,3-dimethyl-1H-indole-5-carboxylic acid. ESI-MS (m/z): 560 [M+1]+.
-
-
- The title compound was prepared following the same general synthetic procedure as described in Steps 1-2, Example 2, using benzyl 4-formylpiperidine-1-carboxylate instead of 4-(tert-butyl)benzaldehyde. ESI-MS (m/z): 263 [M+1]+.
-
- The title compound was prepared following the same general synthetic procedure as described in Steps 3-4, Example 2, starting with ((S)-1-(1-((benzyloxy)carbonyl)piperidin-4-yl)ethanaminium chloride and 1-((2′-(tert-butoxycarbonyl)-[1,1′-biphenyl]-4-yl)methyl)-2,3-dimethyl-1H-indole-5-carboxylic acid instead of (S)-1-(4-(tert-butyl)phenyl)ethanaminium chloride and 1-((2′-(tert-butoxycarbonyl)-[1,1′-biphenyl]-4-yl)methyl)-2,3-dimethyl-1H-indole-5-carboxylic acid. ESI-MS (m/z): 643 [M+1]+.
-
- The title compound was prepared from (S)-4′-((5-((1-(1-((benzyloxy)carbonyl)piperidin-4-yl)ethyl)carbamoyl)-2,3-dimethyl-1H-indol-1-yl)methyl)-[1,1′-biphenyl]-2-carboxylic-acid (0.175 g, 0.250 mmol) following palladium catalyzed hydrogenation (18 mg, 10% Pd/c) in AcOH (5 mL) and subsequent coupling of the resulting piperidine ((S)-tert-butyl-4′-((2,3-dimethyl-5-((1-(piperidin-4-yl)ethyl)carbamoyl)-1H-indol-1-yl)methyl)-[1,1′-biphenyl]-2-carboxylate) with benzyl isocyanate (6.8 mg, 0.049 mmol) in dicholoromethane (DCM) (1 mL)/di-isopropylethylamine (9.2 μL, 0.053 mmol) and then removal of t-butyl ester in TFA/DCM (1:1, 2 mL). Completion at each synthetic step was monitored by analytical HPLC and the title compound was isolated by reverse phase prep-HPLC (MeOH/Acetonitrile/water) ESI-MS (m/z): 642 [M+1]+.
-
- The title compound was prepared following the same general synthetic procedure as described in Steps 3-4, Example 2, starting with (S)-benzyl 3-aminopyrrolidine-1-carboxylate and 1-((2′-(tert-butoxycarbonyl)-[1,1′-biphenyl]-4-yl)methyl)-2,3-dimethyl-1H-indole-5-carboxylic acid instead of (S)-1-(4-(tert-butyl)phenyl)ethanaminium chloride and 1-((2′-(tert-butoxycarbonyl)-[1,1′-biphenyl]-4-yl)methyl)-2,3-dimethyl-1H-indole-5-carboxylic acid. ESI-MS (m/z): 601 [M+1]+.
-
- The title compound was prepared following the same general protocol as described in Steps 1-4, Example 1, using 5-fluoro-2-methoxybenzaldehyde and 1-((2′-(tert-butoxycarbonyl)biphenyl-4-yl)methyl)-2,3-dimethyl-1H-indole-5-carboxylic acid. LC-MS 551.2 (M+H).
-
- The title compound was prepared following the same general protocol as described in Steps 1-4, Example 1, using 5-fluoro-2-methoxybenzaldehyde and 1-((2′-(tert-butoxycarbonyl)biphenyl-4-yl)methyl)-2,3-dimethyl-1H-indole-5-carboxylic acid. LC-MS 551.2 (M+H).
-
- The title compound was prepared following the same general protocol as described in Steps 1-4, Example 1, using 2-trifluoromethylbenzaldehyde and 1-((2′-(tert-butoxycarbonyl)biphenyl-4-yl)methyl)-2,3-dimethyl-1H-indole-5-carboxylic acid. LC-MS 571.2 (M+H).
-
- The title compound was prepared following the same general protocol as described in Steps 1-4, Example 1, using 2-trifluoromethylbenzaldehyde and 1-((2′-(tert-butoxycarbonyl)biphenyl-4-yl)methyl)-2,3-dimethyl-1H-indole-5-carboxylic acid. LC-MS 571.6 (M+H).
-
- The title compound was prepared following the same general protocol as described in Steps 1-4, Example 1, using 2,4-bistrifluoromethylbenzaldehyde and 1-((2′-(tert-butoxycarbonyl)biphenyl-4-yl)methyl)-2,3-dimethyl-1H-indole-5-carboxylic acid. LC-MS 639.2 (M+H).
-
- The title compound was prepared following the same general protocol as described in Steps 1-4, Example 1, using 2,4-bistrifluoromethylbenzaldehyde and 1-((2′-(tert-butoxycarbonyl)biphenyl-4-yl)methyl)-2,3-dimethyl-1H-indole-5-carboxylic acid. LC-MS 639.2 (M+-H).
-
- The title compound was prepared following the same general protocol as described in Steps 1-4, Example 1, using 2-fluoro-5-methylbenzaldehyde and 1-((2′-(tert-butoxycarbonyl)biphenyl-4-yl)methyl)-2,3-dimethyl-1H-indole-5-carboxylic acid. LC-MS 535.2 (M+H).
-
- The title compound was prepared following the same general protocol as described in Steps 1-4, Example 1, using cyclohexanecarboxaldehyde and 1-((2′-(tert-butoxycarbonyl)biphenyl-4-yl)methyl)-2,3-dimethyl-1H-indole-5-carboxylic acid. LC-MS 509.2 (M+H).
-
- The title compound was prepared following the same general protocol as described in Steps 1-4, Example 1, using 2,3-dihydrobenzo[b][1,4]dioxine-2-carbaldehyde and 1-((2′-(tert-butoxycarbonyl)biphenyl-4-yl)methyl)-2,3-dimethyl-1H-indole-5-carboxylic acid. LC-MS 561.2 (M+H).
-
- The title compound was prepared following the same general protocol as described in Steps 1-4, Example 1, using 2,3-dihydrobenzo[b][1,4]dioxine-2-carbaldehyde and 1-((2′-(tert-butoxycarbonyl)biphenyl-4-yl)methyl)-2,3-dimethyl-1H-indole-5-carboxylic acid. LC-MS 561.2 (M+H).
-
- The title compound was prepared following the same general protocol as described in Steps 1-4, Example 1, using 3,5-difluoroisonicotinaldehyde and 1-((2′-(tert-butoxycarbonyl)biphenyl-4-yl)methyl)-2,3-dimethyl-1H-indole-5-carboxylic acid. LC-MS 540.2 (M+H).
-
- The title compound was prepared following the same general protocol as described in Steps 1-4, Example 1, using 3,5-difluoroisonicotinaldehyde and 1-((2′-(tert-butoxycarbonyl)biphenyl-4-yl)methyl)-2,3-dimethyl-1H-indole-5-carboxylic acid. LC-MS 540.2 (M+H).
-
- The title compound was prepared following the same general protocol as described in Steps 1-4, Example 1, using 6-(trifluoromethyl)nicotinaldehyde and 1-((2′-(tert-butoxycarbonyl)biphenyl-4-yl)methyl)-2,3-dimethyl-1H-indole-5-carboxylic acid. LC-MS 572.2 (M+H).
-
- The title compound was prepared following the same general protocol as described in Steps 1-4, Example 1, using 2,3-dihydrobenzofuran-5-carbaldehyde and 1-((2′-(tert-butoxycarbonyl)biphenyl-4-yl)methyl)-2,3-dimethyl-1H-indole-5-carboxylic acid. LC-MS 545.2 (M+H).
-
- The title compound was prepared following the same general protocol as described in Steps 1-4, Example 1, using 2,4-dichlorobenzaldehyde and 1-((2′-(tert-butoxycarbonyl)biphenyl-4-yl)methyl)-2,3-dimethyl-1H-indole-5-carboxylic acid. LC-MS 571.1 (M+H).
-
- The title compound was prepared following the same general protocol as described in Steps 1-4, Example 1, using 3,4-dichlorobenzaldehyde and 1-((2′-(tert-butoxycarbonyl)biphenyl-4-yl)methyl)-2,3-dimethyl-1H-indole-5-carboxylic acid. LC-MS 571.1 (M+).
-
- The title compound was prepared following the same general protocol as described in Steps 1-4, Example 1, using 2-fluoro-5-trifluoromethylbenzaldehyde and 1-((2′-(tert-butoxycarbonyl)biphenyl-4-yl)methyl)-2,3-dimethyl-1H-indole-5-carboxylic acid. LC-MS 589.1 (M+H).
-
- The title compound was prepared following the same general protocol as described in Steps 1-4, Example 1, using 3-trifluoromethyl-4-chlorobenzaldehyde and 1-((2′-(tert-butoxycarbonyl)biphenyl-4-yl)methyl)-2,3-dimethyl-1H-indole-5-carboxylic acid. LC-MS 606.1 (M+H).
-
- The title compound was prepared following the same general protocol as described in Steps 1-4, Example 1, using 2-methoxy-4-trifluoromethylbenzaldehyde and 1-((2′-(tert-butoxycarbonyl)biphenyl-4-yl)methyl)-2,3-dimethyl-1H-indole-5-carboxylic acid. LC-MS 601.2 (M+H).
-
- The title compound was prepared following the same general protocol as described in Steps 1-4, Example 1, using 2-methoxy-4-trifluoromethylbenzaldehyde and 1-((2′-(tert-butoxycarbonyl)biphenyl-4-yl)methyl)-2,3-dimethyl-1H-indole-5-carboxylic acid. LC-MS 601.2 (M+H).
-
- The title compound was prepared following the same general protocol as described in Steps 1-4, Example 1, using 4-ethylbenzaldehyde and 1-((2′-(tert-butoxycarbonyl)biphenyl-4-yl)methyl)-2,3-dimethyl-1H-indole-5-carboxylic acid. LC-MS 531.2 (M+H).
-
- The title compound was prepared following the same general protocol as described in Step 8-9, Example 1, using the (S)-1-(4-chloro-2-methylphenyl)ethanamine hydrochloride and the 1-((2′-(tert-butoxycarbonyl)-[1,1′-biphenyl]-4-yl)methyl)-2,3-dimethyl-1H-indole-5-carboxylic acid. ESI-MS (m/z): 551 [M+H]+.
-
- The title compound was prepared following the same general protocol as described in Step 8-9, Example 1, using the (S)-1-(4-fluoro-2-(trifluoromethyl)phenyl)ethanamine hydrochloride and the 1-((2′-(tert-butoxycarbonyl)-[1,1′-biphenyl]-4-yl)methyl)-2,3-dimethyl-1H-indole-5-carboxylic acid. ESI-MS (m/z): 589 [M+H]+.
-
- The title compound was prepared following the same general protocol as described in Step 8-9, Example 1, using the (S)-1-(3-fluoro-4-(trifluoromethyl)phenyl)ethanamine hydrochloride and the 1-((2′-(tert-butoxycarbonyl)-[1,1′-biphenyl]-4-yl)methyl)-2,3-dimethyl-1H-indole-5-carboxylic acid. ESI-MS (m/z): 589 [M+H]+.
-
- The title compound was prepared following the same general protocol as described in Step 8-9, Example 1, using the (S)-1-(2,3-difluorophenyl)ethanamine hydrochloride and the 1-((2′-(tert-butoxycarbonyl)-[1,1′-biphenyl]-4-yl)methyl)-2,3-dimethyl-1H-indole-5-carboxylic acid. ESI-MS (m/z): 539 [M+H]+.
-
- The title compound was prepared following the same general protocol as described in Step 8-9, Example 1, using the (S)-1-(2-chloro-3-(trifluoromethyl)phenyl)ethanamine hydrochloride and the 1-((2′-(tert-butoxycarbonyl)-[1,1′-biphenyl]-4-yl)methyl)-2,3-dimethyl-1H-indole-5-carboxylic acid. ESI-MS (m/z): 605 [M+H]+.
-
- The title compound was prepared following the same general protocol as described in Step 8-9, Example 1, using the (R)-1-(2-chloro-3-(trifluoromethyl)phenyl)ethanamine hydrochloride and the 1-((2′-(tert-butoxycarbonyl)-[1,1′-biphenyl]-4-yl)methyl)-2,3-dimethyl-1H-indole-5-carboxylic acid. ESI-MS (m/z): 605 [M+H]+.
-
- The title compound was prepared following the same general protocol as described in Step 8-9, Example 1, using (S)-1-(3-chloro-2-fluorophenyl)ethanamine hydrochloride and the 1-((2′-(tert-butoxycarbonyl)-[1,1′-biphenyl]-4-yl)methyl)-2,3-dimethyl-1H-indole-5-carboxylic acid. ESI-MS (m/z): 555 [M+H]+.
-
- The title compound was prepared following the same general protocol as described in Step 8-9, Example 1, using the (S)-1-(3,4-difluorophenyl)ethanamine hydrochloride and the 1-((2′-(tert-butoxycarbonyl)-[1,1′-biphenyl]-4-yl)methyl)-2,3-dimethyl-1H-indole-5-carboxylic acid. ESI-MS (m/z): 539 [M+H]+.
-
- The title compound was prepared following the same general protocol as described in Step 8-9, Example 1, using the (R)-1-(3-fluoro-4-(trifluoromethyl)phenyl)ethanamine hydrochloride and the 1-((2′-(tert-butoxycarbonyl)-[1,1′-biphenyl]-4-yl)methyl)-2,3-dimethyl-1H-indole-5-carboxylic acid. ESI-MS (m/z): 589 [M+H]+.
-
- The title compound was prepared following the same general protocol as described in Step 8-9, Example 1, using the (R)-1-(2,3,6-trifluorophenyl)ethanamine hydrochloride and the 1-((2′-(tert-butoxycarbonyl)-[1,1′-biphenyl]-4-yl)methyl)-2,3-dimethyl-1H-indole-5-carboxylic acid. ESI-MS (m/z): 557 [M+H]+.
-
- The title compound was prepared following the same general protocol as described in Step 8-9, Example 1, using the (S)-1-(2,3,6-trifluorophenyl)ethanamine hydrochloride and the 1-((2′-(tert-butoxycarbonyl)-[1,1′-biphenyl]-4-yl)methyl)-2,3-dimethyl-1H-indole-5-carboxylic acid. ESI-MS (m/z): 557 [M+H]+.
-
- The title compound was prepared following the same general protocol as described in Step 8-9, Example 1, using the (S)-benzyl 2-((S)-1-aminoethyl)pyrrolidine-1-carboxylate hydrochloride and the 1-((2′-(tert-butoxycarbonyl)-[1,1′-biphenyl]-4-yl)methyl)-2,3-dimethyl-1H-indole-5-carboxylic acid. ESI-MS (m/z): 630 [M+H]+.
-
- The title compound was prepared following the same general protocol as described in Step 8-9, Example 1, using the (R)-benzyl 2-((S)-1-aminoethyl)pyrrolidine-1-carboxylate hydrochloride and the 1-((2′-(tert-butoxycarbonyl)-[1,1′-biphenyl]-4-yl)methyl)-2,3-dimethyl-1H-indole-5-carboxylic acid. ESI-MS (m/z): 630 [M+H]+.
-
- The title compound was prepared following the same general protocol as described in Step 8-9, Example 1, using the (R)-1-(5-fluoro-2-(trifluoromethyl)phenyl)ethanamine hydrochloride and the 1-((2′-(tert-butoxycarbonyl)-[1,1′-biphenyl]-4-yl)methyl)-2,3-dimethyl-1H-indole-5-carboxylic acid. ESI-MS (m/z): 589 [M+H]+.
-
- The title compound was prepared following the same general protocol as described in Step 8-9, Example 1, using the (R)-benzyl 3-((S)-1-aminoethyl)pyrrolidine-1-carboxylate hydrochloride and the 1-((2′-(tert-butoxycarbonyl)-[1,1′-biphenyl]-4-yl)methyl)-2,3-dimethyl-1H-indole-5-carboxylic acid. ESI-MS (m/z): 630 [M+H]+.
-
- The title compound was prepared following the same general protocol as described in Step 8-9, Example 1, using the (S)-1-(5-fluoro-2-(trifluoromethyl)phenyl)ethanamine hydrochloride and the 1-((2′-(tert-butoxycarbonyl)-[1,1′-biphenyl]-4-yl)methyl)-2,3-dimethyl-1H-indole-5-carboxylic acid. ESI-MS (m/z): 589 [M+H]+.
-
- The title compound was prepared following the same general protocol as described in Step 8-9, Example 1, using the (S)-1-(5-fluoro-2-(trifluoromethyl)phenyl)ethanamine hydrochloride and the 4′-(bromomethyl)-[1,1′-biphenyl]-2-carbonitrile. ESI-MS (m/z): 526 [M+H]+.
-
- The mixture of (S)-1-((2′-cyano-[1,1′-biphenyl]-4-yl)methyl)-N-(1-(3-isopropylphenyl)ethyl)-2,3-dimethyl-1H-indole-5-carboxamide (0.1 g, 0.19 mmol), azidotrimethylsilane 90.05 mL, 0.38 mmol) and dibutylstannanone (0.005 g, 0.019 mmol) in toluene (3 mL) was heated at 110° C. oil bath for 16 hr. The solvent was removed and the residue was purified by preparative-HPLC to obtain the title compound. ESI-MS (m/z): 569 [M+H]+.
-
- A mixture of hydroxylammoium chloride (0.2 g, 2.88 mmol), sodium hydrogen carbonate (0.3 g, 3.57 mmol) and dimethyl sulfoxide (2 mL) was stirred at 40° C. for 30 min. (S)-1-((2′-cyano-[1,1′-biphenyl]-4-yl)methyl)-N-(1-(3-isopropylphenyl)ethyl)-2,3-dimethyl-1H-indole-5-carboxamide (0.1 g, 0.19 mmol) was added, and the mixture was stirred at 90° C. for 16 hr. The reaction mixture was diluted with ethyl acetate, washed with water and then with brine, and dried over anhydrous sodium sulfate. Thvent was evaporated under reduced pressure, and the residue was dissolved in THF (3 mL), N, N′-carbonyldiimidazole (0.055 g, 0.29 mmol) and then 1,8-diazabicyclo[5,4,0] undec-7-ene (0.05 mL, 0.29 mmol) were added, and the mixture was stirred at room temperature for 2 hr. The reaction mixture was diluted with ethyl acetate, washed with saturated aqueous potassium hydrogensulfate solution and then with brine, and dried over anhydrous sodium sulfate. The solvent was evaporated under reduced pressure, and the residue was purified by preparative-HPLC to obtain the title compound. ESI-MS (m/z): 585 [M+H]+.
-
-
- To the mixture of (S)-4′-((5-((1-(3-isopropylphenyl)ethyl)carbamoyl)-2,3-dimethyl-1H-indol-1-yl)methyl)-[1,1′-biphenyl]-2-carboxylic acid (0.11 g, 0.201 mmol), hydrazine hydrochloride (0.028 g, 0.402 mmol) and HATU (0.092 g, 0.24 mmol) in DCM (2 mL) was added DIEA (0.14 mL, 0.8 mmol). The mixture was stirred at room temperature for 16 h. The solvent was removed and the residue was purified by silica gel to obtain the title compound. ESI-MS (m/z): 559 [M+H]+.
- The mixture of (S)-1-((2′-(hydrazinecarbonyl)-[1,1′-biphenyl]-4-yl)methyl)-N-(1-(3-isopropylphenyl)ethyl)-2,3-dimethyl-1H-indole-5-carboxamide (0.062 g, 0.11 mmol), N,N′-carbonyldiimidazole (0.027 g, 0.16 mmol) and DIEA (0.03 mL, 0.16 mmol) in DMF was stirred at room temperature for 1 h, and then stirred at 50° C. for 1 h. The reaction mixture was poured on to ice-water, and then extracted with ethyl acetate. The combined organic layers were washed with water and brine. Th solvent was remove and the residue was purified with preparative-HPLC to obtain the title compound. ESI-MS (m/z): 585 [M+H]+.
-
-
- The title compound was prepared following the same general protocol as described in
Step 6, Example 1, using theethyl 2,3-dimethyl-1H-indole-5-carboxylate and 4′-(bromomethyl)-N-(tert-butyl)-[1,1′-biphenyl]-2-sulfonamide. ESI-MS (m/z): 519 [M+H]+. -
- The title compound was prepared following the same general protocol as described in
Step 7, Example 1, using the ethyl 1-((2′-(N-(tert-butyl)sulfamoyl)-[1,1′-biphenyl]-4-yl)methyl)-2,3-dimethyl-1H-indole-5-carboxylate. ESI-MS (m/z): 491 [M+H]+. - The title compound was prepared following the same general protocol as described in
Step 8, Example 1, using the (S)-1-(3-isopropylphenyl)ethanamine hydrochloride and 1-((2′-(N-(tert-butyl)sulfamoyl)-[1,1′-biphenyl]-4-yl)methyl)-2,3-dimethyl-1H-indole-5-carboxylic acid. ESI-MS (m/z): 636 [M+H]+. -
- The title compound was prepared following the same general protocol as described in Step 9, Example 1, using the (S)-1-((2′-(N-(tert-butyl)sulfamoyl)-[1,1′-biphenyl]-4-yl)methyl)-N-(1-(3-isopropylphenyl)ethyl)-2,3-dimethyl-1H-indole-5-carboxamide. ESI-MS (m/z): 580 [M+H]+.
-
- To the mixture of (S)—N-(1-(3-isopropylphenyl)ethyl)-2,3-dimethyl-1-((2′-sulfamoyl-[1,1′-biphenyl]-4-yl)methyl)-1H-indole-5-carboxamide (0.058 g, 0.1 mmol) and TEA (0.03 mL, 0.2 mmol) in DCM (0.5 mL) was slowly added acetyl chloride (0.009 g, 0.11 mmol). The mixture was stirred at room temperature for 1 h. The solvent was removed and the residue was purified by preparative-HPLC to obtain the title compound ESI-MS (m/z): 622 [M+H]+.
-
- The title compound was prepared following the same protocol as described in
Step 8 and 9, Example 1, using (R)-chroman-3-amine instead of the (S)-1-(4-bromophenyl) ethanamine. -
- The title compound was prepared following the same protocol as described in
Step 8 and 9, Example 1, using (S)-chroman-3-amine instead of the (S)-1-(4-bromophenyl) ethanamine. -
- The title compound was prepared following the same protocol as described in
Step 8 and 9, Example 1, using (S)-1-(4-propylphenyl)ethanaminium chloride instead of the (S)-1-(4-bromophenyl)ethanamine. ESI-MS (m/z): 545 [M+H]+. -
- The title compound was prepared following the same protocol as described in
Step 8 and 9, Example 1, using (S)-1-(o-tolyl)ethanaminium chloride instead of the (S)-1-(4-bromophenyl)ethanamine. ESI-MS (m/z): 517 [M+H]+. -
- The title compound was prepared following the same protocol as described in
Step 8 and 9, Example 1, using (S)-1-(4-ethoxyphenyl)ethanaminium chloride instead of the (S)-1-(4-bromophenyl)ethanamine. ESI-MS (m/z): 547 [M+H]+. -
- The title compound was prepared following the same protocol as described in
Step 8 and 9, Example 1, using (S)-1-(2-bromophenyl)ethanaminium chloride instead of the (S)-1-(4-bromophenyl)ethanamine. ESI-MS (m/z): 581 [M+H]+. -
- The title compound was prepared following the same protocol as described in
Step 8 and 9, Example 1, using (S)-1-(2-ethylphenyl)ethanaminium chloride instead of the (S)-1-(4-bromophenyl)ethanamine. ESI-MS (m/z): 531 [M+H]+. -
- The title compound was prepared following the same protocol as described in
Step 8 and 9, Example 1, using (S)-1-(2-(trifluoromethoxy)phenyl)ethanaminium chloride instead of the (S)-1-(4-bromophenyl)ethanamine. ESI-MS (m/z): 587 [M+H]+. -
- The title compound was prepared following the same protocol as described in
Step 8 and 9, Example 1, using (S)-1-(2-isopropoxyphenyl)ethanaminium chloride instead of the (S)-1-(4-bromophenyl)ethanamine. ESI-MS (m/z): 561 [M+H]+. -
- The title compound was prepared following the same protocol as described in
Step 8 and 9, Example 1, using (S)-1-(4-(methylsulfonyl)phenyl)ethanaminium chloride instead of the (S)-1-(4-bromophenyl)ethanamine. ESI-MS (m/z): 581 [M+H]+. -
-
- The title compound was prepared following the same general protocol as described in
Step -
- The title compound was prepared following the same general protocol as described in
Step 8, Example 1, using 1-(5-bromopyridin-3-yl)ethanaminium chloride instead of (S)-1-(4-bromophenyl)ethanamine. -
- The title compound was prepared following the same general protocol as described in
Step 1, Example 261, using tert-butyl 4′-((5-((1-(5-bromopyridin-3-yl)ethyl)carbamoyl)-2,3-dimethyl-1H-indol-1-yl)methyl)-[1,1′-biphenyl]-2-carboxylate instead of (S)-tert-butyl 4′-((5-((1-(5-bromopyridin-2-yl)ethyl) carbamoyl)-2,3-dimethyl-1H-indol-1-yl)methyl)-[1,1′-biphenyl]-2-carboxylate. -
- The title compound was prepared following the same general protocol as described in Step 9, Example 1. ESI-MS (m/z): 544 [M+H]+.
-
-
- The title compound was prepared following the same general protocol as described in
Step -
- The title compound was prepared following the same general protocol as described in
Step 8, Example 1, using (S)-1-(5-bromopyridin-2-yl)ethanaminium chloride instead of (S)-1-(4-bromophenyl)ethanamine. -
- The title compound was prepared following the same general protocol as described in Step 9, Example 1. ESI-MS (m/z): 582 [M+H]+.
-
-
- A high-pressure vial was filled with the (S)-tert-
butyl 4′-((5-((1-(5-bromopyridin-2-yl)ethyl) carbamoyl)-2,3-dimethyl-1H-indol-1-yl)methyl)-[1,1′-biphenyl]-2-carboxylate (50 mg, 0.078 mmol), cyclopropylboronic acid (8 mg, 0.09 mmol, 1.2 equiv), Pd(OAc)2 (12 mg, 0.055 mmol, 0.7 equiv), (Cy)3P (8.7 mg, 0.031 mmol, 0.4 equiv), K3PO4 (49 mg, 0.23 mmol, 3 equiv), in toluene-water (10%). The reaction mixture was heated at 100° C. for 3 h under microwaves. The mixture was evaporated in vacuo to obtain the crude which was purified by prep. HPLC (MeOH/Acetonitrile/water) to obtain the title compound. -
- The title compound was prepared following the same general protocol as described in Step 9, Example 1. ESI-MS (m/z): 544 [M+H]+.
-
-
- The title compound was prepared following the same general protocol as described in
Step -
- The title compound was prepared following the same general protocol as described in
Step 8, Example 1, using (S)-1-(6-chloropyridin-3-yl)ethanaminium chloride instead of (S)-1-(4-bromophenyl)ethanamine. -
- The title compound was prepared following the same general protocol as described in Step 9, Example 1. ESI-MS (m/z): 538 [M+H]+.
-
-
- The title compound was prepared following the same general protocol as described in
Step 1, Example 261, using (S)-tert-butyl 4′-((5-((1-(6-chloropyridin-3-yl)ethyl)carbamoyl)-2,3-dimethyl-1H-indol-1-yl)methyl)-[1,1′-biphenyl]-2-carboxylate instead of (S)-tert-butyl 4′-((5-((1-(5-bromopyridin-2-yl)ethyl) carbamoyl)-2,3-dimethyl-1H-indol-1-yl)methyl)-[1,1′-biphenyl]-2-carboxylate. -
- The title compound was prepared following the same general protocol as described in Step 9, Example 1. ESI-MS (m/z): 544 [M+H]+.
-
-
- The title compound was prepared following the same general protocol as described in
Step -
- The title compound was prepared following the same general protocol as described in
Step 8, Example 1, using (R)-1-(6-chloropyridin-3-yl)ethanaminium chloride instead of (S)-1-(4-bromophenyl)ethanamine. -
- The title compound was prepared following the same general protocol as described in
Step 1, Example 261, using (R)-tert-butyl 4′-((5-((1-(6-chloropyridin-3-yl)ethyl)carbamoyl)-2,3-dimethyl-1H-indol-1-yl)methyl)-[1,1′-biphenyl]-2-carboxylate instead of (S)-tert-butyl 4′-((5-((1-(5-bromopyridin-2-yl)ethyl) carbamoyl)-2,3-dimethyl-1H-indol-1-yl)methyl)-[1,1′-biphenyl]-2-carboxylate. -
- The title compound was prepared following the same general protocol as described in Step 9, Example 1. ESI-MS (m/z): 544 [M+H]+.
-
-
- The title compound was prepared following the same general protocol as described in
Step -
- The title compound was prepared following the same general protocol as described in
Step 8, Example 1, using (S)-1-(4-chloropyridin-2-yl)ethanaminium chloride instead of (S)-1-(4-bromophenyl)ethanamine. -
- The title compound was prepared following the same general protocol as described in Step 9, Example 1. ESI-MS (m/z): 538 [M+H]+.
-
-
- The title compound was prepared following the same general protocol as described in
Step 1, Example 261, using (S)-tert-butyl 4′-((5-((1-(4-chloropyridin-2-yl)ethyl)carbamoyl)-2,3-dimethyl-1H-indol-1-yl)methyl)-[1,1′-biphenyl]-2-carboxylate instead of (S)-tert-butyl 4′-((5-((1-(5-bromopyridin-2-yl)ethyl) carbamoyl)-2,3-dimethyl-1H-indol-1-yl)methyl)-[1,1′-biphenyl]-2-carboxylate. -
- The title compound was prepared following the same general protocol as described in Step 9, Example 1. ESI-MS (m/z): 544 [M+H]+.
-
-
- The title compound was prepared following the same general protocol as described in
Step -
- The title compound was prepared following the same general protocol as described in
Step 8, Example 1, using (S)-1-(2-bromopyridin-4-yl)ethanaminium chloride instead of (S)-1-(4-bromophenyl)ethanamine. -
- The title compound was prepared following the same general protocol as described in Step 9, Example 1. ESI-MS (m/z): 582 [M+H]+.
-
-
- The title compound was prepared following the same general protocol as described in
Step 1, Example 261, using (S)-tert-butyl 4′-((5-((1-(2-bromopyridin-4-yl)ethyl)carbamoyl)-2,3-dimethyl-1H-indol-1-yl)methyl)-[1,1′-biphenyl]-2-carboxylate instead of (S)-tert-butyl 4′-((5-((1-(5-bromopyridin-2-yl)ethyl) carbamoyl)-2,3-dimethyl-1H-indol-1-yl)methyl)-[1,1′-biphenyl]-2-carboxylate. -
- The title compound was prepared following the same general protocol as described in Step 9, Example 1. ESI-MS (m/z): 544 [M+H]+.
-
-
- The title compound was prepared following the same general protocol as described in
Step -
- The title compound was prepared following the same general protocol as described in
Step 8, Example 1, using (R)-1-(2-bromopyridin-4-yl)ethanaminium chloride instead of (S)-1-(4-bromophenyl)ethanamine. -
- The title compound was prepared following the same general protocol as described in Step 9, Example 1. ESI-MS (m/z): 582 [M+H]+.
-
-
- The title compound was prepared following the same general protocol as described in
Step 1, Example 261, using (R)-tert-butyl 4′-((5-((1-(2-bromopyridin-4-yl)ethyl)carbamoyl)-2,3-dimethyl-1H-indol-1-yl)methyl)-[1,1′-biphenyl]-2-carboxylate instead of (S)-tert-butyl 4′-((5-((1-(5-bromopyridin-2-yl)ethyl) carbamoyl)-2,3-dimethyl-1H-indol-1-yl)methyl)-[1,1′-biphenyl]-2-carboxylate. -
- The title compound was prepared following the same general protocol as described in Step 9, Example 1. ESI-MS (m/z): 544 [M+H]+.
-
-
- The title compound was prepared following the same general protocol as described in
Step -
- The title compound was prepared following the same general protocol as described in
Step 8, Example 1, using (R)-1-(6-bromopyridin-2-yl)ethanaminium chloride instead of (S)-1-(4-bromophenyl)ethanamine. -
- The title compound was prepared following the same general protocol as described in Step 9, Example 1. ESI-MS (m/z): 582 [M+H]+.
-
-
- The title compound was prepared following the same general protocol as described in
Step -
- The title compound was prepared following the same general protocol as described in
Step 8, Example 1, using (R)-1-(6-chloropyridin-3-yl)ethanaminium chloride instead of (S)-1-(4-bromophenyl)ethanamine. -
- The title compound was prepared following the same general protocol as described in
Step 1, Example 261, using tert-butyl 4′-((5-((1-(6-bromopyridin-2-yl)ethyl)carbamoyl)-2,3-dimethyl-1H-indol-1-yl)methyl)-[1,1′-biphenyl]-2-carboxylate instead of (S)-tert-butyl 4′-((5-((1-(5-bromopyridin-2-yl)ethyl) carbamoyl)-2,3-dimethyl-1H-indol-1-yl)methyl)-[1,1′-biphenyl]-2-carboxylate. -
- The title compound was prepared following the same general protocol as described in Step 9, Example 1. ESI-MS (m/z): 544 [M+H]+.
-
-
- The title compound was prepared following the same general protocol as described in
Step -
- The title compound was prepared following the same general protocol as described in
Step 8, Example 1, using (S)-1-(6-bromopyridin-2-yl)ethanaminium chloride instead of (S)-1-(4-bromophenyl)ethanamine. -
- The title compound was prepared following the same general protocol as described in Step 9, Example 1. ESI-MS (m/z): 582 [M+H]+.
-
-
- The title compound was prepared following the same general protocol as described in
Step 1, Example 261, using (S)-tert-butyl 4′-((5-((1-(6-bromopyridin-2-yl)ethyl)carbamoyl)-2,3-dimethyl-1H-indol-1-yl)methyl)-[1,1′-biphenyl]-2-carboxylate instead of (S)-tert-butyl 4′-((5-((1-(5-bromopyridin-2-yl)ethyl) carbamoyl)-2,3-dimethyl-1H-indol-1-yl)methyl)-[1,1′-biphenyl]-2-carboxylate. -
- The title compound was prepared following the same general protocol as described in Step 9, Example 1. ESI-MS (m/z): 544 [M+H]+.
-
-
- The title compound was prepared following the same general protocol as described in
Step -
- The title compound was prepared following the same general protocol as described in
Step 8, Example 1, using 1-(5-bromopyridin-3-yl)ethanaminium chloride instead of (S)-1-(4-bromophenyl)ethanamine. -
- The title compound was prepared following the same general protocol as described in Step 9, Example 1. ESI-MS (m/z): 582 [M+H]+.
-
-
- The title compound was prepared following the same general protocol as described in
Step -
- The title compound was prepared following the same general protocol as described in
Step 8, Example 1, using (R)-1-(4-(methylsulfonyl)phenyl)ethanaminium chloride instead of (S)-1-(4-bromophenyl)ethanamine. -
- The title compound was prepared following the same general protocol as described in Step 9, Example 1. ESI-MS (m/z): 581 [M+H]+.
-
- The title compound was prepared following the same protocol as described in
Step 5, Example 34, using (S)-1-(4-(trifluoromethyl)phenyl)ethanamine instead of the 1-phenyl propan-1-amine. ESI-MS (m/z): 552 [M+H]+. -
- The title compound was prepared following the same protocol as described in
Step 5, Example 34, using (S)-1-(4-isopropoxyphenyl)ethanamine instead of the 1-phenyl propan-1-amine. ESI-MS (m/z): 542 [M+H]+. -
- The title compound was prepared following the same protocol as described in
Step 5, Example 34, using (S)-1-(4-(trifluoromethoxy)phenyl)ethanamine instead of the 1-phenyl propan-1-amine. ESI-MS (m/z): 568 [M+H]+. -
- The title compound was prepared following the same protocol as described in
Step 5, Example 34, using (S)-1-(3-ethoxyphenyl)ethanamine instead of the 1-phenyl propan-1-amine. ESI-MS (m/z): 528 [M+H]+. -
- The title compound was prepared following the same protocol as described in
Step 5, Example 34, using (S)-1-(3-chlorophenyl)ethanamine instead of the 1-phenyl propan-1-amine. ESI-MS (m/z): 518 [M+H]+. -
- The title compound was prepared following the same protocol as described in
Step 5, Example 34, using (S)-1-(3-(trifluoromethyl)phenyl)ethanamine instead of the 1-phenyl propan-1-amine. ESI-MS (m/z): 552 [M+H]+. -
- The title compound was prepared following the same protocol as described in
Step 5, Example 34, using (S)-1-(4-chlorophenyl)ethanamine instead of the 1-phenyl propan-1-amine. ESI-MS (m/z): 518 [M+H]+. -
- The title compound was prepared following the same protocol as described in
Step 5, Example 34, using (S)-1-(3-bromophenyl)ethanamine instead of the 1-phenyl propan-1-amine. ESI-MS (m/z): 562 [M+H]+. -
- The title compound was prepared following the same protocol as described in
Step 5, Example 34, using (S)-1-(4-methoxyphenyl)ethanamine instead of the 1-phenyl propan-1-amine. ESI-MS (m/z): 514 [M+H]+. -
- The title compound was prepared following the same protocol as described in
Step 5, Example 34, using (S)-1-(2,4-difluorophenyl)ethanamine instead of the 1-phenyl propan-1-amine. ESI-MS (m/z): 520 [M+H]+. -
- The title compound was prepared following the same protocol as described in
Step 5, Example 34, using (S)-1-(2-chlorophenyl)ethanamine instead of the 1-phenyl propan-1-amine. ESI-MS (m/z): 518 [M+H]+. -
- The title compound was prepared following the same protocol as described in
Step 5, Example 34, using (S)-1-(4-methylphenyl)ethanamine instead of the 1-phenyl propan-1-amine. ESI-MS (m/z): 498 [M+H]+. -
- The title compound was prepared following the same protocol as described in
Step 5, Example 34, using (S)-1-(4-ethylphenyl)ethanamine instead of the 1-phenyl propan-1-amine. ESI-MS (m/z): 512 [M+H]+. -
- The title compound was prepared following the same protocol as described in
Step 5, Example 34, using (S)-1-(3,4-dichlorophenyl)ethanamine instead of the 1-phenyl propan-1-amine. ESI-MS (m/z): 552 [M+H]+. -
- The title compound was prepared following the same protocol as described in
Step 5, Example 34, using (S)-1-phenylethanamine instead of the 1-phenyl propan-1-amine. ESI-MS (m/z): 484 [M+H]+. -
- The title compound was prepared following the same protocol as described in
Step 5, Example 34, using (S)-1-(2-methoxyphenyl)ethanamine instead of the 1-phenyl propan-1-amine. ESI-MS (m/z): 514 [M+H]+. -
- The title compound was prepared following the same protocol as described in
Step 5, Example 34, using (S)-1-(3-fluorophenyl)ethanamine instead of the 1-phenyl propan-1-amine. ESI-MS (m/z): 502 [M+H]+. -
- The title compound was prepared following the same general protocol as described in Step 8-9, Example 1, using (1R,2S)-2-phenylcyclopropanamine hydrochloride and 1-((2′-(tert-butoxycarbonyl)-[1,1′-biphenyl]-4-yl)methyl)-2,3-dimethyl-1H-indole-5-carboxylic acid. ESI-MS (m/z): 515 [M+H]+.
-
-
- A mixture of (S)-tert-
butyl 4′-((5-((1-(3-bromophenyl)ethyl)carbamoyl)-2,3-dimethyl-1H-indol-1-yl)methyl)-[1,1′-biphenyl]-2-carboxylate (24 mg, 0.038 mmol), trimethylboroxine (10 mL, 0.072 mmol), Pd(PPh3)4 (11 mg, 0.0095 mmol) and K2CO3 (15 mg, 0.11 mmol) in Dioxane (0.7 ml) were heated in a Biotage Microwave reactor at 100° C. for 2 h. The solvent was removed and the residue was purified by reverse phase prep-HPLC (MeOH/Acetonitrile/water) to obtain the title compound. -
- The title compound was prepared following the same general protocol as described in Step 9, Example 1. ESI-MS (m/z): 517 [M+H]+.
-
-
- The title compound was prepared following the same general protocol as described in
Step 8, Example 1, using (R)-1-(3-bromophenyl)ethanamine instead of (S)-1-(4-bromophenyl)ethanamine. - The title compound was prepared following the same general protocol as described in Step 9, Example 1. ESI-MS (m/z): 581/583 [M+H]+.
-
-
- A mixture of (S)-tert-
butyl 4′-((5-((1-(3-bromophenyl)ethyl)carbamoyl)-2,3-dimethyl-1H-indol-1-yl)methyl)-[1,1′-biphenyl]-2-carboxylate (24 mg, 0.038 mmol), cyclopropylboronic acid (7 mg, 0.081 mmol), Palladium(II) acetate (3.5 mg, 0.016 mmol) tricyclohexylphosphine (9 mg, 0.032 mmol) and potassium phosphate, tribasic, (23 mg, 0.11 mmol) in toluene (0.7 mL) and water (0.07 mL) was heated at 100° C. for 1 h in a Biotage Microwave reactor. The solvent was removed; the residue was filtered and purified by preparative HPLC to yield the title compound as a white solid. -
- The title compound was prepared following the same general protocol as described in Step 9, Example 1. ESI-MS (m/z): 543 [M+H]+.
-
-
- The title compound was prepared following the same general protocol as described in
Step 8, Example 1, using (S)-1-(2-fluoro-4-(trifluoromethyl)phenyl)ethanamine instead of (S)-1-(4-bromophenyl)ethanamine. -
- The title compound was prepared following the same general protocol as described in Step 9, Example 1. ESI-MS (m/z): 589 [M+H]+.
-
-
- The title compound was prepared following the same general protocol as described in
Step 8, Example 1, using (S)-1-(2-fluoro-3-(trifluoromethyl)phenyl)ethanamine instead of (S)-1-(4-bromophenyl)ethanamine. -
- The title compound was prepared following the same general protocol as described in Step 9, Example 1. ESI-MS (m/z): 589 [M+H]+.
-
-
- The title compound was prepared following the same general protocol as described in
Step 8, Example 1, using (S)-1-(2-fluoro-6-(trifluoromethyl)phenyl)ethanamine instead of (S)-1-(4-bromophenyl)ethanamine. -
- The title compound was prepared following the same general protocol as described in Step 9, Example 1. ESI-MS (m/z): 589 [M+H]+.
-
-
- The title compound was prepared following the same general protocol as described in
Step 8, Example 1, using (S)-1-(2,4,5-trifluorophenyl)ethanamine instead of (S)-1-(4-bromophenyl)ethanamine. -
- The title compound was prepared following the same general protocol as described in Step 9, Example 1. ESI-MS (m/z): 557 [M+H]+.
-
-
- The title compound was prepared following the same general protocol as described in
Step 8, Example 1, using (S)-1-(2-chloro-5-(trifluoromethyl)phenyl)ethanamine instead of (S)-1-(4-bromophenyl)ethanamine. - The title compound was prepared following the same general protocol as described in Step 9, Example 1. ESI-MS (m/z): 605 [M+H]+.
-
-
- The title compound was prepared following the same general protocol as described in
Step 8, Example 1, using (S)-1-(2,4-dichlorophenyl)ethanamine instead of (S)-1-(4-bromophenyl)ethanamine. -
- The title compound was prepared following the same general protocol as described in Step 9, Example 1. ESI-MS (m/z): 571 [M+H]+.
-
- A mixture of (S)-4′-((5-((1-(4-bromophenyl)ethyl)carbamoyl)-2,3-dimethyl-1H-indol-1-yl)methyl)-[1,1′-biphenyl]-2-carboxylic acid (28 mg, 0.048 mmol), cyclopropylboronic acid (9 mg, 0.10 mmol), Palladium(II) acetate (3.9 mg, 0.017 mmol) tricyclohexylphosphine (10 mg, 0.036 mmol) and potassium phosphate, tribasic, (22 mg, 0.10 mmol) in toluene (2.5 mL) and water (0.3 mL) was heated at 100° C. for 1 h in a Biotage Microwave reactor. The solvent was removed; the residue was filtered and purified by preparative HPLC to yield the title compound as a white solid. ESI-MS (m/z): 543 [M+H]+.
-
- The title compound was prepared using the same general protocol as described in
Step 8, Example 1. ESI-MS (m/z): 584 [M+H]+. -
- The title compound was prepared using the same general protocol as described in
Step 8, Example 1. ESI-MS (m/z): 614 [M+H]+. -
- The title compound was prepared using the same general protocol as described in
Step 8, Example 1. ESI-MS (m/z): 588 [M+H]+. -
- The title compound was prepared using the same general protocol as described in
Step 8, Example 1. ESI-MS (m/z): 626 [M+H]+. -
- The title compound was prepared using the same general protocol as described in
Step 8, Example 1. ESI-MS (m/z): 659 [M+H]+. -
- The title compound was prepared using the same general protocol as described in
Step 8, Example 1. The TFA salt of the title compound was obtained. ESI-MS (m/z): 615 [M+H]+. -
- The title compound was prepared using the same general protocol as described in
Step 8, Example 1. ESI-MS (m/z): 558 [M+H]+. -
- The title compound was prepared using the same general protocol as described in
Step 8, Example 1. ESI-MS (m/z): 572 [M+H]+. -
-
- The title compound was prepared using the same general protocol as described in
Step 8, Example 1. -
- The solution of (S)-1-((2′-(((tert-Butyldimethylsilyl)oxy)carbamoyl)-[1,1′-biphenyl]-4-yl)methyl)-N-(1-(3-isopropylphenyl)ethyl)-2,3-dimethyl-1H-indole-5-carboxamide in DCM (3 mL) and TFA (0.5 mL) was stirred for 1 h at rt. The solvent was removed and the residue was purified by reverse phase prep-HPLC (MeOH/Acetonitrile/water) to obtain the title compound. ESI-MS (m/z): 560 [M+H]+.
-
- The mixture of (S)-4′-((5-((1-(3-isopropylphenyl)ethyl)carbamoyl)-2,3-dimethyl-1H-indol-1-yl)methyl)-[1,1′-biphenyl]-2-carboxylic acid (30 mg, 0.055 mmol), methanesulfonamide (15 mg, 0.16 mmol), EDAC (25 mg, 0.13 mmol) and DMAP (26 mg, 0.21 mmol) in DMF (3 mL) was stirred at rt for 15 h. The solvent was removed and the residue was purified by reverse phase prep-HPLC (MeOH/Acetonitrile/water) to obtain the title compound. ESI-MS (m/z): 622 [M+H]+.
-
- The title compound was prepared using the same general protocol as described in
Step 8, Example 1. ESI-MS (m/z): 544 [M+H]+. - The assay was performed according to manufacturer protocol. A mixture of 5 nM GST-PPARG-LBD, 5 nM Tb-GST-antibody, 5 nM Fluormone Pan-PPAR Green, and serial dilutions of the experimental compound, beginning at 10 μM downwards, was added to wells of black 384-well low-volume plates (Greiner) to a total volume of 18 μL. All dilutions were made in TR-FRET assay buffer C. DMSO at 2% final concentration was used as a no-ligand control. Experiment was performed in triplicate, and incubated for 2 hours in the dark prior to assay read in Perkin Elmer ViewLux ultra HTS microplate reader. FRET signal was measured by excitation at 340 nm and emission at 520 nm for fluorescein and 490 nm for terbium. Fold change over DMSO was calculated using GraphPad Prism Software (La Jolla, Calif.) by calculating 520 nm/490 nm ratio. Graphs were plotted as fold change of FRET signal for compound treatment over DMSO-only control.
- PPRE is a DNA that contains a binding site for PPARG; thus PPRE is a PPAR response element, used herein as a promoter reporter. The binding site is a DR1 response element with the sequence AGGTCA repeated 3 times in tandem and then fused to a construct for luciferase.
- Thus, PPRE is the basis of the cell based transactivation assay described below. The plasmid DNA is co-transfected along with a plasmid for PPARG into COS-1 cells. After an overnight incubation, cells are treated with DMSO or compounds. In this assay rosiglitazone activates the reporter about 5 fold. Partial agonists such as MRL24 transactivate the reporter about 25% of rosiglitazone response. Compounds of the invention which are non-activators afford no transactivation of the reporter.
- Confluent COS-1 cells were transfected with 4.5 μg murine PPARg2-pSV Sport or full-length human PPARg-pSport6, 4.5
μg 3×PPRE-luciferase reporter and 27 μL X-treme Gene 9 transfection reagent in serum-free opti-mem media (Gibco), followed by overnight incubation at 37° C., 5% CO2. Transfected cells were plated in white Perkin Elmer 384-well plates and incubated 4 hours. Cells were treated with DMSO vehicle only or experimental compounds in increasing doses from 2 μM-220 pM for mouse receptor and 10 μM-111 fM for human. After 18 hour incubation, treated cells were developed with Brite Lite Plus (Perkin Elmer) and read in 384-well Luminescence Perkin Elmer EnVision Multilabel plate reader. Graphs were plotted in triplicate in GraphPad Prism Software as fold change of treated cells over DMSO control cells. The human PPAR nuclear receptor ligand binding domain (LBD) is fused to the DNA-Binding Domain of the yeast GAL4 transcription factor. The hybrid fusion-protein nuclear receptor can activate the luciferase reporter under the control of the GAL4 Upstream Activator Sequence (UAS). - The plasmid Gal4-PPAR DNA is co-transfected along with a plasmid for UAS-luc into HEK 293T cells. After an overnight incubation, cells are treated with DMSO or compounds. In this assay rosiglitazone activates the reporter about 100-fold. Partial agonists transactivate the reporter about 30-40% of rosiglitazone response. Compounds of the invention which are non-activators exhibit <5% transactivation of the receptor at 1 mM.
- HEK 293T cells were transfected with 4.5 μg of Gal4-PPARg, 4.5 μg UAS-luciferase reporter and 27 μL X-treme Gene 9 transfection reagent in serum-free opti-mem media (Gibco), followed by overnight incubation at 37° C., 5% CO2. Transfected cells were replated in white Perkin Elmer 384-well plates and incubated 4 hours. Cells were treated with DMSO vehicle only or experimental compounds in doses from 10 μM-111 fM. After 18 hour incubation, treated cells were developed with Brite Lite Plus (Perkin Elmer) and read in 384-well Luminescence Perkin Elmer EnVision Multilabel plate reader. Graphs were plotted in triplicate in GraphPad Prism Software as fold change of treated cells over DMSO control cells.
- Biodata Tables 1-5, below, provides biological data for the specifically claimed compounds as shown in Table 1, above, listing compound examples of the invention covering almost all of compound examples 1-320. Each line of Biodata Tables 1-5 represents biodata for the corresponding single compound of the set listed in Table 1, with respect to IC50 as determined by the Lanthascreen procedure, and EC50 as determined by the cell-based transactivation assay. A compound with a relatively low IC50 concentration is indicated to have potent PPARG binding activity, whereas a compound with a relatively high EC50 value in the cell-based transactivation assay is indicated to possess non-agonistic properties. In various embodiments, the invention provides compounds combining these two properties, non-agonistic and PPARG binding.
- It is within ordinary skill to evaluate any compound disclosed and claimed herein for effectiveness in non-agonistic binding to PPARG and in the various cellular assays using the procedures described above or found in the scientific literature. Accordingly, the person of ordinary skill can prepare and evaluate any of the claimed compounds without undue experimentation.
- Any compound found to be an effective non-agonist PPARG binding molecular entity can likewise be tested in animal models and in human clinical studies using the skill and experience of the investigator to guide the selection of dosages and treatment regimens.
- The purpose of this example was to determine binding affinities (IC50) of inventive compounds as determined by the Lantha Screen displacement assay (n=3) described above. The following table shows affinities for selected compounds in comparison with rosiglitazone:
-
COMPOUND IC50 Rosiglitazone 60 IB-72 (SR1663) 2 IB-73 (SR1664) 80 IB-2 (SR2595) 30 IA-58 (SR10221) 15 - The purpose of this example was to determine if pharmacological PPARγ repression would impair insulin sensitivity.
- All animal experiments were performed according to procedures approved by Scripps-Florida IACUC Committee. Male C57BL/6J mice were purchased from the Jackson Laboratory (7-week-old) and fed a regular chow diet through experiments. The mice were dosed by oral gavage once daily with 5 mg kg−1 rosiglitazone or 20 mg kg−1 Compound IB-2 (SR2595) for 21 days. For insulin tolerance tests, mice were fasted overnight before i.p. injection of 0.75 U/kg insulin (Sigma). Glucose was then measured by tail vein bleeds at the indicated intervals using an OneTouch Ultra2 glucometer. Plasma insulin concentration was determined by ELISA (Millipore mouse/rat insulin. cat #EZRMI-13K).
- The results are shown in
FIG. 12 , indicating that the pharmacokinetic properties of SR2595 were sufficient to support once daily oral dosing at 20 mg/kg. - The purpose of this example is to demonstrate that the compounds of the invention increase bone mass in pathological conditions of bone loss or to increase bone formation in conditions that compromise fracture healing.
- The compound IA-48 (SR10171) acts as an antagonist to PPARy pro-adipocytic activity, and it has been further tested in vivo for its effect on bone. SR10171 was administered to hyperglycemic C57BL/6 mice, 12 wks old males, that were purchased from the Jackson Laboratories (Bar Harbor, Me.). DIO mice: Animals were fed ad libitum for 11 wks high fat diet (HFD) providing 45 kcal % from fat (D12451; Research Diets, New Brunswick, N.J.) to develop diet induced obesity (DIO).
- DIO mice were separated into three groups (n=8) and fed for 4 wks as follows: HFD (control), HFD supplemented with rosiglitazone at the
dose 25 mg/kg/d, and HFD supplemented with SR10171 at thedose 25 mg/kg/d. The dose of SR10171 was calculated based on the following reasoning: SR10171 binding affinity to PPARy is 10-fold lower and its 5273 phosphorylation blocking activity is 50% lower than rosiglitazone. This together with 2.5-fold higher than rosiglitazone retention levels in plasma of animals treated for 4 days resulted in the decision to treat animals with the same dose of each drug. The exact amount was decided based on our experience that a dose of rosiglitazone between 20-25 mg/kg/day administered for 4 weeks to DIO animals results in significant loss of trabecular bone in both, axial and appendicular skeleton (Kolli, V., et al. Partial Agonist, Telmisartan, Maintains PPARgamma Serine 112 Phosphorylation, and Does Not Affect Osteoblast Differentiation and Bone Mass. PLoS One 9, e96323 (2014). Ingested doses of SR10171 (22 mg/kg/d) and rosiglitazone (24 mg/kg/d) were calculated at the end of treatment based on food intake monitored throughout duration of entire experiment. In parallel, a group of sex- and age-matched control (n=5) was fed regular diet (RD) providing 12 kcal % from fat (2016 Teklad Global, Harlan Laboratories, Indianapolis, Ind.). Second experiment was conducted on 12 wks old males, lean C57BL/6 mice, which were fed for 8 weeks either non-supplemented RD, or RD supplemented with rosiglitazone, or RD supplemented with SR10171. Food intake was monitored during the entire experiment to calculate an ingested dose of SR10171 (12.7 mg/kg/d) and rosiglitazone (11.7 mg/kg/d). The animal treatment and care protocols conformed to the NIH Guidelines and were performed under the University of Toledo Health Science Campus Institutional Animal Care and Utilization Committee protocol. - Fat and lean mass were evaluated at the beginning and at the end of experiment using a Minispec mq10 NMR analyzer (Bruker, Billerica, Mass.). Glucose disposal (glucose tolerance test, GTT) was measured after ip injection of 2 g/kg glucose to animals fasted for 4 hrs. Blood glucose was measured using the AlphaTRAK system appropriate for mice (Abbott Laboratories, North Chicago, Ill.). For indirect calorimetry, mice were evaluated in metabolic cages (CLAMS; Columbus Instruments, Columbus, Ohio) for 4 days with a free access to food and water. Mice were housed individually at room temperature (22 C) under an alternating 12-h light/dark cycle. After one day adaptation, oxygen (VO2) consumption, carbon dioxide (VCO2) production, physical activity, and heat production were measured to determine energy expenditure. Respiratory exchange ratio was calculated as a ratio of the 02 consumption and the CO2 production.
- The effect of SRI0171 on bone mass was compared to the effect of rosiglitazone. At the end of experiment, bones (tibia, femur and vertebra) were isolated and their volume and microarchitecture was analyzed using micro-computed tomography.
- mCT of the tibiae was performed using the μCT-35 system (Scanco Medical AG, Bruettisellen, Switzerland) as previously described (Liu, L., et al. Rosiglitazone inhibits bone regeneration and causes significant accumulation of fat at sites of new bone formation. Calcif Tissue Int 91, 139-148 (2012). Briefly, scans were performed at 7 μm nominal resolution with the x-ray source operating at 70 kVp, and 113 μA settings. Scans consisted of 300 slices starting at the growth plate of proximal tibia and images of trabecular bone were segmented at 220 threshold value using per mille scale following manual contouring starting 10 slices below the growth plate and extending to the end of the image stack. Scans of cortical bone at tibia midshaft consisting of 55 slices were obtained at 7 μm nominal resolution with the x-ray source operating at 70 kVp and 113 μA. Images of cortical bone were contoured in the entire image stack and segmented at 260 threshold using per mille scale. The analysis of the trabecular bone microstructure and the cortical bone parameters was conducted using Evaluation Program V6.5-1 (Scanco Medical AG, Bruettisellen, Switzerland) and conformed to recommended guidelines (Bouxsein, M. L., et al. Guidelines for assessment of bone microstructure in rodents using micro-computed tomography. J
Bone Miner Res 25, 1468-1486 (2010). - For lipid content evaluation, decalcified bone specimens were stained for 1 hr in solution containing 2% osmium tetroxide prepared in 0.1M sodium cacodylate buffer pH 7.4, according to the protocol (Liu et al., 2012). Staining was carried-out in an exhaust hood and away from light due to osmium tetroxide toxicity and light sensitivity. Images of lipid depositions were acquired at 70 kVp and 113 μA settings and 12 μm nominal resolution. Image segmentation was done under global threshold condition by applying a threshold of 480-1000 using permille scale with 3-dimensional noise filter set to sigma 1.2 and support 2.0. Lipid volumes were calculated directly from individual voxel volumes in 3-D reconstructions.
- To obtain static and dynamic bone histomorphometry, animals were injected with 2.5 mg/ml calcein solution in 2% sodium bicarbonate at a
dose 20 mg/kg body weight. First injection was performed 10 days and second 2 days before sacrifice. Undecalcified tibiae were embedded in methyl methacrylate, sectioned and stained with either Golden Trichrome or Von Kossa/McNeal by Histology Core at the Department of Anatomy and Cell Biology, Indiana University (Indianapolis, Ind.). The histomorphometric examination was confined to the secondary spongiosa of proximal tibia and was performed using Nikon NIS-Elements BR3.1 system. The measurements were collected under 40× magnification from six representative fields per bone sample. The terminology and units used were those recommended by the Histomorphometry Nomenclature Committee of the American Society for Bone and Mineral Research (Parfitt, A. M., et al. Bone histomorphometry: standardization of nomenclature, symbols, and units. Report of the ASBMR Histomorphometry Nomenclature Committee. JBone Miner Res 2, 595-610 (1987). - The measurements as described above showed that SR10171 compound increased bone mass and bone size and decreased bone marrow fat content in bone region of trabecular structure.
- In contrast, rosiglitazone at the same pharmacological dose decreased trabecular bone mass by 70% and significantly increased fat content in the bone marrow. In addition, SR10171 increased overall bone size and bone area in midshaft tibia which contains cortical bone. These changes in the bone mass and bone geometry increased bone strength as measured by calculating tortional strength and bone bending strength.
- These findings show that compounds such as SR10171, which do not possess PPARγ transcriptional pro-adipocytic activity can exert a beneficial effect on bone. The findings further indicate that the inventive compounds can be used as bone anabolic drugs to increase bone mass in pathological conditions of bone loss, e.g. osteoporosis, or to increase bone formation in conditions that compromise fracture healing, e.g. diabetes.
- In addition, the data showed that beneficial effects on bone are independent of SR10171 metabolic activity. SR10171 increases energy metabolism and normalizes fat function in animals with diet induced obesity, but unlike rosiglitazone it is neutral in animals with balanced energy metabolism. Our data suggest that SR10171 modulates energy metabolism in an on-demand manner, while having sustained anabolic activity on bone regardless of animal metabolic status.
- In lean mice, SR10171 exerted a more robust positive effect on bone. Trabecular bone mass in proximal tibia was increased by 26% as compared to non-treated animals, whereas animals receiving rosiglitazone-supplemented diet lost 30% of bone mass (
FIG. 13 ). The increase in bone mass was due to increased number of trabeculae, but not their thickness (FIG. 13). In contrast to obese mice, lean mice treated with SR10171 did not experience effects on tibia cortical bone, neither cortical bone area nor cortical thickness.
Claims (20)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US17/478,235 US20240009169A9 (en) | 2014-04-16 | 2021-09-17 | PPARG Modulators for the Treatment of Osteoporosis |
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201461980444P | 2014-04-16 | 2014-04-16 | |
PCT/US2015/026226 WO2015161108A1 (en) | 2014-04-16 | 2015-04-16 | Pparg modulators for treatment of osteoporosis |
US201615302862A | 2016-10-07 | 2016-10-07 | |
US16/028,730 US10744117B2 (en) | 2014-04-16 | 2018-07-06 | PPARG modulators for the treatment of osteoporosis |
US202016909324A | 2020-06-23 | 2020-06-23 | |
US202117168690A | 2021-02-05 | 2021-02-05 | |
US17/478,235 US20240009169A9 (en) | 2014-04-16 | 2021-09-17 | PPARG Modulators for the Treatment of Osteoporosis |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US202117168690A Continuation | 2014-04-16 | 2021-02-05 |
Publications (2)
Publication Number | Publication Date |
---|---|
US20230072933A1 US20230072933A1 (en) | 2023-03-09 |
US20240009169A9 true US20240009169A9 (en) | 2024-01-11 |
Family
ID=54324583
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/302,862 Active US10016394B2 (en) | 2014-04-16 | 2015-04-16 | PPARG modulators for treatment of osteoporosis |
US16/028,730 Active US10744117B2 (en) | 2014-04-16 | 2018-07-06 | PPARG modulators for the treatment of osteoporosis |
US17/478,235 Abandoned US20240009169A9 (en) | 2014-04-16 | 2021-09-17 | PPARG Modulators for the Treatment of Osteoporosis |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/302,862 Active US10016394B2 (en) | 2014-04-16 | 2015-04-16 | PPARG modulators for treatment of osteoporosis |
US16/028,730 Active US10744117B2 (en) | 2014-04-16 | 2018-07-06 | PPARG modulators for the treatment of osteoporosis |
Country Status (2)
Country | Link |
---|---|
US (3) | US10016394B2 (en) |
WO (1) | WO2015161108A1 (en) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10016394B2 (en) | 2014-04-16 | 2018-07-10 | The Scripps Research Institute | PPARG modulators for treatment of osteoporosis |
CN105175309A (en) * | 2015-10-29 | 2015-12-23 | 中国科学院上海药物研究所 | N-benzyl-5/6-formyl amino indol-2-carboxylic acid derivative and application thereof |
CN107434789B (en) * | 2016-05-26 | 2021-04-13 | 中国医学科学院药物研究所 | Benzotriazole derivatives, preparation method thereof, pharmaceutical composition and application thereof |
CN114436833A (en) * | 2021-12-27 | 2022-05-06 | 南京红太阳医药研究院有限公司 | Preparation method of telmisartan key intermediate 4' -methylbiphenyl-2-carboxylic ester |
Family Cites Families (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8524157D0 (en) | 1984-10-19 | 1985-11-06 | Ici America Inc | Heterocyclic amides |
DE3928177A1 (en) | 1989-04-08 | 1991-02-28 | Thomae Gmbh Dr K | BENZIMIDAZOLE, MEDICAMENTS CONTAINING THESE COMPOUNDS AND METHOD FOR THE PRODUCTION THEREOF |
DE4023369A1 (en) | 1990-07-23 | 1992-01-30 | Thomae Gmbh Dr K | New 1-bi:phenylyl:methyl benzimidazole derivs. |
JP3295277B2 (en) | 1994-06-01 | 2002-06-24 | 呉羽化学工業株式会社 | Antinephrotic agent and benzimidazole derivative |
GB9518552D0 (en) * | 1995-09-11 | 1995-11-08 | Fujisawa Pharmaceutical Co | New heterocyclic compounds |
WO1997010319A1 (en) * | 1995-09-13 | 1997-03-20 | Kao Corporation | Lubricating oil composition |
US6348032B1 (en) | 1998-11-23 | 2002-02-19 | Cell Pathways, Inc. | Method of inhibiting neoplastic cells with benzimidazole derivatives |
GB9919411D0 (en) | 1999-08-18 | 1999-10-20 | Zeneca Ltd | Chemical compounds |
JPWO2003011812A1 (en) | 2001-08-01 | 2004-11-18 | 持田製薬株式会社 | Novel amine derivative having human-β-tryptase inhibitory activity and medicament containing the same |
CN100434420C (en) | 2003-01-31 | 2008-11-19 | 株式会社三和化学研究所 | Compound inhibiting dipeptidyl peptidase iv |
DE10306250A1 (en) | 2003-02-14 | 2004-09-09 | Aventis Pharma Deutschland Gmbh | Substituted N-aryl heterocycles, processes for their preparation and their use as pharmaceuticals |
US7501405B2 (en) | 2003-04-11 | 2009-03-10 | High Point Pharmaceuticals, Llc | Combination therapy using an 11β-hydroxysteroid dehydrogenase type 1 inhibitor and an antihypertensive agent for the treatment of metabolic syndrome and related diseases and disorders |
US7129264B2 (en) * | 2003-04-16 | 2006-10-31 | Bristol-Myers Squibb Company | Biarylmethyl indolines and indoles as antithromboembolic agents |
JP2005162657A (en) | 2003-12-02 | 2005-06-23 | Takeda Chem Ind Ltd | Cannabinoid receptor regulator |
JP2007520471A (en) | 2003-12-22 | 2007-07-26 | イーライ リリー アンド カンパニー | Bicyclic derivatives as PPAR receptor modulators |
WO2005090282A1 (en) | 2004-03-12 | 2005-09-29 | Ligand Pharmaceuticals Incorporated | Androgen receptor modulator compounds and methods |
BRPI0517369A (en) | 2004-10-27 | 2008-10-07 | Hoffmann La Roche | compounds, process for their manufacture, compositions comprising them, method for the treatment and / or prophylaxis of diseases that are associated with modulation of cb1 receptors and their use |
MX2008010645A (en) | 2006-02-20 | 2008-10-14 | Astellas Pharma Inc | Amide derivative or salt thereof. |
WO2008044767A1 (en) | 2006-10-13 | 2008-04-17 | Takeda Pharmaceutical Company Limited | Aromatic amine derivative and use thereof |
GB0800035D0 (en) | 2008-01-02 | 2008-02-13 | Glaxo Group Ltd | Compounds |
JP2013500982A (en) | 2009-07-30 | 2013-01-10 | エスタス・セラピューティクス・インコーポレイテッド | Method of treating neuropathic pain with a benzimidazole derivative agonist of PPARγ |
US9051265B2 (en) * | 2011-06-06 | 2015-06-09 | The Scripps Research Institute | N-benzylindole modulators of PPARG |
US8957093B2 (en) * | 2011-06-06 | 2015-02-17 | The Scripps Research Institute | N-biphenylmethylindole modulators of PPARG |
WO2013078237A1 (en) | 2011-11-22 | 2013-05-30 | Ripka Amy S | N-arylylmethylindazole modulators of pparg |
WO2013078240A1 (en) | 2011-11-22 | 2013-05-30 | Ripka Amy S | N-biphenylmethylbenzimidazole modulators of pparg |
WO2013078233A1 (en) | 2011-11-22 | 2013-05-30 | Ripka Amy S | N-benzylbenzimidazole modulators of pparg |
US9567328B2 (en) * | 2011-12-21 | 2017-02-14 | Allergan, Inc. | Compounds acting at multiple prostaglandin receptors giving a general anti-inflammatory response |
US8933199B2 (en) * | 2012-09-13 | 2015-01-13 | Bristol-Myers Squibb Company | Fibronectin based scaffold domain proteins that bind to myostatin |
US10016394B2 (en) * | 2014-04-16 | 2018-07-10 | The Scripps Research Institute | PPARG modulators for treatment of osteoporosis |
-
2015
- 2015-04-16 US US15/302,862 patent/US10016394B2/en active Active
- 2015-04-16 WO PCT/US2015/026226 patent/WO2015161108A1/en active Application Filing
-
2018
- 2018-07-06 US US16/028,730 patent/US10744117B2/en active Active
-
2021
- 2021-09-17 US US17/478,235 patent/US20240009169A9/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
US10744117B2 (en) | 2020-08-18 |
US20170035730A1 (en) | 2017-02-09 |
WO2015161108A1 (en) | 2015-10-22 |
US10016394B2 (en) | 2018-07-10 |
US20180369196A1 (en) | 2018-12-27 |
US20230072933A1 (en) | 2023-03-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20240009169A9 (en) | PPARG Modulators for the Treatment of Osteoporosis | |
US8957093B2 (en) | N-biphenylmethylindole modulators of PPARG | |
JP7252908B2 (en) | Compounds and methods of use thereof for modulating S1P1 activity | |
US20230047816A1 (en) | Pfkfb3 inhibitors and their uses | |
RU2640588C2 (en) | Pyridine derivative | |
US9051265B2 (en) | N-benzylindole modulators of PPARG | |
ES2634716T3 (en) | New stabilizers and modulators of the GLP-1 receptor | |
KR102042290B1 (en) | Heterocyclic inhibitors of glutaminase | |
CN103502237B (en) | Faah inhibitor | |
US9238647B2 (en) | P2X3 receptor antagonists for treatment of pain | |
US9309227B2 (en) | N-biphenylmethylbenzimidazole modulators of PPARG | |
US11712438B2 (en) | Phenyl derivatives as PGE2 receptor modulators | |
US20140249196A1 (en) | N-benzylbenzimidazole modulators of pparg | |
EA027120B1 (en) | Anti-fibrotic pyridinones | |
JP2012502049A (en) | Compounds, compositions and methods of using the same for regulating uric acid levels. | |
MX2012014863A (en) | Thioacetate compounds, compositions and methods of use. | |
KR20180035894A (en) | Beta-substituted beta-amino acids and analogs as chemotherapeutic agents and uses thereof | |
US20110038835A1 (en) | Anilides and analogs as rho kinase inhibitors | |
US9656994B2 (en) | Substituted benzimidazoles as nociceptin receptor modulators | |
JP2013512247A (en) | 5-Alkynyl-thiophene-2-carboxylic acid derivatives and their use for the treatment or prevention of flavivirus infections | |
BR112020019560A2 (en) | CALPAIN MODULATORS AND THERAPEUTIC USES THEREOF | |
US20140288090A1 (en) | N-arylylmethylindazole modulators of pparg | |
US20230114241A1 (en) | Methods of treating epilepsy using the same | |
US6894054B2 (en) | Heterocyclic inhibitors of glycine transporter 2 | |
US9493464B2 (en) | Wee1 degradation inhibitors |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
AS | Assignment |
Owner name: THE SCRIPPS RESEARCH INSTITUTE, CALIFORNIA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:GRIFFIN, PATRICK R.;KAMENECKA, THEODORE MARK;REEL/FRAME:060791/0285 Effective date: 20150723 Owner name: UNIVERSITY OF TOLEDO, OHIO Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:LECKA-CZERNIK, BEATA;REEL/FRAME:060791/0029 Effective date: 20150505 |
|
AS | Assignment |
Owner name: UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED, FLORIDA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:UNIVERSITY OF FLORIDA BOARD OF TRUSTEES;REEL/FRAME:061201/0624 Effective date: 20220401 Owner name: UNIVERSITY OF FLORIDA BOARD OF TRUSTEES, FLORIDA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:THE SCRIPPS RESEARCH INSTITUTE;REEL/FRAME:061201/0563 Effective date: 20220401 |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |